学术周报 · IF≥10 或专科旗舰刊
肿瘤领域文献阅读汇编
2026年第45周 (2026-11-06) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Cancer letters | 36 | IF 11.8 |
| Pharmacological research | 35 | IF 12.2 |
| Biosensors & bioelectronics | 25 | IF 11.8 |
| Biomaterials | 25 | IF 13.6 |
| MedComm | 24 | IF 14.1 |
| Cancer discovery | 23 | IF 29.5 |
| Cancer research | 19 | IF 22.6 |
| Neuro-oncology | 19 | IF 13.1 |
| Genes & diseases | 18 | IF 14.6 |
| Redox biology | 17 | IF 16.2 |
1肿瘤免疫/微环境 (172篇)
临床研究 (36篇)
Oncolytic adenoviruses are immunotherapeutic agents that selectively replicate in malignant cells, inducing direct oncolysis, and reshaping the tumor microenvironment. While neutralizing antibodies (nAbs) are known to limit viral vector efficacy, emerging evidence suggests they may also have a role in improving clinical outcomes. This study investigates the kinetics, composition, and functional roles of nAbs, and association with overall survival and response rate in patients treated with TILT-123 (igrelimogene litadenorepvec), an Ad5/3 oncolytic adenovirus encoding tumor necrosis factor and interleukin-2. Multiple serum samples from 58 patients enrolled in three TILT-123 phase I clinical trials (NCT04695327, NCT04217473, NCT05271318) were analyzed for anti-TILT-123 nAbs using a cell-based functional neutralization assay. ELISA was used to quantify IgM, IgA, and IgG targeting TILT-123. Functional antibody signaling studies included antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis (ADCP) assays. Serum proteomics, peripheral blood mononuclear cell (PBMC) profiling, and tumor immunofluorescence/RNA-seq were used to immunologically contextualize nAb induction. Survival was evaluated by Kaplan-Meier analysis, and responses by RECIST v1.1. Biomarker assessment for clinical benefit was evaluated using confusion matrices. Cross-trial analysis demonstrated induction of nAb titers against TILT-123. Patients achieving high neutralizing titers early on-treatment (days 8–22) had longer survival (median OS 280 vs 190 days) and higher response rates. Baseline anti-TILT-123 IgG and IgM levels correlated with prolonged OS. ADCP activity on day 36 was associated with improved survival and disease control. Integrated serum, PBMC, and tumor IF/RNA-seq analyses supported humoral immune remodeling and increased immune trafficking and identified lymphotoxin-α as a systemic driver of early nAb induction. Early on-treatment high nAb titers emerged as the strongest single biomarker of clinical benefit, while combinatorial analyses suggested that incorporating additional factors, such as baseline nAb titers or lymphotoxin-α levels, may enhance biomarker suitability. High early on-treatment anti-TILT-123 nAb titers were associated with improved clinical outcomes, while ADCP activity and a pro-humoral systemic milieu supported functional roles beyond viral neutralization. These findings identify nAbs and antiviral humoral immunity as candidate biomarkers and potential effector mechanisms in oncolytic virus therapy development.
中文摘要:溶瘤腺病毒是免疫治疗药物,能够在恶性细胞中选择性复制,直接导致溶瘤并重塑肿瘤微环境。中和抗体(nAbs)通常被认为会限制病毒载体的疗效,但新的证据显示其也可能参与改善临床结局。本研究分析了接受TILT-123(igrelimogene litadenorepvec,一种编码肿瘤坏死因子和白介素-2的Ad5/3溶瘤腺病毒)治疗的患者中nAbs的动力学、组成与功能作用,以及与总生存和缓解率的关系。采用基于细胞的功能性中和试验,检测三项TILT-123 I期临床试验(NCT04695327、NCT04217473、NCT05271318)入组的58例患者的多份血清样本中的抗TILT-123 nAbs;用ELISA定量针对TILT-123的IgM、IgA和IgG;功能性抗体信号研究包括抗体依赖细胞介导的细胞毒作用和抗体依赖细胞吞噬作用(ADCP)试验。通过血清蛋白质组学、外周血单个核细胞(PBMC)表型分析和肿瘤免疫荧光/RNA测序,从免疫学角度解释nAb的诱导背景。生存分析采用Kaplan-Meier法,疗效评价采用RECIST v1.1,临床获益的生物标志物评估采用混淆矩阵。跨试验分析显示TILT-123可诱导nAb滴度升高。在治疗早期(第8–22天)即达到高中和滴度的患者生存更长(中位OS 280天对190天),缓解率更高。基线抗TILT-123 IgG和IgM水平与OS延长相关。第36天的ADCP活性与生存改善和疾病控制相关。血清、PBMC与肿瘤免疫荧光/RNA-seq的整合分析支持体液免疫重塑和免疫细胞转运增加,并发现淋巴毒素-α是早期nAb诱导的系统性驱动因素。治疗早期高nAb滴度是临床获益最强的单一生物标志物,联合分析提示纳入基线nAb滴度或淋巴毒素-α水平等其他因素可能提高其作为生物标志物的适用性。治疗早期抗TILT-123 nAb滴度升高与临床结局改善相关,ADCP活性和促体液免疫的系统性环境支持其在病毒中和之外的功能作用。这些结果将nAbs和抗病毒体液免疫确定为溶瘤病毒治疗研发中的候选生物标志物和潜在效应机制。
Previous studies combining the multikinase inhibitor regorafenib with a PD-1 inhibitor showed promising activity in gastric cancer. We conducted a phase 1b/2 trial (NCT05394740) of first-line regorafenib, nivolumab, and chemotherapy in 30 patients with mismatch repair-proficient gastric cancer and investigated its impact on the tumor microenvironment. The primary end point was met; 22 of 30 patients showed objective tumor response (73%; 80% confidence interval, 60.3 to 83.8). Single-cell RNA and T cell receptor sequencing were performed on biopsy samples at baseline, during treatment, and at disease progression. The combination treatment increased tumor antigen-reactive CD8+ T cells and M1-like proinflammatory macrophages and decreased immunosuppressive and tumor-promoting populations, including activated CCR8+ regulatory T cells, LRRC15+ cancer-associated fibroblasts (CAFs), RGS5+ pericytes, and APLN+ tip cells. At progression, LRRC15+ CAFs and APLN+ tip cells remained reduced, activated CCR8+ regulatory T cells reexpanded, and additional treatment-resistant subsets emerged, including APOC1+ lipid-associated macrophages. In murine models of acquired resistance, therapeutic targeting of these suppressive immune cell populations with antibodies against CCR8 or TREM2 in combination with PD-1 blockade restored antitumor immunity. These findings demonstrate dynamic remodeling of the tumor microenvironment and suggest potential therapeutic targets.
中文摘要:既往将多激酶抑制剂瑞戈非尼与PD-1抑制剂联合的研究在胃癌中显示出有前景的活性。我们开展了一项1b/2期试验(NCT05394740),在30例错配修复功能完整胃癌患者中评估一线瑞戈非尼、纳武利尤单抗与化疗联合方案,并考察其对肿瘤微环境的影响。主要终点达到,30例中22例出现客观肿瘤缓解(73%;80%置信区间60.3至83.8)。对基线、治疗期间和疾病进展时的活检样本进行了单细胞RNA与T细胞受体测序。联合治疗增加了肿瘤抗原反应性CD8+ T细胞和M1样促炎巨噬细胞,减少了免疫抑制和促肿瘤细胞群,包括活化的CCR8+调节性T细胞、LRRC15+癌相关成纤维细胞(CAFs)、RGS5+周细胞和APLN+尖端细胞。疾病进展时,LRRC15+ CAFs和APLN+尖端细胞仍减少,活化的CCR8+调节性T细胞重新扩增,并出现其他治疗耐药亚群,包括APOC1+脂质相关巨噬细胞。在获得性耐药小鼠模型中,用抗CCR8或抗TREM2抗体靶向这些抑制性免疫细胞群并与PD-1阻断联合,恢复了抗肿瘤免疫。这些结果揭示了肿瘤微环境的动态重塑,并提示潜在治疗靶点。
Up to one-half of patients treated with licensed biologics for hidradenitis suppurativa (HS) achieve only a partial response, yet no consensus exists on subsequent management. Dose intensification and long-term antibiotic addition are used in routine practice, but real-world data on their effectiveness remain limited. To evaluate a response-pattern-guided biologic optimization framework in HS partial responders. This was a single-center retrospective cohort study conducted at a tertiary dermatology center in France from January 2022 to March 2025. Patients with HS and insufficient response to anti-tumor necrosis factor-α or anti-interleukin 17 (IL-17) therapy (at least 4 flares per year despite at least 3 months of standard-dose biologic) were included. Data were analyzed from August to October 2025. Patients with an end-of-dose effect (recurrence of disease activity before the next injection) underwent dose intensification (optimization group; n = 52); those without received antibiotic addition (combination group; n = 50) per a prespecified algorithm. The primary outcome was International Hidradenitis Suppurativa Severity Score System (IHS4) response (at least 3-point reduction) at 3 to 5 months; secondary outcomes included IHS4 score reduction of 55% or more, IHS4 stage shift, pain numeric rating scale, flare-frequency and flare-duration responses, and patient-reported global improvement. Inverse probability of treatment weighting with doubly robust adjustment addressed allocation bias. Among 107 included patients, 51 (47.7%) were female and 56 (52.3%) were male; the mean (SD) age was 31.7 (9.5) years and the median (IQR) disease duration was 10 (6-16) years. A total of 52 underwent dose intensification and 50 received antibiotic addition. The mean (SD) IHS4 decreased from 7.0 (4.8) to 3.9 (4.2) at 3 to 5 months (P < .001), with 50 of 93 (53.8%) reaching IHS4 response, 50 of 99 (50.5%) a 55% or greater reduction in IHS4 score, 52 of 102 (51.0%) flare-frequency response, and 65 of 100 (65.0%) global improvement. An exploratory between-arm comparison showed a nominally significant signal favoring intensification on flare-duration response (odds ratio, 2.56; 95% CI, 1.07-6.11) that did not persist after multiplicity adjustment (adjusted P = .24). Improvement was sustained at 6 to 12 months in 65 patients. In this cohort of patients with HS who partially responded to biologics, a response-pattern-guided optimization framework was associated with clinically meaningful improvement across all prespecified outcomes. The end-of-dose effect may serve as a candidate phenotyping tool to guide optimization strategy selection, pending prospective confirmation.
中文摘要:接受已获批生物制剂治疗的化脓性汗腺炎(HS)患者中,多达一半仅获部分应答,后续管理尚无共识。常规实践采用剂量强化和长期加用抗生素,但其有效性的真实世界数据仍有限。评估以应答模式为指导的生物制剂优化框架在HS部分应答者中的作用。这项单中心回顾性队列研究于2022年1月至2025年3月在法国一家三级皮肤科中心开展。纳入对肿瘤坏死因子-α或白细胞介素17(IL-17)治疗应答不足的HS患者,即尽管接受至少3个月标准剂量生物制剂治疗,每年仍有至少4次发作。数据于2025年8月至10月分析。出现剂量末效应(下一次注射前疾病活动复发)的患者接受剂量强化(优化组,n=52);无此效应的患者按预设算法加用抗生素(联合组,n=50)。主要结局为3至5个月时国际化脓性汗腺炎严重程度评分系统(IHS4)应答(至少降低3分);次要结局包括IHS4评分降低55%或以上、IHS4分期变化、疼痛数字评分量表、发作频率应答、发作持续时间应答及患者报告的总体改善。采用逆概率治疗加权及双重稳健校正处理分配偏倚。107例纳入患者中,女性51例(47.7%),男性56例(52.3%);平均(SD)年龄31.7(9.5)岁,中位(IQR)病程10(6-16)年。52例接受剂量强化,50例接受加用抗生素。3至5个月时平均(SD)IHS4由7.0(4.8)降至3.9(4.2)(P<.001),93例中50例(53.8%)达到IHS4应答,99例中50例(50.5%)IHS4评分降低55%或以上,102例中52例(51.0%)达到发作频率应答,100例中65例(65.0%)达到总体改善。探索性组间比较显示,在发作持续时间应答方面存在名义显著信号支持剂量强化(比值比2.56;95%CI 1.07-6.11),多重性校正后不再持续(校正P=.24)。65例患者在6至12个月时改善得以维持。在这组对生物制剂部分应答的HS患者中,应答模式指导的优化框架与所有预设结局的临床有意义改善相关。剂量末效应可能作为候选表型工具指导优化策略选择,尚待前瞻性研究确认。
Ovarian carcinoma is the most lethal gynecologic malignancy, with a 5-year survival rate for advanced patients that has remained stubbornly low due to high recurrence and acquired drug resistance. Despite advances in surgery and chemotherapy, a critical gap remains in translating an understanding of the tumor's complex molecular heterogeneity into effective, durable treatments. This review systematically dissects the latest advances in key signaling pathways driving ovarian carcinoma pathogenesis, including the Notch, HER2, DNA damage repair (DDR), PI3K/AKT/mTOR, and angiogenesis (VEGF) pathways, and critically evaluates the clinical progress of corresponding targeted therapies. We particularly focus on the regulatory networks within the tumor microenvironment and the mechanisms of crosstalk between pathways that contribute to treatment resistance. The review synthesizes clinical study outcomes for novel agents such as PARP inhibitors (olaparib and niraparib), antibody-drug conjugates (e.g., T-DXd), and anti-angiogenic therapies (bevacizumab), while analyzing the challenges of primary and acquired resistance. By bridging fundamental pathway biology with emerging clinical data, this review provides a strategic framework for advancing precision medicine and developing rational combination therapies to improve outcomes for patients with this devastating disease.
中文摘要:卵巢癌是致死率最高的妇科恶性肿瘤,晚期患者因高复发率和获得性耐药,5年生存率长期停滞在较低水平。手术与化疗虽有进展,但把对肿瘤复杂分子异质性的认识转化为有效且持久的治疗,仍存在关键缺口。本综述系统梳理驱动卵巢癌发病的关键信号通路研究进展,包括Notch、HER2、DNA损伤修复(DDR)、PI3K/AKT/mTOR及血管生成(VEGF)通路,并对相应靶向治疗的临床进展作批判性评估。重点讨论肿瘤微环境内的调控网络,以及通路间交互作用促成治疗耐药的机制。综述汇总PARP抑制剂(奥拉帕利、尼拉帕利)、抗体偶联药物(如T-DXd)与抗血管生成治疗(贝伐珠单抗)等新型药物的临床研究结果,同时分析原发性和获得性耐药的难题。通过衔接基础通路生物学与新兴临床数据,本综述为推进精准医学、发展合理的联合治疗策略以改善这类高致死性疾病患者的结局提供策略框架。
Immune checkpoint inhibitor (ICI) therapy has transformed melanoma treatment, yet many patients either fail to respond or develop resistance after an initial response. The cellular and spatial determinants within the tumor microenvironment (TME) that underlie these divergent ICI therapy outcomes remain poorly defined. Here, we aimed to characterize the immune composition and spatial organization of the TME associated with ICI response and resistance. We integrated public scRNA-seq data (N = 32) with in-house spatial transcriptomics and imaging mass cytometry from an independent melanoma cohort (N = 6) to achieve high-resolution spatial profiling of the TME. This multimodal approach allowed us to map cellular heterogeneity within discrete spatial neighborhoods. To validate our findings, we constructed a scRNA-seq derived signature-matrix and deconvoluted a bulk RNA-seq cohort (N = 334). Clinical associations were assessed using Kaplan-Meier survival analysis, Cox hazard models, and a machine-learning classifier. We identified a distinct tumor-associated macrophage (TAM) state, termed lipid-associated TAMs (LA-TAMs), characterized by conserved lipid metabolic programs and tumor-specific adaptations in glycolysis under hypoxic conditions. Deep spatial multi-omics profiling revealed divergent immune architectures associated with treatment outcomes. In non-responder patients, LA-TAMs colocalized with sparsely distributed TIM3⁺ exhausted CD8⁺ T cells within an immune-excluded TME. In contrast, responder patients harbored interferon-primed CCL4+ TAMs (IFN-TAMs) spatially associated with Granzyme B⁺ activated CD8⁺ T cells, reflecting an immune-active microenvironment. These findings define contrasting macrophage-centered immune neighborhoods linked to ICI response. Interestingly, patients with LA-TAM-enriched neighborhoods were consistently non-responders or progressed during follow-up, irrespective of the presence of IFN-TAM neighborhoods. Lastly, we constructed a single-cell-derived signature matrix that estimates TAM fractions from bulk RNA-seq data and revealed LA-TAM abundance as a robust, independent predictor of poor ICI response and survival in a validation cohort. Our study defines the spatial landscapes of TAM-heterogeneity in melanoma and identifies LA-TAM neighborhoods as an important feature of ICI resistance. Although patients span a continuum of TAM-centered immune states, the presence of LA-TAM is likely to diminish the beneficial effects of IFN-TAM-associated immune activation. Finally, our proposed Melanoma-TME-derived signature-matrix provides a translatable framework to robustly predict ICI response and resistance.
中文摘要:免疫检查点抑制剂(ICI)治疗改变了黑色素瘤的治疗格局,但仍有不少患者初始无应答,或在初始应答后出现耐药。肿瘤微环境(TME)中导致这些不同ICI治疗结局的细胞与空间决定因素仍不明确。为刻画与ICI应答和耐药相关的TME免疫组成及空间组织,整合了公开单细胞RNA测序数据(32例)与独立黑色素瘤队列(6例)的内部空间转录组和成像质谱流式数据,对TME进行高分辨率空间分析。多模态方法可在离散空间邻域内绘制细胞异质性。为验证发现,构建了单细胞RNA测序来源的特征矩阵,并对一个批量RNA测序队列(334例)进行去卷积。临床关联通过Kaplan-Meier生存分析、Cox风险模型和机器学习分类器评估。识别出一种独特的肿瘤相关巨噬细胞(TAM)状态,称为脂质相关TAM(LA-TAM),其特征为保守的脂质代谢程序以及缺氧条件下肿瘤特异性的糖酵解适应。深度空间多组学分析显示,与治疗结局相关的免疫结构存在差异。在无应答患者中,LA-TAM与稀疏分布的TIM3阳性耗竭CD8阳性T细胞共定位,处于免疫排斥型TME内。相反,应答患者具有干扰素预激活的CCL4阳性TAM(IFN-TAM),其与颗粒酶B阳性活化CD8阳性T细胞在空间上相关,反映免疫活跃的微环境。这些发现界定了与ICI应答相关的、以巨噬细胞为中心的对比性免疫邻域。LA-TAM富集邻域的患者在随访中始终为无应答或发生进展,与是否存在IFN-TAM邻域无关。最后,构建的单细胞来源特征矩阵可从批量RNA测序数据估计TAM比例,并显示LA-TAM丰度是验证队列中ICI应答不佳和生存不良的稳健独立预测因子。该研究描绘了黑色素瘤中TAM异质性的空间图谱,并将LA-TAM邻域确定为ICI耐药的重要特征。患者虽跨越以TAM为中心的连续免疫状态,LA-TAM的存在可能削弱IFN-TAM相关免疫激活带来的有益效应。所提出的黑色素瘤TME来源特征矩阵为稳健预测ICI应答和耐药提供了可转化的框架。
Amsokigene autoleucel (amsoki-cel, OBX-115) is a tumor-infiltrating lymphocyte (TIL) cell therapy engineered to express acetazolamide (ACZ)-regulatable membrane-bound interleukin-15, abrogating the need for interleukin-2. In two single-arm trials (completed phase 1 single-center first-in-human (FIH) and ongoing phase 1/2 multicenter Agni-01), patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma received lymphodepletion and varying doses and schedules of amsoki-cel and ACZ. The primary objective of FIH and Agni-01 phase 1 was safety, tolerability and recommended phase 2 dose (RP2D); the primary objective of Agni-01 phase 2 was objective response rate (ORR) at the RP2D. The first patient treated experienced rapid lymphocyte expansion and vasogenic edema of a previously irradiated brain metastasis, prompting protocol modifications and dose deescalation in FIH, including 80% reduction in maximum amsoki-cel dose and 75% reduction in ACZ dose. After preliminary demonstration of safety at the lower dose, doses were increased in FIH, and reescalation was initiated in Agni-01. Across studies, 37 patients were treated (FIH, n = 17; Agni-01, n = 20). Post hoc pooled analysis demonstrated no dose-limiting toxicities, ICU care or treatment-related mortality. Most common grade 3 or higher treatment-emergent adverse events (TEAEs) included neutropenia (64.9% (24/37)), leukopenia/lymphopenia (56.8% (21/37) each) and anemia/thrombocytopenia (37.8% (14/37) each). Serious TEAEs were reported for 10 patients, including eight patients with grade 3 or higher events (non-hematologic, 13.5% (5/37); hematologic, 13.5% (5/37)). RP2D was selected based on overall safety and tolerability as well as preliminary anti-tumor activity in Agni-01 phase 1. The phase 2 preliminary ORR was 66.7% (6/9). In total, 15 patients were treated at RP2D and comprise the Key Efficacy Set (Agni-01: phase 1, n = 6; phase 2, n = 9), of which 10 patients (66.7%; 95% confidence interval 38-88%) achieved objective responses (including two complete responses). Amsoki-cel demonstrated favorable safety and promising early clinical activity in patients with ICI-resistant melanoma. A separate phase 2 pivotal Agni-01 cohort is ongoing. ClinicalTrials.gov identifiers: NCT05470283 and NCT06060613 .
中文摘要:Amsokigene autoleucel(amsoki-cel,OBX-115)是一种肿瘤浸润淋巴细胞(TIL)细胞疗法,经工程化表达乙酰唑胺(ACZ)可调控的膜结合白细胞介素-15,从而无需白细胞介素-2。两项单臂试验(已完成的一期单中心首次人体FIH试验和正在进行的1/2期多中心Agni-01试验)中,对免疫检查点抑制剂(ICI)耐药的晚期黑色素瘤患者接受淋巴细胞清除以及不同剂量和方案的amsoki-cel与ACZ。FIH和Agni-01 1期主要目标为安全性、耐受性和推荐2期剂量(RP2D);Agni-01 2期主要目标为RP2D下的客观缓解率(ORR)。首例接受治疗患者出现快速淋巴细胞扩增和既往照射脑转移灶的血管源性水肿,促使FIH方案修改和剂量降阶,包括amsoki-cel最高剂量降低80%、ACZ剂量降低75%。在较低剂量初步显示安全性后,FIH中剂量增加,Agni-01重新升阶。跨研究共37例患者接受治疗(FIH,n=17;Agni-01,n=20)。事后汇总分析显示无剂量限制性毒性、ICU治疗或治疗相关死亡。最常见3级及以上治疗中出现的不良事件(TEAE)包括中性粒细胞减少(64.9%(24/37))、白细胞减少/淋巴细胞减少(各56.8%(21/37))和贫血/血小板减少(各37.8%(14/37))。10例患者报告严重TEAE,其中8例为3级及以上事件(非血液学,13.5%(5/37);血液学,13.5%(5/37))。RP2D根据总体安全性、耐受性及Agni-01 1期初步抗肿瘤活性选择。2期初步ORR为66.7%(6/9)。共有15例患者在RP2D接受治疗并构成关键疗效集(Agni-01:1期,n=6;2期,n=9),其中10例(66.7%;95%置信区间38-88%)达到客观缓解(包括2例完全缓解)。Amsoki-cel在ICI耐药黑色素瘤患者中显示出良好安全性和有前景的早期临床活性。一项独立的2期关键性Agni-01队列正在进行。ClinicalTrials.gov注册号:NCT05470283和NCT06060613。
The prognostic significance of programmed death-ligand 1 (PD-L1) in high-grade serous ovarian cancer (HGSOC) remains uncertain, because of heterogeneity in assays, scoring systems, and assessment of tumor and immune compartments across studies. We therefore evaluated its biological and prognostic relevance using a standardized pathological approach in a large, well-annotated phase III trial cohort. In this ancillary retrospective biomarker analysis of PAOLA-1/ENGOT-ov25, PD-L1 was assessed by 22C3 pharmDx immunohistochemistry on whole-slide sections from 324 International Federation of Gynecology and Obstetrics stage III-IV HGSOCs. Three predefined scoring systems commonly used in PD-L1 assessment were applied: tumor proportion score (TPS ≥1%), immune cell score (IC ≥1%), and combined positive score (CPS ≥1). Associations with homologous recombination deficiency (HRD), BRCA1/2 status, and survival were examined using multivariable Cox models adjusted for major clinicopathological factors. PD-L1 positivity was observed in 38.2% of tumors by TPS, 62.4% by IC, and 66.1% by CPS. Positivity did not significantly vary by sampling site or timing of tissue collection relative to chemotherapy. PD-L1 positivity was enriched in HRD-positive tumors (TPS: 42.3% versus 28.0%, P = 0.017; IC: 65.1% versus 52.0%, P = 0.030; CPS: 70.4% versus 53.0%, P = 0.003) and remained independently associated with improved overall survival in adjusted analyses [TPS: adjusted hazard ratio (aHR) 0.70 (95% confidence interval 0.49-1.00), P = 0.046; IC: aHR 0.68 (0.49-0.95), P = 0.025; CPS: aHR 0.70 (0.50-0.97), P = 0.037]. Associations with progression-free survival were not statistically significant after adjustment. In advanced HGSOC, standardized whole-slide PD-L1 assessment identifies an HRD-associated PD-L1-positive immune context independently associated with improved overall survival. Immune-integrated scoring approaches capture this signal more effectively than tumor-cell-restricted assessment and provide a robust framework for future ovarian cancer studies.
中文摘要:程序性死亡配体1(PD-L1)在高级别浆液性卵巢癌(HGSOC)中的预后意义仍不确定,原因包括检测方法、评分系统以及对肿瘤和免疫细胞区域评估的差异。研究在一个样本量大、注释完善的III期试验队列中,采用标准化病理方法评估其生物学和预后相关性。这项PAOLA-1/ENGOT-ov25的回顾性生物标志物辅助分析纳入324例国际妇产科联盟III-IV期HGSOC,采用22C3 pharmDx免疫组化在全切片标本上评估PD-L1。应用三种预先设定且常用于PD-L1评估的评分系统:肿瘤比例评分(TPS ≥1%)、免疫细胞评分(IC ≥1%)和联合阳性评分(CPS ≥1%)。采用校正主要临床病理因素的多变量Cox模型分析其与同源重组缺陷(HRD)、BRCA1/2状态和生存的关系。PD-L1阳性率按TPS为38.2%,按IC为62.4%,按CPS为66.1%。阳性率未随取样部位或组织采集相对于化疗的时间而显著变化。PD-L1阳性在HRD阳性肿瘤中更常见(TPS:42.3%对28.0%,P=0.017;IC:65.1%对52.0%,P=0.030;CPS:70.4%对53.0%,P=0.003),并在校正分析中仍与总生存改善独立相关(TPS:校正风险比aHR 0.70,95%置信区间0.49-1.00,P=0.046;IC:aHR 0.68,0.49-0.95,P=0.025;CPS:aHR 0.70,0.50-0.97,P=0.037)。校正后与无进展生存的关联无统计学意义。在晚期HGSOC中,标准化全切片PD-L1评估识别出一种与HRD相关的PD-L1阳性免疫背景,该背景与总生存改善独立相关。整合免疫的评分方法比仅限肿瘤细胞的评估更能捕捉这一信号,并为未来卵巢癌研究提供了可靠框架。
Prostate cancer frequently metastasizes to bone, marking incurable disease. This progression is driven by an immunologically cold bone tumor microenvironment that fosters resistance to therapy. To define the mechanisms underlying this uniquely immunosuppressive niche, we applied spatial single-cell analyses across primary tumors and metastatic sites. Bone metastases showed marked suppression of tumor-intrinsic type I interferon (IFN-I) signaling and loss of antigen presentation, features that were strongly associated with reduced bone metastasis-free survival. Tumor-intrinsic IFN-I expression correlated with memory T-cell infiltration, whereas the bone myeloid compartment was enriched for protumor macrophages and showed reduced dendritic cell activation and antigen presentation. Digital spatial profiling of matched tumors revealed a broad loss of IFN-I-regulated immunostimulatory and checkpoint molecules. Notably, B7-H3, a putative negative regulator of IFN-I, was highly expressed in bone metastases and inversely associated with antigen presentation. These findings define bone-specific mechanisms of immune resistance and highlight therapeutic vulnerabilities that could inform precision therapeutic strategies for prostate cancer. Prostate cancer bone metastases establish a tumor-driven, immunosuppressive niche featuring global impairment of IFN-I signaling and antigen presentation coupled to elevated B7-H3, highlighting clinically actionable vulnerabilities in advanced prostate cancer.
中文摘要:前列腺癌常转移至骨,标志疾病进入不可治愈阶段。这一进展由免疫学上偏冷的骨肿瘤微环境驱动,该微环境促进治疗耐药。为明确这一独特免疫抑制微环境背后的机制,我们在原发肿瘤和转移部位开展了空间单细胞分析。骨转移灶显示肿瘤内在I型干扰素(IFN-I)信号显著受抑以及抗原提呈缺失,这些特征与无骨转移生存期缩短强相关。肿瘤内在IFN-I表达与记忆T细胞浸润相关,而骨转移髓系细胞区室富集促肿瘤巨噬细胞,并显示树突状细胞活化及抗原提呈减少。对配对肿瘤的数字空间分析显示,IFN-I调控的免疫刺激分子和检查点分子广泛缺失。B7-H3作为IFN-I的假定负调控因子,在骨转移灶中高表达,且与抗原提呈呈负相关。这些发现明确了骨特异性免疫抵抗机制,并提示可用于指导前列腺癌精准治疗策略的治疗脆弱点。前列腺癌骨转移建立了一个由肿瘤驱动的免疫抑制微环境,其特征为IFN-I信号和抗原提呈全面受损,并伴有B7-H3升高,突显了晚期前列腺癌中具有临床可操作性的脆弱点。
Preoperative immune checkpoint inhibitors (ICIs) are active in patients with deficient mismatch repair (dMMR) colon cancer (CC), whereas proficient mismatch repair (pMMR) CC has been consistently considered resistant to first-generation ICIs. In the phase 2 UNICORN trial, we evaluated short-course preoperative botensilimab (BOT; multifunctional Fc-enhanced anti-CTLA-4 monoclonal antibody) alone or in combination with the anti-PD-1 monoclonal antibody balstilimab (BOT + BAL) in 56 patients with resectable, locally advanced CC. Twenty-eight patients with pMMR CC were sequentially enrolled in BOT (n = 14) and BOT + BAL (n = 14) cohorts. Twenty-eight patients with dMMR CC followed the same sequential allocation strategy. The primary endpoint of centrally assessed pathological major response (pMR) rate (≤10% of residual viable tumor) was met in all cohorts, except pMMR BOT. Specifically, the pMR rate was 0% (95% confidence interval (CI): 0-23.2%) in pMMR BOT, 36% (95% CI: 12.8-64.9%) in pMMR BOT + BAL, 36% (95% CI: 12.8-64.9%) in dMMR BOT and 100% (95% CI: 76.8-100%) in dMMR BOT + BAL. Secondary endpoints included safety, quality of life, describing treatment-induced transcriptional dynamics, peripheral blood mononuclear cell dynamics, radiomics and radiogenomics features, fecal microbiota composition and circulating tumor DNA (ctDNA) dynamics. Eight (29%) and 15 (54%) patients treated with BOT and BOT + BAL, respectively, experienced immune-related adverse events, most commonly flu-like syndrome and diarrhea. Single-cell spatial transcriptomic analysis of matched baseline and post-treatment samples highlighted high baseline PD-L1 stromal expression and low post-treatment regulatory T cell signatures in pMMR responders, whereas dMMR responders displayed high baseline FCGR2A and FCGR3A expression on intratumoral macrophages. Clearance of ctDNA before surgery correlated with pathological response and lack of recurrence at data cutoff. Preoperative BOT + BAL elicits pathological responses in patients with pMMR or dMMR CC, supporting the combination as a promising strategy to expand ICI benefits to the early-stage setting. ClinicalTrials.gov identifier: NCT05845450 .
中文摘要:术前免疫检查点抑制剂(ICI)在错配修复缺陷(dMMR)结肠癌(CC)患者中具有活性,而错配修复完整(pMMR)结肠癌一直被认为对第一代ICI耐药。2期UNICORN试验评估了短程术前botensilimab(BOT;一种多功能Fc增强型抗CTLA-4单克隆抗体)单药或联合抗PD-1单克隆抗体balstilimab(BOT+BAL)用于56例可切除局部晚期结肠癌患者。28例pMMR结肠癌患者按顺序进入BOT(n=14)和BOT+BAL(n=14)队列。28例dMMR结肠癌患者采用相同的顺序分配策略。主要终点为中心评估的主要病理缓解(pMR)率(残留存活肿瘤≤10%),除pMMR BOT队列外,各队列均达到主要终点。具体而言,pMR率在pMMR BOT为0%(95%置信区间(CI):0-23.2%),在pMMR BOT+BAL为36%(95% CI:12.8-64.9%),在dMMR BOT为36%(95% CI:12.8-64.9%),在dMMR BOT+BAL为100%(95% CI:76.8-100%)。次要终点包括安全性、生活质量、治疗诱导的转录动态、外周血单核细胞动态、影像组学和影像基因组学特征、粪便微生物组成以及循环肿瘤DNA(ctDNA)动态。接受BOT和BOT+BAL治疗的患者中分别有8例(29%)和15例(54%)发生免疫相关不良事件,最常见为流感样综合征和腹泻。对匹配的基线和治疗后样本进行单细胞空间转录组分析显示,pMMR缓解者基线PD-L1基质表达高、治疗后调节性T细胞特征低,而dMMR缓解者基线肿瘤内巨噬细胞FCGR2A和FCGR3A表达高。术前ctDNA清除与病理缓解及数据截止时无复发相关。术前BOT+BAL在pMMR或dMMR结肠癌患者中均可产生病理缓解,支持该联合方案作为将ICI获益扩展至早期治疗阶段的有前景策略。ClinicalTrials.gov标识符:NCT05845450。
Despite advances in checkpoint inhibitor (CPI) therapy, a substantial proportion of patients with advanced melanoma experience disease progression, and the capacity of CD8+ cytotoxic T lymphocytes (CTLs) specific for wild-type melanoma-associated antigens to persist and remain functionally inducible after CPI failure is poorly understood. Here we report exploratory translational analyses from the BP41054 Phase I trial investigating the combination of simlukafusp alfa (FAP-IL2v), a tumor stroma-targeted IL-2 variant, with pembrolizumab in CPI-experienced patients with advanced melanoma. Methods Peripheral blood mononuclear cells from a subset of 33 CPI-experienced patients were profiled at baseline (C1D1_pre) and on treatment (C2D8) using quantitative immunophenotyping and a panel of 28 melanoma-associated peptide–HLA tetramers spanning 14 antigens and multiple HLA alleles. Antigen-specific CTLs were further characterized functionally by ex vivo peptide challenge and interferon (IFN)-γ intracellular staining. Associations with progression-free survival (PFS) were assessed as exploratory endpoints. Treatment was associated with increased circulating natural killer cells and CD8+ T cells, including effector memory and terminally differentiated effector subsets, as assessed in peripheral blood. CTLs specific for 11 unique peptide-major histocompatibility complexes were identified, with increased frequencies detected during treatment in a subset of patients. These antigen-specific CTLs demonstrated functional activity as indicated by IFN-γ production on peptide challenge, though responses were variable across peptide specificities and patients, and direct cytotoxic activity was not assessed. Signs of incomplete functional rescue, including persistent co-expression of exhaustion markers, were observed. In exploratory descriptive analyses, patients whose antigen-specific CTL diversity increased on treatment had a longer median PFS than those in whom diversity was reduced; with three patients per group, these outcomes are reported descriptively, without formal statistical comparison. Baseline melanoma-associated immunity did not predict clinical outcome. These hypothesis-generating findings indicate that melanoma-specific CD8+ T-cell immunity persists and remains inducible in CPI-experienced patients, supporting the rationale for strategies that re-engage residual antitumor immunity. Validation in larger cohorts with paired tumor and blood sampling will be required to establish clinical relevance.
中文摘要:尽管免疫检查点抑制剂(CPI)治疗取得进展,仍有相当比例的晚期黑色素瘤患者出现疾病进展,而针对野生型黑色素瘤相关抗原的CD8+细胞毒性T淋巴细胞(CTL)在CPI治疗失败后能否持续存在并保持功能可诱导性,仍知之甚少。BP41054 I期试验的探索性转化分析评估simlukafusp alfa(FAP-IL2v,一种靶向肿瘤基质的IL-2变体)联合pembrolizumab用于既往CPI治疗后进展的晚期黑色素瘤患者。方法:对33例CPI经治患者亚组的外周血单个核细胞,在基线(C1D1_pre)和治疗期间(C2D8)采用定量免疫表型分析及涵盖14种抗原和多个HLA等位基因的28种黑色素瘤相关肽-HLA四聚体检测组合进行分析。通过离体肽刺激和干扰素(IFN)-γ胞内染色进一步表征抗原特异性CTL的功能。以探索性终点评估其与无进展生存期(PFS)的关联。外周血评估显示,治疗与循环自然杀伤细胞和CD8+ T细胞增加相关,包括效应记忆和终末分化效应亚群。鉴定出针对11种独特肽-主要组织相容性复合体的CTL,部分患者治疗期间检测到其频率增加。这些抗原特异性CTL在肽刺激后产生IFN-γ,表明具有功能活性,但不同肽特异性和患者间反应存在差异,且未评估直接细胞毒活性。观察到功能挽救不完全的迹象,包括耗竭标志物持续共表达。在探索性描述分析中,治疗期间抗原特异性CTL多样性增加的患者中位PFS长于多样性降低者;每组3例患者,这些结果仅作描述性报告,未进行正式统计比较。基线黑色素瘤相关免疫未预测临床结局。这些产生假设的发现表明,黑色素瘤特异性CD8+ T细胞免疫在CPI经治患者中持续存在并仍可被诱导,支持重新调动残余抗肿瘤免疫策略的依据。需在更大队列中结合配对的肿瘤和血液采样进行验证,以确立临床相关性。
The coexistence of chronic obstructive pulmonary disease (COPD) and lung cancer (LC) presents a complex clinical scenario with distinct pathological interactions. Beyond shared epidemiological and genetic risk factors, COPD reshapes the pulmonary immune microenvironment through reprogrammed immune-cell compartments, aberrant programmed cell death, and epithelial-mesenchymal transition (EMT), fostering an immunologically "hot" but pathologically permissive milieu that simultaneously drives carcinogenesis and influences treatment responsiveness. Recent evidence suggests that COPD may confer an altered immunological microenvironment that paradoxically enhances responsiveness to immune checkpoint inhibitors (ICIs) in patients with LC. This review mainly synthesizes clinical evidence on the efficacy of ICI, currently the most widely used immunotherapy, in LC patients concomitant with COPD and elucidates potential immunological and molecular mechanisms underlying observed clinical benefits, including heightened programmed cell death protein ligand 1 (PD-L1) expression, elevated tumor mutational burden, increased human leukocyte antigen I (HLA-I) expression, enriched tissue-resident memory T cells and mucosal-associated invariant T cells, and a macrophage polarization shift toward a pro-inflammatory phenotype, with benefits appearing largely attributable to patients with mild-to-moderate airflow obstruction. The safety profile of ICIs in this population-exacerbation risk, eosinophilic airway disease, checkpoint inhibitor pneumonitis (CIP), and autoimmune thyroiditis-is appraised, alongside emerging strategies such as lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and T cell immunoreceptor with Ig and ITIM domains (TIGIT) blockade and the immunomodulatory potential of COPD medications (inhaled corticosteroids and long-acting β-agonists). Current evidence remains limited by small retrospective cohorts and heterogeneous stratification. Large-scale prospective studies are warranted. This review aims to clarify the prognostic value of concomitant COPD and guide precision therapeutic strategies for this growing comorbid population.
中文摘要:慢性阻塞性肺疾病(COPD)与肺癌(LC)共存构成复杂的临床情境,并伴随独特的病理相互作用。除共同的流行病学和遗传风险因素外,COPD通过免疫细胞区室重编程、异常程序性细胞死亡及上皮-间质转化(EMT)重塑肺部免疫微环境,形成免疫学上「热」但病理上允许性的环境,既驱动癌变,也影响治疗反应。近期证据提示,COPD可能带来改变的免疫微环境,反而增强肺癌患者对免疫检查点抑制剂(ICI)的反应。本综述主要汇总ICI这一目前最广泛使用的免疫治疗在合并COPD的肺癌患者中疗效的临床证据,并阐释观察到的临床获益背后的潜在免疫与分子机制,包括程序性细胞死亡蛋白配体1(PD-L1)表达升高、肿瘤突变负荷增加、人白细胞抗原I(HLA-I)表达增加、组织驻留记忆T细胞和黏膜相关恒定T细胞富集,以及巨噬细胞极化向促炎表型偏移;获益似乎主要见于轻至中度气流受限患者。文章评估ICI在该人群中的安全性特征,包括急性加重风险、嗜酸性气道疾病、检查点抑制剂肺炎(CIP)和自身免疫性甲状腺炎,并讨论淋巴细胞活化基因3(LAG-3)、T细胞免疫球蛋白及黏蛋白结构域包含蛋白3(TIM-3)和T细胞免疫受体含Ig及ITIM结构域(TIGIT)阻断等新兴策略,以及COPD药物(吸入性糖皮质激素和长效β2受体激动剂)的免疫调节潜力。当前证据仍受小样本回顾性队列和分层异质性限制,需要大规模前瞻性研究。本综述旨在明确合并COPD的预后价值,并为这一不断增长的重症共病人群指导精准治疗策略。
Separate phase III trials of the anti-B7-H3 antibody-drug conjugates tambotatug pelitecan and risvutatug rezetecan significantly improved overall survival, progression-free survival, and objective response rates compared with topotecan in patients with relapsed small-cell lung cancer. In a third trial, the combination of the investigational PD-L1 x VEGF-A bispecific antibody pumitamig plus the anti-B7-H3 ADC elfetabart drozuntecan showed encouraging early efficacy in SCLC across lines of therapy and doses. The studies were presented at the 2026 World Congress on Lung Cancer in Seoul, Republic of Korea.
中文摘要:两项分别开展的III期试验显示,抗B7-H3抗体偶联药物tambotatug pelitecan与risvutatug rezetecan相较拓扑替康,在复发小细胞肺癌患者中显著改善总生存期、无进展生存期和客观缓解率。第三项试验中,在研PD-L1×VEGF-A双特异性抗体pumitamig联合抗B7-H3抗体偶联药物elfetabart drozuntecan,在跨治疗线数和跨剂量的小细胞肺癌中显示出令人鼓舞的早期疗效。这些研究在韩国首尔举行的2026年世界肺癌大会上公布。
Real-world data suggest that SARS-CoV-2 mRNA vaccines, administered within 100 days of immune checkpoint inhibitor (ICI) treatment ("peri-ICI vaccination"), may improve ICI effectiveness through synergistic immune priming. In an independent real-world cohort and reanalysis of a published cohort, both from tertiary cancer centers in the United States, multiple analyses did not support a treatment-synergy hypothesis. Applying a prior analytic framework, although longer survival with peri-ICI vaccination was observed at the start of the pandemic, this association was not seen in periods when vaccination was broadly available. Longer survival with vaccination in the early pandemic was also not specific to ICI therapies. Progression-free survival during periods of high vaccine uptake was not longer than in prevaccination periods. Together, these findings indicate that the previously reported vaccination survival advantage is largely explained by selection bias, with patients who had more favorable prognoses more likely to receive the SARS-CoV-2 vaccination, particularly in the early pandemic. The impact of tumor antigen-agnostic vaccination on immunotherapy response is unclear. In a reanalysis of published data and in an independent cohort, after adjustment for multiple confounders, SARS-CoV-2 mRNA vaccination did not improve immunotherapy-related survival in patients with cancer.
中文摘要:真实世界数据提示,在免疫检查点抑制剂(ICI)治疗前后100天内接种SARS-CoV-2 mRNA疫苗(围ICI接种)可能通过协同免疫启动提高ICI疗效。研究在美国两家三级癌症中心的独立真实世界队列及对已发表队列的再分析中开展多项分析,结果均不支持治疗协同假说。沿用既往分析框架,尽管在大流行初期观察到围ICI接种者生存期更长,但在疫苗广泛可及的时期未见该关联;大流行早期接种与更长生存的关联也并非ICI治疗所特有。疫苗高接种率时期的无进展生存期并不长于接种前时期。这些发现表明,既往报道的接种生存优势在很大程度上可由选择偏倚解释,预后更好的患者更可能接种SARS-CoV-2疫苗,尤其在大流行早期。肿瘤抗原非特异性疫苗接种对免疫治疗反应的影响仍不明确。在对已发表数据的再分析及独立队列中,调整多种混杂因素后,SARS-CoV-2 mRNA疫苗接种并未改善癌症患者与免疫治疗相关的生存。
The combination of immune checkpoint inhibitors and antiangiogenic agents has demonstrated a synergistic antitumor effect in numerous solid tumors, but has rarely been investigated in pulmonary sarcomatoid carcinoma (PSC). We assessed the activity and safety of camrelizumab (a programmed cell death-1 inhibitor) plus famitinib (an antiangiogenic agent) in patients with PSC. CAPSTONE is an open-label, single-arm, Simon two-stage, phase 2 trial done at eight sites in China. Eligible patients were aged between 18 and 75 years and had previously untreated stage IIIB-IV pulmonary sarcomatoid carcinoma, an Eastern Cooperative Oncology Group performance status of 0 or 1, and at least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients received intravenous camrelizumab 200 mg every 3 weeks and oral famitinib 20 mg once daily until disease progression or intolerable toxicity. The primary endpoint was confirmed objective response rate (ORR) as per RECIST version 1.1 in the full analysis set, which included all patients who received at least one dose of study drug. Safety was assessed in all as-treated patients. This study is registered at ClinicalTrials.gov, NCT04888429, and enrollment is complete. Between August 4, 2021 and March 21, 2024, 28 patients were enrolled. With a median follow-up of 18.1 months, the confirmed ORR was 42.9% (95% confidence interval [CI] 24.5-62.8). The disease control rate was 85.7% (95% CI 67.3-96.0). The median duration of response was 16.0 months (95% CI 5.0-29.9); the median progression-free survival was 7.1 months (95% CI 3.5-12.5); and the median overall survival was 18.1 months (95% CI 10.3-28.1). Treatment-related adverse events (TRAEs) of grade 3 or more were observed in 10 (35.7%) patients, the most common being decreased platelet count (four [14.3%]) and decreased neutrophil count (three [10.7%]). Three (10.7%) patients discontinued camrelizumab, and three (10.7%) discontinued famitinib due to TRAEs. Two patients died of unknown cause, which were assessed by the investigator as possibly related to study treatment. Camrelizumab plus famitinib showed antitumor activity in patients with locally advanced or metastatic PSC. This combination may be a potential first-line option for this patient population, and warrants further investigation in a large-sample trial. National Science and Technology Major Project of the Ministry of Science and Technology of China (No. 2024ZD0519700), National Natural Science Foundation of China (62131009, 82472969), Innovation Research Group Program of the Natural Science Foundation of Hubei Province (2026AFA036), Hubei Provincial Health Science and Technology Innovation and Achievement Transformation Project, Jiangsu Hengrui Pharmaceuticals Co., Ltd.
中文摘要:免疫检查点抑制剂与抗血管生成药物联合在多种实体瘤中显示协同抗肿瘤作用,但在肺肉瘤样癌(PSC)中研究较少。评估卡瑞利珠单抗(程序性细胞死亡蛋白1抑制剂)联合法米替尼(抗血管生成药物)在PSC患者中的活性和安全性。CAPSTONE是一项在中国8个中心开展的开放标签、单臂、西蒙两阶段2期试验。入组患者年龄18至75岁,既往未接受治疗的IIIB-IV期肺肉瘤样癌,美国东部肿瘤协作组体能状态评分为0或1,且至少有一个按实体瘤疗效评价标准(RECIST)1.1版可测量病灶。患者接受静脉卡瑞利珠单抗200 mg每3周一次和口服法米替尼20 mg每日一次,直至疾病进展或出现不可耐受毒性。主要终点为全分析集(包括所有接受至少一剂研究药物的患者)中按RECIST 1.1版确认的客观缓解率(ORR)。安全性在所有接受治疗的患者中评估。本研究已在ClinicalTrials.gov注册,NCT04888429,入组已完成。2021年8月4日至2024年3月21日,共入组28例患者。中位随访18.1个月,确认的ORR为42.9%(95%置信区间[CI] 24.5-62.8)。疾病控制率为85.7%(95% CI 67.3-96.0)。中位缓解持续时间为16.0个月(95% CI 5.0-29.9);中位无进展生存期为7.1个月(95% CI 3.5-12.5);中位总生存期为18.1个月(95% CI 10.3-28.1)。10例(35.7%)患者发生3级及以上治疗相关不良事件(TRAE),最常见为血小板计数下降(4例[14.3%])和中性粒细胞计数下降(3例[10.7%])。3例(10.7%)患者因TRAE停用卡瑞利珠单抗,3例(10.7%)停用法米替尼。2例患者死因不明,研究者评估可能与研究治疗相关。卡瑞利珠单抗联合法米替尼在局部晚期或转移性PSC患者中显示出抗肿瘤活性。该联合方案可能成为该患者群体的一线选择,值得在更大样本试验中进一步研究。资助:中国科学技术部国家科技重大专项(No. 2024ZD0519700)、国家自然科学基金(62131009、82472969)、湖北省自然科学基金创新研究群体项目(2026AFA036)、湖北省卫生健康科技创新与成果转化项目、江苏恒瑞医药股份有限公司。
Data to guide use of anti-PD1 immunotherapy with pembrolizumab for gestational trophoblastic neoplasia (GTN) that is chemotherapy-resistant or in adjuvant settings are limited. We conducted an international retrospective study of pembrolizumab in GTN, including patients with ultra-high-risk choriocarcinoma and poor-prognosis placental site and epithelioid trophoblastic tumors (PSTT/ETT), with up to 8 years of follow-up. We collected data on patients with GTN cases who received treatment with pembrolizumab between May 2015 and June 2023 from 20 centers in 16 countries. Cases were identified at Charing Cross Hospital, London; international centers with expertise in GTN were directly invited to identify and submit eligible cases treated during the study period. Clinical data were gathered from medical records using a standardized case-report form, curated centrally. Twenty-three samples were characterized by multiplex immunofluorescence, shallow whole-genome, and whole-transcriptome sequencing. We identified 76 patients with drug-resistant GTN treated with pembrolizumab. This included 60 (78.9%) patients with GTN and measurable disease. Complete response was achieved in 71.7% (n=43 of 60; 95% confidence interval [CI], 60.3 to 83.1). Two-year overall survival (OS) was 85.6% (95% CI, 76.7 to 95.4), with median follow-up from pembrolizumab initiation of 25.4 months (range, 1.4 to 95.7). Sixteen (21.1%) received adjuvant pembrolizumab instead of high-dose chemotherapy, of whom 15 had poor-prognosis PSTT/ETT. No deaths were observed with median follow-up of 33.1 months (range, 7.7 to 68.6) from first remission. There were no identified grade 4 or worse immune-related toxicities. On multiplex immunofluorescence, the median fluorescence intensity between-group difference in cancer cell HLA-G expression (responders minus nonresponders) was 0.6 (95% CI, 0.3 to 1.0). Shallow whole-genome and whole-transcriptome sequencing suggested low HLA-G expression could be due to transcriptional control. In this retrospective study without a control group, pembrolizumab was associated with durable responses in multidrug-resistant GTN and showed potential activity as adjuvant therapy for poor-prognosis PSTT/ETT. HLA-G expression warrants further exploration as a response biomarker. (Funded by Imperial College Experimental Cancer Medicine Centre and others.).
中文摘要:用于指导帕博利珠单抗抗PD-1免疫治疗化疗耐药或辅助治疗妊娠滋养细胞肿瘤(GTN)的数据有限。研究者开展了一项帕博利珠单抗治疗GTN的国际回顾性研究,纳入超高危绒毛膜癌及预后不良的胎盘部位滋养细胞肿瘤和上皮样滋养细胞肿瘤(PSTT/ETT)患者,随访最长8年。研究收集2015年5月至2023年6月在16个国家20个中心接受帕博利珠单抗治疗的GTN患者资料。病例由伦敦Charing Cross Hospital识别,并直接邀请具备GTN专长的国际中心识别和提交研究期间符合条件的病例。临床资料取自病历,使用标准化病例报告表并集中整理。对23份样本进行多重免疫荧光、浅层全基因组和全转录组测序分析。共识别76例接受帕博利珠单抗治疗的耐药GTN患者,其中60例(78.9%)有可测量病灶。完全缓解率为71.7%(60例中43例;95%置信区间[CI] 60.3至83.1)。2年总生存率为85.6%(95% CI 76.7至95.4),自帕博利珠单抗开始治疗起的中位随访时间为25.4个月(范围1.4至95.7)。16例(21.1%)接受辅助帕博利珠单抗而非大剂量化疗,其中15例为预后不良的PSTT/ETT。自首次缓解起中位随访33.1个月(范围7.7至68.6),未观察到死亡。未发现4级或更严重的免疫相关毒性。多重免疫荧光显示,癌细胞HLA-G表达的中位荧光强度组间差异(缓解者减未缓解者)为0.6(95% CI 0.3至1.0)。浅层全基因组和全转录组测序提示,HLA-G低表达可能源于转录调控。在这项无对照组的回顾性研究中,帕博利珠单抗与多药耐药GTN的持久缓解相关,并显示作为预后不良PSTT/ETT辅助治疗的潜在活性。HLA-G表达值得进一步探索为疗效生物标志物。(由Imperial College Experimental Cancer Medicine Centre等资助。)
Optimal patient selection for consolidative metastasis-directed radiotherapy (MDRT) after chemoimmunotherapy (CIT) remains uncertain in nasopharyngeal carcinoma (NPC) with exclusive distant metastasis, defined as distant metastasis without synchronous locoregional recurrence. This study was aimed at estimating the survival benefit of MDRT and identifying patients most likely to benefit. A total of 1083 patients from two independent centers were analyzed using a target trial emulation with cloning, artificial censoring, and inverse probability of censoring weighting. The emulation estimated a 4.2-month gain in 3-year progression-free survival (PFS) restricted mean survival time with the MDRT strategy (95% CI: 2.4-5.9; bootstrap p < 0.001). Eight survival machine-learning algorithms were developed and compared, among which the gradient boosting machine achieved 3-year PFS AUROCs of 0.875 in internal validation and 0.877 in geographical external validation. Heterogeneous treatment effects were further estimated using a T-learner framework across risk groups defined by recursive partitioning analysis. In the external cohort, model-estimated 3-year absolute risk reductions with MDRT were 21.6%, 14.7%, and 5.7% in intermediate-, low-, and high-risk groups, respectively. The framework was subsequently implemented as a web-based clinical decision-support system. These findings support individualized selection of consolidative MDRT after CIT and provide a practical framework for multidisciplinary decision-making.
中文摘要:在仅发生远处转移(无同步局部区域复发)的鼻咽癌中,化疗联合免疫治疗(CIT)后巩固性转移灶定向放疗(MDRT)的最佳患者选择仍不确定。本研究旨在评估MDRT的生存获益并识别最可能获益的患者。研究分析了来自两个独立中心的1083例患者,采用目标试验模拟,结合克隆、人工删失和逆概率删失加权。模拟结果显示,MDRT策略使3年无进展生存(PFS)限制性平均生存时间增加4.2个月(95% CI:2.4-5.9;自助法 p < 0.001)。研究开发并比较了八种生存机器学习算法,其中梯度提升机在内部验证和地理外部验证中的3年PFS AUROC分别为0.875和0.877。进一步在递归分割分析定义的风险组中,使用T-learner框架估计异质性治疗效应。在外部队列中,模型估计MDRT带来的3年绝对风险降低在中危、低危和高危组分别为21.6%、14.7%和5.7%。该框架随后被实现为基于网络的临床决策支持系统。这些发现支持CIT后巩固性MDRT的个体化选择,并为多学科决策提供了实用框架。
Lymph nodes (LNs), principal sites of antitumor immunity, may undergo immune-mediated regression; whether neoadjuvant chemoimmunotherapy (NCIT)-induced regression indicates prognosis in esophageal squamous cell carcinoma (ESCC) remains unclear. We aimed to establish and validate a lymph node regression grade (LNRG) system for prognostic stratification. This multicenter, retrospective cohort study analyzed 965 patients receiving PD-1-based NCIT and surgery at three Chinese tertiary cancer centers. LNRG was the ratio of summed viable tumor area to summed bed area (residual viable plus regressed preexisting tumor) across all dissected LNs. Negative LNs were assigned LNRG 0. Survival and predictive performance were assessed using Kaplan-Meier/Cox regression, time-dependent area under the curve, Brier score, net reclassification improvement, and integrated discrimination improvement. Overall, 28,882 LNs were evaluated; patients were classified as LNRG 0-4 in 385 (39.9%), 150 (15.5%), 26 (2.7%), 141 (14.6%), and 263 (27.3%), respectively. LNRG independently predicted disease-free and overall survival, with Grades 1-2 conferring the most favorable outcomes and Grade 4 the poorest. A random survival forest model incorporating LNRG, tumor regression grade, ypAJCC stage, and perineural invasion predicted 2-year disease-free survival in training and external validation cohorts. LNRG is a novel, independent prognostic indicator after NCIT.
中文摘要:淋巴结是抗肿瘤免疫的主要部位,可能发生免疫介导的退缩;新辅助化疗联合免疫治疗(NCIT)诱导的淋巴结退缩是否提示食管鳞状细胞癌(ESCC)预后仍不清楚。本研究旨在建立并验证用于预后分层的淋巴结退缩分级(LNRG)系统。这项多中心回顾性队列研究分析了中国三家三级肿瘤中心接受以PD-1为基础的NCIT并手术的965例患者。LNRG为所有清扫淋巴结中存活肿瘤面积总和与床面积总和(残留存活肿瘤加退缩的原有肿瘤)的比值。阴性淋巴结的LNRG记为0。采用Kaplan-Meier/Cox回归、时间依赖曲线下面积、Brier评分、净重分类改善和综合判别改善评估生存与预测性能。共评估28,882枚淋巴结;患者按LNRG 0-4分别有385例(39.9%)、150例(15.5%)、26例(2.7%)、141例(14.6%)和263例(27.3%)。LNRG可独立预测无病生存和总生存,1-2级预后最好,4级最差。纳入LNRG、肿瘤退缩分级、ypAJCC分期和神经周围侵犯的随机生存森林模型在训练队列和外部验证队列中预测2年无病生存。LNRG是NCIT后一种新的独立预后指标。
Neoadjuvant chemotherapy (NAC) is the standard treatment for locally advanced rectal cancer (LARC), yet its molecular determinants of response remain unclear. We conducted longitudinal 4D-DIA proteomic profiling of pre- and post-treatment specimens from 156 patients, including 31 patients with matched pre- and post-treatment specimens, and integrated with bulk RNA sequencing, single-cell transcriptomics, and functional validation. At baseline, responders were enriched in innate and adaptive immune pathways, whereas non-responders showed proliferative and metabolic programs. Pre-treatment RAC2, elevated in responders, was positively associated with immune activation, oxaliplatin sensitivity, and survival, and was validated in GSE139255 and GSE35640 (all P < 0.05). Moreover, RAC2 demonstrated strong predictive performance (training AUC = 0.867; testing AUC = 0.857). During treatment, NAC induced fibrosis-related remodeling across all groups (all P < 0.05), while responders uniquely preserved CD8⁺ T cell infiltration (P = 0.031). Responders and RAC2-high tumors exhibited concordant pathway dynamics during NAC. Single-cell analysis further revealed that pre-treatment tumor RAC2, higher in responders, transmitted signals to CD8⁺ T cells while receiving inputs from fibroblasts (P < 0.05). In vitro and in vivo, RAC2 knockdown reduced baseline tumor growth but promoted under oxaliplatin (all P < 0.05). Overall, this study offers proteomic insights into NAC in LARC, supports therapeutic decision-making, and identifies potential targets.
中文摘要:新辅助化疗(NAC)是局部晚期直肠癌(LARC)的标准治疗,但其疗效的分子决定因素仍不清楚。研究对156例患者治疗前、后标本进行纵向4D-DIA蛋白质组分析,其中31例有配对的治疗前后标本,并与bulk RNA测序、单细胞转录组和功能验证整合。基线时,应答者富集固有免疫和适应性免疫通路,非应答者表现为增殖和代谢程序。治疗前RAC2在应答者中升高,与免疫激活、奥沙利铂敏感性和生存正相关,并在GSE139255和GSE35640中得到验证(均P < 0.05)。RAC2显示出较强的预测性能(训练集AUC=0.867;测试集AUC=0.857)。治疗过程中,NAC在各组均诱导纤维化相关重塑(均P < 0.05),而应答者独特地保留了CD8⁺ T细胞浸润(P=0.031)。应答者和RAC2高表达肿瘤在NAC期间表现出一致的通路动态变化。单细胞分析进一步显示,治疗前肿瘤RAC2在应答者中较高,向CD8⁺ T细胞传递信号,同时接受来自成纤维细胞的信号输入(P < 0.05)。体外和体内实验中,敲低RAC2降低基线肿瘤生长,但在奥沙利铂处理下促进生长(均P < 0.05)。总体而言,该研究为LARC的NAC提供了蛋白质组学见解,支持治疗决策,并识别潜在靶点。
Resistance to BRAF/MEK inhibition remains the central therapeutic challenge in BRAF mutant melanoma. Although combined MAPK-targeted therapy induces rapid and often dramatic tumor responses, most patients ultimately develop progressive disease. Over the past decade, translational studies have fundamentally changed our understanding of this process. Resistance is now recognized not as a single genomic event, but as a biologically heterogeneous and adaptive phenomenon involving tumor cell plasticity, microenvironmental remodeling, and immune evolution. This evolving framework has important clinical implications. Recent randomized sequencing clinical trials have shifted treatment paradigms toward a front-line immune checkpoint blockade for many patients. Similarly, triplet approaches combining MAPK inhibition with immunotherapy have shown heterogenous results on progression-free survival benefit and durable overall survival benefits remain uncertain. At the same time, therapeutic options after progression are rapidly expanding and include ERK inhibitors, next-generation pan-RAF inhibitors, vertical pathway targeting strategies, and emerging approaches directed against persister-cell biology and adaptive resistance states. In this review, we integrate current insights from genomic, transcriptomic, single-cell, and spatial studies with the most relevant clinical trial data to provide a contemporary framework for understanding resistance to MAPK-targeted therapy in melanoma. We further discuss how adaptive monitoring approaches, including circulating tumor DNA analysis, may help guide future biomarker-driven and evolution-informed treatment strategies.Author names: Please confirm if the author names are presented accurately and in the correct sequence (given name, middle name/initial, family name). Author 1 Given name: [Turkan Ozturk] Last name [Topcu]. Also, kindly confirm the details in the metadata are correct. Please correct Author 1's name designation as follows: Given name: Turkan; Family name: Ozturk Topcu. Please update both the article and the metadata accordingly.Kindly check and confirm whether the organization division, organization name, street and postcode in affilition 3 has been processed correctly and amend if necessary.Corrected.
中文摘要:BRAF/MEK抑制耐药仍是BRAF突变黑色素瘤的核心治疗难题。MAPK靶向联合治疗虽能带来快速且常较显著的肿瘤应答,多数患者最终仍出现疾病进展。过去十年的转化研究根本改变了对这一过程的认识。如今耐药被视为涉及肿瘤细胞可塑性、微环境重塑和免疫演化的生物学异质性适应现象,而非单一基因组事件。这一认识框架具有重要临床意义。近期随机序贯临床试验使许多患者的治疗范式转向一线免疫检查点阻断。将MAPK抑制与免疫治疗联合的三联方案在无进展生存获益上结果不一,总生存的持久获益仍不确定。疾病进展后的治疗选择正在快速扩展,包括ERK抑制剂、新一代泛RAF抑制剂、垂直通路靶向策略,以及针对持留细胞生物学和适应性耐药状态的 emerging 方法。综述整合基因组、转录组、单细胞和空间研究的最新认识与最相关临床试验数据,为理解黑色素瘤MAPK靶向治疗耐药提供当代框架。文中还讨论包括循环肿瘤DNA分析在内的适应性监测方法如何帮助指导未来生物标志物驱动和以演化信息为基础的治疗策略。
Immune checkpoint inhibitors have changed cancer management. However, immune-related adverse events (irAEs) can disrupt treatment and limit effective combination strategies. The standard of care tends to involve broad immunosuppression, which may compromise antitumor immunity and fail to address the dominant biology of distinct irAEs. Some evidence suggests that irAEs can be mitigated through mechanism-based interventions, including cytokine blockade, tissue-restricted immunomodulation, and strategies targeting pathogenic lymphocytes or humoral pathways. Emerging irAE biomarkers help support personalized risk assessment, diagnosis, and intervention selection. In this review, we examine key advances in targeted interventions and biomarkers and outline a translational and clinical path forward, ranging from clinically useful irAE taxonomies to biomarker-guided trials, to advance precision toxicity control toward clinical practice.
中文摘要:免疫检查点抑制剂改变了肿瘤治疗格局。免疫相关不良事件(irAEs)可能中断治疗并限制有效的联合策略。标准处理往往采用广泛免疫抑制,这可能削弱抗肿瘤免疫,且未能针对不同irAEs的主导生物学。部分证据提示,可通过基于机制的干预减轻irAEs,包括细胞因子阻断、组织限制性免疫调节,以及靶向致病性淋巴细胞或体液通路的策略。新兴irAE生物标志物有助于支持个体化风险评估、诊断和干预选择。文章梳理靶向干预和生物标志物的关键进展,并勾勒转化与临床路径,从临床可用的irAE分类到生物标志物指导的试验,推动精准毒性控制走向临床实践。
Stroke can occur at any age, and the effects can last for the remaining lifetime. To minimize the clinical and economic burden of stroke, we need to develop and test new treatments that have the potential to improve outcomes for people with stroke. Early-phase trials are foundational to testing new treatments in medicine. Early-phase trials encompass dose-ranging, dose-screening, and dose-finding noncomparative designs. A dose-ranging trial aims to establish the safe and tolerable dose range for a given investigational intervention in a target population to progress to a dose-screening or dose-finding trial that systematically identifies an intervention dose(s) in the target population that has signal of efficacy, feasibility, safety, and tolerability. Such designs originated in the oncology field and are gaining prominence in stroke literature. In this article, we first outline the features that differentiate the contribution of early-phase trials from late-phase trials and present a stepwise development program approach to frame our discussion. We then review early-phase trial terminology, discuss the characteristics of early-phase trials and high-quality reporting, and the role, value, and contribution of early-phase trials across the continuum of stroke care using published and ongoing trial examples. Finally, we highlight emerging innovations in early-phase trial design and application to inform future work in stroke.
中文摘要:卒中可发生于任何年龄,其影响可能持续余生。为减轻卒中的临床与经济负担,需要开发并检验有望改善卒中患者结局的新治疗。早期试验是医学中新治疗验证的基础。早期试验包括剂量范围、剂量筛选和剂量探索的非对照设计。剂量范围试验旨在确定目标人群中某研究性干预的安全且可耐受剂量范围,以便推进至剂量筛选或剂量探索试验,后者系统识别目标人群中具有疗效信号、可行性、安全性和耐受性的干预剂量。此类设计起源于肿瘤学领域,在卒中文献中日益受到重视。本文首先概述早期试验与后期试验贡献差异的特征,并给出分阶段开发项目的框架来组织讨论。随后回顾早期试验术语,讨论早期试验特征与高质量报告,并结合已发表和正在进行的试验示例,说明早期试验在卒中全程照护中的作用、价值与贡献。最后重点介绍早期试验设计的新兴创新及其应用,为卒中未来工作提供参考。
Type 2 diabetes (T2D) and cancer frequently coexist and are connected by hyperinsulinemia, hyperglycemia, obesity, chronic inflammation, and multiorgan metabolic dysfunction. These alterations activate insulin/insulin-like growth factor 1, PI3K/AKT/mTOR, MAPK, JAK/STAT, and NF-κB signaling while reshaping the tumor microenvironment through endocrine, immune, and metabolic pathways. This review synthesizes epidemiological and mechanistic evidence linking T2D with cancer and evaluates the oncological implications of major antidiabetic therapies. We discuss how dysfunction of skeletal muscle, adipose tissue, liver, pancreas, and hormonal axes may converge on tumor growth, immune evasion, and treatment resistance. We then critically examine metformin, insulin analogs, sulfonylureas, sodium-glucose cotransporter 2 inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and dual GIP/GLP-1 receptor agonists. Metformin has demonstrated extensive preclinical antitumor activity, whereas randomized clinical studies have generally yielded neutral cancer-specific outcomes. Human findings for other agents vary according to cancer type, metabolic phenotype, treatment duration, and study design, with observational estimates particularly sensitive to diabetes severity, obesity, treatment selection, and reverse causality. In clinical practice, glucose-lowering therapy is therefore best guided by glycemic efficacy, cardiovascular and renal protection, body-weight effects, safety, cancer-treatment context, and prognosis. Integrating pharmacological mechanisms with clinically achievable exposure and human outcome data may enable more precise metabolic management at the diabetes-cancer interface.
中文摘要:2型糖尿病与癌症常同时存在,并通过高胰岛素血症、高血糖、肥胖、慢性炎症和多器官代谢功能障碍相互关联。这些改变激活胰岛素/胰岛素样生长因子1、PI3K/AKT/mTOR、MAPK、JAK/STAT和NF-κB等信号通路,同时经内分泌、免疫和代谢途径重塑肿瘤微环境。该综述整合2型糖尿病与癌症关联的流行病学和机制证据,并评估主要降糖治疗对肿瘤学结局的影响。讨论骨骼肌、脂肪组织、肝脏、胰腺及激素轴功能障碍如何共同作用于肿瘤生长、免疫逃逸和治疗耐药。随后批判性审视二甲双胍、胰岛素类似物、磺脲类、钠-葡萄糖协同转运蛋白2抑制剂、噻唑烷二酮类、二肽基肽酶-4抑制剂、胰高血糖素样肽-1受体激动剂及GIP/GLP-1双受体激动剂。二甲双胍在临床前研究中显示出广泛的抗肿瘤活性,而随机临床研究通常未获得癌种特异性的阳性结局。其他药物的人体研究结果随癌种、代谢表型、治疗时长和研究设计而变化,观察性研究估计尤其易受糖尿病严重程度、肥胖、治疗选择和反向因果影响。临床实践中,降糖治疗宜综合血糖疗效、心血管和肾脏保护、体重影响、安全性、癌症治疗背景及预后进行选择。将药理机制与临床可达到的药物暴露及人体结局数据整合,可能有助于在糖尿病与癌症交汇处实现更精准的代谢管理。
Daily witnessed ingestion in community-based pharmacies is standard practice for methadone maintenance treatment for opioid use disorder in British Columbia, Canada. Whether this practice, compared with take-home methadone, may pose a barrier to sustained retention in treatment and its lifesaving benefits is not known. To assess the different initiation times of methadone take-home doses in terms of time to all-cause mortality and methadone discontinuation, defined as a gap in prescribed doses lasting 5 or more days. This cohort study using principles of target trial emulation used observational data from British Columbia, Canada, 2010-2022. Both incident (no history of opioid agonist treatment [OAT]) and prevalent new-user (no OAT within the past month) designs were used. The study included individuals aged 18 years or older who completed OAT induction, were not pregnant or incarcerated, and had no history of cancer treatment or palliative care. Data analyses were conducted from March 5, 2025, to May 29, 2026. Exposure strategies were (1) no take-home dosing, (2) take-home dose initiation within 0 to 4 weeks after completing induction, (3) take-home dose initiation within 5 to 12 weeks after completing induction, (4) take-home dose initiation within 13 to 24 weeks after completing induction, and (5) take-home dose initiation within 25 to 52 weeks after completing induction. Outcomes were time to all-cause mortality and methadone discontinuation. A clone-censor-weight approach was used to estimate the 78-week adjusted risk difference (ARD). A total of 9788 incident users (median age, 34.1 [IQR, 27.2-44.1] years; 32.8% female) and 31 658 prevalent new users (median age, 36.9 [IQR, 29.7-46.2] years; 33.3% female) were included. Compared with no take-home dosing in prevalent new-user analysis, ARDs for the mortality outcome were -0.87 (95% CI, -1.51 to -0.23) for take-home dose initiation within 0 to 4 weeks after completing induction, -0.98 (95% CI, -1.62 to -0.33) for take-home dose initiation within 5 to 12 weeks after completing induction, -0.82 (95% CI, -1.59 to -0.06) for take-home dose initiation within 13 to 24 weeks after completing induction, and -0.31 (95% CI, -1.05 to 0.44) for take-home dose initiation within 25 to 52 weeks after completing induction. Compared with no take-home dosing in prevalent new-user analysis, the discontinuation outcome ARDs were -2.04 (95% CI, -3.99 to -0.10) for take-home dose initiation within 0 to 4 weeks after completing induction, -5.29 (95% CI, -6.82 to -3.76) for take-home dose initiation within 5 to 12 weeks after completing induction, -5.97 (95% CI, -7.16 to -4.78) for take-home dose initiation within 13 to 24 weeks after completing induction, and -4.39 (95% CI, -5.37 to -3.42) for take-home dose initiation within 25 to 52 weeks after completing induction. Similar patterns were observed among incident users. Multiple sensitivity analyses with sample restrictions, time-0 classifications, timeline restrictions, and addressing residual confounding bias supported the primary results. Results of this study suggest that initiating take-home methadone within 5 to 12 weeks and 13 to 24 weeks after completing induction resulted in the greatest benefits in reducing mortality and treatment discontinuation, although any take-home dosing was consistently better than no take-home dosing. These client-level benefits warrant consideration when refining clinical guidelines on take-home dosing.
中文摘要:在加拿大不列颠哥伦比亚省,社区药房每日目视服药是阿片类使用障碍美沙酮维持治疗的标准做法。与带回家服用美沙酮相比,这种做法是否可能妨碍患者持续留治及其挽救生命的效果尚不清楚。研究旨在评估美沙酮带回家剂量的不同启动时间对全因死亡时间和美沙酮中断(定义为处方剂量间隔持续5天及以上)的影响。这项采用目标试验模拟原则的队列研究使用加拿大不列颠哥伦比亚省2010年至2022年的观察数据,同时采用新发使用者(无阿片受体激动剂治疗[OAT]史)和现患新使用者(过去1个月内无OAT)设计。纳入18岁及以上、完成OAT诱导、未妊娠或监禁、无癌症治疗或姑息治疗史者。数据分析时间为2025年3月5日至2026年5月29日。暴露策略为:不使用带回家剂量;完成诱导后0至4周内启动带回家剂量;完成诱导后5至12周内启动;完成诱导后13至24周内启动;完成诱导后25至52周内启动。结局为全因死亡时间和美沙酮中断时间。采用克隆-删失-加权方法估计78周调整风险差(ARD)。共纳入9788名新发使用者(中位年龄34.1岁[IQR,27.2-44.1];32.8%为女性)和31658名现患新使用者(中位年龄36.9岁[IQR,29.7-46.2];33.3%为女性)。在现患新使用者分析中,与不使用带回家剂量相比,完成诱导后0至4周内启动带回家剂量的死亡结局ARD为-0.87(95%CI,-1.51至-0.23),5至12周内启动为-0.98(95%CI,-1.62至-0.33),13至24周内启动为-0.82(95%CI,-1.59至-0.06),25至52周内启动为-0.31(95%CI,-1.05至0.44)。在现患新使用者分析中,与不使用带回家剂量相比,完成诱导后0至4周内启动带回家剂量的中断结局ARD为-2.04(95%CI,-3.99至-0.10),5至12周内启动为-5.29(95%CI,-6.82至-3.76),13至24周内启动为-5.97(95%CI,-7.16至-4.78),25至52周内启动为-4.39(95%CI,-5.37至-3.42)。新发使用者中观察到相似模式。多项敏感性分析通过样本限制、时间零点分类、时间线限制以及处理残余混杂偏倚,支持主要结果。研究结果提示,完成诱导后5至12周和13至24周内启动带回家美沙酮在降低死亡和治疗中断方面获益最大,任何带回家给药均 consistently 优于不带回家给药。这些患者层面的获益在完善带回家给药临床指南时值得考虑。
Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous breast cancer subtype with limited therapeutic options. While the prevalence of overweight/obese (OW/OB) women continues to rise, the impact of obesity on molecular features of TNBC remains incompletely understood. We investigated clinicopathological and molecular data (including genomic, transcriptomic, proteomic and metabolomic profiling) using our original multi-omics database of TNBC (N = 465) for associations with patient body mass index (BMI). Multi-omics profiling revealed that OW/OB patients exhibited worse survival as well as elevated inflammation of tumor microenvironment, higher expression of immune checkpoints, and dysregulated lipid metabolism. Our in vivo experiments demonstrated that tumors in obese mice displayed faster growth rates, a higher proportion of PD-1+CD8+ T cells and enhanced responsiveness to anti-PD-1 treatment. In addition, we analyzed data from four independent clinical trials and discovered that OW/OB patients demonstrated higher pathological complete response rates and longer progression-free survival following anti-PD-1-based immunotherapy. In conclusion, our study systematically revealed that obesity is associated with coordinated immune-metabolic remodeling in TNBC, characterized by checkpoint enrichment and lipid dysregulation, which may help explain the enhanced anti-PD-1 responsiveness and should be taken into account in the field of precision medicine.
中文摘要:三阴性乳腺癌(TNBC)是一种侵袭性强、异质性高的乳腺癌亚型,治疗选择有限。超重/肥胖女性比例持续上升,肥胖对TNBC分子特征的影响仍未充分阐明。我们利用自建TNBC多组学数据库(N=465)的临床病理和分子数据(包括基因组、转录组、蛋白质组和代谢组图谱),分析其与患者体重指数(BMI)的关联。多组学分析显示,超重/肥胖患者生存更差,肿瘤微环境炎症升高,免疫检查点表达更高,脂质代谢失调。体内实验表明,肥胖小鼠肿瘤生长更快,PD-1+CD8+ T细胞比例更高,对抗PD-1治疗反应增强。我们还分析四项独立临床试验数据,发现超重/肥胖患者在接受以抗PD-1为基础的免疫治疗后病理完全缓解率更高,无进展生存期更长。研究系统揭示肥胖与TNBC中协调的免疫-代谢重塑相关,特征为检查点富集和脂质失调,这可能有助于解释抗PD-1反应增强,并应在精准医学中予以考虑。
Psoriasis progresses to psoriatic arthritis in up to 30% of patients, causing irreversible joint damage and substantial healthcare burden. Whether biologic therapy reduces psoriatic arthritis risk remains unclear. The aim of this paper was to evaluate the association between biologic therapy and psoriatic arthritis risk in psoriasis patients. We conducted a systematic review and meta-analysis of cohort studies (PROSPERO: CRD420251240466), searching PubMed, EMBASE, and Cochrane Library from inception to December 2025. We included cohort studies of adults with psoriasis without prior psoriatic arthritis that reported adjusted risk estimates for incident psoriatic arthritis and used an 'on-drug' analytical framework to account for changes in treatment status over time. Pooled hazard ratio (HRs) with 95% confidence interval (CI) were calculated using fixed- or random-effects models. In total, 15 cohort studies including 124,138 psoriasis patients with over 778,690 person-years of follow-up were included. Biologic use was associated with a 46% lower psoriatic arthritis risk versus non-biologic therapy (pooled HR 0.54, 95% CI 0.43-0.68), consistent versus non-systemic therapies (HR 0.57, 95% CI 0.33-0.97) and methotrexate (HR 0.48, 95% CI 0.45-0.51). Interleukin (IL)-17 inhibitors (HR 0.65, 95% CI 0.49-0.87; 3 studies) and IL-12/23 or IL-23 inhibitors (HR 0.46, 95% CI 0.36-0.60; 4 studies) were associated with lower psoriatic arthritis risk than tumor necrosis factor inhibitors. IL-23 inhibitors showed greater protection than IL-17 inhibitors (HR 0.67, 95% CI 0.58-0.77), while IL-23 inhibitors and IL-12/23 inhibitors did not differ (HR 0.88, 95% CI 0.69-1.13). Biologic therapy for psoriasis, particularly IL-23/IL-17-targeted agents, is associated with reduced incident psoriatic arthritis risk. These findings suggest early pathway suppression may delay clinical psoriatic arthritis diagnosis, though causal inference is limited by the observational data.
中文摘要:银屑病进展为银屑病关节炎的比例最高可达30%,可造成不可逆关节损伤并带来显著医疗负担。生物制剂治疗是否降低银屑病关节炎风险仍不明确。本系统评价与荟萃分析旨在评估银屑病患者中生物制剂治疗与银屑病关节炎风险的关联。研究按照PROSPERO注册方案(CRD420251240466),检索PubMed、EMBASE和Cochrane Library,检索时间自建库至2025年12月。纳入成人银屑病且既往无银屑病关节炎的队列研究,这些研究报告了新发银屑病关节炎的校正风险估计,并采用「用药期间」分析框架处理治疗状态随时间变化。采用固定效应或随机效应模型计算合并风险比(HR)及95%置信区间(CI)。共纳入15项队列研究,包括124138例银屑病患者,随访超过778690人年。与非生物制剂治疗相比,使用生物制剂与新发银屑病关节炎风险降低46%相关(合并HR 0.54,95%CI 0.43-0.68);与非系统性治疗(HR 0.57,95%CI 0.33-0.97)和甲氨蝶呤(HR 0.48,95%CI 0.45-0.51)相比结果一致。与肿瘤坏死因子抑制剂相比,IL-17抑制剂(HR 0.65,95%CI 0.49-0.87;3项研究)和IL-12/23或IL-23抑制剂(HR 0.46,95%CI 0.36-0.60;4项研究)与新发银屑病关节炎风险降低相关。IL-23抑制剂显示的保护作用强于IL-17抑制剂(HR 0.67,95%CI 0.58-0.77),IL-23抑制剂与IL-12/23抑制剂之间无差异(HR 0.88,95%CI 0.69-1.13)。银屑病的生物制剂治疗,尤其是靶向IL-23/IL-17的药物,与新发银屑病关节炎风险降低相关。这些结果提示早期通路抑制可能延迟临床银屑病关节炎诊断,但观察性数据限制了因果推断。
Dordaviprone (ONC201) is the first FDA-approved therapy for H3K27M-mutant diffuse midline glioma (DMG). However, therapeutic response varies among patients, and no imaging biomarkers currently predict long-term benefit. Diffusion-weighted MRI and apparent diffusion coefficient (ADC) obtained during standard clinical imaging reflect tissue cellularity and necrosis, offering potential as an early response indicator. Clinical and imaging data from patients treated with dordaviprone (n = 83) on completed studies underwent centralized neuroradiology review, ADC histogram analysis, and functional diffusion mapping (fDM), which were compared and correlated to CSF tumor DNA (tDNA) and metabolomics when available. Final analysis included 38 patients receiving standardized dordaviprone dosing and treatment schedule. In the pre-progression cohort, early changes in volumetric or cross-sectional RAPNO criteria were not predictive of overall (OS) or progression-free survival (PFS). Importantly, in patients treated pre-progression with dordaviprone post-radiation, tumors with increased diffusion ADC (reduced cellularity) at cycle 3 demonstrated median OS of 732 versus 360 days for those with decreased ADC (increased cellularity, P = .0149); with corresponding PFS of 334 versus 110 days (P = .0132). fDM analysis of spatio-temporal changes of ADC did not correlate with outcomes in a sub-cohort analysis but demonstrated predictive patterns in individual patient time course series. CSF metabolomics stratified by ADC change revealed differences in reductive stress metabolites among dordaviprone responders, linking ADC elevation to dordaviprone-driven metabolic effects. Early increase in ADC correlates with improved response to dordaviprone in H3K27M-DMG and correlates with CSF metabolic changes, suggesting ADC warrants prospective validation as a biomarker.
中文摘要:Dordaviprone(ONC201)是首个获FDA批准用于H3K27M突变型弥漫性中线胶质瘤(DMG)的疗法。但患者治疗反应存在差异,目前尚无影像生物标志物可预测长期获益。标准临床影像中获得的弥散加权MRI和表观弥散系数(ADC)反映组织细胞密度和坏死,可能作为早期反应指标。对已完成研究中接受dordaviprone治疗的患者(n=83)的临床和影像资料进行集中神经影像学复核、ADC直方图分析和功能弥散图(fDM),并在有资料时与脑脊液肿瘤DNA(tDNA)和代谢组学比较及相关分析。最终分析纳入38例接受标准化dordaviprone剂量和治疗方案的患者。在进展前队列中,基于体积或横断面RAPNO标准的早期变化不能预测总生存(OS)或无进展生存(PFS)。在放疗后进展前接受dordaviprone治疗的患者中,第3周期ADC升高(细胞密度降低)的肿瘤中位OS为732天,ADC降低(细胞密度升高)者为360天(P=.0149);相应PFS为334天对110天(P=.0132)。在一亚组分析中,fDM对ADC时空变化的分析未与结局相关,但在个体患者时间过程序列中显示出预测模式。按ADC变化分层的脑脊液代谢组学显示,dordaviprone应答者中还原应激代谢物存在差异,将ADC升高与dordaviprone驱动的代谢效应联系起来。H3K27M-DMG中ADC早期升高与dordaviprone更好反应相关,并与脑脊液代谢变化相关,提示ADC值得作为生物标志物进行前瞻性验证。
The rapid expansion of immunotherapy and targeted oncologic treatments leading to improved overall survival has led to a growing number of patients requiring dermatologic surgery for skin cancer while receiving systemic cancer therapy. However, perioperative management in this setting remains poorly defined. Dermatologic surgeons and oncologists must balance risks of impaired wound healing, bleeding, and infection against potential consequences of skin cancer progression versus treatment interruption, underscoring the need for multidisciplinary guidance. Here, we review perioperative management strategies at a tertiary cancer center and integrate FDA prescribing information, published data, and expert recommendations developed through multidisciplinary meetings between Mohs surgeons and medical oncologists. Our recommendations address key therapeutic classes including targeted therapies, cytotoxic chemotherapies, immunomodulators, proteosome inhibitors, and antibody drug conjugates, each of which presents distinct considerations. Across therapies, optimal management centers on individualized decision-making, preoperative laboratory assessment, careful timing of drug interruption for agents with known wound-healing or hematologic effects, and close postoperative monitoring. As systemic therapies continue to evolve, these expert-based recommendations aim to support safe, personalized perioperative care for the increasing population of oncology patients undergoing dermatologic surgery.
中文摘要:免疫治疗和靶向抗肿瘤治疗的快速扩展改善了总生存期,使越来越多正在接受全身抗肿瘤治疗的患者因皮肤癌需要接受皮肤外科手术。然而,该情形下的围手术期管理仍缺乏明确规范。皮肤外科医生和肿瘤科医生必须在伤口愈合受损、出血和感染风险与皮肤癌进展及治疗中断的潜在后果之间取得平衡,这也凸显多学科指导的必要性。本综述回顾一家三级癌症中心的围手术期管理策略,并结合FDA处方信息、已发表数据以及Mohs外科医生与肿瘤内科医生通过多学科会议形成的专家建议。我们的建议涵盖靶向治疗、细胞毒性化疗、免疫调节剂、蛋白酶体抑制剂和抗体药物偶联物等关键治疗类别,每一类均有不同的考量。总体而言,最佳管理以个体化决策、术前实验室评估、对已知影响伤口愈合或血液学指标的药物谨慎安排停药时机以及密切的术后监测为核心。随着全身治疗不断演进,这些基于专家共识的建议旨在为越来越多接受皮肤外科手术的肿瘤患者提供安全、个体化的围手术期照护。
Despite improved outcomes with atezolizumab plus bevacizumab (A+B) in hepatocellular carcinoma, primary refractoriness (PRef), characterised by early progression or short-lived disease stabilisation following treatment, remains a significant challenge. We analysed 1,296 patients with hepatocellular carcinoma treated with frontline A+B (AB-real) and validated findings in 645 trial participants recruited to IMbrave150 and GO30140. PRef was defined by SITC (Society for the Immunotherapy of Cancer) criteria. We performed a multi-parametric analysis of pre-treatment tumour tissue, including machine learning-based quantification of tumour-infiltrating lymphocytes, imaging mass cytometry and RNA sequencing (RNA-seq) to evaluate differences in the tumour microenvironment (TME) of patients with PRef vs. responders. Two independent cohorts were further used to refine the TME characterisation through single-cell RNA-seq (n = 20) and imaging mass cytometry (n = 16). We employed conditional inference tree analyses to provide a hierarchical organisation of PRef determinants. Among 677 AB-real patients and 378 trial participants evaluable by SITC criteria, PRef was associated with inferior median overall survival compared to response (AB-real: 7.3 vs. 31.5 months, p <0.001; Trials: 10.8 vs. not reached, p <0.001). Patients with PRef exhibited higher baseline systemic inflammation (neutrophil-to-lymphocyte ratio [NLR] ≥3), a distinctly immunosuppressive TME enriched in CD163+ tumour-associated macrophages and vascular cancer-associated fibroblasts, a higher Treg/Teff cell ratio, and pro-tumour supportive cellular interactions. RNA-seq of tumour tissue confirmed lower intrinsic immunogenicity in PRef samples with elevated myeloid infiltration. Conditional inference tree analysis identified IFN-γ signature downregulation combined with NLR ≥3 as the strongest contributor of PRef. PRef to A+B identifies a distinct biological entity characterised by unopposed systemic inflammation, myeloid infiltration, and T-cell depletion. Targeting myeloid-mediated immunosuppression, particularly in patients with low IFN-γ signature expression and elevated NLR might enhance responsiveness to A+B. Atezolizumab plus bevacizumab represents the standard first-line treatment for unresectable hepatocellular carcinoma, yet the biological basis of early treatment failure remains poorly understood. In this multi-cohort translational study, we show that approximately 40% of patients exhibit primary refractoriness according to SITC criteria - clinically validated here for the first time in hepatocellular carcinoma - and identify a distinct immuno-molecular profile of primary refractory tumours characterised by IFN-γ pathway repression, unfavourable myeloid polarisation, and a distinct spatial immune architecture. These findings provide a biological framework that may inform the design of biomarker-stratified trials and rational combination strategies to overcome primary resistance to first-line immunotherapy.
中文摘要:阿替利珠单抗联合贝伐珠单抗(A+B)改善了肝细胞癌的结局,但原发难治(PRef)仍是一项重要挑战,其特征为治疗后早期进展或疾病稳定持续时间短。我们分析了1296例接受一线A+B治疗的肝细胞癌患者(AB-real),并在入组IMbrave150和GO30140试验的645例受试者中验证结果。PRef按SITC标准定义。我们对治疗前肿瘤组织进行了多参数分析,包括基于机器学习的肿瘤浸润淋巴细胞定量、成像质谱流式和RNA测序,以评估PRef患者与治疗有效者肿瘤微环境的差异。另用两个独立队列通过单细胞RNA测序(n=20)和成像质谱流式(n=16)细化肿瘤微环境特征。我们采用条件推断树分析,对PRef决定因素进行层级组织。在677例AB-real患者和378例可按SITC标准评估的试验受试者中,与治疗有效者相比,PRef患者的中位总生存期更差(AB-real:7.3个月对31.5个月,p<0.001;试验:10.8个月对未达到,p<0.001)。PRef患者基线系统性炎症水平更高(中性粒细胞与淋巴细胞比值NLR≥3),肿瘤微环境呈明显免疫抑制,富含CD163+肿瘤相关巨噬细胞和血管性癌相关成纤维细胞,Treg/Teff细胞比值更高,并存在支持肿瘤生长的细胞互作。肿瘤组织RNA测序证实PRef样本内在免疫原性较低,并伴髓系浸润升高。条件推断树分析显示,IFN-γ特征下调合并NLR≥3是PRef最强的贡献因素。A+B治疗相关的PRef代表一种独特生物学实体,以未受抑制的系统性炎症、髓系浸润和T细胞耗竭为特征。针对髓系介导的免疫抑制,尤其在IFN-γ特征表达低且NLR升高的患者中,可能增强对A+B的应答。阿替利珠单抗联合贝伐珠单抗是不可切除肝细胞癌的标准一线治疗,但早期治疗失败的生物学基础仍知之甚少。在这项多队列转化研究中,我们发现约40%的患者按SITC标准表现为原发难治,该标准首次在肝细胞癌中得到临床验证,并识别出原发难治性肿瘤独特的免疫分子特征,表现为IFN-γ通路受抑、不利的髓系极化和独特的空间免疫结构。这些发现提供了生物学框架,可能有助于设计生物标志物分层试验和合理的联合策略,以克服一线免疫治疗的原发耐药。
Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many cancers. It is important for all members of the multidisciplinary teams supporting cancer patients to understand the impact of their clinical practice on immunotherapy response. Multiple medications have been implicated in altered ICI efficacy, of which many are first line treatments for common dermatologic conditions, including those arising as immune-related adverse events (irAEs). Cognizance of potential consequences associated with typical management strategies must be accounted for in this unique population. In this review, we hope to raise awareness of the potential impact that medications commonly prescribed by dermatologists may have on immunotherapy response. Specifically, we review the available evidence regarding the impact of antibiotics, systemic corticosteroids, Janus kinase inhibitors, biologics, and other immunomodulators. Improved understanding of these medication interactions will uphold informed management strategies for irAEs and coincidental dermatologic disorders in patients receiving ICIs, ultimately optimizing outcomes.
中文摘要:免疫检查点抑制剂(ICI)已改变许多癌症的治疗格局。支持癌症患者的多学科团队所有成员都应了解其临床实践对免疫治疗反应的影响。多种药物与ICI疗效改变有关,其中不少是常见皮肤病的一线治疗,包括作为免疫相关不良事件(irAE)出现的皮肤病。在这一特殊人群中,必须考虑常规管理策略可能带来的后果。本综述希望提高对皮肤科医生常用药物可能影响免疫治疗反应的认识。具体而言,我们回顾了抗生素、全身性糖皮质激素、Janus激酶抑制剂、生物制剂及其他免疫调节剂影响的现有证据。更好地理解这些药物相互作用,将有助于对接受ICI患者的irAE及伴发皮肤疾病采取知情的管理策略,最终优化结局。
Laser interstitial thermal therapy (LITT) is a local surgical treatment for brain metastases (BM). Here, we present and discuss the main radiologic findings and challenges related to LITT-treated BM. Prior to LITT, imaging features are useful for prognostic stratification and patient selection, as well as treatment planning. During the LITT session, intra-procedural imaging is acquired immediately at the beginning of the procedure for tumor delineation, during the ablation to monitor treatment using MR thermometry, and immediately post-LITT to evaluate the ablated region. Images obtained during the LITT procedure are useful to estimate the extent of ablation, either by analyzing the real-time thermometry data or by comparing pre- and post-ablation images. In the months following LITT, follow-up scans exhibit characteristic imaging patterns for responding versus progressing lesions, which should be accounted for during post-LITT surveillance. In light of these patterns, and considering the strategies adopted by previous LITT studies, we propose dedicated criteria for local radiologic response and local radiologic progression in clinical trials, by adapting the RANO-BM criteria for local therapies to a "dual baseline" framework dedicated to LITT-treated BM. Finally, we provide suggestions for the adoption of standardized post-LITT imaging protocols based on the current consensus.
中文摘要:激光间质热疗(LITT)是脑转移瘤(BM)的一种局部手术治疗。以下介绍并讨论LITT治疗BM相关的主要影像学表现与挑战。LITT前,影像特征有助于预后分层、患者选择和治疗计划。LITT过程中,术中影像在操作开始时即刻采集以勾画肿瘤,消融期间通过MR测温监测治疗,LITT后即刻采集以评估消融区域。LITT操作期间获得的图像可用于估计消融范围,方法包括分析实时测温数据或比较消融前后图像。LITT后数月内,随访扫描对应答与进展病灶呈现特征性影像模式,LITT后监测时应予考虑。鉴于这些模式并考虑既往LITT研究采用的策略,我们将RANO-BM标准中针对局部治疗的部分适配为专用于LITT治疗BM的「双基线」框架,提出临床试验中局部影像学应答和局部影像学进展的专门标准。最后,基于当前共识,对采用标准化LITT后影像方案提出建议。
Siglecs are a family of sialic acid-binding immunoglobulin-like lectins that regulate immune signaling and maintain homeostasis through glycan recognition. Despite their central role in immune modulation, their therapeutic potential remains underexplored. Advances in antibody engineering, glycan biology, and molecular design have greatly expanded our understanding of Siglec-ligand interactions, revealing their promise in regulating immunosuppression in cancer and autoimmunity. The current clinical landscape shows trials targeting mainly Siglec-2 and -3, with a predominant focus on hematological cancers. This review evaluates preclinical and recent clinical progress in Siglec-targeted immunotherapies, emphasizing mechanisms, safety, and efficacy, and proposes a translational framework to accelerate therapy development and broader immunotherapy advancements.
中文摘要:Siglecs 是一类唾液酸结合免疫球蛋白样凝集素,通过识别聚糖调控免疫信号并维持稳态。它们在免疫调节中处于核心位置,但治疗潜力仍未得到充分探索。抗体工程、聚糖生物学和分子设计的进展大幅拓展了对 Siglec-配体相互作用的认识,显示其在调控癌症和自身免疫中的免疫抑制方面具有前景。当前临床格局显示,试验主要靶向 Siglec-2 和 Siglec-3,且集中于血液肿瘤。该综述评估 Siglec 靶向免疫治疗的临床前和近期临床进展,重点讨论机制、安全性和疗效,并提出一个转化框架,以加快疗法开发并推动更广泛的免疫治疗进展。
Multiplexed spatial profiling has shown that tumor architecture influences therapy response, yet few spatial phenotypes are in clinical use. We opine that the immediate priority is simplification and validation of complex spatial features. We draw a parallel to cartography: maps are useful because they carry a limited set of named features whose meaning is agreed. Tumor maps could be built the same way: from the presence of a defined cell type, its proximity to another, its location within a tissue compartment, its state of activation, or combinations of these. Such features may have more clinical applicability than variable, unsupervised two-dimensional 'neighborhoods'. We propose cancer cartography as the process of assembling such validated features into tumor maps that guide treatment selection.
中文摘要:多重空间图谱分析显示,肿瘤结构影响治疗反应,但用于临床的空间表型仍很少。我们认为,当前优先事项是简化并验证复杂的空间特征。可以类比制图学:地图之所以有用,是因为它只承载一组数量有限、已命名且含义获得共识的特征。肿瘤地图也可按同样方式构建:依据特定细胞类型的存在、其与另一类细胞的邻近关系、其在组织分区中的位置、其活化状态,或这些要素的组合。相较于多变的无监督二维「邻域」,这类特征可能具有更强的临床适用性。我们提出「肿瘤制图」这一过程,即把经过验证的特征组装成可指导治疗选择的肿瘤地图。
Advancements in in vivo stable isotope tracing have revolutionized our understanding of cancer metabolism, transitioning the field from static metabolomic snapshots to dynamic metabolic pathway activities. However, interpreting raw fractional enrichment data presents significant biological and analytical challenges. This review systematically examines the methodological landscape of in vivo tracing, addressing the interpretive gap created by clinical constraints, such as single-timepoint surgical sampling. We dissect how secondary circulating tracers and the inherent heterogeneity of the tumor microenvironment can confound metabolic signals. We highlight the critical transition to metabolic flux analysis as the requisite computational step to overcome these challenges and to identify targetable metabolic vulnerabilities in precision oncology.
中文摘要:体内稳定同位素示踪技术的进步改变了人们对癌症代谢的认识,使该领域从静态代谢组快照转向动态代谢通路活性。然而,解读原始分数富集数据在生物学和分析层面均存在显著挑战。本综述系统梳理体内示踪的方法学图景,应对单时间点手术取样等临床限制造成的解读缺口。我们剖析循环中的二次示踪剂及肿瘤微环境固有异质性如何混淆代谢信号。我们强调向代谢通量分析的关键转变,这是克服上述挑战并在精准肿瘤学中识别可靶向代谢脆弱性的必要计算步骤。
Non-surgical treatment of patients with early-stage (1-2 cm diameter) cutaneous squamous cell carcinoma (CSCC) remains an unmet need. This study investigates low-dose intralesional cemiplimab for these patients. The primary objective was safety of low-dose intralesional cemiplimab. Efficacy was a secondary objective. This was an open-label, phase 1 pilot study with dose escalation and expansion cohorts (NCT03889912). One lesion was injected per patient. Cemiplimab was initially administered at 5, 15, and 44 mg weekly, for 12 weeks. Subsequently, Expansion Cohorts A and B received 5 mg intralesional cemiplimab weekly or every 2 weeks, respectively, for 6 weeks. Visual response assessments were performed at Weeks 7 and 13, and surgery at Week 13. Across 41 patients, cemiplimab showed an acceptable safety profile. In Expansion Cohorts A and B, treatment-emergent adverse events were all grade ≤2. Week 13 visual and pathologic complete response rates were both 58.3% in Cohort A and 41.7% and 66.7%, respectively, in Cohort B. The small number of participants limits generalizability. Intralesional cemiplimab administration may have been variable. Low-dose intralesional cemiplimab demonstrated efficacy against early-stage CSCC, with an acceptable safety profile. These data support further study of 5 mg intralesional cemiplimab weekly.
中文摘要:早期(直径1-2 cm)皮肤鳞状细胞癌(CSCC)患者的非手术治疗仍存在未满足需求。本研究考察低剂量病灶内cemiplimab用于这些患者。主要目标是低剂量病灶内cemiplimab的安全性,疗效为次要目标。这是一项开放标签、1期探索性研究,包含剂量递增和扩展队列(NCT03889912)。每例患者注射一个病灶。Cemiplimab初始按5、15、44 mg每周给药,持续12周。随后,扩展队列A和B分别接受5 mg病灶内cemiplimab每周或每2周一次,持续6周。第7周和第13周进行视觉反应评估,第13周手术。41例患者中,cemiplimab显示出可接受的安全性。扩展队列A和B中,治疗中出现的不良事件均为≤2级。第13周,队列A的视觉完全缓解率和病理完全缓解率均为58.3%,队列B分别为41.7%和66.7%。参与者数量少限制普遍性。病灶内cemiplimab给药可能存在差异。低剂量病灶内cemiplimab对早期CSCC显示出疗效,安全性可接受。这些数据支持进一步研究5 mg病灶内cemiplimab每周给药。
Chemoimmunotherapy has become the standard first-line treatment for de novo metastatic nasopharyngeal carcinoma (dmNPC). However, the role and optimal timing of locoregional radiotherapy in dmNPC in the chemoimmunotherapy era remain unclear. This study aims to evaluate whether salvage locoregional radiotherapy (SLRRT), deferred until locoregional progression in patients with well-controlled distant metastases, compromises survival compared with immediate locoregional radiotherapy (ILRRT) in responders to first-line chemoimmunotherapy. This retrospective cohort study included consecutive patients with dmNPC who achieved a complete or partial response after first-line platinum-based chemotherapy combined with anti-programmed cell death protein 1 therapy. The primary endpoint was overall survival (OS). Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline characteristics. Survival outcomes were assessed using Kaplan-Meier analyses and a multivariate Cox regression model. A total of 439 patients were included, with a median follow-up of 35.0 months (interquartile range, 24.0-45.2). Of these, 331 patients were assigned to the ILRRT cohort and 108 to the SLRRT cohort. After IPTW adjustment, SLRRT was not associated with inferior OS compared with ILRRT [2-year OS, 97.4% versus 90.1%; hazard ratio (HR) 0.93, 95% confidence interval (CI) 0.54-1.59, P = 0.78]. SLRRT was associated with worse locoregional control (HR 4.78, 95% CI 2.98-7.66, P < 0.001) but better distant control (HR 0.62, 95% CI 0.41-0.95, P = 0.03). Radiotherapy-related adverse effects were substantially more frequent in the ILRRT cohort. Deferring SLRRT until locoregional progression did not compromise survival among responders to first-line chemoimmunotherapy. These findings support a response-adapted, de-escalated treatment strategy that may reduce treatment-related toxicities and improve quality of life without adversely affecting survival.
中文摘要:化疗联合免疫治疗已成为初诊转移性鼻咽癌(dmNPC)的标准一线治疗。局部区域放疗在dmNPC化疗免疫治疗时代的作用及最佳时机仍不明确。本研究评估在一线化疗免疫治疗有效者中,对远处转移控制良好患者延迟至局部区域进展才给予挽救性局部区域放疗(SLRRT),与立即局部区域放疗(ILRRT)相比是否损害生存。这项回顾性队列研究纳入连续收治的dmNPC患者,这些患者在一线铂类化疗联合抗程序性细胞死亡蛋白1治疗后达到完全或部分缓解。主要终点为总生存期(OS)。采用逆概率治疗加权(IPTW)校正基线特征。通过Kaplan-Meier分析和多因素Cox回归模型评估生存结局。共纳入439例患者,中位随访35.0个月(四分位距24.0-45.2)。其中331例归入ILRRT队列,108例归入SLRRT队列。IPTW校正后,与ILRRT相比,SLRRT未显示与更差OS相关[2年OS,97.4%对90.1%;风险比(HR)0.93,95%置信区间(CI)0.54-1.59,P=0.78]。SLRRT与较差的局部区域控制相关(HR 4.78,95%CI 2.98-7.66,P<0.001),但与更好的远处控制相关(HR 0.62,95%CI 0.41-0.95,P=0.03)。放疗相关不良反应在ILRRT队列中明显更常见。在一线化疗免疫治疗有效者中,将SLRRT延迟至局部区域进展并未损害生存。这些结果支持一种根据疗效调整、降阶梯的治疗策略,该策略可能减少治疗相关毒性并改善生活质量,而不对生存造成不利影响。
Obesity remains a growing global health crisis, affecting nearly one billion adults worldwide and substantially increasing the risk of cardiometabolic disease, malignancy, and premature mortality. Metabolic and bariatric surgery (MBS) has evolved into an effective and durable treatment for severe obesity, providing sustained weight loss and significant remission of obesity-related comorbidities (i.e., type 2 diabetes mellitus and cardiovascular disease). Despite dramatic improvements in safety, efficacy, and long-term outcomes over time, MBS remains markedly underutilized, reaching fewer than 1% of eligible patients. Persistent barriers include limited patient and provider awareness, misconceptions regarding surgical risk, and significant disparities in access to care. Concurrently, the rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has transformed the medical management of obesity, offering effective pharmacologic weight loss but raising questions regarding their impact on MBS utilization, durability, and cost-effectiveness. Emerging evidence demonstrates that while MBS produces greater and more durable weight loss than GLP-1 RAs alone, these therapies need not be competitive. Rather, GLP-1 RAs may serve as 'neoadjuvant' treatment to optimize surgical candidacy or as adjunctive treatment for inadequate weight loss or postoperative weight regain. This review synthesizes contemporary data on MBS procedures, outcomes, disparities in access, and evolving perceptions of obesity treatment in the GLP-1 RA era. We propose a chronic weight management model that integrates pharmacotherapy, surgery, and multidisciplinary care along a continuous treatment spectrum. Positioning MBS and GLP-1 RAs as complementary modalities within individualized care pathways may improve long-term outcomes, expand access, and better address the complex, chronic nature of obesity.
中文摘要:肥胖仍是持续加重的全球健康危机,影响近十亿成年人,并显著增加心血管代谢疾病、恶性肿瘤和过早死亡的风险。代谢与减重手术(MBS)已成为治疗重度肥胖的有效且持久的手段,能够带来持续减重并显著缓解肥胖相关合并症,如2型糖尿病和心血管疾病。尽管安全性、疗效和长期结局不断改善,MBS的使用仍明显不足,仅覆盖不到1%的符合条件患者。持续存在的障碍包括患者和医生认知有限、对手术风险的误解以及获得诊疗方面的显著差异。与此同时,胰高血糖素样肽-1受体激动剂(GLP-1 RA)的快速应用改变了肥胖的药物治疗格局,可带来有效的药物减重,但也引发其对MBS使用率、持久性和成本效果影响的疑问。新出现的证据显示,MBS带来的减重幅度和持久性优于单用GLP-1 RA,但两类治疗并非必须竞争。GLP-1 RA可作为「新辅助」治疗以优化手术适宜性,也可作为辅助治疗用于减重不足或术后体重反弹。本综述整合MBS术式、结局、获得诊疗差异以及GLP-1 RA时代肥胖治疗观念演变的最新数据。我们提出一种慢性体重管理模式,在连续的治疗谱系中整合药物治疗、手术和多学科照护。将MBS与GLP-1 RA定位为个体化诊疗路径中的互补手段,可能改善长期结局、扩大可及性,并更好地应对肥胖复杂而慢性的特征。
基础研究 (136篇)
Colorectal cancer liver metastases (CRC-LMs) are associated with poor survival and frequently resist immunotherapy, yet the mechanisms underlying this immune refractoriness remain incompletely defined. Here, we identify a tumor-intrinsic type I interferon (IFN-I)-high state in CRC-LMs associated with loss of the IFN-α/β receptor subunit 1 (IFNAR1) on effector T lymphocytes within immune-enriched perimetastatic niches. Reduced IFNAR1 expression stratifies patients with poor clinical outcomes. Transcriptional profiling of patient-derived organoids and complementary preclinical models revealed heterogeneous but recurrent tumor-derived IFN-I production in CRC-LMs. In IFN-Ihigh contexts, sustained signaling promoted IFNAR1 internalization on effector CD8+ T cells, impairing their persistence, survival, and effector function. Pharmacologic or genetic stabilization of IFNAR1 on cell surface restored CD8+ T cell fitness and selectively enhanced T cell receptor- and chimeric antigen receptor-based immunotherapies in IFN-Ihigh tumors. These findings define a context-dependent IFN-Ihigh / IFNAR1low axis that constrains antitumor immunity in CRC-LMs and identify IFNAR1 stabilization as a strategy to convert chronic IFN signaling from a suppressive barrier into a therapeutic vulnerability.
中文摘要:结直肠癌肝转移(CRC-LMs)与生存期差相关,且常对免疫治疗耐药,但这种免疫难治性的机制仍未完全阐明。研究在CRC-LMs中识别出肿瘤内在的I型干扰素(IFN-I)高表达状态,该状态与免疫富集的转移灶周围微环境内效应T淋巴细胞上IFN-α/β受体亚基1(IFNAR1)缺失相关。IFNAR1表达降低可将患者分层为临床结局较差者。患者来源类器官及补充的临床前模型的转录谱分析显示,CRC-LMs中存在异质性但反复出现的肿瘤来源IFN-I产生。在IFN-I高表达背景下,持续信号传导促进效应CD8+ T细胞上IFNAR1内化,损害其持久性、存活和效应功能。通过药物或遗传学方式稳定细胞表面IFNAR1,可恢复CD8+ T细胞功能适应度,并在IFN-I高表达肿瘤中选择性增强基于T细胞受体和嵌合抗原受体的免疫治疗。这些发现界定了一个情境依赖的IFN-I高表达/IFNAR1低表达轴,该轴限制CRC-LMs的抗肿瘤免疫,并提示稳定IFNAR1可将慢性IFN信号从抑制性屏障转化为治疗易感性。
Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a novel risk factor for pancreatic cancer, particularly early liver metastasis. However, the underlying mechanisms and effective therapeutic strategies remain largely unclear. Here, based on clinical databases, patient tissue samples, and single-cell sequencing of mouse models, we identified CD44 as a key contributor to MAFLD-associated pancreatic cancer progression. High CD44 expression was significantly associated with poor survival in patients with pancreatic cancer and was further elevated in MAFLD-associated liver metastatic lesions. Considering that the limited effects of single treatment, we developed a cationic DOTAP/cholesterol liposomal nanoplatform co-loaded with gemcitabine, IR780, and CD44 siRNA (GIR@Lip) for combined chemotherapy, photothermal therapy, and immunotherapy. GIR@Lip nanoparticles exhibited excellent size uniformity, stability, and photothermal conversion efficiency, which could efficiently inhibit KPC cells' viability, migration and invasion, downregulate CD44 expression and stimulate immune response. Furthermore, GIR@Lip efficiently accumulated in tumor tissues in vivo, exhibiting a significant reduction in liver metastatic lesions and remodeling the M1 type tumor associated macrophages (TAMs), CD4+ and CD8+ T cells. Collectively, these findings identify CD44 as a potential therapeutic target for MAFLD-associated pancreatic cancer liver metastasis and highlight GIR@Lip as a promising multimodal strategy for its treatment.
中文摘要:代谢功能障碍相关脂肪性肝病(MAFLD)已成为胰腺癌尤其是早期肝转移的新风险因素,但其潜在机制和有效治疗策略仍不清楚。基于临床数据库、患者组织样本和小鼠模型单细胞测序,研究发现 CD44 是 MAFLD 相关胰腺癌进展的关键促进因子。高 CD44 表达与胰腺癌患者生存期差显著相关,并在 MAFLD 相关肝转移灶中进一步升高。考虑到单一治疗效果有限,构建了阳离子 DOTAP/胆固醇脂质体纳米平台,共载吉西他滨、IR780 和 CD44 siRNA(GIR@Lip),用于化疗、光热治疗和免疫治疗联合。GIR@Lip 纳米颗粒具有良好粒径均一性、稳定性和光热转换效率,可有效抑制 KPC 细胞活力、迁移和侵袭,下调 CD44 表达并激发免疫应答。GIR@Lip 在体内有效蓄积于肿瘤组织,显著减少肝转移灶,并重塑 M1 型肿瘤相关巨噬细胞(TAMs)、CD4+ 和 CD8+ T 细胞。这些发现表明 CD44 是 MAFLD 相关胰腺癌肝转移的潜在治疗靶点,GIR@Lip 是有前景的多模式治疗策略。
Although cancer is a chronic disease, conventional oncology has largely relied on maximum tolerated dose (MTD) chemotherapy to achieve rapid tumor killing. However, the limited specificity of these agents frequently results in substantial systemic toxicity and necessitates prolonged treatment-free intervals that may permit tumor regrowth and therapeutic resistance. Metronomic chemotherapy (MET) has emerged as a promising alternative approach, characterized by continuous or intermittent administration of low-dose chemotherapeutic agents over extended periods (often incorporating scheduled drug-free breaks ranging from daily up to weekly). Rather than relying primarily on direct cytotoxicity, MET exerts anti-tumor effects through repeated anti-angiogenic activity, immune modulation, and alteration of tumor microenvironment, while minimizing treatment-related toxicity. These properties make MET particularly attractive for long-term cancer management. Despite its clinical promise, broader implementation of MET remains constrained by challenges associated with drug delivery and administration. For chronic therapeutic regimens, the peroral route represents the most practical and patient-friendly option, offering improved adherence, reduced healthcare burden, and fewer hospital visits. However, many chemotherapeutic agents possess poor aqueous solubility, limited membrane permeability, and unfavorable pharmacokinetic properties, resulting in inadequate peroral bioavailability. In this review, we discuss the evolving role of MET in cancer treatment, compare available routes of administration, and examine the major biopharmaceutical barriers to effective peroral delivery. We further highlight emerging formulation strategies and advanced drug delivery systems designed to overcome these limitations. Collectively, these advances may facilitate the transition of cancer therapy from an episodic, high-intensity intervention toward a sustainable long-term disease management strategy.
中文摘要:癌症虽属慢性疾病,传统肿瘤治疗却主要依赖最大耐受剂量(MTD)化疗以获得快速杀瘤效果。此类药物特异性有限,常带来明显全身毒性,并需要较长无治疗间歇,期间肿瘤可能再生长并产生治疗抵抗。节拍化疗(MET)作为有前景的替代方式,特点是长期持续或间歇给予低剂量化疗药,常安排从每日至每周不等的无药间歇。MET并非主要依赖直接细胞毒性,而是通过反复抗血管生成、免疫调节及改变肿瘤微环境发挥抗肿瘤作用,同时降低治疗相关毒性。这些特性使MET适合长期肿瘤管理。尽管具有临床前景,MET的推广仍受药物递送与给药难题限制。慢性治疗方案中,口服途径最实用且便于患者,可提高依从性、减轻医疗负担、减少就医次数。许多化疗药水溶性差、膜通透性有限、药代动力学性质不理想,导致口服生物利用度不足。本综述讨论MET在肿瘤治疗中不断演变的作用,比较现有给药途径,并分析有效口服递送面临的主要生物药剂学障碍。进一步介绍为克服这些限制而设计的新型制剂策略和先进药物递送系统。这些进展有望推动肿瘤治疗从阶段性高强度干预转向可持续的长期疾病管理。
Upon DNA damage, chromatin remodeling is rapidly initiated to promote chromatin accessibility. Although this enhanced accessibility has been linked to poly(ADP-ribose) polymerase (PARP) activity, how cells overcome the nucleosome barrier remains unclear. We discovered that PARP1 directly and asymmetrically evicts histone dimers proximal to DNA strand breaks from nucleosomes to generate oriented hexasomes. In the presence of histone PARylation factor 1 (HPF1), PARP1 generates stable PARylated hexasomes that can facilitate recruitment of DNA- and PAR-dependent factors. In human cells, PARP activity directly drives chromatin accessibility and generates subnucleosomal species. Unexpectedly, we identified the C-terminal tail of histone H2A, a motif harboring recurrent cancer-associated mutations, as a critical determinant of efficient PARP1-mediated nucleosome disassembly. Deletion of the H2A tail sensitizes human cells to DNA-damaging treatments, implicating a functional role of PARP1-mediated nucleosome disassembly in DNA repair. Together, our findings support a model in which PARP1 promotes histone eviction to form subnucleosomes that facilitate efficient DNA repair.
中文摘要:DNA损伤后,染色质重塑迅速启动以促进染色质可及性。这种可及性增强与聚ADP核糖聚合酶(PARP)活性相关,但细胞如何越过核小体屏障仍不清楚。研究发现,PARP1可直接且不对称地从核小体上驱逐DNA链断裂附近的组蛋白二聚体,生成有方向性的六体。存在组蛋白PAR化因子1(HPF1)时,PARP1生成稳定的PAR化六体,可促进DNA依赖和PAR依赖因子的募集。在人细胞中,PARP活性直接驱动染色质可及性并产生亚核小体组分。研究还意外发现,组蛋白H2A的C端尾部——一个携带反复出现的癌症相关突变的基序——是PARP1高效介导核小体解聚的关键决定因素。删除H2A尾部使人细胞对DNA损伤处理更敏感,提示PARP1介导的核小体解聚在DNA修复中具有功能作用。这些结果支持一个模型:PARP1促进组蛋白驱逐,形成亚核小体,从而促进高效DNA修复。
Immune checkpoint inhibitor (ICI) therapies, such as anti-PD-1 treatment, have achieved great success in various cancers, including hepatocellular carcinoma. Tumor-infiltrating lymphocytes have major roles in the mechanism of action for ICIs, but numerous other components of the tumor microenvironment also contribute to the effectiveness of immunotherapy. However, little is known about the changes in the tumor microenvironment after ICI therapy, which may sustainably affect tumor progression. Integrated single-cell RNA sequencing data were collected for hepatocellular carcinoma (HCC) patient samples and analyzed to characterize immune cell alterations within the tumor microenvironment. Three different orthotopic allograft HCC models were established for ICI therapy and microenvironment component detection by using flow cytometry and multiple ELISA assays. Transwell assays were combined with flow cytometry to evaluate neutrophil migration. In vitro coculture systems were employed to investigate communication between different cell types. Multiplex immunochemistry analysis was conducted for human clinical samples to confirm the findings. Our results indicate that neutrophil infiltration was significantly reduced after effective ICI therapy, but not in patients with failed immunotherapy. Mechanistically, we found that effective anti-PD-1 therapy activates T cells, which secrete interferon-γ and other cytokines that act on tumor-associated macrophages. This T cell-macrophage crosstalk suppresses tumor-associated neutrophil-related chemokines secreted by macrophages. Consequently, neutrophil infiltration into the tumor microenvironment is diminished. Our findings show that immunotherapy reinvigorates T cells, but also remodels the myeloid compartment and reduces neutrophil recruitment, potentially alleviating neutrophil-mediated immunosuppression, thereby providing potential myeloid-targeted combinatorial strategies for improving checkpoint blockade responses.
中文摘要:免疫检查点抑制剂(ICI)治疗,例如anti-PD-1治疗,已在包括肝细胞癌在内的多种癌症中取得显著成功。肿瘤浸润淋巴细胞在ICI作用机制中占主要地位,但肿瘤微环境中的许多其他成分也影响免疫治疗的有效性。ICI治疗后肿瘤微环境的变化仍知之甚少,而这些变化可能持续影响肿瘤进展。研究收集肝细胞癌患者样本的整合单细胞RNA测序数据并分析,以刻画肿瘤微环境内的免疫细胞改变。建立三种不同的原位同种移植肝细胞癌模型用于ICI治疗及微环境成分检测,采用流式细胞术和多组ELISA。将Transwell实验与流式细胞术结合评估中性粒细胞迁移。采用体外共培养体系研究不同细胞类型间的通讯。对人临床样本进行多重免疫组化分析以验证发现。结果显示,有效ICI治疗后中性粒细胞浸润显著减少,而免疫治疗失败的患者未见这一变化。机制上,有效的anti-PD-1治疗激活T细胞,使其分泌干扰素-γ及其他细胞因子并作用于肿瘤相关巨噬细胞。这种T细胞与巨噬细胞的交互作用抑制巨噬细胞分泌的肿瘤相关中性粒细胞相关趋化因子,进而减少中性粒细胞向肿瘤微环境的浸润。研究结果表明,免疫治疗在重新激活T细胞的同时也重塑髓系细胞组分并减少中性粒细胞募集,可能减轻中性粒细胞介导的免疫抑制,为改善检查点阻断应答提供潜在的髓系靶向联合策略。
Anion-π+ photosensitizers (PSs) possess exceptional reactive oxygen species (ROS) generation and precise organelle targeting that could disrupt intracellular metabolic homeostasis and induce nonapoptotic cell death, offering unique advantages in overcoming immunosuppression. However, previous reports mainly focused on modifying the π+ core but often overlooked the crucial role of anions. Herein, we present a facile perfluoroalkyl anion strategy to modulate the fluorescence intensity and ROS generation capacity of anion-π+ PSs. Perfluorobutanesulfonate (PFB) anions with a single-sided perfluoroalkyl chain and bis(perfluorobutylsulfonyl)amide (BPFB) anions bearing double-sided perfluoroalkyl chains were employed to readily replace the hexafluoroantimonate (HFA) counterions in A/HFA and TPQ/HFA, yielding A/PFB, TPQ/PFB, A/BPFB, and TPQ/BPFB. Compared to the incorporated PFB anions, the BPFB anions more effectively restrict intramolecular motion through anion-π+ and van der Waals interactions, thereby significantly enhancing the fluorescence intensity of the phototheranostic agents─by 50.8-fold and 4.2-fold in A/BPFB nanoparticles (NPs) and TPQ/BPFB NPs compared to their HFA analogues, respectively. Concurrently, TPQ/BPFB NPs with second near-infrared emission demonstrated superior ROS generation, excellent mitochondrial targeting, and remarkable resistance to photobleaching. Strikingly, TPQ/BPFB NPs can activate both necroptosis and ferroptosis under irradiation, triggering a robust systemic immune response. Additionally, the lipophilicity granted by BPFB enables TPQ/BPFB NPs to infiltrate deeper into tumors, guaranteeing a more extensive photodynamic therapy with a 95% tumor suppression rate. Crucially, the immune memory triggered by TPQ/BPFB NPs effectively decreases the occurrence of lung metastases. Altogether, the perfluoroalkyl anion strategy proposed in this study offers new insights for developing potent anion-π+ PSs.
中文摘要:阴离子-π+型光敏剂(PSs)具有突出的活性氧(ROS)生成能力和精准的细胞器靶向能力,可扰乱细胞内代谢稳态并诱导非凋亡性细胞死亡,在克服免疫抑制方面具备独特优势。已有报道多集中于对π+核心的修饰,却常忽略阴离子的关键作用。本研究提出一种简便的全氟烷基阴离子策略,用于调控阴离子-π+型PSs的荧光强度和ROS生成能力。采用具有单侧全氟烷基链的全氟丁磺酸根(PFB)阴离子和具有双侧全氟烷基链的双(全氟丁基磺酰)胺(BPFB)阴离子,直接置换A/HFA和TPQ/HFA中的六氟锑酸根(HFA)反离子,得到A/PFB、TPQ/PFB、A/BPFB和TPQ/BPFB。与引入PFB阴离子相比,BPFB阴离子通过阴离子-π+作用和范德华作用更有效地限制分子内运动,从而显著增强光诊疗剂的荧光强度:A/BPFB纳米颗粒(NPs)和TPQ/BPFB NPs的荧光强度分别较其HFA类似物提高50.8倍和4.2倍。与此同时,具有第二近红外发射的TPQ/BPFB NPs表现出更优的ROS生成、良好的线粒体靶向性和显著抗光漂白能力。在光照下,TPQ/BPFB NPs可同时激活坏死性凋亡和铁死亡,触发强烈的全身免疫应答。BPFB赋予的脂溶性使TPQ/BPFB NPs能够更深地渗透肿瘤,保障更广泛的光动力治疗,肿瘤抑制率达95%。TPQ/BPFB NPs引发的免疫记忆可有效减少肺转移的发生。该研究提出的全氟烷基阴离子策略为开发高效阴离子-π+型PSs提供了新思路。
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of haematological malignancies, but its efficacy remains limited by multiple negative regulatory mechanisms intrinsic to T cells1-4. Here we perform a high-throughput in vivo CAR-T double-knockout (DKO) CRISPR screen, and identify multiple DKO gene pairs that are both effective and synergistic. The top pair, NR4A1-SOCS3 DKO, has multiple favourable immunological features. Whole-transcriptome profiling and in vivo single-cell RNA sequencing reveal that NR4A1-SOCS3 DKO specifically upregulates metabolic pathways in CAR-T cells, which show significantly higher metabolic fitness and mitochondrial activity. NR4A1-SOCS3 DKO CAR-T cells and T cells exhibit exceptionally potent antitumour efficacy and long-term tumour control across different tumour models without compromising safety features. NR4A1-SOCS3 DKO outperforms several benchmark single-gene and dual-gene modifications in T cells and CAR-T cells5-9. These data demonstrate high-throughput in vivo CAR-T DKO screening for rapid discovery of combination targets, and establish NR4A1-SOCS3 as a promising pair of intracellular checkpoints to engineer high-performance CAR-T therapies against cancer.
中文摘要:嵌合抗原受体(CAR)-T细胞疗法改变了血液系统恶性肿瘤的治疗格局,但其疗效仍受T细胞内在的多重负性调控机制限制1-4。我们开展了高通量体内CAR-T双基因敲除(DKO)CRISPR筛选,鉴定出多个既有效又具协同作用的DKO基因对。排名最高的基因对NR4A1-SOCS3 DKO具有多项有利的免疫学特征。全转录组分析和体内单细胞RNA测序显示,NR4A1-SOCS3 DKO特异性上调CAR-T细胞的代谢通路,这些细胞表现出显著更高的代谢适应性和线粒体活性。NR4A1-SOCS3 DKO的CAR-T细胞和T细胞在不同肿瘤模型中显示出极强的抗肿瘤疗效和长期肿瘤控制,且未损害安全性特征。NR4A1-SOCS3 DKO优于T细胞和CAR-T细胞中若干基准单基因和双基因改造5-9。这些数据表明,高通量体内CAR-T DKO筛选可快速发现联合靶点,并确立NR4A1-SOCS3作为一对有前景的细胞内检查点,用于工程化高性能抗肿瘤CAR-T疗法。
The T-cell-mediated antitumor immune response has emerged as a key axis for controlling cancer growth and progression, as shown by the widespread success of immune checkpoint blockade (ICB). Unfortunately, ICB therapy still fails in a large percentage of patients, and there is a growing need to identify novel targets to increase anticancer immunity and enhance existing treatments. Among emerging therapeutic targets, deubiquitinases (DUBs) have attracted increasing attention because of their central role in regulating ubiquitin signaling. As key components of the ubiquitin system, DUBs catalyze the removal of ubiquitin from substrate proteins, thereby dynamically reversing ubiquitination and fine-tuning protein stability, localization, activity, and protein‒protein interactions. Accumulating evidence indicates that DUBs regulate not only tumor-intrinsic pathways that promote immune evasion but also T-cell activation, differentiation, and effector function, positioning them as promising therapeutic targets at the interface between cancer and immunity. However, DUBs are rarely considered holistically involved in both T-cell immunity and tumor-intrinsic immune evasion, despite the growing appreciation that individual DUBs often act in both compartments. In this review, we comprehensively examine the roles of DUBs in T-cell immunity and tumor-intrinsic immune evasion and discuss perspectives on therapeutic strategies targeting DUBs along this axis.
中文摘要:T细胞介导的抗肿瘤免疫反应已成为控制肿瘤生长和进展的关键轴,免疫检查点阻断(ICB)的广泛成功证明了这一点。ICB治疗仍在很大比例患者中失败,识别新靶点以增强抗肿瘤免疫并提升现有治疗的需求不断增加。在新兴治疗靶点中,去泛素化酶(DUBs)因在调控泛素信号中的核心作用而受到越来越多关注。作为泛素系统的关键组分,DUBs催化底物蛋白去除泛素,动态逆转泛素化并精细调节蛋白稳定性、定位、活性及蛋白-蛋白相互作用。越来越多证据表明,DUBs不仅调控促进免疫逃逸的肿瘤内在通路,也调控T细胞活化、分化和效应功能,使其成为肿瘤与免疫交界处有前景的治疗靶点。DUBs很少被整体视为同时参与T细胞免疫和肿瘤内在免疫逃逸,尽管越来越认识到单个DUB常在这两个区室中发挥作用。本综述全面审视DUBs在T细胞免疫和肿瘤内在免疫逃逸中的作用,并讨论沿此轴靶向DUBs的治疗策略展望。
The clinical success of T-cell-based immunotherapies has transformed oncology, yet tumor immune evasion remains a formidable barrier. In this review, we delineate the developmental and molecular landscapes that shape antitumor T-cell immunity. Following a brief overview of CD4+ helper T-cell contributions, we focus primarily on CD8+ cytotoxic lineages. Rather than a passive loss of effector function, CD8+ T-cell exhaustion is increasingly recognized as functional attrition and profound oligoclonality. In the immunosuppressive tumor microenvironment (TME), unremitting antigenic pressure drives an iterative selection process that` narrows a highly diverse T-cell pool into a constricted, oligoclonal population, a phenomenon termed "clonal contraction". We expand the conceptual scale of T-cell clonal selection during the immune response, tracing this clonal evolution from early thymic selection and primary antigen priming to exhaustive terminal differentiation. We further propose a structural model demonstrating how the biophysical constraints of a fixed T-cell receptor (TCR) repertoire create a profound imbalance against rapidly diversifying tumor antigens. Within this framework, we highlight tissue-resident memory (Trm) as a crucial spatial reservoir that safeguards the host against the depletion of functional clones. Finally, we contextualize the therapeutic paradigm of immune checkpoint inhibition (ICI) and note that, under some circumstances, durable clinical efficacy can be driven by systemic "clonal replacement". Ultimately, we argue that next-generation T-cell-based immunotherapies may shift `from attempting only to reverse functional exhaustion to actively engineering continuous clonal selection and preserving TCR repertoire diversity.
中文摘要:基于T细胞的免疫治疗在临床上取得成功,改变了肿瘤治疗格局,但肿瘤免疫逃逸仍是巨大障碍。本综述梳理塑造抗肿瘤T细胞免疫的发育与分子图景。简要概述CD4+辅助性T细胞的作用后,重点讨论CD8+细胞毒性谱系。CD8+ T细胞耗竭并非被动的效应功能丧失,而日益被视为功能性衰退和显著寡克隆化。在免疫抑制性肿瘤微环境(TME)中,持续抗原压力驱动反复选择过程,使高度多样的T细胞库收窄为受限的寡克隆群体,这一现象称为「clonal contraction」。我们将免疫应答中T细胞克隆选择的概念尺度扩展,追溯其从早期胸腺选择、初次抗原致敏到耗竭性终末分化的克隆演化。进一步提出结构模型,说明固定T细胞受体(TCR)库的生物物理约束如何与快速多样化的肿瘤抗原形成深刻失衡。在此框架下,强调组织驻留记忆(Trm)T细胞作为关键空间储备,保护宿主免于功能性克隆耗竭。最后,将免疫检查点抑制(ICI)的治疗范式置于背景中,并指出在某些情况下,持久临床疗效可由系统性「clonal replacement」驱动。最终认为,下一代T细胞免疫治疗可能从仅试图逆转功能性耗竭,转向主动工程化持续克隆选择并保存TCR库多样性。
MYCN is a member of the MYC family of transcription factors and a potent oncogenic driver across neural crest, neuroectodermal, and neuroendocrine malignancies, including neuroblastoma, where MYCN amplification remains one of the most powerful molecular predictors of treatment failure and poor survival. MYCN has long been considered an ideal therapeutic target, given its restricted expression in postnatal tissues and potent oncogenic activity. However, direct and selective MYCN targeting therapies have yet to be established and translated into the clinic. This reflects the challenges of drugging MYC family proteins, which lack enzymatic active sites and defined binding pockets targeted by conventional small molecules. Here, we examine the landscape of MYCN targeting strategies, from direct approaches such as MYC-MAX dimerization inhibitors to indirect approaches targeting MYCN expression, its interactors, and downstream oncogenic dependencies. We also highlight the potential of targeted protein degrader technology for directly and selectively depleting MYCN protein. We further discuss the profound immunosuppressive tumor microenvironment characteristic of MYCN-amplified neuroblastoma and the therapeutic vulnerabilities this creates. Together, these advances in understanding and technology present a renewed opportunity to translate four decades of MYCN biology into effective therapies to improve outcomes for patients with neuroblastoma and other MYCN-driven cancers.
中文摘要:MYCN 是 MYC 转录因子家族成员,也是神经嵴、神经外胚层和神经内分泌恶性肿瘤中的强效致癌驱动因子,包括神经母细胞瘤;在神经母细胞瘤中,MYCN 扩增仍是治疗失败和生存不良最强的分子预测因素之一。MYCN 在出生后组织中表达受限,且具有强致癌活性,长期被视为理想治疗靶点。直接且选择性的 MYCN 靶向治疗尚未建立并转化至临床,这反映了靶向 MYC 家族蛋白的困难:这类蛋白缺乏可被传统小分子作用的酶活性位点和明确结合口袋。综述梳理 MYCN 靶向策略格局,从 MYC-MAX 二聚化抑制剂等直接方法,到靶向 MYCN 表达、相互作用蛋白及下游致癌依赖的间接方法。也讨论靶向蛋白降解剂技术直接、选择性耗竭 MYCN 蛋白的潜力。进一步讨论 MYCN 扩增神经母细胞瘤具有的显著免疫抑制性肿瘤微环境及其产生的治疗脆弱性。这些认识与技术进展带来新机会,有望把四十年 MYCN 生物学转化为有效疗法,改善神经母细胞瘤及其他 MYCN 驱动癌症患者的结局。
Protein nanocages: Programmable biomaterial platforms for therapeutics, bioimaging, and diagnostics.
Protein nanocages are monodisperse, hollow structures formed through the symmetric self-assembly of protein subunits. Their genetically encoded architectures combine the geometric precision of nanoscale assemblies with the intrinsic biocompatibility and functional versatility of naturally evolved proteins. Well-defined internal cavities and engineerable interior and exterior surfaces enable the spatial organization of therapeutic cargoes, molecular recognition elements, and bioactive components within a single nanoscale platform. In this Review, we examine the structural organization, self-assembly mechanisms, physicochemical properties, and functional diversity of representative protein nanocages, including ferritin, the pyruvate dehydrogenase E2 core, DNA-binding proteins from starved cells (Dps), small heat shock proteins (sHSPs), encapsulins, and lumazine synthase. We discuss how their structural features and assembly behavior govern biological performance and support biomedical applications in targeted drug delivery, cancer immunotherapy, vaccine development, and in vivo and in vitro diagnostics. Beyond describing individual platforms, we establish a unifying framework that positions protein nanocages as programmable molecular organizers and highlights five transferable design principles: multivalent ligand display, spatial compartmentalization, receptor-guided targeting, reporter organization and signal enhancement, and stimulus-responsive cargo release and functional activation. We also examine persistent challenges in structural stability, immunogenicity, scalable manufacturing, and clinical translation, alongside emerging opportunities in protein engineering, synthetic biology, and computational protein design. Collectively, these principles establish protein nanocages as versatile biomaterial platforms for integrating sensing, targeting, imaging, and therapy within a single molecular architecture, providing a foundation for next-generation precision nanomedicine. STATEMENT OF SIGNIFICANCE: Reviews typically treat protein nanocages individually, obscuring shared structural features and the extent to which design strategies transfer across systems. This Review addresses this gap by establishing a comparative framework spanning structurally diverse nanocages and distilling their similarities into a concise set of generalizable design principles. It reframes protein nanocages not merely as passive delivery vehicles but as programmable molecular scaffolds that organize cargo with controlled spatial arrangement and stoichiometry. This framework provides biomaterials researchers with a transferable basis for engineering protein assemblies for precision nanomedicine while identifying key challenges in structural stability, immunogenicity, and scalable manufacturing that must be addressed to facilitate clinical translation.
中文摘要:蛋白质纳米笼是由蛋白质亚基对称自组装形成的单分散中空结构。其基因编码结构将纳米级组装体的几何精确性与天然进化蛋白固有的生物相容性和功能多样性结合起来。明确的内腔以及可工程化的内部和外部表面,使治疗货物、分子识别元件和生物活性组分能够在单一纳米级平台内实现空间组织。这篇综述考察代表性蛋白质纳米笼的结构组织、自组装机制、理化性质和功能多样性,包括铁蛋白、丙酮酸脱氢酶E2核心、饥饿细胞DNA结合蛋白(Dps)、小热休克蛋白(sHSPs)、包封蛋白和lumazine合酶。文中讨论这些纳米笼的结构特征和组装行为如何决定生物学性能,并支撑靶向药物递送、癌症免疫治疗、疫苗开发以及体内外诊断中的生物医学应用。在描述单个平台之外,本综述建立统一框架,将蛋白质纳米笼定位为可编程分子组织者,并提出五项可迁移设计原则:多价配体展示、空间区室化、受体引导的靶向、报告元件组织与信号增强、刺激响应性货物释放与功能激活。文中也考察结构稳定性、免疫原性、可规模化制造和临床转化方面的持续挑战,以及蛋白质工程、合成生物学和计算蛋白质设计中的新兴机会。这些原则共同将蛋白质纳米笼确立为将传感、靶向、成像和治疗整合于单一分子架构的多功能生物材料平台,为下一代精准纳米医学提供基础。意义陈述:综述通常单独讨论蛋白质纳米笼,掩盖了共享的结构特征以及设计策略跨系统迁移的程度。这篇综述通过建立涵盖结构多样纳米笼的比较框架,并将其相似性提炼为一组简洁的可推广设计原则,弥补这一空白。它将蛋白质纳米笼重新界定为不只是被动递送载体,而是可编程分子支架,能够以受控的空间排列和化学计量组织货物。该框架为生物材料研究者提供可迁移的基础,用于为精准纳米医学工程化蛋白质组装体,同时指出结构稳定性、免疫原性和可规模化制造等关键挑战,这些挑战必须解决以促进临床转化。
The perivascular (Pv) niche coordinates immune-stromal interactions that facilitate cancer progression. Pharmacological inhibition or genetic inactivation of the enzyme heme oxygenase-1 (HO-1) in LYVE-1+ Pv tumor-associated macrophages (PvTAMs) synergizes with cytotoxic chemotherapy (CCT) to achieve immunological tumor control in murine breast cancer models. We investigated the tumor microenvironment (TME) during the transition to immunological control and identified an increase in stem-like TCF1+PD-1+CD8+ T cells and enrichment of tumor-selective effector T cells. Stem-like CD8+ T cells were clonally diverse and rapidly acquired a TCF1- differentiated phenotype in the TME. Their tumor accumulation depended on CXCR4 and was associated with a treatment-induced expansion of proliferating CXCL12+CD34+ Pv cancer-associated fibroblasts (CAFs). In human breast cancer, greater abundance of the stem-like CD8+ T cell program was associated with improved outcomes following CCT. These findings identify PvTAM HO-1 activity as a regulator of a stromal-stem-like T cell axis that limits chemotherapy efficacy and anti-tumor immunity.
中文摘要:血管周围(Pv)微环境协调免疫-基质相互作用,促进癌症进展。在LYVE-1+ Pv肿瘤相关巨噬细胞(PvTAMs)中,药物抑制或基因失活血红素加氧酶-1(HO-1)与细胞毒性化疗(CCT)协同,在小鼠乳腺癌模型中实现免疫学肿瘤控制。对向免疫控制转变过程中的肿瘤微环境(TME)进行分析,发现干细胞样TCF1+PD-1+CD8+ T细胞增多,肿瘤选择性效应T细胞富集。干细胞样CD8+ T细胞克隆多样,并在TME中迅速获得TCF1-分化表型。其在肿瘤中的积聚依赖CXCR4,并与治疗诱导的增殖性CXCL12+CD34+ Pv癌相关成纤维细胞(CAFs)扩增相关。在人类乳腺癌中,干细胞样CD8+ T细胞程序丰度较高与CCT后结局改善相关。这些发现确定PvTAM的HO-1活性是限制化疗疗效和抗肿瘤免疫的基质-干细胞样T细胞轴的调节因子。
Tertiary lymphoid structures (TLSs) in tumors are associated with improved responses to immunotherapy. Here, we examined the impact of type 1 conventional dendritic cells (cDC1s) in TLS formation. Reprogrammed tumor cells into cDC1-like cells remodeled the tumor microenvironment and induced immunogenic TLSs (imgTLSs) across melanoma, colon, bladder, breast, and pancreatic cancer models with distinct genetic backgrounds. cDC1-like cells activated lymphotoxin, TNF, and interferon programs and engaged early with T cells through MHC class I and CD40 signaling to induce imgTLSs containing BCL6+ germinal centers, independently of endogenous cDC1s. Intratumoral positioning shaped distinct cDC1-like cell states, with DC-LAMP+ CCR7+ migratory cDC1s nucleating niches enriched in CD4+, CD8+ T cells, and B cells in mouse and human tumors. ImgTLSs sustained B and T cell responses and promoted systemic immunity through expansion of shared clonotypes in distant, untreated tumors. Our findings outline the spatial organization, signaling programs and interactions of cDC1-like cells that initiate intratumoral lymphoid structures and establish cellular reprogramming as a strategy toward overcoming resistance to immunotherapy.
中文摘要:肿瘤中的三级淋巴结构(TLS)与免疫治疗应答改善相关。为考察1型经典树突状细胞(cDC1)在TLS形成中的作用,将肿瘤细胞重编程为cDC1样细胞,可在黑色素瘤、结肠癌、膀胱癌、乳腺癌和胰腺癌等遗传背景不同的模型中重塑肿瘤微环境并诱导免疫原性TLS(imgTLS)。cDC1样细胞激活淋巴毒素、TNF和干扰素程序,并通过MHC I类和CD40信号与T细胞早期接触,从而诱导含BCL6+生发中心的imgTLS,这一过程不依赖内源性cDC1。瘤内定位塑造了不同的cDC1样细胞状态,DC-LAMP+ CCR7+迁移性cDC1在小鼠和人肿瘤中形成富含CD4+、CD8+ T细胞和B细胞的生态位。imgTLS维持B细胞和T细胞应答,并通过在远处未治疗肿瘤中扩增共享克隆型促进全身免疫。这些发现勾勒出启动瘤内淋巴结构的cDC1样细胞的空间组织、信号程序和相互作用,并将细胞重编程确立为克服免疫治疗耐药的策略。
Targeted biologics have transformed the treatment of inflammatory skin diseases such as plaque psoriasis. However, some patients with psoriasis paradoxically develop eczematous skin reactions after therapy targeting tumor necrosis factor (TNF), interleukin-17 (IL-17), or IL-23. Although paradoxical eczema (PE) resembles atopic dermatitis (AD) clinically and histologically, the molecular mechanisms that drive its development remain poorly understood. Here, we generated high-resolution cellular and spatial maps of human skin using single-cell RNA sequencing, spatial transcriptomics, immunohistochemistry, and in vitro assays, profiling lesional biopsies from patients with PE (n = 8 donors), alongside healthy control, psoriasis, and AD skin (n = 4 donors per group). In PE, we identified distinct transcriptional changes characterized by myeloid and T cell expansion and an altered keratinocyte phenotype shaped by TNF-like weak inducer of apoptosis (TWEAK; encoded by TNFSF12) signaling through its receptor TNFRSF12A, confirmed at the protein level by immunohistochemistry. To define the underlying mechanism, we stimulated immortalized (N-TERT) and primary human keratinocytes and found that TWEAK acted together with IL-13 to drive a T helper 2- and type I interferon-polarized epithelial program that partially recapitulated the keratinocyte signature of PE lesions. We validated key target genes by quantitative polymerase chain reaction in primary keratinocytes. In THP-1 cells and primary human CD14+ monocytes, anti-TNF treatment induced TWEAK expression, suggesting a compensatory inflammatory circuit. Together, these findings identify the TWEAK-IL-13 axis as a key driver of PE and suggest how cytokine blockade may reshape cutaneous immune responses.
中文摘要:靶向生物制剂改变了斑块状银屑病等炎症性皮肤病的治疗格局。部分银屑病患者在接受TNF、IL-17或IL-23靶向治疗后出现矛盾性湿疹样皮肤反应。矛盾性湿疹(PE)在临床和组织学上类似特应性皮炎(AD),驱动其发生的分子机制仍不清楚。我们利用单细胞RNA测序、空间转录组学、免疫组化和体外实验构建人皮肤高分辨率细胞与空间图谱,分析PE患者皮损活检(n=8名供者)以及健康对照、银屑病和AD皮肤(每组n=4名供者)。在PE中识别出以髓系和T细胞扩增及角质形成细胞表型改变为特征的转录变化,该表型由TNF样弱凋亡诱导因子(TWEAK,由TNFSF12编码)经其受体TNFRSF12A信号驱动,并由免疫组化在蛋白水平确认。为明确机制,刺激永生化(N-TERT)和原代人角质形成细胞,发现TWEAK与IL-13共同驱动Th2和I型干扰素极化的上皮程序,部分重现PE皮损的角质形成细胞特征。在原代角质形成细胞中用定量聚合酶链反应验证关键靶基因。在THP-1细胞和原代人CD14+单核细胞中,抗TNF处理诱导TWEAK表达,提示代偿性炎症环路。这些发现将TWEAK-IL-13轴确定为PE的关键驱动因素,并提示细胞因子阻断可能重塑皮肤免疫反应。
Metal-organic frameworks (MOFs) can form a multifunctional platform for cancer therapy due to their tunable metal nodes, designable organic ligands, large surface areas, and controllable pore architectures. These features enable MOFs not only to serve as carriers for drugs, nucleic acids, and diverse therapeutic agents, but also to participate directly in local therapeutic processes through photodynamic, photothermal, and chemodynamic effects. MOF-based platforms contribute to improved loading capacity, microenvironment responsiveness, catalytic activity, and local therapeutic efficacy, which have been widely explored in drug delivery, photodynamic therapy, photothermal therapy, chemodynamic therapy, and combination therapy recently. MOFs can also achieve tumor localization, in vivo distribution tracking, tumor marker identification, microenvironment monitoring, and treatment effect evaluation through imaging and biosensing functions. This review systematically summarizes recent advances of MOFs in cancer treatment, focusing on their roles in major therapeutic strategies and their potential as a comprehensive treatment platform that integrates treatment, monitoring, and feedback. The current challenges restricting their clinical translation are also comprehensively discussed, including issues related to the complex in vivo mechanism of action, stability, safety, and the consistency of material large-scale preparation. Furthermore, future perspectives and development directions of advanced MOF-based therapeutic platforms are prospected.
中文摘要:金属有机框架(MOFs)凭借可调金属节点、可设计有机配体、较大比表面积和可控孔结构,可构建用于癌症治疗的多功能平台。这些特征使MOFs不仅可作为药物、核酸及多种治疗剂的载体,也能通过光动力、光热和化学动力效应直接参与局部治疗过程。基于MOF的平台有助于提高载药能力、微环境响应性、催化活性和局部治疗效果,近期已在药物递送、光动力治疗、光热治疗、化学动力治疗及联合治疗中得到广泛探索。MOFs还可借助成像与生物传感功能实现肿瘤定位、体内分布追踪、肿瘤标志物识别、微环境监测和治疗效果评价。该综述系统总结MOFs在癌症治疗中的近期进展,重点讨论其在主要治疗策略中的作用,以及作为整合治疗、监测和反馈的综合治疗平台的潜力。文中也全面讨论限制其临床转化的当前挑战,包括复杂体内作用机制、稳定性、安全性及材料规模化制备一致性等问题。进一步展望先进MOF治疗平台的未来前景和发展方向。
Chemotherapeutic drugs, either alone or in combination with immunotherapy, are routinely used in cancer treatment. However, cancer cells frequently develop resistance to chemotherapy, and the underlying mechanisms remain incompletely understood. Using head and neck squamous cell carcinoma as a model, we show that chemotherapy activates the cGAS-STING pathway, leading to the induction of TNF. TNF mediates a paracrine signalling pathway in recipient tumour cells, leading to IKKβ activation and ATG9A phosphorylation at serine 654, thereby promoting autophagy. Moreover, IKKβ activation and ATG9A S654 phosphorylation are induced by TNF, nutrient deprivation and mTOR inhibition, suggesting that the IKKβ-ATG9A axis may represent a common regulatory mechanism of autophagy. Analysis of patient samples further reveals that chemotherapy induces autophagy, and elevated phosphorylation of ATG9A at S654 correlates with poor chemotherapy response. Of note, TNF blockade enhances therapeutic efficacy in both chemotherapy alone and chemotherapy combined with immune checkpoint inhibition. Together, our findings uncover a previously unrecognized TNF-IKKβ-ATG9A signalling axis that promotes autophagy and highlight TNF blockade as a promising strategy to overcome chemotherapy resistance.
中文摘要:化疗药物无论单用还是与免疫治疗联用,均常规用于肿瘤治疗。但肿瘤细胞常对化疗产生耐药,其机制仍未完全阐明。以头颈部鳞状细胞癌为模型,我们发现化疗激活cGAS-STING通路,诱导TNF产生。TNF在受体肿瘤细胞中介导旁分泌信号通路,导致IKKβ激活及ATG9A第654位丝氨酸磷酸化,从而促进自噬。TNF、营养缺乏和mTOR抑制均可诱导IKKβ激活与ATG9A S654磷酸化,提示IKKβ-ATG9A轴可能是自噬的共通调控机制。患者样本分析进一步显示化疗诱导自噬,ATG9A S654磷酸化升高与化疗反应差相关。TNF阻断可增强单用化疗及化疗联合免疫检查点抑制的疗效。这些结果揭示了一条此前未识别的促进自噬的TNF-IKKβ-ATG9A信号轴,并提示阻断TNF是克服化疗耐药的有前景策略。
Tumor-derived lactic acid (LA) plays a dual role in shaping the immunosuppressive tumor microenvironment by directly modulating immune cell function. Tumor-infiltrating B cells enhance antitumor immunity by promoting T-cell proliferation, whereas immunosuppressive subsets such as regulatory B cells (Bregs) counteract these effects via IL-10 sretion. However, the metabolic impact of lactate on B-cell functionality remains unclear. Using flow cytometry, we analyzed LA-induced phenotypic alterations in B cells and assessed Breg immunosuppressive activity via suppression assays. The tumor-inhibitory effects of blocking lactate receptor signaling were examined in animal models. Here, we reveal a previously unrecognized immunosuppressive mechanism mediated by CD25+CD81+ B cells (Bregs) in lung cancer. In murine models, LA induced ROS production in splenic and intratumoral Bregs through G protein-coupled receptor 81 (GPR81) signaling, thereby suppressing T-cell responses. Mechanistically, LA binding to GPR81 activates the cAMP/TAZ/PPARα axis, which orchestrates ROS generation in Bregs. Genetic ablation of lactate dehydrogenase A (LDHA) in tumor cells disrupted this signaling cascade in vivo, resulting in reduced ROS levels and restored T-cell activity. Pharmacological inhibition of GPR81 or PPARα similarly attenuated Breg-mediated immunosuppression and delayed tumor progression. Clinically, we identified ROS+ Breg populations in lung cancer patients, and elevated tumor LDHA expression correlated with poor prognosis. Our findings establish the LA-GPR81/TAZ/PPARα/ROS axis in Bregs as a redox-dependent checkpoint for tumor immune evasion, and highlighting novel therapeutic targets for lung cancer immunotherapy.
中文摘要:肿瘤来源乳酸(LA)通过直接调控免疫细胞功能,在塑造免疫抑制性肿瘤微环境中发挥双重作用。肿瘤浸润B细胞通过促进T细胞增殖增强抗肿瘤免疫,而调节性B细胞(Bregs)等免疫抑制亚群通过分泌IL-10抵消这些作用。乳酸对B细胞功能的代谢影响仍不清楚。我们使用流式细胞术分析LA诱导的B细胞表型改变,并通过抑制实验评估Breg免疫抑制活性。在动物模型中检查阻断乳酸受体信号的抑瘤作用。研究揭示肺癌中CD25+CD81+ B细胞(Bregs)介导的一种此前未认识的免疫抑制机制。在小鼠模型中,LA通过G蛋白偶联受体81(GPR81)信号诱导脾脏和瘤内Bregs产生ROS,从而抑制T细胞反应。机制上,LA与GPR81结合激活cAMP/TAZ/PPARα轴,协调Bregs中ROS生成。肿瘤细胞中乳酸脱氢酶A(LDHA)的基因敲除在体内破坏该信号级联,降低ROS水平并恢复T细胞活性。药物抑制GPR81或PPARα同样减弱Breg介导的免疫抑制并延缓肿瘤进展。临床上,我们在肺癌患者中鉴定出ROS+ Breg群体,肿瘤LDHA表达升高与不良预后相关。这些发现确立Bregs中的LA-GPR81/TAZ/PPARα/ROS轴作为肿瘤免疫逃逸的氧化还原依赖性检查点,并突出肺癌免疫治疗的新靶点。
The successful implementation of antitumor immunity hinges largely on a chain of stepwise events known as the cancer-immunity cycle (CIC). In this cycle, tumor cell death caused by T lymphocytes triggers inflammatory rounds of antigen-presenting cell (APC)-mediated antigen presentation and T-cell stimulation, sustaining active tumoricidal immunity, whereas tumor immunosuppressive networks impose multifaceted detrimental effects on essential elements involved in the CIC, which are considered therapeutic targets for improved tumor immunotherapy. Tremendous evidence has thrown light on the pivotal roles of metal ions in oncology, especially in antitumor immunity. Metal ions participate in modulating the step-by-step events occurring in the CIC, principally via their structural, catalytic, or modulatory interactions with immunosensors, ion transporters, and downstream effectors, as exemplified by Mn2+ that sensitizes cyclic GMP-AMP synthase and the stimulator of interferon genes pathway to trigger antitumor T-cell immunity. Owing to their lack of targeting ability, metal ions used alone cannot serve as immunotherapeutics. Inspired by the excellent targeting properties of nanomedicines and the unique ability of metal ions to self-assemble with diverse functional ligands, recent decades have witnessed rapid advances in metal-ligand coordination nanomaterials for enhanced tumor immunotherapy. Unlike other nanomedicines, metal coordination complexes can serve as multifunctional immunotherapeutic platforms, due to their chemical tunability and design versatility. Their unique composition and structure allow them to exhibit substantial outstanding properties, blazing the promising trail of tumor immunotherapy. In this Account, we summarize our recent breakthroughs in the development of metal-ligand coordination nanomedicines, especially in the therapeutic mechanisms tailored for CIC, with the ultimate purpose of ameliorative cancer immunotherapy. These promising nanomedicines are designed on the basis of stepwise events within the CIC, in which the targets can be subdivided into (1) tumor cells, (2) APCs, and (3) T cells. Once targeted to tumor cells, these nanomaterials generally induce immunogenic tumor cell death, leading to the release of numerous danger-associated molecular patterns that exert immune-stimulating effects on the APCs. Metal coordination complexes also directly activate APCs by the intrinsic immunostimulatory properties of metal ions or by delivering other adjuvants. Both pathways promote APC activation and antigen presentation for the subsequent priming of antitumor T-cell responses. Apart from indirect APC-to-T immunostimulatory pathways, these nanomedicines directly act on T cells and reinforce their antitumor functions, including activation, trafficking, infiltration, and tumor-killing capabilities. In addition, both future challenges and the anticipated development blueprint of these medicines as clinical therapeutics are emphasized.
中文摘要:抗肿瘤免疫的成功实施在很大程度上依赖一系列逐步发生的事件,即肿瘤-免疫循环(CIC)。在该循环中,T淋巴细胞引起的肿瘤细胞死亡触发炎症性的抗原提呈细胞(APC)介导的抗原提呈和T细胞刺激,从而维持活跃的杀瘤免疫;肿瘤免疫抑制网络则对CIC中的关键要素产生多方面不利影响,这些要素被视为改善肿瘤免疫治疗的靶点。大量证据揭示了金属离子在肿瘤学尤其是抗肿瘤免疫中的关键作用。金属离子参与调控CIC中逐步发生的事件,主要通过其与免疫传感器、离子转运蛋白及下游效应物的结构、催化或调节性相互作用实现,例如Mn2+可使环鸟苷酸-腺苷酸合成酶及干扰素基因刺激因子通路敏化,从而触发抗肿瘤T细胞免疫。由于缺乏靶向能力,单独使用金属离子不能作为免疫治疗药物。受纳米药物优异靶向性和金属离子与多种功能配体自组装独特能力的启发,近几十年来用于增强肿瘤免疫治疗的金属-配体配位纳米材料取得快速进展。与其他纳米药物不同,金属配位复合物因化学可调性和设计多样性,可作为多功能免疫治疗平台。其独特组成和结构使其表现出诸多突出性质,为肿瘤免疫治疗开辟了有前景的路径。本论述总结我们在金属-配体配位纳米药物开发方面的近期突破,尤其是针对CIC的治疗机制,最终目标是改善肿瘤免疫治疗。这些有前景的纳米药物依据CIC中的逐步事件设计,靶点可细分为(1)肿瘤细胞、(2)APC和(3)T细胞。靶向肿瘤细胞后,这些纳米材料通常诱导免疫原性肿瘤细胞死亡,导致大量损伤相关分子模式释放,对APC产生免疫刺激作用。金属配位复合物还可通过金属离子固有的免疫刺激特性或递送其他佐剂直接激活APC。这两条途径促进APC活化和抗原提呈,为随后启动抗肿瘤T细胞应答奠定基础。除间接的APC到T细胞免疫刺激途径外,这些纳米药物直接作用于T细胞并增强其抗肿瘤功能,包括激活、转运、浸润和杀瘤能力。文中还强调了这些药物作为临床治疗药物的未来挑战和预期发展蓝图。
Defective tumor antigen presentation promotes immune evasion and resistance to immune checkpoint blockade. Here, we identified the short-chain fatty acid propionate as a potent enhancer of major histocompatibility complex class I (MHC class I) antigen presentation. Propionate stabilizes MHC class I on tumor cells, promotes CD8+ T cell infiltration and activation, and suppresses tumor growth. Mechanistically, the E3 ubiquitin (Ub) ligase STUB1 directly interacts with human leukocyte antigen (HLA)-A to mediate K168/K170 polyubiquitination and subsequent degradation. Propionate directly binds STUB1 through hydrogen bonds involving K30 and N34, residues that overlap with the MHC class I-binding interface. This interaction blocks STUB1-mediated MHC class I polyubiquitination, thereby stabilizing MHC class I, enhancing T cell receptor (TCR) engagement and T cell activation, and restraining tumor growth. Importantly, propionate or the propionate-producing probiotic Akkermansia muciniphila markedly enhanced anti-PD-1 efficacy. These findings uncover a non-metabolic moonlighting function of short-chain fatty acids in regulating tumor immunity and provide a rationale for leveraging dietary propionate or propionate-producing probiotics to enhance immune checkpoint therapy.
中文摘要:肿瘤抗原呈递缺陷促进免疫逃逸和对免疫检查点阻断的耐药。研究鉴定短链脂肪酸丙酸为主要组织相容性复合体I类(MHC class I)抗原呈递的强效增强剂。丙酸稳定肿瘤细胞表面的MHC class I,促进CD8+ T细胞浸润与活化,并抑制肿瘤生长。机制上,E3泛素连接酶STUB1直接与人白细胞抗原(HLA)-A相互作用,介导K168/K170多聚泛素化及后续降解。丙酸通过涉及K30和N34的氢键直接结合STUB1,这些残基与MHC class I结合界面重叠。该相互作用阻断STUB1介导的MHC class I多聚泛素化,从而稳定MHC class I,增强T细胞受体(TCR)结合和T细胞活化,并抑制肿瘤生长。丙酸或产丙酸益生菌嗜黏蛋白阿克曼菌显著增强抗PD-1疗效。这些发现揭示短链脂肪酸在调控肿瘤免疫中的非代谢性兼职功能,并为利用膳食丙酸或产丙酸益生菌增强免疫检查点治疗提供依据。
Aberrant extracellular matrix (ECM) remodeling in tumors is characterized by altered deposition, enzymatic cross-linking, degradation, and organization of matrix molecules that in turn can contribute directly to tumor invasiveness, immune evasion, and resistance to therapy. Traditionally, cancer-associated fibroblasts (CAF) have been considered the principal architects of ECM remodeling in tumors. However, the role of non-fibroblast cell populations in modulating ECM structure and function and how these processes intersect with immune regulation, metabolism, and metastasis are also crucial but currently underappreciated. Challenging the prevailing fibroblast-centric paradigm, this review provides an overview of how non-fibroblast cell types engage in dynamic cross-talk and collectively shape the biochemical and biomechanical landscape of tumors. Therapeutic strategies targeting these alternative stromal players could disrupt protumor ECM dynamics, enhance antitumor immunity, and restore tissue homeostasis. Thus, a comprehensive understanding of the intricate network of non-fibroblast stromal cells within the tumor microenvironment (TME) can help elucidate opportunities for precision medicine and personalized cancer care, leading to the development of innovative therapeutic interventions targeting the TME.
中文摘要:肿瘤中异常的细胞外基质(ECM)重塑表现为基质分子沉积、酶促交联、降解及组织方式改变,这些改变可直接促进肿瘤侵袭、免疫逃逸和治疗耐药。传统上,肿瘤相关成纤维细胞(CAF)被视为肿瘤ECM重塑的主要构建者。非成纤维细胞群体在调节ECM结构与功能中的作用,以及这些过程如何与免疫调节、代谢和转移相互交织,同样关键但目前认识不足。本综述挑战以成纤维细胞为中心的现有范式,概述非成纤维细胞类型如何参与动态互作并共同塑造肿瘤的生化与生物力学景观。靶向这些替代性基质细胞成分的治疗策略可能破坏促肿瘤ECM动态、增强抗肿瘤免疫并恢复组织稳态。全面理解肿瘤微环境(TME)中非成纤维基质细胞的复杂网络,有助于阐明精准医学和个体化癌症治疗的机会,推动针对TME的新型治疗干预开发。
The immune system can eradicate cancer, but various immunosuppressive mechanisms active within a tumor curb this beneficial response. However, unraveling the effects of multimodal interactions between tumor and immune cells and their contributions to tumor control using an experimental approach alone is time and resource intensive. To identify the critical immunologic features associated with tumor control and escape, we built a mechanistic, structurally identifiable mathematical model of the interactions between CD8+ T cells, regulatory T cells (Treg), dendritic cells, and tumor cells deeply rooted in current biological concepts. The model captured Treg accrual occurring after checkpoint blockade immunotherapy. After successfully fitting the mathematical model to experimental data from an immunogenic melanoma mouse model with acquired resistance to PD-1 immunotherapy and ensuring that the model was practically identifiable, hundreds of parameter sets were generated, each of which fit the data well and represented a unique "virtual mouse" to capture variability across individuals. The model indicated that the initial tumor and immune conditions instruct cancer control or progression and that optimal initial ratios of immune cells exist that result in improved tumor control. The model further predicted that Treg influx into the tumor is a key determinant of resistance to PD-1 immunotherapy. Experimental studies validated all these predictions from the model. Overall, this integrated approach of modeling and experimental validation identified crucial determinants of resistance to PD-1 immunotherapy and can be used to guide the development of more effective therapeutic strategies. The combination of mathematical models and immediate experimental validation enables time- and resource-efficient identification of Treg influx into the tumor as a crucial mechanism of secondary resistance to PD-1 immunotherapy.
中文摘要:免疫系统能够清除癌症,但肿瘤内活跃的多种免疫抑制机制会削弱这一有益反应。仅依靠实验方法解析肿瘤细胞与免疫细胞之间多模态相互作用及其对肿瘤控制的影响,耗时且耗费资源。为识别与肿瘤控制和逃逸相关的关键免疫特征,我们构建了一个机制性、结构可识别的数学模型,描述CD8+ T细胞、调节性T细胞(Treg)、树突状细胞和肿瘤细胞之间的相互作用,模型深深植根于现有生物学概念。该模型捕捉了免疫检查点阻断治疗后发生的Treg积聚。在将模型成功拟合至具有PD-1免疫治疗获得性抵抗的免疫原性黑色素瘤小鼠模型的实验数据,并确认模型具有实际可识别性后,生成了数百组参数集,每组均能较好拟合数据并代表一个独特的「虚拟小鼠」,以刻画个体间变异。模型提示初始肿瘤与免疫状态决定肿瘤控制或进展,并存在可改善肿瘤控制的最佳初始免疫细胞比例。模型进一步预测,Treg流入肿瘤是PD-1免疫治疗抵抗的关键决定因素。实验研究验证了模型的全部这些预测。总体而言,这种建模与实验验证相结合的方法识别了PD-1免疫治疗抵抗的关键决定因素,可用于指导更有效治疗策略的开发。数学模型与即时实验验证的结合,能够以省时省资源的方式确认Treg流入肿瘤是PD-1免疫治疗继发性抵抗的重要机制。
The development and validation of prognostic and predictive biomarkers in breast cancer are limited by the availability of well-annotated datasets linking tumor molecular features to treatment response and survival outcomes. To address this need, we generated an extensive mouse model dataset comprised of 26 immunocompetent mammary tumor models spanning diverse genetic backgrounds, epithelial-mesenchymal states, the basal-luminal axis, and distinct immune microenvironments. For each model, survival was measured under no treatment, immune checkpoint inhibition (ICI), and carboplatin/paclitaxel chemotherapy, and RNA sequencing was performed on baseline tumors and on 7-day on-treatment samples for both regimens. Baseline murine tumor gene expression features were used to train a machine learning elastic net model that predicted survival outcomes on multiple human breast cancer datasets with performance comparable with that of existing prognostic assays. Models trained for ICI benefit, using either the untreated or 7-day ICI-treated samples, predicted ICI benefit on human ICI-treated datasets, with the 7-day treated tumor model showing better performance. A predictor of carboplatin/paclitaxel response developed from the murine mammary tumor data performed well in mice but did not generalize to human chemotherapy cohorts. Finally, comparison of multiple computational approaches, including XGBoost, random forests, and support vector regression, showed that all methods successfully predicted survival outcomes, with elastic net offering the best performance and interpretability. These results indicate conserved cancer biology between mouse and human tumors for prognosis and ICI response and establish a large preclinical dataset with linked phenotypic and genomic data as a resource for biomarker discovery. The development of a genomically and phenotypically diverse murine tumor dataset with linked treatment outcomes establishes a robust translational resource to develop, test, and benchmark clinically relevant prognostic and therapeutic response biomarkers.
中文摘要:乳腺癌预后与预测生物标志物的开发及验证受限于缺乏将肿瘤分子特征与治疗反应和生存结局关联且注释完善的数据集。为弥补这一需求,我们构建了一个大型小鼠模型数据集,包含26个免疫健全乳腺肿瘤模型,覆盖多样遗传背景、上皮-间质状态、基底-管腔轴及不同免疫微环境。对每个模型,在未治疗、免疫检查点抑制和卡铂/紫杉醇化疗条件下测量生存,并对基线肿瘤以及两种方案治疗7天时的样本进行RNA测序。以基线小鼠肿瘤基因表达特征训练机器学习弹性网络模型,该模型在多个人类乳腺癌数据集上预测生存结局,性能与现有预后检测相当。利用未治疗或免疫检查点抑制治疗7天样本训练的免疫检查点抑制获益模型,在人类免疫检查点抑制治疗数据集上预测获益,其中治疗7天肿瘤模型表现更好。基于小鼠乳腺肿瘤数据建立的卡铂/紫杉醇反应预测器在小鼠中表现良好,但未能推广到人类化疗队列。对XGBoost、随机森林和支持向量回归等多种计算方法进行比较,所有方法均能成功预测生存结局,其中弹性网络性能和可解释性最佳。这些结果提示小鼠与人类肿瘤在预后和免疫检查点抑制反应方面具有保守的肿瘤生物学,并建立了一个连接表型与基因组数据的大型临床前数据集,可作为生物标志物发现的资源。构建具有基因组和表型多样性且关联治疗结局的小鼠肿瘤数据集,为开发、测试和基准评估临床相关的预后与治疗反应生物标志物提供了稳健的转化资源。
Fasting-mimicking diets (FMD) have been reported to increase the antitumor efficacy in preclinical studies in various cancers. FMD can affect the tumor microenvironment (TME), and elucidating the mechanisms and cells mediating the effects of FMD may uncover combination treatment strategies. Here, we performed single-cell transcriptomic sequencing to characterize the TME changes induced by FMD intervention in a mouse model of spontaneous breast cancer. The sequencing data indicated that FMD suppressed tumor cell stemness, promoted apoptosis, and increased the infiltration of innate and adaptive immune cells, especially natural killer (NK) cells and effector CD8+ T cells. Importantly, FMD induced phenotypic reprogramming of cancer-associated fibroblasts (CAF), leading to a decrease in the immunosuppressive inflammatory CAF (iCAF) subset. Mechanistically, FMD decreased platelet-derived growth factor C (PDGFC) secretion in tumor cells by reducing glucose levels and inhibiting glycolysis to reprogram CAFs. PDGFC increased the activation of the JAK-STAT3 pathway, which induced iCAF differentiation. Combining FMD with PDGF receptor (PDGFR) inhibitors increased the efficacy of anti-PD-L1 immunotherapy in vivo. Overall, this study reveals a mechanism of metabolic-immune rewiring through which FMD suppresses tumor progression, providing preliminary evidence for the potential of combination FMD-based strategies in breast cancer treatment. Fasting-mimicking diet blocks breast cancer cell-induced generation of immunosuppressive fibroblasts, thereby facilitating tumor infiltration of immune cells and stimulating antitumor immunity to sensitize breast cancer to immunotherapy.
中文摘要:空腹模拟饮食(FMD)在多种癌症的临床前研究中被报道可增强抗肿瘤疗效。FMD能够影响肿瘤微环境(TME),阐明介导FMD作用的机制和细胞类型可能为联合治疗策略提供依据。本研究对自发性乳腺癌小鼠模型中FMD干预引起的TME变化进行了单细胞转录组测序分析。测序数据显示,FMD抑制肿瘤细胞干性、促进凋亡,并增加固有免疫和适应性免疫细胞的浸润,尤其是自然杀伤(NK)细胞和效应CD8+ T细胞。FMD诱导癌症相关成纤维细胞(CAF)发生表型重编程,使免疫抑制性炎症型CAF(iCAF)亚群减少。机制上,FMD通过降低葡萄糖水平并抑制糖酵解,减少肿瘤细胞中血小板衍生生长因子C(PDGFC)的分泌,从而重编程CAF。PDGFC增强JAK-STAT3通路激活,进而诱导iCAF分化。FMD与血小板衍生生长因子受体(PDGFR)抑制剂联合可在体内提高抗PD-L1免疫治疗的疗效。该研究揭示了一种代谢-免疫重编程机制,FMD通过该机制抑制肿瘤进展,为基于FMD的联合策略在乳腺癌治疗中的潜力提供了初步证据。空腹模拟饮食阻断乳腺癌细胞诱导的免疫抑制性成纤维细胞生成,促进免疫细胞向肿瘤浸润并激发抗肿瘤免疫,使乳腺癌对免疫治疗更敏感。
Antibody-drug conjugates (ADC) show clinical efficacy against several solid malignancies, inducing cytotoxic effects in malignant cells accompanied by changes in the composition of the tumor stroma. The therapeutic effects of some ADCs have been shown to be potentiated by combination with anti-PD-(L)1 checkpoint inhibitors, highlighting the potential of combining ADCs and immunotherapy. In this study, we investigated the potential of combining ADCs with agonist monoclonal antibodies targeting CD137 (4-1BB), a costimulatory receptor expressed on antigen-primed T lymphocytes and activated NK cells. The combination of monomethyl auristatin E- and deruxtecan-conjugated ADCs toward NECTIN-4 or HER2 with anti-CD137 agonists elicited synergistic effects in mouse tumor models. Treatment with the ADCs increased CD137 expression on intratumor CD8+ and CD4+ T lymphocytes. Moreover, the synergistic antitumor therapeutic efficacy was dependent on conventional type 1 dendritic cells (cDC1s) and CD8+ T cells. ADCs induced features of immunogenic cell death in malignant cells, resulting in cross-presentation and maturation of cDC1s that cross-prime CD8+ T cells to become CD137-positive. Importantly, the anti-CD137 plus ADC synergistic combination attained efficacy against concomitant tumor lesions that failed to express the ADC target. Together, these findings demonstrate that anti-CD137 agonists hold promise for combination strategies with ADCs. Antibody-drug conjugates synergize with CD137-agonists by inducing higher infiltration and surface expression of CD137 on CD8+ T cells as a result of cDC1-mediated cross-priming, eliciting robust antitumor activity.
中文摘要:抗体药物偶联物(ADC)在多种实体恶性肿瘤中显示临床疗效,可对恶性细胞产生细胞毒作用,并改变肿瘤间质组成。部分ADC与抗PD-(L)1检查点抑制剂联合后疗效增强,提示ADC与免疫治疗联合的潜力。本研究探讨将ADC与靶向CD137(4-1BB)的激动型单克隆抗体联合。CD137是表达于抗原致敏T淋巴细胞和活化NK细胞上的共刺激受体。将靶向NECTIN-4或HER2、分别偶联单甲基澳瑞他汀E(MMAE)和德鲁替康的ADC与抗CD137激动剂联合,在小鼠肿瘤模型中产生协同效应。ADC治疗提高瘤内CD8+和CD4+ T淋巴细胞上CD137的表达。协同抗肿瘤疗效依赖经典1型树突状细胞(cDC1)和CD8+ T细胞。ADC在恶性细胞中诱导免疫原性细胞死亡特征,促使cDC1交叉呈递和成熟,后者交叉致敏CD8+ T细胞使其变为CD137阳性。抗CD137抗体与ADC的协同组合对不表达ADC靶点的伴发肿瘤病灶也有效。这些发现表明抗CD137激动剂与ADC联合策略具有前景。ADC通过cDC1介导的交叉致敏,提高CD8+ T细胞浸润及CD137表面表达,与CD137激动剂协同产生强效抗肿瘤活性。
Esophageal squamous cell carcinoma (ESCC) exhibits heterogeneous responses to immune checkpoint blockade, highlighting the need to define tumor-intrinsic mechanisms driving resistance to PD-L1 inhibition. In this study, we identified GTP-binding protein overexpressed in skeletal muscle (GEM) as a tumor cell-intrinsic regulator associated with poor response to anti-PD-L1 therapy in ESCC. GEM expression in tumor cells drove tumor-associated macrophage-mediated immunosuppression, leading to reduced CD8+ T-cell infiltration and impaired cytotoxic function. Mechanistically, GEM induced serpin family E member 1 (SERPINE1) expression that was secreted and acted on macrophage low-density lipoprotein receptor-related protein 1 (LRP1) to drive alternative activation and suppress antitumor immunity. GEM enhanced SERPINE1 expression through a MKK3-RACK1-p38-MEF2A cascade. GEM signaling was reinforced by a metabolically coupled feedback mechanism. Macrophages exposed to GEM-high tumor cells promoted tumor cell glycolysis and lactate production, which drove AARS1-dependent lactylation of GEM and strengthened its interaction with RACK1 to amplify downstream signaling. Disruption of the SERPINE1-LRP1 axis restored CD8+ T-cell activity and enhanced response to PD-L1 blockade in vivo. Pharmacologic perturbation of GEM-dependent signaling remodeled the tumor immune microenvironment and improved responses to PD-L1 blockade. Together, these findings define a GEM-SERPINE1-LRP1 signaling axis that drives macrophage-mediated immunosuppression and suggest that targeting this pathway may enhance the efficacy of PD-L1 blockade in ESCC. GEM signaling engenders an immunosuppressive tumor microenvironment and promotes resistance to PD-L1 blockade, highlighting the potential of targeting GEM as a strategy to improve immunotherapy efficacy.
中文摘要:食管鳞状细胞癌(ESCC)对免疫检查点阻断的反应存在异质性,因此需要明确驱动PD-L1抑制耐药性的肿瘤内在机制。本研究发现,骨骼肌中过表达的GTP结合蛋白(GEM)是与ESCC抗PD-L1治疗反应不佳相关的肿瘤细胞内在调控因子。肿瘤细胞中的GEM表达驱动肿瘤相关巨噬细胞介导的免疫抑制,导致CD8+ T细胞浸润减少、细胞毒功能受损。机制上,GEM诱导serpin家族E成员1(SERPINE1)表达,SERPINE1被分泌后作用于巨噬细胞的低密度脂蛋白受体相关蛋白1(LRP1),驱动替代性活化并抑制抗肿瘤免疫。GEM通过MKK3-RACK1-p38-MEF2A级联增强SERPINE1表达。GEM信号还受到代谢耦联反馈机制的强化:暴露于GEM高表达肿瘤细胞的巨噬细胞促进肿瘤细胞糖酵解和乳酸生成,乳酸驱动AARS1依赖的GEM乳酰化,增强GEM与RACK1的相互作用,从而放大下游信号。阻断SERPINE1-LRP1轴可恢复CD8+ T细胞活性,并在体内增强对PD-L1阻断的反应。药物扰动GEM依赖信号可重塑肿瘤免疫微环境,改善对PD-L1阻断的反应。这些发现界定了一条驱动巨噬细胞介导免疫抑制的GEM-SERPINE1-LRP1信号轴,提示靶向该通路可能提高ESCC中PD-L1阻断的疗效。GEM信号塑造免疫抑制性肿瘤微环境并促进对PD-L1阻断的耐药,表明靶向GEM有望成为改善免疫治疗疗效的策略。
Three recent papers show the potential benefits of several hundred new organoids, spheroids, and other cancer models. One study demonstrates that more than 600 of the models mirror their parent tumors. A second study uses organoids to uncover new cancer dependencies, or essential genes, in 147 organoids from 10 cancer types. The third study also identifies new cancer dependencies and shows that organoids from individual patients might lead to new treatment choices.
中文摘要:三篇近期论文展示了数百个新类器官、球状体及其他癌症模型的潜在价值。一项研究显示,其中600多个模型与其来源肿瘤相对应。第二项研究利用类器官在来自10种癌症类型的147个类器官中发现了新的癌症依赖基因或必需基因。第三项研究同样识别出新的癌症依赖关系,并表明来自单个患者的类器官可能带来新的治疗选择。
Living systems, including cells and viruses, exhibit intrinsic adaptivity that enables them to navigate complex biological environments through dynamic regulation of their structural and functional states. Inspired by these natural processes, bio-inspired adaptive nanoparticles have emerged as a promising strategy to overcome the limitations of static nanocarriers. These engineered systems sense or recognize changes in the local microenvironment and subsequently undergo spatiotemporal remodeling of their structures, biointerfaces, or biological functions, thereby meeting stage-specific requirements for cancer delivery and therapy. In this Review, we summarize recent advances in bio-inspired adaptive nanoparticles for cancer applications. We first outline representative natural adaptive particles and their underlying adaptive mechanisms. We then discuss how these principles guide the design of structurally and functionally adaptive nanoparticles to overcome tumor-delivery barriers and regulate the tumor microenvironment. Finally, we highlight approaches for the mechanistic and quantitative validation of adaptive behavior and discuss the major challenges and future directions for developing next-generation adaptive nanomedicines with translational potential.
中文摘要:细胞和病毒等生命系统具有内在适应性,可通过动态调节结构与功能状态在复杂生物环境中导航。受这些自然过程启发,仿生适应性纳米颗粒成为克服静态纳米载体局限的一种有前景策略。这类工程化系统能够感知或识别局部微环境变化,并随后对其结构、生物界面或生物学功能进行时空重塑,从而满足癌症递送与治疗在不同阶段的需求。本综述总结仿生适应性纳米颗粒在癌症应用中的近期进展。概述代表性天然适应性颗粒及其适应性机制,讨论这些原理如何指导结构与功能适应性纳米颗粒的设计,以克服肿瘤递送屏障并调控肿瘤微环境。还重点介绍适应性行为的机制性与定量验证方法,并讨论开发具有转化潜力的下一代适应性纳米药物面临的主要挑战和未来方向。
Synergistic therapeutic nanoplatforms are of considerable interest in tumor therapy, but their translational potential is often limited by complex multicomponent designs and unknown in vivo degradation behavior. Herein, we show a degradable, single-component manganese nanoparticles (Mn NPs) using liquid-phase exfoliation of commercial bulk manganese powder for cancer therapy. In the acidic tumor environment, Mn NPs react with H+ to generate Mn2+ and H2 and raise the local pH. The released Mn2+ drives Fenton-like reactions to produce ROS, while H2 causes mitochondrial damage, which together lead to tumor cell death. In addition, Mn2+ activates cGAS-STING signaling and initiates antitumor immunity. Moreover, Mn NPs inhibit tumor growth in CT26, 4T1, and B16F10 mouse models and show better effects than Mn2+ alone. Transcriptomic analysis further reveals activation of multiple immune-related signaling pathways following Mn NP treatment. In a bilateral tumor model, unilateral injection of Mn NPs triggers a systemic antitumor immune response, leading to effective inhibition of distant, untreated tumor growth. Collectively, this study identifies Mn NPs as a simple, biodegradable, single-component nanoplatform that offers a promising new route for multimodal tumor therapy.
中文摘要:协同治疗纳米平台在肿瘤治疗中受到较多关注,但其转化潜力常受多组分设计复杂和体内降解行为不明确限制。本研究展示一种可降解单组分锰纳米颗粒(Mn NPs),由商用块体锰粉经液相剥离制备,用于肿瘤治疗。在酸性肿瘤环境中,Mn NPs与H+反应生成Mn2+和H2并提高局部pH。释放的Mn2+驱动类Fenton反应产生ROS,H2造成线粒体损伤,两者共同导致肿瘤细胞死亡。Mn2+还可激活cGAS-STING信号并启动抗肿瘤免疫。Mn NPs在CT26、4T1和B16F10小鼠模型中抑制肿瘤生长,效果优于单独Mn2+。转录组分析进一步显示Mn NP处理后多条免疫相关信号通路被激活。在双侧肿瘤模型中,单侧注射Mn NPs引发全身抗肿瘤免疫反应,有效抑制远处未治疗肿瘤生长。该研究将Mn NPs确定为一种简单、可生物降解的单组分纳米平台,为多模式肿瘤治疗提供了有前景的新途径。
Protein lactylation has emerged as a metabolically responsive posttranslational modification linking lactate accumulation to epigenetic and functional adaptation in cancer. Initially identified on histones, lactylation is now recognized on diverse nonhistone proteins involved in DNA damage repair, immune regulation, redox homeostasis, metabolic remodeling, and cellular plasticity. However, current evidence remains fragmented across treatment modalities, and many reported lactylation events lack site-specific functional validation and translational assessment. This review addresses this gap by integrating the metabolic and enzymatic basis of protein lactylation with its roles in chemotherapy, radiotherapy, targeted therapy, and immunotherapy. We critically examine how lactylation may promote tumor persistence under therapeutic pressure by enhancing genome maintenance, immune evasion, stress-survival signaling, metabolic adaptability, and tumor microenvironment remodeling. We also evaluate emerging strategies targeting lactate production and transport, lactylation-regulating enzymes, and functionally validated substrates, including their potential use in combination therapies. Finally, we discuss major barriers to clinical translation, including incomplete characterization of regulatory enzymes, limitations in site-specific lactylome mapping, insufficient causal validation, lack of clinically qualified biomarkers, tumor metabolic heterogeneity, and challenges in achieving therapeutic selectivity. Collectively, protein lactylation represents an emerging mechanistic framework for understanding cancer treatment adaptation and a potentially targetable axis whose clinical relevance requires rigorous validation.
中文摘要:癌症中的蛋白质乳酰化:从机制到治疗。蛋白质乳酰化已成为一种代谢响应性翻译后修饰,将乳酸积累与癌症中的表观遗传及功能适应联系起来。最初在组蛋白上发现,如今已在参与DNA损伤修复、免疫调节、氧化还原稳态、代谢重塑和细胞可塑性的多种非组蛋白上得到识别。然而,现有证据在不同治疗方式之间仍呈碎片化,许多已报道的乳酰化事件缺乏位点特异性功能验证和转化评估。本综述通过整合蛋白质乳酰化的代谢与酶学基础及其在化疗、放疗、靶向治疗和免疫治疗中的作用来弥补这一空白。我们批判性审视乳酰化如何通过增强基因组维持、免疫逃逸、应激生存信号、代谢适应性和肿瘤微环境重塑,在治疗压力下促进肿瘤持续存在。我们也评估靶向乳酸生成与转运、乳酰化调节酶及功能验证底物的新兴策略,包括其在联合治疗中的潜在用途。最后,我们讨论临床转化的主要障碍,包括调节酶表征不完整、位点特异性乳酰化组图谱绘制受限、因果验证不足、缺乏临床合格生物标志物、肿瘤代谢异质性以及实现治疗选择性方面的挑战。总体而言,蛋白质乳酰化代表了一个理解癌症治疗适应的新兴机制框架,也是一个潜在可靶向的轴,其临床相关性需要严格验证。
Neutrophils are the most abundant circulating leukocytes and are essential components of innate immunity, contributing to host defense, inflammation, tissue remodeling, and disease progression. Increasing evidence has revealed substantial neutrophil heterogeneity and functional plasticity, which enable distinct neutrophil populations to exert protective or pathogenic effects depending on the tissue and disease context. These properties have attracted growing interest in neutrophils as therapeutic targets and as vehicles for targeted drug delivery. This review summarizes the biological characteristics and functional heterogeneity of neutrophils, with particular emphasis on their recruitment, phagocytosis, oxidative responses, extracellular trap formation, and interactions with the tissue microenvironment. We further discuss the diverse roles of neutrophils in cancer, inflammatory diseases, infectious diseases, and other pathological conditions, highlighting their context-dependent functions. Building on these insights, we review current and emerging therapeutic strategies, ranging from broad neutrophil modulation to precision targeting and neutrophil-based drug delivery. Living neutrophil carriers, neutrophil membrane-coated nanoparticles, and neutrophil-derived vesicles are comparatively evaluated in terms of preparation, cargo loading, targeting properties, advantages, limitations, and translational potential. Finally, we discuss key challenges in the development and clinical translation of neutrophil-based therapies, including manufacturing, quality control, safety, and therapeutic precision, and highlight future opportunities for their clinical application.
中文摘要:中性粒细胞是循环白细胞中数量最多的一类,也是固有免疫的重要组成部分,参与宿主防御、炎症、组织重塑与疾病进展。越来越多的证据显示,中性粒细胞具有显著的异质性与功能可塑性,不同亚群可依组织与疾病背景发挥保护性或致病性作用。这些特性使中性粒细胞成为治疗靶点和靶向递药的载体,受到越来越多的关注。本综述总结中性粒细胞的生物学特征与功能异质性,重点涉及募集、吞噬、氧化反应、胞外诱捕网形成以及与组织微环境的相互作用。综述还讨论中性粒细胞在肿瘤、炎症性疾病、感染性疾病及其他病理状态中的多样作用,强调其功能依赖具体背景。在此基础上,梳理现有与新兴的治疗策略,涵盖从广谱的中性粒细胞调控到精准靶向以及基于中性粒细胞的药物递送。对活性中性粒细胞载体、中性粒细胞膜包覆纳米颗粒与中性粒细胞来源囊泡,从制备、载药、靶向性能、优势、局限及转化潜力等方面进行比较评估。中性粒细胞疗法在开发与临床转化中仍面临生产、质量控制、安全性与治疗精准性等关键挑战,其临床应用机会也一并展望。
Radiopharmaceuticals have progressed from diagnostic agents toward theranostic. With the accelerating development of therapeutic radiopharmaceuticals, radiopharmaceutical therapy (RPT) is being increasingly implemented in clinical practice in oncology. However, current therapeutic radiopharmaceuticals often contribute to tumor stabilization rather than complete remission. A major determinant of this limited clinical response is the tumor microenvironment (TME), which critically influences the delivery, penetration, and retention of radiopharmaceuticals. Meanwhile, the radiopharmaceuticals can modulate multiple components of the TME, thereby contributing to antitumor effects. These interactions provide opportunities for advancing radiopharmaceuticals to enhance RPT efficacy. In this review, the bidirectional relationship between therapeutic radiopharmaceuticals and TME in solid malignancies is comprehensively discussed. First, common therapeutic strategies that modulate TME are outlined. The impact of the TME on radiopharmaceutical efficacies and how radiopharmaceuticals reshape the TME are then highlighted. In addition to elucidating the bidirectional interplay between RPT and the TME, we examine two fundamental clinical barriers that constrain RPT efficacy: dosimetric limitations and systemic immune collateral damage. Finally, critical challenges and potential strategies to enhance next-generation therapeutic radiopharmaceuticals in solid malignancies are inspected.
中文摘要:放射性药物已从诊断药物向诊疗一体化发展。随着治疗性放射性药物研发加速,放射性药物治疗(RPT)在肿瘤临床实践中的应用日益增多。然而,现有治疗性放射性药物多使肿瘤稳定而非完全缓解。这种有限临床反应的主要决定因素是肿瘤微环境(TME),其关键影响放射性药物的递送、穿透和滞留。同时,放射性药物可调节TME的多个组分,从而参与抗肿瘤效应。这些相互作用为改进放射性药物、提高RPT疗效提供了机会。本综述系统讨论实体恶性肿瘤中治疗性放射性药物与TME的双向关系。文中概述了调节TME的常见治疗策略,重点阐述TME对放射性药物疗效的影响以及放射性药物如何重塑TME。除阐明RPT与TME的双向作用外,还审视了限制RPT疗效的两个基本临床障碍:剂量学限制和全身免疫连带损伤。文中还梳理了增强下一代实体恶性肿瘤治疗性放射性药物的关键挑战与潜在策略。
Gastric cancer is a multifactorial disease shaped by diverse risk factors and a complex pathogenesis spanning from chronic atrophic gastritis to invasive malignancy. Its global incidence shows marked geographic disparities, and advances in understanding its pathogenic mechanisms have improved diagnosis and treatment. Although the relationship between gastric cancer and macrophages has been extensively investigated, a systematic review integrating the entire clinical and biological continuum of gastric cancer, from epidemiology to management, with a focus on macrophages remains lacking. This review summarizes the epidemiology and multidimensional risk factors for gastric cancer, including infectious, dietary, genetic, microbiome, and metabolite-related factors. We describe the evolution of precancerous conditions, molecular alterations such as miRNA expression, and the bidirectional interactions between gastric cancer cells and macrophages that drive tumor progression within the tumor microenvironment. We also review clinical features, diagnostic approaches based on screening and endoscopy, and current management strategies, including surgery, systemic therapies, targeted therapies, immunotherapy, macrophage-targeted therapies, macrophage metabolic reprogramming, and recent preclinical and clinical advances. Overall, this review integrates evidence from epidemiology, molecular biology, immunology, and pathology to provide a comprehensive framework for understanding gastric cancer pathogenesis and current as well as emerging therapeutic strategies.
中文摘要:胃癌是一种多因素疾病,其发生受多种危险因素影响,发病机制复杂,从慢性萎缩性胃炎逐步发展至浸润性恶性肿瘤。全球发病率呈现明显的地域差异,对发病机制认识的深入推动了诊断与治疗的进步。胃癌与巨噬细胞的关系已有大量研究,但尚缺少一部将流行病学到临床管理这一完整临床与生物学连续谱加以整合、并以巨噬细胞为焦点的系统综述。本综述梳理胃癌的流行病学与多维度危险因素,涵盖感染、饮食、遗传、微生物组及代谢物相关因素;描述癌前病变的演变过程、miRNA 表达等分子改变,以及肿瘤微环境中胃癌细胞与巨噬细胞之间驱动肿瘤进展的双向相互作用;同时评述临床特征、基于筛查与内镜的诊断路径以及现行管理策略,包括外科手术、全身治疗、靶向治疗、免疫治疗、巨噬细胞靶向治疗、巨噬细胞代谢重编程,以及近期的临床前与临床进展。综述整合流行病学、分子生物学、免疫学与病理学的证据,为理解胃癌发病机制及现有与新兴治疗策略提供整体框架。
Tissue-resident macrophages originate from distinct developmental sources, but their adult replenishment is thought to depend exclusively on circulating monocytes. Here we identify a previously unrecognized CD4-lineage erythro-myeloid progenitor (EMPROR) in the adult bone marrow that provides an alternative pathway for macrophage generation. EMPROR cells are phenotypically and transcriptionally distinct from hematopoietic stem cells, common myeloid progenitors and monocyte precursors, lacking Csf1r and Ccr2 while expressing Cd4 and Kit. Single-cell RNA sequencing, RNA velocity analysis and lineage assays reveal macrophage, neutrophil, megakaryocytic and erythroid potential. EMPROR cells generate perivascular and tumor-associated macrophages independently of CCR2-mediated monocyte recruitment and contribute to erythroid and granulocytic lineages under inflammatory and neoplastic conditions. Transcriptomic comparisons position EMPROR cells closest to embryonic erythro-myeloid progenitors, indicating the persistence of an embryonic-like program in adult bone marrow. These findings reveal an alternative pathway of adult myelopoiesis that sustains macrophage diversity beyond the classical monocyte lineage.
中文摘要:组织驻留巨噬细胞来源不同,但成体中的补充被认为完全依赖循环单核细胞。我们在成体骨髓中鉴定出一种此前未被认识的CD4谱系红系-髓系祖细胞(EMPROR),它为巨噬细胞生成提供了替代途径。EMPROR细胞在表型和转录上不同于造血干细胞、共同髓系祖细胞及单核前体细胞,不表达Csf1r和Ccr2,而表达Cd4和Kit。单细胞RNA测序、RNA速率分析和谱系实验显示其具有巨噬细胞、中性粒细胞、巨核细胞和红系潜能。EMPROR细胞可不依赖CCR2介导的单核细胞招募生成血管周围和肿瘤相关巨噬细胞,并在炎症和肿瘤条件下参与红系和粒细胞谱系。转录组比较显示EMPROR细胞最接近胚胎红系-髓系祖细胞,提示成体骨髓中保留胚胎样程序。这些发现揭示了成体髓系生成的替代途径,使巨噬细胞多样性得以超越经典单核细胞谱系。
SIRPα is an inhibitory receptor with the canonical ligand CD47. Here, we show that human serine protease inhibitor A3 (SERPINA3) and its mouse ortholog SERPINA3k function as soluble binders and activators of SIRPα, suppressing SIRPα+ macrophages, neutrophils, dendritic cells and natural killer cells. SERPINA3(k) treatment alleviates lipopolysaccharide-induced pneumonia and ameliorates experimental autoimmune encephalomyelitis and rheumatoid arthritis. Although wild-type SERPINA3 provokes inflammation in cardiomyocytes and brain vascular endothelial cells, the SERPINA3D2 mutant, identified through functional domain mapping for SIRPα interaction, abolishes these adverse effects while retaining full inhibitory capacity. Notably, cancer cells secrete large amounts of SERPINA3(k), exceeding CD47 levels. Anti-SERPINA3(k) antibodies, used alone or in combination with blockade of programmed cell death 1 receptor/programmed cell death ligand 1, inhibit tumor growth in multiple preclinical models. This work identifies a potent soluble SIRPα ligand, offering effective therapeutic strategies for inflammatory/autoimmune diseases and a promising target for cancer immunotherapy.
中文摘要:SIRPα是一种抑制性受体,经典配体为CD47。这里显示,人丝氨酸蛋白酶抑制剂A3(SERPINA3)及其小鼠同源物SERPINA3k可作为SIRPα的可溶性结合蛋白和激活因子,抑制SIRPα阳性巨噬细胞、中性粒细胞、树突状细胞和自然杀伤细胞。SERPINA3(k)处理可减轻脂多糖诱导的肺炎,并改善实验性自身免疫性脑脊髓炎和类风湿关节炎。野生型SERPINA3会在心肌细胞和脑血管内皮细胞中引发炎症,而通过针对SIRPα相互作用的功能结构域定位鉴定出的SERPINA3D2突变体消除了这些不良作用,同时保留完整的抑制能力。癌细胞可大量分泌SERPINA3(k),其水平超过CD47。抗SERPINA3(k)抗体单用或联合程序性死亡受体1/程序性死亡配体1阻断,可在多种临床前模型中抑制肿瘤生长。这项工作鉴定出一种强效可溶性SIRPα配体,为炎症/自身免疫性疾病提供有效治疗策略,并为肿瘤免疫治疗提供有前景的靶点。
Efferocytosis plays a critical role in maintaining tissue homeostasis and controlling inflammation. However, in the tumor microenvironment, this process is hijacked to promote immune suppression. Treatments like radiotherapy and chemotherapy lead to widespread tumor cell death, which triggers efferocytosis and drives macrophages into an immunosuppressive state, allowing the tumor to evade the immune system and resist treatment. Nonetheless, the way efferocytic signals alter macrophage function and promote protumor effects during the recognition, engulfment, and digestion of apoptotic cells remains largely unclear. Therefore, this review thoroughly examines the influence of signaling molecules during the three stages of efferocytosis on macrophage phenotype and function. Subsequently, we explore the impact of polarized M2-type macrophages on shaping the immunosuppressive tumor microenvironment and regulating the development of drug resistance. Additionally, we critically evaluate the current status of clinical translation of efferocytosis receptor-related drugs and analyze the potential reasons for their synergistic or antagonistic interactions with chemotherapy and immunotherapy. This study provides a comprehensive understanding of the regulatory mechanisms of efferocytosis in macrophage polarization, enhancing knowledge of the fundamental mechanisms underlying tumor immune evasion and offering important guidance for the development of anticancer therapies targeting the efferocytosis process.
中文摘要:胞葬作用在维持组织稳态和控制炎症中起关键作用。但在肿瘤微环境中,这一过程被劫持以促进免疫抑制。放疗和化疗等治疗造成广泛肿瘤细胞死亡,触发胞葬作用,使巨噬细胞进入免疫抑制状态,肿瘤得以逃避免疫系统并产生治疗抵抗。在识别、吞噬和消化凋亡细胞的过程中,胞葬信号如何改变巨噬细胞功能并促进促肿瘤效应仍不清楚。本综述系统梳理胞葬作用三个阶段中的信号分子对巨噬细胞表型和功能的影响。进一步分析M2型极化巨噬细胞对免疫抑制肿瘤微环境的塑造及对耐药发展的调控。并批判性评估胞葬受体相关药物的临床转化现状,分析其与化疗和免疫治疗产生协同或拮抗作用的可能原因。该综述提供对胞葬作用调控巨噬细胞极化的全面认识,增进对肿瘤免疫逃逸基本机制的理解,并为开发靶向胞葬过程的抗癌治疗提供重要指导。
Natural killer (NK) cells are valuable for cancer immunotherapy because they kill tumor cells without prior sensitization or human leukocyte antigen (HLA) restriction. However, their efficacy is often limited by immune-evasion, especially major histocompatibility complex I (MHC-I)-mediated NK cell inhibition. NK cell engagers (NKCEs) can redirect NK cells to tumor for more effective immunotherapy, but most current NKCEs target tumor-associated antigens (TAAs), risking on-target, off-tumor toxicity in clinical applications. Neoantigens, as tumor-specific antigens (TSAs) arising from somatic mutations and presented by MHC-I on tumor cell surfaces, represent ideal tumor-specific target. Here, we engineered NKCEs built on neoantigen-targeting TCR-mimic antibodies (TCRm-Abs) to enhance tumor-specific NK cell-mediated cytotoxicity. Using a high-throughput hydrogel-based microwell single-cell chip (HMSC-chip) coupled with T2 cell-based de-selection, we identified C33-Ab, a functional TCRm-Ab specific for p53R175H/HLA-A*02:01, from ∼500,000 hybridoma cells within 8 weeks. Based on this TCRm-Ab, we constructed a bispecific NKCE (C33×CD16), a single-chain diabody (scDb) linking C33-Ab to an anti-CD16 scFv. C33×CD16 specifically bridges NK cells with p53R175H/HLA-A*02:01-positive cancer cells. It potently enhanced NK cell-mediated cytotoxicity in vitro and antitumor efficacy in vivo upon adoptive NK-cell transfer. This TCRm-Ab-based bispecific NKCE offers a promising strategy for tumor-specific NK cell-mediated immunotherapy by targeting intracellular oncogenic hotspot mutations.
中文摘要:自然杀伤(NK)细胞在肿瘤免疫治疗中具有价值,因其无需预先致敏且不受HLA限制即可杀伤肿瘤细胞。但免疫逃逸常限制其疗效,尤其是MHC-I介导的NK细胞抑制。NK细胞衔接器(NKCE)可将NK细胞重定向至肿瘤,从而增强免疫治疗,但现有NKCE多靶向肿瘤相关抗原(TAA),临床应用存在瘤外毒性风险。新抗原由体细胞突变产生并经MHC-I呈递于肿瘤细胞表面,属于肿瘤特异性抗原(TSA),是理想的肿瘤特异性靶点。研究构建了基于靶向新抗原的TCR模拟抗体(TCRm-Ab)的NKCE,以增强肿瘤特异性NK细胞杀伤。利用高通量水凝胶微孔单细胞芯片(HMSC-chip)结合基于T2细胞的去选择,在8周内从约50万个杂交瘤细胞中鉴定出C33-Ab,这是一种针对p53R175H/HLA-A*02:01的功能性TCRm-Ab。基于该抗体构建双特异性NKCE(C33×CD16),即用单链双体抗体(scDb)将C33-Ab与抗CD16 scFv连接。C33×CD16可特异性桥接NK细胞与p53R175H/HLA-A*02:01阳性肿瘤细胞,在体外显著增强NK细胞介导的细胞毒性,并在过继NK细胞回输后提高体内抗肿瘤效果。这种基于TCRm-Ab的双特异性NKCE通过靶向细胞内致癌热点突变,为肿瘤特异性NK细胞免疫治疗提供了有前景的策略。
Most patients with solid tumors fail to sustain antitumor immunity, in part because immune cells cannot outcompete cancer cells inside the immunosuppressive tumor microenvironment. Here, we show the lipid-sensing transcription factor PPARδ is a compartment-specific determinant of cancer-immune fitness balance and immunotherapy efficacy. Activating PPARδ in cancer cells promotes their growth and impairs antitumor immunity, whereas activating it in immune cells drives tumor suppression and overrides tumor-promoting effects of cancer-intrinsic activation. Mechanistically, PPARδ enhances CD8+ T cell fitness against cancer through effector-associated chromatin remodeling and Cpt1a-mediated fatty acid oxidation. Therapeutically, PPARδ-activated CD8+ T cells sensitize immunotherapy-resistant microsatellite stable metastatic colorectal cancer to checkpoint blockade in mice, and pharmacological or genetic PPARδ activation enhances human chimeric antigen receptor T cell function. These findings identify compartment-specific PPARδ activity as a targetable driver of immune cell fitness that can be harnessed to improve outcomes in immunotherapy-resistant tumors.
中文摘要:多数实体瘤患者无法维持抗肿瘤免疫,部分原因是免疫细胞在免疫抑制性肿瘤微环境内不能胜过癌细胞。脂质感知转录因子PPARδ是决定癌细胞与免疫细胞适应度平衡及免疫治疗疗效的区室特异性因素。在癌细胞中激活PPARδ促进其生长并削弱抗肿瘤免疫,而在免疫细胞中激活PPARδ则驱动肿瘤抑制,并可压过癌细胞内在激活的促瘤效应。机制上,PPARδ通过效应相关的染色质重塑和Cpt1a介导的脂肪酸氧化增强CD8+ T细胞对抗癌细胞的适应度。治疗层面,PPARδ激活的CD8+ T细胞使小鼠中对免疫治疗耐药、微卫星稳定的转移性结直肠癌对检查点阻断敏感,药物或遗传学激活PPARδ可增强人嵌合抗原受体T细胞功能。这些发现表明,区室特异性PPARδ活性是可靶向的免疫细胞适应度驱动因素,可用于改善免疫治疗耐药肿瘤的结局。
Engineering autologous T cells for adoptive therapies has revolutionized cancer treatment, yet limited persistence remains a major barrier to robust clinical responses and durable disease control. Although costimulation with 4-1BB markedly improves CAR-T-cell persistence, no comparably effective approach has been identified to enhance persistence in T-cell therapies that rely on native TCR signaling, including conventional TCR-T cells and synthetic T-cell receptor and antigen receptor (STAR) T cells. To identify intrinsic persistence regulators in a TCR-based context, we performed an in vivo CRISPR activation screen in STAR-T cells and identified the noncanonical NF-κB axis, with RELB as the top hit. Direct RELB overexpression, however, exhibited dose-dependent cytotoxicity, motivating a translational alternative: overexpression of p52, the ncNF-κB transcription partner of RELB. Under prolonged antigen exposure, p52 overexpression sustained proliferation, preserved effector functions, and increased the intratumoral trafficking potential, particularly in CD8⁺ T cells, thereby yielding superior tumor control. Mechanistically, transcriptomic profiling revealed coordinated upregulation of cell cycle programs and chemokine receptors, along with downregulation of apoptosis and exhaustion-associated modules. Moreover, p52 overexpression restored RELB nuclear translocation in the context of PD-1/PD-L1 engagement, indicating partial resistance to checkpoint-mediated suppression and sustained ncNF-κB activity in PD-L1hi immunosuppressive environments. Collectively, our findings identify p52 as an antigen-dependent enhancer of ncNF-κB, conferring durable persistence and checkpoint resilience on TCR-based T cells and providing a feasible strategy to improve therapeutic effects in solid tumors.
中文摘要:改造自体T细胞用于过继治疗已革新肿瘤治疗,但持久性有限仍是实现稳健临床应答和持久疾病控制的主要障碍。4-1BB共刺激可显著提高CAR-T细胞持久性,但在依赖天然TCR信号的T细胞治疗中,包括传统TCR-T细胞和合成T细胞受体与抗原受体(STAR)T细胞,尚未找到同样有效的增强持久性的方法。为在TCR背景下识别内在持久性调控因子,我们在STAR-T细胞中进行了体内CRISPR激活筛选,发现非经典NF-κB轴,其中RELB为最显著命中。直接过表达RELB却表现出剂量依赖性细胞毒性,这促使我们采用一种转化替代方案:过表达p52,即RELB的ncNF-κB转录伙伴。在长时间抗原暴露下,p52过表达维持增殖、保留效应功能,并提高瘤内迁移潜能,尤其在CD8⁺ T细胞中,从而获得更优的肿瘤控制。机制上,转录组分析显示细胞周期程序和趋化因子受体协同上调,同时凋亡及耗竭相关模块下调。在PD-1/PD-L1结合的情况下,p52过表达恢复了RELB核转位,提示其对检查点介导的抑制具有部分抵抗,并在PD-L1高表达免疫抑制环境中维持ncNF-κB活性。这些结果将p52确定为ncNF-κB的抗原依赖性增强因子,使基于TCR的T细胞获得持久存续和检查点韧性,并为改善实体瘤治疗效果提供了可行策略。
Colorectal cancer (CRC) remains a leading cause of cancer mortality. Tumor-associated macrophages (TAMs) regulate CRC progression through functional polarization and metabolic reprogramming. Beyond the classical M1/M2 paradigm, single-cell and spatial studies reveal heterogeneous TAM subsets with distinct metabolic programs, spatial organization, and stage-dependent functions. This review delineates how TAM metabolic reprogramming drives CRC via metabolite-induced PD-L1 expression, oncogenic signaling, and crosstalk with chronic inflammation and gut microbiota. We emphasize spatial metabolic heterogeneity, TAM-tumor metabolic symbiosis, the stage-dependent duality of M2-like macrophages in colitis versus CRC, and pathogen-driven cross-kingdom manipulation. Clinical evidence linking TAM metabolic features to molecular subtypes, metastasis, prognosis, and treatment response is integrated, and methodological challenges in distinguishing true metabolic reprogramming from phenotypic changes are discussed. Therapeutic strategies targeting TAM metabolism, including small molecules, chemotherapeutics, TCM, nanomedicine, probiotics, and combinations, are summarized, offering precise TAM reprogramming to reverse immunosuppression and overcome CRC therapeutic bottlenecks.
中文摘要:结直肠癌仍是癌症死亡的主要原因之一。肿瘤相关巨噬细胞通过功能极化和代谢重编程调控结直肠癌进展。超出经典M1/M2范式,单细胞与空间研究揭示了具有不同代谢程序、空间组织和分期依赖功能的异质性肿瘤相关巨噬细胞亚群。本综述阐述肿瘤相关巨噬细胞代谢重编程如何经代谢物诱导的PD-L1表达、致癌信号以及与慢性炎症和肠道菌群的交互作用驱动结直肠癌。重点讨论空间代谢异质性、肿瘤相关巨噬细胞与肿瘤的代谢共生、M2样巨噬细胞在结肠炎与结直肠癌中的分期依赖双重性,以及病原体驱动的跨界操控。整合了将肿瘤相关巨噬细胞代谢特征与分子亚型、转移、预后和治疗反应相关联的临床证据,并讨论区分真正代谢重编程与表型变化的方法学挑战。总结靶向肿瘤相关巨噬细胞代谢的治疗策略,包括小分子、化疗药、中药、纳米药物、益生菌及联合方案,为精准重编程肿瘤相关巨噬细胞以逆转免疫抑制、突破结直肠癌治疗瓶颈提供思路。
Metabolic reprogramming and immune evasion are hallmarks of cancer. Although leucine is well known for regulating protein synthesis, its role in immunometabolic interactions within the tumor microenvironment (TME) remains unclear. In this study, we found that leucine supplementation significantly inhibited tumor growth. Metabolomic analysis revealed that isovaleric acid (IVA) was the main differential metabolite produced during leucine degradation by the gut microbiota. Mechanistically, IVA directly binds to EIF3I at lysine 17 (K17), increasing its ubiquitination and promoting its proteasomal degradation. The degradation of EIF3I reduces the expression of SMAD3/p-SMAD3, thus suppressing the transcription of the chemokines CCL2 and CXCL12. The decreased expression of CCL2 and CXCL12 reduces the recruitment of myeloid-derived suppressor cell (MDSC) and restores the infiltration and cytotoxic activity of CD8+ T cells. Overall, our study reveals a novel immunometabolic axis linking isovaleric acid to tumor microenvironment remodeling and suggests that targeting EIF3I may represent a potential therapeutic strategy.
中文摘要:代谢重编程与免疫逃逸是癌症的标志。亮氨酸以调控蛋白合成著称,但它在肿瘤微环境(TME)免疫代谢相互作用中的作用仍不清楚。补充亮氨酸可显著抑制肿瘤生长。代谢组分析显示,异戊酸(IVA)是肠道菌群降解亮氨酸过程中产生的主要差异代谢物。机制上,IVA直接结合EIF3I的赖氨酸17(K17),增加其泛素化并促进蛋白酶体降解。EIF3I降解降低SMAD3/p-SMAD3表达,抑制趋化因子CCL2和CXCL12转录。CCL2和CXCL12表达下降减少髓源性抑制细胞(MDSC)募集,恢复CD8+ T细胞浸润与杀伤活性。这些结果揭示了一条连接异戊酸与肿瘤微环境重塑的新型免疫代谢轴,并提示靶向EIF3I可能成为潜在治疗策略。
Antimetabolites have been used to treat cancer since the 1950s, yet how tumors survive remains unclear. Two studies by Moss and colleagues and Witus and colleagues show that surviving cells recycle nucleotides and reshape mitochondria, revealing a shared resistance program. Because this program is measurable, it could identify, before treatment, which patients would benefit from drugs that block it.
中文摘要:抗代谢药自20世纪50年代起用于治疗癌症,但肿瘤如何存活仍不清楚。Moss及其同事以及Witus及其同事的两项研究表明,存活细胞会回收核苷酸并重塑线粒体,揭示出一个共有的耐药程序。由于该程序可被测量,它有可能在治疗前识别哪些患者会从阻断该程序的药物中获益。
Immune checkpoint blockade has revolutionized cancer therapy, but durable benefit remains limited by immune-cold tumor states, poor antigen presentation, T cell exhaustion, and adaptive resistance. Recent studies position lysine-specific demethylase 1 (LSD1) as a druggable epigenetic regulator that links these barriers across tumor and immune cells. Emerging evidence shows that targeting LSD1 can restore major histocompatibility complex class I antigen presentation, activate viral mimicry and interferon programs, modulate programmed death-ligand 1 in a context-dependent manner, influence CD8+ T cell state transitions, and restrain tumor plasticity. In this review, we feature these mechanistic advances, compare evolving drug classes, and outline biomarker-guided strategies that may support the rational development of next-generation combination immunotherapy.
中文摘要:免疫检查点阻断改变了肿瘤治疗格局,但持久获益仍受限于免疫冷肿瘤状态、抗原呈递不足、T细胞耗竭和适应性耐药。近期研究将赖氨酸特异性去甲基化酶1(LSD1)定位为可成药的表观遗传调控因子,在肿瘤细胞与免疫细胞之间连接上述障碍。新出现的证据显示,靶向LSD1可恢复主要组织相容性复合体I类抗原呈递,激活病毒模拟与干扰素程序,以情境依赖方式调节程序性死亡配体1,影响CD8+ T细胞状态转换,并限制肿瘤可塑性。本综述聚焦这些机制进展,比较不断演变的药物类别,并概述可能支持下一代联合免疫治疗合理开发的生物标志物指导策略。
Radiotherapy is a fundamental modality in cancer treatment, used in the management of more than half of cancer patients. Beyond direct cytotoxicity, ionizing radiation activates innate immune pathways and inflammatory cytokines required for local tumor control and systemic (abscopal) responses. Yet in human tumors, DNA damage-induced immune activation is attenuated compared with the robust responses observed in mice, suggesting a human-biased checkpoint that constrains radioimmunity. Here, we identify a tumor-intrinsic, human-biased farnesoid X receptor (FXR)-tripartite motif containing 22 (TRIM22)-STAT1 proteostatic checkpoint that suppresses radiation-induced type I interferon signaling. Ionizing radiation stabilizes FXR, a nuclear receptor, through ubiquitin-specific peptidase 7 (USP7)-dependent deubiquitination, enabling FXR to transcriptionally induce the E3 ligase TRIM22. TRIM22 selectively binds STAT1 and catalyzes its K48-linked ubiquitination and degradation, extinguishing interferon-stimulated gene (ISG) programs downstream of cGAS-STING signaling. This regulatory circuit is absent in murine tumor cells, which lack a TRIM22 family member capable of destabilizing STAT1, providing a mechanistic explanation for the stronger radiation-induced immune responses observed in mice. Genetic disruption of FXR or TRIM22 preserves STAT1, amplifies type I interferon signaling, and enhances CD8⁺ T-cell activation and abscopal tumor control in peripheral blood mononuclear cell-humanized mice. Pharmacologic modulation of this pathway with ursodeoxycholic acid, a bile acid used clinically with reported FXR-antagonistic activity, suppresses radiation-induced TRIM22, restores STAT1-ISG signaling, and potentiates radiotherapy alone or with anti-PD-1 without overt toxicity in humanized models. Collectively, these findings define a human-biased checkpoint that limits radiotherapy-induced immunity and is absent in murine tumor cells, and highlight the FXR-TRIM22-STAT1 axis as an actionable target to enhance cancer radioimmunotherapy.
中文摘要:放疗是癌症治疗的基本手段,用于超过一半癌症患者的管理。除直接细胞毒性外,电离辐射激活先天免疫通路和炎症细胞因子,这些是局部肿瘤控制和全身(远隔)反应所需的。然而在人肿瘤中,DNA损伤诱导的免疫激活相比小鼠中观察到的强反应被削弱,提示存在限制放射免疫的人偏向性检查点。这里鉴定了一个肿瘤内在的人偏向性法尼醇X受体(FXR)-含三重基序蛋白22(TRIM22)-STAT1蛋白稳态检查点,抑制辐射诱导的I型干扰素信号。电离辐射通过泛素特异性肽酶7(USP7)依赖性去泛素化稳定核受体FXR,使FXR转录诱导E3连接酶TRIM22。TRIM22选择性结合STAT1并催化其K48连接泛素化和降解,熄灭cGAS-STING信号下游的干扰素刺激基因(ISG)程序。该调控回路在小鼠肿瘤细胞中缺失,因为小鼠缺乏能够使STAT1失稳的TRIM22家族成员,这为小鼠中观察到的更强辐射诱导免疫反应提供机制解释。遗传破坏FXR或TRIM22可保留STAT1,放大I型干扰素信号,并增强外周血单个核细胞人源化小鼠中的CD8⁺ T细胞活化和远隔肿瘤控制。使用熊去氧胆酸(一种临床使用的胆汁酸,报道具有FXR拮抗活性)对该通路进行药理调控,可抑制辐射诱导的TRIM22,恢复STAT1-ISG信号,并在人源化模型中增强单用放疗或联合抗PD-1的疗效,且无明显毒性。这些发现定义了一个限制放疗诱导免疫且在小鼠肿瘤细胞中缺失的人偏向性检查点,并突出FXR-TRIM22-STAT1轴作为增强癌症放射免疫治疗的可操作靶点。
Polysaccharides from Lycium barbarum L., particularly LBP3, exhibit immunomodulatory and anti-tumor properties, yet their active constituents remain unclear. Here, LBP3 was fractionated into PolyA, PolyB, and PolyC. PolyC emerged as the key bioactive component, enhancing phagocytosis in vitro and showing superior anti-tumor efficacy to PolyA in vivo (125 mg/kg). Mechanistically, PolyC upregulates gp91 and p47 expression involving Dectin-1, driving M2 macrophages toward an M1 phenotype and enhancing antigen presentation and adaptive immunity. Purification of PolyC yielded its major subfraction, PolyD, which was structurally characterized as a predominant α-(1 → 4)-linked glucan with α-(1 → 6)-branching and a terminal β-linkage. Despite its α-configuration, PolyD retains Dectin-1 agonistic activity, suggesting that Dectin-1 may recognize specific α-glucan conformations. In summary, this study establishes PolyC as the key bioactive component of LBP3 and PolyD as its structurally defined α-glucan, demonstrating that PolyC's anti-tumor activity involves Dectin-1-mediated NOX2 upregulation in TAMs, expanding the chemical diversity of Dectin-1 agonists and informing immunotherapy design.
中文摘要:枸杞多糖尤其是LBP3具有免疫调节和抗肿瘤作用,但其活性成分尚不清楚。LBP3被分离为PolyA、PolyB和PolyC。PolyC是关键生物活性组分,体外增强吞噬作用,体内125 mg/kg剂量下抗肿瘤效果优于PolyA。机制上,PolyC通过涉及Dectin-1的途径上调gp91和p47表达,促使M2巨噬细胞向M1表型转化,并增强抗原提呈和适应性免疫。纯化PolyC获得主要亚组分PolyD,结构表征为以α-(1→4)连接的葡聚糖为主,带α-(1→6)分支和末端β-连接。尽管为α构型,PolyD仍保留Dectin-1激动活性,提示Dectin-1可能识别特定α-葡聚糖构象。该研究确定PolyC为LBP3的关键生物活性组分,PolyD为其结构明确的α-葡聚糖,并证明PolyC的抗肿瘤活性涉及TAMs中Dectin-1介导的NOX2上调,拓展了Dectin-1激动剂的化学多样性,并为免疫治疗设计提供依据。
The composition and functional activity of the gut microbiome are important host-associated factors that influence the efficacy and responsiveness of cancer immunotherapy. Traditional microbiome modulation methods lack precision, consistency, and extensive clinical applicability. Engineered nanoparticles (NPs) represent an emerging platform for investigating more controllable approaches to microbiome-associated therapeutic modulation. NPs possess physicochemical characteristics that can influence the gut microbial ecosystem. This review introduces the concept of "nanoparticle pharmacomicrobiomics" as an emerging framework that links NP design to defined microbial shifts and their potential pharmacological and immunological consequences. Through integrated literature synthesis, bibliometric co-occurrence analysis, clinical trial synthesis, and mechanistic interpretation, we develop a conceptual framework that describes potential relationships among NP properties, microbial ecology, metabolite signalling, immune modulation, and cancer immunotherapy. We emphasize the integration of nanomaterials, microbiome science, and immunology as an emerging interdisciplinary direction in oncology. This framework provides a conceptual basis that may facilitate the development of future strategies that integrate nanotechnology with microbiome and immune modulation to improve precision cancer immunotherapy.
中文摘要:肠道微生物组的组成和功能活动是影响癌症免疫治疗疗效和反应性的重要宿主相关因素。传统微生物组调控方法缺乏精确性、一致性及广泛临床适用性。工程化纳米颗粒(NPs)为探索更可控的微生物组相关治疗调控方法提供了新兴平台。NPs的理化特性可影响肠道微生物生态系统。「纳米颗粒药物微生物组学」概念被引入,作为一个新兴框架,将NP设计与明确的微生物群变化及其潜在药理学和免疫学后果联系起来。通过整合文献综合、文献计量共现分析、临床试验综合和机制阐释,构建了一个概念框架,描述NP特性、微生物生态、代谢物信号、免疫调节和癌症免疫治疗之间的潜在关系。纳米材料、微生物组科学与免疫学的整合被视为肿瘤学中新兴的跨学科方向。该框架提供了概念基础,可能促进未来将纳米技术与微生物组和免疫调节相结合的策略开发,以改善精准癌症免疫治疗。
Colorectal cancer liver metastasis (CRLM) represents a formidable clinical challenge, yet the metabolic mechanisms by which tumor cells dismantle hepatic immune surveillance and remodel the tumor microenvironment (TME) remain elusive. Here, integrating single-cell RNA sequencing (scRNA-seq), transcriptomic analysis, and mass cytometry (CyTOF), we uncover MAL2 as a key regulator of immune-metabolic crosstalk in CRLM. MAL2 is significantly upregulated and specifically enriched in malignant epithelial cells within liver metastatic lesions. Transcriptomic analysis demonstrates that MAL2 activates non-canonical NF-κB (ncNF-κB) signaling, directly driving FASN transcription, enhancing lipid droplet (LD) biogenesis and secretion, and promoting epithelial-mesenchymal transition (EMT). CyTOF-based immune mapping further indicates that these tumor-derived LDs, upon entering the metastatic microenvironment, selectively recruit PLIN2+ neutrophils and induce neutrophil extracellular traps (NETs), which entrap FABP1+ macrophages and forge an immunosuppressive niche that accelerates metastatic outgrowth. Conceptually, these LDs function as "Trojan horses," appearing as innocuous metabolic gifts while harboring hidden MAL2-driven signals. Once inside the liver, they "open the gates" by recruiting and reprogramming myeloid cells, ultimately dismantling immune defenses from within. Our study establishes MAL2-induced LDs as critical mediators of metastatic immune evasion and nominates the MAL2-ncNF-κB-FASN axis as a therapeutic vulnerability in CRLM.
中文摘要:结直肠癌肝转移(CRLM)是严峻的临床难题,肿瘤细胞如何通过代谢机制瓦解肝脏免疫监视并重塑肿瘤微环境(TME),仍不清楚。该研究整合单细胞RNA测序(scRNA-seq)、转录组分析和质谱流式(CyTOF),发现MAL2是CRLM中免疫-代谢互作的关键调控因子。MAL2在肝转移灶恶性上皮细胞中显著上调并特异性富集。转录组分析显示,MAL2激活非经典NF-κB(ncNF-κB)信号,直接驱动FASN转录,增强脂滴(LD)生成与分泌,并促进上皮-间质转化(EMT)。基于CyTOF的免疫图谱进一步表明,这些肿瘤来源脂滴进入转移微环境后,选择性招募PLIN2+中性粒细胞并诱导中性粒细胞胞外诱捕网(NETs),后者捕获FABP1+巨噬细胞,构建加速转移灶生长的免疫抑制生态位。概念上,这些脂滴如同「特洛伊木马」,看似无害的代谢礼物,实则携带隐藏的MAL2驱动信号。进入肝脏后,它们通过招募并重编程髓系细胞「打开城门」,最终从内部瓦解免疫防御。该研究确立MAL2诱导的脂滴是转移性免疫逃逸的重要介质,并将MAL2-ncNF-κB-FASN轴列为CRLM的潜在治疗脆弱点。
In cancer, T-cell state strongly influences antitumor immunity and response to immunotherapy. High-parameter cytometry, single-cell transcriptomics, and multiomic profiling now resolve lineage identity, differentiation history, clonality, metabolic fitness, and tissue adaptation in parallel. These studies place naïve, activated, effector, memory, exhausted, and senescent T cells along continuous, context-dependent trajectories rather than within rigid subset boundaries. Their transitions are shaped by interacting transcriptional, epigenetic, signaling, and metabolic programs that integrate antigen strength, co-stimulation, and cytokines with cues from the tumor microenvironment. Within that microenvironment, suppressive myeloid, erythroid, and stromal populations, extracellular matrix (ECM) remodeling and spatial exclusion, nutrient competition, and tissue-specific conditioning impose a chronic stress that, together with sustained immune-checkpoint signaling, drives exhaustion and senescence and underlies immune evasion. This mechanistic view shifts the therapeutic question from how broadly to activate T cells to which states should be generated, preserved, or rescued. We organize dysfunctional T-cell states along five complementary dimensions: reversibility, antigen dependence, proliferative history, epigenetic fixation, and metabolic collapse. We then map precision cytokines, spatially restricted co-stimulation, metabolic interventions, epigenetic modulation, immune-checkpoint blockade, and genome engineering onto the state transitions they are intended to influence. This framework separates clinically established approaches from exploratory strategies and provides a testable basis for state-informed biomarker development and therapeutic design.
中文摘要:在肿瘤中,T细胞状态强烈影响抗肿瘤免疫与免疫治疗应答。高参数流式细胞术、单细胞转录组学与多组学分析如今可并行解析谱系身份、分化历史、克隆性、代谢适应性与组织适应特征。这些研究把初始、活化、效应、记忆、耗竭与衰老T细胞置于连续的、依赖情境的轨迹上,而非僵硬的亚群边界内。其状态转换由相互作用的转录、表观遗传、信号与代谢程序塑造,这些程序整合抗原强度、共刺激与细胞因子以及来自肿瘤微环境的信号。在该微环境中,抑制性髓系、红系与基质细胞群体、细胞外基质重塑与空间排斥、营养竞争以及组织特异性适应共同施加慢性应激,与持续的免疫检查点信号一起驱动耗竭与衰老,并构成免疫逃逸的基础。这一机制视角将治疗问题从「如何广泛激活T细胞」转为「应生成、维持或挽救哪些状态」。我们沿五个互补维度组织功能异常的T细胞状态:可逆性、抗原依赖性、增殖历史、表观遗传固定与代谢崩溃。随后把精准细胞因子、空间限制性共刺激、代谢干预、表观遗传调控、免疫检查点阻断与基因组工程对应到其意图影响的状态转换上。该框架区分了临床已确立的方法与探索性策略,并为基于状态的生物标志物开发与治疗设计提供了可检验的基础。
Conventional fractionated radiotherapy (CFRT) remains a mainstay for many solid tumors, yet it often fails to elicit durable anti-tumor immunity. How CFRT engages tumor-cell programs to shape the immune microenvironment and determine therapeutic outcome remains unclear. Here we show in preclinical mouse models that CFRT is associated with increased tumor-cell HMGB1 relative to stereotactic body radiotherapy (SBRT), and that loss of tumor-cell HMGB1 eliminates the efficacy gap between the regimens. HMGB1 deficiency markedly restrains tumor progression under CFRT in immunocompetent, but not immunodeficient, hosts, accompanied by increased intratumoral CD8+ T cells and effector function. In esophageal squamous cell carcinoma (ESCC) specimens from patients receiving CFRT plus platinum-based chemotherapy, tumor-cell HMGB1 increases after treatment, and elevated pretreatment HMGB1 is associated with poor treatment response, reduced post-treatment CD8+ T-cell infiltration, and adverse outcomes. Mechanistically, HMGB1 restrains CFRT-induced CD8+ T-cell immunity through two convergent arms: CCL2-CCR2-dependent accumulation of suppressive monocytes and FUT8-linked regulation of PD-L1 fucosylation in tumor cells. TCF4 is linked to HMGB1-dependent induction of CCL2 and FUT8. Blocking CCL2 or inhibiting PD-L1 fucosylation restores CD8+ T-cell effector function and enhances CFRT efficacy, alone or in combination with anti-PD-1 therapy. Together, these findings identify a tumor-cell HMGB1 program that underpins CFRT-associated immune suppression and nominate actionable targets to improve CFRT-immunotherapy combinations.
中文摘要:常规分割放疗(CFRT)仍是许多实体瘤的主要治疗手段,但常难以激发持久的抗肿瘤免疫。CFRT如何调动肿瘤细胞程序以塑造免疫微环境并决定治疗结局仍不清楚。我们在临床前小鼠模型中发现,与立体定向体部放疗(SBRT)相比,CFRT与肿瘤细胞HMGB1升高相关,而肿瘤细胞HMGB1缺失消除了两种方案之间的疗效差距。在免疫功能正常而非免疫缺陷宿主中,HMGB1缺失显著抑制CFRT期间的肿瘤进展,并伴随瘤内CD8+ T细胞增多和效应功能增强。在接受CFRT联合铂类化疗的食管鳞状细胞癌(ESCC)患者标本中,治疗后肿瘤细胞HMGB1升高,治疗前HMGB1较高与治疗反应差、治疗后CD8+ T细胞浸润减少及不良结局相关。机制上,HMGB1通过两条汇聚通路抑制CFRT诱导的CD8+ T细胞免疫:CCL2-CCR2依赖的抑制性单核细胞积聚,以及FUT8相关的肿瘤细胞PD-L1岩藻糖基化调控。TCF4与HMGB1依赖的CCL2和FUT8诱导相关。阻断CCL2或抑制PD-L1岩藻糖基化可恢复CD8+ T细胞效应功能并增强CFRT疗效,单用或与抗PD-1治疗联合均有效。这些发现识别出支撑CFRT相关免疫抑制的肿瘤细胞HMGB1程序,并提出可操作的靶点以改善CFRT与免疫治疗联合。
Tertiary lymphoid structures (TLS), which form as tumor-localized lymphoid-like structures, play a critical role in enhancing immune responses and improving prognosis. However, native TLS is highly prone to developmental arrest within the tumor microenvironment (TME), and conventional free-circulating drugs suffer from significant drawbacks such as short half-lives and high systemic toxicity. Nanomedicines, with their advantages of spatiotemporally controlled release, deep physical penetration, and multi-target co-delivery, offer an engineered solution for reshaping the TME and inducing TLS formation. This article systematically summarizes engineered intervention strategies for nanomedicine-induced TLS formation across three key aspects: activating chemotactic networks to accelerate immune cell homing; targeting matrix reprogramming to induce high-endothelial microvessels for physical scaffold construction; and enhancing antigen cross-presentation to drive germinal center (GC) maturation. Furthermore, the paper explores in depth how nanomedicine-mediated TLS functions as an immunological hub, generating synergistic effects with existing immune checkpoint inhibitors, cellular therapies, and physical therapies. Finally, it analyzes the current barriers to clinical translation in this field and outlines a blueprint for future development. Through a multidisciplinary perspective, this paper provides theoretical guidance and a technical roadmap for the design and clinical application of next-generation precision immunotherapy nanomedicines.
中文摘要:三级淋巴结构(TLS)作为肿瘤局部形成的淋巴样结构,在增强免疫应答和改善预后中起关键作用。天然TLS在肿瘤微环境(TME)中极易发育停滞,传统游离药物存在半衰期短、全身毒性高等明显缺陷。纳米药物具有时空可控释放、深层物理穿透和多靶点共递送等优势,为重塑TME并诱导TLS形成提供了工程化解决途径。本文从三个关键方面系统总结纳米药物诱导TLS形成的工程化干预策略:激活趋化网络以加速免疫细胞归巢;靶向基质重编程以诱导高内皮微静脉并构建物理支架;增强抗原交叉呈递以驱动生发中心(GC)成熟。文章进一步深入探讨纳米药物介导的TLS如何作为免疫枢纽,与现有免疫检查点抑制剂、细胞治疗和物理治疗产生协同效应。最后分析该领域临床转化面临的当前障碍,并勾勒未来发展蓝图。通过多学科视角,本文为下一代精准免疫治疗纳米药物的设计与临床应用提供理论指导和技术路线图。
Loss-of-function mutations in Kelch-like ECH-associated protein 1 (KEAP1) frequently occur in lung adenocarcinoma and are associated with poor prognosis and limited benefit from immunotherapy. However, the mechanisms linking KEAP1 deficiency to immune evasion remain elusive. We combined clinical data analysis, in vivo tumor models, and in vitro co-culture systems to investigate how KEAP1 deficiency shapes dendritic cell (DC) biology and response to PD-1 blockade. Ferroptosis induction assays, damage-associated molecular patterns (DAMPs) quantification, cytokine profiling, and mechanistic interrogation of the FSP1-CoQ10 axis were performed to delineate pathways. KEAP1 mutations correlated with poor response to PD-1 blockade and reduced DC infiltration. In mice, KEAP1-deficient tumors exhibited accelerated growth and reduced DC and CD8+ T-cell infiltration, consistent with an immune-cold phenotype. Mechanistically, KEAP1 loss impaired DC function in vitro, as evidenced by reduced maturation, phagocytosis, and naïve CD8+ T-cell priming capacity. This defect was linked to two mechanisms. First, KEAP1-deficient tumor cells resisted ferroptosis and failed to release immunogenic DAMPs, including extracellular ATP, HMGB1, and calreticulin. Second, KEAP1 deficiency reprogrammed the cytokine secretion profile, with downregulation of CCL2, IL-6, CXCL1, and CXCL2, thereby diminishing DC recruitment and inflammatory signaling. Notably, inhibition of the FSP1-CoQ10 antioxidant axis restored ferroptosis-associated immunogenic cell death. Our study identifies KEAP1 deficiency as a driver of immune-cold tumor microenvironments and resistance to PD-1 blockade, acting through impaired ferroptosis-induced immunogenic cell death and disrupted DC function. Genetic FSP1 deletion restored ferroptosis-associated immunogenicity and DC activation in KEAP1-deficient cells, supporting FSP1 as a potential therapeutic target for further in vivo evaluation.
中文摘要:Kelch样ECH相关蛋白1(KEAP1)功能缺失突变常见于肺腺癌,与预后差及免疫治疗获益有限相关。KEAP1缺陷导致免疫逃逸的机制仍不清楚。我们整合临床数据分析、体内肿瘤模型和体外共培养体系,研究KEAP1缺陷如何影响树突状细胞(DC)生物学及PD-1阻断治疗反应。通过铁死亡诱导实验、损伤相关分子模式(DAMPs)定量、细胞因子谱分析和FSP1-CoQ10轴的机制探究来解析相关通路。KEAP1突变与PD-1阻断反应差及DC浸润减少相关。小鼠中,KEAP1缺陷肿瘤生长加速,DC和CD8+ T细胞浸润减少,符合免疫冷表型。机制上,KEAP1缺失在体外损害DC功能,表现为成熟、吞噬和初始CD8+ T细胞启动能力下降。这一缺陷与两种机制有关。第一,KEAP1缺陷肿瘤细胞抵抗铁死亡,未能释放免疫原性DAMPs,包括胞外ATP、HMGB1和钙网蛋白。第二,KEAP1缺陷重编程细胞因子分泌谱,CCL2、IL-6、CXCL1和CXCL2下调,从而削弱DC募集和炎症信号。抑制FSP1-CoQ10抗氧化轴可恢复铁死亡相关免疫原性细胞死亡。该研究将KEAP1缺陷确定为免疫冷肿瘤微环境的驱动因素及PD-1阻断抵抗的原因,其作用通过受损的铁死亡诱导免疫原性细胞死亡和DC功能紊乱实现。遗传性FSP1缺失在KEAP1缺陷细胞中恢复铁死亡相关免疫原性和DC活化,支持FSP1作为进一步体内评估的潜在治疗靶点。
Human cancer cells and malignant tumours operate immune evasion machinery, which consists of a set of cross-linked biochemical pathways that suppress the activities of immune cells, such as cytotoxic T cells and natural killer cells. Recent evidence demonstrated that the immune evasion machinery operated by human cancer cells is self-sustaining. However, the mechanisms underlying self-regulation of cancer immune evasion networks remain to be understood. Here we report for the very first time that the cell surface receptor CD44 acts as an enhancer of immune evasion activity in human cancer cells rather than an immune checkpoint per se. Furthermore, upon interaction with galectin-9, CD44 was found to alter cell membrane potential and induce the secretion of TGF-β. Secreted TGF-β displays autocrine and paracrine activities following TGF-β receptor (TGFBR) engagement, which was shown to then activate the Smad3 transcriptional pathway. CD44 complexed to galectin-9 allosterically enhances activity of the TGFBR complex and this was shown to substantially amplify the expression of immune checkpoint proteins crucially associated with suppressing the anti-cancer activities of cytotoxic lymphoid cells. We also demonstrated that this is a fundamental pathway used by human embryos to prevent immune rejection and by innate immune cells to facilitate anti-bacterial innate immune response. Cancer cells and malignant tumours hijack and successfully adapt this fundamental pathway to escape immune surveillance and suppress anti-cancer immune reactions. As such, this autocrine loop allows for the self-regulation of immune evasion networks operated by cancer cells and can be considered as a promising target for highly efficient immunotherapy of cancer.
中文摘要:人癌细胞和恶性肿瘤会运行免疫逃逸机制,该机制由一组相互交联的生化通路构成,可抑制细胞毒性T细胞、自然杀伤细胞等免疫细胞的活性。近期证据显示,人癌细胞运行的免疫逃逸机制具有自我维持能力,但癌症免疫逃逸网络自我调控的机制仍待阐明。研究报告首次发现,细胞表面受体CD44在人癌细胞中发挥免疫逃逸活性增强因子的作用,而非免疫检查点本身。CD44与galectin-9相互作用后,可改变细胞膜电位并诱导TGF-β分泌。分泌的TGF-β在结合TGF-β受体后表现自分泌和旁分泌活性,并激活Smad3转录通路。CD44与galectin-9形成的复合物以变构方式增强TGFBR复合物活性,明显放大与抑制细胞毒性淋巴样细胞抗癌活性密切相关的免疫检查点蛋白表达。研究还显示,这是一条基本通路,人胚胎利用它防止免疫排斥,固有免疫细胞利用它促进抗细菌固有免疫应答。癌细胞和恶性肿瘤劫持并成功适应这条基本通路,以逃避免疫监视并抑制抗癌免疫反应。因此,这一自分泌环路使癌细胞能够自我调控其运行的免疫逃逸网络,可作为实现高效癌症免疫治疗的有前景靶点。
Ovarian cancer (OC) remains a highly lethal malignancy characterised by diffuse peritoneal dissemination and frequent treatment resistance. Beyond tumor-intrinsic alterations and classical stromal support, the peripheral nervous system is emerging as an important component of the tumor microenvironment. Here, we develop an OC-focused framework of a nerve-dependent metastatic niche, integrating tumor-associated neural remodeling, subtype-specific neural signalling and neuro-immune crosstalk across disease progression. We outline the physiological basis of ovarian and tubo-ovarian innervation and examine how OC may co-opt peripheral neural programmes through neurotrophic factors, axon-guidance molecules and extracellular vesicle signalling. Particular emphasis is placed on sensory and adrenergic pathways implicated in angiogenesis, tumor-cell survival, invasion and immune regulation, while distinguishing OC-specific evidence from mechanisms established in other malignancies. We further consider how neural responsiveness may be reconfigured during peritoneal dissemination through interactions with ascitic, adipose, immune, stromal and mechanical niches. Finally, we discuss emerging neuro-targeted strategies, including receptor antagonism, neurotransmitter-synthesis inhibition, neural manipulation and AAV-enabled neuroengineering, and highlight the translational opportunities and current limitations of targeting nerve-tumor crosstalk in OC.
中文摘要:卵巢癌(OC)仍是高度致死性恶性肿瘤,以弥漫性腹膜播散和频繁治疗耐药为特征。除肿瘤内在改变和经典基质支持外,外周神经系统正成为肿瘤微环境的重要组成部分。本文构建以卵巢癌为核心的神经依赖性转移微环境框架,整合疾病进展中的肿瘤相关神经重塑、亚型特异性神经信号及神经免疫交互。文中概述卵巢与输卵管卵巢神经支配的生理基础,并审视卵巢癌如何通过神经营养因子、轴突导向分子和细胞外囊泡信号利用外周神经程序。重点放在与血管生成、肿瘤细胞存活、侵袭和免疫调节相关的感觉与肾上腺素能通路,同时区分卵巢癌特异性证据与其他恶性肿瘤中已确立的机制。进一步讨论腹膜播散过程中神经反应性如何通过与腹水、脂肪、免疫、基质和力学微环境的相互作用而被重塑。最后讨论新兴神经靶向策略,包括受体拮抗、神经递质合成抑制、神经调控和AAV介导的神经工程,并指出靶向卵巢癌神经-肿瘤交互的转化机会与当前局限。
Chemotherapy-induced cognitive impairment (CICI), often termed chemobrain, is a clinically important complication of cancer treatment that can affect memory, attention, executive function, and processing speed during and after therapy. Doxorubicin is of particular mechanistic interest because brain parenchymal exposure is limited, yet preclinical studies consistently identify neuroinflammatory, oxidative, vascular, and synaptic abnormalities after treatment. This critical narrative review evaluates whether intestinal injury and disruption of the microbiota-gut-brain axis may contribute to these central effects. Preclinical evidence indicates that doxorubicin can alter microbial community structure, injure the intestinal barrier, modify SCFA-associated taxa or predicted functions, alter selected metabolite profiles, and promote systemic inflammatory and metabolic signaling. These peripheral changes could interact with brain endothelial cells, glia, mitochondria, hippocampal neurogenesis, and synaptic-plasticity pathways. However, the proposed doxorubicin-gut-brain pathway remains a predominantly preclinical and incompletely tested framework. No longitudinal human study has yet established, within the same patients, the temporal sequence linking doxorubicin exposure, microbiome or metabolome changes, systemic inflammation, and objective cognitive outcomes. Existing animal studies also vary in dose, regimen, tumor context, sampling time, microbiome methodology, and control of behavioral or microbiological confounders, while causal rescue experiments remain limited. Key priorities are therefore longitudinal human cohorts with pretreatment baselines and repeated multi-omics and cognitive assessments; animal studies that test temporal precedence and causal rescue or pathway blockade in the same model; mediation analyses that determine whether microbial or metabolic changes lie between treatment and cognitive dysfunction; and mechanism-informed clinical trials that demonstrate target engagement, cognitive benefit, oncology safety, and preservation of antitumor efficacy. Microbiome-directed interventions are promising but remain investigational for doxorubicin-associated CICI.
中文摘要:化疗相关认知障碍(CICI),常被称为化疗脑,是癌症治疗中具有临床重要性的并发症,可在治疗期间和治疗后影响记忆、注意力、执行功能和处理速度。多柔比星在机制上尤其值得关注,因为其脑实质暴露有限,但临床前研究一致发现治疗后出现神经炎症、氧化应激、血管和突触异常。这篇批判性叙述性综述评估肠道损伤及微生物群-肠-脑轴紊乱是否可能参与这些中枢效应。临床前证据提示,多柔比星可改变微生物群落结构、损伤肠道屏障、改变与短链脂肪酸相关的类群或预测功能、改变部分代谢物谱,并促进全身炎症和代谢信号传导。这些外周变化可能与脑内皮细胞、胶质细胞、线粒体、海马神经发生和突触可塑性通路相互作用。然而,所提出的多柔比星-肠-脑通路仍主要是临床前且未经充分检验的框架。尚无纵向人体研究在同一批患者中建立多柔比星暴露、微生物组或代谢组变化、全身炎症与客观认知结局之间的时间顺序。现有动物研究在剂量、方案、肿瘤背景、采样时间、微生物组方法学以及行为或微生物混杂因素控制方面也存在差异,因果性挽救实验仍然有限。因此,关键优先事项包括:具备治疗前基线的纵向人类队列,并重复进行多组学和认知评估;在同一模型中检验时间先后关系以及因果性挽救或通路阻断的动物研究;判断微生物或代谢变化是否位于治疗与认知功能障碍之间的中介分析;以及展示靶点结合、认知获益、肿瘤学安全性和抗肿瘤疗效得以保留的机制导向临床试验。微生物组导向干预具有前景,但针对多柔比星相关CICI仍处于研究阶段。
Programmed cell death evasion fuels malignant progression and undermines therapeutic efficacy across diverse neoplasms. Ferroptosis, an iron-driven membrane lipid oxidation that culminates in catastrophic membrane integrity loss, has emerged as a metabolically distinct liability amenable to therapeutic exploitation through radiotherapy and immunotherapy combinations. Ionising radiation overwhelms cellular antioxidant buffering capacities within the tumour microenvironment, shifting the redox balance toward peroxidative membrane injury and bypassing resistance mechanisms active in treatment refractory tumours. Ferroptotic corpses release alarmins and lipid peroxidation products, triggering immunogenic cell death that reshapes immune surveillance, draws in antigen presenting cells, and reduces activation barriers for immune checkpoint inhibitors and adoptive cellular therapies. At the same time, radiotherapy triggered metabolic reprogramming of the tumour microenvironment marked by glutamine dependence, lipid peroxidation accumulation, and cystine limitation aligns with immunomodulatory effects to strengthen anti-tumour immunity. This Review deconstructs the enzymatic cascades and metabolic checkpoints that govern ferroptotic vulnerability, mapping how radiation induced metabolic rewiring links cytotoxic and immune stimulatory therapeutic goals. We examine whether ferroptosis serves as a central node connecting radiotherapy and immunotherapy, assessing preclinical data on radio immunotherapy combination strategies that leverage this dual functionality. Translational barriers remain. Constrained therapeutic windows, lack of validated pharmacodynamic markers, and unclear toxicological consequences in normal tissues require careful evaluation prior to clinical application. We outline a conceptual framework for deploying ferroptosis as a mechanistic bridge between radiotherapy and immunotherapy, suggesting that its targeted induction under tumour specific metabolic conditions could reshape multimodal treatment strategies and enhance cancer treatment outcomes beyond the marginal gains achievable with single agent approaches.
中文摘要:逃逸程序性细胞死亡会推动恶性进展,并削弱多种肿瘤的治疗效果。铁死亡由铁驱动的膜脂氧化所引发,最终导致膜完整性灾难性丧失,已成为一种代谢上具有独特性的治疗弱点,可通过放疗与免疫治疗联合加以利用。电离辐射使肿瘤微环境内细胞的抗氧化缓冲能力不堪重负,使氧化还原平衡向膜脂过氧化损伤偏移,并绕开难治性肿瘤中活跃的耐药机制。发生铁死亡的细胞残骸释放警报素与脂质过氧化产物,诱发免疫原性细胞死亡,重塑免疫监视,招募抗原提呈细胞,并降低免疫检查点抑制剂与过继细胞治疗的激活门槛。放疗引发的肿瘤微环境代谢重编程以谷氨酰胺依赖、脂质过氧化蓄积和胱氨酸受限为标志,与免疫调节效应相契合,增强抗肿瘤免疫。综述解析调控铁死亡易感性的酶级联与代谢检查点,勾勒放疗诱导的代谢重塑如何把细胞毒作用与免疫刺激这两类治疗目标连接起来。文章考察铁死亡是否构成连接放疗与免疫治疗的中心节点,并评估利用这一双重功能的放免联合策略的临床前数据。转化层面的障碍依然存在。治疗窗狭窄、缺乏经验证的药效学标志物、正常组织中毒理学后果不明,这些都需要在临床应用前审慎评估。文章提出一套概念框架,将铁死亡用作放疗与免疫治疗之间的机制桥梁,并提示在肿瘤特异性代谢条件下靶向诱导铁死亡,可能重塑多模式治疗策略,使疗效超出单药方案所能获得的有限增益。
Adoptive T cell therapy faces significant hurdles in solid tumors due to the immunosuppressive tumor microenvironment (TME), wherein aberrant accumulation of reactive oxygen species (ROS) serves as a critical driver of therapeutic resistance. Conventional systemic antioxidant strategies are constrained by their non-selectivity and potential to disrupt physiological ROS signaling. Here, we systematically delineate the inherent heterogeneity among T cell subsets-including effector, memory, and regulatory T cells-with respect to metabolic preferences, mitochondrial dynamics, and antioxidant gene expression, revealing their divergent susceptibilities to oxidative stress. Furthermore, the intricate interplay between ROS and diverse immune subsets within the TME, such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), collectively orchestrates an immunosuppressive network that underscores the imperative for selective intervention. Building upon this foundation, we propose a multi-layered intervention framework encompassing: (i) reinforcement of intrinsic antioxidant defenses; (ii) metabolic reprogramming to potentiate redox capacity; and (iii) nanomaterial-based remodeling of the pro-oxidative microenvironment. Notably, we introduce the first combinatorial framework centered on nanomaterial-enabled TME modulation integrated with T cell-intrinsic orchestration-a strategy rationally designed to synergistically preserve stem-like memory phenotypes and augment antitumor persistence through multidimensional redox regulation. This framework emphasizes the profound coupling between metabolic and redox homeostasis while critically addressing current challenges, including cellular selectivity, therapeutic windows, and the risk of reductive stress. By providing an integrated mechanistic roadmap and a clear translational trajectory, this review aims to guide future efforts toward subset-selective interventions, spatiotemporally controlled redox modulation, and synergistic integration with existing immunotherapies, ultimately advancing adoptive T cell therapy for solid tumors.
中文摘要:过继性T细胞治疗在实体瘤中受制于免疫抑制性肿瘤微环境(TME),其中活性氧(ROS)的异常蓄积是治疗耐药的关键驱动因素。传统全身性抗氧化策略受限于缺乏选择性与可能干扰生理性ROS信号。本文系统梳理了T细胞亚群(包括效应T细胞、记忆T细胞与调节性T细胞)在代谢偏好、线粒体动力学和抗氧化基因表达方面的内在异质性,揭示其对氧化应激的敏感性差异。同时,TME内ROS与髓源性抑制细胞(MDSCs)、肿瘤相关巨噬细胞(TAMs)等多种免疫亚群之间的复杂相互作用共同构建了免疫抑制网络,凸显选择性干预的必要性。在此基础上,提出多层干预框架:(i)强化内在抗氧化防御;(ii)通过代谢重编程提升氧化还原能力;(iii)以纳米材料重塑促氧化微环境。文中首次提出以纳米材料介导的TME调控与T细胞内在调控相结合的联合框架,该策略通过多维氧化还原调控协同维持干性样记忆表型并增强抗肿瘤持久性。该框架强调代谢稳态与氧化还原稳态之间的深度耦联,并审视细胞选择性、治疗窗与还原性应激风险等现实挑战。通过提供整合的机制路线图与明确的转化路径,本综述旨在为亚群选择性干预、时空可控的氧化还原调控以及与现有免疫治疗的协同整合提供指引,推动过继性T细胞治疗在实体瘤中的应用。
Therapeutic cancer vaccines are designed to induce tumor-specific immunity and durable antitumor surveillance. However, their clinical efficacy remains limited by antigen heterogeneity, defective antigen presentation, immune exhaustion, and immunosuppression within the tumor microenvironment (TME). Advances in sequencing, immunopeptidomics, artificial intelligence (AI)-assisted neoantigen prioritization, nucleic acid engineering, dendritic cell (DC) biology, and combination therapy have shifted the field from empirical antigen exposure toward mechanism-guided vaccine design. This review outlines the historical development of therapeutic cancer vaccines, neoantigen identification strategies, and recent progress in DNA, RNA, peptide, cellular, and viral vaccine platforms. Key mechanisms shaping vaccine response and resistance are also discussed, including pattern-recognition receptor (PRR) signaling, dendritic cell-mediated antigen presentation, T-cell effector and memory differentiation, metabolic adaptation, epitope spreading, and TME remodeling. Future therapeutic cancer vaccines should be developed as integrated immunological systems that coordinate antigen discovery, precise delivery, innate immune calibration, memory maintenance, and local immune suppression reversal to achieve reproducible clinical benefit.
中文摘要:治疗性癌症疫苗旨在诱导肿瘤特异性免疫和持久的抗肿瘤监视。然而,其临床疗效仍受抗原异质性、抗原提呈缺陷、免疫耗竭以及肿瘤微环境(TME)内免疫抑制的限制。测序、免疫肽组学、人工智能(AI)辅助的新抗原优选、核酸工程、树突状细胞(DC)生物学和联合治疗的进展,使该领域从经验性抗原暴露转向机制指导的疫苗设计。本综述概述治疗性癌症疫苗的历史发展、新抗原鉴定策略,以及DNA、RNA、肽、细胞和病毒疫苗平台的最新进展。还讨论影响疫苗应答与抵抗的关键机制,包括模式识别受体(PRR)信号、树突状细胞介导的抗原提呈、T细胞效应与记忆分化、代谢适应、表位扩展和TME重塑。未来的治疗性癌症疫苗应作为整合免疫系统来开发,协调抗原发现、精准递送、固有免疫校准、记忆维持和局部免疫抑制逆转,以实现可重复的临床获益。
Systemic glucocorticoid (GC) effects in oncology are well recognized; however, the role of local GC metabolism within the tumor microenvironment remains poorly defined. Epithelial 11β-hydroxysteroid dehydrogenase 2 (HSD11β2), which inactivates GCs, may regulate GC-driven immune suppression in head and neck squamous cell carcinoma (HNSCC). We combined clinical survival analyses from an HNSCC cohort (ORIEN) with mechanistic studies in CRISPR/Cas9 Hsd11β2-knockout (KO) cell lines, an epithelial-specific Hsd11β2 conditional KO (eHSD-/-) mouse model, and an orthotopic model with exogenous GC exposure. Immune profiling, GC quantification, and transcriptomic analyses were performed. Apigenin was evaluated as a pharmacologic inducer of HSD11β2. In the retrospective HNSCC cohort, GC (Prednisolone) exposure was associated with inferior overall survival (HR = 2.1, 95% CI 1.3-3.46; p < 0.0001). Loss of epithelial Hsd11β2 increased active GC bioavailability, enhanced tumor proliferation, and suppressed T cell effector function, accompanied by expansion of immunosuppressive myeloid populations. Transcriptomic analyses revealed activation of GC-responsive and pro-tumor pathways with concurrent depletion of lymphocyte activation signatures. Pharmacologic induction of HSD11β2 with apigenin reduced active GC levels, suppressed tumor growth, and restored T cell function. Notably, apigenin retained partial antitumor effects in Hsd11β2 KO models, indicating both HSD11β2 dependent and complementary mechanisms. These findings support a role for local GC metabolism as an immunometabolic checkpoint in HNSCC. In experimental models, restoring epithelial GC inactivation via HSD11β2 reduces immune suppression and restrains tumor progression. Pharmacologic induction of HSD11β2 represents a promising strategy to counter steroid-driven immune evasion and may enhance responses to immunotherapy.
中文摘要:肿瘤学中全身性糖皮质激素(GC)效应已被广泛认识,但肿瘤微环境内局部GC代谢的作用仍不清楚。上皮11β-羟基类固醇脱氢酶2(HSD11β2)可灭活GC,可能调控头颈鳞状细胞癌(HNSCC)中GC驱动的免疫抑制。我们将HNSCC队列(ORIEN)的临床生存分析与机制研究结合,机制研究包括CRISPR/Cas9构建的Hsd11β2敲除(KO)细胞系、上皮特异性Hsd11β2条件性敲除(eHSD-/-)小鼠模型,以及外源性GC暴露的原位模型。研究进行了免疫表型分析、GC定量和转录组分析。评估芹菜素作为HSD11β2药理学诱导剂的作用。在回顾性HNSCC队列中,GC(泼尼松龙)暴露与较差的总生存相关(HR=2.1,95%CI 1.3-3.46;p<0.0001)。上皮Hsd11β2缺失增加了活性GC的生物利用度,促进肿瘤增殖并抑制T细胞效应功能,同时伴随免疫抑制性髓系细胞群扩增。转录组分析显示GC反应性和促肿瘤通路激活,同时淋巴细胞活化特征减少。芹菜素药理学诱导HSD11β2降低了活性GC水平,抑制肿瘤生长并恢复T细胞功能。在Hsd11β2 KO模型中,芹菜素仍保留部分抗肿瘤作用,提示其作用既依赖HSD11β2,也存在互补机制。这些发现支持局部GC代谢作为HNSCC的免疫代谢检查点。在实验模型中,通过HSD11β2恢复上皮GC灭活可减轻免疫抑制并限制肿瘤进展。药理学诱导HSD11β2是对抗类固醇驱动免疫逃逸的有前景策略,并可能增强免疫治疗应答。
The incidence of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma (MASH-HCC) continues to rise worldwide, highlighting an urgent need for effective therapies. Natural products represent a vital source for anticancer drug discovery. Huachansu tablets (HCS), a clinically approved adjunctive antitumor agent, remain poorly characterized regarding their therapeutic efficacy and molecular mechanisms in MASH-HCC. This study found that HCS markedly suppressed the initiation and progression of MASH-HCC, alleviated metabolic abnormalities within the tumor microenvironment, and restored the antitumor function of CD8⁺T cells. In MASH-HCC mouse models, HCS significantly suppressed tumor progression and reprogrammed the tumor immune microenvironment. Further investigation revealed that HCS substantially reduced the production of tumor derived lactate and associated metabolites, thereby alleviating lactate mediated immunosuppression and restoring CD8⁺T cell effector function and antitumor immunity. Mechanistic studies identified PKLR as a key target through which HCS regulates tumor lactate metabolism. HCS inhibited ChREBP nuclear translocation, thereby downregulating PKLR expression and enzymatic activity, which subsequently attenuated glycolytic flux and reduced lactate production. Rescue experiments confirmed that HCS exerts its immunometabolic reprogramming effects primarily by targeting the ChREBP/PKLR-lactate metabolic axis. Moreover, combining HCS with anti-PD-1 therapy further enhanced CD8⁺T cell function and sensitized MASH-HCC to ICIs. Collectively, our findings reveal that HCS suppresses MASH-HCC progression through the coordinated remodeling of tumor metabolism and the immune microenvironment. Furthermore, the ChREBP/PKLR-lactate axis represents a promising therapeutic target, providing a mechanistic rationale for the clinical application of HCS in this disease.
中文摘要:代谢功能障碍相关脂肪性肝炎相关肝细胞癌(MASH-HCC)的发病率在全球持续上升,亟需有效治疗手段。天然产物是抗肿瘤药物发现的重要来源。华蟾素片(HCS)是已获批的临床辅助抗肿瘤药物,但其对MASH-HCC的治疗效果和分子机制仍缺乏充分研究。HCS显著抑制MASH-HCC的发生和进展,缓解肿瘤微环境中的代谢异常,并恢复CD8⁺T细胞的抗肿瘤功能。在MASH-HCC小鼠模型中,HCS显著抑制肿瘤进展并重编程肿瘤免疫微环境。进一步研究显示,HCS大幅减少肿瘤来源乳酸及相关代谢物的产生,从而减轻乳酸介导的免疫抑制,恢复CD8⁺T细胞的效应功能和抗肿瘤免疫。机制研究确定PKLR是HCS调控肿瘤乳酸代谢的关键靶点。HCS抑制ChREBP核转位,进而下调PKLR表达和酶活性,随后减弱糖酵解通量并减少乳酸生成。回补实验证实,HCS主要通过靶向ChREBP/PKLR-乳酸代谢轴发挥免疫代谢重编程作用。HCS与抗PD-1治疗联用进一步增强CD8⁺T细胞功能,并使MASH-HCC对ICIs敏感。这些结果说明,HCS通过协同重塑肿瘤代谢和免疫微环境抑制MASH-HCC进展。ChREBP/PKLR-乳酸轴是有前景的治疗靶点,为该病中HCS的临床应用提供了机制依据。
Cancer-associated fibroblasts (CAFs) foster an immunosuppressive tumor microenvironment (TME) and confer resistance to immune checkpoint blockade (ICB) in gastric cancer (GC). However, the mechanisms by which specific CAF subsets regulate metabolic crosstalk and immune evasion remain poorly defined. We integrated bulk and single-cell RNA-sequencing data, spatial transcriptomics, and clinical cohorts of GC patients treated with immunotherapy. Functional validation was performed using in vitro co-culture systems, multiple murine models, and lipid nanoparticle (LNP)-encapsulated siRNA targeting Postn. We identified POSTN + CAFs as a key subset enriched in ICB non-responders and associated with poor prognosis. Mechanistically, POSTN secreted by CAFs engaged integrin β1 (ITGB1) on tumor cells and macrophages, activating the PI3K/AKT/mTOR signaling axis and upregulating PPARγ. This signaling cascade drove lipid metabolic reprogramming, characterized by increased lipid accumulation and oxidative stress, and promoted the polarization of macrophages toward an immunosuppressive, lipid-stressed M2 phenotype. Targeting POSTN signaling with LNP-formulated siPostn attenuated tumor growth, suppressed lipid metabolism, and reduced M2 macrophage infiltration in the TME. This work reveals that POSTN + CAFs establish an immunosuppressive TME and are associated with ICB non-response in GC by remodeling lipid metabolism through the ITGB1-PI3K/AKT/mTOR-PPARγ axis, a finding that underscores the therapeutic value of intervening in this specific CAF-macrophage metabolic crosstalk.
中文摘要:癌症相关成纤维细胞(CAFs)塑造免疫抑制性肿瘤微环境(TME),并使胃癌(GC)对免疫检查点阻断(ICB)产生耐药。特定CAF亚群如何调控代谢互作与免疫逃逸的机制仍不明确。我们整合了bulk与单细胞RNA测序数据、空间转录组学以及接受免疫治疗的GC患者临床队列。利用体外共培养体系、多种小鼠模型和靶向Postn的脂质纳米颗粒(LNP)包裹siRNA进行功能验证。我们鉴定POSTN+ CAFs为在ICB无应答者中富集并与不良预后相关的关键亚群。机制上,CAFs分泌的POSTN与肿瘤细胞和巨噬细胞上的整合素β1(ITGB1)结合,激活PI3K/AKT/mTOR信号轴并上调PPARγ。该信号级联驱动脂质代谢重编程,表现为脂质蓄积和氧化应激增加,并促进巨噬细胞向免疫抑制性、脂质应激的M2表型极化。用LNP配制的siPostn靶向POSTN信号可减轻肿瘤生长、抑制脂质代谢并减少TME中M2巨噬细胞浸润。该工作揭示POSTN+ CAFs通过ITGB1-PI3K/AKT/mTOR-PPARγ轴重塑脂质代谢,建立免疫抑制性TME,并与GC的ICB无应答相关,这一发现凸显了干预该特定CAF-巨噬细胞代谢互作的治疗价值。
Aberrant angiogenesis is a hallmark of cancer that promotes tumor progression and therapeutic resistance. The resulting tumor vasculature is structurally and functionally abnormal, leading to inadequate perfusion and hypoxia. Beyond supporting tumor growth, such vascular abnormalities also restrict immune cell infiltration and impair antitumor immune responses. Accordingly, tumor vasculature emerges as a potential target to improve therapeutic outcomes. This review summarizes the cellular composition, functional heterogeneity, and diverse types of tumor vasculature, as well as the crosstalk between abnormal blood vessels and immune cells. We further outline the current vascular-targeting approaches, with a particular focus on their immunomodulatory effects and synergistic potential with immunotherapies. Diagnostic classification of tumor vasculature, together with the combination of vascular-targeted therapy and immunotherapy, may offer new opportunities for precision tumor treatment.
中文摘要:异常血管生成是癌症的一个标志,促进肿瘤进展和治疗抵抗。由此形成的肿瘤血管在结构和功能上异常,导致灌注不足和缺氧。除支持肿瘤生长外,这类血管异常还限制免疫细胞浸润并削弱抗肿瘤免疫反应。因此,肿瘤血管成为改善治疗结局的潜在靶点。本综述总结肿瘤血管的细胞组成、功能异质性及多种类型,以及异常血管与免疫细胞之间的相互作用。进一步概述当前靶向血管的治疗策略,重点关注其免疫调节作用及与免疫治疗协同的潜力。肿瘤血管的诊断性分类,连同血管靶向治疗与免疫治疗的联合,可能为肿瘤精准治疗提供新机会。
Cancer pain is increasingly recognized as an active output of tumor-nerve-immune biology rather than a passive consequence of tissue damage. Tumor-derived algogens, neurotrophic factors, stress signals and immune mediators can sensitize nociceptors, facilitate perineural invasion, remodel myeloid and lymphoid compartments and recruit central glial mechanisms that may maintain persistent pain. However, the evidence base is asymmetric: many causal circuits were defined in selected bone-metastasis, perineural-invasion, oral-cancer, sarcoma or chemotherapy-induced neuropathy models, whereas applicability to human cancer pain varies by tumor type, pain phenotype, immune contexture and treatment exposure. This critical narrative Review evaluates peripheral, central, immune and pharmacological evidence using explicit model-to-human boundaries. Recent patient studies in oral squamous cell carcinoma link pain with CGRP-positive nerve density, circulating or tissue CGRP, perineural invasion and reduced CD8-positive T-cell density, but these associations do not establish human causality; validated biomarkers of spinal glial mechanisms are still lacking. We examine druggable nodes including NGF-TrkA, SLIT2-ROBO1, CGRP-CALCRL/RAMP1, CSF1R-dependent myeloid or glial signaling, voltage-gated sodium channels and opioid-neuroimmune interactions. Clinical trial and cohort examples illustrate therapeutic paradoxes in which analgesia must be balanced against joint safety, tissue repair, host defense and potentially confounded associations with immunotherapy outcomes. We finally propose a phenotype-matched model-selection framework and a druggable circuit-state strategy for patient-stratified pharmacological development.
中文摘要:癌痛日益被视为肿瘤-神经-免疫生物学主动输出的结果,而非组织损伤的被动后果。肿瘤来源的致痛物质、神经营养因子、应激信号和免疫介质可使伤害感受器敏化,促进神经周围侵犯,重塑髓系和淋巴系细胞区室,并招募可能维持持续性疼痛的中枢胶质机制。然而证据基础并不对称:许多因果环路是在选定的骨转移、神经周围侵犯、口腔癌、肉瘤或化疗诱导神经病变模型中确定的,而其对人类癌痛的适用性随肿瘤类型、疼痛表型、免疫背景和治疗暴露而异。本批判性叙述综述以明确的模型到人类边界评估外周、中枢、免疫和药理学证据。近期口腔鳞状细胞癌患者研究将疼痛与CGRP阳性神经密度、循环或组织CGRP、神经周围侵犯及CD8阳性T细胞密度降低联系起来,但这些关联并未确立人类因果关系;脊髓胶质机制的经验证生物标志物仍然缺乏。我们考察可成药节点,包括NGF-TrkA、SLIT2-ROBO1、CGRP-CALCRL/RAMP1、CSF1R依赖的髓系或胶质信号、电压门控钠通道以及阿片-神经免疫相互作用。临床试验和队列示例说明治疗悖论:镇痛须与关节安全性、组织修复、宿主防御以及可能与免疫治疗结局存在混杂的关联相平衡。最后,我们提出表型匹配的模型选择框架和用于患者分层药物开发的可成药环路状态策略。
Recurrence and peritoneal metastasis remain major challenges in gastric cancer (GC), highlighting the need to identify actionable stromal-tumor signaling circuits within the tumor microenvironment (TME). Integrated transcriptomic analyses and clinical validation identified TAGLN as a fibroblast-enriched factor associated with GC progression and poor prognosis. Functional studies showed that TAGLN expression in cancer-associated fibroblasts (CAFs) enhanced HGF production, at least in part through NF-κB activation, thereby promoting GC-cell malignant phenotypes via paracrine HGF/c-MET signaling. Mechanistically, HGF/c-MET activation promoted DDX5 phosphorylation, with Tyr595 identified as a critical phosphorylation site, and increased DDX5 nuclear accumulation. Nuclear DDX5 was enriched at the CAV1 promoter and enhanced CAV1 transcription, whereas CAV1 promoted malignant phenotypes by activating the PI3K/AKT/mTOR signaling. Salvianolic acid A (SA-A) showed TAGLN target engagement in DARTS and CETSA assays and attenuated TAGLN-associated CAF activity. In vivo, SA-A suppressed CAF-driven tumor growth and peritoneal dissemination. Collectively, these findings define a CAF-TAGLN/HGF/c-MET/DDX5/CAV1 signaling cascade linking stromal activation to tumor-cell transcriptional reprogramming and CAF-tumor crosstalk within the TME, and identify TAGLN as a potential therapeutic vulnerability for microenvironment-directed intervention in GC.
中文摘要:复发和腹膜转移仍是胃癌(GC)的主要难题,需要识别肿瘤微环境(TME)中可干预的基质-肿瘤信号环路。整合转录组分析与临床验证显示,TAGLN是一种富集于成纤维细胞、与GC进展和不良预后相关的因子。功能研究显示,癌相关成纤维细胞(CAFs)中的TAGLN表达可增强HGF产生,至少部分通过NF-κB激活实现,并经旁分泌HGF/c-MET信号促进GC细胞恶性表型。机制上,HGF/c-MET激活促进DDX5磷酸化,Tyr595被鉴定为关键磷酸化位点,并增加DDX5核内积聚。核内DDX5富集于CAV1启动子并增强CAV1转录,而CAV1通过激活PI3K/AKT/mTOR信号促进恶性表型。丹酚酸A(SA-A)在DARTS和CETSA实验中显示可与TAGLN靶点结合,并减弱TAGLN相关CAF活性。体内实验中,SA-A抑制CAF驱动的肿瘤生长和腹膜播散。这些结果共同界定了一条CAF-TAGLN/HGF/c-MET/DDX5/CAV1信号级联,将基质激活与肿瘤细胞转录重编程及TME内CAF-肿瘤串扰联系起来,并提示TAGLN是GC微环境导向干预的潜在治疗脆弱点。
Acquired resistance and the immunosuppressive microenvironment remain major challenges in the treatment of advanced lung cancer. By leveraging dual-target synergy, bispecific antibodies (BsAbs) mediate multiple functions, including immune cell engagement, immune checkpoint blockade, and signaling pathway inhibition. These properties offer novel strategies to overcome existing therapeutic limitations. This review comprehensively describes the structural features and core mechanisms of action of BsAbs, reviews their key clinical advances in lung cancer, and analyzes ongoing clinical challenges, such as resistance, mechanism-based toxicities, and biomarker identification. Furthermore, it discusses future directions in structural optimization and combination therapy to provide insights for precision oncology in lung cancer.
中文摘要:晚期肺癌治疗中,获得性耐药与免疫抑制性微环境仍是主要难题。双特异性抗体借助双靶点协同作用,可介导免疫细胞募集、免疫检查点阻断与信号通路抑制等多重功能,为突破现有治疗局限提供了新思路。本综述系统梳理双特异性抗体的结构特征与核心作用机制,回顾其在肺癌领域的关键临床进展,并分析耐药、机制相关毒性、生物标志物筛选等尚待解决的临床问题,进而讨论结构优化与联合治疗的未来方向,为肺癌精准肿瘤学提供参考。
Cardiac fibrosis is a central pathological hallmark of diverse cardiovascular disorders, driving myocardial stiffening, ventricular dysfunction, and the progression of heart failure. Following cardiac injury, resident quiescent fibroblasts activate into pro‑fibrotic myofibroblasts, which overproduce extracellular matrix and perpetuate maladaptive cardiac remodeling. Current clinical interventions fail to specifically target pathological cells or reverse established fibrosis, leaving a major unmet therapeutic need. Chimeric antigen receptor (CAR)-based immunotherapy, originally revolutionizing oncology, has emerged as a precision strategy to selectively recognize, eliminate, or regulate cardiac fibrotic drivers. Its application to cardiac fibrosis, primarily through targeting activated fibroblasts and fibrotic niches, shows preclinical promise in halting or reversing disease. Although most evidence remains preclinical, early clinical translation has begun for selected fibrosis-targeted immunomodulatory cell therapies. This Review synthesizes advances in CAR-based immunotherapy for cardiac fibrosis, focusing on disease pathobiology, validated and emerging target antigens, diverse cellular platforms, preclinical evidence, and the key barriers to safe and effective clinical translation.
中文摘要:心脏纤维化是多种心血管疾病的核心病理标志,导致心肌僵硬、心室功能障碍和心力衰竭进展。心脏损伤后,驻留的静息成纤维细胞活化为促纤维化肌成纤维细胞,过度产生细胞外基质并使适应不良的心脏重构持续存在。当前临床干预无法特异性地靶向病理细胞或逆转已形成的纤维化,存在重大未满足的治疗需求。基于嵌合抗原受体(CAR)的免疫治疗最初在肿瘤学领域带来革命性变化,现已作为精准策略出现,用于选择性识别、清除或调控心脏纤维化驱动因素。其应用于心脏纤维化主要针对活化成纤维细胞和纤维化微环境,在临床前显示出阻止或逆转疾病的希望。尽管多数证据仍处于临床前阶段,针对特定纤维化的免疫调节细胞疗法已开始早期临床转化。本综述总结CAR免疫治疗用于心脏纤维化的进展,聚焦疾病病理生物学、已验证和新兴的靶抗原、多种细胞平台、临床前证据以及安全有效临床转化的关键障碍。
Natural killer (NK) cells are central to antitumor immunity but rapidly lose function in the tumor microenvironment (TME). Here, we identify CD55, previously recognized as a complement regulatory protein, as an inducible membrane organizer that coordinates activating receptor signaling to potentiate NK cell-mediated antitumor responses. Upon initial tumor encounter, NK cells upregulate CD55 via an NKG2D-p65 transcriptional axis. Unlike in T-cells, where it has a known co-stimulatory role, CD55 on NK cells directly engages tumor-expressed CD97 in trans to trigger lipid raft aggregation and LCK activation, acting as a self-sufficient primary signal initiator that drives cytotoxicity. However, upon prolonged tumor exposure, CD55 expression on NK cells progressively declines, coinciding with the well‑recognized downregulation of NKG2D upon chronic exposure. Within the TME, this loss of CD55 causally impairs NK-cell function. In cancer patients, low CD55 expression in tumor-infiltrating NK cells correlates with poor clinical outcomes. Restoring CD55 expression in both conventional and chimeric antigen receptor-engineered NK cells augments LCK signaling, enhances effector function and persistence, and improves antitumor efficacy in vivo. Thus, NK cells deploy a CD55-dependent autonomous activation mechanism upon tumor encounter, whereas chronic exposure drives CD55 loss and functional dysfunction, a state that can be therapeutically reversed by CD55 restoration.
中文摘要:自然杀伤(NK)细胞在抗肿瘤免疫中居核心地位,但在肿瘤微环境(TME)中迅速失去功能。研究识别出CD55——既往被视为补体调节蛋白——是一种可诱导的膜组织者,协调激活性受体信号,从而增强NK细胞介导的抗肿瘤应答。NK细胞初次遇到肿瘤时,通过NKG2D-p65转录轴上调CD55。与T细胞中已知的共刺激作用不同,NK细胞上的CD55直接与肿瘤表达的CD97发生反式结合,触发脂筏聚集和LCK活化,作为自给自足的一级信号启动者驱动细胞毒作用。然而,肿瘤长期暴露后,NK细胞CD55表达逐步下降,与慢性暴露时NKG2D公认的下调相吻合。在TME内,CD55缺失因果性地损害NK细胞功能。癌症患者中,肿瘤浸润NK细胞CD55低表达与不良临床结局相关。在常规NK细胞和嵌合抗原受体工程化NK细胞中恢复CD55表达,可增强LCK信号、提升效应功能与持久性,并改善体内抗肿瘤疗效。因此,NK细胞遭遇肿瘤时启动依赖CD55的自主激活机制,而慢性暴露导致CD55丢失与功能失调,这一状态可通过恢复CD55实现治疗性逆转。
Hydrogen sulfide (H2S) is a redox-active gasotransmitter implicated in tumor progression and immune regulation. The enzyme 3-mercaptopyruvate sulfurtransferase (3-MST) is a key contributor to endogenous H2S and polysulfide production, but its role in tumor-immune interactions remains poorly defined. Here, we show that 3-MST is the most abundantly expressed H2S-synthesizing enzyme in human renal cell carcinoma cells (RCC) and that high 3-MST expression correlates with reduced patient survival. Pharmacological inhibition of 3-MST lowered intracellular H2S levels in Renca renal carcinoma cells, suppressed proliferation, induced apoptosis, disrupted cellular metabolism, and increased expression of immune-related genes and proteins. In immune cells, partial inhibition of 3-MST promoted T cell activation, as evidenced by increased CD69 expression on CD3+, CD4+, and CD8+ T cells. In contrast, complete inhibition of 3-MST, achieved by high concentrations of the inhibitor, modestly reduced CD8+ T cell proliferation. Functionally, 3-MST inhibition potentiated antigen-specific CD8+ T cell-mediated killing of tumor cells, an effect further amplified by PD-L1 blockade. These results establish 3-MST as a redox-sensitive metabolic driver of tumor growth and immune evasion in RCC and demonstrate that its inhibition can boost antitumor immune responses, offering a potential avenue for combination immunotherapy.
中文摘要:硫化氢(H2S)是一种具有氧化还原活性的气体信号分子,参与肿瘤进展和免疫调节。酶3-巯基丙酮酸硫转移酶(3-MST)是内源性H2S和多硫化物生成的关键贡献者,但其在肿瘤与免疫相互作用中的作用仍不明确。研究发现,3-MST是人肾细胞癌细胞中表达最丰富的H2S合成酶,高3-MST表达与患者生存降低相关。药理学抑制3-MST降低了Renca肾癌细胞内的H2S水平,抑制增殖,诱导凋亡,破坏细胞代谢,并增加免疫相关基因和蛋白的表达。在免疫细胞中,部分抑制3-MST促进T细胞活化,表现为CD3+、CD4+和CD8+ T细胞上CD69表达增加。相反,通过高浓度抑制剂实现的3-MST完全抑制,轻度降低CD8+ T细胞增殖。在功能上,抑制3-MST增强了抗原特异性CD8+ T细胞介导的肿瘤细胞杀伤,PD-L1阻断进一步放大了这一效应。这些结果确立3-MST是肾细胞癌中肿瘤生长和免疫逃逸的氧化还原敏感代谢驱动因素,并证明其抑制可增强抗肿瘤免疫反应,为联合免疫治疗提供了潜在途径。
Cell-surface sialoglycans overexpressed on cancer cells suppress activation of tumor-infiltrating immune cells (TIICs) and thus represent promising targets for cancer immunotherapy. However, the functional roles of sialylation in TIICs remain incompletely understood. Here we developed a strategy for single-cell correlative analysis of α2,3- and α2,6-linked sialoglycans and transcriptomes to determine the correlations of cell-surface sialylation with gene expression of the same cells in a linkage-specific manner by single-cell RNA sequencing. We found that α2,3- and α2,6-sialoglycans were distinctively regulated across specific TIIC subpopulations in murine tumors. Notably, downregulation of α2,6-sialoglycans was identified as a cell-surface marker for intratumoral tumor-specific antigen-reactive CD8+ T cells with high avidity. Mechanistically, high-avidity (but not low-avidity) activation of murine CD8+ T cells within the tumor suppressed β-galactoside α2,6-sialyltransferase 1 expression, which downregulates α2,6-sialylation and exposes galectin-1 ligands. Functionally, galectin-1 binding promoted T cell apoptosis and immune evasion in cancer. This work demonstrates the functional significance and therapeutic potential of specific sialoglycans on TIICs.
中文摘要:肿瘤细胞表面过表达的细胞表面唾液酸聚糖会抑制肿瘤浸润免疫细胞的活化,因而成为癌症免疫治疗的有前景靶点。肿瘤浸润免疫细胞中唾液酸化的功能作用仍不完全清楚。作者建立了对α2,3-和α2,6-连接唾液酸聚糖与转录组进行单细胞关联分析的策略,通过单细胞RNA测序以连接方式特异的方式确定同一细胞表面唾液酸化与基因表达的相关性。在小鼠肿瘤中,α2,3-和α2,6-唾液酸聚糖在不同肿瘤浸润免疫细胞亚群间受到差异化调控。α2,6-唾液酸聚糖下调被鉴定为瘤内肿瘤特异性抗原反应性、高亲和力CD8+ T细胞的细胞表面标志。机制上,瘤内小鼠CD8+ T细胞的高亲和力活化而非低亲和力活化抑制β-半乳糖苷α2,6-唾液酸转移酶1表达,进而下调α2,6-唾液酸化并暴露半乳糖凝集素-1配体。功能上,半乳糖凝集素-1结合促进T细胞凋亡和癌症免疫逃逸。该工作展示了肿瘤浸润免疫细胞上特定唾液酸聚糖的功能意义和治疗潜力。
The central nervous system (CNS) harbors a distinct immune memory programming system, wherein immunogenic cell death (ICD) acts as a pivotal signaling hub. A spectrum of insults, from systemic metabolic dysfunction to local protein aggregation and ionic dyshomeostasis, can provoke ICD in neurons, glia, and resident immune cells. This process orchestrates the release of damage-associated molecular patterns (DAMPs) from distinct subcellular compartments. These DAMPs synergistically initiate both innate trained immunity (TI), characterized by profound metabolic-epigenetic reprogramming, and antigen-specific adaptive immune responses that traverse the blood-brain barrier. Together, these pathways constitute an integral network of central immune surveillance. Crucially, this ICD-driven immune programming exhibits a striking functional dichotomy depending on the pathological context. In non-neoplastic conditions such as neural injury and neurodegenerative diseases, uncontrolled ICD signaling can establish a pathological trained immune memory, driving a self-perpetuating cycle of chronic neuroinflammation and tissue damage. Conversely, within the tumor microenvironment of malignancies like glioma, the adaptive immune responses elicited by ICD are frequently subverted by potent immunosuppressive mechanisms, culminating in tumor immune escape. This review dissects the differential regulatory mechanisms of ICD-mediated immune memory in CNS tumors versus non-tumor diseases. We aim to elucidate the molecular switches that govern the transition of this immune program from a beneficial, compensatory state to a pathological, detrimental phenotype. By exploring emerging therapeutic strategies, including gene editing, nanomaterials, and bioactive phytochemicals that precisely target ICD pathways, we provide a theoretical framework for understanding CNS immune homeostasis and for the rational design of precision immunotherapies.
中文摘要:中枢神经系统具有独特的免疫记忆编程系统,免疫原性细胞死亡(ICD)在其中作为关键信号枢纽发挥作用。从全身代谢功能障碍到局部蛋白聚集和离子稳态失衡,多种损伤因素均可诱发神经元、胶质细胞和驻留免疫细胞发生ICD。该过程协调来自不同亚细胞区域的损伤相关分子模式(DAMPs)释放。这些DAMPs协同启动以深度代谢-表观遗传重编程为特征的先天训练免疫(TI),并启动可跨越血脑屏障的抗原特异性适应性免疫应答。上述通路共同构成中枢免疫监视的整合网络。关键在于,这种由ICD驱动的免疫编程依病理情境呈现显著的功能二分性。在神经损伤和神经退行性疾病等非肿瘤性条件下,失控的ICD信号可建立病理性训练免疫记忆,驱动慢性神经炎症与组织损伤的自我持续循环。相反,在胶质瘤等恶性肿瘤的肿瘤微环境中,ICD激发的适应性免疫应答常被强效免疫抑制机制颠覆,最终导致肿瘤免疫逃逸。该综述剖析ICD介导的免疫记忆在中枢神经系统肿瘤与非肿瘤疾病中的差异调控机制。旨在阐明控制该免疫程序从有益代偿状态转向病理性有害表型的分子开关。通过探讨精准靶向ICD通路的新兴治疗策略,包括基因编辑、纳米材料和生物活性植物化学物,为理解中枢神经系统免疫稳态及合理设计精准免疫治疗提供理论框架。
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally, with many patients presenting with advanced disease that does not respond to standard treatments. While immune checkpoint inhibitors (ICIs) have improved outcomes, their effectiveness is limited in immunologically "cold" tumors, highlighting the urgent need to elucidate the complexity of the tumor immune microenvironment (TIME). Tertiary lymphoid structures (TLSs), ectopic and organized lymphoid aggregates that form at sites of chronic inflammation, have become key players in antitumor immunity. This review thoroughly covers the composition, multistage formation, and functional maturation of TLSs in HCC. We emphasize that the prognostic and predictive value of TLSs depends not only on their presence but also on their spatial localization, structural maturity, and specific immune cell composition. A high density of intratumoral TLSs (iTLSs), especially those with mature germinal centers containing B cells, T follicular helper (Tfh) cells, and dendritic cells (DCs), is strongly linked to better survival and lower recurrence rates. Additionally, TLSs serve as biomarkers for predicting favorable responses to ICIs in both neoadjuvant and adjuvant settings. We also explore how locoregional therapies and specific chemokine axes induce or modulate TLS formation. Finally, we discuss the emerging field of non-invasive TLS evaluation using radiomics and advanced imaging techniques, which promises to guide patient stratification for immunotherapy. TLSs therefore represent promising therapeutic targets with the potential to reprogram the immune milieu of HCC and enable more effective, personalized treatment approaches.
中文摘要:肝细胞癌(HCC)仍是全球癌症相关死亡的主要原因之一,许多患者确诊时已属晚期,对标准治疗无应答。免疫检查点抑制剂(ICI)改善了疗效,但在免疫「冷」肿瘤中作用有限,凸显出阐明肿瘤免疫微环境(TIME)复杂性的紧迫性。三级淋巴结构(TLS)是在慢性炎症部位形成的异位、有组织的淋巴聚集体,已成为抗肿瘤免疫中的关键参与者。本综述系统梳理了HCC中TLS的组成、多阶段形成与功能成熟过程。TLS的预后与预测价值不仅取决于其是否存在,还取决于空间定位、结构成熟度以及特定免疫细胞组成。瘤内TLS(iTLS)密度高,尤其是含有B细胞、滤泡辅助性T细胞(Tfh)和树突状细胞(DC)的成熟生发中心者,与更长的生存期和更低的复发率密切相关。TLS还可作为生物标志物,用于预测新辅助与辅助治疗场景下对ICI的良好应答。文中亦探讨了局部区域治疗与特定趋化因子轴如何诱导或调控TLS形成。最后讨论了利用影像组学与先进成像技术无创评估TLS这一新兴领域,其有望指导免疫治疗的患者分层。TLS因此是有前景的治疗靶点,具备重编程HCC免疫环境、推动更有效个体化治疗的潜力。
The CC chemokine family is a group of low-molecular-weight secreted proteins that can induce various cells to migrate to specific tissues. CC chemokines are also coordinators of many cellular activities, including hematopoiesis, wound healing, tumor growth and metastasis, fibrosis, etc. Recently, CC chemokines play a pleiotropic role in regulating the occurrence and progression of cardiovascular and cerebrovascular diseases, mainly by exacerbating the diseases, and their effects vary at different stages of disease progression. Moreover, the expression of many CC chemokines is highly specific in cardiovascular and cerebrovascular diseases. These CC chemokines can serve as potential biomarkers for predicting future cardiovascular events. Intervention strategies targeting CC chemokines to alleviate diseases, such as blocking the interaction between CC chemokines and their receptors, interfering with the binding of chemokines with glycosaminoglycans, have shown great potential for application. In this review, we present the structure, physiological functions, and regulatory mechanisms of CC family, particularly elaborate on the association between CC chemokines and cardiovascular and cerebrovascular diseases, and reviewing the therapeutic applications of CC chemokines. This review demonstrates the great potential of CC chemokines in the treatment of cardiovascular and cerebrovascular diseases and proposes directions for future research.
中文摘要:CC趋化因子家族是一类低分子量分泌蛋白,可诱导多种细胞迁移至特定组织。CC趋化因子也协调多种细胞活动,包括造血、伤口愈合、肿瘤生长与转移、纤维化等。近年来,CC趋化因子在调控心脑血管疾病发生和进展中发挥多效作用,主要通过加重疾病发挥作用,且在不同疾病进展阶段效应不同。许多CC趋化因子在心脑血管疾病中的表达具有高度特异性。这些CC趋化因子可作为预测未来心血管事件的潜在生物标志物。以CC趋化因子为靶点的干预策略,如阻断CC趋化因子与其受体相互作用、干扰趋化因子与糖胺聚糖结合,已显示出较大应用潜力。这篇综述介绍CC家族的结构、生理功能和调控机制,重点阐述CC趋化因子与心脑血管疾病的关联,并回顾CC趋化因子的治疗应用。综述表明CC趋化因子在心脑血管疾病治疗中具有较大潜力,并提出未来研究方向。
Cellular senescence and immune dysfunction intersect as central biological processes shaping disease progression and therapeutic responses across ageing-related pathologies. Rather than acting independently, senescent cells (SnCs) and immune cells engage in a dynamic and bidirectional crosstalk that influences immune surveillance, inflammatory signaling, and tissue remodeling. This review focuses on the molecular and cellular mechanisms through which SnCs modulate immune composition and function, emphasizing immune checkpoint ligands, stress-associated surface molecules, and senescence-associated transcriptional programs governing senescence-associated secretory phenotype (SASP) expression. We further examine how immune-targeted therapies can, in turn, remodel senescent niches by promoting immune-mediated clearance or altering senescence-associated phenotypes. Integrating evidence from cancer to metabolic and chronic inflammatory diseases, we discuss how senotherapies reshape immune landscapes and how immunotherapies impact senescent cell burden and function. Building on these mechanistic insights, we propose that the senescence-immune axis constitutes a tractable therapeutic vulnerability that can be exploited through rational combination strategies. Finally, we outline five conceptual frameworks and biomarker-guided trial archetypes for integrating senotherapies and immunotherapies in a bidirectional crosstalk, aiming to enhance therapeutic efficacy while mitigating ageing- and treatment-associated toxicities. By reframing senescence and immunity as interconnected therapeutic targets, this review provides a mechanistic foundation for next-generation combinatorial interventions across ageing-associated diseases.
中文摘要:细胞衰老与免疫功能障碍相互交织,是塑造衰老相关疾病进展和治疗反应的核心生物学过程。衰老细胞(SnCs)与免疫细胞并非独立发挥作用,而是形成动态的双向串扰,影响免疫监视、炎症信号和组织重塑。本综述聚焦SnCs调控免疫组成与功能的分子和细胞机制,重点讨论免疫检查点配体、应激相关表面分子以及调控衰老相关分泌表型(SASP)表达的衰老相关转录程序。进一步分析免疫靶向治疗如何通过促进免疫介导的清除或改变衰老相关表型来重塑衰老微环境。整合从癌症到代谢性疾病和慢性炎症性疾病的证据,讨论衰老治疗如何重塑免疫格局,以及免疫治疗如何影响衰老细胞负荷和功能。基于这些机制认识,提出衰老-免疫轴构成可操作的治疗脆弱性,可通过合理的联合策略加以利用。最后,概述五种概念框架和生物标志物引导的试验原型,用于在双向串扰中整合衰老治疗与免疫治疗,旨在提高疗效并减轻衰老及治疗相关毒性。通过将衰老与免疫重新界定为相互关联的治疗靶点,本综述为衰老相关疾病的下一代联合干预提供机制基础。
Multidrug resistance (MDR) in colorectal cancer (CRC) arises from interacting tumour-cell, pharmacological and microenvironmental programmes that undermine both drug activity and delivery. Chemotherapy-associated MDR is the principal focus of this review, while resistance to targeted therapy and immunotherapy is considered where it directly affects delivery design or patient selection. Bioactive compounds can modulate several resistance pathways, but their translational value is constrained by poor solubility, instability, rapid metabolism and inadequate exposure at resistant lesions. This review critically examines when nanomedicine can make such mechanistic activity pharmacologically and translationally meaningful. We link resistance biology to delivery functions, evaluate bioactive chemosensitiser candidates against human exposure, compare major nanomedicine design strategies, and assess nano-bio interactions, repeat-dose safety, manufacturing and clinical positioning. Across the evidence, three limitations recur. First, concentrations associated with chemosensitisation for curcumin, resveratrol, epigallocatechin gallate and quercetin generally exceed measured human parent-analyte exposure. Second, many resistance claims rely on parental or poorly characterised models, whereas studies combining defined resistance provenance with functional mechanism and exposure confirmation remain uncommon. Third, human studies demonstrate feasibility, tissue exposure or treatment response, but not mechanism-specific reversal of CRC MDR by a bioactive compound or bioactive nanomedicine. Progress therefore depends less on adding new particle classes than on matching a necessary formulation function to a defined resistance or spatial barrier, quantifying active exposure in the relevant compartment, validating mechanism in appropriate models, and integrating repeat-dose safety, scalable manufacturing and biomarker-guided clinical development.
中文摘要:结直肠癌的多药耐药源于肿瘤细胞、药理学和微环境程序之间的相互作用,这些程序同时削弱药物活性和药物递送。化疗相关多药耐药是本文的主要焦点,靶向治疗和免疫治疗耐药仅在直接影响递送设计或患者选择时讨论。生物活性化合物可调节多条耐药通路,但其转化价值受溶解度差、不稳定、快速代谢以及在耐药病灶暴露不足的限制。本文批判性审视纳米医学何时能使这类机制活性具有药理学和转化意义,将耐药生物学与递送功能联系起来,依据人体暴露评估生物活性化疗增敏候选物,比较主要纳米医学设计策略,并评估纳米-生物相互作用、重复给药安全性、生产和临床定位。贯穿现有证据,有三项局限反复出现。第一,姜黄素、白藜芦醇、表没食子儿茶素没食子酸酯和槲皮素与化疗增敏相关的浓度通常超过实测人体原型分析物暴露。第二,许多耐药主张依赖亲本模型或表征不足的模型,而将明确的耐药来源、功能机制和暴露确认结合起来的研究仍不常见。第三,人体研究证明了可行性、组织暴露或治疗反应,但未证明某种生物活性化合物或生物活性纳米药物对结直肠癌多药耐药的机制特异性逆转。因此,进展较少取决于增加新的颗粒类别,而更多取决于将必要的制剂功能与明确的耐药屏障或空间屏障相匹配,量化相关隔室中的活性暴露,在合适模型中验证机制,并整合重复给药安全性、可扩展生产和生物标志物引导的临床开发。
Cancer progression is closely associated with dysregulated redox homeostasis within the tumour microenvironment (TME), where reactive oxygen and nitrogen species influence tumour survival, immune evasion, and therapeutic resistance. While physiological redox signalling supports antitumour immunity, persistent oxidative stress promotes immunosuppression and limits the efficacy of immunotherapies, making redox modulation an attractive therapeutic strategy. Naturally occurring polyphenols have emerged as promising redox-regulating agents due to their antioxidant, anti-inflammatory, and immunomodulatory properties. Beyond scavenging reactive species, they regulate pathways involved in immune activation, metabolic reprogramming, ferroptosis, and tumour-immune interactions. However, their clinical application is hindered by poor bioavailability, rapid metabolism, and limited tumour accumulation. Nanotechnology-based delivery systems, including liposomes, polymeric nanoparticles, metal-based nanoplatforms, biomimetic vesicles, and stimuli-responsive carriers, have been developed to overcome these limitations. These platforms enhance polyphenol stability, targeted delivery, and controlled release while enabling synergistic interactions with immunotherapy. Importantly, they can function as programmable redox-immunomodulatory systems capable of remodelling the TME, inducing immunogenic cell death, promoting ferroptosis, and activating innate and adaptive immune responses. This review discusses the interplay between redox regulation and tumour immunity, examines the immunomodulatory mechanisms of polyphenols, and highlights recent advances in nanocarrier-based delivery strategies. Challenges related to biological heterogeneity, biomarker development, manufacturing scalability, regulatory approval, and clinical translation are also considered, together with future perspectives for precision redox medicine based on polyphenol-enabled nanotechnologies.
中文摘要:癌症进展与肿瘤微环境内氧化还原稳态失衡密切相关,活性氧和活性氮影响肿瘤存活、免疫逃逸及治疗耐药。生理性氧化还原信号支持抗肿瘤免疫,持续氧化应激则促进免疫抑制并限制免疫治疗疗效,使氧化还原调控成为有吸引力的治疗策略。天然多酚因具有抗氧化、抗炎和免疫调节特性,成为有前景的氧化还原调节剂。除清除活性物种外,多酚还调控免疫激活、代谢重编程、铁死亡及肿瘤-免疫相互作用相关通路。其临床应用受生物利用度低、代谢快和肿瘤蓄积有限制约。脂质体、聚合物纳米颗粒、金属基纳米平台、仿生囊泡和刺激响应载体等纳米递送系统被用于克服这些限制,可提高多酚稳定性、靶向递送和控释能力,并促进与免疫治疗的协同作用。这类平台可作为可编程的氧化还原-免疫调节系统,重塑肿瘤微环境、诱导免疫原性细胞死亡、促进铁死亡并激活固有和适应性免疫应答。本综述讨论氧化还原调控与肿瘤免疫的相互作用,梳理多酚的免疫调节机制,并总结纳米载体递送策略的最新进展,同时讨论生物异质性、生物标志物开发、生产可扩展性、监管审批和临床转化等挑战,以及基于多酚纳米技术的精准氧化还原医学前景。
The human gut microbiota constitutes the largest and most metabolically active microbial ecosystem in the body, and accumulating evidence links dynamic alterations in microbial composition and function to the initiation, progression, and treatment responses of multiple gastrointestinal (GI) cancers, including esophageal, gastric, hepatocellular, pancreatic, and colorectal malignancies. This review synthesizes current evidence on dysbiosis signatures, mechanistic pathways, and translational opportunities across major GI cancer types, with a focus on microbe-derived metabolites and microbe-associated molecular patterns that shape inflammation, epithelial barrier integrity, and antitumor immunity. Across GI cancers, recurrent patterns include enrichment of pro-inflammatory/pathobiont taxa, depletion of homeostasis-maintaining and butyrate-producing commensals, and perturbations in metabolic axes centered on bile acids and short-chain fatty acids. Mechanistically, these changes can remodel the tumor microenvironment via epithelial and immune signaling, epigenetic regulation, and metabolic reprogramming. Importantly, the gut microbiota is increasingly recognized as a modifiable determinant of the efficacy and toxicity of immune checkpoint blockade, adoptive cell therapies, chemotherapy, and radiotherapy. Despite rapid advances, key challenges persist in translating microbiome research into cancer care, including validation, standardization, variability, and safety. Future success likely depends on function-oriented, targeted modulation, supported by multi-omics, strong causal evidence, and clinical trials.
中文摘要:人体肠道微生物群是体内最大且代谢最活跃的微生物生态系统,越来越多证据将微生物组成与功能的动态改变同多种消化道肿瘤的发生、进展和治疗反应联系起来,涉及食管癌、胃癌、肝细胞癌、胰腺癌和结直肠癌。综述汇总了主要消化道肿瘤中菌群失调特征、机制通路和转化机会的现有证据,重点讨论微生物来源代谢物和微生物相关分子模式如何塑造炎症、上皮屏障完整性和抗肿瘤免疫。在各类消化道肿瘤中,反复出现的模式包括促炎/致病共生菌群富集、维持稳态及产丁酸共生菌减少,以及以胆汁酸和短链脂肪酸为中心的代谢轴紊乱。机制上,这些变化可通过上皮与免疫信号、表观遗传调控和代谢重编程重塑肿瘤微环境。肠道微生物群正日益被视为免疫检查点阻断、过继细胞治疗、化疗和放疗疗效与毒性的可调节决定因素。尽管进展迅速,将微生物组研究转化为肿瘤诊疗仍面临验证、标准化、变异性和安全性等关键挑战。未来成功可能取决于以功能为导向的靶向调控,并需多组学、强因果证据和临床试验支持。
Messenger RNA (mRNA) therapeutics have emerged as a transformative biomedical platform with broad potential in vaccination, protein replacement, gene editing, and cancer immunotherapy. Despite substantial progress, the broader clinical translation of mRNA therapeutics requires further optimization of delivery systems to address challenges related to stability, biodistribution, intracellular delivery efficiency, and biosafety. In this review, we discuss the rational design of redox-responsive nanomaterials that exploit physiological intracellular redox compartmentalization or, in selected systems, disease-associated oxidative or reductive dysregulation to improve mRNA delivery. We first summarize the biological basis of redox-responsive delivery by linking disease-associated redox imbalance with the engineering principles of responsive nanomaterials. We then systematically discuss major classes of redox-responsive systems, including oxidation-responsive, reduction-responsive, and dual-responsive platforms across polymeric, lipid-based, and hybrid nanomaterial formulations. Particular emphasis is placed on how distinct chemical architectures and responsive motifs influence intracellular delivery behavior, cargo release, immune compatibility, and therapeutic performance. Finally, we discuss current translational challenges, including long-term biosafety, repeated administration, immunogenicity, and large-scale manufacturing, while highlighting emerging opportunities such as AI-assisted material design and personalized theranostic applications. Collectively, this review provides a comprehensive framework for understanding how redox-responsive nanomaterial engineering may advance the next generation of precise and clinically translatable mRNA therapeutics.
中文摘要:信使RNA(mRNA)疗法已成为具有转化潜力的生物医学平台,在疫苗接种、蛋白替代、基因编辑和肿瘤免疫治疗中展现出广泛前景。临床转化仍受稳定性、生物分布、细胞内递送效率及生物安全性等问题制约,递送系统需要进一步优化。本综述讨论氧化还原响应型纳米材料的理性设计:利用细胞内氧化还原区室化,或在部分系统中利用疾病相关氧化或还原失衡,改善mRNA递送。内容覆盖氧化还原响应递送的生物学基础,并将疾病相关氧化还原失衡与响应型纳米材料的工程原理相联系;系统梳理氧化响应、还原响应和双重响应平台,涉及聚合物、脂质基及杂化纳米材料制剂;重点分析不同化学结构与响应基元对细胞内递送行为、货物释放、免疫相容性和治疗性能的影响。转化层面的长期生物安全性、重复给药、免疫原性和规模化生产仍是待解问题,人工智能辅助材料设计和个体化诊疗一体化应用则提供了新的可能。本综述为理解氧化还原响应型纳米材料工程如何推进下一代精准且可临床转化的mRNA疗法提供了综合框架。
Sialylation, a dynamic post-translational modification catalyzed by sialyltransferases and counterbalanced by neuraminidases, entails the attachment of sialic acids to the terminal residues of glycoproteins and glycolipids. This modification profoundly influences diverse biological processes, including early embryogenesis, neurodevelopment, maintenance of stem cell pluripotency, and oncogenic transformation. In cancer, aberrant sialylation manifests as altered linkage patterns and dysregulated expression of sialylated glycans, which directly drive malignant behaviors such as uncontrolled proliferation, enhanced adhesion and invasion, immune evasion, and therapy resistance. Deciphering the underlying molecular mechanisms is therefore crucial for advancing our understanding of tumor biology. In this review, we systematically summarize recent advances in the study of sialylation in cancer, with a focus on the biological functions of distinct sialyltransferases and neuraminidases. We further discuss the diagnostic, prognostic, and therapeutic implications of targeting sialylation, highlighting its emerging potential as a promising avenue for cancer treatment.
中文摘要:唾液酸化是由唾液酸转移酶催化、并由神经氨酸酶反向平衡的动态翻译后修饰,将唾液酸连接到糖蛋白和糖脂的末端残基。该修饰影响早期胚胎发生、神经发育、干细胞多能性维持以及致癌转化等多种生物学过程。在癌症中,异常唾液酸化表现为连接方式改变和唾液酸化聚糖表达失调,直接驱动失控增殖、黏附与侵袭增强、免疫逃逸和治疗耐药等恶性行为。解析其分子机制对深化肿瘤生物学认识至关重要。综述系统总结癌症唾液酸化研究的最新进展,重点关注不同唾液酸转移酶和神经氨酸酶的生物学功能,并讨论靶向唾液酸化的诊断、预后和治疗意义,指出其作为癌症治疗有前景方向的潜力。
T cell exhaustion (TCE), a hallmark of chronic infections and cancer, is characterized by progressive loss of effector function, sustained expression of inhibitory receptors, and stable transcriptional/epigenetic reprogramming. Within the tumor microenvironment (TME), exhausted CD8+ T cells fail to eliminate malignant cells, contributing to immune evasion and resistance to immunotherapy. Although checkpoint blockade has provided clinical benefit, outcomes remain variable, underscoring the need to better understand the temporal and mechanistic basis of exhaustion. Current modeling efforts have yielded valuable insights; however, they often focus on isolated aspects of tumor-immune interactions. Deterministic models such as ordinary, partial, and delay differential equations capture population dynamics, but omit stochastic variation and single-cell heterogeneity. Stochastic and agent-based models address randomness and spatial structure at a greater computational cost. Hybrid and multiscale approaches increasingly integrate these methods, but few explicitly capture the progressive, time-series nature of TCE as revealed by recent epigenetic and transcriptomics studies. This review analyzes various mathematical and computational frameworks including deterministic, stochastic, and hybrid approaches that have been applied to study TCE in viral and cancer contexts. We distinguish between TCE-specific models that directly represent exhaustion dynamics and TCE-relevant frameworks that model tumor-immune interactions, spatial tumor microenvironment features, and pharmacological interventions that could be adapted to optimize future TCE models. By comparing strengths and limitations across frameworks, we identify key gaps including limited integration of temporal resolution, lack of multiscale intracellular regulation, and scarce validation with longitudinal experimental data. We also highlight how TCE-relevant models can support pharmacological and translational questions, including dose optimization, pharmacokinetic /pharmacodynamic (PK/PD) integration, and mechanisms of immunotherapy failure. Future models that adopt hybrid, time-resolved, and multiscale designs linking intracellular regulatory networks, population-level signaling, and spatially heterogeneous TME features, calibrated with time-series omics data, would be invaluable in addressing these gaps. Such frameworks would provide mechanistic insights into exhaustion trajectories, supporting advances in immunotherapy design and clinical outcomes.
中文摘要:T细胞耗竭(TCE)是慢性感染和癌症的标志,表现为效应功能进行性丧失、抑制性受体持续表达以及稳定的转录/表观遗传重编程。在肿瘤微环境(TME)中,耗竭的CD8+ T细胞无法清除恶性细胞,促成免疫逃逸和对免疫治疗的抵抗。检查点阻断已带来临床获益,但结局仍不一致,凸显了更深入理解耗竭的时间与机制基础的必要性。现有建模工作已提供有价值的见解,但常聚焦于肿瘤-免疫相互作用的孤立方面。常微分、偏微分和时滞微分方程等确定性模型可刻画群体动力学,却遗漏随机变异和单细胞异质性。随机模型和基于智能体的模型以更高的计算成本处理随机性与空间结构。混合与多尺度方法日益整合这些手段,但少有模型明确刻画近期表观遗传学和转录组研究所揭示的TCE渐进性时间序列特征。本综述分析已用于病毒和癌症情境下TCE研究的多种数学与计算框架,包括确定性、随机和混合方法。我们区分直接表征耗竭动力学的TCE特异模型与TCE相关框架,后者建模肿瘤-免疫相互作用、空间肿瘤微环境特征以及可被改造以优化未来TCE模型的药理学干预。通过比较各框架的优势与局限,我们识别关键缺口,包括时间分辨率整合有限、多尺度胞内调控缺失以及纵向实验数据验证不足。我们也强调TCE相关模型如何支持药理学与转化问题,包括剂量优化、药代动力学/药效动力学(PK/PD)整合以及免疫治疗失败机制。采用混合、时间分辨和多尺度设计,并将胞内调控网络、群体水平信号传导与空间异质性TME特征相连接、再用时间序列组学数据校准的未来模型,将有助于弥补这些缺口。此类框架可为耗竭轨迹提供机制见解,支持免疫治疗设计与临床结局的进步。
Triterpenoids are important natural secondary metabolites with diverse bioactivities, including antioxidant, anti-inflammatory, and anti-cancer properties, making them valuable for applications in the pharmaceutical, cosmetic, and food industries. Currently, triterpenoids are mainly obtained through natural extraction or chemical synthesis. However, these conventional approaches are often limited by production efficiency, environmental burdens, and product diversity. Rapid advances in metabolic engineering and synthetic biology have promoted the emergence of heterologous biosynthesis as a promising, efficient, and sustainable strategy for triterpenoids production. In this review, we first summarize the classification and bioactive properties of triterpenoids, together with the challenges and potential solutions associated with their microbial synthesis. Then, we analyze the key characteristics of microbial hosts and their corresponding biosynthetic pathways for triterpenoids production, aiming to establish programmable platforms that overcome the limitations of natural biosynthesis. Subsequently, we propose metabolic engineering and synthetic biology strategies, including enzyme optimization, pathway optimization, compartmentalization engineering, and systems biology approaches, for optimizing matter and energy transmission and thereby enhancing triterpenoids production. We further discuss the potential challenges for scaling up triterpenoids production from laboratory-scale studies to industrial-scale applications, including the optimization of large-scale fermentation process and the improvement of downstream extraction and recovery. Finally, we discuss the techno-economic feasibility and industrial prospects of microbial triterpenoid production, highlight current regulation and governance in synthetic biology related to triterpenoids biosynthesis, analyze existing limitations, and propose potential solutions to provide insights for future research on the biomanufacturing of triterpenoids.
中文摘要:三萜类化合物是重要的天然次生代谢产物,具有抗氧化、抗炎和抗癌等多种生物活性,在制药、化妆品和食品工业中具有应用价值。目前三萜类化合物主要通过天然提取或化学合成获得,但这些传统方法常受生产效率、环境负担和产物多样性限制。代谢工程与合成生物学的快速进展推动了异源生物合成作为一种有前景、高效且可持续的三萜类生产策略的出现。该综述总结三萜类化合物的分类和生物活性特性,以及微生物合成相关挑战和潜在解决方案;分析微生物宿主的关键特征及其相应的三萜类生物合成途径,以建立可编程平台来克服天然生物合成的局限;提出酶优化、途径优化、区室化工程和系统生物学方法等代谢工程与合成生物学策略,用于优化物质与能量传递,从而提高三萜类产量;讨论从实验室规模研究向工业规模应用放大的潜在挑战,包括大规模发酵过程优化以及下游提取与回收的改进;讨论微生物生产三萜类的技术经济可行性和工业前景,强调与三萜类生物合成相关的合成生物学现行监管与治理,分析现有局限并提出潜在解决方案,为今后三萜类生物制造研究提供思路。
Protein arginine methyltransferases (PRMTs) catalyze the formation of arginine methylations in histones and nonhistone proteins. PRMT family members strongly affect the malignant progression of cancer. Recently, an increasing number of studies have shown that the interactions of protein arginine methylation and ubiquitination play crucial roles in various essential biological processes related to cancer, such as the DNA damage response (DDR), protein stability, immune escape and signal transduction, which significantly influence cancer progression. This article presents an overview of the mechanisms by which the crosstalk between arginine methylation and ubiquitination impacts cancer. Moreover, we explore future research directions related to arginine methylation and ubiquitination crosstalk in cancer treatment. The goal is to provide a theoretical foundation and potential applications for related basic research and the development of anticancer drugs.
中文摘要:蛋白精氨酸甲基转移酶(PRMTs)催化组蛋白和非组蛋白中精氨酸甲基化的形成。PRMT家族成员对癌症的恶性进展有显著影响。近年来越来越多研究表明,蛋白精氨酸甲基化与泛素化的相互作用在DNA损伤应答(DDR)、蛋白稳定性、免疫逃逸和信号转导等与癌症相关的多种关键生物学过程中发挥重要作用,并显著影响癌症进展。该文概述精氨酸甲基化与泛素化之间的交互作用影响癌症的机制,并探讨癌症治疗中精氨酸甲基化与泛素化交互作用相关的未来研究方向,旨在为相关基础研究和抗癌药物研发提供理论基础与潜在应用。
The fibroblast growth factor (FGF) 15/19-FGF receptor (FGFR) 4 signaling pathway is a crucial endocrine regulatory pathway within the FGF family. The FGF15/19-FGFR4 signaling pathway plays multiple key roles in the liver, involving core physiological processes such as metabolic regulation, bile acid homeostasis maintenance, and hepatocyte proliferation and repair, and is also closely related to the pathogenesis of various liver diseases. At present, targeted therapeutic strategies for the FGF19-FGFR4 signaling axis have shown significant therapeutic potential. Agonists that simulate the physiological functions of FGF19 have been proven to effectively regulate bile acid and lipid metabolism in metabolic diseases and improve liver steatosis and fibrosis. Meanwhile, drugs that selectively inhibit FGFR4 have also demonstrated positive anti-tumor activity in specific tumor types driven by FGF19 overexpression. Given the crucial role of FGF19-FGFR4, clarifying the key mechanisms of this pathway in both physiology and pathology, as well as summarizing targeted therapy, is of vital importance. This review highlights the key role of FGF15/19-FGFR4 signaling in regulating liver physiological functions and reveals how its abnormal expression contributes to the occurrence of benign and malignant liver diseases. In addition, this review points out the potential of FGF15/19-FGFR4 signaling as a biomarker in different liver diseases and briefly discusses the existing treatment strategies for this signaling pathway.
中文摘要:成纤维细胞生长因子(FGF)15/19-FGF受体(FGFR)4信号通路是FGF家族中重要的内分泌调节通路。FGF15/19-FGFR4信号通路在肝脏中发挥多种关键作用,涉及代谢调节、胆汁酸稳态维持以及肝细胞增殖与修复等核心生理过程,也与多种肝脏疾病的发生密切相关。目前,针对FGF19-FGFR4信号轴的靶向治疗策略已显示出明显的治疗潜力。模拟FGF19生理功能的激动剂已被证明可在代谢性疾病中有效调节胆汁酸和脂质代谢,并改善肝脏脂肪变性和纤维化;同时,选择性抑制FGFR4的药物在由FGF19过表达驱动的特定肿瘤类型中也表现出积极的抗肿瘤活性。鉴于FGF19-FGFR4的重要作用,阐明该通路在生理和病理状态下的关键机制并总结靶向治疗具有重要价值。该综述强调FGF15/19-FGFR4信号在调节肝脏生理功能中的关键作用,并揭示其异常表达如何促进良性和恶性肝脏疾病的发生。该综述还指出FGF15/19-FGFR4信号作为不同肝脏疾病生物标志物的潜力,并简要讨论针对该信号通路的现有治疗策略。
Antibody-drug conjugates (ADCs), a revolutionary tumor therapeutic modality integrating the targeting specificity of monoclonal antibodies and the cytotoxicity of payloads, have undergone four generations of development, with over 20 approved drugs and more than 300 candidates in clinical trials globally. Despite their remarkable success in treating both hematological malignancies and solid tumors, traditional ADCs still face intractable challenges, including heterogeneity in target antigen expression, insufficient internalization, payload-mediated drug resistance, and severe treatment-related adverse events. This review elaborates on the latest design optimization strategies and research advances of next-generation function-enhanced ADCs, focusing on four core directions: bispecific ADC construction, internalization efficiency improvement, binding affinity enhancement, and payload combination innovation.
中文摘要:抗体偶联药物(ADC)将单克隆抗体的靶向特异性与载荷的细胞毒性结合起来,是一类具有变革意义的肿瘤治疗方式,已历经四代发展,全球范围内有超过20款获批药物和300余个处于临床试验阶段的候选药物。ADC在血液系统恶性肿瘤和实体瘤治疗中取得了显著成功,但传统ADC仍面临靶抗原表达异质性、内化不足、载荷介导的耐药以及严重的治疗相关不良事件等难题。本综述阐述下一代功能增强型ADC的最新设计优化策略与研究进展,围绕双特异性ADC构建、内化效率提升、结合亲和力增强和载荷组合创新四个核心方向展开。
Chitinase-3-like-1 (CHI3L1, also known as YKL-40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite lacking catalytic activity, CHI3L1's conserved chitinase fold and glycan-decorated surface acts as a modular scaffold linking cytokine, metabolic, and stress signals to immune suppression and fibrotic remodeling. Through its chitinase-like structure it engages with receptor triad complex, including IL-13Rα2, TMEM219, and Galectin-3, activating signaling pathways such as MAPK, PI3K/AKT, and TGF-β/Smad. Through these interactions, CHI3L1 has been reported to promote fibroblast activation, angiogenesis, and immune suppression, creating environments where immune cells are excluded or silenced. These checkpoint-like effects are not limited to cancer; they also appear in fibrosis, infection, and neuroinflammatory diseases, linking CHI3L1 to a broad spectrum of immune-resistant conditions. This review integrates structural glycobiology, receptor pharmacology, and immunometabolic mechanisms to reveal CHI3L1 as a unifying regulator of stromal-immune crosstalk. It further highlights preclinical and clinical evidence demonstrating that antibody, RNA-based, and small-molecule inhibitors of CHI3L1 restore immune surveillance and limit pathological remodeling. Targeting this pseudoenzymatic checkpoint alongside canonical PD-1 and CTLA-4 blockade represents a promising strategy to overcome immune resistance and normalize pathogenic tissue remodeling across diverse diseases.
中文摘要:几丁质酶-3样蛋白-1(CHI3L1,也称YKL-40)长期被视为炎症与组织重塑的生物标志物,如今又被认识为一种伪酶免疫检查点。近期的结构学、免疫学与转化研究将其重新定义为免疫抑制的主动调节因子,而非被动的疾病标志物。CHI3L1缺乏催化活性,但其保守的几丁质酶折叠和聚糖修饰表面构成模块化支架,把细胞因子、代谢与应激信号连接到免疫抑制和纤维化重塑。借助几丁质酶样结构,它与由IL-13Rα2、TMEM219和Galectin-3组成的受体三联复合物结合,激活MAPK、PI3K/AKT和TGF-β/Smad等信号通路。通过这些相互作用,CHI3L1被报道可促进成纤维细胞活化、血管生成和免疫抑制,形成免疫细胞被排除或被沉默的环境。这类检查点样效应并不限于癌症,也出现在纤维化、感染和神经炎症性疾病中,使CHI3L1与广泛的免疫抵抗状态相关。该综述整合结构糖生物学、受体药理学和免疫代谢机制,揭示CHI3L1是基质-免疫互作的统一调节因子。文中还强调临床前与临床证据,显示CHI3L1的抗体、基于RNA的抑制剂和小分子抑制剂可恢复免疫监视并限制病理性重塑。将这一伪酶检查点与经典PD-1和CTLA-4阻断联合靶向,是克服免疫抵抗并使多种疾病中的致病性组织重塑正常化的有前景策略。
Chimeric antigen receptor (CAR)-based immunotherapy has evolved from early linear receptor designs into increasingly sophisticated biological signal processing systems. While conventional CAR-T cell therapies have achieved remarkable clinical success, particularly in hematologic malignancies, their broader application is constrained by limited scalability, manufacturing complexity, and treatment-related toxicities. These challenges have driven the expansion of CAR engineering beyond T cells to alternative immune cell types, including natural killer (NK) cells and macrophages, as well as the diversification of genetic delivery and control strategies. Concurrently, advances in synthetic biology have reframed CARs not merely as static receptors but as programmable immune circuits capable of integrating multiple inputs, executing logical operations, and generating context-dependent outputs. Such circuit-based designs enable precise regulation of immune activation, improved discrimination between tumor and healthy tissues, and enhanced functional persistence within heterogeneous and immunosuppressive microenvironments. In this review, we conceptualize CAR-based immunotherapy as a form of biological signal processing and systematically trace its transition from linear CAR architectures to programmable immune circuits. We summarize engineering strategies for both ex vivo and in situ reprogramming of immune cells, compare viral and nonviral gene delivery platforms, and discuss key design principles underlying circuit CARs across different disease contexts.
中文摘要:基于嵌合抗原受体(CAR)的免疫治疗已从早期线性受体设计发展为日益复杂的生物信号处理系统。常规CAR-T细胞疗法在血液系统恶性肿瘤等场景取得显著临床成功,但其更广泛应用受限于可扩展性有限、生产复杂以及治疗相关毒性。这些挑战推动CAR工程从T细胞拓展至自然杀伤(NK)细胞、巨噬细胞等替代免疫细胞类型,并促进基因递送与控制策略多样化。合成生物学进展使CAR不再仅被视为静态受体,而被重新定义为可编程免疫回路,能够整合多种输入、执行逻辑运算并产生依赖情境的输出。此类回路设计可精确调控免疫激活、改善肿瘤与健康组织区分,并增强在异质性和免疫抑制微环境中的功能持久性。文章将基于CAR的免疫治疗概念化为一种生物信号处理形式,系统梳理其从线性CAR结构向可编程免疫回路转变的过程,总结体外与原位重编程免疫细胞的工程策略,比较病毒与非病毒基因递送平台,并讨论回路CAR在不同疾病背景下的关键设计原则。
Dendritic cells (DCs) comprise a heterogeneous population of specialized antigen-presenting cells that play central roles in the initiation and coordination of innate and adaptive immune responses. Recent advances in single-cell technologies and mechanistic studies have substantially expanded our understanding of DC subset heterogeneity, developmental trajectories, and functional specialization. Within the tumor microenvironment (TME), DCs are essential for the priming and maintenance of antitumor T cell immunity; however, they are also vulnerable to tumor-derived signals that drive dysfunction. Increasing evidence indicates that the functional status of DCs critically influences responsiveness to immunotherapies, particularly immune checkpoint blockade (ICB). Accordingly, therapeutic strategies aimed at restoring or enhancing DC function have emerged as promising approaches for the induction of durable antitumor immunity. In this review, we outline recent insights into DC subset diversity and functional states, discuss the consequences of DC dysfunction in cancer, and highlight emerging DC-centered therapeutic strategies for cancer immunotherapy.
中文摘要:树突状细胞(DC)是一群异质性抗原提呈细胞,在固有免疫与适应性免疫应答的启动和协调中发挥核心作用。单细胞技术与机制研究的进展显著拓展了对DC亚群异质性、发育轨迹及功能分工的认识。在肿瘤微环境(TME)中,DC对启动和维持抗肿瘤T细胞免疫至关重要,同时也易受肿瘤来源信号影响而发生功能障碍。越来越多证据表明,DC的功能状态深刻影响免疫治疗尤其是免疫检查点阻断(ICB)的应答。以恢复或增强DC功能为目标的治疗策略因此成为诱导持久抗肿瘤免疫的有前景方向。本综述梳理DC亚群多样性与功能状态的最新认识,讨论DC功能障碍在肿瘤中的后果,并聚焦以DC为中心的新兴肿瘤免疫治疗策略。
Immune cells in the tumor microenvironment are not only powerful regulators of immunosuppression and tumorigenesis but also a dominant cell population, with tumor-associated macrophages (TAMs) comprising up to 50% solid tumor mass. Immunotherapies such as immune checkpoint inhibitors derive efficacy from this cancer-immune interface; however, immune-related adverse events from systemic blockade remain a major challenge. To address this need for potent, tumor-specific immunotherapies, we developed tumor immune cell targeting chimeras (TICTACs) that selectively deplete immune checkpoint receptors such as SIRPα from TAM surfaces. These chimeras consist of a synthetic ligand targeting CD206, a TAM marker, conjugated to a nonblocking antibody that binds to the checkpoint receptor without inhibiting it. By engaging CD206, which constitutively recycles between the plasma membrane and early endosomes, TICTACs drive robust checkpoint degradation in CD206high macrophages, with no effect on CD206low cells. This decoupling of antibody selectivity from blocking function presents a new paradigm for tumor-specific immunotherapies.
中文摘要:肿瘤微环境中的免疫细胞不仅是免疫抑制和肿瘤发生的有力调节者,也是占主导地位的细胞群体,肿瘤相关巨噬细胞(TAMs)可占实体瘤质量的50%。免疫检查点抑制剂等免疫疗法从这一肿瘤-免疫界面获得疗效;但全身性阻断带来的免疫相关不良事件仍是主要挑战。为满足对强效、肿瘤特异性免疫治疗的需求,我们开发了肿瘤免疫细胞靶向嵌合体(TICTACs),可选择性清除TAM表面的免疫检查点受体如SIRPα。这些嵌合体由靶向CD206(TAM标志物)的合成配体偶联到一种非阻断抗体构成,该抗体结合检查点受体但不抑制其功能。通过结合在质膜与早期内体之间持续循环的CD206,TICTACs在CD206高表达巨噬细胞中驱动显著的检查点降解,对CD206低表达细胞无影响。这种将抗体选择性与阻断功能解耦的策略为肿瘤特异性免疫治疗提供了新范式。
Immunosuppressive tumor microenvironment remains a major obstacle to effective cancer immunotherapy, largely due to insufficient initiation and amplification of antitumor immune responses. Herein, we report a mechanism-driven nanotherapeutic strategy that establishes a self-amplifying cuproptosis-STING cascade to overcome tumor immune resistance. The multifunctional copper/manganese-phenolic nanocapsules (HLCM@Cap) undergo pH-responsive release in the acidic tumor microenvironment, enabling efficient intratumoral copper accumulation and triggering cuproptosis characterized by mitochondrial dysfunction and proteotoxic stress. The resulting release of mitochondrial DNA activates the cGAS-STING pathway, while concurrently released Mn2+ further amplifies STING signaling. Meanwhile, Mn2+ also enables T1-weighted magnetic resonance imaging for real-time monitoring of intratumoral nanocapsule accumulation and release, allowing optimization of the administration window. To counteract tumor adaptive resistance, a Wnt/β-catenin inhibitor is incorporated to suppress glycolytic reprogramming and copper efflux, thereby enhancing intracellular copper toxicity and metabolic stress. This coordinated regulation forms a positive feedback loop that reinforces STING activation through persistent damage-associated signaling. Consequently, the cascade promotes dendritic cell maturation, enhances CD8+ T cell infiltration, remodels the immunosuppressive tumor microenvironment, and induces durable immune memory. In a 4T1 tumor model, HLCM@Cap achieves significant antitumor and antimetastatic effects, which are further enhanced in combination with αPD-L1 therapy. Overall, this work presents a self-amplifying cuproptosis-STING cascade to convert immunologically "cold" tumors into "hot" tumors, offering a promising and translatable strategy for synergistic cancer immunotherapy.
中文摘要:免疫抑制性肿瘤微环境仍是有效癌症免疫治疗的主要障碍,主要原因在于抗肿瘤免疫应答的启动与放大不足。本研究报道一种机制驱动的纳米治疗策略,建立自放大的铜死亡-STING级联反应,以克服肿瘤免疫抵抗。多功能铜/锰-酚纳米胶囊(HLCM@Cap)在酸性肿瘤微环境中发生pH响应释放,实现肿瘤内铜的有效蓄积,并触发以线粒体功能障碍和蛋白毒性应激为特征的铜死亡。随之释放的线粒体DNA激活cGAS-STING通路,同时释放的Mn2+进一步放大STING信号。Mn2+还可实现T1加权磁共振成像,用于实时监测纳米胶囊在肿瘤内的蓄积与释放,从而优化给药窗口。为对抗肿瘤适应性抵抗,体系中引入Wnt/β-catenin抑制剂,抑制糖酵解重编程和铜外排,增强细胞内铜毒性与代谢应激。这种协同调控形成正反馈环路,通过持续损伤相关信号强化STING激活。该级联反应促进树突状细胞成熟,增强CD8+ T细胞浸润,重塑免疫抑制性肿瘤微环境,并诱导持久免疫记忆。在4T1肿瘤模型中,HLCM@Cap取得显著抗肿瘤与抗转移效果,与αPD-L1治疗联合后效果进一步增强。该工作提出一种自放大的铜死亡-STING级联反应,将免疫学上的「冷」肿瘤转化为「热」肿瘤,为协同癌症免疫治疗提供有希望且可转化的策略。
Cancer stem cells (CSCs) are a subpopulation of tumor cells with stem cell-like properties, which are endowed with unique self-renewal capacity and heterogeneity. Specifically, they drive tumor initiation, progression, recurrence, and therapeutic resistance. As the core drivers of tumor development and treatment resistance, CSCs exhibit distinct metabolic characteristics that sustain their self-renewal and differentiation potential. Various cells in the tumor microenvironment (TME) interact with CSCs, thereby creating a favorable niche for maintaining CSCs stemness. Furthermore, the metabolic patterns of CSCs themselves can modulate the functions of other TME-resident cells; collectively, these bidirectional interactions promote tumor recurrence and therapeutic resistance. A growing body of evidence has confirmed the critical role of CSCs in tumor progression, drug resistance, and recurrence, which lays a solid foundation for the development of potential therapeutic targets and intervention strategies. This review systematically summarizes the biological characteristics and targeted therapeutic strategies of CSCs, and explores potential directions to break through current therapeutic bottlenecks in combination with the latest status of clinical research.
中文摘要:肿瘤干细胞(CSCs)是具有干细胞样特性的肿瘤细胞亚群,具备独特的自我更新能力和异质性。它们驱动肿瘤起始、进展、复发和治疗耐药。作为肿瘤发展和治疗耐药的核心驱动因素,CSCs表现出支持其自我更新与分化潜能的独特代谢特征。肿瘤微环境(TME)中的多种细胞与CSCs相互作用,形成有利于维持CSCs干性的生态位。CSCs自身的代谢模式也能调节其他TME驻留细胞的功能;这些双向相互作用共同促进肿瘤复发和治疗耐药。越来越多证据证实CSCs在肿瘤进展、耐药和复发中的关键作用,为开发潜在治疗靶点和干预策略奠定基础。本综述系统总结CSCs的生物学特征和靶向治疗策略,并结合临床研究的最新状况探讨突破当前治疗瓶颈的潜在方向。
Multidrug resistance (MDR) is a common and leading cause of treatment failure and mortality in cancer patients. While numerous biological processes contribute to drug resistance, recent studies have revealed that most anticancer drugs rapidly bind to and damage newly synthesized proteins upon entering cells. This process, termed acute drug protein damage (ADPD), occurs before the drugs act on their canonical targets. To evade the lethal effects of ADPD, cancer cells rapidly initiate a series of protective responses collectively termed the protein damage response (PDR). This cascade includes damage recognition via protein ubiquitination, damage clearance through the proteasome system, and subsequent mitophagy to remove damaged mitochondria caused by the co-import of drugs and damaged proteins. Here, we review the current understanding of multiple biological processes underlying drug resistance, with a focus on the mechanisms of ADPD induced by anticancer drugs, the pivotal role of PDR in driving MDR, and its potential applications in predicting and overcoming drug resistance.
中文摘要:多药耐药是肿瘤患者治疗失败和死亡的常见且主要原因。尽管众多生物学过程都参与耐药形成,近期研究显示多数抗癌药物进入细胞后会迅速结合并损伤新合成的蛋白质,这一过程被称为急性药物蛋白损伤,发生在药物作用于其经典靶点之前。为规避急性药物蛋白损伤带来的致死效应,肿瘤细胞迅速启动一系列保护性反应,统称蛋白损伤应答。该级联反应包括通过蛋白质泛素化识别损伤、经蛋白酶体系统清除损伤,以及随后启动线粒体自噬以清除药物与受损蛋白共同转入所造成的受损线粒体。本文综述对耐药背后多种生物学过程的现有认识,重点讨论抗癌药物诱导急性药物蛋白损伤的机制、蛋白损伤应答在驱动多药耐药中的关键作用,以及其在预测和克服耐药方面的潜在应用。
DNA nanodevices have emerged as versatile tools for intracellular biosensing and imaging, yet their broader application is constrained by limited tumor specificity and insufficient subcellular precision. Here, we report a sequentially responsive DNA nanodevice (SRDN) for spatially selective imaging of mitochondrial microRNAs (miRNAs) in live tumor cells and early assessment of treatment efficacy. The sensing function of SRDN is initially silenced through the strategic integration of an abasic site and a blocking DNA element, but can be sequentially activated by human apurinic/apyrimidinic endonuclease 1 (APE1) in the cytoplasm and mitochondria-encoded ribosomal RNA, thereby achieving accurate mitochondrial miRNA imaging with improved spatial resolution. This cascade-activated mechanism significantly reduces off-site signals and enhances the tumor-to-background contrast, enabling tumor-specific mitochondrial miRNA imaging. Furthermore, we demonstrate the performance of SRDN in dynamically monitoring mitochondrial miRNA levels in tumor cells during therapeutic intervention, supporting reliable assessment of treatment efficacy. Collectively, this study provides a robust platform for detecting biomolecules at the subcellular level and investigating treatment-related signaling pathways, underscoring its prospective applications in disease diagnosis and drug development.
中文摘要:DNA纳米器件已成为细胞内生物传感与成像的多功能工具,但肿瘤特异性有限、亚细胞精度不足,使其更广泛的应用受到限制。我们报道了一种顺序响应型DNA纳米器件(SRDN),用于活肿瘤细胞中线粒体微小RNA(miRNA)的空间选择性成像以及治疗效果的早期评估。通过引入脱碱基位点和封闭DNA元件,SRDN的传感功能被预先沉默,随后可被细胞质中的人脱嘌呤/脱嘧啶核酸内切酶1(APE1)和线粒体编码的核糖体RNA依次激活,从而实现空间分辨率更高的线粒体miRNA精准成像。这种级联激活机制明显降低脱靶信号并提升肿瘤与本底的对比度,使肿瘤特异性线粒体miRNA成像得以实现。我们还展示了SRDN在治疗干预过程中动态监测肿瘤细胞线粒体miRNA水平的表现,支持对疗效的可靠评估。该工作为亚细胞水平检测生物分子、研究治疗相关信号通路提供了稳健平台,显示出在疾病诊断和药物研发中的应用前景。
Tumor metastasis is the primary cause of death from malignant tumors. The elucidation of its molecular mechanism is of great significance for breakthroughs in targeted therapy. In this study, a microfluidic chip platform integrating "dynamic dilution-precise capture-mechanical stimulation-in situ analysis" was constructed. Through the design of bionic narrow channels, efficient separation of exosomes and functional research at the single-cell level were achieved. On the one hand, the mechanical microenvironment within the chip was utilized to regulate the secretion of tumor cell exosomes (increasing secretion levels by more than twofold) and the expression of key proteins, revealing the exosome-mediated cell invasion behavior. On the other hand, using breast cancer as a model, the malignant transformation effects of exosomes derived from highly metastatic MDA-MB-231 cells and low-metastatic MCF-7 cells on normal MCF-10A breast epithelial cells were comparatively analyzed. The transformation efficiency was preliminarily verified using the CD43 (a marker associated with malignant transformation), and the reasonable inference was established regarding the regulatory role of PD-L1 in the epithelial-mesenchymal transition (EMT) process. Experiments were then conducted on whole blood samples (processing time for 0.5 mL whole blood <10 min). The study provides new potential targets and intervention strategies for cancer immunotherapy.
中文摘要:肿瘤转移是恶性肿瘤死亡的主要原因。阐明其分子机制对靶向治疗取得突破具有重要意义。本研究构建了集「动态稀释-精确捕获-机械刺激-原位分析」于一体的微流控芯片平台。通过仿生狭窄通道设计,实现外泌体高效分离及单细胞水平功能研究。一方面,利用芯片内机械微环境调控肿瘤细胞外泌体分泌(分泌水平提高两倍以上)及关键蛋白表达,揭示外泌体介导的细胞侵袭行为。另一方面,以乳腺癌为模型,比较分析高转移性MDA-MB-231细胞与低转移性MCF-7细胞来源外泌体对正常乳腺上皮MCF-10A细胞的恶性转化作用。借助CD43(与恶性转化相关的标志物)初步验证转化效率,并就PD-L1在上皮-间质转化(EMT)过程中的调控作用建立合理推断。随后在全血样本上开展实验(0.5 mL全血处理时间<10 min)。该研究为肿瘤免疫治疗提供新的潜在靶点与干预策略。
Osteosarcoma (OS) responds poorly to immunotherapy owing to its highly immunosuppressive phenotype. Photodynamic therapy (PDT) can induce mitochondrial damage by generating reactive oxygen species (ROS), thereby triggering immunogenic cell death (ICD) and activating antitumor immunity. However, mitochondrial damage readily activates mitophagy, which attenuates oxidative stress and compromises therapeutic efficacy. In this study, we construct a multifunctional nanoparticle (TPSM@IT-4Cl), which co-loads the photosensitizer IT-4Cl and the mitochondrial fission inhibitor Mdivi-1 and can target mitochondria. TPSM@IT-4Cl is selectively delivered to the mitochondria of tumor cells and releases drugs in a glutathione (GSH)-responsive manner within a high-GSH microenvironment. Under localized light irradiation, TPSM@IT-4Cl efficiently generates ROS via IT-4Cl to induce mitochondrial damage, while the released Mdivi-1 inhibits mitochondrial fission and thereby indirectly interferes with mitophagy, ultimately amplifying the efficacy of PDT. Both in vitro and in vivo studies indicated that the resulting ICD remodels the tumor immune microenvironment and elicits potent anti-tumor immunity. Moreover, TPSM@IT-4Cl exhibits significant antitumor efficacy in OS patient-derived xenograft (PDX) models, highlighting its translational potential. Collectively, we developed a mitochondria-targeted photodynamic nanoparticle with concomitant mitophagy inhibition, which may provide a feasible strategy to overcome the limitations of immunotherapy in OS.
中文摘要:骨肉瘤(OS)因高度免疫抑制表型对免疫治疗反应不佳。光动力治疗(PDT)可通过产生活性氧(ROS)造成线粒体损伤,触发免疫原性细胞死亡(ICD)并激活抗肿瘤免疫。线粒体损伤又容易激活线粒体自噬,削弱氧化应激并降低疗效。本研究构建多功能纳米颗粒 TPSM@IT-4Cl,共载光敏剂 IT-4Cl 与线粒体分裂抑制剂 Mdivi-1,并可靶向线粒体。TPSM@IT-4Cl 选择性递送至肿瘤细胞线粒体,在高 GSH 微环境中以谷胱甘肽(GSH)响应方式释放药物。局部光照下,TPSM@IT-4Cl 经 IT-4Cl 高效生成 ROS 诱导线粒体损伤,释放的 Mdivi-1 抑制线粒体分裂,间接干扰线粒体自噬,最终放大 PDT 疗效。体外和体内研究均表明,由此产生的 ICD 重塑肿瘤免疫微环境并激发强效抗肿瘤免疫。TPSM@IT-4Cl 在骨肉瘤患者来源异种移植(PDX)模型中表现出显著抗肿瘤效果,显示转化潜力。我们开发了一种可同步抑制线粒体自噬的线粒体靶向光动力纳米颗粒,或为克服骨肉瘤免疫治疗局限提供可行策略。
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease primarily characterized by symmetrical synovial inflammation, leading to joint swelling, pain, and progressive cartilage and bone destruction. Unfortunately, the clinical treatment of RA still faces numerous challenges. Although melatonin (MT), the circadian rhythm hormone, is known to relieve the pathological process of RA, the underlying mechanism remains poorly understood. Herein, we assess the impacts of MT on collagen or K/BxN serum-induced arthritis (two well-established models of RA) and confirm its excellent therapeutic effect. Mechanistically, MT activates MTNR1A (melatonin receptor 1A) to promote mitophagy for the elimination of reactive oxygen (ROS) and leaked mitochondrial DNA triggered by damaged mitochondria, which in turn limits NLRP3 (NLR family pyrin domain containing 3) inflammasome activation and pro-inflammatory cytokine release. Mice with deletion of the autophagy-related gene Atg5 in myeloid cells (atg5fl/fl Lyz2/LysM-cre) barely display any benefits of MT in K/BxN serum-induced arthritis. Our results indicate that mitophagy promoted by MT is essential to deactivate NLRP3 inflammasome and alleviate the development of arthritis, which provides a candidate for the treatment of RA.Abbreviations: 3-MA: 3-methyladenine; ACP5/TRAP: acid phosphatase 5, tartrate resistant; ANOVA: analysis of variance; ATG5: autophagy releated 5; ATP: adenosine triphosphate; BMD: bone mineral density; BMDMs: bone marrow derived macrophages; BV:TV: bone volume to tissue volume; CASP1: caspase 1; CYCS: cytochrome c; DNM1L/DRP1: dynamin 1 like; EtBr: ethidium bromide; FCCP: carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; GSDMD: gasdermin D; IL1B/IL-1β: interleukin 1 beta; IL18: interleukin 18; LPS: lipopolysaccharide; MT: melatonin; MTNR1A: melatonin receptor 1A; MTNR1B: melatonin receptor type 1B; MFF: mitochondrial fission factor; mtROS: mitochondrial reactive oxygen species; mt-DNA: mitochondrial DNA; NAC: N-acetylcysteine; NT-GSDMD: N-terminal gasdermin D; NLRP3: NLR family pyrin domain containing 3; Ox-mtDNA: oxidized mitochondrial DNA; PINK1: PTEN induced kinase 1; PRKAA/AMPK: protein kinase AMP-activated catalytic subunit alpha; PRKN: parkin RBR E3 ubiquitin protein ligase; PYCARD/ASC: PYD and CARD domain containing; RA: rheumatoid arthritis; ROS: reactive oxygen; SD: standard deviation; SQSTM1/p62: sequestosome 1; Tb.N: trabecular number; Tb.Th: trabecular thickness; TNF/TNF-α: tumor necrosis factor; ULK1: unc-51 like autophagy activating kinase 1.
中文摘要:类风湿关节炎(RA)是一种慢性系统性自身免疫病,主要特征为对称性滑膜炎,可导致关节肿胀、疼痛以及进行性软骨和骨破坏。RA的临床治疗仍面临诸多挑战。昼夜节律激素褪黑素(MT)已知可缓解RA的病理过程,但其潜在机制仍不清楚。在此评估MT对胶原诱导性或K/BxN血清诱导性关节炎(两种成熟的RA模型)的影响,并证实其良好的治疗作用。机制上,MT激活MTNR1A(褪黑素受体1A)促进线粒体自噬,以清除受损线粒体引发的活性氧(ROS)和泄漏的线粒体DNA,进而限制NLRP3(NLR家族含pyrin结构域3)炎症小体激活和促炎细胞因子释放。在髓系细胞中敲除自噬相关基因Atg5的小鼠(atg5fl/fl Lyz2/LysM-cre)在K/BxN血清诱导性关节炎中几乎未表现出MT的益处。结果提示,MT促进的线粒体自噬对于失活NLRP3炎症小体和缓解关节炎进展至关重要,为RA治疗提供了候选方案。缩略语:3-MA:3-甲基腺嘌呤;ACP5/TRAP:抗酒石酸酸性磷酸酶5;ANOVA:方差分析;ATG5:自噬相关5;ATP:三磷酸腺苷;BMD:骨密度;BMDMs:骨髓来源巨噬细胞;BV:TV:骨体积与组织体积比;CASP1:半胱天冬酶1;CYCS:细胞色素c;DNM1L/DRP1:动力蛋白1样蛋白;EtBr:溴化乙锭;FCCP:羰基氰-4-(三氟甲氧基)苯腙;GSDMD:gasdermin D;IL1B/IL-1β:白细胞介素1β;IL18:白细胞介素18;LPS:脂多糖;MT:褪黑素;MTNR1A:褪黑素受体1A;MTNR1B:褪黑素受体1B;MFF:线粒体分裂因子;mtROS:线粒体活性氧;mt-DNA:线粒体DNA;NAC:N-乙酰半胱氨酸;NT-GSDMD:N端gasdermin D;NLRP3:NLR家族含pyrin结构域3;Ox-mtDNA:氧化型线粒体DNA;PINK1:PTEN诱导激酶1;PRKAA/AMPK:蛋白激酶AMP激活催化亚基α;PRKN:parkin RBR E3泛素蛋白连接酶;PYCARD/ASC:含PYD和CARD结构域蛋白;RA:类风湿关节炎;ROS:活性氧;SD:标准差;SQSTM1/p62:螯合体1;Tb.N:骨小梁数目;Tb.Th:骨小梁厚度;TNF/TNF-α:肿瘤坏死因子;ULK1:unc-51样自噬激活激酶1。
Lung metastasis remains a major clinical challenge, often associated with poor prognosis due to its highly immunosuppressive microenvironment and fibrosis-induced complications. Current treatment strategies, including chemotherapy, radiotherapy, and immunotherapy, have shown limited efficacy in addressing lung metastases, and less attention has been given to their associated fibrosis. Here, we develop a 'cell-in-cell' delivery platform (i.e., lyophilized bacteria-infected tumor cells (LyoBT)) to simultaneously target lung metastasis and their associated fibrosis. This approach leverages the intrinsic lung tropism of tumor cells and the immunostimulatory properties of both tumor cells and bacteria, while mitigating tumorigenic and pathogenic risks through lyophilization. Notably, bacterial infection led to phenotypic changes in tumor cells. Specifically, characterization of LyoBT revealed upregulated expression of CD47, CD44, and E-cadherin, further enhancing lung targeting. Furthermore, increased calreticulin (CRT) exposure in LyoBT coupled with bacterial immune-stimulatory properties, promoted anti-tumor immunity. In a melanoma lung metastasis model, LyoBT demonstrated efficient accumulation in the lungs, leading to robust anti-tumor immune activation and significant inhibition of tumor progression. Notably, LyoBT also reduced fibrosis-associated immune cell infiltration and cytokine release, alleviating lung metastasis-induced fibrosis. Furthermore, LyoBT served as a drug delivery platform for immune checkpoint inhibitors (aPD-L1), with LyoBT@aPD-L1 demonstrating enhanced therapeutic efficacy. Our findings highlight the potential of LyoBT as a dual-functional strategy to combat both lung metastases and their associated fibrosis, offering a promising new avenue for bacterial-based cancer immunotherapy.
中文摘要:肺转移仍是重要的临床难题,其高度免疫抑制的微环境和纤维化相关并发症常导致预后不良。化疗、放疗和免疫治疗等现有策略对肺转移的疗效有限,而对其相关纤维化关注不足。我们构建了一种「细胞套细胞」递送平台,即冻干细菌感染的肿瘤细胞(LyoBT),用于同时靶向肺转移及其相关纤维化。该策略利用肿瘤细胞固有的肺趋向性以及肿瘤细胞和细菌的免疫刺激特性,并通过冻干降低致瘤和致病风险。细菌感染使肿瘤细胞表型发生变化。LyoBT表征显示CD47、CD44和E-cadherin表达上调,进一步增强肺靶向。LyoBT中钙网蛋白(CRT)暴露增加,结合细菌免疫刺激特性,促进抗肿瘤免疫。在黑色素瘤肺转移模型中,LyoBT在肺内高效蓄积,激活强效抗肿瘤免疫并显著抑制肿瘤进展。LyoBT还减少纤维化相关免疫细胞浸润和细胞因子释放,缓解肺转移诱导的纤维化。LyoBT可作为免疫检查点抑制剂(aPD-L1)的递送平台,LyoBT@aPD-L1显示出增强的治疗效果。这些发现提示LyoBT作为同时对抗肺转移及其相关纤维化的双功能策略具有潜力,为基于细菌的肿瘤免疫治疗提供新途径。
Therapeutic cancer vaccines remain constrained by insufficient intracellular antigen trafficking and weak activation of innate immunity. Here, we report an immunoactive dendrimer-based nanovaccine platform that integrates efficient antigen cytosolic transport with intrinsic stimulation of innate immunity. Through screening a library of thiourea-modified dendrimers, we identify a naphthyl-functionalized polymer (D15) that forms stable antigen nanocomplexes via noncovalent interactions, enabling rapid endosomal escape and efficient cytosolic antigen release in dendritic cells. Mechanistic investigations demonstrated that D15 triggered STING-associated signaling in a cGAS-independent manner, likely related to endosomal membrane perturbation, thereby promoting type I interferon secretion and dendritic cell activation. Owing to its modular structure, D15 also enabled flexible incorporation of additional immunoadjuvants. Incorporation of CpG enhanced lymph node dendritic cell activation and antigen presentation, whereas loading of cGAMP further potentiated STING signaling and intratumoral immune responses. Both CpG- and cGAMP-adjuvanted D15 nanovaccines elicit potent antitumor immune responses in melanoma-bearing mice. Moreover, combination with PD-1 blockade markedly improved tumor suppression, cytotoxic T-cell infiltration, and survival outcomes. Collectively, this work establishes D15 as a multifunctional immunoactive nanocarrier with considerable potential for the construction of next-generation cancer nanovaccines.
中文摘要:治疗性癌症疫苗仍受限于抗原胞内转运不足和先天免疫激活较弱。我们报道一种基于免疫活性树状大分子的纳米疫苗平台,将高效抗原胞质转运与先天免疫的内在刺激整合起来。通过筛选硫脲修饰树状大分子库,鉴定出萘基功能化聚合物D15,其经非共价相互作用形成稳定抗原纳米复合物,使树突状细胞中内体快速逃逸并高效释放抗原至胞质。机制研究显示,D15以不依赖cGAS的方式触发STING相关信号,可能与内体膜扰动有关,从而促进I型干扰素分泌和树突状细胞活化。得益于模块化结构,D15还可灵活装载其他免疫佐剂。装载CpG增强淋巴结树突状细胞活化和抗原呈递,装载cGAMP进一步增强STING信号和瘤内免疫应答。含CpG或cGAMP佐剂的D15纳米疫苗均在黑色素瘤荷瘤小鼠中诱导强效抗肿瘤免疫应答。与PD-1阻断联合显著改善肿瘤抑制、细胞毒性T细胞浸润和生存结局。该工作确立D15为多功能免疫活性纳米载体,在构建下一代癌症纳米疫苗方面具有可观潜力。
Tumor heterogeneity induces resistance of programmed cell death (PCD), together with a highly immunosuppressive tumor microenvironment (TME), collectively constraining the efficacy of cancer therapies. Herein, a Janus TiO2-CoOX@PEG nanoplatform featuring a Z-scheme heterojunction was developed as a novel sonosensitizer, enabling efficient ultrasound-induced charge separation to boost sonodynamic therapy (SDT) activity. Moreover, the obtained TiO2-CoOX@PEG was endowed with multienzyme activity, including glutathione (GSH) oxidase- and catalase-like activities, which could regulate TME (e.g., relieve hypoxia), amplify oxidative stress, and collaboratively break intracellular redox homeostasis, thereby dismantling tumor defense barriers. More interestingly, upon ultrasound (US) irradiation, SDT together with chemodynamic therapy (CDT) was found to concurrently activate three programmed cell death pathways, i.e., apoptosis, ferroptosis, and pyroptosis to overcome tumor treatment resistance. This multiple death-pathway efficiently induced immunogenic cell death (ICD), promoting the release of damage-associated molecular patterns (DAMPs) and inflammatory cytokines. As a result, the in vivo tumor growth was significantly suppressed and the immunosuppressive TME was remodeled, as characterized by tumor-associated macrophages (TAMs) polarizing towards the M1 phenotype, maturation of dendritic cells (DCs), infiltration of abundant cytotoxic T lymphocytes (CTLs), and depletion of regulatory T cells (Tregs), which ultimately impeded the formation of distant lung metastases. Collectively, this work presents a sonodynamic-immunotherapeutic synergistic strategy based on Janus heterojunction nanoparticles to induce multi-pathway cell death and immune activation, offering a promising solution to overcome treatment resistance and achieve sustained systemic antitumor immunity.
中文摘要:肿瘤异质性会诱导对程序性细胞死亡(PCD)的抵抗,并伴随高度免疫抑制的肿瘤微环境(TME),共同限制肿瘤治疗效果。本研究构建了具有Z型异质结的Janus TiO2-CoOX@PEG纳米平台作为新型声敏剂,可实现高效的超声诱导电荷分离,从而增强声动力治疗(SDT)活性。所得TiO2-CoOX@PEG还具备多酶活性,包括谷胱甘肽(GSH)氧化酶样活性和过氧化氢酶样活性,能够调控TME(例如缓解缺氧)、放大氧化应激并协同破坏细胞内氧化还原稳态,从而瓦解肿瘤防御屏障。在超声(US)照射下,SDT与化学动力治疗(CDT)可同时激活三条程序性细胞死亡通路,即凋亡、铁死亡和焦亡,以克服肿瘤治疗抵抗。这种多死亡通路有效诱导免疫原性细胞死亡(ICD),促进损伤相关分子模式(DAMPs)和炎症细胞因子的释放。体内肿瘤生长受到显著抑制,免疫抑制性TME发生重塑,表现为肿瘤相关巨噬细胞(TAMs)向M1表型极化、树突状细胞(DCs)成熟、大量细胞毒性T淋巴细胞(CTLs)浸润以及调节性T细胞(Tregs)耗竭,最终阻碍远处肺转移灶形成。该工作提出了一种基于Janus异质结纳米颗粒的声动力-免疫治疗协同策略,通过诱导多通路细胞死亡和免疫激活,为克服治疗抵抗并实现持续的系统性抗肿瘤免疫提供了有前景的解决方案。
Transarterial chemoembolization (TACE) is hindered by the instability of embolic agents, as well as the tumor microenvironment post-embolization, which is characterized by angiogenesis and immune tolerance. Here, we identify a coupled angiogenesis-immune tolerance axis as a key mechanism underlying post-TACE therapeutic resistance. In this study, we developed a novel combination formulation of regorafenib and R837 designed to reprogram the tumor microenvironment following embolization. Using a supercritical carbon dioxide-assisted method, we successfully synthesized carrier-free pure drug nanoparticles of regorafenib and R837, achieving nanoparticles-stabilized lipiodol Pickering emulsions (PE-RR) preparation. This stable formulation not only significantly enhances the embolic stability and sustained drug release, but also effectively reverses post-embolization hypoxia, angiogenesis and immune tolerance through the therapeutic combination of regorafenib and R837. This study demonstrated that locoregional therapy with PE-RR significantly suppressed the hypoxia-angiogenesis signaling axis. These effects are mediated by the coordinated inhibition of angiogenesis (HIF-1α/VEGF axis) and activation of anti-tumor immunity, establishing a mechanistic linkage between vascular normalization and immune reprogramming. By strengthening antigen release and localized delivery of immune agonists, PE-RR facilitated anti-tumor immune activation and improved the therapeutic response to embolization, overcoming the adverse tumor microenvironment associated with conventional lipiodol embolization. Additionally, in bilateral tumor models, PE-RR could boost the therapeutic efficacy of PD-1 checkpoint blockade, increase the generation of anti-tumor immune memory and minimize the low responsiveness of immune checkpoint inhibitors in liver cancer. The stable Pickering embolic emulsion offers an innovative approach for the clinical translation of embolization therapy.
中文摘要:经导管动脉化疗栓塞(TACE)受到栓塞剂稳定性不足以及栓塞后肿瘤微环境改变的限制,后者以血管生成和免疫耐受为特征。研究识别出一条偶联的血管生成-免疫耐受轴,作为TACE后治疗抵抗的关键机制。本研究开发了瑞戈非尼与R837的新型联合制剂,用于重编程栓塞后的肿瘤微环境。采用超临界二氧化碳辅助方法,成功制备了瑞戈非尼和R837的无载体纯药纳米粒,并实现纳米粒稳定的碘油Pickering乳液(PE-RR)。该稳定制剂不仅显著提高栓塞稳定性和药物缓释,还通过瑞戈非尼与R837的联合治疗有效逆转栓塞后缺氧、血管生成和免疫耐受。研究显示,PE-RR局部治疗显著抑制缺氧-血管生成信号轴,其作用由协同抑制血管生成(HIF-1α/VEGF轴)和激活抗肿瘤免疫介导,建立了血管正常化与免疫重编程之间的机制联系。通过增强抗原释放和免疫激动剂的局部递送,PE-RR促进抗肿瘤免疫激活并改善栓塞治疗反应,克服传统碘油栓塞相关的不良肿瘤微环境。在双侧肿瘤模型中,PE-RR还可增强PD-1检查点阻断的疗效,增加抗肿瘤免疫记忆的生成,并降低免疫检查点抑制剂在肝癌中的低反应性。稳定的Pickering栓塞乳液为栓塞治疗的临床转化提供了新途径。
Intrahepatic cholangiocarcinoma (ICC) is notoriously resistant to treatment, largely due to a "cold" microenvironment shaped by the Warburg effect. This metabolic signature leads to excessive lactate buildup, which acts as a physical and chemical shield against T-cell infiltration. To breach this barrier, we developed ultrasound-activated GdMnO3 (GMO) perovskite nanozymes that forcibly reverse the Warburg effect by accelerating the lactate-to-pyruvate metabolic switch. Through Gd-incorporating, we optimized the Mn-based electronic structure to achieve high-efficiency lactate catabolism, which is pulsed by ultrasound to maximize enzymatic turnover. This intervention does not merely deplete lactate; it reshapes the tumor's "bioenergetic engine" from glycolytic acidification toward mitochondrial oxidation. When cloaked in M1 macrophage membranes (GMO@M), these nanozymes selectively accumulate in ICC tissues. The subsequent Mn2+ release triggers the cGAS-STING pathway, synergizing with the metabolic shift to flip the immunological status of the tumor. Combined with αPD-L1, this ultrasound-driven metabolic recalibration yields potent systemic immunity and durable tumor regression. Our findings demonstrate that targeting the Warburg effect via responsive nanozymes is a decisive strategy for sensitizing recalcitrant ICC to immunotherapy.
中文摘要:肝内胆管癌(ICC)治疗抵抗性很强,很大程度上源于Warburg效应塑造的「冷」微环境。这种代谢特征导致乳酸过度堆积,形成阻碍T细胞浸润的物理和化学屏障。为突破该屏障,我们开发了超声激活的GdMnO3(GMO)钙钛矿纳米酶,通过加速乳酸向丙酮酸的代谢转换来强制逆转Warburg效应。通过引入Gd,我们优化了Mn基电子结构,实现高效乳酸分解,并以超声脉冲最大化酶周转。该干预不仅消耗乳酸,还将肿瘤的「生物能量引擎」从糖酵解酸化转向线粒体氧化。用M1巨噬细胞膜包裹后(GMO@M),这些纳米酶选择性蓄积于ICC组织。随后释放的Mn2+触发cGAS-STING通路,与代谢转变协同翻转肿瘤免疫状态。与αPD-L1联合,这种超声驱动的代谢重校准产生强效系统性免疫和持久肿瘤消退。我们的发现表明,通过响应性纳米酶靶向Warburg效应是使难治性ICC对免疫治疗敏感的决定性策略。
Dysregulated cell death represents a cornerstone of cancer development and therapeutic resistance. This review systematically deciphers the molecular architecture underlying various regulated cell death modalities and their crosstalk. Moving beyond a mere catalog of mechanisms, it critically evaluates the translational landscape of agents that are designed to precisely trigger these pathways. We then critically evaluate the translational strategies that target their key components via diverse agents, from small molecules to PROTACs and nanomedicines. A key focus is the strategic induction of immunogenic cell death to convert tumor cell killing into durable antitumor immunity. This review synthesizes evidence on how distinct death pathways, such as ferroptosis, can be leveraged to remodel the immunosuppressive tumor microenvironment and potentiate immune checkpoint blockade. It further examines the contextual factors that determine the immunogenic outcome of cell death, providing a rationale for combination therapies (e.g., the synergistic effect between ferroptosis inducers and immune checkpoint inhibitors). By integrating mechanistic insights with therapeutic innovations, we provide a framework for developing next-generation therapies that precisely manipulate cell death to overcome treatment resistance and activate immune surveillance. Finally, the review outlines future directions, suggesting the need for the integration of multidisciplinary approaches to discover novel targets, develop selective inducers, and rationally combine cell death modulation with immunotherapy to achieve sustained clinical responses.
中文摘要:细胞死亡失调是肿瘤发生和治疗耐药的核心环节。本综述系统解析多种调节性细胞死亡模式的分子架构及其交互作用,并不止于罗列机制,而是重点评估精准触发这些通路的药物的转化前景。随后讨论通过小分子、PROTAC和纳米药物等多样化手段靶向关键组分的转化策略。一个核心关注点是策略性诱导免疫原性细胞死亡,将肿瘤细胞杀伤转化为持久的抗肿瘤免疫。综述整合不同死亡通路尤其是铁死亡如何被用于重塑免疫抑制性肿瘤微环境并增强免疫检查点阻断的证据,并进一步考察决定细胞死亡免疫原性结局的情境因素,为联合治疗提供依据,例如铁死亡诱导剂与免疫检查点抑制剂的协同效应。通过整合机制认识与治疗创新,提出开发精准操控细胞死亡以克服治疗耐药并激活免疫监视的下一代疗法的框架。最后,综述展望未来方向,提出需要融合多学科方法发现新靶点、开发选择性诱导剂,并将细胞死亡调控与免疫治疗合理联合,以实现持续临床缓解。
Oncolytic bacteria have emerged as a promising platform for targeted cancer therapy owing to their intrinsic ability to preferentially colonize tumor tissues, induce direct tumor cell killing, and remodel the tumor microenvironment to activate antitumor immunity. However, native bacteria alone rarely meet the requirements of precision oncology, particularly in terms of spatial specificity, temporal control, and safety. Recent advances in synthetic biology have enabled the construction of stimulus-responsive gene circuits that confer programmable control over therapeutic gene expression in tumor-colonizing bacteria by coupling defined exogenous triggers or endogenous tumor-associated cues to tightly regulated genetic programs. These engineered systems support the tumor-specific delivery of diverse therapeutic payloads, including cytotoxic agents, cytokines, immunomodulatory ligands, prodrug-converting enzymes, metabolic modulators, and nucleic acid-based therapeutics, while minimizing off-target activity. This review thus summarizes recent developments in stimulus-responsive oncolytic bacteria, highlights key design principles and performance trade-offs, and discusses emerging strategies to advance bacteria as programmable living therapeutics for cancer treatment.
中文摘要:溶瘤细菌能优先定植肿瘤组织、直接杀伤肿瘤细胞,并重塑肿瘤微环境以激活抗肿瘤免疫,因而成为靶向癌症治疗的有前景平台。天然细菌单独使用很少能满足精准肿瘤学对空间特异性、时间控制和安全性的要求。合成生物学进展使构建刺激响应基因回路成为可能,通过将明确的外源触发因素或内源性肿瘤相关线索与严格调控的遗传程序耦合,可对定植肿瘤的细菌中治疗基因表达实现可编程控制。这些工程化系统支持多种治疗载荷的肿瘤特异性递送,包括细胞毒性药物、细胞因子、免疫调节配体、前药转化酶、代谢调节剂和核酸类治疗药物,同时尽量减少脱靶活性。以下内容梳理刺激响应溶瘤细菌的最新进展,归纳关键设计原则与性能权衡,并讨论推动细菌成为癌症治疗可编程活体治疗药物的新兴策略。
Immunotherapy offers a promising opportunity for cancer treatment; while only a subset of patients derive substantial benefits because of its low response efficacy and potential off-target side effects. Unlike conventional immunotherapy, we herein report an X-ray programmable interleukin-12 (IL-12) expression via a calcium ion (Ca2+) signaling-gated nanoplasmid (SPNCP) system for cancer immunotherapy. Such SPNCP are designed to be destructible upon reactive oxygen species (ROS) respond, composing of a semiconducting polymer core as a radiosensitizer, transient receptor potential vanilloid 1 (TRPV1) agonist capsaicin and engineering plasmid containing Ca2+-responsive c-fos promoter and IL-12 as the target gene. SPNCP are responded to produce ROS with low-dose X-ray activation by radiosensitization effect, which leads to the on-demand release of capsaicin and plasmid. As such, capsaicin turns on TRPV1 ion channel to facilitate extracellular Ca2+ influx and subsequent activation of MAPK/ERK signaling pathway. This signaling cascade then initiates the Ca2+-responsive c-fos promoter to drive IL-12 expression of the engineering plasmids, thereby allowing for potent IL-12-based immunotherapy. This X-ray programmable immunotherapy strategy shows obvious antitumor effects in TRPV1-positive orthotopic glioblastoma and metastatic breast cancer murine models. This current study highlights the potential and application of X-ray programmable immunotherapy strategy for renovating cancer treatments.
中文摘要:免疫治疗为癌症治疗提供了有前景的机会,但仅有部分患者获得显著获益,原因在于其应答疗效较低并可能存在脱靶副作用。与常规免疫治疗不同,我们报道了一种通过钙离子(Ca2+)信号门控纳米质粒(SPNCP)系统实现X射线可编程白细胞介素-12(IL-12)表达的策略,用于癌症免疫治疗。SPNCP被设计为在活性氧(ROS)响应下可破坏,由作为放射增敏剂的半导体聚合物核心、瞬时受体电位香草酸亚型1(TRPV1)激动剂辣椒素以及含Ca2+响应性c-fos启动子和靶基因IL-12的工程质粒组成。SPNCP在低剂量X射线激活下通过放射增敏效应响应产生ROS,从而按需释放辣椒素和质粒。辣椒素开启TRPV1离子通道,促进细胞外Ca2+内流并随后激活MAPK/ERK信号通路。该信号级联随后启动Ca2+响应性c-fos启动子,驱动工程质粒的IL-12表达,从而实现强效的基于IL-12的免疫治疗。该X射线可编程免疫治疗策略在TRPV1阳性原位胶质母细胞瘤和转移性乳腺癌小鼠模型中显示出明显的抗肿瘤效果。本研究凸显了X射线可编程免疫治疗策略在革新癌症治疗方面的潜力与应用。
Emerging evidence highlights that tumor metastasis is critically regulated by key dynamic vascular components, including endothelial cells (ECs) and pericytes, which engage in persistent intercellular crosstalk, both with one another and with other cell types in the tumor microenvironment. These interactions drive not only the structural and functional remodeling of vessels but also the assembly of immunosuppressive clusters that support metastatic dissemination. By synthesizing recent advances, this review aims to establish a new conceptual framework focused on spatiotemporal dynamics and functional interactions within the vascular niche. This framework elucidates the mechanisms through which vascular components dynamically evolve and cooperate to drive metastasis.
中文摘要:新出现的证据表明,肿瘤转移受关键动态血管组分(包括内皮细胞与周细胞)的重要调控,这些组分彼此之间以及与肿瘤微环境中其他细胞类型之间持续进行细胞间对话。此类相互作用不仅驱动血管的结构与功能重塑,还促成支持转移播散的免疫抑制细胞簇的组装。本综述通过整合近期进展,旨在建立以血管龛内时空动态与功能相互作用为核心的新概念框架,阐明血管组分动态演化并协同驱动转移的机制。
The tumor microenvironment (TME) is a metabolically dynamic niche characterized by active metabolic crosstalk between tumor cells and various stromal and immune cell subsets, which critically influences tumor progression and therapeutic outcomes. Within this ecosystem, solute carrier (SLC) transporters are gatekeepers that mediate the transport of a wide range of metabolites, including nutrients, ions, and signaling molecules, across cellular membranes. SLC transporters have emerged as active regulators of TME composition and intercellular communication, representing promising yet underexplored therapeutic targets in cancer. This review highlights the central role of SLC transporters in orchestrating the competitive uptake of nutrients and the exchange of oncometabolites, thereby modulating immune responses, angiogenesis, and metabolic adaptation in the TME. By outlining strategies targeting SLC transporters for cancer therapy, this review also underscores the emerging potential of SLC transporters as therapeutic targets and offers a renewed perspective on targeting TME metabolism.
中文摘要:肿瘤微环境(TME)是一个代谢活跃的生态位,肿瘤细胞与多种基质细胞和免疫细胞亚群之间存在活跃的代谢交流,这种交流对肿瘤进展和治疗结局具有关键影响。在该生态系统中,溶质载体(SLC)转运体承担守门功能,介导营养物质、离子和信号分子等多种代谢物跨细胞膜转运。SLC转运体已成为TME组成和细胞间通讯的活跃调控者,是癌症治疗中有前景但仍待深入探索的靶点。本综述强调SLC转运体在协调营养竞争性摄取和肿瘤代谢物交换中的核心作用,进而调控TME中的免疫反应、血管生成和代谢适应。通过梳理靶向SLC转运体的癌症治疗策略,本综述也指出SLC转运体作为治疗靶点的新兴潜力,并为靶向TME代谢提供新的视角。
Owing to the reticular structure and dense lymphocyte concentration within the spleen, spleen-targeted vaccines can overcome the challenges faced by conventional vaccines, such as inefficient antigen delivery and delayed immune activation. However, the existing spleen-targeted vaccines are ineffective in preventing and treating immunologically cold tumors. Herein, we develop a spleen/tumor dual-target hybrid vaccine that combines red blood cell membrane-derived vesicles (RBCVs) and bacterial outer membrane vesicles (OMVs) to deliver tumor antigens. This hybrid vaccine utilizes RBCVs to enhance the biosafety of OMVs and endows them with a spleen-targeting ability. Co-delivery of OMVs as adjuvants with tumor antigens to the spleen triggers rapid and robust immune responses, promoting immune memory formation to prevent the development and metastasis of immunologically cold tumors. In addition to acting as vaccine adjuvants, OMVs can target and remodel the immunosuppressive tumor microenvironment by reprogramming tumor-associated macrophages and downregulating regulatory T cells, thereby enhancing the immune responses induced by vaccines and immune checkpoint inhibitors. Because of their antigen-loading flexibility, these versatile vesicles can be used for the spleen-targeted delivery of various protein- or nucleic acid-based antigens, offering a safe and promising strategy for the prevention and treatment of diverse tumors and pathogens.
中文摘要:脾脏内具有网状结构和密集的淋巴细胞,脾脏靶向疫苗可克服传统疫苗抗原递送效率低、免疫激活延迟等问题。现有脾脏靶向疫苗在预防和治疗免疫冷肿瘤方面效果不佳。本研究构建了一种脾脏/肿瘤双靶向杂合疫苗,将红细胞膜衍生囊泡(RBCVs)与细菌外膜囊泡(OMVs)结合以递送肿瘤抗原。该杂合疫苗利用RBCVs提高OMVs的生物安全性,并赋予其脾脏靶向能力。将作为佐剂的OMVs与肿瘤抗原共同递送至脾脏,可触发快速而强烈的免疫应答,促进免疫记忆形成,从而预防免疫冷肿瘤的发生和转移。OMVs不仅作为疫苗佐剂,还能通过重编程肿瘤相关巨噬细胞、下调调节性T细胞来靶向并重塑免疫抑制性肿瘤微环境,增强疫苗和免疫检查点抑制剂诱导的免疫应答。由于抗原装载具有灵活性,这类多功能囊泡可用于脾脏靶向递送多种蛋白类或核酸类抗原,为多种肿瘤和病原体的预防与治疗提供安全且有前景的策略。
Immunotherapies hold great promise for cancer treatment, yet only a small fraction of patients respond to current approaches. We introduce a strategy that redirects pre-existing, vaccine-induced immunity to recognize and eliminate tumors. This method employs newly engineered phage-derived nanoparticles that achieve multilayered tumor specificity through ligand-mediated cell entry, transcriptional targeting, and the delivery of non-mammalian antigens absent from healthy tissues. By leveraging established immune memory, this platform enables highly specific and potent antitumor responses. We validated this concept using a malaria vaccine prototype for redirecting pathogen-specific immunity toward cancer. Specifically, we exploited the malaria epitope Pb9 (SYIPSAEKI), delivered by phage selectively to tumors in mice previously immunized with the Ad.ME-TRAP vaccine. In vitro, Pb9-expressing tumor cells were selectively recognized and destroyed by immune cells from immunized mice, accompanied by robust interferon-γ and tumor necrosis factor-α production. In vivo, systemic administration of the phage nanocarrier achieved highly selective Pb9 expression in tumors while sparing healthy organs. This tumor-restricted expression induced infiltration of antigen-specific cytotoxic T cells and natural killer cells, activation of pro-inflammatory pathways, and apoptosis within tumors. Interestingly, the combination of Ad.ME-TRAP immunization and phage-mediated Pb9 gene delivery led to complete tumor regression in a substantial proportion of animals, with durable long-term cures in over 40% of treated mice. These findings demonstrate a versatile immunotherapeutic strategy that redirects pre-existing vaccine-induced immune responses toward tumors using phage-derived, tumor-selective vectors. Beyond the malaria model, this platform offers a broadly applicable approach for repurposing preventive vaccines into safe and effective cancer immunotherapies.
中文摘要:免疫疗法对癌症治疗具有很大潜力,但当前方法仅一小部分患者有反应。我们提出一种策略,将疫苗诱导的既有免疫重定向至识别并清除肿瘤。该方法采用新构建的噬菌体来源纳米颗粒,通过配体介导的细胞进入、转录靶向以及递送健康组织不存在的非哺乳动物抗原来实现多层肿瘤特异性。借助已建立的免疫记忆,该平台可产生高度特异且强效的抗肿瘤反应。我们以疟疾疫苗原型验证这一概念,把病原体特异性免疫重定向至癌症。具体而言,我们利用噬菌体将疟疾表位Pb9(SYIPSAEKI)选择性递送至先前接种Ad.ME-TRAP疫苗的小鼠肿瘤。体外实验中,表达Pb9的肿瘤细胞被免疫小鼠的免疫细胞选择性识别并破坏,并伴随强烈的干扰素-γ和肿瘤坏死因子-α产生。体内实验中,全身给予噬菌体纳米载体使Pb9在肿瘤中选择性表达,而健康器官基本不受影响。这种肿瘤限制性表达诱导抗原特异性细胞毒性T细胞和自然杀伤细胞浸润、促炎通路激活以及肿瘤内凋亡。有趣的是,Ad.ME-TRAP免疫与噬菌体介导的Pb9基因递送联合后,相当比例动物出现肿瘤完全消退,超过40%的治疗小鼠获得持久长期治愈。这些结果证明一种通用的免疫治疗策略,利用噬菌体来源的肿瘤选择性载体将既有疫苗诱导的免疫反应重定向至肿瘤。除疟疾模型外,该平台为将预防性疫苗重新用于安全有效的癌症免疫治疗提供了广泛适用的途径。
Tumor vaccines are considered a promising approach in immunotherapy, designed to boost the immune system's capacity to identify tumor-associated antigens and subsequently trigger immune responses against tumors. However, the inherent genetic instability of tumor cells frequently results in decreased expression or loss of antigen and/or major histocompatibility complex (MHC) expression and upregulation of immune checkpoint molecule PD-L1, thus evading endogenous immune recognition and surveillance. Herein, we developed a hierarchical self-adjuvanted nanoCRISPR-based vaccine (HEDERA) loaded with LSD1/PD-L1 dual-editing CRISPR/Cas9 system, seeking to reinstate the endogenous immune detection and monitoring mechanisms to enhance adaptive immune reactions. Knockdown of LSD1 increases the presence of tumor-specific antigens and major histocompatibility complex class I molecules on the surface of cancer cells, thereby restoring immune recognition. Simultaneously, silencing PD-L1 alleviates the "exhaustion" of T cells and reactivates their cytotoxic activity. Moreover, LSD1 knockdown activates the type I interferon pathway to induce a self-adjuvant effect that enhances innate immune responses and thereby strengthens T cell-mediated adaptive immunity. This dual strategy achieves unprecedented efficacy, with 90% primary tumor inhibition, and demonstrates an 87.3% and 90.6% inhibition rate for post-surgical metastatic and recurrent tumors, respectively. Overall, HEDERA overcomes the single-action constraint of traditional tumor vaccines, and avoids combined medication-related poor patient compliance, delivering a more efficient, convenient integrated tumor immunotherapy solution.
中文摘要:肿瘤疫苗被认为是一种有前景的免疫治疗手段,旨在增强免疫系统识别肿瘤相关抗原的能力,并由此触发针对肿瘤的免疫反应。然而,肿瘤细胞固有的遗传不稳定性常导致抗原和/或主要组织相容性复合体(MHC)表达降低或缺失,并上调免疫检查点分子PD-L1,从而逃避内源性免疫识别与监视。为此,我们构建了一种负载LSD1/PD-L1双编辑CRISPR/Cas9系统的层级自佐剂纳米CRISPR疫苗(HEDERA),试图恢复内源性免疫检测与监控机制,以增强适应性免疫反应。敲低LSD1可增加肿瘤特异性抗原和主要组织相容性复合体I类分子在癌细胞表面的存在,从而恢复免疫识别。同时,沉默PD-L1可缓解T细胞「耗竭」并重新激活其细胞毒活性。LSD1敲低还可激活I型干扰素通路,诱导自佐剂效应,增强先天免疫反应,进而强化T细胞介导的适应性免疫。这一双重策略取得了前所未有的疗效,原发肿瘤抑制率达90%,对术后转移瘤和复发瘤的抑制率分别为87.3%和90.6%。整体上,HEDERA克服了传统肿瘤疫苗作用单一的局限,避免了联合用药相关患者依从性差的问题,提供了一种更高效、便捷的肿瘤免疫治疗集成方案。
Lymph nodes serve as strategic targets for cancer vaccines by enhancing interactions with antigen-presenting cells (APCs) and promoting immune activation. Herein, we report that serum albumin can be chemically modified via in situ reduction with a short PEG linker, which subsequently coordinates with Mn2+ to generate a lymph nodes targeting metallo-albumin nano-scaffold (MANS) capable of chelating His-tagged antigens and immunostimulatory adjuvants. Maintaining the "hitchhiking" effect of albumin, the MANS chelating antigens (E7 or AH1) accumulates in lymph nodes, where it triggers the responsive release of metal ions and adjuvants to synergistically activate the cGAS-STING pathway. Following uptake by bone marrow dendritic cells (BMDCs), MANS promoted the expression of maturation markers and cytokine release. In multiple murine TC-1 and CT26 tumor models, the MANS vaccine suppresses tumor growth and prolongs survival while elevating antigen-specific CD8+ T cells frequency by an order of magnitude; however, these effects were not observed in STING-knockout mice (STING-KO). The MANS vaccine also remodeled the tumor immune microenvironment (TME) by downregulating immunosuppressive cells in the tumor tissues with long-term immune memory, verified by a tumor rechallenge model.
中文摘要:淋巴结是癌症疫苗的重要靶点,可增强疫苗与抗原呈递细胞(APC)的相互作用并促进免疫激活。本研究报道,血清白蛋白可通过短PEG连接子进行原位还原化学修饰,随后与Mn2+配位,生成靶向淋巴结的金属白蛋白纳米支架(MANS),该支架能够螯合His标签抗原和免疫刺激性佐剂。MANS保留了白蛋白的「搭便车」效应,螯合抗原(E7或AH1)后在淋巴结蓄积,并触发金属离子与佐剂的响应性释放,协同激活cGAS-STING通路。被骨髓树突状细胞(BMDC)摄取后,MANS促进成熟标志物表达和细胞因子释放。在多种小鼠TC-1和CT26肿瘤模型中,MANS疫苗抑制肿瘤生长并延长生存期,同时使抗原特异性CD8+ T细胞频率提高一个数量级;但在STING敲除小鼠(STING-KO)中未观察到这些效应。MANS疫苗还通过下调肿瘤组织中的免疫抑制细胞重塑肿瘤免疫微环境(TME),并形成长期免疫记忆,这一点在肿瘤再挑战模型中得到验证。
Live bacterial therapy holds great promise in tumor treatment due to its inherent ability to target tumors and activate the immune system. However, its clinical translation faces significant challenges, including limited antitumor efficacy and safety risks posed by bacterial residue. To address these challenges, we developed a self-limiting, light-activatable biohybrid system named OTTQ-Cl@HEcN. It consists of the probiotic Escherichia coli Nissle 1917 (EcN) covalently conjugated with a hypoxia-tolerant Type I photosensitizer (PS) OTTQ-Cl via a genetically engineered HaloTag conjugation strategy. Upon light irradiation, OTTQ-Cl@HEcN generates localized reactive oxygen species (ROS), simultaneously killing tumor cells and bacteria. This built-in bacterial self-elimination ensures effective tumor clearance and minimizes systemic exposure. In multiple tumor models, OTTQ-Cl@HEcN elicited potent local and systemic antitumor immunity, characterized by robust dendritic cells (DCs) maturation, enhanced T cells activation, and the establishment of long-term immune memory that prevented tumor recurrence and metastasis. The key features of OTTQ-Cl@HEcN include its precise tumor targeting, hypoxia compatibility, potent immune activation, and intrinsic biosafety, collectively enabling a controlled and effective antitumor response.
中文摘要:活菌治疗因具有靶向肿瘤并激活免疫系统的固有能力,在肿瘤治疗中前景广阔。但其临床转化仍面临明显挑战,包括抗肿瘤疗效有限以及细菌残留带来的安全风险。为应对这些问题,我们构建了一种可自限、光激活的生物杂合系统OTTQ-Cl@HEcN。该系统由益生菌大肠杆菌Nissle 1917(EcN)通过基因工程HaloTag偶联策略与耐缺氧Ⅰ型光敏剂OTTQ-Cl共价连接而成。光照后,OTTQ-Cl@HEcN产生局部活性氧,同时杀伤肿瘤细胞和细菌。这种内置的细菌自消除机制保障了有效清除肿瘤并减少全身暴露。在多种肿瘤模型中,OTTQ-Cl@HEcN激发了强效的局部和全身抗肿瘤免疫,表现为树突状细胞成熟增强、T细胞活化增强,并建立可阻止肿瘤复发和转移的长期免疫记忆。OTTQ-Cl@HEcN的关键特征包括精准靶向肿瘤、适配缺氧环境、强效免疫激活和固有生物安全性,共同实现可控且有效的抗肿瘤反应。
Meniscus injuries present dual challenges, including limited regenerative capacity due to avascularity and a persistent inflammatory microenvironment following injury. Herein, we reported a decellularized meniscus extracellular matrix (dmECM) scaffold functionalized with a hyaluronic acid (HA) and celecoxib (CLX) grafted (dmECM-HC) through carbodiimide chemistry. This design integrates acute immunomodulation with long-term regenerative support. The dmECM scaffold recapitulated the ECM architecture of the native meniscus, while the HA-CLX enhanced its elasticity and immunomodulatory capacity. The dmECM-HC scaffold exhibited superior mechanical performance retention during 1000 cyclic compression cycles and demonstrated sustained release of CLX for up to 7 weeks in vitro. It promoted M2 polarization of lipopolysaccharide (LPS)-stimulated macrophages and effectively modulated acute inflammation through Toll-like receptor, tumor necrosis factor (TNF), and Nuclear factor kappa-B (NF-κB) signaling pathways. Together with its robust antioxidant capacity, the dmECM-HC scaffold provided a pro-regenerative microenvironment. Furthermore, it significantly facilitated stem cell recruitment and ECM deposition. In a rabbit meniscus defect model, the dmECM-HC scaffold promoted tissue repair by activating NF-κB and calcium signaling pathways. At 12 weeks, it significantly enhanced tissue maturation and collagen arrangement in the defect area and mitigated cartilage degeneration. This strategy guides meniscus healing with a dual function by modulating the inflammatory environment while providing biomimetic structural support.
中文摘要:半月板损伤带来双重挑战:无血管特性导致再生能力有限,损伤后持续存在炎症微环境。我们报道了一种脱细胞半月板细胞外基质(dmECM)支架,通过碳二亚胺化学将透明质酸(HA)与塞来昔布(CLX)接枝使其功能化(dmECM-HC)。该设计将急性免疫调节与长期再生支持结合。dmECM支架重现天然半月板的ECM结构,HA-CLX增强其弹性与免疫调节能力。dmECM-HC支架在1000次循环压缩中表现出更优的力学性能保持,并在体外持续释放CLX达7周。它促进脂多糖(LPS)刺激巨噬细胞的M2极化,并通过Toll样受体、肿瘤坏死因子(TNF)和核因子κB(NF-κB)信号通路有效调节急性炎症。结合其较强抗氧化能力,dmECM-HC支架提供促再生微环境。它显著促进干细胞募集与ECM沉积。在兔半月板缺损模型中,dmECM-HC支架通过激活NF-κB与钙信号通路促进组织修复。12周时,它显著增强缺损区组织成熟与胶原排列,并减轻软骨退变。该策略通过调节炎症环境并提供仿生结构支持,以双重功能引导半月板愈合。
The complexity and heterogeneity of the tumor microenvironment significantly influence cancer progression and therapeutic outcomes, highlighting the need for physiologically relevant in vitro models. In this study, we present vascularized tumor assembloids (VTASs) constructed via organoid bioprinting using a cell aggregate-rich living gel composed of endothelialized hepatic tumor aggregates and suspended endothelial cells. These VTASs recapitulate dense, volumetric, and hierarchical tissue architectures with functional vasculature and hepatic characteristics. Drug screening revealed reduced apoptosis and delayed intracellular drug accumulation in VTASs with dense microvasculature compared with cell-based or sparsely vascularized models, demonstrating differential responses to cisplatin, sorafenib, combination therapy, and doxorubicin. Co-culture with immune cells captured monocyte-endothelial interactions under inflammatory stimulation. Upon in vivo implantation, VTASs formed perfused tumorlike structures that recapitulated key histological and functional features of human cancer. Thus, VTASs provide a scalable and physiologically relevant platform for studying tumor biology, immune interactions, and high-throughput anticancer drug evaluation.
中文摘要:肿瘤微环境的复杂性与异质性显著影响癌症进展和治疗结果,需要生理相关的体外模型。本研究通过类器官生物打印构建血管化肿瘤组装体(VTASs),使用由内皮化肝肿瘤聚集体和悬浮内皮细胞组成的富含细胞聚集体的活性凝胶。这些VTASs重现了致密、体积化、层次化的组织结构,并具有功能性血管系统和肝脏特征。药物筛选显示,与基于细胞的模型或血管稀疏模型相比,具有密集微血管的VTASs细胞凋亡减少、细胞内药物蓄积延迟,对顺铂、索拉非尼、联合治疗和多柔比星表现出不同反应。与免疫细胞共培养捕捉了炎症刺激下单核细胞与内皮细胞的相互作用。体内植入后,VTASs形成灌注的肿瘤样结构,重现了人类癌症的关键组织学和功能特征。因此,VTASs为研究肿瘤生物学、免疫相互作用和高通量抗癌药物评估提供了可扩展且生理相关的平台。
Oral diseases, including periodontitis, peri-implantitis, pulpitis, mucosal lesions, and oral squamous cell carcinoma, affect billions of people, which are increasingly recognized as immune-driven conditions with systemic implications. Unlike other tissues, the oral cavity presents a uniquely complex immune landscape shaped by continuous microbial exposure, stratified epithelial barriers, and inductive lymphoid structures. Traditional treatments focus on mechanical repair, antimicrobial control, and tissue regeneration, but often fail to address the underlying immune dysregulation directly. This review highlights biomaterial strategies that modulate oral immunity to drive resolution of the disease, restore homeostasis, and promote regeneration. We first discuss the oral mucosal immune environment and its role in disease pathogenesis, particularly the contributions of macrophages, T cells, and tissue-resident populations. Next, we highlight five immunomodulatory approaches: (1) delivery platforms such as mucoadhesive coatings, hydrogels, particles, and microneedles for the local delivery of bioactive payloads; (2) the physicochemical properties of biomaterials such as micro/nanotopography, wettability, surface charge, and immunoactive ion release that directly program innate and adaptive responses; (3) multi-functional platforms that integrate biomaterial structural functions and delivery capability; (4) cell-based immunomodulation; and (5) delivery of cell secretome such as extracellular vesicles. Applications span periodontitis and peri-implantitis, temporomandibular joint (TMJ) inflammation, and oral squamous cell carcinoma. Finally, we discuss how mechanistic investigations, innovative technologies, emerging diagnostic and therapeutic approaches, and the integration with artificial intelligence (AI) may transform the future directions in the field. Together, immunomodulatory biomaterials enable innovative approaches in oral medicine and patient-specific therapies.
中文摘要:口腔疾病包括牙周炎、种植体周围炎、牙髓炎、黏膜病变和口腔鳞状细胞癌,影响数十亿人,日益被视为具有全身影响的免疫驱动性疾病。与其他组织不同,口腔具有独特而复杂的免疫景观,由持续微生物暴露、分层上皮屏障和诱导性淋巴结构塑造。传统治疗侧重机械修复、抗菌控制和组织再生,却常未能直接处理潜在的免疫失调。这篇综述聚焦通过调控口腔免疫促进疾病消退、恢复稳态和促进再生的生物材料策略。我们讨论口腔黏膜免疫环境及其在疾病发病中的作用,尤其巨噬细胞、T细胞和组织驻留细胞群的贡献。随后概述五类免疫调控途径:(1) 黏附涂层、水凝胶、颗粒和微针等递送平台,用于局部递送生物活性载荷;(2) 生物材料的理化性质,如微/纳米形貌、润湿性、表面电荷和免疫活性离子释放,直接编程先天性和适应性免疫应答;(3) 整合生物材料结构功能与递送能力的多功能平台;(4) 基于细胞的免疫调控;(5) 细胞分泌组如细胞外囊泡的递送。应用范围覆盖牙周炎和种植体周围炎、颞下颌关节炎症及口腔鳞状细胞癌。文末讨论机制研究、创新技术、新兴诊断和治疗手段以及与人工智能的整合如何改变该领域的未来方向。免疫调控生物材料共同推动口腔医学和患者个体化治疗的创新路径。
The stimulator of interferon genes (STING) pathway is a promising immuno-oncology target. Despite their potential, STING agonists have yielded underwhelming results in clinical trials due to pharmacological barriers that limit their safety and efficacy. Herein, we describe the design and pre-clinical evaluation of a polymeric dimeric amidobenzimidazole (diABZI) STING agonist delivery platform for cancer immunotherapy. Central to our technology is a stimuli-responsive diABZI-functionalized reversible addition-fragmentation chain transfer (RAFT) polymerization chain transfer agent (CTA) that allows well-defined polymer chains to be grown directly from a single STING agonist. Using a biocompatible poly(N,N'-dimethylacrylamide) polymer as a first-generation scaffold and a disulfide as a clinically relevant linker, we demonstrate our platform liberates a potent diABZI analog under reducing conditions to trigger STING-driven inflammatory gene expression in tumors, thereby stimulating antitumor immunity in multiple murine models and synergizing with α-PD-1 immune checkpoint blockade to eliminate tumors. This work therefore establishes a promising delivery platform for microenvironmental regulation of STING activation with promise as an immunotherapy for cancer.
中文摘要:干扰素基因刺激因子(STING)通路是颇具前景的免疫肿瘤学靶点。尽管具有潜力,STING激动剂因药理学屏障限制其安全性和有效性,在临床试验中结果并不理想。在此,我们介绍一种用于癌症免疫治疗的聚合型二聚酰胺基苯并咪唑(diABZI)STING激动剂递送平台的设计与临床前评价。该技术的核心是一种刺激响应型diABZI官能化可逆加成-断裂链转移(RAFT)聚合链转移剂(CTA),可使结构明确的聚合物链直接从单一STING激动剂上生长。以生物相容性聚(N,N'-二甲基丙烯酰胺)聚合物作为第一代支架,并以二硫键作为具有临床相关性的连接子,我们证明该平台在还原条件下释放强效diABZI类似物,触发肿瘤中STING驱动的炎性基因表达,从而在多种小鼠模型中激发抗肿瘤免疫,并与α-PD-1免疫检查点阻断协同消除肿瘤。因此,这项工作建立了一个有前景的递送平台,可对STING激活进行微环境调控,并有望成为癌症免疫治疗手段。
The heterogeneity of the tumor microenvironment poses a significant challenge to the success of anti-cancer therapeutics. Consequently, there is an urgent need to generate comprehensive data to elucidate the mechanisms underlying tumor resistance and to inform the rational and systematic application of anti-cancer drugs to mitigate drug resistance. In-vitro tumor models based on established cell lines are widely employed in studying the mechanisms of action of drugs; however, these traditional models often fail to accurately recapitulate the complexity of native tumors, particularly in terms of the heterogenous and intricate tumor microenvironment, including cellular composition, intercellular communication, and interactions between cells and extracellular matrix. As a result, preclinical data often diverges from clinical outcomes. In recent years, the emergence of patient-derived three-dimensional (3D) models including spheroids, organoids, tumor-on-a-chip systems, and 3D bioprinting has offered promising alternatives for addressing these limitations and enhancing the predictive power of tumor drug screening. In this review, we explore the relationship between the complexity of the tumor microenvironment, tumor drug resistance, and then introduce the current biofabrication techniques enabling the reconstruction of 3D tumor models in vitro. We delve deeper into a myriad of applications of such models for a wide range of cancer indications. These models offer a morfailures andlly relevant platform for evaluating anti-cancer drugs with the potential to improve translational accuracy, reduce drug development failures, and accelerate the discovery of cancer therapies.
中文摘要:肿瘤微环境的异质性给抗肿瘤治疗的成功带来显著挑战。因此,急需产生全面的数据,以阐明肿瘤耐药机制,并为合理、系统地应用抗肿瘤药物提供依据,从而减轻耐药。基于已建细胞系的体外肿瘤模型被广泛用于研究药物作用机制;但这类传统模型往往不能准确再现原发肿瘤的复杂性,尤其在异质且复杂的肿瘤微环境方面,包括细胞组成、细胞间通讯以及细胞与细胞外基质的相互作用。其结果是,临床前数据常与临床结局不一致。近年来,患者来源的三维模型,包括球状体、类器官、肿瘤芯片系统和三维生物打印,为克服这些局限、提高肿瘤药物筛选的预测能力提供了有希望的替代方案。文章探讨肿瘤微环境复杂性、肿瘤耐药之间的关系,继而介绍当前用于在体外重建三维肿瘤模型的生物制造技术,并进一步深入讨论此类模型在多种癌症适应症中的广泛应用。这些模型为评估抗肿瘤药物提供了更具临床相关性的平台,有望提高转化准确性、减少药物开发失败并加速癌症疗法的发现。
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; however, a significant proportion of patients fail to respond, in part due to persistent immunosuppression mediated by regulatory T cells (Tregs). Previous efforts to target Tregs focused primarily on immune co-signaling pathways such as cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1, but these approaches resulted in limited clinical benefits, as they address only part of the biology maintaining Treg dominance within the tumor microenvironment. Consequently, recent strategies have expanded beyond co-signaling to target metabolic, cytokine, chemokine, and transcriptional pathways that may act synergistically with ICIs. In this review, we summarize the biological rationale and current clinical progress of key non-co-signaling Treg-targeting strategies, including interleukin-2/CD25, transforming growth factor-beta, forkhead box P3, CD39/CD73 adenosine axis, and C-C motif chemokine receptor 4/8 chemokine pathways. We further discuss emerging opportunities such as selectively targeting tumor-infiltrating Treg-enriched molecules, developing refined biomarkers for patient selection, and applying novel engineering modalities to improve therapeutic precision and durability across broader patient populations.
中文摘要:免疫检查点抑制剂(ICIs)改变了肿瘤治疗格局,但仍有相当比例患者不能获得应答,部分原因在于调节性T细胞(Tregs)介导的持续免疫抑制。既往靶向Tregs的努力主要集中于细胞毒性T淋巴细胞相关蛋白4和程序性细胞死亡蛋白1等免疫共信号通路,然而这些方法仅触及维持肿瘤微环境中Treg优势的部分生物学机制,临床获益有限。近期策略因此从共信号通路扩展到代谢、细胞因子、趋化因子和转录通路,并可能与ICIs产生协同作用。本综述总结关键的非共信号Treg靶向策略的生物学依据和当前临床进展,包括白细胞介素-2/CD25、转化生长因子-β、叉头框蛋白P3、CD39/CD73腺苷轴以及C-C基序趋化因子受体4/8趋化因子通路。文中还讨论新出现的机会,如选择性靶向肿瘤浸润Treg富集分子、开发更精细的生物标志物用于患者选择,以及应用新的工程化手段提高治疗精准度和持久性,使更广泛患者群体获益。
Abnormal protein aggregation and a dysregulated neuroimmune environment are defining features of many neurodegenerative disorders. In Alzheimer's disease, systemic monoclonal antibodies against amyloid-β provide proof of principle that immunotherapy can modify disease trajectory. However, clinical benefit is limited by low brain exposure, short-lived activity, the need for repeated dosing, and inflammation-linked toxicity. Building on transformative clinical success in oncology, chimeric antigen receptor (CAR) immunotherapies offer a complementary approach to address these limitations, combining the molecular precision of antibody-derived binders with the versatility and persistence of engineered immune cells. These technologies are being explored for central nervous system (CNS) proteinopathies, where they can couple the selective recognition of pathogenic proteoforms to immune programs that are compatible with the CNS's low tolerance for collateral inflammation. Here, we review CAR strategies for aggregate-selective targeting and explore how to incorporate tunable controls and safety mechanisms. Finally, we examine how distinct CAR-engineered effector cell types may modulate key processes in neurodegeneration, from aggregate clearance to immune rebalancing. Together, these advances define CAR design principles for durable, programmable, and targeted immunomodulation in neurodegenerative disease.
中文摘要:异常蛋白聚集和神经免疫环境失调是多种神经退行性疾病的标志性特征。在阿尔茨海默病中,针对β-淀粉样蛋白的系统性单克隆抗体提供了免疫治疗可改变疾病轨迹的原理验证。然而,脑内暴露低、活性持续时间短、需要重复给药以及与炎症相关的毒性限制了临床获益。基于肿瘤学中具有变革性的临床成功,嵌合抗原受体(CAR)免疫治疗提供了一种补充性策略来应对这些限制,将抗体衍生结合分子的分子精确性与工程化免疫细胞的多功能性和持久性结合起来。这些技术正在中枢神经系统(CNS)蛋白病中探索,可将对致病蛋白形式的选择性识别与符合CNS对附带炎症低耐受的免疫程序相连接。综述聚焦用于聚集物选择性靶向的CAR策略,并探讨如何整合可调控的控制与安全机制。最后,考察不同CAR工程化效应细胞类型如何调节神经退行性变中的关键过程,从聚集物清除到免疫再平衡。这些进展共同确立了用于神经退行性疾病持久、可编程和靶向免疫调节的CAR设计原则。
Men experience higher cancer incidence and mortality than women, and accumulating evidence implicates androgen receptor (AR) signaling as a key biological driver of these sex-based disparities. AR signaling can suppress adaptive anticancer immunity. Preclinical studies across multiple cancer types show that AR inhibition enhances T cell function and sensitizes tumors to immune checkpoint inhibition. However, recent Phase 3 trials combining AR suppression with immune checkpoint blockade in prostate cancer (PCa) failed to demonstrate clinical benefit. We discuss these developments and summarize recent studies defining the role of AR signaling in anticancer immunity. We propose strategies to translate emerging insights into rational trial designs that optimize the integration of AR suppression with immunotherapy.
中文摘要:男性癌症发病率和死亡率高于女性,越来越多的证据表明雄激素受体(AR)信号是这种性别差异的关键生物学驱动因素。AR信号可抑制适应性抗肿瘤免疫。多种癌症的临床前研究显示,抑制AR可增强T细胞功能,并使肿瘤对免疫检查点抑制更敏感。然而,近期在前列腺癌(PCa)中联合AR抑制与免疫检查点阻断的3期试验未能显示临床获益。我们讨论这些进展,并总结近期界定AR信号在抗肿瘤免疫中作用的研究。我们提出策略,将新出现的认识转化为合理的试验设计,以优化AR抑制与免疫治疗的整合。
Mitochondria are organelles that are essential for their multiple roles in cell biology, including energy metabolism. Accumulating evidence has revealed that intercellular mitochondrial transfer occurs within the tumor microenvironment (TME). The mitochondrial transfer among the TME components can profoundly affect tumor progression, immune surveillance, and stromal remodeling. Importantly, cancer cells function not only as recipients but also as donors of mitochondria, underscoring the bidirectional nature of this process. This review summarizes the multifaceted roles of mitochondria in cancer cells, immune cells, and stromal cells, with particular emphasis on emerging insights into mitochondrial transfer. In addition, the current implications of mitochondria-targeting therapies and future challenges in this evolving field are highlighted.
中文摘要:线粒体是细胞生物学中具有多种功能的重要细胞器,能量代谢是其中一项关键作用。越来越多证据显示,肿瘤微环境(TME)内存在细胞间线粒体转移。TME各组分之间的线粒体转移可深刻影响肿瘤进展、免疫监视和基质重塑。癌细胞既可作为线粒体的接受者,也可作为供体,体现该过程的双向性。综述总结线粒体在癌细胞、免疫细胞和基质细胞中的多重作用,重点讨论线粒体转移的新兴认识,并概述线粒体靶向治疗目前的启示及该领域未来挑战。
SHP2 is a tyrosine phosphatase that mediates intracellular signaling downstream of transmembrane receptors regulated by a pair of src homology 2 (SH2) domains. Its overexpression and mutation are pivotal in driving tumor progression by influencing various cancer's fundamental characteristics, such as metastasis, DNA repair, angiogenesis, immunosuppression, and telomere extension. SHP2 acts as a convergent node of oncogenic signaling pathways including MAPK, PI3K-AKT, VEGF, JAK-STAT making it an attractive target for cancer therapeutics. Preclinical studies demonstrate that SHP2 allosteric inhibitors in combination with EGFR, PD-1, KRAS, or MEK inhibitors, show potent antitumour activity and effectively overcome adaptive resistance beyond conventional therapies. Multiple SHP2 allosteric inhibitors are currently in clinical trials to assess their effectiveness, safety, and tolerability in treating various malignancies. Despite these advancements, SHP2's complex role presents challenges for the efficacy of SHP2 monotherapy and in the context of SHP2 mutants. Current allosteric inhibitors lack a well-defined mode of action for selectively targeting hyperactive SHP2 in malignancies. Moreover, a deeper understanding of SHP2's regulatory mechanisms and its interactions within the tumor microenvironment is needed to optimize SHP2-directed therapies. This review highlights these challenges, with a focus on SHP2 regulation, disease-associated mutants, its role in cancer cells and the tumor microenvironment, current and future therapeutic prospects.
中文摘要:SHP2是一种酪氨酸磷酸酶,由一对src同源2(SH2)结构域调控,介导跨膜受体下游的细胞内信号传导。其过表达与突变通过影响多种肿瘤的基本特征——如转移、DNA修复、血管生成、免疫抑制和端粒延长——在推动肿瘤进展中起关键作用。SHP2作为MAPK、PI3K-AKT、VEGF、JAK-STAT等致癌信号通路的汇聚节点,使其成为有吸引力的肿瘤治疗靶点。临床前研究显示,SHP2变构抑制剂与EGFR、PD-1、KRAS或MEK抑制剂联用具有强效抗肿瘤活性,并可有效克服常规治疗之外的适应性耐药。多种SHP2变构抑制剂正处于临床试验阶段,以评估其治疗多种恶性肿瘤的有效性、安全性与耐受性。尽管取得上述进展,SHP2作用的复杂性仍给SHP2单药治疗以及针对SHP2突变体的疗效带来挑战。现有变构抑制剂尚缺乏明确的作用方式以选择性靶向恶性肿瘤中过度活化的SHP2。此外,需更深入理解SHP2的调控机制及其在肿瘤微环境中的相互作用,以优化SHP2导向的治疗。本综述聚焦SHP2的调控、疾病相关突变体、其在肿瘤细胞与肿瘤微环境中的作用,以及当前与未来的治疗前景,并对上述挑战加以阐述。
Chimeric antigen receptor T (CAR-T) cell therapy shows limited efficacy in solid tumors, partly owing to poorly defined tumor-intrinsic resistance mechanisms. Here we show that the epigenetic regulator BAZ2A drives resistance to CD70-targeted CAR-T therapy by reprogramming tumor lipid metabolism. Using an in vivo CRISPR screen in a mouse renal cell carcinoma model, we identify BAZ2A as a key mediator that promotes the production and accumulation of palmitic acid, a saturated fatty acid in the tumor microenvironment. Excess palmitic acid is taken up by CAR-T cells and impairs mitochondrial fitness by inhibiting PGC-1α activity, thereby enforcing a dysfunctional state. Pharmacologic inhibition of BAZ2A reduces lipid accumulation and restores CAR-T cell activity in vivo. These findings reveal an epigenetic-metabolic mechanism of immune resistance and suggest that targeting tumor lipid remodeling represents a therapeutic strategy to overcome CAR-T resistance in solid tumors.
中文摘要:嵌合抗原受体T细胞(CAR-T)疗法在实体瘤中的疗效有限,部分原因在于肿瘤内在的耐药机制尚未被充分阐明。本研究发现,表观遗传调控因子BAZ2A通过重编程肿瘤脂质代谢,驱动对靶向CD70的CAR-T疗法产生抵抗。在小鼠肾细胞癌模型中开展体内CRISPR筛选后,我们确定BAZ2A是促进棕榈酸生成与积累的关键介质;棕榈酸是一种饱和脂肪酸,可在肿瘤微环境中累积。过量棕榈酸被CAR-T细胞摄取后,通过抑制PGC-1α活性损害线粒体适应度,使CAR-T细胞进入功能障碍状态。药物抑制BAZ2A可减少脂质积累,并在体内恢复CAR-T细胞活性。这些发现揭示了免疫抵抗的表观遗传-代谢机制,并提示靶向肿瘤脂质重塑可作为克服实体瘤CAR-T抵抗的治疗策略。
Tumor-associated macrophages (TAMs) are abundant in the hepatocellular carcinoma (HCC) tumor microenvironment (TME) and undergo metabolic reprogramming to support an immunosuppressive phenotype. While G protein-coupled receptors are known sensors of environmental cues, the specific role of the inhibitory G protein subunit alpha i3 (Gαi3) in linking metabolic stress to TAMs-mediated immunosuppression remains undefined. Clinical associations were evaluated by multiplex immunohistochemistry, Kaplan-Meier analysis, and multivariable Cox regression. Myeloid-specific Gnai3-deficient mice were studied in DEN/CCl4 or DEN/HFD-induced and orthotopic HCC models. Metabolic reprogramming was assessed by targeted metabolomics, Seahorse analysis, and pharmacological inhibition of fatty acid oxidation. Mechanistic studies included co-immunoprecipitation, a cell-free kinase assay using recombinant AMPK and Gαi3, chromatin immunoprecipitation, promoter-reporter assays, cycloheximide-chase analysis, surface-biotinylation-based EGFR recycling assays, and GBF1 knockdown/rescue experiments. Gαi3 was upregulated in TAMs within glucose-deprived HCC regions and was associated with M2-like polarization, CD8+T cell exhaustion, and shorter overall survival. High TAM Gαi3 remained associated with overall survival after adjustment for clinical covariates. Myeloid-specific Gnai3 deletion suppressed HCC progression and restored cytotoxic CD8+T cell activity. Etomoxir phenocopied Gnai3 deficiency and attenuated macrophage-mediated T-cell suppression, supporting a requirement for fatty acid oxidation. Mechanistically, glucose deprivation activated AMPK-dependent phosphorylation of Gαi3; the cell-free kinase assay, mass spectrometry, and S143A mutagenesis together supported Ser143 as the relevant regulatory site. Active Gαi3 stabilized EGFR through a GBF1-associated trafficking program, promoted EGFR-dependent PKM2 nuclear translocation, and enhanced formation of a nuclear PKM2/HIF-1α transcriptional complex that activated Pparg and sustained an immunosuppressive fatty acid oxidation program. Our study identifies Gαi3 as a critical metabolic checkpoint that orchestrates TAMs immunosuppression in the glucose-deprived TME. The Gαi3-EGFR-PKM2-PPARγ signaling axis drives metabolic reprogramming towards lipid oxidation, thereby inhibiting antitumor immunity. Targeting Gαi3 represents a novel immunotherapeutic strategy to reverse TAMs-mediated immunosuppression and improve outcomes in HCC.
中文摘要:肿瘤相关巨噬细胞(TAMs)在肝细胞癌(HCC)肿瘤微环境(TME)中大量存在,并发生代谢重编程以支持免疫抑制表型。G蛋白偶联受体已知可感知环境信号,但抑制性G蛋白αi3亚基(Gαi3)在连接代谢应激与TAMs介导的免疫抑制中的具体作用仍未明确。临床相关性通过多重免疫组化、Kaplan-Meier分析和多变量Cox回归评估。研究在DEN/CCl4或DEN/HFD诱导的原位HCC模型中使用髓系特异性Gnai3缺失小鼠。代谢重编程通过靶向代谢组学、Seahorse分析和脂肪酸氧化药理抑制进行评估。机制研究包括共免疫沉淀、使用重组AMPK与Gαi3的无细胞激酶实验、染色质免疫沉淀、启动子报告基因实验、放线菌酮追踪分析、基于表面生物素化的EGFR再循环实验以及GBF1敲低/回补实验。Gαi3在葡萄糖缺乏的HCC区域内的TAMs中上调,并与M2样极化、CD8+T细胞耗竭和较短总生存期相关。校正临床协变量后,TAM Gαi3高表达仍与总生存期相关。髓系特异性Gnai3缺失抑制HCC进展并恢复细胞毒性CD8+T细胞活性。Etomoxir可模拟Gnai3缺失的表型并减弱巨噬细胞介导的T细胞抑制,支持脂肪酸氧化的必要性。机制上,葡萄糖缺乏激活AMPK依赖的Gαi3磷酸化;无细胞激酶实验、质谱和S143A突变共同支持Ser143为相关调控位点。活性Gαi3通过GBF1相关运输程序稳定EGFR,促进EGFR依赖的PKM2核转位,并增强核内PKM2/HIF-1α转录复合体形成,该复合体激活Pparg并维持免疫抑制性脂肪酸氧化程序。Gαi3被确定为在葡萄糖缺乏TME中协调TAMs免疫抑制的关键代谢检查点。Gαi3-EGFR-PKM2-PPARγ信号轴驱动向脂质氧化的代谢重编程,从而抑制抗肿瘤免疫。靶向Gαi3是一种新的免疫治疗策略,可逆转TAMs介导的免疫抑制并改善HCC结局。
Tumor epigenetic reprogramming serves as a critical hallmark of cancer, fostering transcriptional plasticity of gene expression and driving alterations in the suppressive inflammatory responses within the tumor microenvironment, which pose significant challenges to the advancement of novel CAR-macrophage (CAR-M)-based antitumor therapies. However, it remains limited mechanistic investigations exploring how epigenetic reprogramming strategies impact the efficacy of CAR-M treatments. Human epidermal growth factor receptor 2 (HER2)-targeted CAR-Ms containing either an α1β1 integrin-mediated Fc-gamma receptor I (FcγRI) or CD3ζ signaling domain were generated and compared for tumor-directed migration and antitumor activity. HER2-positive tumor cells were pretreated with decitabine (DAC). CAR-M function, tumor-cell death, transcriptomic and inflammatory pathway changes, tumor immune remodeling, and therapeutic efficacy were assessed using in vitro assays, RNA sequencing, and murine tumor and metastasis models. Full-dose and half-dose CAR-M regimens were evaluated. α1β1 integrin-FcγRI CAR-Ms displayed significantly greater migration toward HER2-positive tumor cells than CD3ζ CAR-Ms. DAC potentiated anti-HER2 CAR-M activity by reprogramming tumor-cell gene expression and shifting the dominant cell-death mode from apoptosis to gasdermin E (GSDME)-dependent pyroptosis. RNA sequencing demonstrated enrichment of inflammatory immune-response programs, including nuclear factor kappa B and Janus kinase-signal transducer and activator of transcription signaling, after DAC treatment. DAC also favorably remodeled the tumor immune microenvironment, thereby supporting CAR-M activity. In murine models, DAC plus CAR-M therapy enhanced inflammatory antitumor immunity and improved control of primary tumor growth and metastatic disease compared with CAR-M monotherapy. Notably, DAC pretreatment combined with half-dose CAR-Ms achieved therapeutic efficacy comparable to that of full-dose CAR-M treatment. DAC-mediated DNA demethylation sensitizes HER2-positive tumors to CAR-M therapy through GSDME-dependent pyroptosis, activation of inflammatory signaling, and favorable remodeling of the tumor microenvironment. Epigenetic priming may improve CAR-M efficacy while reducing the required cell dose, supporting further translational development of this combination strategy for solid tumors.
中文摘要:肿瘤表观遗传重编程是癌症的重要标志,促进基因表达的转录可塑性,并驱动肿瘤微环境中抑制性炎症反应改变,给新型CAR巨噬细胞(CAR-M)抗肿瘤疗法的发展带来显著挑战。表观遗传重编程策略如何影响CAR-M疗效的机制研究仍然有限。研究构建了含α1β1整合素介导的Fcγ受体I(FcγRI)或CD3ζ信号域的靶向人表皮生长因子受体2(HER2)的CAR-M,并比较其向肿瘤定向迁移和抗肿瘤活性。HER2阳性肿瘤细胞经地西他滨(DAC)预处理。通过体外实验、RNA测序以及小鼠肿瘤和转移模型评估CAR-M功能、肿瘤细胞死亡、转录组和炎症通路变化、肿瘤免疫重塑及治疗效果。评估了全剂量和半剂量CAR-M方案。α1β1整合素-FcγRI CAR-M向HER2阳性肿瘤细胞的迁移显著高于CD3ζ CAR-M。DAC通过重编程肿瘤细胞基因表达并将主要细胞死亡方式从凋亡转向gasdermin E(GSDME)依赖性焦亡,增强抗HER2 CAR-M活性。RNA测序显示DAC处理后炎症免疫反应程序富集,包括核因子κB和Janus激酶-信号转导及转录激活因子信号。DAC还良性重塑肿瘤免疫微环境,从而支持CAR-M活性。在小鼠模型中,与CAR-M单药治疗相比,DAC联合CAR-M治疗增强炎症性抗肿瘤免疫,并改善原发肿瘤生长和转移性疾病控制。DAC预处理联合半剂量CAR-M达到与全剂量CAR-M治疗相当的治疗效果。DAC介导的DNA去甲基化通过GSDME依赖性焦亡、炎症信号激活和肿瘤微环境有利重塑,使HER2阳性肿瘤对CAR-M治疗敏感。表观遗传启动可提高CAR-M疗效并降低所需细胞剂量,支持该联合策略用于实体瘤的进一步转化开发。
Microsatellite-stable colorectal cancer (MSS-CRC) remains broadly refractory to immune checkpoint blockade, underscoring the need for strategies that convert immunologically "cold" tumors into therapy-responsive states. Here, we identify 4-hydroxyphenylpyruvate dioxygenase (HPD), the rate-limiting enzyme in tyrosine catabolism, as a modulator of sorafenib sensitivity in MSS-CRC. Pharmacological inhibition of HPD by the FDA-approved orphan drug nitisinone synergized with sorafenib across patient-derived organoids, human PBMC-tumor co-cultures, and immunocompetent orthotopic models. Mechanistically, nitisinone imposes strict glutaminolysis dependency, whereas sorafenib disrupts cRaf-MEK-ERK signaling to trigger proteasomal cMYC degradation and transcriptional repression of GLS1, thereby ablating compensatory glutamine anaplerosis. This dual metabolic blockade creates a synthetic lethal trap, provoking irreversible mitochondrial collapse and mtDNA release, which activates the cGAS-STING pathway and drives intratumoral infiltration of cytotoxic NK and CD8+ T cells. Critically, ρ⁰ cells and STING-deficient models confirm mitochondrial damage as the "trigger" of cell death and STING as the "amplifier" of antitumor immunity. In TCGA MSS-CRC cohorts, a double-low glutamine/tyrosine metabolic signature was associated with prolonged survival, enhanced cGAS-STING signaling, and immune-hot tumor features, findings corroborated by single-cell RNA-seq analyses. Finally, the triple combination of nitisinone, sorafenib, and anti-PD-1 therapy achieved superior antitumor efficacy with favorable tolerability in vivo. Collectively, our findings delineate a metabolic-mitochondrial-STING axis and support repurposing nitisinone as a promising translational strategy to sensitize MSS-CRC to immunotherapy.
中文摘要:微卫星稳定型结直肠癌(MSS-CRC)对免疫检查点阻断普遍难治,亟需将免疫「冷」肿瘤转化为治疗敏感状态的策略。研究识别出酪氨酸分解代谢限速酶4-羟基苯丙酮酸双加氧酶(HPD)是MSS-CRC中索拉非尼敏感性的调节因子。以FDA批准的孤儿药尼替西农抑制HPD,可在患者来源类器官、人PBMC-肿瘤共培养及免疫健全原位模型中与索拉非尼协同。机制上,尼替西农造成严格的谷氨酰胺分解依赖,索拉非尼则破坏cRaf-MEK-ERK信号,触发蛋白酶体途径的cMYC降解并抑制GLS1转录,由此消除补偿性谷氨酰胺回补。这种双重代谢阻断形成合成致死陷阱,引起不可逆的线粒体崩溃和mtDNA释放,激活cGAS-STING通路,并促进细胞毒性NK细胞和CD8+ T细胞向瘤内浸润。ρ⁰细胞和STING缺陷模型证实线粒体损伤是细胞死亡的「触发因素」,STING则是抗肿瘤免疫的「放大器」。在TCGA MSS-CRC队列中,谷氨酰胺/酪氨酸代谢双低特征与生存期延长、cGAS-STING信号增强及免疫热肿瘤特征相关,单细胞RNA测序分析亦支持这些发现。体内实验中,尼替西农、索拉非尼与抗PD-1三联治疗取得更优的抗肿瘤疗效,耐受性良好。上述结果勾勒出代谢-线粒体-STING轴,并支持将尼替西农重定位为使MSS-CRC对免疫治疗敏感的转化策略。
CMTM6 is known to stabilize PD-L1 on cancer cells, facilitating immune evasion, but its role in normal hematopoiesis remains unexplored. Hematopoietic stem cell (HSC) homeostasis is tightly regulated by interferon (IFN) signaling, yet the mechanisms controlling IFN receptor stability are unclear. In this study we investigated whether CMTM6 regulates HSC maintenance and elucidated the underlying molecular pathways. Using a conditional Cmtm6 knockout mouse model (Vav-Cre), we performed flow cytometry, competitive transplantation, single-cell RNA sequencing, co-immunoprecipitation, and functional assays on bone marrow HSCs. Cmtm6 deficiency led to increased HSC proliferation but impaired reconstitution capacity, accompanied by elevated DNA damage and disrupted cell polarity. Single-cell analysis revealed a marked reduction in IFN response pathways. Mechanistically, CMTM6 directly interacted with IFNAR1 and IFNGR1, stabilizing their protein expression. Downstream, Cmtm6 deletion impaired STAT1 phosphorylation and reduced KLF4 expression; single-cell analysis revealed a significant positive correlation between Stat1 activity and Klf4 expression, and STAT1 inhibition in HSCs confirmed that STAT1 activity is required for maintaining KLF4 expression. Notably, KLF4 overexpression partially rescued colony-forming defects and reduced γH2AX foci in Cmtm6-deficient HSCs, identifying KLF4 as a key downstream effector. Additionally, we observed accompanying molecular changes including reduced SIAH2, elevated DYRK2, decreased c-MYC, and increased P53, which may contribute to the observed phenotypes. These findings demonstrate that CMTM6 maintains HSC homeostasis by stabilizing IFN receptors and regulating the IFNR-STAT1-KLF4 signaling axis, revealing a novel physiological function for CMTM6 in hematopoiesis.
中文摘要:CMTM6已知可稳定癌细胞表面的PD-L1,促进免疫逃逸,但其在正常造血中的作用尚未被探索。造血干细胞(HSC)稳态受干扰素(IFN)信号严格调控,然而控制IFN受体稳定性的机制仍不清楚。本研究探讨CMTM6是否调控HSC维持,并阐明其分子通路。采用条件性Cmtm6敲除小鼠模型(Vav-Cre),对骨髓HSC进行流式细胞术、竞争性移植、单细胞RNA测序、免疫共沉淀和功能实验。Cmtm6缺失导致HSC增殖增加但重建能力受损,并伴随DNA损伤升高和细胞极性紊乱。单细胞分析显示IFN反应通路明显下降。机制上,CMTM6直接与IFNAR1和IFNGR1相互作用,稳定其蛋白表达。下游方面,Cmtm6缺失削弱STAT1磷酸化并降低KLF4表达;单细胞分析显示Stat1活性与Klf4表达呈显著正相关,在HSC中抑制STAT1证实STAT1活性是维持KLF4表达所必需。KLF4过表达可部分挽救Cmtm6缺陷HSC的集落形成缺陷并减少γH2AX灶,表明KLF4是关键下游效应分子。同时还观察到SIAH2降低、DYRK2升高、c-MYC降低和P53升高等伴随分子变化,这些变化可能参与上述表型。这些发现表明CMTM6通过稳定IFN受体并调控IFNR-STAT1-KLF4信号轴维持HSC稳态,揭示了CMTM6在造血中的新生理功能。
The synergistic combination of oncolytic adenovirus (oAd) and paclitaxel chemodrug holds great potential for cancer therapy as it can enhance cell apoptosis, the viral replication in cancer cells, and induce a potent antitumor effect. However, clinical output is insufficient because of the rapid blood clearance and inactivation of viral activity within high-reactive oxygen species (ROS) tumor microenvironment (TME). In this regard, we have developed an ROS responsive supramolecular hydrogel (mPEG-b-PCL-DPMP/α-cyclodextrin (α-CD) (DPMP/α-CD hydrogel)) system to protect oAd bioactivity while providing sustained, localized co-delivery of paclitaxel (PTX). The amount of ROS was evaluated by fluorescence measurements using H2DCFDA as a probe and confirmed that there was a significant decrease in ROS level by mPEG-b-PCL-DPMP/α-CD hydrogel. An in vivo degradation study showed that the hydrogel underwent substantial degradation within one week. Furthermore, oAd and PTX encapsulated in mPEG-b-PCL-DPMP/α-CD hydrogel were released consistently and retained the viral activity, exhibiting cancer cell killing efficacy under strong tumor microenvironment conditions. In vivo, a single intratumoral injection formed a stable depot that persisted for over a week, leading to superior tumor regression in H460 xenograft models compared to naked oAd or PTX alone. Histological and biochemical analyses confirmed no detectable histopathological abnormalities in the examined major organs or elevations in the measured serum liver and kidney injury markers under the conditions evaluated. Altogether, this ROS-responsive shield-and-release injectable supramolecular hydrogel platform loaded with oAd/PTX exhibits downregulated ROS level at tumor microenvironment and enhanced anti-tumor effect. STATEMENT OF SIGNIFICANCE: • An active shield-scavenge-release hydrogel was engineered to enhance oncolytic adenovirus/paclitaxel (oAd/PTX) combination therapy. • The hydrogel protects oxidation-sensitive adenovirus while enabling sustained local viral release. • ROS-responsive dipentaerythritol hexakis(3-mercaptopropionate) (DPMP) segments convert the oxidative tumor microenvironment into a therapeutic release trigger. • PTX-loaded hydrophobic domains support prolonged chemotherapy without disrupting hydrogel architecture. • Sustained oAd/PTX co-release amplifies viral replication, tumor cell killing, and antitumor efficacy. • A single intratumoral administration achieves durable tumor suppression with minimal systemic toxicity.
中文摘要:溶瘤腺病毒(oAd)与紫杉醇化疗药的协同联合在癌症治疗中具有很大潜力,可增强细胞凋亡、促进病毒在癌细胞中的复制并诱导强效抗肿瘤效应。但临床效果不足,原因包括血液清除快以及在高活性氧(ROS)肿瘤微环境(TME)中病毒活性失活。为此,我们开发了一种ROS响应性超分子水凝胶(mPEG-b-PCL-DPMP/α-环糊精(α-CD)(DPMP/α-CD水凝胶))系统,用于保护oAd生物活性,同时实现紫杉醇(PTX)的持续、局部共递送。以H2DCFDA为探针通过荧光测定评估ROS量,证实mPEG-b-PCL-DPMP/α-CD水凝胶显著降低ROS水平。体内降解研究显示水凝胶在一周内发生明显降解。封装于mPEG-b-PCL-DPMP/α-CD水凝胶中的oAd和PTX可持续释放并保持病毒活性,在强肿瘤微环境条件下表现出杀伤癌细胞的效力。体内单次瘤内注射形成稳定储库并持续超过一周,在H460异种移植模型中较裸oAd或单用PTX带来更优的肿瘤消退。组织学和生化分析证实,在所评估条件下,受检主要器官未见可检测的组织病理学异常,所测血清肝肾功能损伤标志物也未升高。总体而言,这种负载oAd/PTX的ROS响应性屏蔽-释放可注射超分子水凝胶平台可下调肿瘤微环境ROS水平并增强抗肿瘤效果。意义声明:• 构建了一种主动屏蔽-清除-释放水凝胶以增强溶瘤腺病毒/紫杉醇(oAd/PTX)联合治疗。• 该水凝胶保护对氧化敏感的腺病毒,同时实现持续局部病毒释放。• ROS响应性二季戊四醇六(3-巯基丙酸酯)(DPMP)片段将氧化性肿瘤微环境转化为治疗释放触发因素。• 负载PTX的疏水结构域支持延长化疗而不破坏水凝胶结构。• 持续oAd/PTX共释放放大了病毒复制、肿瘤细胞杀伤和抗肿瘤疗效。• 单次瘤内给药实现持久肿瘤抑制且全身毒性极低。
Cells experiencing mitochondrial stress can undergo apoptosis or cell death that triggers innate immune activation. We examined the mechanisms determining these distinct outcomes in cancer. Abundant mitochondrial DNA (mtDNA) and high expression of the cGAS-STING pathway were features of KRAS-mutant cancers. In a pharmacological screen, MEK inhibitor (MEKi) effectively induced mtDNA release into the cytosol in KRAS-mutant cancer cells. However, MEKi also induced PRKN-mediated mitophagy, which limited mtDNA release by eliminating damaged mitochondria. Inhibition of mitophagy sustained mtDNA efflux and amplified cGAS-STING signaling. Mechanistically, PRKN-mediated mitophagy restrained mitochondrial outer membrane permeabilization (MOMP) to limit mtDNA efflux. The balance between mtDNA and cytochrome c (cyt.c) release defined two immunologically distinct outcomes: immunogenic cell death (ICD) and apoptosis. In preclinical models, combined inhibition of MEK and mitophagy induced robust dendritic cell (DC) activation and promoted CD8+ T cell-mediated antitumor immunity. Consistently, PRKN expression negatively correlated with immune infiltration in human cancers. Collectively, these findings provide a rationale for combination strategies targeting mitochondrial dynamics to augment antitumor immunity.
中文摘要:经历线粒体应激的细胞可发生凋亡,或发生能触发先天免疫激活的细胞死亡。研究考察了肿瘤中决定这两种不同结局的机制。KRAS突变肿瘤具有线粒体DNA(mtDNA)丰度高和cGAS-STING通路高表达的特征。在药物筛选中,MEK抑制剂(MEKi)有效诱导KRAS突变癌细胞将mtDNA释放至胞质。但MEKi也诱导PRKN介导的线粒体自噬,通过清除受损线粒体限制mtDNA释放。抑制线粒体自噬可维持mtDNA外流并放大cGAS-STING信号。机制上,PRKN介导线粒体自噬抑制线粒体外膜通透化(MOMP),从而限制mtDNA外流。mtDNA与细胞色素c(cyt.c)释放之间的平衡决定两种免疫学上不同的结局:免疫原性细胞死亡(ICD)与凋亡。在临床前模型中,联合抑制MEK与线粒体自噬可强烈激活树突状细胞(DC),并促进CD8+ T细胞介导的抗肿瘤免疫。在人类肿瘤中,PRKN表达与免疫浸润呈负相关,与上述结果一致。这些发现为靶向线粒体动态以增强抗肿瘤免疫的联合策略提供了依据。
Aberrant glutamine metabolism undermines the efficacy of cancer radiotherapy (RT) by promoting DNA repair, increasing oxygen consumption, and imposing metabolic stress that compromises the viability and function of cytotoxic T lymphocytes (CTLs). Here, we report a mitochondria-enriched, metabolism-regulating monolayered metal-organic framework (MOF) nanoplatform, Hf-Ir/DON, constructed by incorporating the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) into a radiosensitizing hafnium-iridium (Hf-Ir) MOF to inhibit glutaminolysis. This design markedly sensitizes tumor cells to RT and, upon x-ray irradiation, enables mitochondria-targeted RT-radiodynamic therapy with substantially enhanced reactive oxygen species accumulation. The resulting oxidative stress induces extensive DNA damage, mitochondrial dysfunction, and immunogenic tumor cell pyroptosis. Concurrently, Hf-Ir/DON alleviates metabolic constraints on activated T cells, preserving CTL viability while sustaining effector and memory functions. In a murine colon cancer model, low-dose RT combined with Hf-Ir/DON achieved >95% tumor growth inhibition. Further combination with anti-PD-L1 therapy induced regression of bilateral triple-negative breast tumors and prevented lung metastasis. These results establish a radiometabolic MOF nanoplatform that potentiates RT while promoting durable antitumor immunity.
中文摘要:异常谷氨酰胺代谢会促进DNA修复、增加耗氧,并造成代谢应激,削弱细胞毒性T淋巴细胞(CTL)的活力和功能,从而降低肿瘤放疗(RT)疗效。研究构建了线粒体富集、可调节代谢的单层金属有机框架(MOF)纳米平台Hf-Ir/DON,将谷氨酰胺拮抗剂6-重氮-5-氧代-L-正亮氨酸(DON)引入具有放射增敏作用的铪铱(Hf-Ir)MOF,以抑制谷氨酰胺分解。该设计显著增强肿瘤细胞对RT的敏感性,并在X线照射下实现线粒体靶向的放疗-放射动力治疗,大幅提高活性氧蓄积。由此产生的氧化应激引起广泛DNA损伤、线粒体功能障碍和免疫原性肿瘤细胞焦亡。同时,Hf-Ir/DON减轻活化T细胞所受的代谢限制,维持CTL活力并保持效应和记忆功能。在小鼠结肠癌模型中,低剂量RT联合Hf-Ir/DON实现超过95%的肿瘤生长抑制。进一步联合抗PD-L1治疗使双侧三阴性乳腺癌消退,并阻止肺转移。这些结果建立了可增强RT并促进持久抗肿瘤免疫的放射代谢MOF纳米平台。
Whole-genome doubling (WGD) occurs frequently in human cancer and influences tumor evolution, metastasis, and treatment response. Here, we integrate bulk, single-cell, and spatial data to dissect the subclonal dynamics of WGD. Single-cell data analysis shows that WGD cells are prevalent even in tumors that are classified as non-WGD (nWGD). WGD subclones actively acquire somatic copy number alterations as they expand, suggesting ongoing evolution. We developed and rigorously validated a gene expression-based method, WAGES, to map WGD cell clonal fraction in bulk tumors. Applying WAGES to nWGD tumors, we reveal genomic correlates including TP53 mutations and chromosomal instability that are consistent with the presence of WGD subclones. Clinically, WAGES scores are strongly correlated with tumor metastatic potential, response to treatments including chemotherapy and immunotherapy, and patient prognosis. These findings reveal widespread WGD subclones in nWGD tumors and demonstrate their substantial impact on cancer evolution and therapeutic outcomes.
中文摘要:全基因组加倍(WGD)在人类癌症中频繁发生,影响肿瘤演化、转移与治疗反应。本研究整合bulk、单细胞与空间数据,解析WGD的亚克隆动态。单细胞数据分析显示,即便在判定为非WGD(nWGD)的肿瘤中,WGD细胞依然普遍存在。WGD亚克隆在扩增过程中持续获得体细胞拷贝数变异,提示其处于持续演化之中。我们开发并严格验证了一种基于基因表达的方法WAGES,用于在bulk肿瘤中评估WGD细胞克隆比例。将WAGES应用于nWGD肿瘤,发现与WGD亚克隆存在相符的基因组特征,包括TP53突变与染色体不稳定。在临床上,WAGES评分与肿瘤转移潜能、化疗与免疫治疗等治疗反应以及患者预后密切相关。这些结果揭示nWGD肿瘤中广泛存在WGD亚克隆,并显示其对癌症演化与治疗结局有实质影响。
Epithelial surfaces are the primary sites of lytic herpes simplex virus 1 (HSV-1) infection following initial exposure or reactivation from latency. To model this complex environment, we used human hair-bearing skin organoids and combined single-cell spatial transcriptomics with imaging to map viral spread and host responses across skin architecture. Our data suggest delayed progression of the HSV-1 life cycle in epidermal keratinocytes and hair follicle cells compared to the dermis. Infection triggered spatially organized host responses, including induction of IER3 in papillary fibroblasts. In basal keratinocytes, IRF3 was up-regulated in both infected and neighboring uninfected cells, consistent with paracrine activation of antiviral signaling. Inflammatory responses were compartmentalized in a cell type-specific manner, with TNFSF9 (4-1BBL) induced in papillary fibroblasts and tumor necrosis factor-α (TNF-α) induced in keratinocytes. Enzyme-linked immunosorbent assays confirmed secretion of these cytokines and the TNF-α-responsive chemokines CXCL2 and CXCL10. CXCL2 expression was enriched in cells adjacent to TNF-α-expressing cells, highlighting spatial coordination of inflammatory signaling. While interferon-β reduced viral replication, TNF-α and 4-1BBL did not, suggesting that their primary role is to orchestrate immune cell recruitment and activation. These findings establish human hair-bearing skin organoids as a physiologically relevant model for investigating spatial host-HSV-1 interactions.
中文摘要:上皮表面是HSV-1初次暴露或潜伏再激活后发生裂解性感染的主要部位。为模拟这一复杂环境,使用人含毛皮肤类器官,并将单细胞空间转录组学与成像结合,以绘制病毒在皮肤结构中的扩散和宿主反应。数据提示,与真皮相比,表皮角质形成细胞和毛囊细胞中HSV-1生命周期进程延迟。感染触发空间组织的宿主反应,包括乳头层成纤维细胞中IER3的诱导。在基底角质形成细胞中,感染细胞和邻近未感染细胞的IRF3均上调,符合抗病毒信号的旁分泌激活。炎症反应以细胞类型特异性方式分区,TNFSF9(4-1BBL)在乳头层成纤维细胞中诱导,肿瘤坏死因子-α(TNF-α)在角质形成细胞中诱导。酶联免疫吸附试验证实这些细胞因子以及TNF-α响应趋化因子CXCL2和CXCL10的分泌。CXCL2表达富集于邻近表达TNF-α的细胞,显示炎症信号的空间协调。干扰素-β降低病毒复制,TNF-α和4-1BBL未降低病毒复制,提示其主要作用在于协调免疫细胞募集和激活。这些发现确立人含毛皮肤类器官作为研究宿主与HSV-1空间相互作用的生理相关模型。
Regulatory T cell (Treg) accumulation within the tumor microenvironment is a major contributor to immune evasion and immunotherapy resistance. However, the metabolic signals orchestrating Treg lineage commitment remain poorly defined. We identify that the oxysterol 7α,25-dihydroxycholesterol (7α,25-OHC), produced by Vimentin+ stromal cells, acts through GPR183 to promote Treg differentiation and suppressive identity. In patients with gastric cancer (GC), GPR183+ Treg infiltration correlates with advanced disease and poor survival. In syngeneic tumor models, conditional GPR183 deletion, specifically in CD4+ T cells or Treg cells, demonstrates its cell-intrinsic requirement for high-cholesterol-diet-induced Treg expansion and tumor growth, thereby abrogating immune evasion and restoring CD8+ T cell effector function. Mechanistically, 7α,25-OHC-GPR183 signaling activates the AXL-JAK2-STAT5 pathway to reinforce Foxp3 expression. Last, GPR183 antagonism modestly enhances anti-PD-1 efficacy in a model-dependent manner and prevents therapy-induced Treg expansion. These findings identify the 7α,25-OHC-GPR183-AXL axis as a potential metabolic checkpoint linking cholesterol metabolism to immune suppression, suggesting a potential therapeutic strategy to enhance antitumor immunity.
中文摘要:肿瘤微环境中调节性T细胞(Treg)积聚是免疫逃逸和免疫治疗耐药的重要驱动因素。调控Treg谱系定向的代谢信号仍不清楚。研究发现,由波形蛋白阳性(Vimentin+)基质细胞产生的氧固醇7α,25-二羟基胆固醇(7α,25-OHC)通过GPR183促进Treg分化并塑造其抑制性表型。胃癌患者中,GPR183+ Treg浸润与疾病进展和生存期缩短相关。在同系肿瘤模型中,于CD4+ T细胞或Treg细胞中条件性敲除GPR183,证明GPR183以细胞内在方式参与高胆固醇饮食诱导的Treg扩增和肿瘤生长所必需,敲除后可削弱免疫逃逸并恢复CD8+ T细胞效应功能。机制上,7α,25-OHC-GPR183信号激活AXL-JAK2-STAT5通路,增强Foxp3表达。GPR183拮抗可适度增强抗PD-1疗效,效果呈模型依赖性,并能阻止治疗诱导的Treg扩增。这些结果提示7α,25-OHC-GPR183-AXL轴是连接胆固醇代谢与免疫抑制的潜在代谢检查点,为增强抗肿瘤免疫提供了潜在治疗策略。
Cellular senescence contributes dynamically to fibrosis and cancer depending on the senescent cell type and its tissue remodeling senescence-associated secretory phenotype; however, current senotherapies lack specificity in targeting pathogenic senescent cells and have limiting toxicities. In a recent issue of Science, Hinterleitner and colleagues designed P-selectin-directed nanoparticles (SMNPs) capable of delivering senotherapies specifically to pathogenic P-selectin+ senescent macrophages in fibrotic tissues while preventing uptake in beneficial senescent endothelial cells. Precision targeting by SMNPs resolved fibrosis and restored organ function in the lung and liver and minimized senotherapeutic toxicity in mice. In tumor models, SMNP targeting of this small senescent macrophage subset was sufficient to overcome fibrosis-mediated immune exclusion and sensitize liver and lung cancers to T cell-directed immunotherapy. P-selectin+ macrophages with senescent features were also enriched in fibrotic human tissues and treatment-refractory cancer patient samples. Overall, this study provides a platform for reducing the toxicity and enhancing the specificity of senotherapies necessary to advance their clinical development for treating chronic disease.
中文摘要:细胞衰老对纤维化和癌症的贡献是动态的,取决于衰老细胞类型及其组织重塑的衰老相关分泌表型;现有衰老细胞疗法在靶向致病性衰老细胞方面缺乏特异性,并存在毒性限制。在近期一期《Science》中,Hinterleitner及其同事设计了P-选择素导向的纳米颗粒(SMNPs),能够将衰老细胞疗法特异递送至纤维化组织中致病的P-选择素阳性衰老巨噬细胞,同时避免被有益衰老内皮细胞摄取。SMNPs的精准靶向在小鼠中缓解了纤维化并恢复肺和肝脏器官功能,降低了衰老细胞疗法的毒性。在肿瘤模型中,SMNP靶向这一小群衰老巨噬细胞足以克服纤维化介导的免疫排斥,使肝癌和肺癌对T细胞导向免疫治疗敏感。具有衰老特征的P-选择素阳性巨噬细胞也在人类纤维化组织和治疗难治性癌症患者样本中富集。这项研究提供了一个平台,可降低毒性并提高衰老细胞疗法的特异性,这是推进其用于慢性病治疗的临床开发所必需的。
Sex is a critical determinant of cancer susceptibility, clinical prognosis, and therapeutic response. Sex chromosome aberrations, particularly somatic loss of the Y chromosome (LOY) in male malignancies, exert profound impacts on transcriptional regulation, tumor immune microenvironment remodeling, and malignant progression, highlighting an urgent demand for comprehensive integration of single-cell and spatial omics profiles dissecting sex-biased and LOY landscapes across human cancers. Here, we developed XYcellAtlas (http://www.xycellatlas.top/), an integrative database for integration and multidimensional visualization of sex disparities and LOY features across human tissues at single-cell transcriptomic, epigenomic, and spatial-transcriptomic resolutions. This resource aggregates data from 6764 patient samples covering 18 cancer types, eight precancerous lesions, and 21 tissue origins, encompassing over 25.8 million single cells and one million spatial-transcriptomic spots. Leveraging random forest classifiers trained on normal tissue datasets, XYcellAtlas quantifies cell-type-specific LOY frequencies across cell types. Furthermore, it systematically catalogs sex-biased and LOY-associated molecular alterations, including differentially expressed genes, chromatin peaks, core transcription factors, as well as their functional annotations and dysregulatory signatures within malignant cells and the tumor microenvironment. In summary, XYcellAtlas provides a unified, all-in-one analytical platform enabling researchers to query, inspect, quantify, and visualize sex-associated and LOY-derived multi-omics features underlying tumor evolutionary processes.
中文摘要:性别是癌症易感性、临床预后和治疗反应的关键决定因素。性染色体畸变,尤其是男性恶性肿瘤中Y染色体的体细胞丢失(LOY),对转录调控、肿瘤免疫微环境重塑和恶性进展产生深远影响,亟需整合单细胞与空间组学图谱,解析人类癌症中的性别偏倚和LOY景观。为此,我们开发了XYcellAtlas(http://www.xycellatlas.top/),一个整合数据库,可在单细胞转录组、表观基因组和空间转录组分辨率上整合并多维可视化人体组织中的性别差异和LOY特征。该资源汇总了6764份患者样本的数据,覆盖18种癌症类型、8种癌前病变和21种组织来源,包含超过2580万个单细胞和100万个空间转录组位点。利用在正常组织数据集上训练的随机森林分类器,XYcellAtlas量化了不同细胞类型中细胞类型特异性的LOY频率。该数据库还系统编目了性别偏倚和LOY相关分子改变,包括差异表达基因、染色质峰、核心转录因子,以及它们在恶性细胞和肿瘤微环境中的功能注释和失调特征。XYcellAtlas提供统一的一站式分析平台,使研究者能够查询、检查、量化和可视化与性别相关及LOY衍生的多组学特征,这些特征支撑肿瘤演化过程。
Cancer-associated fibroblasts (CAFs) are integral components of the tumor microenvironment (TME) and are increasingly recognized as critical regulators of nearly every hallmark of cancer. Once viewed as a uniform, protumorigenic cell type, it is now clear that CAFs comprise a spectrum of dynamic and plastic functional states with both tumor-promoting and tumor-restraining capacities. This functional duality, conceptualized within the framework of cancer as a "wound that fails to heal", is dictated by their diverse cellular origins, the specific activation pathways engaged (such as TGF-β and PDGF), and the evolving cues from the TME. In this Review, we dissect the multifaceted roles of CAFs, from their promotion of cancer cell proliferation, invasion and angiogenesis through secreted factors and extensive extracellular matrix (ECM) remodeling, to their profound influence on the immune landscape. We detail how distinct CAF subsets, such as myofibroblastic (myCAFs) and inflammatory (iCAFs) CAFs, orchestrate an immunosuppressive niche and contribute to therapeutic resistance. We also explore the compelling evidence for tumor-suppressive CAF functions, which have catalyzed a paradigm shift in therapeutic strategies-moving away from indiscriminate CAF ablation towards nuanced approaches aimed at reprogramming their state. These strategies include modulating key signaling pathways, normalizing the CAF-remodeled ECM, and exploiting unique metabolic vulnerabilities. Finally, we discuss how advances in single-cell and spatial transcriptomics are resolving this complexity, paving the way for the development of precision therapies that can selectively neutralize pro-tumorigenic CAF activities while harnessing their beneficial functions to improve patient outcomes.
中文摘要:癌症相关成纤维细胞(CAFs)是肿瘤微环境(TME)的重要组成部分,日益被视为癌症几乎所有标志性特征的关键调控者。CAFs一度被看作均一、促瘤的细胞类型,如今已明确其包含一系列动态且可塑的功能状态,兼具促瘤与抑瘤能力。这种功能双重性可在癌症作为「无法愈合的伤口」的框架内理解,并由其多样的细胞来源、所激活的特定通路(如TGF-β和PDGF)以及TME不断变化的信号所决定。这篇综述剖析CAFs的多方面作用,从其通过分泌因子和广泛的细胞外基质(ECM)重塑促进癌细胞增殖、侵袭和血管生成,到其对免疫格局的深刻影响。文中详述不同CAF亚群,如肌成纤维细胞型(myCAFs)和炎症型(iCAFs),如何组织免疫抑制微环境并促成治疗耐药。也探讨肿瘤抑制性CAF功能的有力证据,这些证据推动治疗策略发生范式转变——从无差别清除CAF转向重编程其状态的精细方法。这些策略包括调节关键信号通路、正常化CAF重塑的ECM以及利用独特的代谢脆弱性。最后讨论单细胞和空间转录组学的进展如何解析这一复杂性,为开发精准疗法铺路,以选择性中和促瘤CAF活性,同时利用其有益功能改善患者结局。
Chronic exposure to severe social and environmental stressors is a major risk factor for tumor initiation and progression, yet the central nervous system (CNS)-driven mechanisms linking stress to cancer immunity remain poorly defined. Here, we identify activation of the hypothalamic-pituitary-bone marrow (HPB) axis as a critical driver of oral squamous cell carcinoma (OSCC). Chronic stress activates hypothalamic paraventricular nucleus (PVN) neurons, inducing pituitary overexpression of POMC and aberrant secretion of α‑MSH. This neuroendocrine activation increases the frequency of PMN-MDSCs in the bone marrow and upregulates the chemokine CXCL13 in the tumor microenvironment. Mechanistic studies show that this stress-responsive neuroendocrine circuit remodels the tumor immune microenvironment by promoting PMN-MDSC recruitment, suppressing CD8⁺ T cell infiltration, and skewing macrophages toward an M2 phenotype, collectively establishing profound immunosuppression. Chronic stress further amplifies this axis, accelerating OSCC progression and recurrence. Therapeutic blockade of MC5R restores antitumor immune surveillance and markedly potentiates PD-1 checkpoint inhibition. These findings delineate a previously underappreciated neuro-immune regulatory pathway governing malignant progression and highlight a tractable target for improving immunotherapy efficacy in stress-associated cancers.
中文摘要:长期暴露于严重的社会和环境应激源是肿瘤发生和进展的重要危险因素,但中枢神经系统驱动应激影响肿瘤免疫的机制仍不清楚。研究识别出下丘脑-垂体-骨髓轴激活是口腔鳞状细胞癌的关键驱动因素。慢性应激激活下丘脑室旁核神经元,促使垂体过表达POMC并异常分泌α-MSH。这种神经内分泌激活提高骨髓中PMN-MDSC频率,并上调肿瘤微环境中的趋化因子CXCL13。机制研究显示,这一应激反应性神经内分泌环路通过促进PMN-MDSC募集、抑制CD8⁺ T细胞浸润、使巨噬细胞向M2表型偏移来重塑肿瘤免疫微环境,共同形成深度免疫抑制。慢性应激进一步放大该轴,加速口腔鳞状细胞癌进展和复发。治疗性阻断MC5R可恢复抗肿瘤免疫监视,并显著增强PD-1检查点抑制。这些发现勾勒出一条此前未被充分认识的神经免疫调控通路,该通路控制恶性进展,并提示一个可用于改善应激相关癌症免疫治疗疗效的可干预靶点。
To elucidate the mechanisms underlying therapy-induced resistance, we investigated the temporal dynamics of the polyploid giant cancer cell (PGCC) life cycle following treatment with the microtubule-destabilizing agent vincristine (VCR). Longitudinal live-cell fluorescence imaging revealed that VCR-induced mitotic suppression activated a distinct PGCC life cycle characterized by nuclear amplification and progressive cellular reprogramming. PGCCs then entered a senescence-like state accompanied by an enhanced senescence-associated secretory phenotype (SASP), increased epithelial-mesenchymal transition (EMT), acquisition of early embryonic-like features, and multilineage differentiation potential into ectoderm, mesoderm, and endoderm. PGCC-derived progeny exhibited dose- and time-dependent changes in proliferative behavior, aggressive phenotypes in vitro, along with time-dependent tumorigenic potential in vivo. Remarkably, at the tissue level, PGCCs also underwent spatial nuclear reorganization and self-organization into morphologically defined glandular epithelial structures exhibiting varying degrees of tissue maturation, reminiscent of early embryonic development. Silencing IL1β, IL6, or IL8, or pharmacologically inhibiting their receptors, suppressed PGCC formation, budding, EMT, and embryonic-like reprogramming associated with tissue morphogenesis. Furthermore, NAMPT emerged as a key regulator of embryonic-like stemness, glandular morphogenesis, and structural expansion. Together, these findings reveal that therapeutic stress activates a PGCC life cycle capable of generating two divergent outcomes: resistant tumor regeneration through clonal selection of undifferentiated tumor cells and organized tissue differentiation through spatial nuclear reprogramming. Our study establishes a conceptual framework linking therapy-induced polyploidization, developmental plasticity, and resistance generation at higher order tissue levels.
中文摘要:为阐明治疗诱导耐药背后的机制,研究考察了微管去稳定剂长春新碱(VCR)处理后多倍体巨癌细胞(PGCC)生命周期的时序动态。纵向活细胞荧光成像显示,VCR诱导的有丝分裂抑制激活了一种独特的PGCC生命周期,其特征为核扩增和渐进性细胞重编程。随后PGCC进入类衰老状态,伴随衰老相关分泌表型(SASP)增强、上皮–间质转化(EMT)增加、早期胚胎样特征获得,以及向外胚层、中胚层和内胚层多向分化的潜能。PGCC来源的子代在增殖行为上呈剂量和时间依赖性变化,体外表现侵袭性表型,体内致瘤潜能随时间变化。在组织层面,PGCC还发生空间核重排并自组织形成形态学上明确的腺上皮结构,这些结构呈现不同程度的组织成熟,类似早期胚胎发育。沉默IL1β、IL6或IL8,或药理学抑制其受体,可抑制PGCC形成、出芽、EMT以及与组织形态发生相关的胚胎样重编程。NAMPT成为胚胎样干性、腺体形态发生和结构扩张的关键调控因子。这些发现表明,治疗应激激活的PGCC生命周期可产生两种不同结局:通过未分化肿瘤细胞的克隆选择实现耐药性肿瘤再生,以及通过空间核重编程实现有序组织分化。该研究建立了连接治疗诱导多倍化、发育可塑性与更高层次组织水平耐药产生的概念框架。
The serine/glycine biosynthesis pathway plays a critical role in tumor progression and has emerged as a promising therapeutic target in cancer. Phosphoserine aminotransferase 1 (PSAT1) is a key enzyme in this pathway and has been implicated in the progression of multiple malignancies. However, the functional significance and underlying mechanisms of PSAT1 in hepatocellular carcinoma (HCC) remain largely undefined. In this study, we identify PSAT1 as a critical determinant of ferroptosis resistance in HCC. Elevated PSAT1 expression was positively associated with ferroptosis resistance and poor clinical outcomes in patients with HCC. Both in vitro and in vivo functional assays demonstrated that PSAT1 promotes HCC cell proliferation and suppresses ferroptosis through an HSPA5-mediated adaptive endoplasmic reticulum response. Mechanistically, PSAT1 interacts with and stabilizes BCLAF1, thereby enhancing HSPA5 messenger RNA stability and translation in HCC cells. In addition, PSAT1 remodels the tumor immune microenvironment by promoting M2 tumor-associated macrophage polarization and regulatory T cell infiltration. PSAT1 up-regulates NRF2 expression, which directly binds to the CCL5 promoter to enhance CCL5 production and secretion by tumor cells, thereby fostering an immunosuppressive microenvironment. Therapeutically, pharmacological inhibition of PSAT1 with aminooxyacetic acid markedly potentiated the antitumor efficacy of anti-PD-1 immunotherapy. Our study reveals a previously unrecognized role of PSAT1 in coordinating ferroptosis resistance and immune escape in HCC and highlights therapeutic targeting of PSAT1 as a promising strategy for HCC treatment.
中文摘要:丝氨酸/甘氨酸生物合成通路在肿瘤进展中起关键作用,并已成为有前景的癌症治疗靶点。磷酸丝氨酸氨基转移酶1(PSAT1)是该通路中的关键酶,与多种恶性肿瘤的进展相关,但其在肝细胞癌(HCC)中的功能意义和潜在机制仍大多不明确。本研究发现PSAT1是HCC铁死亡抵抗的关键决定因素。PSAT1表达升高与HCC患者铁死亡抵抗及不良临床结局呈正相关。体外和体内功能实验表明,PSAT1通过HSPA5介导的适应性内质网反应促进HCC细胞增殖并抑制铁死亡。机制上,PSAT1与BCLAF1相互作用并使其稳定,从而增强HCC细胞中HSPA5信使RNA的稳定性和翻译。PSAT1还通过促进M2型肿瘤相关巨噬细胞极化和调节性T细胞浸润重塑肿瘤免疫微环境。PSAT1上调NRF2表达,NRF2直接结合CCL5启动子,增强肿瘤细胞CCL5的产生和分泌,从而促成免疫抑制微环境。治疗上,用氨基氧乙酸对PSAT1进行药理抑制,显著增强了抗PD-1免疫治疗的抗肿瘤疗效。研究揭示了PSAT1在协调HCC铁死亡抵抗和免疫逃逸中的先前未被认识的作用,并强调靶向PSAT1是HCC治疗的有前景策略。
Intratumoral microbial antigens, which mimic tumor antigens, can be presented by human leukocyte antigen (HLA) molecules, thereby eliciting antitumor immune responses. However, a comprehensive pan-cancer characterization of such molecularly mimicking microbial epitopes is still lacking. Here, we construct a pan-cancer microbial epitope landscape from 1190 samples across 24 cancer types. Pan-cancer analyses reveal that microbial epitopes exhibit higher hydrophobicity, aliphatic indices, and stability than human epitopes. Nine HLA-I alleles tend to bind microbial epitopes, and HLA-C alleles show a stronger tendency to present microbial epitopes than HLA-A and HLA-B alleles. Moreover, we reveal that microbial species capable of generating HLA-I epitopes are more prevalent in tumors, that broadly detected epitopes span more cancer types, and that multiple microbial genera generate numerous immunogenic epitopes. Notably, homologous microbial epitopes and tumor antigens elicit cross-reactive T cell responses, and experimental evidence demonstrates that microbial epitopes exhibit enhanced immunogenicity and antitumor efficacy. Overall, our findings provide a foundation for microbial epitope vaccine development, offering insights for cancer prevention and therapy.
中文摘要:瘤内微生物抗原可模拟肿瘤抗原,并被人类白细胞抗原(HLA)分子提呈,从而引发抗肿瘤免疫应答。此类分子模拟微生物表位的泛癌特征仍缺乏系统描述。本研究基于24种癌症类型的1190份样本构建泛癌微生物表位图谱。泛癌分析显示,微生物表位较人类表位具有更高的疏水性、脂肪族指数和稳定性。9种HLA-I等位基因倾向结合微生物表位,HLA-C等位基因提呈微生物表位的倾向强于HLA-A和HLA-B等位基因。可产生HLA-I表位的微生物物种在肿瘤中更常见,广泛检测到的表位覆盖更多癌种,多个微生物属可产生大量免疫原性表位。同源微生物表位与肿瘤抗原可引发交叉反应性T细胞应答,实验证据表明微生物表位具有增强的免疫原性和抗肿瘤效果。这些发现为微生物表位疫苗开发提供基础,并为癌症预防和治疗提供线索。
Immunotherapy is increasingly reshaping the therapeutic landscape of clinical oncology by inducing effective tumor regression and durable responses in various types of human cancers. However, a substantial fraction of patients resist immunotherapy, or even experience relapse after an initial response. Clinically, the conventional biomarkers often exhibit limited predictive accuracy and poor transferability across tumor types. These limitations highlight the urgent need for more robust, data-driven strategies to decipher tumor-immune dynamics and guide personalized treatment. Recently, artificial intelligence (AI) has emerged as a transformative paradigm in immuno-oncology, offering scalable solutions to decode high-dimensional and heterogeneous biomedical data. The evolution of AI can be broadly divided into six key stages: early machine learning (ML) classifiers, unsupervised representation learning, graph-based modeling of cell-cell interactions, multimodal foundation and biomedical language models, reinforcement and active learning paradigms, and AI virtual cells. At the molecular level, AI facilitates the integration of genomics, transcriptomics, proteomics, and spatially resolved single-cell omics, supporting fine-grained reconstruction of the tumor immune microenvironment (TIME). At the clinical interface, the application of deep learning (DL) in liquid biopsy, digital pathology, and radiologic imaging has advanced response prediction, biomarker discovery, and early detection of immune-related adverse events (irAEs), driving personized immunotherapy. This review synthesizes recent progress in AI-guided precision immunotherapy across molecular, cellular, and phenotypic area. By outlining key methodological advances and translational opportunities, we highlight that multimodal AI frameworks can pave the way toward the more interpretable, robust, and individualized immunotherapy strategies for cancer treatment.
中文摘要:免疫治疗通过诱导有效的肿瘤消退和持久缓解,正在重塑临床肿瘤学的治疗格局,并在多种人类癌症中显示出疗效。然而仍有相当比例的患者对免疫治疗耐药,或在初始缓解后出现复发。临床上,传统生物标志物的预测准确性有限,跨瘤种迁移能力也较差。这些局限使人们迫切需要更稳健的数据驱动策略,用以解析肿瘤与免疫系统的动态并指导个体化治疗。近年来,人工智能(AI)成为免疫肿瘤学中的变革性范式,为解读高维、异质的生物医学数据提供了可扩展的解决方案。AI的演进大致可分为六个关键阶段:早期机器学习分类器、无监督表征学习、基于图的细胞间相互作用建模、多模态基础模型与生物医学语言模型、强化学习与主动学习范式,以及AI虚拟细胞。在分子层面,AI推动基因组学、转录组学、蛋白质组学与空间分辨单细胞组学的整合,支持对肿瘤免疫微环境(TIME)的精细重建。在临床环节,深度学习(DL)在液体活检、数字病理与放射影像中的应用,推进了疗效反应预测、生物标志物发现以及免疫相关不良事件(irAEs)的早期识别,推动个体化免疫治疗。本综述汇总了AI引导的精准免疫治疗在分子、细胞与表型层面的近期进展。通过梳理关键方法学进展与转化机会,我们强调多模态AI框架可为更可解释、更稳健、更个体化的癌症免疫治疗策略铺路。
2消化系统肿瘤 (79篇)
临床研究 (33篇)
Professional oncology societies have invested in initiatives to enhance the racial and ethnic representation of the oncology physician workforce, particularly since 2020. Whether these initiatives have contributed to changes in the racial or ethnic representation among oncology trainees and nononcology trainees who provide cancer-related care is unclear. To assess trends in the distribution of underrepresented in medicine (URiM) physician trainees over time across oncology and nononcology specialties, with a focus on trends pre- and post-2020. The URiM category included individuals who identified as American Indian or Alaskan Native; Black or African American; Hispanic, Latino, or of Spanish origin; or Native Hawaiian or Pacific Islander race or ethnicity. This repeated cross-sectional study used race and ethnicity data from the Accreditation Council for Graduate Medical Education for trainees in medical, radiation, or surgical oncology; general surgery; and primary care from 2011 to 2025. Data were analyzed from April 2025 to August 2026. The proportion of URiM trainees was calculated by year and specialty. Segmented logistic regression was used to estimate the odds of being URiM overall and by specialty. Overall changes in the likelihood of a trainee being URiM post-2020 (level change) and the annual trend post-2020 (slope change) were estimated. There were 658 891 trainee observations in the cohort, of whom 113 937 trainees (17.3%) were URiM. The percentage of trainees who were URiM was relatively stable from 2011 (5435 trainees [16.1%]) to 2020 (8192 trainees [16.4%]), then increased to 13 345 trainees (20.4%) in 2025. After 2020, there was an overall 5% increase in the likelihood of a trainee being URiM (OR, 1.05; 95% CI, 1.03-1.08), as well as a 5% annual increase (OR, 1.05; 95% CI, 1.05-1.06). Within individual specialties, significant post-2020 increases were observed in surgical oncology and general surgery. The post-2020 increase was greatest in radiation oncology (OR, 1.20; 95% CI, 1.11-1.30). There was no statistically significant change in URiM representation among medical oncology trainees over the study period. This cross-sectional study found that the proportion of trainees who provide cancer care identifying as URiM increased from 2011 to 2025, particularly since 2020; however, URiM representation still did not match the diversity of the general US population in 2025.
中文摘要:专业肿瘤学会持续投入项目,以提升肿瘤内科医师队伍的种族和族裔代表性,2020年以来尤为明显。这些项目是否改变了肿瘤学培训生及提供肿瘤相关照护的非肿瘤学培训生的种族或族裔代表性,尚不清楚。研究评估医学领域代表性不足(URiM)医师培训生在肿瘤学与非肿瘤学专科中的分布随时间的变化趋势,重点关注2020年前后的趋势。URiM包括自认为美洲印第安人或阿拉斯加原住民、黑人或非裔美国人、西班牙裔、拉丁裔或西班牙来源,或夏威夷原住民或太平洋岛民种族或族裔者。该重复横断面研究使用美国毕业后医学教育认证委员会2011年至2025年医学肿瘤学、放射肿瘤学、外科肿瘤学、普通外科和初级保健培训生的种族与族裔数据。数据分析时间为2025年4月至2026年8月。按年份和专科计算URiM培训生比例。采用分段logistic回归估计总体及分专科成为URiM的比值比。估计2020年后培训生成为URiM可能性的总体变化(水平变化)及2020年后的年度趋势(斜率变化)。队列共包含658891例培训生观察,其中113937名培训生(17.3%)为URiM。URiM培训生比例从2011年(5435名,16.1%)到2020年(8192名,16.4%)相对稳定,2025年增至13345名(20.4%)。2020年后,培训生成为URiM的可能性总体增加5%(OR,1.05;95% CI,1.03-1.08),年增加5%(OR,1.05;95% CI,1.05-1.06)。在各专科内,外科肿瘤学和普通外科在2020年后出现显著增加。放射肿瘤学增幅最大(OR,1.20;95% CI,1.11-1.30)。医学肿瘤学培训生的URiM代表性在研究期间无统计学显著变化。该横断面研究发现,提供肿瘤照护的培训生中自认为URiM的比例从2011年至2025年上升,2020年以来尤为明显;但2025年URiM代表性仍未达到美国一般人群的多样性水平。
The cost-utility of a mature cancer screening programme can shift as disease incidence, costs, and population risk change. We examined how these changes affected Korea's National Cancer Screening Program (NCSP) for gastric cancer by comparing two hypothetical cohorts parameterized with 2012 and 2022 conditions. Two structurally identical state-transition models simulated biennial endoscopic screening versus no organised screening in adults aged 40-79 years over a lifetime horizon, incorporating period-specific screen-detected health-state distributions, effective screening sensitivity, NCSP participation, and treatment costs. Incremental cost-utility ratios (ICURs) per quality-adjusted life-years (QALYs) were calculated in period-specific prices. For cross-period comparison, incremental costs were converted to 2025 KRW, and net monetary benefit (NMB) was calculated at a willingness-to-pay threshold of KRW 50 million/QALY(USD 40,000). The ICUR increased from KRW 9.62 million/QALY(USD 7,694) in the 2012 model to KRW 48.62 million/QALY(USD 38,895) in the 2022 model, and NMB in 2025 KRW decreased from KRW 1.73 million to KRW -0.05 million per person. In 2022, the ICUR was KRW 28.20 million/QALY(USD 22,558) for men and KRW 84.37 million/QALY(USD 67,497) for women. The increase was driven mainly by a shift in the screen-detected histologic composition of neoplasia toward lower-risk non-adenomatous findings and by higher costs. The cost-effectiveness of uniform biennial endoscopic screening in Korea declined substantially between 2012 and 2022 and the 2022 results were markedly less favourable for women than for men. These findings support periodic reassessment of mature screening programmes and further evaluation of differentiated screening approaches.
中文摘要:成熟癌症筛查项目的成本效用会随疾病发病率、成本和人群风险变化而改变。我们通过比较以2012年和2022年条件参数化的两个假设队列,考察这些变化如何影响韩国国家癌症筛查项目(NCSP)的胃癌筛查。两个结构相同的状态转移模型模拟40-79岁成人终身时间范围内每两年一次内镜筛查与无组织筛查的比较,纳入各时期筛查检出健康状态分布、有效筛查灵敏度、NCSP参与率和治疗成本。按各时期价格计算每质量调整生命年(QALY)的增量成本效用比(ICUR)。为进行跨时期比较,将增量成本折算为2025年韩元,并按每QALY 5000万韩元(4万美元)的支付意愿阈值计算净货币收益(NMB)。ICUR从2012年模型的每QALY 962万韩元(7694美元)升至2022年模型的每QALY 4862万韩元(38895美元),2025年韩元计价的人均NMB从173万韩元降至-5万韩元。2022年,男性ICUR为每QALY 2820万韩元(22558美元),女性为每QALY 8437万韩元(67497美元)。ICUR上升主要由筛查检出新生物的组织学构成向低风险非腺瘤性发现转移以及成本上升驱动。韩国统一每两年一次内镜筛查的成本效果在2012年至2022年间显著下降,2022年结果对女性明显不如男性有利。这些发现支持对成熟筛查项目进行定期再评估,并进一步评价差异化筛查策略。
Exercise induces a variety of changes in the tumor microenvironment, with beneficial effects in several tumor types. However, a better understanding of the clinical effects of exercise and mediating mechanisms is needed to maximize the utility of exercise for patients. In this study, we analyzed tumors from patients with pancreatic ductal adenocarcinoma (PDAC) in the PancFit trial and identified an exercise-induced reduction in cells expressing α-smooth muscle actin (αSMA). Interrogation of changes in tumor stromal composition with exercise in a murine PDAC model revealed a microbially influenced reduction in αSMA+ cells and Il6-expressing inflammatory cancer-associated fibroblasts (iCAF). Cholic acid, a microbial bile acid, was increased in both patients and murine models with exercise, as a potential mediator of exercise-induced reduction in iCAFs. Consistent with these findings, patients that exercised more also exhibited fewer iCAFs and lower tumor IL6 expression, supporting a stromal remodeling effect of physical activity. In summary, this study demonstrates that the antitumor effect of exercise includes stromal remodeling, which is affected by microbial metabolites. Exercise-induced changes in cancer-associated fibroblasts vary with microbiome composition, which may explain the heterogeneity in tumor responses to exercise and could guide future exercise trials in cancer patients.
中文摘要:运动可诱导肿瘤微环境发生多种变化,并在多种肿瘤中产生有益作用。要充分发挥运动对患者的效用,仍需更好理解运动的临床效应及其中介机制。该研究分析PancFit试验中胰腺导管腺癌(PDAC)患者的肿瘤,发现运动可减少表达α-平滑肌肌动蛋白(αSMA)的细胞。在小鼠PDAC模型中考察运动引起的肿瘤基质组成变化,发现αSMA+细胞和表达Il6的炎症性癌相关成纤维细胞(iCAF)减少,且这一变化受微生物影响。微生物胆汁酸胆酸在运动和运动的小鼠模型中均升高,可能是运动诱导iCAF减少的潜在介质。与这些发现一致,运动更多的患者iCAF更少、肿瘤IL6表达更低,支持体力活动具有基质重塑作用。该研究显示运动的抗肿瘤作用包括基质重塑,并受微生物代谢物影响。运动诱导的癌相关成纤维细胞变化随微生物组组成而不同,这可能解释肿瘤对运动反应的异质性,并可为未来癌症患者运动试验提供指导。
Cancer remains a major health concern worldwide. Shear-wave elastography (SWE) holds promise for cancer detection by quantifying linear elastic changes in tissue through shear-wave (SW) velocity estimation. However, shear viscosity and nonlinearity are often over-looked, despite their potential as additional biomarkers. This study evaluates the visco-hyperelastic properties of soft tissue, including linear shear modulus, shear viscosity, and shear nonlinearity. We propose using Volterra kernels to characterize local nonlinear SW dynamics, with kernel identification based on SW particle velocity measurements at adjacent locations. The method was validated using in-silico simulations and in-vitro gelatin phantoms. To evaluate its clinical relevance, we applied the method for prostate cancer (PCa) detection. To our knowledge, this is the first in-vivo assessment of voxel-based visco-hyperelastic properties of the prostate. In 90 patients, our results indicated that the linear kernel correlated with the linear shear modulus, while the quadratic kernel reflected both viscosity and nonlinearity. A convolutional neural network trained on these parameters with registered histopathology as ground truth achieved area under the receiver operating characteristic curve (AUC) values of 0.60 (95% confidence interval [CI]: 0.57, 0.62) and 0.66 (95% CI: 0.64, 0.68) for PCa detection, respectively-both significantly outperforming the linear shear modulus (AUC of 0.54; 95% CI, 0.52 to 0.56). Our findings suggest that Volterra kernels reflect information related to the visco-hyperelastic properties of prostate tissue, highlighting the potential of viscosity and nonlinearity as additional biomarkers for PCa detection.
中文摘要:癌症仍是全球重大健康问题。剪切波弹性成像(SWE)通过估计剪切波(SW)速度来量化组织线性弹性变化,有望用于癌症检测。然而,剪切黏性和非线性常被忽视,尽管它们可能作为额外生物标志物。该工作评估软组织的黏超弹性特性,包括线性剪切模量、剪切黏性和剪切非线性。我们提出使用Volterra核表征局部非线性SW动力学,核识别基于相邻位置的SW粒子速度测量。该方法通过计算机仿真和体外明胶体模验证。为评估临床相关性,我们将该方法应用于前列腺癌(PCa)检测。据我们所知,这是首次在体内评估前列腺基于体素的黏超弹性特性。在90例患者中,结果显示线性核与线性剪切模量相关,而二次核反映黏性和非线性。以配准组织病理学为金标准,在这些参数上训练的卷积神经网络用于PCa检测的受试者工作特征曲线下面积(AUC)分别为0.60(95%置信区间[CI]:0.57,0.62)和0.66(95% CI:0.64,0.68),均显著优于线性剪切模量(AUC为0.54;95% CI,0.52至0.56)。研究结果表明,Volterra核反映与前列腺组织黏超弹性特性相关的信息,突显黏性和非线性作为PCa检测额外生物标志物的潜力。
Maximal safe glioma resection requires distinguishing infiltrative tumor from surrounding brain. Visible 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX (PpIX) fluorescence guides surgery, but low or heterogeneous PpIX accumulation and optical attenuation limit sensitivity. We tested whether combined fluorescence spectroscopy (FS) and diffuse reflectance spectroscopy (DRS) could improve tumor-tissue discrimination beyond visible fluorescence. Thirty-three patients with historically classified low-grade (LGG), high-grade (HGG), or recurrent glioma underwent 5-ALA-guided surgery. A handheld bimodal probe acquired in vivo FS and DRS from biopsy-paired and navigation-defined presumed non-tumor sites. A light-transport model estimated optical properties, corrected fluorescence, and quantified biomarkers. Five predictor representations were evaluated using supervised machine learning for non-tumor versus tumor discrimination and sequential LGG versus HGG classification with patient-grouped leave-one-patient-out cross-validation. Patient-clustered bootstrapping compared FS+DRS with visible fluorescence. Across 212 sites, FS+DRS achieved 85.82% sensitivity, 74.36% specificity, 80.09% balanced accuracy, and 0.81 AUROC for tumor discrimination. FS and DRS alone achieved 73.16% and 66.17% balanced accuracy, respectively. Compared with visible fluorescence, FS+DRS increased sensitivity by 34.3 percentage points (95% CI, 19.3-47.5; p < 0.001), while specificity differed by - 11.5 points (95% CI, -27.8-4.0; p = 0.2). FS+DRS detected 55/65 nonfluorescent tumor sites, including 19/23 historical LGG sites. For grade discrimination, biomarkers achieved 71.98% balanced accuracy and 0.71 AUROC. Combined FS+DRS improved tumor detection and identified histology-positive tumor not visible with standard fluorescence. Prospective multicenter evaluation should use a locked model, molecularly classified cohorts, prespecified clinical endpoints, and spatial registration to determine whether the added signal improves intraoperative decisions and patient outcomes.
中文摘要:胶质瘤最大安全切除需要区分浸润性肿瘤与周围脑组织。可见的5-氨基乙酰丙酸(5-ALA)诱导原卟啉IX(PpIX)荧光可引导手术,但PpIX积聚低或不均一以及光学衰减限制了灵敏度。我们检验联合荧光光谱(FS)与漫反射光谱(DRS)能否在可见荧光之外改善肿瘤-组织区分。33例经历史分类为低级别(LGG)、高级别(HGG)或复发胶质瘤的患者接受了5-ALA引导手术。手持双模态探头从活检配对位点和导航定义的假定非肿瘤位点获取体内FS与DRS。光传输模型估计光学特性、校正荧光并量化生物标志物。采用监督机器学习评估五种预测变量表征,用于非肿瘤与肿瘤区分以及序贯LGG与HGG分类,并使用按患者分组的留一患者交叉验证。以患者聚类自助法比较FS+DRS与可见荧光。在212个位点中,FS+DRS区分肿瘤的灵敏度为85.82%,特异度为74.36%,平衡准确率为80.09%,AUROC为0.81。单独FS和DRS的平衡准确率分别为73.16%和66.17%。与可见荧光相比,FS+DRS使灵敏度提高34.3个百分点(95% CI,19.3-47.5;p < 0.001),特异度差异为-11.5个百分点(95% CI,-27.8-4.0;p = 0.2)。FS+DRS检出55/65个无荧光肿瘤位点,其中包括19/23个历史LGG位点。对于分级判别,生物标志物达到71.98%平衡准确率和0.71 AUROC。联合FS+DRS改善了肿瘤检出,并识别出标准荧光不可见的组织学阳性肿瘤。前瞻性多中心评估应使用锁定模型、分子分型队列、预设临床终点和空间配准,以确定新增信号是否改善术中决策与患者结局。
Eileen M. O'Reilly, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, NY, whose research focuses on therapies for pancreas cancer, spoke with Cancer Discovery's Suzanne Rose about daraxonrasib combinations, treatment strategies under development, the need for genomic testing, and what big headlines might come in pancreas cancer.
中文摘要:纽约纪念斯隆凯特琳癌症中心的肿瘤内科医生Eileen M. O'Reilly(医学博士)研究方向为胰腺癌治疗。她与《Cancer Discovery》的Suzanne Rose交谈,内容涉及daraxonrasib联合治疗、正在开发的治疗策略、基因组检测需求,以及胰腺癌可能出现的重大头条。
Prostate cancer is characterized by profound clinical and molecular heterogeneity. Although its genomic heterogeneity is well characterized, its epigenomic heterogeneity remains less understood. We therefore created a compendium of 3,001 multiancestry prostate methylomes spanning normal tissue through localized disease of all grades to polymetastatic disease. A subset of 884 samples had multiomic DNA and/or RNA characterization. We identify four epigenomic subtypes that risk-stratify patients and reflect distinct evolutionary trajectories. We demonstrate extensive regulatory interplay between DNA copy number and methylation, with transcriptional consequences that vary across genes and disease stages. We define epigenetic dysregulation signatures for 15 important clinicomolecular features, creating predictive models for each. For example, we identify specific epigenetic features that predict patient outcome and are synergistic with clinical prognostic features. These results define a complex interplay between tumor genetics and epigenetics that converges to modify gene expression programs and clinical presentation, in part through modulation of epigenetic aging. We define the largest prostate cancer methylome resource to date, revealing four epigenomic subtypes that stratify cancers by their genetics, evolution, and clinical phenotypes. These data demonstrate that genome-epigenome interactions are stage-dependent, positioning DNA methylation as a central, clinically informative driver of prostate cancer heterogeneity.
中文摘要:前列腺癌具有显著的临床与分子异质性。其基因组异质性已得到较好刻画,表观基因组异质性仍认识不足。研究者建立了包含3,001例多祖先前列腺癌甲基化组的汇编,覆盖正常组织、各级别局限性病变至多转移性疾病;其中884例样本具备DNA和/或RNA多组学特征。研究识别出四种表观基因组亚型,可对患者进行风险分层,并反映不同的演化轨迹。DNA拷贝数与甲基化之间存在广泛的调控互作,其转录后果随基因和疾病阶段而变化。研究为15项重要临床分子特征定义了表观遗传失调特征谱,并为每项特征构建预测模型。例如,识别出可预测患者结局并与临床预后特征具有协同作用的特定表观遗传特征。这些结果揭示了肿瘤遗传学与表观遗传学之间的复杂互作,二者汇聚于改变基因表达程序和临床表现,部分通过调节表观遗传衰老实现。研究建立了迄今最大的前列腺癌甲基化组资源,揭示四种表观基因组亚型,可依据遗传学、演化和临床表型对癌症进行分层。这些数据表明基因组—表观基因组互作具有阶段依赖性,并将DNA甲基化定位为前列腺癌异质性的核心且具有临床信息价值的驱动因素。
Background The incidence of lymph node (LN) metastasis in patients with part-solid nodules (PSNs) is known to be low, which makes the intraoperative evaluation of LNs a controversial issue. Purpose To investigate the incidence of LN metastasis and explore clinical-radiologic predicting factors for LN metastasis in PSN lung adenocarcinomas with a solid portion diameter of 30.0 mm or less in a large surgical study sample. Materials and Methods This retrospective study included patients with part-solid lung adenocarcinomas with solid portion diameters of 30.0 mm or less on preoperative CT images from July 2023 to December 2024. For each PSN, overall tumor size, solid portion diameter, consolidation-to-tumor ratio (CTR), location, margin, shape, spiculation, lobulation, pleural retraction, bubble-like lucency, and air bronchogram were independently evaluated by two chest radiologists blinded to clinical information and pathology results. Univariable and multivariable logistic regression analyses were performed. Diagnostic performance was evaluated using receiver operating characteristic curve, calibration, and decision curve analysis. Results This study included 1444 patients (median age, 59 years; IQR, 51-67 years; 931 women). The frequency of LN metastasis was 4.7% (68 of 1444 patients). None of the 115 patients with a CTR of 0.25 or less had LN metastasis (N1: 0 of 115; N2: 0 of 115). Rarely (0.2%, one of 552), LN metastasis was found in patients with a solid portion diameter of 6.0 mm or less. Solid portion diameter was the only independent predictor of LN metastasis (odds ratio, 1.25; 95% CI: 1.20, 1.31) in multivariable analysis and showed a superior diagnostic performance compared with CTR (area under the receiver operating characteristic curve, 0.86 [95% CI: 0.82, 0.90] vs 0.75 [95% CI: 0.68, 0.80]; P < .001), along with better calibration (Brier score, 0.039 vs 0.044) and greater net benefit. The clinical actionable cutoff for solid portion diameter was 7.3 mm (sensitivity, 95.6%; specificity, 49.6%). Conclusion Solid portion diameter had a superior diagnostic performance compared with CTR in predicting LN metastasis in patients with part-solid lung adenocarcinomas of solid portion diameter of 30.0 mm or less at CT. © RSNA, 2026 Supplemental material is available for this article.
中文摘要:背景:部分实性结节(PSN)患者淋巴结转移发生率较低,使术中淋巴结评估存在争议。目的:在大样本手术研究样本中,探讨实性部分直径≤30.0 mm的部分实性肺腺癌淋巴结转移发生率,并探索其临床-影像学预测因素。材料与方法:本回顾性研究纳入2023年7月至2024年12月术前CT显示实性部分直径≤30.0 mm的部分实性肺腺癌患者。每例PSN的总体肿瘤大小、实性部分直径、实性成分与肿瘤直径比(CTR)、位置、边缘、形态、毛刺征、分叶征、胸膜牵拉、空泡样透亮影和空气支气管征由两名胸部影像科医师在不知晓临床信息和病理结果的情况下独立评估。进行单因素和多因素logistic回归分析。采用受试者工作特征曲线、校准和决策曲线分析评估诊断性能。结果:研究纳入1444例患者(中位年龄59岁;IQR 51-67岁;931例女性)。淋巴结转移发生率为4.7%(68/1444)。CTR≤0.25的115例患者均无淋巴结转移(N1:0/115;N2:0/115)。实性部分直径≤6.0 mm的患者中淋巴结转移罕见(0.2%,1/552)。多因素分析中,实性部分直径是淋巴结转移的唯一独立预测因素(OR 1.25;95% CI 1.20, 1.31),诊断性能优于CTR(AUC 0.86 [95% CI 0.82, 0.90] vs 0.75 [95% CI 0.68, 0.80];P < .001),校准更好(Brier评分0.039 vs 0.044),净获益更大。实性部分直径的临床可操作截断值为7.3 mm(敏感度95.6%;特异度49.6%)。结论:在CT显示实性部分直径≤30.0 mm的部分实性肺腺癌患者中,实性部分直径预测淋巴结转移的诊断性能优于CTR。© RSNA, 2026 补充材料可在线获取。
This retrospective study was designed to evaluate the safety and efficacy of adding a thalidomide-based cocktail (the TCC cocktail-comprising thalidomide, carmofur, and compound mylabris capsule) to transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) in real-world practice. Data from 433 unresectable HCC patients treated with TACE at four hospitals were collected (from March 2014 to May 2018, followed up to July 2023) and overall survival (OS), overall response rate (ORR), disease control rate (DCR), and adverse events (AEs) were analyzed. After 1: 2 propensity score matching (PSM), 114 patients in the cocktail group (TACE + TCC) were compared with 228 patients in the control group (TACE alone). The median OS of the cocktail group was significantly better than that of the control group (p < 0.001; 42.5 vs. 12.5 months) after PSM. ORR (29.8% vs. 21.1%, p = 0.081) and DCR (79.8% vs. 61.8%, p < 0.001) at 6 months were also better in the cocktail group after PSM. Moreover, no life-threatening AEs (grade 4 or 5) occurred in either group. In this retrospective cohort, the addition of the TCC cocktail to TACE was associated with improved survival and tumor response, with a manageable safety profile.
中文摘要:这项回顾性研究评估在真实世界实践中,将基于沙利度胺的联合用药方案(TCC方案,即沙利度胺、卡莫氟与复方斑蝥胶囊)加入经动脉化疗栓塞(TACE)治疗不可切除肝细胞癌的安全性与疗效。研究收集了四家医院2014年3月至2018年5月接受TACE治疗的433例不可切除肝细胞癌患者资料,随访至2023年7月,分析总生存期、总体缓解率、疾病控制率与不良事件。经1:2倾向性评分匹配后,联合用药组(TACE+TCC)114例与对照组(单用TACE)228例进行比较。匹配后联合用药组中位总生存期显著优于对照组(p<0.001;42.5个月对12.5个月)。匹配后6个月时联合用药组的总体缓解率(29.8%对21.1%,p=0.081)与疾病控制率(79.8%对61.8%,p<0.001)也更优。两组均未出现危及生命的不良事件(4级或5级)。在这一回顾性队列中,TACE基础上加用TCC方案与生存期及肿瘤缓解的改善相关,安全性可控。
Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with adverse liver and non-liver outcomes, but the impact of coexisting sarcopenia-related abnormalities (e.g., low muscle strength [MS], muscle mass, and physical performance) remains unclear. In a prospective UK Biobank cohort (n = 438,748), we evaluated their joint associations with incidence and risks of all-cause mortality, cirrhosis, hepatocellular carcinoma (HCC), cardiovascular disease (CVD), chronic kidney disease (CKD), non-liver cancers, and obesity-related cancers across MASLD and sarcopenia-related abnormality status. Over a median follow-up of 13.8 years, 401 HCC, 1714 cirrhosis, 39,534 CVD, 19,637 CKD, 38,240 non-liver cancers, 12,536 obesity-related cancers, and 34,801 deaths occurred. A stepwise increase in both incidence and adjusted risk of liver and non-liver outcomes was observed across MASLD and sarcopenia strata. Within the coexistence group, the obesity (vs. non-obesity) subgroup generally had higher risks. For example, for cirrhosis, adjusted hazard ratios increased from 3.93 to 7.36 then 8.48 with MASLD alone, coexisting MASLD with low MS overall and coexisting MASLD, low MS and obesity, respectively. Similar findings were observed in external validation analyses using the 2011-2018 US National Health and Nutrition Examination Survey cohort. Together, these observations inform risk stratification strategy and management of MASLD to include sarcopenia assessment.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)与不良肝脏及非肝脏结局相关,但合并肌少症相关异常(如低肌肉力量、肌肉量和身体功能)的影响仍不清楚。研究基于前瞻性英国生物银行队列(n=438,748),评估在不同MASLD与肌少症相关异常状态下,这些因素与全因死亡、肝硬化、肝细胞癌、心血管疾病、慢性肾脏病、非肝脏癌症及肥胖相关癌症的发病率和风险的联合关联。中位随访13.8年期间,发生401例肝细胞癌、1714例肝硬化、39,534例心血管疾病、19,637例慢性肾脏病、38,240例非肝脏癌症、12,536例肥胖相关癌症和34,801例死亡。随着MASLD与肌少症分层递进,肝脏和非肝脏结局的发病率及校正后风险均呈逐步升高。在共存组内,肥胖亚组通常较非肥胖亚组风险更高。以肝硬化为例,仅MASLD、MASLD合并低肌肉力量、MASLD合并低肌肉力量及肥胖时,校正风险比由3.93升至7.36,再升至8.48。利用2011—2018年美国国家健康与营养调查队列进行的外部验证分析也观察到类似结果。这些观察结果提示,MASLD的风险分层策略和管理应纳入肌少症评估。
AbstractUsing data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program, we examined colorectal cancer incidence rates in the United States between 2000 and 2023. SEER 21 covers 45.8% of the U.S. population. The age-adjusted incidence rate was 55.2 per 100,000 (95% CI, 54.8 to 55.6) in 2000, 36.7 per 100,000 (95% CI, 36.4 to 37.0) in 2022, and 38.3 per 100,000 (95% CI, 38.0 to 38.6) in 2023. The apparent increase in 2023 was the first since the inception of SEER 21 and warrants additional surveillance and investigation.
中文摘要:利用美国国家癌症研究所监测、流行病学和最终结果(SEER)项目的数据,分析了2000年至2023年美国结直肠癌的发病率。SEER 21覆盖美国45.8%的人口。年龄标化发病率在2000年为每10万人55.2例(95% CI,54.8至55.6),2022年为每10万人36.7例(95% CI,36.4至37.0),2023年为每10万人38.3例(95% CI,38.0至38.6)。2023年出现的上升是SEER 21启动以来的首次,需要进一步监测和调查。
The impact of cancer therapy on chronic health condition (CHC) burden in childhood cancer survivors is well-established; however, the role of neighborhood-level social determinants of health (SDOH) remains underexplored. In this single-center cohort study in the U.S., we analyzed 2508 survivors enrolled in the St. Jude Lifetime Cohort Study between 9/13/2007 and 4/20/2020, who were ≥5 years from diagnosis, ≥18 years of age, and had ≥2 clinical assessments. SDOH encompassed social vulnerability (Social Vulnerability Index) and environmental/healthcare access vulnerabilities (e.g., primary care physician [PCP] availability, food inaccessibility), categorized into quartiles. A total of 177 clinically assessed CHCs were aggregated into 48 CHC groups and a global burden. Multivariable logistic regressions examined associations between baseline SDOH and CHC progression from baseline to follow-up, adjusting for clinical and sociodemographic factors. Global CHC burden progression was the prespecified primary outcome; analyses of specific CHC groups and effect modification by personal socioeconomic status were exploratory. Survivors residing in the most vs. least vulnerable neighborhoods, characterized by low income (odds ratio [OR]: 1.83, 95% confidence interval [CI]: 1.36-2.46), limited PCP availability (OR: 1.30, 95% CI: 1.03-1.64), and food inaccessibility (OR: 1.49, 95% CI: 1.08-2.07), had higher risks of global CHC burden progression. Living in SDOH-vulnerable neighborhoods was associated with higher risks of new-onset/worsening of multiple CHC groups, including low education for peripheral nervous system disorders (OR: 2.69, 95% CI: 1.63-4.43), food inaccessibility for arrhythmias (OR: 4.36, 95% CI: 1.32-14.35), and poor walkability for abnormal glucose metabolism (OR: 4.60, 95% CI: 1.41-15.04). Among publicly insured survivors, limited PCP availability and poor walkability were associated with higher risk of peripheral musculoskeletal disorder (OR: 6.11, 95% CI: 2.33-16.04, OR: 7.37, 95% CI: 2.82-19.27). SDOH are associated with CHC severity progression among childhood cancer survivors, supporting multilevel social risk assessment in survivorship care and further evaluation of neighborhood-informed risk stratification. U.S. National Cancer Institute.
中文摘要:癌症治疗对儿童癌症幸存者慢性健康状况(CHC)负担的影响已明确;社区层面的健康社会决定因素(SDOH)作用仍研究不足。在这项美国单中心队列研究中,我们分析了2007年9月13日至2020年4月20日纳入St. Jude Lifetime Cohort Study的2508名幸存者,纳入条件为诊断后≥5年、年龄≥18岁且至少有2次临床评估。SDOH包括社会脆弱性(Social Vulnerability Index)和环境/医疗可及性脆弱性(如初级保健医生(PCP)可及性、食物获取困难),按四分位数分类。共177项临床评估的CHC汇总为48个CHC组和总体负担。多变量logistic回归分析基线SDOH与从基线到随访期间CHC进展的关联,并校正临床和社会人口学因素。总体CHC负担进展为预设主要结局;特定CHC组分析及个人社会经济地位的效应修饰分析为探索性。与居住在脆弱性最低社区相比,居住在脆弱性最高社区的幸存者总体CHC负担进展风险更高,其特征包括低收入(OR 1.83,95%CI 1.36-2.46)、PCP可及性有限(OR 1.30,95%CI 1.03-1.64)和食物获取困难(OR 1.49,95%CI 1.08-2.07)。居住在SDOH脆弱社区与多个CHC组新发/加重的更高风险相关,包括低教育水平与周围神经系统疾病(OR 2.69,95%CI 1.63-4.43)、食物获取困难与心律失常(OR 4.36,95%CI 1.32-14.35)、步行便利性差与糖代谢异常(OR 4.60,95%CI 1.41-15.04)。在公共保险幸存者中,PCP可及性有限和步行便利性差与周围肌肉骨骼疾病风险升高相关(OR 6.11,95%CI 2.33-16.04;OR 7.37,95%CI 2.82-19.27)。SDOH与儿童癌症幸存者的CHC严重程度进展相关,支持在生存者照护中开展多层次社会风险评估,并进一步评估基于社区信息的风险分层。美国国家癌症研究所资助。
Oxaliplatin chemotherapy-induced peripheral neuropathy (CIPN) is dose-limiting, severe, and often permanent. Whether reduced oxaliplatin exposure (ROE) preserves efficacy while limiting toxicity across gastrointestinal (GI) cancers remains uncertain. We conducted a systematic review and meta-analysis of studies comparing ROE strategies versus standard-duration oxaliplatin-based therapy in GI malignancies. Random-effects meta-analyses were performed according to PRISMA guidelines. Primary endpoints were disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS). Secondary endpoints included grade 2 CIPN, grade ≥ 3 CIPN, and any grade ≥ 3 adverse events (AEs). Twenty-four studies (15 randomized trials, 9 retrospective cohorts) involving 30,395 patients were included; 13,348 received ROE and 17,047 standard therapy. In adjuvant colorectal cancer, ROE was not associated with differences in DFS [HR 1.06, 95% CI 0.97-1.17; P = 0.15] or OS (HR 0.99, 95% CI 0.90-1.09; P = 0.80). In metastatic colorectal cancer, no differences were observed in PFS (HR 1.11, 95% CI 0.99-1.25; P = 0.07) or OS (HR 1.06, 95% CI 0.92-1.23; P = 0.33). In metastatic gastroesophageal cancers, PFS (HR 0.82, 95% CI 0.34-1.99; P = 0.44) and OS (HR 0.90, 95% CI 0.67-1.21; P = 0.26) were also not statistically different. ROE reduced grade 2 CIPN (OR 0.46, 95% CI 0.25-0.84), grade ≥ 3 CIPN (OR 0.34, 95% CI 0.21-0.57), and grade ≥ 3 AEs (OR 0.67, 95% CI 0.48-0.92). ROE was not associated with statistically significant differences in survival outcomes but with reduced neurotoxicity and high-grade AEs, supporting planned limitation of oxaliplatin exposure to improve the therapeutic index across GI malignancies. The evidence was driven predominantly by colorectal cancer, while data in pancreatic and gastroesophageal cancers remain limited.
中文摘要:奥沙利铂化疗诱导的周围神经病变(CIPN)具有剂量限制性、严重且常为永久性的特点。减少奥沙利铂暴露(ROE)能否在消化道肿瘤中既保持疗效又限制毒性仍不确定。我们按PRISMA指南开展系统综述和随机效应荟萃分析,比较ROE策略与标准疗程奥沙利铂方案。主要终点为无病生存期(DFS)、无进展生存期(PFS)和总生存期(OS)。次要终点包括2级CIPN、≥3级CIPN和任何≥3级不良事件(AE)。共纳入24项研究(15项随机试验、9项回顾性队列),涉及30395例患者;13348例接受ROE,17047例接受标准治疗。在辅助结直肠癌中,ROE与DFS无差异相关(HR 1.06,95% CI 0.97-1.17;P=0.15),与OS也无差异相关(HR 0.99,95% CI 0.90-1.09;P=0.80)。在转移性结直肠癌中,PFS(HR 1.11,95% CI 0.99-1.25;P=0.07)和OS(HR 1.06,95% CI 0.92-1.23;P=0.33)均无差异。在转移性胃食管癌中,PFS(HR 0.82,95% CI 0.34-1.99;P=0.44)和OS(HR 0.90,95% CI 0.67-1.21;P=0.26)也无统计学差异。ROE降低了2级CIPN(OR 0.46,95% CI 0.25-0.84)、≥3级CIPN(OR 0.34,95% CI 0.21-0.57)和≥3级AE(OR 0.67,95% CI 0.48-0.92)。ROE与生存结局无统计学显著差异相关,但降低了神经毒性和高级别AE,支持通过计划性限制奥沙利铂暴露来提高消化道肿瘤治疗指数。证据主要来自结直肠癌,胰腺癌和胃食管癌数据仍有限。
Timely integration of palliative care is critical in the management of patients with glioblastoma. This study evaluated the frequency and determinants of potentially inappropriate care in the final 3 months of life on population level. Patient characteristics and healthcare utilization were extracted from medical records for deceased patients diagnosed with glioblastoma, who survived at least 3 months after diagnosis and received routine care at a single tertiary hospital between January 2015 and February 2026. Potentially inappropriate care was defined as the proportion of patients with any of these indicators in the final 3 months of life: ≥2 emergency department visits, ≥2 hospital admissions, >14 consecutive hospitalization days, intensive care unit admission, chemotherapy administration, or in-hospital death. Logistic regression analyses were performed to identify factors associated with receiving potentially inappropriate care. The cohort included 310 patients (median age 66 [IQR 56-72], 60% male), of whom 22% (n = 67/310) received potentially inappropriate care in the final 3 months of life. Chemotherapy was the main driver (n = 58/67, 87%), followed by ≥2 hospital admissions (n = 10/67, 15%) and in-hospital death (n = 9/67, 13%). Older patients (OR 0.97, 95% CI, 0.94-0.99) or those with an unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter (OR 0.42, 95% CI, 0.23-0.75) were less likely to receive potentially inappropriate care. One in 5 patients with glioblastoma received potentially inappropriate care at the end of life, predominantly through chemotherapy. Younger patients and those with methylated MGMT promoters were most affected. Identification of patients at risk may support targeted palliative care interventions.
中文摘要:及时整合姑息治疗对胶质母细胞瘤患者的管理至关重要。本研究在人群层面评估生命最后3个月中潜在不适当照护的发生频率及决定因素。从病历中提取2015年1月至2026年2月期间在一家三级医院接受常规诊疗、确诊胶质母细胞瘤且诊断后生存至少3个月的已故患者的特征和医疗资源使用情况。潜在不适当照护定义为生命最后3个月内出现以下任一指标的患者比例:≥2次急诊就诊、≥2次住院、连续住院>14天、入住重症监护病房、接受化疗或院内死亡。采用logistic回归分析识别与接受潜在不适当照护相关的因素。队列纳入310例患者(中位年龄66岁[IQR 56-72],60%男性),其中22%(n=67/310)在生命最后3个月接受了潜在不适当照护。化疗是主要驱动因素(n=58/67,87%),其次是≥2次住院(n=10/67,15%)和院内死亡(n=9/67,13%)。年龄较大(OR 0.97,95% CI 0.94-0.99)或O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子未甲基化(OR 0.42,95% CI 0.23-0.75)的患者接受潜在不适当照护的可能性较低。每5例胶质母细胞瘤患者中约1例在生命终末期接受潜在不适当照护,主要涉及化疗。较年轻患者和MGMT启动子甲基化患者受影响最大。识别存在风险的患者可能有助于开展有针对性的姑息治疗干预。
Most individuals with steatotic liver disease (SLD) do not develop advanced liver disease. Multiple risk scores for SLD-associated cirrhosis and hepatocellular carcinoma (HCC) have been proposed, but their utility to inform decisions about surveillance for advanced liver disease is unknown. To compare the clinical utility of SLD risk scores for predicting cirrhosis and hepatocellular carcinoma in patients with noncirrhotic steatotic liver disease. This cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD without viral hepatitis or primary liver disease from 2008 and 2020. Nine clinical risk scores were calculated at the time of the first imaging results that demonstrated hepatic steatosis. Individuals were followed up until cirrhosis, HCC, death, or 6 months after last follow-up visit. Data were analyzed between November 1, 2025, and May 11, 2026. Nine risk scores evaluated for prediction of cirrhosis or HCC within 10 years were: (1) ALBI, albumin-bilirubin; (2) aMAP, age-male-albumin-bilirubin-platelet; (3) APRI, the aspartate aminotransferase-to-platelet ratio; (4) BARD, body mass index, age, alanine aminotransferase-to-aspartate aminotransferase ratio, and diabetes; (5) FIB-4, fibrosis-4 index; (6) NFS, nonalcoholic fatty liver disease fibrosis; (7) SAFE, steatosis-associated fibrosis estimator; and 2 additional scores. First diagnosis of cirrhosis and first diagnosis of HCC identified using VA and Medicare diagnosis codes and data from the VA Cancer Registry. Cox proportional hazards models were used to calculate time-dependent 10-year probabilities of each outcome predicted by 9 risk scores. Decision curves were generated for each outcome by calculating the net benefit, a weighted measure of true and false positives over a prespecified range of risk thresholds at which a clinician may reasonably recommend intervention. Nine risk scales were used to quantify the risk of cirrhosis or HCC within 10 years. The analysis included 853 131 patients (median [IQR] age, 61 [51-68] years; 62 168 females [7.3%] and 790 965 males [92.7%]) whose median (IQR) BMI was 31.3 (27.6-35.5) and 275 898 (32.3%) had diabetes; of these, 33 794 (3.96%) developed cirrhosis and 2978 (0.35%) developed HCC within 10 years. The FIB-4, APRI, and SAFE scores demonstrated the greatest discrimination of cirrhosis risk, while the SAFE, Tate, and FIB-4 scores demonstrated the greatest discrimination of HCC risk. The SAFE score demonstrated the greatest net benefit predicting cirrhosis. A score of 29.5 corresponded to a 10-year cirrhosis risk of 2.5% and yielded a net benefit of 0.019, or 1.9 additional individuals who develop cirrhosis per 100 individuals classified as at-risk patients. At a 0.25% 10-year risk of HCC, the SAFE score had a net benefit of 0.0016 (1.6 additional true positives per 1000 individuals). The findings of this cohort study show that the SAFE score may inform decisions to repeat screening for cirrhosis in patients with SLD. Clinical risk scores for HCC demonstrated minimal utility to inform HCC screening decisions for patients with noncirrhotic SLD.
中文摘要:大多数脂肪性肝病(SLD)患者不会发展为晚期肝病。已有多种用于SLD相关肝硬化和肝细胞癌(HCC)的风险评分,但其指导晚期肝病监测决策的价值尚不明确。本研究比较SLD风险评分在非肝硬化SLD患者中预测肝硬化和HCC的临床效用。该队列研究使用美国退伍军人事务部全国健康系统2008年至2020年的数据,纳入影像确诊SLD、无病毒性肝炎或原发性肝病的成人。在首次影像显示肝脂肪变性时计算9种临床风险评分。随访至肝硬化、HCC、死亡或末次随访后6个月。数据分析时间为2025年11月1日至2026年5月11日。评估10年内肝硬化或HCC预测的9种风险评分为:ALBI(白蛋白-胆红素)、aMAP(年龄-男性-白蛋白-胆红素-血小板)、APRI(天冬氨酸氨基转移酶与血小板比值)、BARD(体重指数、年龄、丙氨酸氨基转移酶与天冬氨酸氨基转移酶比值及糖尿病)、FIB-4(纤维化-4指数)、NFS(非酒精性脂肪性肝病纤维化)、SAFE(脂肪变性相关纤维化估计器)以及另外2种评分。肝硬化首次诊断和HCC首次诊断通过VA与Medicare诊断代码及VA癌症登记数据确定。采用Cox比例风险模型计算9种风险评分预测各结局的时间依赖10年概率。针对各结局生成决策曲线,通过在预设风险阈值范围内计算净获益来评估,净获益是真正例和假正例的加权指标,该阈值范围反映临床医生可能合理推荐干预的风险水平。9种风险量表用于量化10年内肝硬化或HCC风险。分析纳入853 131例患者,中位年龄61岁(IQR 51-68岁),女性62 168例(7.3%),男性790 965例(92.7%),中位BMI为31.3(IQR 27.6-35.5),275 898例(32.3%)患有糖尿病;其中33 794例(3.96%)在10年内发生肝硬化,2 978例(0.35%)发生HCC。FIB-4、APRI和SAFE评分对肝硬化风险的区分度最高,SAFE、Tate和FIB-4评分对HCC风险的区分度最高。SAFE评分预测肝硬化的净获益最大。评分29.5对应10年肝硬化风险2.5%,净获益为0.019,即每100例被归类为风险患者中多识别1.9例会发生肝硬化者。在10年HCC风险0.25%时,SAFE评分的净获益为0.0016,即每1000例中多识别1.6例真正例。该队列研究的结果显示,SAFE评分可能有助于决定SLD患者重复筛查肝硬化的策略。HCC临床风险评分对非肝硬化SLD患者HCC筛查决策的效用很小。
This study aimed to investigate switching strategies of biologics in noninfectious uveitis (NIU) refractory to anti-tumor necrosis factor alpha (TNFα) agents. Noninfectious uveitis often requires biologic therapy when conventional immunosuppression fails. Tumor necrosis factor alpha inhibitors, such as adalimumab and infliximab, are commonly used as first-line biologics, but up to one-third of patients experience inadequate responses. We conducted a systematic review and meta-analysis to evaluate clinical outcomes following biologic switching in patients with NIU refractory to anti-TNFα therapy. This review was registered at PROSPERO (CRD420251071702). PubMed, EMBASE, and Cochrane Library were searched through January 5, 2025. Switching strategies were categorized as either intraclass (switching between anti-TNFα agents) or interclass (switching from an anti-TNFα agent to a different class biologic). Pooled response rates were compared between the two approaches. Risk of bias was assessed using the Joanna Briggs Institute (JBI) checklists for case reports/series and the Newcastle-Ottawa Scale for comparative studies. Certainty of evidence for primary outcome was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation approach. A total of 136 studies (129 case reports/series and 7 comparative studies) were included for systematic review, with 89 studies contributing to the meta-analysis. Using the JBI tool, 11 of 77 studies had high risk of bias, while the remainder were of at least fair quality. Among comparative studies, one-third had moderate risk of bias, while the rest were rated as low risk. The overall pooled response rate after switching was 83% (95% confidence interval [CI]: 76%-90%; I2 = 30.2%; 466 patients). Intraclass switching showed a pooled response rate of 77% (95% CI: 65%-87%; I2 = 36%), which was lower than that of interclass switching showing 89% (95% CI: 80%-96%; I2 = 18%, P = 0.0995). Sensitivity analyses showed a 71% (95% CI: 59%-82%, I2 = 54.5%) pooled response rate for intraclass switch and 85% (95% CI: 77%-93%, I2 = 32.8%) for interclass switch, revealing statistically significant difference (P = 0.044). The certainty of evidence was graded as low for the overall pooled response rate after switching. Both intraclass and interclass switching strategies appear effective, with interclass switching showing higher response rates; however, these findings warrant cautious interpretation given the limited certainty of evidence. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
中文摘要:本研究旨在探讨抗肿瘤坏死因子α(TNFα)治疗无效的非感染性葡萄膜炎(NIU)中生物制剂的切换策略。非感染性葡萄膜炎在传统免疫抑制治疗失败时常需生物制剂治疗。阿达木单抗、英夫利西单抗等TNFα抑制剂常作为一线生物制剂,但多达三分之一患者应答不足。我们开展系统评价和荟萃分析,评估抗TNFα治疗无效的NIU患者切换生物制剂后的临床结局。本评价已在PROSPERO注册(CRD420251071702)。检索PubMed、EMBASE和Cochrane Library至2025年1月5日。切换策略分为类别内切换(抗TNFα药物之间切换)和类别间切换(从抗TNFα药物切换至其他类别生物制剂)。比较两种策略的汇总应答率。偏倚风险采用Joanna Briggs Institute(JBI)病例报告/系列清单和Newcastle-Ottawa量表评估比较研究。主要结局的证据确定性采用GRADE方法评价。共136项研究(129项病例报告/系列和7项比较研究)纳入系统评价,89项研究进入荟萃分析。采用JBI工具,77项研究中11项为高偏倚风险,其余至少为一般质量。比较研究中三分之一为中度偏倚风险,其余为低风险。切换后总体汇总应答率为83%(95%置信区间[CI]:76%-90%;I²=30.2%;466例患者)。类别内切换汇总应答率为77%(95%CI:65%-87%;I²=36%),低于类别间切换的89%(95%CI:80%-96%;I²=18%,P=0.0995)。敏感性分析显示,类别内切换汇总应答率为71%(95%CI:59%-82%,I²=54.5%),类别间切换为85%(95%CI:77%-93%,I²=32.8%),差异有统计学意义(P=0.044)。切换后总体汇总应答率的证据确定性评为低。类别内和类别间切换策略均显现有效性,类别间切换应答率更高;证据确定性有限,这些发现需谨慎解释。专有或商业披露可见文末脚注和披露部分。
Gastric cancer (GC) ranks as the fifth most common cancer worldwide, however, accurate and non-invasive diagnostic modalities for GC remain limited. Cell-free DNA (cfDNA) fragmentomics has emerged as a promising tool for cancer cell detection. Here we develop a gastric cancer detection model, named GaFraD model. The GaFraD model uses four cfDNA fragmentomics features, including fragment size ratio (FSR), copy number variation (CNV), 9-bp end motif (Motif), and fragment size at transcription start sites (TF). This model achieves an area under the receiver-operating characteristic curve (AUC) of 0.970 (95% CI: 0.944 - 0.990), a sensitivity of 95.0% and a specificity of 80.9%. By combining the GaFraD model and conventional protein biomarkers CA19-9 and PG-I/PG-II, the CONFIRM model was generated. The CONFIRM model attained an AUC of 0.986 (95% CI: 0.966 - 1.000), a sensitivity of 95.0% and a specificity of 95.6% in detecting GC. Moreover, the CONFIRM model achieved remarkable performance (AUC = 0.983, sensitivity 95.6%, specificity 94.2%) in distinguishing patients with early-stage GC from controls. Our work showed the high discriminatory power in distinguishing GC patients from controls, indicating the clinical potential of using cfDNA fragmentomics combined with protein biomarkers for non-invasive GC detection. The results of the study provide a new avenue for early, accurate, and non-invasive clinical diagnosis of GC.
中文摘要:胃癌在全球常见癌症中居第五位,而准确、无创的诊断手段仍然有限。游离DNA片段组学已成为检测癌细胞的一种有前景的工具。本研究建立了胃癌检测模型GaFraD,使用四个游离DNA片段组学特征:片段大小比例(FSR)、拷贝数变异(CNV)、9碱基末端基序(Motif)和转录起始位点片段大小(TF)。该模型的受试者工作特征曲线下面积(AUC)为0.970(95% CI:0.944-0.990),敏感性95.0%,特异性80.9%。将GaFraD模型与常规蛋白标志物CA19-9及PG-I/PG-II联合,构建了CONFIRM模型,其检测胃癌的AUC为0.986(95% CI:0.966-1.000),敏感性95.0%,特异性95.6%。CONFIRM模型在区分早期胃癌患者与对照者方面同样表现突出(AUC=0.983,敏感性95.6%,特异性94.2%)。研究显示该方案在区分胃癌患者与对照者方面具有较高的判别能力,提示游离DNA片段组学联合蛋白标志物用于无创胃癌检测的临床潜力,为胃癌早期、准确、无创的临床诊断提供了新途径。
Colonoscopy quality and diagnostic outcomes in Lynch syndrome have historically been heterogeneous. Following the introduction of the Lynch syndrome Bowel Cancer Screening Programme (BCSP), we assessed colonoscopy quality and diagnostic yield in Lynch syndrome using the National Endoscopy Database (NED), comparing outcomes between BCSP and non-BCSP providers. We performed a cross-sectional analysis of UK Lynch syndrome colonoscopies from NED between June 2024 and June 2025. Colonoscopy quality indicators and endoscopic detection rates for polyp (PDR) and advanced neoplasia (eANDR; polyps ≥10 mm or cancer; histopathology linkage was unavailable) were calculated and compared between BCSP and non-BCSP providers. Factors associated with neoplasia detection were identified using logistic regression. Among 3196 colonoscopies, most were performed in England (90.2%), with 34.1% undertaken within BCSP. Overall colonoscopy quality was high: 97.6% were complete, 89.0% had adequate bowel preparation, and 96.3% had adequate tolerance. BCSP procedures demonstrated higher rates of completion (98.5% vs. 97.1%; P = 0.02) and adequate bowel preparation (92.7% vs. 86.7%; P < 0.001) than non-BCSP colonoscopies. PDR and eANDR were 46.8% and 4.7%, respectively, and were higher in BCSP than non-BCSP procedures (PDR 53.7% vs. 43.3%; eANDR 5.7% vs. 3.9%). Higher polyp detection was associated with increasing age (odds ratio [OR] 1.03, 95%CI 1.03-1.04), male gender (OR 1.48, 95%CI 1.26-1.73), BCSP status (OR 1.50, 95%CI 1.28-1.77), adequate bowel preparation (OR 1.81, 95%CI 1.40-2.34), and England nation (OR 1.99, 95%CI 1.22-3.36). Our NED evaluation demonstrated high colonoscopy performance in Lynch syndrome, with superior quality and endoscopic yield in BCSP procedures, supporting national integration of surveillance to establish Lynch syndrome-specific quality benchmarks.
中文摘要:Lynch 综合征的结肠镜质量与诊断结果历来存在差异。在 Lynch 综合征肠癌筛查计划(BCSP)启动后,我们借助国家内镜数据库(NED)评估 Lynch 综合征的结肠镜质量与诊断检出率,并比较 BCSP 与非 BCSP 执行机构的结果。研究对 2024 年 6 月至 2025 年 6 月间 NED 中的英国 Lynch 综合征结肠镜检查进行横断面分析,计算结肠镜质量指标及息肉检出率(PDR)与进展期肿瘤检出率(eANDR;息肉≥10 mm 或癌;因组织病理学数据无法关联),并在 BCSP 与非 BCSP 执行机构间比较。采用 logistic 回归分析肿瘤检出相关因素。3196 例结肠镜检查中,多数在英国完成(90.2%),34.1% 在 BCSP 内实施。总体结肠镜质量较高:97.6% 完成检查,89.0% 肠道准备充分,96.3% 耐受性良好。BCSP 操作的完成率(98.5% 对 97.1%;P = 0.02)与肠道准备充分率(92.7% 对 86.7%;P < 0.001)均高于非 BCSP 操作。PDR 与 eANDR 分别为 46.8% 和 4.7%,BCSP 操作高于非 BCSP(PDR 53.7% 对 43.3%;eANDR 5.7% 对 3.9%)。息肉检出率较高与年龄增长(比值比 [OR] 1.03,95%CI 1.03-1.04)、男性(OR 1.48,95%CI 1.26-1.73)、BCSP 身份(OR 1.50,95%CI 1.28-1.77)、肠道准备充分(OR 1.81,95%CI 1.40-2.34)及英格兰地区(OR 1.99,95%CI 1.22-3.36)相关。NED 评估显示 Lynch 综合征的结肠镜执行水平较高,BCSP 操作在质量与内镜检出方面更优,支持将监测纳入国家体系以建立 Lynch 综合征专属质量基准。
In fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening, colonoscopy after a positive FIT often identifies no CRC or advanced neoplasia, leaving management poorly standardized. We mapped evidence on definitions, extracolonic evaluation, colonoscopy quality, residual CRC risk, and screening re-entry after a positive FIT and nonexplanatory colonoscopy. This registered scoping review followed PRISMA-ScR guidance. PubMed/MEDLINE, Scopus, and Web of Science were searched until April 2026, along with reference-list screening and targeted searching of official screening program/policy documents. Sources were charted by one reviewer; included sources, uncertain eligibility decisions, and key findings underwent second-reviewer verification. We included 10 studies on definitions, 11 empirical studies plus three contextual evidence syntheses on evaluation beyond the colon, 11 core empirical studies on colonoscopy quality/residual CRC risk, and nine empirical studies on management and screening re-entry, supplemented by policy mapping. Definitions varied substantially, supporting "nonexplanatory colonoscopy" as a pragmatic umbrella term. Routine upper gastrointestinal or small-bowel evaluation was not supported in otherwise asymptomatic individuals. Reassurance was quality dependent; residual CRC risk was low in the short term, but not zero. Screening re-entry pathways varied and were not evidence based. Management should first be to establish whether the index colonoscopy is reliable enough to justify reassurance. After a trusted negative examination, the evidence does not support routine upper gastrointestinal or small-bowel evaluation, or routine early repeat colonoscopy in otherwise asymptomatic individuals. Residual CRC risk remains low but not zero, and optimal screening re-entry remains uncertain.
中文摘要:在基于粪便免疫化学检测(FIT)的结直肠癌(CRC)筛查中,FIT阳性后行结肠镜常未发现CRC或进展期肿瘤,后续管理缺乏统一标准。本范围综述已注册并遵循PRISMA-ScR指南,检索PubMed/MEDLINE、Scopus和Web of Science至2026年4月,同时筛查参考文献列表,并定向检索官方筛查项目与政策文件。资料由一名研究者提取,纳入文献、资格判断不确定者及关键发现经第二研究者核验。共纳入10项关于定义的研究、11项关于结肠外评估的实证研究及3项情境证据综合、11项关于结肠镜质量与残余CRC风险的核心实证研究、9项关于管理与筛查再入组的实证研究,并补充政策梳理。定义差异很大,支持将「非解释性结肠镜」作为实用性总括术语。对无症状个体,常规上消化道或小肠评估缺乏支持。安抚是否可靠取决于检查质量;短期残余CRC风险较低但并非为零。筛查再入组路径各不相同,且缺乏证据基础。管理应先判断指数结肠镜是否足够可靠以支持安抚。在可信的阴性检查后,证据不支持对无症状个体常规进行上消化道或小肠评估,也不支持常规早期重复结肠镜。残余CRC风险仍低但非零,最佳筛查再入组路径仍不确定。
Non-pharmacological treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) aims at modifying lifestyle patterns that promote metabolic dysfunction and hepatic fat accumulation. These include unhealthy dietary habits, which are characterised by excess energy intake and a qualitatively poor diet that is high in ultra-processed food, saturated fat, free sugar, red and processed meat and/or sweetened beverages, and low in fibre. In addition, sedentary habits, and sleep and circadian rhythm disruption have been identified as detrimental lifestyle factors. Lifestyle interventions act upstream of the main pathophysiological mechanisms driving MASLD and, therefore, provide benefits that extend beyond the liver, also improving cardiometabolic health. Weight loss remains the cornerstone of non-pharmacological strategies, and even modest weight loss has been proven beneficial in individuals with MASLD with or without obesity. To achieve weight loss, energy restriction should be combined with physical activity/exercise, since the effects of the latter are partly independent of weight reduction. Importantly, exercise is associated with a dose-dependent reduction in the risk of hepatic steatosis, fibrosis and hepatocellular carcinoma. Despite lifestyle changes proving highly effective for improving MASLD, their implementation is challenging and requires multidisciplinary efforts. Adherence is suboptimal, particularly in the long term, and the variability in individual response calls for research on biomarkers to achieve a more personalised approach. This review provides an overview of evidence of the impact of lifestyle changes/non-pharmacological interventions on MASLD.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)的非药物治疗旨在改变促进代谢功能障碍和肝脏脂肪堆积的生活方式。这些生活方式包括不健康饮食习惯,其特征是能量摄入过多和饮食质量差,表现为超加工食品、饱和脂肪、游离糖、红肉和加工肉和/或含糖饮料摄入高而纤维摄入低。久坐习惯以及睡眠和昼夜节律紊乱也被认定为有害的生活方式因素。生活方式干预作用于驱动MASLD的主要病理生理机制上游,因此其获益超出肝脏,还可改善心血管代谢健康。减重仍是非药物策略的基石,即使轻度减重也已证明对伴或不伴肥胖的MASLD个体有益。为实现减重,能量限制应与体力活动/运动相结合,因为后者的效应部分独立于体重下降。运动与肝脂肪变、纤维化和肝细胞癌风险呈剂量依赖性降低相关。尽管生活方式改变对改善MASLD高度有效,但其实施具有挑战性,需要多学科努力。依从性欠佳,尤其在长期;个体反应存在差异,要求开展生物标志物研究以实现更个性化的方案。本综述概述生活方式改变/非药物干预对MASLD影响的证据。
Physicians treating patients with malignant central nervous system tumors frequently experience patient deaths, yet the impact of professional grief on burnout has not been examined in neuro-oncology. This study investigated whether acute grief responses following patient deaths (short-term bereavement reactions, SBR) and long-term changes resulting from cumulative loss exposure (accumulated global changes, AGC) are associated with emotional exhaustion (EE) among neuro-oncologists in Germany, and whether resilience moderates these relationships. This cross-sectional study included n = 131 physicians working in neuro-oncology in Germany. Validated instruments assessed professional grief, burnout, resilience, self-compassion, psychological distress, and neuroticism. Hierarchical regression tested associations and moderation hypotheses. Cluster analysis identified stress-vulnerability-capacity profiles. The sample comprised physicians across 5 neuro-oncological specialties (mean age 45.5, 48.1% female). Short-term bereavement reactions were significantly associated with higher EE after controlling for self-compassion, neuroticism, and psychological distress (B = 0.46, 95% CI: 0.27-0.64, P < .001), whereas AGC was not (B = 0.04, P = .602). Resilience did not moderate these associations. Self-compassion was independently associated with lower EE (B = -0.33, P = .012). Cluster analyses identified 3 distinct stress-vulnerability profiles: Low Risk (51.1%), Moderate (35.1%), and High Risk (13.7%). Emotional exhaustion differed substantially across profiles (η² = 0.34), with 72.2% of the High-Risk group exceeding clinical EE thresholds; 40.5% of participants desired supervision that was unavailable. Short-term bereavement reactions, but not AGC, were associated with EE among neuro-oncologists. The high-risk profile may represent a clinically relevant target for screening. Self-compassion and access to supervision warrant further investigation as potential intervention targets.
中文摘要:治疗恶性中枢神经系统肿瘤患者的医生常经历患者死亡,但神经肿瘤学领域中职业性哀伤对倦怠的影响尚未被考察。本研究探讨德国神经肿瘤科医生在患者死亡后的急性哀伤反应(短期丧亲反应,SBR)以及累积丧失暴露导致的长期变化(累积性整体变化,AGC)是否与情绪耗竭(EE)相关,并检验心理韧性是否调节这些关系。这项横断面研究纳入131名在德国从事神经肿瘤工作的医生。研究使用经验证的工具评估职业性哀伤、倦怠、心理韧性、自我慈悲、心理痛苦和神经质。采用分层回归检验关联和调节假设,聚类分析识别压力—脆弱性—能力特征。样本覆盖5个神经肿瘤亚专业(平均年龄45.5岁,女性占48.1%)。控制自我慈悲、神经质和心理痛苦后,短期丧亲反应与更高的EE显著相关(B=0.46,95% CI:0.27-0.64,P<.001),AGC则无显著关联(B=0.04,P=.602)。心理韧性未调节这些关联。自我慈悲与较低的EE独立相关(B=-0.33,P=.012)。聚类分析识别出3种不同的压力—脆弱性特征:低风险(51.1%)、中等风险(35.1%)和高风险(13.7%)。不同特征间EE差异明显(η²=0.34),高风险组中72.2%超过临床EE阈值;40.5%的参与者希望获得但无法获得督导。短期丧亲反应而非AGC与神经肿瘤科医生的EE相关。高风险特征可能成为具有临床意义的筛查目标。自我慈悲和获得督导的机会值得作为潜在干预目标进一步研究。
Merkel cell carcinoma (MCC) recurs in 17% to 30% of patients with stage I to II disease, with local recurrence rates between 2% and 27%. Per established guidelines, conventional postoperative radiotherapy (cPORT; ∼50 Gray across 25 fractions) should be considered for localized MCC when risk factors are present. cPORT can be morbid and logistically challenging. Single-fraction radiotherapy (SFRT) of 8 Gray has utility and low toxicity for palliation but remains underexplored postoperatively. Evaluate postoperative SFRT for stage I to II MCC, compared to observation and cPORT. Local recurrences were assessed for observation (n = 108 patients), cPORT (n = 156), or SFRT (n = 43) groups. Observation patients had fewer per-patient risk factors (mean: 1.2 vs 1.6 for SFRT [P = .020] and 1.6 for cPORT [P = .001]). Despite this, 3-year local control was better for cPORT (97.4%; P < .001) and SFRT (100%; P = .012) groups than observation (91.0%), particularly in patients with narrow surgical margins (≤1 cm). Adverse events occurred in 21% of SFRT patients (all grade 1). Single-center retrospective study. The SFRT group experienced improved local control relative to observation and had comparable local control to the cPORT group. For early-stage narrowly excised MCC, SFRT is feasible, well tolerated, and warrants exploration in a prospective multicenter study.
中文摘要:默克尔细胞癌(MCC)在I至II期患者中的复发率为17%至30%,局部复发率为2%至27%。现有指南建议,对有危险因素的局限性MCC考虑常规术后放疗(cPORT,约50 Gy分25次)。cPORT可能带来较多不良反应,实施上也存在不便。单次8 Gy放疗(SFRT)用于姑息治疗有效且毒性低,但术后应用仍研究不足。评估I至II期MCC术后SFRT,并与观察和cPORT比较。按观察组(108例)、cPORT组(156例)或SFRT组(43例)评估局部复发。观察组每例患者的危险因素较少(均值1.2,SFRT组1.6,P=.020;cPORT组1.6,P=.001)。尽管如此,cPORT组(97.4%;P<.001)和SFRT组(100%;P=.012)的3年局部控制优于观察组(91.0%),在手术切缘较窄(≤1 cm)的患者中尤为明显。SFRT组21%的患者发生不良事件,均为1级。单中心回顾性研究。SFRT组局部控制优于观察组,与cPORT组相当。对于早期、切缘较窄切除的MCC,SFRT可行、耐受良好,值得在前瞻性多中心研究中进一步探索。
Identifying patients at high risk for recurrence after endoscopic resection of T1 colorectal cancer (CRC) remains challenging. This study aimed to identify recurrence risk subtypes and develop an interpretable risk stratification framework. This retrospective study analyzed 1123 patients with T1 CRC treated with endoscopic resection alone across 26 Japanese institutions (July 2009-December 2016). Patients were divided into development (68%) and evaluation (32%) cohorts based on institutional stratification. K-means clustering was applied to clinicopathologic variables to identify recurrence risk subtypes. A decision tree classifier was subsequently developed to generate transparent risk stratification rules. Three distinct subtypes were identified in the development cohort. Subtype 1 exhibited a numerically higher recurrence rate (5.4%) than Subtype 2 (0.9%) and Subtype 3 (1.4%). Although subtypes 2 and 3 showed comparable recurrence rates, they were clearly differentiated by morphology (flat vs. polypoid). In the evaluation cohort, Subtype 1 continued to show a numerically higher recurrence (4.8%) compared with subtypes 2 (1.6%) and 3 (1.1%). The decision tree model stratified recurrence risk hierarchically: submucosal invasion <1000 μm indicated low risk, whereas invasion ≥1000 μm required morphologic assessment, with polypoid lesions classified as high risk and flat lesions further stratified using a 2000-μm threshold. Three clinically distinct recurrence risk subtypes were identified in T1 CRC following endoscopic resection, suggesting that morphologic subclassification of T1b lesions may refine stratification beyond conventional depth-based criteria. The decision framework offers a preliminary exploratory basis for recurrence risk assessment in this population.
中文摘要:T1期结直肠癌经内镜切除后,识别复发高风险患者仍属难点。本研究拟识别复发风险亚型并构建可解释的风险分层框架。该回顾性研究纳入日本26家机构2009年7月至2016年12月间单用内镜切除治疗的1123例T1期结直肠癌患者,按机构分层划分为开发队列(68%)与评价队列(32%)。对临床病理变量行K-means聚类以识别复发风险亚型,随后建立决策树分类器以生成透明的风险分层规则。开发队列中识别出三种不同亚型,亚型1的复发率数值上高于亚型2与亚型3(5.4%对0.9%对1.4%)。亚型2与亚型3复发率相近,但形态学上(平坦型与息肉型)可清晰区分。评价队列中亚型1的复发率仍数值上高于亚型2与亚型3(4.8%对1.6%对1.1%)。决策树模型对复发风险作分层:黏膜下浸润小于1000 μm为低风险;浸润达到或超过1000 μm者需评估形态,息肉型病变归为高风险,平坦型病变则进一步以2000 μm为界分层。T1期结直肠癌内镜切除后可区分出三种临床特征不同的复发风险亚型,提示对T1b病变作形态学细分可能在常规基于浸润深度的标准之外改善分层。该决策框架为这一人群的复发风险评估提供了初步的探索性依据。
Computer-aided quality assurance (CAQ) can provide feedback to improve mucosal inspection during colonoscopy. This systematic review and meta-analysis of randomized controlled trials (RCTs) evaluated the efficacy of CAQ versus standard colonoscopy in enhancing colonoscopy quality indicators. Adhering to PRISMA guidelines, we searched MEDLINE, Embase, and CENTRAL for RCTs comparing CAQ with standard colonoscopy. The primary outcome was adenoma detection rate (ADR). Secondary outcomes included detection rates for advanced adenoma (AADR) and adenocarcinoma (ACDR), adenomas per colonoscopy (APC), and withdrawal time. Pooled risk ratios (RRs) and weighted mean differences (WMDs) were calculated using random-effects models. Six RCTs involving 5687 colonoscopies (CAQ 2895; standard colonoscopy 2792) were included. Compared with standard colonoscopy, CAQ increased ADR by 43% (RR [95%CI]: 1.43 [1.17-1.73]; P < 0.001, I2 = 73.5%), with heterogeneity decreasing substantially after omitting one study (1.52 [1.32-1.75]; P < 0.001, I2 = 11.9%); AADR by 54% (1.54 [1.26-1.87]; P < 0.001, I2 = 0.0%); ACDR by 30% (1.30 [1.00-1.68]; P = 0.047, I2 = 0.0%); APC by 0.14 adenomas (WMD [95%CI]: 0.14 [0.08-0.20]; P < 0.001, I2 = 53.2%); adenomas ≥10 mm by 0.03 adenomas (0.03 [0.02-0.05]; P < 0.001, I2 = 45.1%); and withdrawal time increased by 0.64 minutes (0.64 [0.04-1.24]; P = 0.04, I2 = 96.1%). CAQ significantly improved ADR and detection of clinically significant lesions. While findings for AADR and ACDR should be interpreted with caution due to low event rates, the improvements in detection of adenomas ≥10 mm and APC suggest that CAQ may lower the risk of post-colonoscopy colorectal cancer, a hypothesis that warrants evaluation in future long-term analyses of patient outcomes.
中文摘要:计算机辅助质量保证(CAQ)可在结肠镜检查中提供反馈以改善黏膜观察。该系统评价与荟萃分析纳入随机对照试验(RCT),评估CAQ相较标准结肠镜在提升结肠镜质量指标方面的效果。按PRISMA指南检索MEDLINE、Embase和CENTRAL中比较CAQ与标准结肠镜的RCT。主要结局为腺瘤检出率(ADR)。次要结局包括进展期腺瘤检出率(AADR)、腺癌检出率(ACDR)、每次结肠镜检查腺瘤数(APC)及退镜时间。采用随机效应模型计算合并风险比(RR)和加权均数差(WMD)。共纳入6项RCT,涉及5687次结肠镜检查(CAQ 2895次;标准结肠镜2792次)。与标准结肠镜相比,CAQ使ADR提高43%(RR [95%CI]:1.43 [1.17-1.73];P < 0.001,I2 = 73.5%),剔除一项研究后异质性明显下降(1.52 [1.32-1.75];P < 0.001,I2 = 11.9%);AADR提高54%(1.54 [1.26-1.87];P < 0.001,I2 = 0.0%);ACDR提高30%(1.30 [1.00-1.68];P = 0.047,I2 = 0.0%);APC增加0.14个腺瘤(WMD [95%CI]:0.14 [0.08-0.20];P < 0.001,I2 = 53.2%);≥10 mm腺瘤增加0.03个(0.03 [0.02-0.05];P < 0.001,I2 = 45.1%);退镜时间增加0.64分钟(0.64 [0.04-1.24];P = 0.04,I2 = 96.1%)。CAQ显著改善ADR及临床意义病变的检出。AADR和ACDR事件率较低,结果需谨慎解读;≥10 mm腺瘤和APC的改善提示CAQ可能降低结肠镜后结直肠癌风险,该假设有待未来患者结局的长期分析评估。
Colorectal neoplasia outcomes in Lynch syndrome are heterogeneous and limited by inconsistently reported quality metrics, while benchmarks for neoplasia detection rates remain undefined. This systematic review and meta-analysis evaluated neoplasia detection rates in Lynch syndrome and assessed demographic, genotype, and risk factors for neoplasia development. We searched MEDLINE, EMBASE, classic+EMBASE, Cochrane Library, and ClinicalTrials.gov to February 2025 for studies reporting colorectal neoplasia detection rates in Lynch syndrome. The primary outcomes were pooled detection rates for adenoma (ADR), advanced adenoma (AADR), serrated lesion (SLDR), and colorectal cancer (CRCDR). Subgroup analyses were performed to evaluate risk factors and the impact of colonoscopy quality. 36 studies were included, comprising 45 421 colonoscopies in 15 227 Lynch syndrome carriers. Pooled detection rates were: ADR 23.3% (95%CI 20.6-26.3), AADR 5.3% (95%CI 4.5-6.3), SLDR 8.6% (95%CI 6.3-11.7), and CRCDR 2.5% (95%CI 1.9-3.3), with higher proximal ADR (16.4% vs. 11.9% distal) and increased proportion of flat adenomas (flat ADR 16.1%). Completion and bowel preparation data were available for 16 647 (36.7%) and 13 637 (30.0%) procedures, respectively. ADR was highest among trial populations excluding poor-quality or incomplete procedures (30.7%), followed by prospective (24.0%) and retrospective observational studies (18.5%). Advanced neoplasia rates were higher among MLH1/MSH2 than MSH6/PMS2 carriers: MLH1 (AADR 5.1%, CRCDR 5.1%) and MSH2/EPCAM (AADR 6.3%, CRCDR 4.7%) versus MSH6 (AADR 3.5%, CRCDR 3.1) and PMS2 (AADR 4.1%, CRCDR 4.2%). This study characterized neoplasia detection in Lynch syndrome and confirmed higher detection rates with high-quality procedures, supporting the need to benchmark quality standards and neoplasia detection outcomes.
中文摘要:Lynch综合征的结直肠肿瘤结局存在异质性,并受质量指标报告不一致的限制,肿瘤检出率的基准仍未明确。该系统综述和荟萃分析评估Lynch综合征的肿瘤检出率,并分析肿瘤发生的人口学、基因型和风险因素。检索MEDLINE、EMBASE、classic+EMBASE、Cochrane Library和ClinicalTrials.gov至2025年2月,纳入报告Lynch综合征结直肠肿瘤检出率的研究。主要结局为腺瘤检出率、进展期腺瘤检出率、锯齿状病变检出率和结直肠癌检出率的合并值。开展亚组分析以评估风险因素和结肠镜检查质量的影响。共纳入36项研究,包含15 227名Lynch综合征携带者的45 421次结肠镜检查。合并检出率为:腺瘤检出率23.3%(95%CI 20.6-26.3),进展期腺瘤检出率5.3%(95%CI 4.5-6.3),锯齿状病变检出率8.6%(95%CI 6.3-11.7),结直肠癌检出率2.5%(95%CI 1.9-3.3);近端腺瘤检出率更高(16.4%对远端11.9%),平坦型腺瘤比例增加(平坦型腺瘤检出率16.1%)。完成率和肠道准备数据的可获取例数分别为16 647次(36.7%)和13 637次(30.0%)操作。腺瘤检出率在排除质量差或不完整操作的试验人群中最高(30.7%),其次为前瞻性观察研究(24.0%)和回顾性观察研究(18.5%)。进展期肿瘤发生率在MLH1/MSH2携带者中高于MSH6/PMS2携带者:MLH1(进展期腺瘤检出率5.1%,结直肠癌检出率5.1%)和MSH2/EPCAM(进展期腺瘤检出率6.3%,结直肠癌检出率4.7%)对MSH6(进展期腺瘤检出率3.5%,结直肠癌检出率3.1%)和PMS2(进展期腺瘤检出率4.1%,结直肠癌检出率4.2%)。研究刻画了Lynch综合征的肿瘤检出情况,并确认高质量操作可提高检出率,支持建立质量标准和肿瘤检出结局基准的必要性。
Long-term outcome data for focal therapy using high-intensity focused ultrasound (HIFU) or cryotherapy for nonmetastatic prostate cancer are needed. We report 10-yr cancer control outcomes. Patients with nonmetastatic prostate cancer who underwent primary focal HIFU or cryotherapy and had at least 6 mo follow-up were identified from the UK HIFU Evaluation and Assessment of Treatment (HEAT) and International Cryotherapy Evaluation (ICE) prospectively maintained registries. The intervention included up to two focal ablative sessions. The primary outcome was cancer-specific mortality. Secondary outcomes were all-cause mortality, metastasis, local retreatment, radical treatment, and androgen-deprivation therapy (ADT) use. A total of 3477 patients (HIFU: n = 2897; cryotherapy: n = 580) were included from 14 UK centres (2004-2024). A total of 48%, 23%, and 25% had European Association of Urology (EAU) 2025-version favourable intermediate-, unfavourable-intermediate-, and high-risk disease, respectively. Ten-yr cancer-specific mortality was 0.13% (95% confidence interval [CI] = 0.027-0.45%). Ten-yr all-cause mortality and metastases were 12% (95% CI = 8.8-15%) and 3.3% (95% CI = 2.1-4.9%), respectively. Ten-yr ADT use was 14% (95% CI = 11-17%). Ten-yr local retreatment and radical treatment were 33% (95% CI = 30-37%) and 30% (95% CI = 27-34%), respectively, on an intention-to-treat basis. In a post hoc per-protocol analysis, undertaken to estimate outcomes under stricter adherence to the two focal ablative session protocol, patients who underwent radical treatment despite being potentially eligible for a further focal ablative session were censored at the time of radical treatment; 10-yr local retreatment and radical treatment were 13% (95% CI = 11-16%) and 8.9% (95% CI = 6.9-11%), respectively. The observational study design is the main limitation. Focal therapy using up to two sessions of focal HIFU or cryotherapy could be considered as a first-line treatment for well-selected patients of nonmetastatic prostate cancer alongside radical treatment. Future research priorities should include the development of a dedicated prognostic risk calculator, further prospective assessment of focal therapy for high-risk disease, and improvements in the detection and management of locally recurrent disease.
中文摘要:非转移性前列腺癌采用高强度聚焦超声(HIFU)或冷冻治疗进行局灶治疗,需要长期结局数据。报告10年肿瘤控制结局。从英国HIFU评估与治疗(HEAT)及国际冷冻治疗评估(ICE)前瞻性维护登记数据库中,纳入接受初次局灶HIFU或冷冻治疗且随访至少6个月的非转移性前列腺癌患者。干预为最多两次局灶消融治疗。主要结局为前列腺癌特异性死亡。次要结局为全因死亡、转移、局部再治疗、根治性治疗及雄激素剥夺治疗(ADT)使用。共纳入来自英国14个中心的3477例患者(HIFU 2897例,冷冻治疗580例),时间范围为2004年至2024年。分别有48%、23%和25%的患者为欧洲泌尿外科学会(EAU)2025版预后良好中危、预后不良中危和高危疾病。10年前列腺癌特异性死亡率为0.13%(95%置信区间0.027-0.45%)。10年全因死亡率和转移率分别为12%(95%置信区间8.8-15%)和3.3%(95%置信区间2.1-4.9%)。10年ADT使用率为14%(95%置信区间11-17%)。在意向性治疗分析中,10年局部再治疗率和根治性治疗率分别为33%(95%置信区间30-37%)和30%(95%置信区间27-34%)。事后符合方案分析用于估计更严格遵循两次局灶消融方案时的结局;在该分析中,尽管可能适合再次局灶消融但仍接受根治性治疗的患者,在根治性治疗时点作删失处理;10年局部再治疗率和根治性治疗率分别为13%(95%置信区间11-16%)和8.9%(95%置信区间6.9-11%)。观察性研究设计是主要局限。对经充分选择的非转移性前列腺癌患者,最多两次局灶HIFU或冷冻治疗的局灶治疗可作为与根治性治疗并列的一线治疗选择。未来研究重点包括开发专用的预后风险计算器、进一步前瞻性评估局灶治疗用于高危疾病,以及改进局部复发疾病的检测和管理。
Magnetic resonance imaging-targeted prostate biopsy relies heavily on costly software-fusion platforms, limiting global accessibility. We aimed to determine whether cognitive fusion (mental registration) is noninferior to software-based fusion targeted biopsy for detecting clinically significant prostate cancer (csPCa). This multicenter, randomized, blinded, noninferiority trial enrolled 648 predominantly biopsy-naive men (prostate-specific antigen 4-20 ng/ml; Prostate Imaging Reporting and Data System ≥3) at nine centers in China. Participants were randomly assigned 1:1 to cognitive fusion or software-based fusion targeted biopsy, followed by systematic biopsy. The primary outcome was csPCa (ISUP grade group ≥2) detection on targeted biopsy, evaluated using generalized estimating equations with a prespecified -10 percentage point noninferiority margin. In the intention-to-treat population (327 cognitive and 321 software), targeted biopsy detected csPCa in 32% and 34% of the patients, respectively. The adjusted risk difference was -1.02 percentage points (90% confidence interval [CI], -5.6 to 3.6), establishing noninferiority. Combined targeted and systematic biopsy detected csPCa in 35-39% of the patients, respectively (difference, -1.50% [90% CI, -6.4 to 3.4]). A significant body mass index (BMI) interaction was observed (p < 0.001): cognitive fusion performed best in men with BMI <24 kg/m2, whereas software-based fusion improved detection in men with BMI ≥24 kg/m2. Adverse event rates were comparable (15% vs 18%). Limitations include conducting the trial predominantly in Asian populations, necessitating cautious geographic extrapolation of specific BMI cutoffs. Cognitive fusion is diagnostically noninferior to software-based fusion within a prespecified -10% margin overall. However, a significant BMI interaction raises serious concerns regarding the diagnostic feasibility of cognitive fusion in obese populations, where software-based fusion is strictly superior. Future prospective trials in both Asian and Western populations must evaluate the BMI effect as a primary end point. ClinicalTrials.gov NCT04271527.
中文摘要:磁共振成像靶向前列腺活检高度依赖昂贵的软件融合平台,限制了全球可及性。本研究旨在确定认知融合(心理配准)在检出临床显著性前列腺癌(csPCa)方面是否非劣于软件融合靶向活检。这项多中心、随机、盲法、非劣效试验在中国9个中心纳入648名以初次活检为主的前列腺特异性抗原4-20 ng/ml、前列腺影像报告和数据系统评分≥3的男性。参与者按1:1随机分配接受认知融合或软件融合靶向活检,随后进行系统活检。主要结局为靶向活检检出的csPCa(ISUP分级分组≥2),采用广义估计方程评估,预设非劣效界值为-10个百分点。在意向治疗人群(认知融合327例,软件融合321例)中,靶向活检分别检出32%和34%的csPCa。调整后风险差为-1.02个百分点(90%置信区间-5.6至3.6),确立非劣效性。联合靶向与系统活检分别检出35-39%的csPCa(差值-1.50%,90%置信区间-6.4至3.4)。观察到显著的体重指数(BMI)交互作用(p<0.001):认知融合在BMI<24 kg/m2的男性中表现最佳,软件融合在BMI≥24 kg/m2的男性中提高检出。不良事件发生率相当(15%对18%)。局限性包括试验主要在亚洲人群中开展,对特定BMI切点的地理外推需谨慎。总体上,在预设-10%界值内,认知融合的诊断效能非劣于软件融合。然而,显著的BMI交互作用引发对认知融合在肥胖人群中诊断可行性的严重担忧,在该人群中软件融合严格更优。未来在亚洲和西方人群中开展的前瞻性试验必须将BMI效应作为主要终点评估。ClinicalTrials.gov NCT04271527。
Esophageal cancer (EC) remains highly lethal partly because many patients are diagnosed at advanced stages, and current diagnostic pathways rely on invasive endoscopy and centralized molecular testing. Circulating microRNAs (miRNAs) are promising minimally invasive biomarkers, yet amplification-based assays can be workflow-intensive and introduce protocol-dependent bias. Here we report an amplification-free, dual-readout gold nanoparticle (AuNP) biosensor for hsa-miR-320b analysis in plasma RNA extracts. Target miR-320b bridges a biotinylated capture probe on streptavidin magnetic beads and a thiolated detection probe on 40-nm AuNPs to form sandwich complexes. A shared magnetic-separation workflow enables two sequential readouts: a colorimetric verification based on AuNP depletion in the supernatant (LOD 0.085 pM) and a digital release-to-count (R2C) mode, in which RNase H selectively cleaves the RNA strand within the DNA/RNA heteroduplex to release AuNP-DNA labels for dark-field single-particle counting (LOD 5.3 fM) without nucleic-acid amplification. The assay demonstrates single-base mismatch discrimination, short-term storage stability, and spike recoveries of 89.8 -92.9% in plasma RNA extracts. In a cohort of 60 clinical plasma samples (20 EC, 20 benign lesions, 20 healthy controls), the R2C digital readout showed an EC-associated elevation of plasma miR-320b relative to benign lesions and healthy controls, with trends consistent with reverse transcription quantitative PCR (RT-qPCR) on the same extracts. This work provides a practical route to amplification-free digital miRNA quantification using countable plasmonic labels and is readily extended to other circulating targets.
中文摘要:食管癌(EC)致死率较高,部分原因在于许多患者确诊时已处晚期,现有诊断路径依赖侵入性内镜和集中化分子检测。循环microRNA(miRNA)是有前景的微创生物标志物,但基于扩增的检测流程较繁复,并可能引入依赖方案的偏倚。我们报道一种无扩增、双读出金纳米颗粒(AuNP)生物传感器,用于血浆RNA提取物中hsa-miR-320b分析。目标miR-320b将链霉亲和素磁珠上的生物素化捕获探针与40 nm AuNP上的硫醇化检测探针桥接,形成三明治复合物。共享的磁分离流程支持两种连续读出:基于上清液中AuNP耗减的比色验证(检出限0.085 pM),以及数字释放计数(R2C)模式,其中RNase H选择性切割DNA/RNA异源双链中的RNA链,释放AuNP-DNA标记用于暗场单颗粒计数(检出限5.3 fM),无需核酸扩增。该检测可区分单碱基错配,具有短期储存稳定性,在血浆RNA提取物中的加标回收率为89.8–92.9%。在60例临床血浆样本(20例EC、20例良性病变、20例健康对照)队列中,R2C数字读出显示,相对于良性病变和健康对照,EC相关的血浆miR-320b升高,其趋势与同一提取物上的逆转录定量PCR(RT-qPCR)一致。这项工作为利用可计数等离激元标记实现无扩增数字miRNA定量提供了可行路径,并易扩展至其他循环靶标。
Endoscopists' colonoscopy adenoma detection rates (ADRs) are inversely associated with their patients' risk of postcolonoscopy colorectal cancer death. Although randomized controlled trials have found that computer-aided detection (CADe) devices significantly improve ADRs, real-world studies have generally failed to demonstrate a benefit. In this pragmatic quality improvement study, randomly selected Veterans Health Administration facilities were equipped with CADe devices between October 2022 and February 2023. Control facilities were assigned a random deployment date. Adenoma detection was determined for colonoscopies, and mixed effects logistic regression was used to assess the independent effect of CADe availability on colonoscopy outcomes. Colonoscopy data were available from 269 endoscopists at 42 facilities with CADe performing 71,594 pre- and 35,399 postdeployment colonoscopies; and from 547 endoscopists at 97 control facilities performing 151,792 pre- and 75,415 postdeployment colonoscopies. Comparing post- with predeployment colonoscopies, the absolute increase in ADR was 4.2 percentage points (95% CI, 3.48 to 4.74 percentage points), from 50.7% to 54.9%, at CADe sites and ADR decreased by 0.7 percentage points (95% CI, -1.16 to -0.28 percentage points), from 51.8% to 51.1%, at control sites. Using multivariable regression, CADe availability was associated with a significantly increased odds of adenoma detection (odds ratio, 1.22; 95% CI, 1.15 to 1.28), but was not associated with detection of other lesions or changes in withdrawal time. Baseline endoscopist ADR quintiles were not associated with the impact of CADe availability on ADR. Availability of CADe devices was associated with a significant increase in adenoma detection compared with usual care. The impact on cancer outcomes and potential endoscopist deskilling remains undetermined. gov Number: NCT05888623.
中文摘要:内镜医师的结肠镜腺瘤检出率(ADR)与其患者结肠镜检查后结直肠癌死亡风险呈负相关。随机对照试验发现计算机辅助检测(CADe)设备可显著提高ADR,但真实世界研究通常未能显示获益。在这项实用性质量改进研究中,2022年10月至2023年2月期间为随机选取的退伍军人健康管理局机构配备CADe设备,对照机构则被分配一个随机启用日期。研究针对结肠镜检查判定腺瘤检出情况,并用混合效应logistic回归评估CADe可用性对结肠镜检查结局的独立影响。数据来自42家配备CADe机构的269名内镜医师,其设备启用前后分别完成71,594例和35,399例结肠镜检查;以及97家对照机构的547名内镜医师,启用前后分别完成151,792例和75,415例结肠镜检查。与启用前相比,CADe机构启用后的ADR绝对升高4.2个百分点(95% CI,3.48至4.74个百分点),由50.7%升至54.9%;对照机构的ADR则下降0.7个百分点(95% CI,-1.16至-0.28个百分点),由51.8%降至51.1%。多变量回归显示,CADe可用性与腺瘤检出几率显著升高相关(比值比1.22;95% CI,1.15至1.28),但与其它病变的检出或退镜时间的变化无关。内镜医师基线ADR五分位与CADe可用性对ADR的影响无关。与常规诊疗相比,CADe设备的可用性与腺瘤检出显著增加相关。其对癌症结局的影响以及内镜医师技能可能退化的风险仍未确定。gov编号:NCT05888623。
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects the majority of individuals with diabetes and severe obesity, and is one of the most common indications for liver transplantation in the U.S. Emerging evidence underscores the synergistic and detrimental impact of alcohol and metabolic disease on liver and overall health. In 2023, the nomenclature for steatotic liver disease was revised to include a new subcategory known as MetALD (metabolic dysfunction- and alcohol-associated liver disease), which acknowledges alcohol use as a cofactor in liver injury alongside metabolic risk factors. This review offers key insights into the role of alcohol use as both a direct hepatotoxin and an indirect contributor to insulin resistance, dyslipidemia, and obesity. Notably, even light-to-moderate alcohol intake may hasten MASLD progression to cirrhosis and hepatocellular carcinoma, especially in individuals with existing metabolic disease, and can worsen cardiovascular disease risk. MetALD is associated with increased all-cause, cancer-related, and liver-related mortality in comparison with MASLD, reinforcing the importance of accurate alcohol assessment in managing diabetes and obesity. Diagnosis now requires stratifying alcohol use and integrating tools such as the Alcohol Use Disorders Identification Test (AUDIT) questionnaire and phosphatidylethanol testing. The caveats and use of these tools in clinical practice are discussed. Management strategies for MASLD focus on lifestyle changes, weight loss, and medications such as glucagon-like peptide 1 receptor agonists, with emerging evidence suggesting that these agents may also reduce alcohol consumption. However, treatment data on MetALD are limited. This review offers practical guidance for health care professionals on how to integrate alcohol use into existing, recommended MASLD care pathways.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)影响大多数糖尿病和重度肥胖个体,也是美国肝移植最常见适应证之一。新证据强调酒精与代谢疾病对肝脏及整体健康具有协同且有害的影响。2023年,脂肪性肝病命名修订,纳入新亚类MetALD(代谢功能障碍和酒精相关肝病),承认酒精使用与代谢危险因素共同参与肝损伤。该综述提供关键认识:酒精既作为直接肝毒素,也间接促进胰岛素抵抗、血脂异常和肥胖。即使轻至中度饮酒也可能加速MASLD向肝硬化和肝细胞癌进展,尤其在已有代谢疾病者中,并可加重心血管疾病风险。与MASLD相比,MetALD与全因死亡、癌症相关死亡和肝相关死亡增加相关,凸显在糖尿病和肥胖管理中准确评估酒精使用的重要性。诊断现在需要对酒精使用进行分层,并整合酒精使用障碍筛查试验(AUDIT)问卷和磷脂酰乙醇检测等工具。文中讨论这些工具的注意事项及临床实践中的使用。MASLD管理策略聚焦生活方式改变、减重以及胰高血糖素样肽1受体激动剂等药物,新证据提示这类药物也可能减少酒精摄入。然而,MetALD的治疗数据有限。该综述为医疗专业人员提供实用指导,说明如何将酒精使用纳入现有推荐的MASLD照护路径。
Bi-parametric magnetic resonance imaging (bpMRI) is widely used for non-invasive diagnosis of clinically significant prostate cancer (csPCa). Although the Prostate Imaging Reporting and Data System (PI-RADS) standardizes interpretation through structured diagnostic criteria, clinical assessment remains highly operator-dependent. Vision-language models (VLMs), such as CLIP, offer a promising automated solution by leveraging the imaging-language coupling inherent in PI-RADS. However, existing VLM adaptation methods generally treat medical diagnosis as a generic image-to-label matching task. This conventional "label-driven" paradigm relies on superficial semantic correlations, fundamentally failing to capture the structured reasoning, anatomical context, and sequence prioritization defined by clinical guidelines like PI-RADS. To address this fundamental limitation, we propose KAMP-Net, a multi-modal prompt-tuning network that shifts the paradigm toward "knowledge-driven" learning. Our core algorithmic novelty lies in mathematically translating structured PI-RADS criteria directly into the network's computational graph. Specifically, rather than employing generic feature fusion and global alignment, KAMP-Net utilizes zone-aware modality routing to dynamically gate heterogeneous bpMRI sequences, and enforces a hierarchical vision-language alignment that structurally mirrors a radiologist's bottom-up diagnostic workflow. Experiments on a multi-center cohort comprising two public and one private datasets, plus an external private dataset, show that KAMP-Net delivers competitive performance in both patient-level diagnosis and lesion-level localization. Beyond standalone performance, we evaluated its clinical utility in an AI-assisted workflow. Notably, for challenging equivocal cases (PI-RADS = 3), this human-in-the-loop strategy successfully reduces false positives without risking missed diagnoses, demonstrating its strong potential as a reliable decision-support tool. Code is available at: https://github.com/IsYuchenYuan/KAMP-Net.
中文摘要:双参数磁共振成像(bpMRI)广泛用于临床显著性前列腺癌(csPCa)的无创诊断。前列腺影像报告和数据系统(PI-RADS)通过结构化诊断标准规范了图像解读,但临床评估仍高度依赖操作者。CLIP等视觉语言模型(VLMs)可利用PI-RADS中固有的影像与语言耦合,为自动化诊断提供有前景的方案。现有VLM适配方法通常将医学诊断视为通用的图像到标签匹配任务,这种「标签驱动」范式依赖表层语义关联,难以捕捉PI-RADS等临床指南定义的结构化推理、解剖语境和序列优先级。为克服这一根本限制,我们提出KAMP-Net,一种多模态提示调优网络,将范式转向「知识驱动」学习。其核心算法创新在于将结构化PI-RADS标准以数学方式直接转化为网络计算图。具体而言,KAMP-Net不采用通用特征融合与全局对齐,而是使用分区感知的模态路由对异质bpMRI序列进行动态门控,并实施分层视觉语言对齐,使结构与放射科医师自下而上的诊断流程相呼应。在包含两个公共数据集和一个私有数据集的多中心队列以及一个外部私有数据集上的实验显示,KAMP-Net在患者级诊断和病灶级定位方面均具有有竞争力的性能。除独立性能外,我们还在AI辅助工作流中评估其临床效用。对于困难的模棱两可病例(PI-RADS = 3),这种人机协同策略在不增加漏诊风险的情况下成功减少了假阳性,显示出其作为可靠决策支持工具的较强潜力。代码见:https://github.com/IsYuchenYuan/KAMP-Net。
Off-label use of anticancer medicines is common. Investigator-initiated trials evaluating off-label indications often do not result in label expansion. Additionally, off-label use is often considered when approved treatments are lacking or exhausted. Such use may lead to uncertain efficacy and safety and poses reimbursement challenges. This study examines the Dutch framework to evaluate off-label indications for population-level reimbursement. We quantify national off-label oncology drug use and analyse its supporting evidence to identify clinical needs and support policy development. We identified reimbursable oncology indication-drug pairs (IDPs) using the World Health Organization Anatomical Therapeutic Chemical classification. Approved and off-label indications were mapped using European Medicines Agency marketing authorisations, European Society for Medical Oncology guidelines, medical literature, and the national medicines database. National 2023 health care registry data were analysed to quantify off-label prescribing and expenditure for high-cost oncology drugs. Evidence supporting selected off-label treatments was evaluated using public assessment reports and clinical guidelines. As of January 2025, 331 of 930 (35.6%) reimbursable oncology IDPs were off-label, mainly involving high-cost drugs (n = 299 of 331, 90.3%). Off-label treatments frequently involved chemotherapy, accounting for 67.1% (n = 163 of 331) of off-label IDPs. Targeted therapies comprised 32.9% (n = 109 of 331). For high-cost drugs, 24.4% (n = 41 238 of 169 043) of prescriptions were off-label in 2023, representing only 2.3% (€30.3 million of €1.3 billion) of total expenditure on these drugs. Targeted therapies posed the largest financial impact, representing 67.7% (€20.5 of €30.3 million) of off-label expenditure. The Dutch framework reimbursed off-label treatments meeting thresholds for clinical benefit. Frequently used off-label treatments were supported by strong evidence. Evidence levels varied for rarer indications. The high prevalence of off-label oncology treatments in The Netherlands underscores the importance of a framework to evaluate off-label indications for reimbursement, ensuring access to effective and financially sustainable treatments. It also highlights the need for policy reform to encourage regulatory approval.
中文摘要:抗癌药物的超说明书使用很常见。评估超说明书适应症的研究者发起试验往往未能带来标签扩展。此外,在缺乏或已用尽获批治疗时,常会考虑超说明书使用。此类使用可能导致疗效和安全性不确定,并带来报销难题。本研究考察荷兰针对超说明书适应症人群层面报销的框架。我们量化全国肿瘤药物超说明书使用情况,并分析其支持性证据,以识别临床需求并支持政策制定。我们使用世界卫生组织解剖治疗化学分类识别可报销的肿瘤适应症-药物对(IDPs)。获批与超说明书适应症通过欧洲药品管理局上市许可、欧洲肿瘤内科学会指南、医学文献和国家药品数据库进行映射。分析2023年全国医疗登记数据,以量化高成本肿瘤药物的超说明书处方和支出。所选超说明书治疗的支持性证据通过公开评估报告和临床指南进行评估。截至2025年1月,930个可报销肿瘤IDPs中有331个(35.6%)为超说明书,主要涉及高成本药物(331个中299个,90.3%)。超说明书治疗常涉及化疗,占超说明书IDPs的67.1%(331个中163个)。靶向治疗占32.9%(331个中109个)。对于高成本药物,2023年24.4%的处方为超说明书(169043张中41238张),仅占这些药物总支出的2.3%(13亿欧元中3030万欧元)。靶向治疗带来的财务影响最大,占超说明书支出的67.7%(3030万欧元中2050万欧元)。荷兰框架报销达到临床获益阈值的超说明书治疗。频繁使用的超说明书治疗有强证据支持。较罕见适应症的证据水平不一。荷兰肿瘤超说明书治疗的高比例凸显了建立评估超说明书适应症以进行报销的框架的重要性,以确保患者获得有效且财务可持续的治疗。这也凸显了推动监管批准的政策改革需求。
Early diagnosis and accurate staging are essential for improving treatment efficacy and clinical outcomes of pancreatic cancer (PC), but remain challenging because of limited early PC-specific biomarkers and high-performance detection methods. In this paper, we developed a machine learning (ML)-enhanced terahertz (THz)-colorimetric dual-mode metadevice based on metallic nanonetworks for multiplexed microRNA (miRNA) detection and early PC diagnosis. Clinical sample measurements and bioinformatics analysis identified miRNA-21, miRNA-1290, and miRNA-320a as candidate PC biomarkers. Target miRNAs triggered the assembly of DNA-functionalized Fe and Au nanoparticles (NPs) with PEI-modified CuS NPs into ternary Fe/Au/Cu nanonetworks, generating THz and colorimetric signals through their dielectric and peroxidase-like properties. This target-triggered assembly enabled three-miRNA panel analysis without enzyme-mediated nucleic acid amplification and achieved attomolar-level miRNA profiling. Six ML algorithms were integrated to develop predictive models for PC diagnosis and staging. Linear discriminant analysis (LDA) achieved diagnostic accuracies of 97.8% (95% CI: 88.2-99.9%) in the training cohort (n = 45) and 96.7% (95% CI: 82.8-99.9%) in the validation cohort (n = 30), with 100% sensitivity for early PC in both cohorts. Compared with CA19-9, CA125, and CEA, the multiplexed miRNA-based dual-mode metadevice showed higher efficacy (area under the curve, AUC: 1.00 vs 0.905), supporting its potential for clinical miRNA-based liquid biopsy.
中文摘要:早期诊断和准确分期对提高胰腺癌的治疗效果和临床结局至关重要,但早期胰腺癌特异性生物标志物有限、高性能检测方法不足,使这一目标仍面临挑战。研究构建了基于金属纳米网络的机器学习增强太赫兹-比色双模式超构器件,用于多重微小RNA检测和胰腺癌早期诊断。临床样本检测和生物信息学分析筛选出miRNA-21、miRNA-1290和miRNA-320a作为候选胰腺癌生物标志物。目标miRNA触发DNA功能化铁纳米颗粒和金纳米颗粒与PEI修饰的CuS纳米颗粒组装成三元Fe/Au/Cu纳米网络,并借助其介电特性和类过氧化物酶特性产生太赫兹信号和比色信号。这种目标触发的组装无需酶介导的核酸扩增即可完成三种miRNA组合分析,并实现阿托摩尔级miRNA谱分析。整合六种机器学习算法建立胰腺癌诊断和分期的预测模型。线性判别分析在训练队列(n = 45)中的诊断准确率为97.8%(95% CI:88.2-99.9%),在验证队列(n = 30)中为96.7%(95% CI:82.8-99.9%),两个队列对早期胰腺癌的敏感性均为100%。与CA19-9、CA125和CEA相比,基于多重miRNA的双模式超构器件表现出更高效能(曲线下面积,AUC:1.00 对 0.905),支持其用于临床miRNA液体活检的潜力。
基础研究 (46篇)
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest human cancers, driven in 90% of cases by KRAS mutations and characterized by an intense desmoplastic reaction, early metastasis, and therapy resistance. The mechanisms driving PDAC initiation, however, remain poorly understood because early acinar transformation is difficult to model in a controlled microenvironment. Here, we introduce a microvalve-bioprinted 3D pancreatic cancer initiation niche that supports culture of primary acini from wild-type and Kras-mutant mice, up to 14 days, within gelatin-methacryloyl (GelMA) hydrogels. Our printing strategy enables tuning of hydrogel stiffness to cover the range reported for healthy murine pancreas and early stages of desmoplastic remodelling. In this system, wild-type acini retain a predominantly acinar phenotype, whereas intermediate GelMA conditions cooperate with pre-existing oncogenic Kras to promote acinar-to-ductal metaplasia and proliferative programs associated with early neoplastic reprogramming. Multimodal readouts revealed a stiffness-permissive window in which mechanical cues cooperated with oncogenic Kras to promote acinar transdifferenciation, proliferation and distinct stiffness-dependent secretory programs, including inflammatory and stromal-associated factors with previously reported relevance to PDAC biology. The deterministic droplet geometry supported reproducible, high-throughput, and longitudinal analysis under conditions inaccessible to conventional extrusion or laser‑assisted bioprinting, providing an experimental framework to study early Kras-driven acinar reprogramming.
中文摘要:胰腺导管腺癌(PDAC)仍是最致命的人类癌症之一,其中90%的病例由KRAS突变驱动,以强烈的促结缔组织增生反应、早期转移和治疗抵抗为特征。然而,由于早期腺泡转化难以在可控微环境中建模,PDAC发生的驱动机制仍不清楚。在此,我们介绍一种微阀生物打印的3D胰腺癌起始微环境,可在明胶甲基丙烯酰基(GelMA)水凝胶中支持野生型和Kras突变小鼠原代腺泡培养长达14天。我们的打印策略能够调节水凝胶硬度,覆盖健康小鼠胰腺以及促结缔组织增生重塑早期阶段所报道的硬度范围。在该系统中,野生型腺泡主要保持腺泡表型,而中等GelMA条件与预先存在的致癌Kras协同,促进腺泡-导管化生和与早期肿瘤性重编程相关的增殖程序。多模式读出揭示了一个硬度允许窗口,其中机械线索与致癌Kras协同促进腺泡转分化、增殖以及不同的硬度依赖性分泌程序,包括炎症和基质相关因子,这些因子此前已被报道与PDAC生物学相关。确定性的液滴几何结构支持在传统挤出或激光辅助生物打印无法实现的条件下进行可重复、高通量和纵向分析,为研究早期Kras驱动的腺泡重编程提供了实验框架。
The rapid growth of metabolomics data has increased the need for integrated storage, analysis, and reuse. Here, we present Metabolomics Subcenter (Met-SC) V1.0 (https://metabolomics.dicp.ac.cn/), an integrated database and platform for standardized data deposition, spectral-resource management, online analysis, and disease-focused knowledge mining. The deposition framework captures project, sample, pretreatment, and instrument metadata across chromatographic, capillary electrophoresis-mass spectrometry, and nuclear magnetic resonance workflows. Met-SC contains 7 756 867 reference spectra associated with 1 989 680 unique compounds and 73 014 049 unknown-feature spectra derived from diverse biological matrices and experimental conditions. Its web-based analysis module provides 27 functions for data preprocessing, quality-control visualization, and statistical analysis. Metabolism-centered knowledge graph for colorectal cancer (MetKG-CRC) comprises 108 679 biomolecular entities and 600 093 literature-supported evidence triples. By linking data deposition, spectral resources, analysis, and evidence-supported knowledge exploration in a single platform, Met-SC facilitates reproducible metabolomics data management and downstream discovery.
中文摘要:代谢组学数据的快速增长增加了对整合存储、分析和再利用的需求。这里介绍 Metabolomics Subcenter(Met-SC)V1.0(https://metabolomics.dicp.ac.cn/),一个用于标准化数据提交、谱资源管理、在线分析和以疾病为导向的知识挖掘的整合数据库与平台。其数据提交框架可记录项目、样本、预处理和仪器元数据,覆盖色谱、毛细管电泳-质谱和核磁共振工作流程。Met-SC 包含 7 756 867 张参考谱,关联 1 989 680 个唯一化合物,并包含 73 014 049 张未知特征谱,来源于多种生物基质和实验条件。其基于网页的分析模块提供 27 项功能,用于数据预处理、质量控制可视化和统计分析。以代谢为核心的结直肠癌知识图谱(MetKG-CRC)包含 108 679 个生物分子实体和 600 093 条文献支持的证据三元组。通过将数据提交、谱资源、分析和证据支持的知识探索连接在同一平台,Met-SC 促进可重复的代谢组学数据管理和下游发现。
Transposable elements (TEs) are broadly reactivated in tumors, but their repetitive nature has limited transcript-level characterization. Here, we systematically investigate the TE-derived splicing landscape across pan-cancer samples and define a splice-resolved subset of TE-derived transcripts, termed TEtrans, with tumor enrichment and gene independence. TEtrans initiate within TEs, spliced within or between TE loci, and are composed predominantly of TE sequences. Their expression was associated with stemness and inflammation regulators in a context-dependent manner. Functional analyses identify an endogenous retrovirus-derived TEtrans that promotes colorectal cancer growth by enhancing topoisomerase I-mediated DNA relaxation. A subset of TEtrans encodes shared tumor antigens that elicit antigen-specific cytotoxic T cell responses, while a murine TEtrans-like transcript mediates antigen-dependent tumor control in vivo. Collectively, TEtrans represent a splice-resolved source of TE-derived oncogenic drivers and actionable tumor antigens, broadening the scope of TE reactivation in cancer.
中文摘要:转座元件(TE)在肿瘤中广泛重新激活,但其重复性限制了转录本水平的表征。我们对泛癌样本中的TE来源剪接图谱进行了系统研究,定义了一类经剪接解析的TE来源转录本亚群,称为TEtrans,具有肿瘤富集和基因独立性。TEtrans起始于TE内部,在TE位点内或位点间剪接,主要由TE序列组成。其表达与干性和炎症调控因子相关,并呈情境依赖。功能分析鉴定出一个内源性逆转录病毒来源的TEtrans,通过增强拓扑异构酶I介导的DNA松弛促进结直肠癌生长。一部分TEtrans编码共享肿瘤抗原,可引发抗原特异性细胞毒性T细胞反应;一个小鼠TEtrans样转录本在体内介导抗原依赖性肿瘤控制。这些结果说明,TEtrans是经剪接解析的TE来源致癌驱动因子和可操作肿瘤抗原的来源,拓宽了TE在癌症中重新激活的范围。
Controlling the delivery of chemotherapy to the tumor site is a long-standing goal of the medical field, as it could not only enhance the anticancer activity of the treatment but also reduce damage to the rest of the body. The emergence of bioorthogonal catalysis as a strategy capable of mediating continuous drug production in a nonenzymatic fashion has created the opportunity to develop so-called "bioorthogonal therapies," which aim to generate the anticancer agents inside the tumors. Herein, we describe a novel class of supramolecular materials comprising ultrathin palladium nanosheets and fluorenylmethoxycarbonyl-diphenylalanine that self-assemble in water to form injectable, self-healing, biocompatible catalytic gels that convert inactive prodyes and prodrugs into active small molecules. The relatively weak physicochemical cross-links generated by the hybrid metal-peptide fibers facilitate the flow of the gel under mild shear stress (shear-thinning), thereby enabling precise intratumoral injections in vivo and localized prodrug activation. The strategy was validated in an aggressive pancreatic cancer xenograft model in mice, setting out a new direction for the field of bioorthogonal therapies.
中文摘要:将化疗药物精准递送至肿瘤部位是医学领域长期追求的目标,这既能增强治疗的抗癌活性,也能减轻对身体其他部位的损伤。生物正交催化能够以非酶方式介导药物的持续生成,这一策略的出现为发展所谓「生物正交疗法」创造了机会,其目标是在肿瘤内部生成抗癌药物。这里描述了一类新型超分子材料,由超薄钯纳米片与芴甲氧羰基-二苯丙氨酸组成,可在水中自组装形成可注射、自修复、生物相容的催化凝胶,将非活性前体染料和前药转化为活性小分子。杂化金属-肽纤维产生的物理化学交联相对较弱,使凝胶在温和剪切应力下流动(剪切变稀),从而能够在体内实现精准瘤内注射和局部前药活化。该策略在侵袭性胰腺癌小鼠异种移植模型中得到验证,为生物正交疗法领域指明了新方向。
Ribosomal frameshifting, an uncommon translational recoding event, is best known for its regulatory roles in viral gene expression1,2, whereas its physiological relevance in mammals remains poorly understood. Here we show that specific codon pairs trigger efficient -1 frameshifting preferentially in cancer cells. Mechanistically, this recoding arises from ribosomal pausing associated with tRNA and amino acid availability, and is amplified by impaired ribosome quality control and sustained phosphorylation of ribosomal protein S6. We found that this codon-pair-specific frameshifting represents an intrinsic state of translational dysregulation, which is prevalent across cancer cells and reshapes protein synthesis. Taking advantage of this frameshifting-permissive state in cancer cells, we engineered a frameshifting-activated synthetic therapeutic circuit (FAST) that conditionally expresses the pyroptotic effector gasdermin D. FAST is activated across diverse cancer cell types, inducing potent and selective pyroptosis, while sparing normal tissues from detectable toxicity. As a proof of concept, systemic AAV9-mediated delivery of FAST in mouse models of colorectal and pancreatic cancer elicited pronounced tumour regression, robust immune activation and synergistic effects with immune checkpoint blockade. Collectively, these findings reveal codon-pair-dependent ribosomal frameshifting as a feature of translational dysregulation in cancer cells and establish translation-coupled gene circuits as a strategy for cancer-selective therapy.
中文摘要:核糖体移码是一种不常见的翻译重编码事件,已知主要调控病毒基因表达,但其在哺乳动物中的生理相关性仍不清楚。研究发现,特定密码子对可优先在癌细胞中触发高效的-1移码。机制上,这种重编码源于与tRNA和氨基酸可利用性相关的核糖体停滞,并因核糖体质量控制受损及核糖体蛋白S6持续磷酸化而增强。密码子对特异性移码构成一种内在的翻译失调状态,普遍存在于癌细胞中并重塑蛋白质合成。利用癌细胞这种允许移码的状态,研究构建了移码激活的合成治疗回路FAST,可条件性表达焦亡效应分子gasdermin D。FAST在多种癌细胞类型中激活,诱导强效且选择性的焦亡,同时正常组织未出现可检测毒性。作为概念验证,在结直肠癌和胰腺癌小鼠模型中经全身给予AAV9递送FAST,引起明显肿瘤消退、强烈免疫激活,并与免疫检查点阻断产生协同效应。这些结果揭示密码子对依赖性核糖体移码是癌细胞翻译失调的一个特征,并确立翻译偶联基因回路作为癌症选择性治疗策略。
Hepatocellular carcinoma (HCC) typically arises within fibrotic, mechanically rigid microenvironments where matrix stiffness directly drives primary tumor proliferation and invasion. However, whether and how tumor cells retain these mechanical adaptations upon disseminating to softer metastatic sites has remained unclear. In this issue of Cancer Research, Luo and colleagues demonstrate that HCC cells retain a "mechanical memory" of matrix stiffness that persists even after metastasizing to soft secondary niches, such as the lungs. Mechanistically, this memory is mediated by contractility-dependent suppression of mitochondrial fission. The resulting accumulation of acetyl-CoA fuels sustained histone hyperacetylation, preserving a proliferative state across subsequent cell generations. These findings uncover a novel mechano-metabolic-epigenetic axis that sustains HCC proliferation during metastatic dissemination. See related article by Luo et al., p. 5354.
中文摘要:肝细胞癌(HCC)通常发生于纤维化、机械僵硬的微环境中,基质刚度直接驱动原发肿瘤的增殖和侵袭。然而,肿瘤细胞在播散至较软的转移部位后是否以及如何保留这些机械适应仍不清楚。在本期《Cancer Research》中,Luo等证明,HCC细胞保留了对基质刚度的「机械记忆」,即使转移到肺等软性继发生态位后这种记忆仍持续存在。机制上,该记忆由收缩力依赖的线粒体分裂抑制所介导。由此产生的乙酰辅酶A积累促进持续性的组蛋白高乙酰化,在后续细胞世代中维持增殖状态。这些发现揭示了一条新的机械-代谢-表观遗传轴,在转移播散过程中维持HCC增殖。参见Luo等第5354页的相关文章。
Fungi are crucial components of the human gut microbiota. Here, we investigated the role of fungi in metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma (MASLD-HCC). Rhizopus arrhizus was the top enriched fungus across the progression from MASLD to MASLD-HCC, accelerating tumorigenesis in multiple mouse models. R. arrhizus-conditioned medium increased cell proliferation while reducing cell cycle arrest and apoptosis in human MASLD-HCC cells. Kynurenic acid (KYNA) was identified as the crucial metabolite generated from R. arrhizus, and its upregulation was confirmed in portal vein, liver tissues, and stools of R. arrhizus-treated mice. KYNA promoted the proliferation of MASLD-HCC cells and accelerated tumorigenesis in mice. Mechanistically, KYNA directly bound to IQ motif containing GTPase activating protein 1 (IQGAP1) in tumor cells and activated the oncogenic mitogen-activated protein kinase (MAPK) signaling pathway, thereby facilitating MASLD-HCC development. In summary, R. arrhizus is a pathogenic fungus that promotes MASLD-HCC by producing KYNA. Blocking this host-fungi interaction is a potential therapeutic strategy to suppress MASLD-HCC.
中文摘要:真菌是人体肠道微生物群的重要组成部分。本研究探讨真菌在代谢功能障碍相关脂肪性肝病相关肝细胞癌(MASLD-HCC)中的作用。少根根霉(Rhizopus arrhizus)是在MASLD向MASLD-HCC进展过程中富集最显著的真菌,并在多种小鼠模型中加速肿瘤发生。少根根霉条件培养基可促进人MASLD-HCC细胞增殖,同时减少细胞周期阻滞和凋亡。犬尿喹啉酸(KYNA)被鉴定为少根根霉产生的关键代谢物,并且在少根根霉处理小鼠的门静脉、肝组织和粪便中确认其上调。KYNA促进MASLD-HCC细胞增殖,并加速小鼠肿瘤发生。机制上,KYNA在肿瘤细胞中直接结合含IQ基序的GTP酶激活蛋白1(IQGAP1),激活致癌性丝裂原活化蛋白激酶(MAPK)信号通路,从而促进MASLD-HCC发展。少根根霉是一种通过产生KYNA促进MASLD-HCC的致病真菌。阻断这种宿主与真菌的相互作用是抑制MASLD-HCC的潜在治疗策略。
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of hepatocellular carcinoma (HCC), but how metabolic zonation drives regional transformation remains unclear. We identify sirtuin 2 (SIRT2) as a zonated cholesterol sensor that initiates reprogramming to drive MASLD-HCC. Lineage tracing establishes zone 1 hepatocytes as the cellular origin of tumors. SIRT2 overexpression in zone 1 triggers HCC, whereas its deletion prevents carcinogenesis by restoring cholesterol and bile acid metabolism and CD8+ T cell recruitment. Mechanistically, cholesterol binds and activates SIRT2, which deacetylates sterol carrier protein 2 (SCP2) at Lys546, thereby blocking peroxisome proliferator-activated receptor α (PPARα) recruitment to the Cyp7b1 promoter, suppressing alternative bile acid synthesis, and permitting 27-hydroxycholesterol accumulation. SIRT2 inhibition reverses this cascade in mice and human hepatic organoids. Patient specimens confirm zonal SIRT2 and cytochrome P450 7B1 (CYP7B1) dysregulation. Our findings establish spatially compartmentalized cholesterol sensing as a new regulatory layer and identify SIRT2 as a druggable target in liver cancer.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)是肝细胞癌(HCC)的主要病因之一,但代谢分区如何驱动区域转化仍不清楚。研究识别出Sirtuin 2(SIRT2)作为一种分区分布的胆固醇感受器,启动重编程并驱动MASLD-HCC。谱系追踪确定1区肝细胞是肿瘤的细胞来源。1区SIRT2过表达触发HCC,而SIRT2缺失通过恢复胆固醇和胆汁酸代谢及CD8+ T细胞募集阻止癌变。机制上,胆固醇结合并激活SIRT2,SIRT2使甾醇载体蛋白2(SCP2)第546位赖氨酸去乙酰化,从而阻断过氧化物酶体增殖物激活受体α(PPARα)募集到Cyp7b1启动子,抑制替代性胆汁酸合成,允许27-羟基胆固醇积累。抑制SIRT2可在小鼠和人肝类器官中逆转这一级联。患者标本证实SIRT2和细胞色素P450 7B1(CYP7B1)的分区失调。这些发现确立空间分隔的胆固醇感知作为新的调控层,并将SIRT2确定为肝癌的可成药靶点。
Histone lactylation is an epigenetic modification triggered by lactate produced during glycolysis. In cancer, histone lactylation can coordinate metabolic and epigenetic states to promote tumor development and progression. In this study, we identified circ2891 as a driver of metabolic reprogramming and histone lactylation in colorectal cancer. In patients, circ2891 was aberrantly upregulated in tumors and correlated with poor outcomes. Elevated circ2891 potentiated aerobic glycolysis and lactate production in colorectal cancer cells, supporting enhanced cell proliferation and tumor growth. Mechanistically, circ2891 specifically interacted with the m6A reader FXR1 and facilitated its phase separation, which stabilized PGK1 and ENO1 mRNAs by enhancing the recognition of their m6A modification sites. Consequently, elevated PGK1 and ENO1 led to increased aerobic glycolysis and drove histone lactylation, thereby transcriptionally activating the RNA helicase DDX21 to promote colorectal cancer progression. Simultaneously targeting circ2891 and histone lactylation suppressed patient-derived organoid and xenograft tumor growth. Together, these findings show that circ2891 promotes colorectal cancer by stabilizing PGK1/ENO1 via phase separation of FXR1, boosting glycolysis and histone lactylation to activate expression of DDX21. Targeting circ2891 offers a promising therapeutic strategy enhancing clinical outcomes. A regulatory network orchestrated by circ2891 induces metabolic and epigenetic reprogramming to support tumor progression, highlighting circ2891 as a promising biomarker and therapeutic target in colorectal cancer.
中文摘要:组蛋白乳酸化是由糖酵解产生的乳酸触发的一种表观遗传修饰。在肿瘤中,组蛋白乳酸化可协调代谢与表观遗传状态,促进肿瘤发生和进展。circ2891 被鉴定为结直肠癌代谢重编程和组蛋白乳酸化的驱动因子。患者中,circ2891 在肿瘤内异常上调,并与不良结局相关。circ2891 升高增强结直肠癌细胞有氧糖酵解和乳酸生成,支持细胞增殖和肿瘤生长。机制上,circ2891 特异性结合 m6A 阅读蛋白 FXR1 并促进其相分离,通过增强对 PGK1 和 ENO1 mRNA m6A 修饰位点的识别而稳定二者。PGK1 和 ENO1 升高增加有氧糖酵解并驱动组蛋白乳酸化,进而转录激活 RNA 解旋酶 DDX21,促进结直肠癌进展。同时靶向 circ2891 和组蛋白乳酸化可抑制患者来源类器官和异种移植瘤生长。这些结果说明 circ2891 通过促进 FXR1 相分离稳定 PGK1/ENO1,增强糖酵解和组蛋白乳酸化以激活 DDX21 表达,从而促进结直肠癌。靶向 circ2891 有望成为改善临床结局的治疗策略。circ2891 编排的调控网络诱导代谢和表观遗传重编程以支持肿瘤进展,提示 circ2891 是结直肠癌有前景的生物标志物和治疗靶点。
Colorectal cancer (CRC) is one of the most diagnosed malignancies worldwide, with chronic inflammation playing a critical role in its pathogenesis and progression. Surgery represents the primary treatment option, though some patients suffer from relapse, leading to considerable morbidity and mortality. A better molecular understanding of CRC pathogenesis is therefore essential for identifying patients at increased risk of recurrence and improving clinical management. Here we identified the X-linked inhibitor of apoptosis protein (XIAP) as an independent predictor of overall survival in primary resected CRC patients. To model CRC patients with low versus high XIAP expression, we established conditional mouse lines for intestinal epithelial cell (IECs)-specific Xiap knock-out and XIAP knock-in, and employed a colitis-associated murine model for CRC. We found that XIAP promotes inflammatory signalling and exacerbates colitis-driven colorectal tumorigenesis by shaping a distinct tumor inflammatory microenvironment characterized by increased immune-cell infiltration, including neutrophils, and enhanced vascularisation. The pro-inflammatory role of XIAP was further validated in CRC patient-derived organoids and human CRC tumor specimens. Collectively, our findings identify XIAP as a potential biomarker of CRC-associated inflammation and a candidate marker for identifying patients at increased risk of disease recurrence. Moreover, these results provide a rationale for exploring XIAP-targeting strategies as a potential component of multimodal therapeutic approaches for CRC.
中文摘要:结直肠癌是全球最常见恶性肿瘤之一,慢性炎症在其发生和进展中起关键作用。手术是主要治疗选择,但部分患者出现复发,带来较高患病率和死亡率。因此,更深入理解CRC发病分子机制对于识别复发风险增高患者和改进临床管理十分必要。研究在原发灶切除的CRC患者中确认X连锁凋亡抑制蛋白(XIAP)是总生存期的独立预测因素。为模拟XIAP低表达和高表达CRC患者,建立肠上皮细胞特异性Xiap敲除和XIAP敲入的条件小鼠品系,并采用结肠炎相关小鼠CRC模型。发现XIAP促进炎症信号,并通过塑造独特的肿瘤炎症微环境加重结肠炎驱动的结直肠肿瘤发生,该微环境以免疫细胞浸润增加(包括中性粒细胞)和血管化增强为特征。XIAP的促炎作用在CRC患者来源类器官和人CRC肿瘤标本中得到进一步验证。这些发现将XIAP确定为CRC相关炎症的潜在生物标志物,以及识别疾病复发风险增高患者的候选标志物。这些结果为探索XIAP靶向策略作为CRC多模式治疗潜在组成部分提供了依据。
KRAS is the most frequently mutated oncogene in pancreatic cancer, with over 90% of patients harboring KRAS mutations, approximately 45% of which are G12D substitutions. The development of KRASG12D selective inhibitors, such as HRS-4642, MRTX1133 and RMC-9805, has brought new hope for treating this patient population. However, the clinical efficacy of these inhibitors is limited by the emergence of acquired resistance, the mechanisms of which remain incompletely understood. Our study employed a KRAS saturation mutagenesis library to systematically map the landscape of KRAS mutations conferring resistance to HRS-4642 and MRTX1133. We identified several secondary mutations-including R73P, E63P, D69W, and M72K-that confer resistance to both inhibitors, while M72H was found specifically resistant to HRS-4642. We further characterized the impact of these mutations on KRAS downstream signaling and performed structural modeling of the mutant proteins. Through molecular dynamics simulations, we suggested that the R73P mutation, although distant from the binding pocket, is predicted to exert a global dynamic effect on the allosteric site, thereby disrupting inhibitor-protein interactions. This suggests the existence of a novel class of KRAS resistance mutations and a previously unrecognized mechanism of acquired resistance to KRAS-targeted therapies. Furthermore, we identified Y64W, A59G, and R73P as mutations that concurrently confer resistance to the tri-complex inhibitor RMC-9805, as well as to the allosteric inhibitors MRTX1133 and HRS-4642. This comprehensive analysis delineates the global landscape of secondary resistance mutations to KRASG12D-selective inhibitors.
中文摘要:KRAS是胰腺癌中最常发生突变的癌基因,超过90%的患者携带KRAS突变,其中约45%为G12D替换。HRS-4642、MRTX1133和RMC-9805等KRAS G12D选择性抑制剂的开发为治疗这一患者群体带来了新希望。这类抑制剂的临床疗效受到获得性耐药出现的限制,其机制仍未完全阐明。本研究采用KRAS饱和突变文库,系统绘制了导致HRS-4642和MRTX1133耐药的KRAS突变图谱。研究鉴定出R73P、E63P、D69W和M72K等继发突变,它们可同时对这两种抑制剂产生耐药,而M72H仅对HRS-4642耐药。进一步表征了这些突变对KRAS下游信号传导的影响,并对突变蛋白进行了结构建模。通过分子动力学模拟,研究提示R73P突变尽管远离结合口袋,仍预计会对变构位点产生全局动态效应,从而破坏抑制剂与蛋白的相互作用。这提示存在一类新的KRAS耐药突变,以及一种此前未被认识的KRAS靶向治疗获得性耐药机制。研究还鉴定出Y64W、A59G和R73P可同时导致对三复合物抑制剂RMC-9805以及变构抑制剂MRTX1133和HRS-4642耐药。该综合分析勾勒出KRAS G12D选择性抑制剂继发耐药突变的整体图谱。
How intracellular proteins, normally hidden from the immune system, become targets of tumor-associated antibody responses remains unresolved, as does the function of such autoantibodies encoded by tumor-infiltrating B cells (TIL-Bs). Using monoclonal antibodies (mAbs) cloned from TIL-Bs in a spontaneous hepatocellular carcinoma (HCC) model, we define a class of antigens: secreted intracellular antigens (SICAs). Tumors co-opt upregulated autophagy to release cytosolic proteins, exemplified by ALDH1L1, through HSP90-mediated autophagy-dependent unconventional secretion. The resulting autoantibodies form immune complexes at the tumor site, where the SICA is locally available, recruiting and reprogramming neutrophils into tumor-associated neutrophils that drive tumor progression. Both neutrophil depletion and loss of Fcγ receptor binding abolish this effect. Autophagy-mediated SICA secretion and the corresponding autoantibody response are conserved in HCC patients and extend to lung, breast and cervical cancers. Tumors thus reshape their secretome to hijack humoral immunity, highlighting the SICA-autoantibody-FcγR axis as a potential therapeutic target.
中文摘要:细胞内蛋白通常被免疫系统屏蔽,它们如何成为肿瘤相关抗体应答的靶点仍未明确,肿瘤浸润B细胞(TIL-Bs)所编码的这类自身抗体的功能同样不清楚。研究者利用从自发性肝细胞癌(HCC)模型TIL-Bs中克隆的单克隆抗体(mAbs),界定出一类抗原:分泌型细胞内抗原(SICAs)。肿瘤利用上调的自噬,经HSP90介导的自噬依赖性非经典分泌途径释放胞质蛋白,ALDH1L1即为其中一例。由此产生的自身抗体在SICA局部可及的肿瘤部位形成免疫复合物,募集中性粒细胞并使其重编程为肿瘤相关中性粒细胞,从而推动肿瘤进展。清除中性粒细胞或丧失Fcγ受体结合能力均可消除该效应。自噬介导的SICA分泌及相应自身抗体应答在HCC患者中保守存在,并见于肺癌、乳腺癌和宫颈癌。肿瘤由此重塑其分泌蛋白组以劫持体液免疫,提示SICA–自身抗体–FcγR轴可作为潜在治疗靶点。
Although studies of microbiota in hepatocellular carcinoma (HCC) and possible involvement of the gut-liver axis are of significant interest, the origin and functional role of the liver and intratumoral microbiota in HCC have remained unclear. Liu and colleagues show that gut pathobionts, in particular Bacteroides fragilis, translocate through the gut-liver axis, colonize and reshape the intrahepatic microbiome, and promote HCC through a distinct mechanism in which bacterial enolase binds hepatocyte vimentin, revealing potential therapeutic opportunities. See related article by Liu et al., p. 2392.
中文摘要:肝细胞癌(HCC)微生物群研究及肠-肝轴可能参与其中备受关注,但HCC中肝脏与瘤内微生物群的来源和功能作用仍不清楚。Liu等发现,肠道致病共生菌,尤其是脆弱拟杆菌,可经肠-肝轴易位,定植并重塑肝内微生物组,并通过细菌烯醇化酶结合肝细胞波形蛋白这一独特机制促进HCC,提示潜在治疗机会。详见Liu等第2392页相关文章。
Multiple strategies to target RAS are now available to treat pancreatic cancer. As pancreatic precancers also have KRAS mutations, these tools hold great promise for cancer interception.
中文摘要:目前已有多种靶向RAS的策略可用于治疗胰腺癌。胰腺癌前病变同样携带KRAS突变,这些工具在癌症拦截方面具有很大前景。
Tumor microbes are increasingly recognized for modulating tumor behavior and therapy responses. Intratumoral microbial burden (ITMB) analysis across cancers revealed regulation of immune pathways and activated mast cells, mostly in colorectal and gastric cancers. High-ITMB colorectal cancer leads to interferon (IFN) regulation and is associated with improved outcomes in advanced disease. Single-cell sequencing revealed induction of IFN-related genes (IRG) within microbe-containing human colorectal cancer. Gastrointestinal-luminal mismatch repair-deficient (MMRd) tumors had higher ITMB than proficient tumors. In a rectal MMRd cohort with 100% remission after immune checkpoint blockade (ICB), tumor microbes and microbe-containing mast cells increased. In ICB-sensitive syngeneic murine MMRd tumor models, local tumor microbial depletion impaired ICB efficacy while downregulating IFN signaling. Forced upregulation of IRGs in ADAR1-deficient cancer cells restored immunotherapy responses during microbial ablation. These data highlight dynamic interplay among ITMB, host defense, and immunogenicity, which seems key to determine therapy responses. The ITMB is linked to transcriptional and immune functional changes that seem to determine tumor sensitivity to immunotherapy. These findings highlight the key role of tumor-resident microbes in shaping the tumor ecosystem, which could be targeted to modulate therapy responses.
中文摘要:肿瘤微生物日益被认为可调节肿瘤行为和治疗反应。对跨癌种瘤内微生物负荷(ITMB)的分析显示其调控免疫通路并激活肥大细胞,主要见于结直肠癌和胃癌。高ITMB结直肠癌引起干扰素(IFN)调控,并与晚期疾病结局改善相关。单细胞测序显示,含微生物的人结直肠癌中IFN相关基因(IRG)被诱导。胃肠道腔面错配修复缺陷(MMRd)肿瘤的ITMB高于错配修复功能正常肿瘤。在免疫检查点阻断(ICB)后缓解率100%的直肠MMRd队列中,肿瘤微生物和含微生物的肥大细胞增加。在ICB敏感的鼠MMRd同基因肿瘤模型中,局部肿瘤微生物清除削弱ICB疗效,同时下调IFN信号。在ADAR1缺陷癌细胞中强制上调IRG,可在微生物清除期间恢复免疫治疗反应。这些数据突出ITMB、宿主防御和免疫原性之间的动态相互作用,这似乎是决定治疗反应的关键。ITMB与转录和免疫功能变化相关,这些变化似乎决定肿瘤对免疫治疗的敏感性。这些发现强调肿瘤驻留微生物在塑造肿瘤生态系统中的关键作用,或可靶向以调节治疗反应。
The role of intrahepatic microbiome in hepatocellular carcinoma (HCC) remains elusive. In this study, we profiled matched gut and intrahepatic microbiomes from patients with HCC and healthy subjects. Compared with healthy subjects, we observed increased gut-liver microbiome similarity and a gut pathobiont-centered network in HCC, implying microbial transfer via the gut-liver axis. Consistently, HCC stool transplantation to germ-free mice impaired gut barrier function and increased bacterial load in the liver. Multisite analysis of intrahepatic microbiome and host transcriptome revealed that gut pathobionts in tumor regions positively correlate with host cytokine expression and oncogenic pathways. Administration of HCC-enriched Bacteroides fragilis disrupted gut barrier in mice and led to live bacteria translocation to the liver. B. fragilis exacerbated liver damage and promoted HCC development in mice. Mechanistically, B. fragilis surface protein enolase interacts with and activates vimentin on hepatocytes, triggering oncogenic cascades. Our findings provide insight into how gut pathobionts translocate to the liver to promote hepatocarcinogenesis. Parallel characterization of stool and intrahepatic microbiomes from patients with HCC and healthy subjects revealed gut-liver microbial transfer. The gut pathobiont B. fragilis disrupts gut barrier and translocates as live bacteria to the liver. Its surface protein enolase binds hepatocyte vimentin to activate proinflammatory and oncogenic signaling, thereby promoting liver tumorigenesis. See related commentary by Chojnacka and Grivennikov, p. 2214.
中文摘要:肝内微生物组在肝细胞癌(HCC)中的作用仍不清楚。本研究对HCC患者与健康受试者配对的肠道与肝内微生物组进行了分析。与健康受试者相比,HCC中肠道与肝脏微生物组的相似性升高,并出现以肠道致病菌为核心的网络,提示经肠肝轴发生微生物转移。与此一致,将HCC患者粪便移植给无菌小鼠后,小鼠肠道屏障功能受损,肝脏内细菌载量增加。对肝内微生物组与宿主转录组的多位点分析显示,肿瘤区域的肠道致病菌与宿主细胞因子表达及致癌通路呈正相关。给予HCC中富集的脆弱拟杆菌可破坏小鼠肠道屏障,并导致活菌转移至肝脏。脆弱拟杆菌加重肝损伤并促进小鼠HCC发生。机制上,脆弱拟杆菌表面蛋白烯醇化酶与肝细胞波形蛋白结合并将其激活,启动致癌级联反应。上述结果揭示了肠道致病菌如何转移至肝脏并促进肝癌发生。对HCC患者与健康受试者粪便及肝内微生物组的平行分析揭示了肠肝之间的微生物转移。肠道致病菌脆弱拟杆菌破坏肠道屏障,并以活菌形式转移至肝脏;其表面蛋白烯醇化酶结合肝细胞波形蛋白,激活促炎与致癌信号,从而促进肝脏肿瘤发生。参见Chojnacka与Grivennikov的相关评论,第2214页。
Helicobacter pylori is a Gram-negative bacterium that establishes colonization in the human stomach and is estimated to infect over half of the global population. It is recognized as a significant causative agent of chronic gastritis, peptic ulcers, and gastric cancer. Neutrophils play a central role in innate defence against H. pylori; however, dysregulated neutrophil activation contributes to epithelial injury and persistent inflammation. Here, we show that H. pylori enhance neutrophil exocytosis and stimulates the release of extracellular vehicles (EVs) with distinct biophysical and molecular characteristics. Infected neutrophils released smaller and more abundant EVs than uninfected controls. These H. pylori-induced neutrophil EVs (HPN-EVs) suppressed PI3K/Akt signalling, increased reactive oxygen species, disrupted mitochondrial integrity, and induced cytochrome c release, caspase activation, and apoptosis in infected gastric epithelial cells. Proteomics profiling revealed enrichment of neutrophil granule proteins, particularly LL-3, and depletion of proteins associated with cellular homeostasis. EV-mediated LL-37 delivery reproduced key pro-apoptotic effects of HPN-EVs, supporting its functional role in epithelial injury. Consistent with these findings, circulating EVs from H. pylori-infected patients exhibited elevated LL-37 levels and induced similar pro-apoptotic responses. Together, these findings identify LL-37-enriched HPN-EVs as important mediators of neutrophil-epithelial crosstalk and investigating EV-associated cargo as a potential therapeutic target in H. pylori-associated disease.
中文摘要:幽门螺杆菌是定植于人类胃部的革兰阴性菌,估计感染全球超过一半人口,被认为是慢性胃炎、消化性溃疡和胃癌的重要致病因素。中性粒细胞在抵抗幽门螺杆菌的先天防御中起核心作用,但失调的中性粒细胞活化会导致上皮损伤和持续炎症。研究显示幽门螺杆菌增强中性粒细胞胞吐,并刺激释放具有独特生物物理和分子特征的细胞外囊泡。与未感染对照相比,感染的中性粒细胞释放的囊泡更小且数量更多。这些幽门螺杆菌诱导的中性粒细胞囊泡抑制PI3K/Akt信号,增加活性氧,破坏线粒体完整性,并诱导感染胃上皮细胞释放细胞色素c、活化半胱天冬酶及发生凋亡。蛋白质组分析显示中性粒细胞颗粒蛋白富集,尤其是LL-37,而与细胞稳态相关的蛋白减少。囊泡介导的LL-37递送重现了HPN-EVs的关键促凋亡效应,支持其在上皮损伤中的功能作用。与这些发现一致,幽门螺杆菌感染患者循环囊泡中LL-37水平升高,并诱导相似的促凋亡反应。这些结果将富含LL-37的HPN-EVs确定为中性粒细胞与上皮细胞相互作用的重要介质,并提示研究囊泡相关货物可作为幽门螺杆菌相关疾病的潜在治疗靶点。
Claudins (CLDNs), as major components of tight junctions in epithelial cells, are emerging as attractive non-mutant targets for controlling the growth and metastasis of various cancers. However, the mechanisms by which CLDNs modulate tumor progression remain largely unclear. Here, we unexpectedly found that CLDN12 is expressed in cancer-associated fibroblasts (CAFs), which are generally not considered tight junction-forming cells. CLDN12 expression in fibroblasts increased their motility and, importantly, promoted direct adhesion to pancreatic cancer cells through homophilic CLDN12-CLDN12 interactions. This CLDN12-dependent physical interaction between fibroblasts and tumor cells markedly enhanced cancer cell invasion. Moreover, TGF-β produced by cancer cells further induced the upregulation of CLDN12 expression in fibroblasts. In vivo, CLDN12-positive fibroblasts facilitated distant metastasis of pancreatic cancer to liver and diaphragm. Targeting CLDN12 with the synthetic peptide C12-pm efficiently decreased the liver metastasis of pancreatic cancer. Taken together, these findings reveal a previously unrecognized role of CLDN12-expressing fibroblasts in promoting pancreatic cancer metastasis through direct physical interactions with tumor cells and highlight CLDN12-mediated interactions as a potential therapeutic target for metastatic pancreatic cancer.
中文摘要:Claudins(CLDNs)是上皮细胞紧密连接的主要成分,正逐渐成为控制多种癌症生长和转移的有吸引力的非突变靶点。CLDNs调控肿瘤进展的机制仍大多不清楚。本研究发现,CLDN12意外表达于通常不被认为形成紧密连接的癌相关成纤维细胞(CAFs)中。成纤维细胞中的CLDN12表达提高其运动能力,并通过CLDN12与CLDN12的同型相互作用促进其与胰腺癌细胞直接黏附。这种依赖CLDN12的成纤维细胞与肿瘤细胞间的物理相互作用明显增强癌细胞侵袭。癌细胞产生的TGF-β进一步诱导成纤维细胞中CLDN12表达上调。在体内,CLDN12阳性成纤维细胞促进胰腺癌向肝和膈的远处转移。用合成肽C12-pm靶向CLDN12可有效减少胰腺癌肝转移。这些结果揭示了表达CLDN12的成纤维细胞通过与肿瘤细胞直接物理相互作用促进胰腺癌转移这一此前未被认识的作用,并提示CLDN12介导的相互作用可作为转移性胰腺癌的潜在治疗靶点。
Reticulon-3 (RTN3) was initially studied as an endoplasmic reticulum (ER)-resident reticulon family protein involved in membrane shaping, apoptosis, and amyloid precursor protein processing. More recent work has considerably expanded this view and now places RTN3 at the intersection of ER remodeling, selective ER-phagy, cargo trafficking, lipid handling, and stress signaling. This shift is especially relevant to pharmacology, because RTN3 appears to exhibit heterogeneous effects across tissues and disease states: RTN3 upregulation is maladaptive in obesity, nonalcoholic fatty liver disease, cardiac lipotoxicity, post-myocardial infarction heart failure, and some vascular conditions, whereas RTN3 loss aggravates renal injury, renal fibrosis, and pulmonary fibrosis. Viral infection and hepatocellular carcinoma further illustrate that RTN3 can either support membrane remodeling programs or constrain disease progression, depending on the biological environment. In this review, we reorganize RTN3 biology around mechanism-driven processes and discuss how these processes converge on cardiometabolic, fibrotic, infectious, and oncologic phenotypes. Current evidence suggests that RTN3 is better regarded as a membrane organizing regulator with therapeutic potential rather than a disease specific marker. However, future efforts to target RTN3 will likely need to consider tissue type and pathway specificity.
中文摘要:Reticulon-3(RTN3)最初作为内质网驻留的reticulon家族蛋白被研究,参与膜塑形、凋亡及淀粉样前体蛋白加工。较新的工作大幅拓展了这一认识,将RTN3置于内质网重塑、选择性内质网自噬、货物运输、脂质处理和应激信号的交汇点。这一转变对药理学尤为重要,因为RTN3在不同组织和疾病状态下呈现异质性效应:RTN3上调在肥胖、非酒精性脂肪性肝病、心脏脂毒性、心肌梗死后心力衰竭及部分血管病变中具有适应不良作用,而RTN3缺失则加重肾损伤、肾纤维化和肺纤维化。病毒感染和肝细胞癌进一步表明,RTN3既可支持膜重塑程序,也可限制疾病进展,取决于生物学环境。该综述围绕机制驱动过程重新组织RTN3生物学,并讨论这些过程如何汇聚于心脏代谢、纤维化、感染和肿瘤表型。现有证据提示,将RTN3视为具有治疗潜力的膜组织调控因子比视为疾病特异性标志物更合适。然而,未来靶向RTN3的努力很可能需要考虑组织类型和通路特异性。
Intrahepatic cholangiocarcinoma is a highly lethal malignancy characterized by a rising incidence and a dismal 5-year survival rate of < 10%. While targeted therapies and immunotherapies have expanded treatment paradigms, their clinical efficacy remains hampered by modest patient response rates. Here, we identify total glucosides of paeony and its principal bioactive monomer, paeoniflorigenone (PFG), as potential effective therapeutic agents against ICC, demonstrating potent suppression of malignant phenotypes across multi-dimensional ICC models. Transcriptomic profiling identified ferroptosis as the primary mechanism driving PFG-induced ICC cell death, which is hallmarked by intracellular Fe²⁺ overload, robust ROS generation, and lipid peroxidation. Mechanistically, PFG directly binds to TRIM28, triggering its phosphorylation at Ser824. This modification alleviates repressive H3K9me3 occupancy at the HMOX1 promoter, thereby unlocking local chromatin accessibility to drive HMOX1 transcription and culminate in ferroptosis. Notably, PFG-induced ferroptosis not only curbs ICC cell proliferation and migration but also activates antigen presentation and reshapes a tumoricidal immune microenvironment, characterized by enhanced infiltration and activation of CD8⁺ cytotoxic T cells. In summary, this study unveils a previously unrecognized ferroptosis regulatory pathway-the TRIM28/H3K9me3/HMOX1 axis-and demonstrates that PFG may represent a potential natural small-molecule candidate for ICC treatment.
中文摘要:肝内胆管癌是一种高度致命的恶性肿瘤,发病率不断上升,5年生存率不足10%。靶向治疗和免疫治疗拓展了治疗格局,但患者应答率有限,临床疗效仍受制约。该研究识别出白芍总苷及其主要生物活性单体芍药内酯苷元(PFG)作为针对ICC的潜在有效治疗药物,并在多维ICC模型中显示出对恶性表型的有力抑制。转录组分析确定铁死亡是驱动PFG诱导ICC细胞死亡的主要机制,其特征为细胞内Fe²⁺超载、ROS大量生成和脂质过氧化。机制上,PFG直接结合TRIM28,触发其Ser824位点磷酸化。该修饰减轻H3K9me3在HMOX1启动子区的抑制性占据,从而打开局部染色质可及性,驱动HMOX1转录并最终导致铁死亡。PFG诱导的铁死亡不仅抑制ICC细胞增殖和迁移,还激活抗原呈递并重塑具有杀肿瘤作用的免疫微环境,表现为CD8⁺细胞毒性T细胞浸润和活化增强。该研究揭示了一条此前未被认识的铁死亡调控通路——TRIM28/H3K9me3/HMOX1轴,并表明PFG可能成为治疗ICC的潜在天然小分子候选物。
Although neurons innervate all organs in which solid tumors grow, the role of neurons in cancer biology has long been neglected. Over the past decade, numerous studies have elucidated the critical role of the nervous system in cancer pathophysiology, culminating in the birth of Cancer Neuroscience. The recognition that neurons dictate many aspects of tumor biology not only provides new opportunities for therapeutic targeting of these stromal dependencies but also underscores the strong bi-directional relationships between tumors and the nervous system that result in cancer-associated symptomatology. By recognizing the key place of neurons in tumor biology, Cancer Neuroscience has ushered in a new era in which brain cancers should be conceptualized as diseases of dysregulated neurodevelopment, neuroplasticity, and neurophysiological function, usurped to drive brain cancer growth, progression, and therapeutic resistance. Likewise, the nervous system governs the initiation, growth, spread, and survival of most (if not all) extracranial cancers, while also mediating communication from cancers to the brain. Herein, we outline the current state of Cancer Neuroscience and the roles for neuro-oncologists in this new aspect of cancer care as an introduction to an upcoming series of articles in Neuro-Oncology on cellular interactions in the healthy nervous system and in the setting of cancer.
中文摘要:神经元支配着所有实体瘤生长所在的器官,但神经元在肿瘤生物学中的作用长期被忽视。过去十年间,大量研究阐明了神经系统在肿瘤病理生理中的关键作用,促成了癌症神经科学的诞生。认识到神经元决定肿瘤生物学的诸多方面,既为针对这类基质依赖性的治疗提供了新机会,也凸显了肿瘤与神经系统之间强烈的双向关系,这种关系正是癌症相关症状的来源。癌症神经科学确认了神经元在肿瘤生物学中的核心位置,由此开启了一个新时代:脑肿瘤应被理解为神经发育、神经可塑性与神经生理功能失调的疾病,这些过程被劫持以驱动脑肿瘤的生长、进展与治疗抵抗。同样,神经系统调控大多数(若非全部)颅外癌症的发生、生长、播散与存活,同时介导肿瘤向大脑的信息传递。本文概述癌症神经科学的现状,以及神经肿瘤学家在这一肿瘤诊疗新领域中承担的角色,作为《Neuro-Oncology》即将推出的、关于健康神经系统中及癌症状态下细胞相互作用系列文章的导言。
The liver is the primary site of metastasis in pancreatic ductal adenocarcinoma (PDAC), and liver metastases are a major cause of mortality1,2. Nutrient availability in the metastatic niche influences colonization efficiency; however, the metabolic heterogeneity of disseminated tumour cells can also reshape the local microenvironment3-5. Loss of phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in de novo serine biosynthesis, is observed in nearly 40% of PDACs, and renders these cells dependent on exogenous serine (exSer)6. Although a neuron-tumour metabolic cross-talk supports exSer-dependent PDAC cells at the primary site6, it remains unclear how these cells adapt to the metastatic liver niche. Here we show that exSer-dependent PDAC cells reprogram neighbouring hepatocytes through a CXCL5-CXCR2 axis. Activation of CXCR2 in hepatocytes promotes PI3K-AKT signalling, leading to the sequestration of FOXO3A in the cytoplasm and derepression of PHGDH transcription, thereby enhancing serine production in hepatocytes. This hepatocyte-derived serine supports the outgrowth of exSer-dependent PDAC liver metastases. Accordingly, genetic or pharmacological inhibition of individual nodes within the CXCL5-CXCR2-PI3K-AKT-FOXO3A axis, or hepatocyte-specific deletion of Phgdh or Cxcr2, markedly reduces the liver-metastasis burden in mice and prolongs survival, particularly when dietary serine is restricted. Our findings reveal a cancer cell-hepatocyte metabolic cross-talk and identify therapeutic targets for exSer-dependent PDAC liver metastases.
中文摘要:肝脏是胰腺导管腺癌(PDAC)转移的主要部位,肝转移也是其死亡的重要原因。转移龛中的营养可用性影响定植效率,但播散肿瘤细胞的代谢异质性也可重塑局部微环境。近40%的PDAC存在磷酸甘油酸脱氢酶(PHGDH,de novo丝氨酸生物合成限速酶)缺失,使这些细胞依赖外源性丝氨酸(exSer)。尽管神经-肿瘤代谢交互作用可在原发部位支持依赖exSer的PDAC细胞,但这些细胞如何适应肝转移龛仍不清楚。研究显示,依赖exSer的PDAC细胞通过CXCL5-CXCR2轴重编程邻近肝细胞。肝细胞中CXCR2激活促进PI3K-AKT信号,导致FOXO3A滞留于胞质并使PHGDH转录去抑制,从而增强肝细胞产生丝氨酸。肝细胞来源的丝氨酸支持依赖exSer的PDAC肝转移灶生长。据此,遗传或药理抑制CXCL5-CXCR2-PI3K-AKT-FOXO3A轴中的任一节点,或肝细胞特异性敲除Phgdh或Cxcr2,可显著降低小鼠肝转移负荷并延长生存,尤其在限制膳食丝氨酸时。研究揭示了癌细胞与肝细胞之间的代谢交互作用,并为依赖exSer的PDAC肝转移确定了治疗靶点。
Licorice flavonoids (LF), bioactive components of Glycyrrhiza uralensis Fisch, exhibit promising anti-colorectal cancer (CRC) potential. However, the mechanism by which LF inhibits CRC remains unclear. In this study, we attempt to elucidate how indoleamine 2,3-dioxygenase 1 (IDO1) functions as a convergent downstream effector of both microbiota-derived signals and host oncogenic pathways in order to mediate the chemopreventive effects of LF on CRC. Using AOM/DSS and Apcmin/+ CRC mice models and colonic epithelial cells, we combined 16S rRNA sequencing, metabolomics, transcriptomics, and functional assays including IDO1 knockout, fecal microbiota transplantation, and antibiotic treatment. LF markedly inhibited colorectal tumorigenesis and restored intestinal barrier integrity. Mechanistically, LF remodeled the gut microbiota to enrich SCFAs‑producing genera, including Parabacteroides, Paramuribaculum, and Parasutterella, thereby increasing the levels of SCFAs such as butyric acid, isobutyric acid, valeric acid, and isovaleric acid in feces. These SCFAs downregulated IDO1 in CRC cells, and genetic ablation of IDO1 largely abolished SCFAs‑induced anti‑proliferative effects, establishing IDO1 as a critical downstream mediator. This regulation rewired tryptophan metabolism, reducing kynurenine metabolites and elevating microbiota-related indoles. Notably, the protective effect of LF against CRC was substantially diminished in IDO1‑knockout mice, underscoring IDO1 as a critical mediator. Additionally, LF treatment was associated with suppression of WNT/TGF‑β signaling. Collectively, these results identify IDO1 as a critical downstream effector that responds to the regulation of gut microbiota-SCFAs signaling and host WNT/TGF‑β pathways by LF, suggesting that LF‑induced IDO1 inhibition may represent a promising translational strategy for CRC prevention through concurrent modulation of microbial and host pathways.
中文摘要:甘草黄酮(LF)是乌拉尔甘草(Glycyrrhiza uralensis Fisch)的生物活性成分,具有抗结直肠癌(CRC)潜力,但其抑制CRC的机制仍不清楚。为阐明吲哚胺2,3-双加氧酶1(IDO1)如何作为微生物来源信号与宿主致癌通路的共同下游效应分子,介导LF对CRC的化学预防作用,利用AOM/DSS和Apcmin/+ CRC小鼠模型及结肠上皮细胞,结合16S rRNA测序、代谢组学、转录组学以及IDO1敲除、粪菌移植和抗生素处理等功能实验。LF显著抑制结直肠肿瘤发生并恢复肠道屏障完整性。机制上,LF重塑肠道菌群,富集产短链脂肪酸(SCFAs)的菌属,包括Parabacteroides、Paramuribaculum和Parasutterella,从而提高粪便中丁酸、异丁酸、戊酸和异戊酸等SCFAs水平。这些SCFAs下调CRC细胞中的IDO1,IDO1基因敲除在很大程度上消除了SCFAs诱导的抗增殖作用,表明IDO1是关键下游介导因子。该调控重编程色氨酸代谢,减少犬尿氨酸代谢物并提高微生物相关吲哚类物质。LF对CRC的保护作用在IDO1敲除小鼠中显著减弱,凸显IDO1是关键介导因子。LF处理还与WNT/TGF-β信号抑制相关。这些结果确定IDO1是响应LF调控肠道菌群-SCFAs信号和宿主WNT/TGF-β通路的关键下游效应分子,提示LF诱导的IDO1抑制可能通过同时调控微生物和宿主通路,成为CRC预防的有前景的转化策略。
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting approximately one-third of the global adult population, acting as the primary driver of cirrhosis and hepatocellular carcinoma. Despite its growing incidence and substantial clinical and socioeconomic toll, clinical treatment of MASLD remains severely limited by the absence of U.S. Food and Drug Administration (FDA)-approved pharmacotherapies, suboptimal hepatic targeting of existing agents, off-target adverse effects, and limited infiltration into the fibrotic hepatic microenvironment. Nanomedicine has emerged as a promising strategy to address these limitations and advance precision treatment for chronic liver diseases, yet a systematic review unifying the multifactorial pathogenesis of MASLD, rational target selection, and advanced nanoplatform development remains lacking. Herein, we systematically elaborate the multi-hit pathogenic cascade of MASLD, covering metabolic imbalance, oxidative and inflammatory injury, aberrant programmed cell death, inter-organ signaling crosstalk, and fibrogenic transformation, with a focus on recently identified mechanisms, including single-cell transcriptomic heterogeneity and epigenetic regulation. We further clinically translatable therapeutic targets, and comprehensively summarize the rational design, structure-activity relationships, hepatic targeted delivery strategies, therapeutic outcomes, and underlying molecular mechanisms of state-of-the-art nanosystems. Moreover, we evaluate preclinical achievements and dissect core translational obstacles and highlight future frontiers, including artificial intelligence-assisted nanodesign, theranostic integration, and oral liver-targeted nanosystems.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)是全球最常见的慢性肝病,影响约三分之一的全球成年人口,是肝硬化和肝细胞癌的主要驱动因素。尽管其发病率不断上升,临床和社会经济负担沉重,MASLD的临床治疗仍受限于缺乏美国食品药品监督管理局(FDA)批准的药物治疗、现有药物肝靶向性不佳、脱靶不良反应以及向纤维化肝脏微环境渗透有限。纳米医学已成为应对这些局限并推进慢性肝病精准治疗的有前景策略,但仍缺乏将MASLD多因素发病机制、合理靶点选择与先进纳米平台开发相统一的系统综述。系统梳理MASLD的多重打击致病级联,涵盖代谢失衡、氧化与炎症损伤、异常程序性细胞死亡、器官间信号串扰和纤维化转化,并重点关注新近发现的机制,包括单细胞转录组异质性和表观遗传调控。进一步讨论具有临床转化潜力的治疗靶点,全面总结先进纳米系统的合理设计、构效关系、肝靶向递送策略、治疗结局及潜在分子机制。评估临床前研究成果,剖析核心转化障碍,并强调未来前沿方向,包括人工智能辅助纳米设计、诊疗一体化以及口服肝靶向纳米系统。
Immunogenic cell death (ICD) is a robust strategy to reprogram immunologically "cold" pancreatic ductal adenocarcinoma (PDAC) into "hot" tumors and augment immunotherapeutic efficacy, yet clinically viable ICD-inducing regimens and their regulatory mechanisms remain elusive. Here, we sought to develop an optimized combinatorial therapy for ICD induction in PDAC and decipher its core molecular pathway. Spatial transcriptomics of human PDAC tissues revealed that elevated ICD activity in cancer lesions correlates strongly with favorable patient prognosis. In vitro and in vivo functional assays demonstrated that co-treatment with elesclomol‑CuCl₂ (ES‑CU, a potent cuproptosis inducer) and oxaliplatin (L‑OHP) synergistically suppresses PDAC cell proliferation, migration and invasion, while triggering robust reactive oxygen species (ROS)-dependent ICD. Mechanistically, this regimen inhibits calreticulin (CALR) palmitoylation at Cys137, abrogating CALR degradation via the autophagy‑lysosome pathway and facilitating its ER-to-membrane translocation to initiate ICD signaling. This potent ICD response promotes dendritic cell maturation and enhances CD8⁺T cell-mediated cytotoxicity through the TLR4/NF‑κB axis, which single-cell RNA sequencing of clinical PDAC samples supported in neoadjuvant therapy responders. Collectively, our findings identify CALR palmitoylation inhibition as a key driver of L‑OHP/ES‑CU-induced ICD, reshaping the tumor immune microenvironment to provide a promising chemo-immunotherapeutic strategy for PDAC.
中文摘要:免疫原性细胞死亡(ICD)可将免疫学「冷」的胰腺导管腺癌(PDAC)重编程为「热」肿瘤并增强免疫治疗疗效,但临床可行的ICD诱导方案及其调控机制仍不明确。本研究旨在建立PDAC中诱导ICD的优化联合治疗并解析其核心分子通路。人PDAC组织的空间转录组显示,癌灶内ICD活性升高与患者预后良好密切相关。体外和体内功能实验表明,elesclomol-CuCl₂(ES-CU,一种强效铜死亡诱导剂)与奥沙利铂(L-OHP)联合处理可协同抑制PDAC细胞增殖、迁移和侵袭,同时触发强烈的活性氧(ROS)依赖性ICD。机制上,该方案抑制钙网蛋白(CALR)在Cys137位点的棕榈酰化,阻断CALR经自噬-溶酶体途径降解,并促进其由内质网向膜转位以启动ICD信号。这一强效ICD反应通过TLR4/NF-κB轴促进树突状细胞成熟并增强CD8⁺T细胞介导的细胞毒性;临床PDAC样本的单细胞RNA测序结果在新辅助治疗应答者中支持这一点。这些结果将CALR棕榈酰化抑制确定为L-OHP/ES-CU诱导ICD的关键驱动因素,重塑肿瘤免疫微环境,为PDAC提供有前景的化疗-免疫治疗策略。
Lipocalin 2 (LCN2) is upregulated in many cancers, including pancreatic ductal adenocarcinoma (PDAC), and contributes to tumor development. LCN2 regulates microbial composition, which can influence PDAC outcomes, and has been implicated in ferroptosis resistance in several cancer types. However, the role of tumor-derived LCN2 in mediating ferroptosis and the tumor microbiome in PDAC remains unclear. Here, we show that human PDAC tumors with high LCN2 expression have altered expression of genes involved in ferroptosis, oxidative stress responses, and microbial regulation. Loss of LCN2 in PDAC cells dysregulates ferroptosis-associated pathways, increases lipid peroxidation, and sensitizes cells to ferroptosis induction. In orthotopic PDAC models, the ferroptosis inducer imidazole ketone erastin (IKE) promoted tumor growth in Lcn2-expressing tumors, whereas this effect was absent in tumors lacking LCN2. In addition, tumor-derived Lcn2 expression and ferroptosis induction were associated with distinct changes in the pancreatic tumor microbiome. Overall, these findings identify tumor-derived LCN2 as an important modulator of ferroptotic stress responses in PDAC and suggest that inhibition of tumor-derived LCN2 may enhance susceptibility to ferroptosis-based therapeutic strategies.
中文摘要:Lipocalin 2(LCN2)在包括胰腺导管腺癌(PDAC)在内的多种癌症中表达上调,并促进肿瘤发展。LCN2 可调节微生物组成,进而影响 PDAC 结局,并已在若干癌种中与铁死亡抵抗相关。肿瘤来源 LCN2 在介导 PDAC 铁死亡及肿瘤微生物组中的作用仍不清楚。LCN2 高表达的人 PDAC 肿瘤中,参与铁死亡、氧化应激反应和微生物调控的基因表达发生改变。PDAC 细胞缺失 LCN2 会导致铁死亡相关通路失调、脂质过氧化增加,并使细胞对铁死亡诱导更敏感。在原位 PDAC 模型中,铁死亡诱导剂 imidazole ketone erastin(IKE)促进表达 Lcn2 的肿瘤生长,而缺失 LCN2 的肿瘤中未见这一效应。肿瘤来源 Lcn2 表达与铁死亡诱导还伴随胰腺肿瘤微生物组的不同变化。这些发现将肿瘤来源 LCN2 确定为 PDAC 铁死亡应激反应的重要调节因子,并提示抑制肿瘤来源 LCN2 可能增强对铁死亡治疗策略的敏感性。
Anaphylatoxins are active complement components that regulate immune cells. However, their role in shaping the tumor immune microenvironment (TIME) in hepatocellular carcinoma (HCC) remains poorly understood. This study utilized CRISPR/Cas9 technology to knock out complements proteins C3 or C5 in mouse liver cancer cells. Both in vivo and in vitro experiments revealed that C5 knockout significantly inhibited tumor growth in mouse models. Moreover, C5ar1-knockout mice were generated using C57BL/6 J mice, and immune cell profiles within subcutaneous tumors were analyzed using mass spectrometry and flow cytometry. The results demonstrated that C5ar1 knockout significantly reduced the infiltration of regulatory T cells (Tregs) and M2-like tumor-associated macrophages (TAMs) into the TIME. Conversely, the infiltration of effector CD8+ T cells, known for their tumor-killing activity, was markedly enhanced. Mechanistically, C5a was shown to promote the M2-like polarization of macrophages and the C-C-motif chemokine ligand 5 (CCL5) expression by activating the AKT signaling pathway. Further studies identified TAM-derived CCL5 as a key driver of the chemotactic activity of Tregs. Finally, blocking the C5a/C5ar1 axis synergistically enhanced the anti-tumor effects of PD-1 monoclonal antibody in both transplanted and spontaneous liver cancer mouse models. Overall, these findings reveal that cancer cell-derived anaphylatoxin C5a plays a pivotal role in promoting an inhibitory TIME in liver tumor tissues. Blocking the C5a/C5ar1 axis in combination with immune checkpoint inhibitors could represent a promising strategy for treating HCC.
中文摘要:过敏毒素是调节免疫细胞的活性补体成分,其在肝细胞癌(HCC)肿瘤免疫微环境(TIME)塑造中的作用尚不清楚。本研究采用CRISPR/Cas9技术敲除小鼠肝癌细胞中的补体蛋白C3或C5。体内与体外实验均显示,C5敲除显著抑制小鼠模型的肿瘤生长。研究还用C57BL/6J小鼠构建了C5ar1敲除小鼠,并用质谱和流式细胞术分析皮下肿瘤内的免疫细胞组成。结果显示,C5ar1敲除显著减少调节性T细胞(Tregs)与M2样肿瘤相关巨噬细胞(TAMs)向TIME的浸润,而具有杀瘤活性的效应CD8+ T细胞浸润明显增强。机制上,C5a通过激活AKT信号通路促进巨噬细胞的M2样极化及C-C趋化因子配体5(CCL5)表达。进一步研究确定TAM来源的CCL5是Tregs趋化活性的关键驱动因素。最后,阻断C5a/C5ar1轴在移植性与自发性肝癌小鼠模型中均协同增强了PD-1单克隆抗体的抗肿瘤效应。这些结果揭示,癌细胞来源的过敏毒素C5a在促进肝肿瘤组织形成抑制性TIME中起关键作用;阻断C5a/C5ar1轴联合免疫检查点抑制剂可能是治疗HCC的有前景策略。
Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality, and the clinical utility of β-lapachone (β-Lap) is limited by dose-dependent toxicity. Here, we identify cryptotanshinone (CPT), a bioactive compound derived from Salvia miltiorrhiza, as a synergistic partner that enables dose reduction while enhancing antitumor efficacy. Integrated transcriptomic profiling, biochemical analyses, target engagement assays, and in vivo validation support that β-Lap and CPT cooperatively induce ferroptosis through disruption of iron-redox homeostasis. Mechanistically, β-Lap and CPT engage Raptor and mTOR, respectively, in vitro, supporting a model wherein their cooperative action leads to dual suppression of mTORC1 signaling. mTORC1 inhibition activates NCOA4-mediated ferritinophagy, promoting ferritin degradation and expansion of the labile Fe2+ pool. The consequent iron-dependent Fenton reaction drives excessive reactive oxygen species (ROS) accumulation and lipid peroxidation, culminating in ferroptotic cell death. Notably, this process occurs without downregulation of the canonical GPX4-SLC7A11 axis, defining a non-canonical, iron-amplified ferroptosis pathway. In xenograft models, the combination therapy significantly suppressed tumor growth without detectable systemic toxicity and recapitulated the molecular hallmarks observed in vitro, including mTORC1 inhibition, enhanced ferritinophagy, iron overload, and lipid peroxidation. Collectively, our findings support cooperative mTORC1 inhibition as a strategy to trigger ferritinophagy-dependent iron-redox collapse and non-canonical ferroptosis, providing a mechanistically informed and low-toxicity therapeutic approach for HCC.
中文摘要:肝细胞癌(HCC)仍是癌症死亡的主要原因之一,β-拉帕醌(β-Lap)的临床使用受剂量依赖性毒性限制。丹参来源生物活性成分隐丹参酮(CPT)被确定为协同伙伴,可在提高抗肿瘤疗效的同时降低剂量。整合转录组分析、生化分析、靶点结合实验和体内验证支持β-Lap与CPT通过破坏铁-氧化还原稳态协同诱导铁死亡。机制上,β-Lap与CPT在体外分别结合Raptor和mTOR,支持二者协同作用导致mTORC1信号双重抑制的模型。mTORC1抑制激活NCOA4介导的铁蛋白自噬,促进铁蛋白降解并扩大不稳定Fe2+池。随后的铁依赖性Fenton反应驱动活性氧(ROS)过度积累和脂质过氧化,最终导致铁死亡性细胞死亡。该过程未伴随经典GPX4-SLC7A11轴下调,界定了一条非经典、铁放大的铁死亡通路。在异种移植模型中,联合治疗显著抑制肿瘤生长,未检测到全身毒性,并重现体外观察到的分子特征,包括mTORC1抑制、铁蛋白自噬增强、铁过载和脂质过氧化。这些发现支持协同抑制mTORC1作为一种触发铁蛋白自噬依赖性铁-氧化还原崩溃和非经典铁死亡的策略,为HCC提供了一种机制指导的低毒治疗途径。
Segmentation models can surpass radiologists, classification models, and vision-language models in tumor detection. Furthermore, segmentation models outline tumors, allowing radiologists to better verify and trust the AI output. However, their main limitation is the scarcity of tumor masks: creating one 3D tumor mask takes up to 30 min, so most public CT datasets contain only a few hundred masks, and even the largest private datasets contain only a couple of thousand. Tumor masks are not produced in clinical routine, but radiology reports are. Public datasets contain tens of thousands of CT-Report pairs, and hospitals contain hundreds of thousands. These reports describe tumors in detail, providing large-scale, informative training data. Here, we introduce Report Supervision (R-Super), a training framework that uses reports to directly supervise and improve tumor segmentation. R-Super introduces new loss functions that teach segmentation models to segment tumors that match report descriptions of tumor count, sizes, and locations. Reports are only used for training. We evaluated R-Super on kidney and pancreatic tumor segmentation, exploring diverse training data sizes, up to 41,418 CT-Report pairs plus 3488 CT-Mask pairs. On external validation, R-Super increased tumor detection F1-Score and segmentation DSC by up to +15% with respect to mask-only training. It also surpassed alternative methods such as CLIP and multi-task learning. It enabled pancreatic tumor detection on non-contrast CT without requiring tumor masks from non-contrast CT. In summary, by leveraging numerous readily available reports to supplement scarce masks, R-Super strongly improves AI performance when very few training masks are available (e.g., 50), and when many masks are available (e.g., 3488), unlocking scale in tumor segmentation. Project: https://github.com/MrGiovanni/R-Super.
中文摘要:分割模型在肿瘤检测上可超过放射科医师、分类模型与视觉语言模型。分割模型还能勾画肿瘤轮廓,便于放射科医师核验并信任 AI 的输出。其核心限制在于肿瘤掩膜的稀缺:制作一个 3D 肿瘤掩膜最长需要 30 分钟,因此多数公开 CT 数据集仅含几百个掩膜,即便最大的私有数据集也只含数千个。临床常规并不产生肿瘤掩膜,但会产生放射学报告。公开数据集含数万对 CT-报告数据,医院则拥有数十万对。这些报告详细描述肿瘤,可提供大规模、信息丰富的训练数据。为此,作者提出 Report Supervision(R-Super)训练框架,用报告直接监督并改进肿瘤分割。R-Super 引入新的损失函数,使分割模型学到的肿瘤分割结果与报告所描述的肿瘤数目、大小和位置相匹配。报告仅用于训练。作者在肾脏与胰腺肿瘤分割上评估 R-Super,探索了从少到多的多种训练数据规模,最多达 41,418 对 CT-报告数据加 3488 对 CT-掩膜数据。在外部验证中,相比仅用掩膜训练,R-Super 使肿瘤检测 F1 分数与分割 DSC 提升最多 +15%,并优于 CLIP 与多任务学习等替代方法。它使平扫 CT 上的胰腺肿瘤检测成为可能,且无需平扫 CT 的肿瘤掩膜。总之,R-Super 利用大量易得的报告来补充稀缺的掩膜,在训练掩膜很少(如 50 个)以及掩膜较多(如 3488 个)时都显著提升 AI 性能,释放了肿瘤分割的规模潜力。项目地址:https://github.com/MrGiovanni/R-Super。
SERHL regulates invasion and metastasis through KLF16-PLCB1/PRKCA signaling in gastric cancer cells.
Human SERHL, a pseudogene-derived lncRNA, plays a key role in cancer progression. However, the mechanism by which SERHL modulates gastric cancer (GC) is mostly unknown. This study found that SERHL was down-regulated in GC and inversely related to its malignancy. Overexpression of SERHL inhibited cell growth and metastasis in GC cells. Mechanistically, SERHL interacts with KLF16, promoting the degradation of KLF16 via ubiquitination in GC cells. The transcription factor KLF16 binds to the promoters of PLCB1 and PRKCA genes, increasing their expression and enhancing GC invasion and metastasis. SERHL reduces motility by inhibiting the KLF16-PLCB1/PRKCA signaling pathway in GC cells. These results highlight the function and mechanism of SERHL in GC progression, indicating that SERHL has the potential to be a diagnostic marker and therapeutic target in GC.
中文摘要:人SERHL是一种由假基因衍生的lncRNA,在癌症进展中起关键作用。但SERHL调控胃癌的机制大多未知。本研究发现SERHL在胃癌中下调,且与其恶性程度呈负相关。过表达SERHL抑制胃癌细胞生长和转移。机制上,SERHL与KLF16相互作用,通过泛素化促进胃癌细胞中KLF16降解。转录因子KLF16结合PLCB1和PRKCA基因启动子,提高其表达并增强胃癌侵袭和转移。SERHL通过抑制胃癌细胞中KLF16-PLCB1/PRKCA信号通路降低运动能力。这些结果突出SERHL在胃癌进展中的功能与机制,表明SERHL有潜力成为胃癌诊断标志物和治疗靶点。
Accurate compensation of brain deformation is critical for reliable image-guided neurosurgery. Surgical manipulation and tumor resection induce tissue motion, causing preoperative planning images to become misaligned with the intraoperative anatomy. In this review, we examine data-driven methods developed between 2020 and 2025 for brain deformation registration and modeling, with a particular focus on learning-based approaches. A comprehensive literature search was conducted in PubMed, IEEE Xplore, Scopus, and Web of Science using predefined inclusion and exclusion criteria for computational methods addressing brain deformation in neurosurgical imaging, resulting in 46 eligible studies. We provide a unified analysis of methodological strategies, including deep learning-based image registration, direct deformation field regression, synthesis-driven multimodal alignment, resection-aware architectures for handling missing correspondences, and hybrid models integrating biomechanical priors. We also examine dataset utilization, evaluation metrics, validation protocols, and the assessment of uncertainty and generalization across studies. While learning-based methods demonstrate promising accuracy and computational efficiency, current approaches remain limited by out-of-distribution robustness, standardized benchmarking, interpretability, and readiness for clinical deployment. Our review highlights these gaps and outlines future directions toward more robust, generalizable, and clinically translatable solutions for neurosurgical guidance. By organizing recent advances and critically assessing evaluation practices, this work provides a comprehensive reference for researchers and clinicians working on data-driven registration and modeling of brain deformation.
中文摘要:准确补偿脑变形对可靠的图像引导神经外科至关重要。手术操作和肿瘤切除引起组织运动,使术前规划图像与术中解剖结构发生错位。本综述考察2020年至2025年间用于脑变形配准与建模的数据驱动方法,重点关注基于学习的方法。按照预设纳入与排除标准,在PubMed、IEEE Xplore、Scopus和Web of Science中检索处理神经外科成像中脑变形的计算方法,共纳入46项合格研究。文中对方法学策略作统一分析,包括基于深度学习的图像配准、直接变形场回归、合成驱动的多模态对齐、处理缺失对应的切除感知架构,以及整合生物力学先验的混合模型。还考察数据集使用、评价指标、验证方案,以及各研究对不确定性和泛化性的评估。基于学习的方法在精度和计算效率上表现良好,现有方法仍受分布外稳健性、标准化基准、可解释性和临床部署准备度限制。本综述指出这些缺口,并展望更稳健、可泛化且可临床转化的神经外科引导方案。通过梳理近期进展并批判性评估评价实践,本工作为研究数据驱动脑变形配准与建模的研究者和临床医生提供综合参考。
Four-dimensional magnetic resonance fingerprinting (4DMRF) provides multi-parametric and motion-resolved tissue property quantification, promising to enhance the precision of liver cancer radiotherapy. However, its clinical translation is hindered by prolonged reconstruction time. Deep learning acceleration is fundamentally constrained by the lack of ground-truth 4D data. To this end, we propose SS-4DMRF, the first self-supervised reconstruction framework for 4DMRF, to reconstruct motion-resolved tissue maps without using supervised image labels. SS-4DMRF features a core temporal low-rank-constrained registration (TelReg) network for precise motion modeling. It leverages the intrinsic low-rank compressibility of respiratory motion and is directly self-supervised by the original highly undersampled k-space data and the derived subspace images. Motion-resolved tissue maps are reconstructed using a motion-informed compensation approach via a physics-informed pattern matching (PiPM) network. PiPM network incorporates novel multi-scale Swin Transformers with Bloch-equation-guided subspace denoising to achieve high-fidelity tissue quantification. SS-4DMRF was validated on digital phantom (n=30) and in vivo liver cancer patient (n=33) datasets. Compared to state-of-the-art 4DMRF methods, SS-4DMRF demonstrated superior tissue quantification and motion measurement accuracy. It achieved significantly reduced NRMSE in 4D tissue property quantification and improved inter-phase structural repeatability in 4D motion characterization (Paired Student's t-tests, p<0.001). The measured tumor motion trajectory presented strong Peason correlation with motion reference (r=0.939±0.057). Crucially, SS-4DMRF achieves this dual improvement in accuracy with a 10-fold acceleration in reconstruction time compared with conventional 4DMRF methods. By enabling rapid, precise, and motion-resolved quantitative imaging, SS-4DMRF advances the precision of liver cancer radiotherapy and establishes a clinically feasible platform for abdominal quantitative MRI in oncology.
中文摘要:四维磁共振指纹(4DMRF)可同时给出多参数、运动分辨的组织属性定量,有望提升肝癌放疗的精度。重建时间过长却制约了它的临床转化。深度学习加速受制于缺乏四维真值数据这一根本困难。为此,我们提出 SS-4DMRF,这是首个面向4DMRF的自监督重建框架,可在不使用监督图像标签的情况下重建运动分辨的组织参数图。SS-4DMRF 的核心是时间低秩约束配准网络(TelReg),用于精确的运动建模;该网络利用呼吸运动固有的低秩可压缩性,直接以原始高欠采样k空间数据及由此导出的子空间图像进行自监督。运动分辨的组织参数图通过物理引导的模式匹配网络(PiPM)以运动引导的补偿方式重建。PiPM 网络融合新型多尺度 Swin Transformer 与由 Bloch 方程引导的子空间去噪,实现高保真的组织定量。SS-4DMRF 在数字体模(n=30)与在体肝癌患者(n=33)数据集上完成验证。与当前先进的4DMRF方法相比,SS-4DMRF 在组织定量与运动测量精度上均有优势,四维组织属性定量的 NRMSE 显著降低,四维运动表征的相位间结构可重复性提高(配对 Student t 检验,p<0.001)。测得的肿瘤运动轨迹与运动参考值呈强 Pearson 相关(r=0.939±0.057)。相较传统4DMRF方法,SS-4DMRF 在重建时间上加速10倍的同时取得上述双重精度提升。SS-4DMRF 实现了快速、精确、运动分辨的定量成像,提升肝癌放疗精度,并为肿瘤学腹部定量MRI建立临床可行的平台。
Early detection of colorectal polyps is crucial to reduce the morbidity and mortality associated with colorectal cancer. However, during endoscopy, continuous camera motion and the complex clinical environment often degrade key visual cues (e.g., polyp morphology, texture, and boundaries). This leads to cross-frame view shifts, which are characterized by heterogeneous appearances of the same lesion over time, thereby introducing spurious correlations that hinder reliable assessment. To address this, we propose a causality-inspired representation learning framework with spatiotemporal memory for polyp detection in colonoscopy videos (CIRL-Polyp). Specifically, we develop a novel View-Shift-Aware Causal Intervention Module (VACIM) to remove non-causal influences by enforcing prediction invariance under view shift perturbations. To further constrain non-causal factors, we introduce a dual-branch detection framework that processes the original and intervention frame sequences in parallel and enforces prediction consistency across branches, thereby promoting invariance to non-causal variations. In addition, we propose Causal Temporal Consistency Memory (CTCM) to leverage long sequence-dependency features and stabilize causal representations by constructing memory banks across branches and performing temporal consistency-enhanced cross-attention. Comprehensive experiments on two public video datasets and a private dataset demonstrate that CIRL-Polyp outperforms existing methods, which validates the effectiveness and suggests the clinical potential of the proposed framework from a causal perspective.
中文摘要:结直肠息肉的早期检出对降低结直肠癌相关发病率和死亡率至关重要。内镜检查过程中,持续相机运动和复杂临床环境常削弱关键视觉线索,例如息肉形态、纹理和边界。这会造成跨帧视图偏移,表现为同一病变随时间呈现异质外观,并引入伪相关,妨碍可靠评估。为此,提出一种面向结肠镜视频息肉检测、带有时空记忆的因果启发表征学习框架CIRL-Polyp。具体而言,设计视图偏移感知因果干预模块VACIM,通过在视图偏移扰动下强制预测不变性来移除非因果影响。为进一步约束非因果因素,引入双分支检测框架,并行处理原始帧序列和干预帧序列,并强制分支间预测一致性,从而提升对非因果变化的不变性。还提出因果时间一致性记忆CTCM,通过跨分支构建记忆库并执行时间一致性增强的交叉注意力,利用长序列依赖特征并稳定因果表征。在两个公开视频数据集和一个私有数据集上的综合实验表明,CIRL-Polyp优于现有方法,验证了所提框架的有效性,并从因果角度提示其临床潜力。
The clinical translation of stimulator of interferon genes (STING)agonist-based cancer immunotherapy is limited by uncontrolled and sustained STING activation, which leads to immune exhaustion and systemic toxicity. In this forum, we critically analyze recent advances, including stimuli-responsive, biomimetic, pulsatile, intracellular-triggered release, and synergistic systems that enable precise spatiotemporal STING activation, as well as associated gaps in clinical translation. Finally, we present futuristic perspectives on next-generation STING-based cancer immunotherapy strategies.
中文摘要:基于干扰素基因刺激因子(STING)激动剂的肿瘤免疫治疗在临床转化中受制于STING激活失控且持续,进而引起免疫耗竭和全身毒性。该论坛对近期进展作批判性分析,涵盖刺激响应型、仿生型、脉冲式、胞内触发释放型及协同系统,这些系统可实现STING的精准时空激活,同时讨论临床转化中的相关缺口。最后,对下一代基于STING的肿瘤免疫治疗策略提出前瞻性展望。
Sonic hedgehog-medulloblastoma (SHH-MB) represents a biologically diverse and clinically challenging subgroup, especially in high-risk variants characterized by metastatic dissemination. Despite progress in molecular stratification, current treatments rely on intensive multimodal regimens that are associated with substantial long-term neurotoxicity. Identifying novel oncogenic mechanisms that can be therapeutically exploited is therefore a critical priority. We combined transcriptomic analyses of patient datasets with immunohistochemistry, RNAscope, and protein profiling to evaluate PTX3 expression in MB subgroups. Functional studies were performed in SHH-MB cell lines following PTX3 knockdown or knockout. Effects on proliferation, migration, and angiogenesis were assessed through multiple in vitro assays. In vivo relevance was tested using subcutaneous and orthotopic xenograft models. Mechanistic insights were obtained through phospho-kinase arrays, Western blotting, and GSEA. A high-throughput drug screen and combination studies with specific inhibitors and standard chemotherapy (vincristine/cisplatin/cyclophosphamide; VCC) were performed to assess therapeutic potential. Our results reveal that PTX3 was strongly enriched in SHH-MB subgroup, where it supported proliferation, motility, and angiogenesis. Mechanistically, PTX3 activated a TLR4-dependent IRAK1/PI3K-Akt/GSK-3/β-catenin signaling cascade. Genetic downregulation or pharmacologic blockade of PTX3-TLR4 significantly reduced tumor growth and angiogenesis in vivo. Moreover, the TLR4 inhibitor TAK-242 markedly impacted SHH-MB growth in vitro, and combination therapy of TAK-242 and VCC produced additive/synergistic effects in vitro and significantly prolonged survival in orthotopic SHH-MB-bearing mice. Our findings identify PTX3-TLR4 signaling as key oncogenic driver and a promising therapeutic -vulnerability in SHH-MB. Targeting this pathway enhances the efficacy of standard therapy and represents a rationale for mechanism-based combination strategies.
中文摘要:SHH型髓母细胞瘤(SHH-MB)是生物学异质性强、临床治疗困难的亚组,高危变异以转移播散为特征。分子分型已有进展,当前治疗仍依赖强化多模式方案,并带来明显的长期神经毒性。寻找可转化为治疗靶点的新致癌机制因此十分关键。研究结合患者数据集的转录组分析、免疫组化、RNAscope和蛋白谱分析,评估PTX3在不同MB亚组中的表达;在PTX3敲低或敲除的SHH-MB细胞系中开展功能研究,通过多种体外实验评估对增殖、迁移和血管生成的影响;用皮下和原位异种移植模型检验体内相关性;通过磷酸化激酶芯片、蛋白印迹和GSEA获得机制线索;并进行高通量药物筛选,以及PTX3/TLR4相关特异性抑制剂与标准化疗(长春新碱/顺铂/环磷酰胺,VCC)的联合研究,以评估治疗潜力。结果显示,PTX3在SHH-MB亚组中明显富集,并支持增殖、运动能力和血管生成。机制上,PTX3激活TLR4依赖的IRAK1/PI3K-Akt/GSK-3/β-catenin信号级联。遗传性下调或药理性阻断PTX3-TLR4可显著降低体内肿瘤生长和血管生成。TLR4抑制剂TAK-242在体外明显抑制SHH-MB生长,TAK-242与VCC联合在体外产生相加/协同效应,并显著延长原位SHH-MB小鼠的生存期。这些发现将PTX3-TLR4信号确定为SHH-MB的关键致癌驱动因素和有前景的治疗脆弱点;靶向该通路可增强标准治疗疗效,并为基于机制的联合策略提供依据。
Cholangiocarcinomas (CCAs) are cancers that arise in the peripheral or central bile ducts. They have substantial heterogeneity in their etiologies and histopathologic phenotypes, ranging from cholangiolar carcinomas arising from the smallest bile ducts or from dedifferentiating hepatocytes through cellular plasticity, to ductular cancers in medium and large-sized bile ducts. The surgical delineation of intrahepatic, perihilar, and distal CCAs does not match the biological classification, as intrahepatic CCAs include both small duct cholangiolar carcinoma and intermediate duct ductular or mucinous CCAs, which have different genomic and genetic characteristics. Despite their overall poor prognosis, CCAs have proven to include the most actionable target-rich types of cancer, with intrahepatic CCAs including relatively high percentages of fibroblast growth factor receptor 2 fusions and isocitrate dehydrogenase 1 or 2 mutations, as well as other currently or potentially targetable aberrations. We discuss the etiologies and risk factors for CCAs, review the pathophysiologic basis for tumor molecular heterogeneity in CCA, and discuss the known links with mutational signatures in subgroups of CCA, such as oxidative stress, aging, and exogenous exposures. The potential roles of differences in cell type-specific replication timing and immunoselective and metabolic pressures are discussed, as are the implications of synergistic or antagonistic oncogenic effects, leading to unique patterns of co-occurrence vs mutual exclusivity of alterations. In addition, we review the impacts of common genetic variants and known pathogenic germline or somatic variants that predispose carriers to CCA. Finally, we discuss the role of epigenetics and variations in DNA methylation in heterogeneity of CCA within the context of evolving treatment options and remaining key gaps in knowledge.
中文摘要:胆管癌(CCA)发生于外周或中央胆管。其病因与组织病理表型具有显著异质性,既包括起源于最小胆管或经细胞可塑性由去分化肝细胞形成的胆管小管癌,也包括发生于中、大胆管的胆管细胞癌。肝内、肝门部和远端CCA的外科划分与生物学分类并不一致,因为肝内CCA同时包含小胆管型胆管小管癌和中间胆管型胆管细胞癌或黏液性CCA,二者基因组与遗传学特征不同。尽管总体预后较差,CCA已被证明属于可靶向靶点最丰富的癌种之一,肝内CCA中成纤维细胞生长因子受体2融合和异柠檬酸脱氢酶1或2突变占相对较高比例,并存在其他当前或潜在可靶向的异常。讨论CCA的病因与危险因素,回顾肿瘤分子异质性的病理生理基础,并讨论CCA亚组中与突变特征相关的已知联系,如氧化应激、衰老和外源性暴露。讨论细胞类型特异性复制时序差异以及免疫选择压力和代谢压力的潜在作用,也讨论协同或拮抗致癌效应导致改变共现与互斥的独特模式及其意义。综述常见遗传变异以及已知使携带者易患CCA的致病性胚系或体细胞变异的影响。在治疗选择不断演变和关键知识空白仍存在的背景下,讨论表观遗传学和DNA甲基化变异在CCA异质性中的作用。
Organoids have emerged as one of the most predictive preclinical models in medical research due to their ability to closely retain the genetic and phenotypic characteristics of original tissues. Nevertheless, the application in the systematic evaluation of innovative medical devices (especially biodegradable metals) remains largely unexplored, whereas conventional analytical approaches have significant limitations in data throughput, objectivity, and reproducibility. Recent advances in deep learning-based artificial intelligence (AI) image analysis offer powerful quantitative tools to overcome this bottleneck. In this study, we established a high-throughput quantitative in vitro evaluation platform for the dynamic assessment of biodegradable metal ions by integrating patient-derived colorectal cancer organoids with an OrganoSeg-based deep learning AI image analysis system. Systematic assessments revealed that Mg2+ and Zn2+ had significant concentration-dependent effects on organoid growth, and the organoid model exhibited sensitivity profiles distinct from conventional cell lines. RNA-seq analysis further revealed that high concentrations of Mg2+ induced cell cycle arrest by activating the p53/CDKN1C signaling axis. In contrast, high concentrations of Zn2+ disrupted intracellular zinc homeostasis by regulating metallothionein family members and the zinc transporter SLC39A10, triggering a robust inflammatory response and ultimately leading to apoptosis. This work not only confirms the considerable potential of integrating organoids with AI technology in the evaluation of medical devices, but also reveals the differential mechanism of action of bioactive metal ions Mg2+ and Zn2+ in a model closer to the human environment. This study establishes a reliable and generalizable paradigm for high-throughput and high-content biomedical research.
中文摘要:类器官因能较好保留原始组织的遗传与表型特征,已成为医学研究中预测性较强的临床前模型之一。其在创新医疗器械尤其是可降解金属的系统评价中的应用仍很少被探索,而传统分析方法在数据通量、客观性和可重复性方面存在明显局限。基于深度学习的AI图像分析进展为突破这一瓶颈提供了有力的定量工具。本研究将患者来源结直肠癌类器官与基于OrganoSeg的深度学习AI图像分析系统结合,建立了用于动态评估可降解金属离子的高通量体外定量评价平台。系统评估显示,Mg2+和Zn2+对类器官生长具有明显的浓度依赖性作用,类器官模型的敏感性特征不同于常规细胞系。RNA-seq分析进一步显示,高浓度Mg2+通过激活p53/CDKN1C信号轴诱导细胞周期阻滞。与之相对,高浓度Zn2+通过调控金属硫蛋白家族成员和锌转运体SLC39A10破坏细胞内锌稳态,引发强烈炎症反应并最终导致凋亡。这项工作不仅证实了类器官与AI技术整合在医疗器械评价中的较大潜力,也揭示了生物活性金属离子Mg2+和Zn2+在更接近人体环境的模型中存在不同的作用机制。本研究为高通量、高内涵生物医学研究建立了可靠且可推广的范式。
HFE-related hereditary hemochromatosis is caused by loss-of-function mutations in the HFE gene, leading to excessive intestinal iron absorption and hepatic deposition. The C282Y variant in homozygosity accounts for 80-90% of diagnosed cases. If untreated, iron accumulation can cause liver fibrosis, cirrhosis, and hepatocellular carcinoma. We employed lipid nanoparticles (LNPs) to deliver base editor mRNA and single-guide RNA for in vivo correction of the HFE C282Y mutation in a murine model under iron challenge. Additionally, patient-derived induced pluripotent stem cells (iPSCs) and hepatocyte-like cells were edited using the same approach. Base editing achieved a conversion rate of 73.6 ± 4.9% in cultured murine hepatocytes and up to 67% in vivo. No off-target effects were detected at genomic sites with one or two mismatches, as confirmed by next-generation sequencing. Treated mice showed significantly reduced hepatic iron overload despite continued high dietary iron intake. Transcriptomic analysis revealed decreased signatures associated with fibrosis and cancer. For preclinical evaluation, iPSCs from C282Y homozygous patients were differentiated into hepatocyte-like cells. LNP-mediated base editing achieved up to 63.8 ± 0.8% correction in these cells, again without detectable off-target activity. These results provide proof of concept that base editing of the C282Y variant is both safe and efficient in vivo and in human-derived cells, effectively reducing hepatic iron accumulation and preventing fibrotic remodeling. HFE C282Y-related hemochromatosis lacks causal therapies and carries a risk of iron-driven liver disease, supporting the need for precise in vivo gene correction. Here, LNP-mediated adenine base editor delivery enabled efficient editing in hepatocytes and induced pluripotent stem cell-derived models, reducing hepatic iron and normalizing biomarkers without detectable safety concerns. These findings highlight translational potential for non-viral gene correction, though further validation in larger and long-term studies is required.
中文摘要:HFE相关的遗传性血色病由HFE基因功能缺失突变引起,导致肠道铁吸收过多和肝脏铁沉积。C282Y变异纯合占已诊断病例的80-90%。若不治疗,铁蓄积可导致肝纤维化、肝硬化和肝细胞癌。我们利用脂质纳米颗粒(LNP)递送碱基编辑器mRNA和单向导RNA,在铁负荷小鼠模型中体内纠正HFE C282Y突变。同时,用同一方法编辑患者来源的诱导多能干细胞(iPSC)及肝细胞样细胞。碱基编辑在培养的小鼠肝细胞中达到73.6 ± 4.9%的转换率,在体内最高达67%。下一代测序证实,在一个或两个错配的基因组位点未检测到脱靶效应。尽管继续摄入高膳食铁,治疗小鼠的肝脏铁过载显著减轻。转录组分析显示纤维化和癌症相关特征减少。为进行临床前评估,将C282Y纯合患者的iPSC分化为肝细胞样细胞。LNP介导的碱基编辑在这些细胞中最高实现63.8 ± 0.8%的纠正,同样未检测到脱靶活性。这些结果提供概念验证:C282Y变异的碱基编辑在体内和人源细胞中安全有效,可有效减少肝脏铁蓄积并防止纤维化重塑。HFE C282Y相关血色病缺乏病因治疗,并存在铁驱动肝病风险,支持精准体内基因纠正的必要性。此处,LNP介导的腺嘌呤碱基编辑器递送在肝细胞和诱导多能干细胞来源模型中实现高效编辑,降低肝脏铁并使生物标志物正常化,未发现安全性问题。这些发现凸显非病毒基因纠正的转化潜力,但仍需在更大规模和长期研究中进一步验证。
Sensitive and accurate prostate-specific antigen (PSA) detection plays an important role in the early diagnosis of prostate cancer, but achieving such detection remains challenging due to the extremely low concentration of PSA biomarkers in human serum. In this work, a novel photoelectrochemical (PEC) immunosensor for ultra-trace value detection of PSA was prepared based on a synergistic nanocomposite composed of polyaniline, graphene quantum dots, tungsten oxide, and gold (PANI-GQDs-WOx/Au). The PANI-GQDs-WOx nanocomposite was co-electrodeposited on the graphenized screen-printed carbon electrode (GSCPE), which was subsequently modified with gold nanoparticles. The rational design of engineered nanocomposites provided enhanced electrical conductivity, efficient electron transfer, enhanced photocurrent response, superior catalytic activity, and an ideal substrate for stable immobilization of the bioreceptor. Under the optimized conditions, the PEC immunosensor exhibited significantly improved photocatalytic performance, achieving a very low limit of detection of 75 fg mL-1 and a wide linear range from 0.1 pg mL-1 to 100 ng mL-1. Most importantly, the performance of the immunosensor was successfully confirmed in real human serum samples, without dilution and deproteinization. These results highlight the promising potential of PANI-GQDs-WOx/Au nanocomposite for the development of rapid and accurate point-of-care diagnostic platforms and are an important step towards improving prostate cancer diagnosis.
中文摘要:灵敏、准确地检测前列腺特异性抗原(PSA)对前列腺癌的早期诊断具有重要作用,但人血清中PSA标志物浓度极低,此类检测仍难以实现。本工作基于聚苯胺、石墨烯量子点、氧化钨与金组成的协同纳米复合物(PANI-GQDs-WOx/Au),制备了一种用于超痕量PSA检测的新型光电化学(PEC)免疫传感器。PANI-GQDs-WOx纳米复合物被共电沉积在石墨化丝网印刷碳电极(GSCPE)上,随后修饰金纳米颗粒。该纳米复合物的合理设计提供了增强的导电性、高效的电子传递、增强的光电流响应与优良的催化活性,并为生物受体的稳定固定提供了理想基底。在优化条件下,该PEC免疫传感器表现出明显改善的光催化性能,检出限低至75 fg mL-1,线性范围为0.1 pg mL-1至100 ng mL-1。该免疫传感器的性能在未经稀释和去蛋白处理的实际人血清样本中得到成功验证。上述结果显示了PANI-GQDs-WOx/Au纳米复合物在构建快速、准确的即时诊断平台方面的潜力,也是改善前列腺癌诊断的重要一步。
Photodynamic therapy (PDT) offers precise cancer treatment, yet conventional photosensitizers frequently suffer from aggregation-caused quenching (ACQ) and oxygen dependence. Here, we report a platinum (Pt)-modulated supramolecular metallacage, TPE-Pt-Cage, constructed from aggregation-induced emission (AIE) ligands to overcome these limitations. Pt coordination rigidifies the AIE framework at the molecular level, suppressing intramolecular motions and π-π stacking, while the resulting supramolecular assembly adopts an open architecture with accessible cavities that facilitates oxygen and substrate diffusion. These synergistic structural features empower TPE-Pt-Cage to achieve ROS generation efficiencies far exceeding its precursor and leading commercial photosensitizers under light irradiation. Under hypoxia, TPE-Pt-Cage engages a sequential electron-transfer pathway in which water acts as the oxygen source, producing in situ O2 that is subsequently converted into O2•- and •OH. This mechanism is supported by hypoxia-tolerant radical species production and redox potentials sufficient to oxidize H2O, enabling dominant type I ROS output when external oxygen is scarce. Together with the intrinsic chemotherapeutic activity of Pt, TPE-Pt-Cage achieves synergistic tumor inhibition in vitro and in vivo. This hypoxia-resilient PDT strategy, combined with Pt-mediated chemotherapy, drives potent tumor suppression and defines a generalizable design principle for developing AIE-based metallacages as effective PDT agents in oxygen-deficient solid tumors.
中文摘要:光动力治疗(PDT)可实现精准肿瘤治疗,但传统光敏剂常受聚集导致猝灭(ACQ)和氧依赖限制。一种由聚集诱导发光(AIE)配体构建的铂(Pt)调控超分子金属笼TPE-Pt-Cage被开发用于克服这些局限。Pt配位在分子层面刚性化AIE骨架,抑制分子内运动和π-π堆积,所得超分子组装体呈开放结构并具有可接近空腔,有利于氧气和底物扩散。这些协同结构特征使TPE-Pt-Cage在光照下产生ROS的效率远高于其前体和领先的商业光敏剂。在缺氧条件下,TPE-Pt-Cage走序贯电子转移途径,水作为氧源原位生成O2,随后转化为O2•-和•OH。该机制得到耐缺氧自由基物种产生以及足以氧化H2O的氧化还原电位支持,使外部氧不足时以I型ROS输出为主。结合Pt固有的化疗活性,TPE-Pt-Cage在体外和体内均实现协同抑瘤。这种耐缺氧PDT策略与Pt介导化疗结合,产生强效肿瘤抑制,并为开发基于AIE的金属笼作为缺氧实体瘤有效PDT药物确立可推广的设计原则。
Mechanical and structural cues of the extracellular matrix (ECM) regulate tumor cell metabolism and drug response, yet the molecular mediators that link these biophysical signals are unclear. We present an elastically supported surface platform bioengineered with varying stiffness and collagen fiber anisotropy to replicate the fibrotic and mechanically inhomogeneous liver cancer microenvironment. Using this system, we identify Kelch-like ECH-associated protein 1 (KEAP1) as a mechanoresponsive mediator linking ECM stiffness to mitochondrial dynamics, redox adaptation, and chemoresistance in hepatocellular carcinoma (HCC). In substrate stiffness increase, biphasic KEAP1 expression, time-dependent mitochondrial remodeling via a KEAP1-BCL-2-DRP1 cascade, suppression of reactive oxygen species, and activation of antioxidant and glycolytic transcriptional programs were triggered. RNA sequencing revealed stiffness-dependent repression of mitochondrial fission genes and induction of AGE-RAGE signaling. At a functional level, cells grown in stiffer matrix demonstrated augmented proliferation and chemoresistance to cisplatin and sorafenib with nuclear translocation of NRF2. Multiplex imaging of human HCC tissues confirmed that collagen-rich regions co-localize with high KEAP1 and TOM20 expression, confirming the in vitro findings. This study demonstrates ECM stiffness to be a bioactive material property that guides mitochondrial and redox networks through KEAP1 signaling, and the mechanically tunable collagen platforms to be of a utility for dissection and manipulation of tumor adaptation mechanisms.
中文摘要:细胞外基质的力学与结构线索调控肿瘤细胞代谢和药物反应,但连接这些生物物理信号的分子介导者仍不清楚。我们构建了一种弹性支撑的表面平台,通过改变刚度和胶原纤维各向异性,复现纤维化且力学不均一的肝癌微环境。利用该系统,我们发现Kelch样ECH相关蛋白1(KEAP1)是将细胞外基质刚度与肝细胞癌(HCC)线粒体动态、氧化还原适应和化疗耐药联系起来的机械响应介导者。随着基底刚度升高,KEAP1表达呈双相变化,经KEAP1-BCL-2-DRP1级联发生时间依赖性线粒体重塑,活性氧受到抑制,抗氧化与糖酵解转录程序被激活。RNA测序显示线粒体分裂基因受刚度依赖性地抑制,AGE-RAGE信号被诱导。在功能层面,较硬基质中生长的细胞增殖增强,对顺铂和索拉非尼的耐药性提高,并伴NRF2核转位。人HCC组织多重成像证实,富含胶原的区域与高KEAP1和TOM20表达共定位,印证了体外结果。该研究说明细胞外基质刚度是一种生物活性材料属性,可通过KEAP1信号引导线粒体与氧化还原网络,力学可调的胶原平台可用于解析和操控肿瘤适应机制。
The rapid development of nanomedicine has significantly improved the targeting and biosafety of cancer therapy. However, most current nanotherapeutics require 4-24 h of intracellular delivery and signaling responses, leading to delayed responses, increased risks of resistance and metastasis. Achieving efficient tumor cell killing within minutes holds promise for overcoming these limitations and enabling more thorough tumor elimination. In this study, we synthesized a nanosheet material, Bi2Fe4O9@Au (BFO@Au NSs), which integrates membrane thiol-targeting recognition with potent oxidative-damage capability. By efficiently depleting sulfhydryl groups on the surface of tumor cell membranes and disrupting membrane functional proteins within minutes, BFO@Au NSs rapidly induces membrane dysfunction, triggering metabolic disorders, mitochondrial membrane potential collapse, and redox imbalance, ultimately leading to irreversible necrosis of tumor cells, thereby successfully achieving 'membrane necrotherapy'. This process simultaneously induces an immunogenic cell death (ICD)-like response, effectively promoting the dendritic cell maturation and the M1 polarization of macrophages, enhancing antitumor immune responses and suppressing distant metastasis. Importantly, the oxidative activity of BFO@Au NSs decays rapidly after reacting with tumor membranes, significantly reducing toxicity to biological tissues. This study proposes a new synergistic anti-tumor strategy based on membrane function disruption, providing a theoretical basis and application prospects for efficient and safe nanotherapeutic systems.
中文摘要:纳米医学的快速发展显著改善了肿瘤治疗的靶向性与生物安全性,但现有多数纳米治疗药物需要4至24小时的胞内递送和信号响应,容易造成响应延迟,并增加耐药与转移风险。若能在数分钟内高效杀伤肿瘤细胞,有望克服上述局限并实现更彻底的肿瘤清除。本研究合成了纳米片材料Bi2Fe4O9@Au(BFO@Au NSs),将膜巯基靶向识别与强氧化损伤能力整合在一起。BFO@Au NSs可在数分钟内高效耗竭肿瘤细胞膜表面的巯基并破坏膜功能蛋白,快速诱导膜功能障碍,引发代谢紊乱、线粒体膜电位崩溃和氧化还原失衡,最终导致肿瘤细胞不可逆坏死,从而实现「膜坏死治疗」。该过程同时诱导类免疫原性细胞死亡反应,有效促进树突状细胞成熟和巨噬细胞M1极化,增强抗肿瘤免疫应答并抑制远处转移。BFO@Au NSs与肿瘤膜反应后氧化活性迅速衰减,明显降低对生物组织的毒性。该研究提出了一种基于膜功能破坏的协同抗肿瘤新策略,为高效、安全的纳米治疗体系提供了理论依据与应用前景。
Precise and controllable RNA editing presents a powerful therapeutic strategy for oncogene silencing in cancer treatment. Here, we introduce a photothermal-activatable host-guest supramolecular delivery system enabling spatiotemporally regulated expression of CasRx, a compact RNA-guided RNA endonuclease, for targeted survivin mRNA knockdown in hepatocellular carcinoma. The modular platform is constructed through dynamic assembly of β-cyclodextrin-conjugated polydisulfide and adamantane-functionalized conjugated small molecules through host-guest interactions, enabling the integration of photothermal agents into the delivery vectors that can encapsulate the heat-inducible expression of plasmid encoding CasRx. Upon the near-infrared (NIR) laser irradiation, the moieties containing conjugated small molecules can convert light to heat so as to trigger the specific expression of CasRx in tumor tissue, leading to efficient and selective degradation of survivin transcripts. This supramolecular platform integrates the photothermal switch and delivery carriers and precisely controls RNA editing in vivo, avoiding potential systemic toxicity induced by off-target delivery. Our study establishes a programmable and precise RNA regulation platform in vivo by means of supramolecular assembly for safe, tunable, and effective RNA-based cancer therapy.
中文摘要:精准可控的RNA编辑为癌症治疗中沉默致癌基因提供了有力的治疗策略。该研究构建了一种可由光热激活的主客体超分子递送系统,可在时空上调控CasRx的表达;CasRx是一种紧凑型RNA引导RNA内切核酸酶,用于靶向敲低肝细胞癌中的survivin mRNA。该模块化平台通过β-环糊精修饰的聚二硫化物与金刚烷功能化共轭小分子之间的主客体相互作用动态组装而成,可将光热试剂整合到递送载体中,并包载编码CasRx的热诱导表达质粒。近红外激光照射后,含共轭小分子的部分可将光转化为热,从而触发肿瘤组织中CasRx的特异性表达,实现对survivin转录本高效且选择性的降解。该超分子平台将光热开关与递送载体整合,在体内精准控制RNA编辑,避免脱靶递送可能引起的全身毒性。该工作通过超分子组装建立了体内可编程、精准的RNA调控平台,为安全、可调且有效的RNA癌症治疗提供途径。
Biomolecular condensates formed through liquid-liquid phase separation (LLPS) have emerged as central organizers of cellular biochemistry. In cancer, dysregulated phase separation gives rise to oncogenic condensates that reprogram transcriptional, signaling, and stress-response networks. By selectively concentrating oncogenic proteins and nucleic acids, these dynamic assemblies create permissive regulatory microenvironments that stabilize malignant cell states and facilitate therapeutic resistance. Accumulating evidence now indicates that oncogenic condensates are pharmacologically tractable, opening new opportunities for targeted intervention. In this Review, we synthesize current mechanistic insights into condensate assembly, regulation, and material state transitions; examine their context-dependent behaviors and functional heterogeneity across tumor ecosystems; and delineate emerging therapeutic strategies, including small-molecule modulators, peptide-based inhibitors, targeted protein degraders, and RNA-directed approaches. We further highlight recent translational advances-exemplified by DPTX-3186, a first-in-class condensate modulator granted FDA Orphan Drug Designation for Wnt-driven gastric cancer-that underscore the clinical promise of condensate-directed therapies. Finally, we discuss key mechanistic, pharmacodynamic, and biomarker-related challenges that must be addressed to fully integrate condensate biology into next-generation precision oncology.
中文摘要:通过液-液相分离(LLPS)形成的生物分子凝聚体已成为细胞生物化学的核心组织者。在癌症中,相分离失调产生致癌性凝聚体,重编程转录、信号传导和应激反应网络。这些动态组装体通过选择性富集致癌蛋白和核酸,形成有利于维持恶性细胞状态并促进治疗耐药的调控微环境。越来越多的证据表明,致癌性凝聚体可在药理学上被干预,为靶向治疗带来新机会。整合当前关于凝聚体组装、调控和物质状态转变的机制认识;考察其在肿瘤生态系统中的情境依赖行为和功能异质性;并梳理新兴治疗策略,包括小分子调节剂、肽类抑制剂、靶向蛋白降解剂和RNA导向方法。进一步强调近期转化进展——以DPTX-3186为例,这是一种首创性凝聚体调节剂,已获FDA孤儿药资格用于Wnt驱动的胃癌——凸显凝聚体导向治疗的临床前景。讨论将凝聚体生物学全面纳入下一代精准肿瘤学所需解决的关键机制、药效学和生物标志物相关挑战。
Vγ9Vδ2 T cells mediate HLA-independent targeting of tumor cells, offering unique opportunities for cancer immunotherapy, yet their therapeutic efficacy remains limited. Here, using a genome-wide CRISPR screen, we identify UDP-galactose 4-epimerase (GALE) as a tumor-intrinsic checkpoint that restricts Vγ9Vδ2 T cell-mediated killing. GALE is a key nucleotide-sugar metabolic enzyme that controls the interconversion of UDP-galactose and UDP-glucose, thereby supporting protein glycosylation and cell-surface glycan remodeling. Mechanistically, GALE promotes complex N-glycosylation of CD155 and CEACAM1, favoring their engagement with the inhibitory receptors TIGIT and TIM3, respectively, while limiting CD155 binding to the activating receptor CD226. GALE loss potentiates Vγ9Vδ2 T cell-mediated tumor killing in multiple mouse models and colorectal cancer patient-derived organoids. Together, these findings reveal how nucleotide-sugar metabolism shapes tumor-immune communication through complex N-glycan remodeling and identify GALE and its downstream receptor-ligand interactions as potential therapeutic targets for enhancing Vγ9Vδ2 T cell antitumor activity.
中文摘要:Vγ9Vδ2 T细胞可介导不依赖HLA的肿瘤细胞杀伤,为肿瘤免疫治疗提供了独特机会,但其治疗效果仍有限。本研究通过全基因组CRISPR筛选,鉴定出UDP-半乳糖4-差向异构酶(GALE)是限制Vγ9Vδ2 T细胞杀伤作用的肿瘤内在检查点。GALE是关键的核苷酸-糖代谢酶,控制UDP-半乳糖与UDP-葡萄糖的相互转化,从而支持蛋白糖基化和细胞表面聚糖重塑。机制上,GALE促进CD155和CEACAM1的复杂N-糖基化,分别有利于它们与抑制性受体TIGIT和TIM3结合,同时限制CD155与激活性受体CD226结合。GALE缺失在多种小鼠模型和结直肠癌患者来源类器官中增强Vγ9Vδ2 T细胞介导的肿瘤杀伤。这些发现揭示了核苷酸-糖代谢如何通过复杂N-聚糖重塑塑造肿瘤-免疫通讯,并将GALE及其下游受体-配体相互作用确定为增强Vγ9Vδ2 T细胞抗肿瘤活性的潜在治疗靶点。
In pancreatic ductal adenocarcinoma (PDAC), the fibroblastic stroma constitutes most of the tumor mass and is remarkably devoid of functional blood vessels, leaving unresolved how PDAC cells obtain essential metabolites and water-insoluble lipids. We find that cancer-associated fibroblasts (CAFs) acquire and transfer lipids from blood-borne particles to PDAC cells through trogocytosis of CAF plasma membranes, a process requiring the CAF-expressed phospholipid scramblase anoctamin 6 (ANO6) to promote PDAC cell survival. Cancer cells and CAFs form synapse-like contacts that induce cytosolic calcium influx in CAFs through Orai channels, activating ANO6 and driving phosphatidylserine exposure on CAF membranes, which initiates trogocytosis and transfer of membrane lipids, including cholesterol, to PDAC cells. This ANO6-dependent phosphatidylserine externalization also supports CAF-mediated immunosuppression of cytotoxic T cells through trogocytosis. Blockade of ANO6 antagonizes tumor growth, partly by disrupting cholesterol delivery to cancer cells, and attenuates immune suppression, identifying ANO6 as a candidate therapeutic target in PDAC.
中文摘要:胰腺导管腺癌(PDAC)中,纤维母细胞性间质构成大部分肿瘤体积,且显著缺乏功能性血管,PDAC 细胞如何获取必需代谢物和水不溶性脂质仍未明确。我们发现,癌症相关成纤维细胞(CAF)通过 CAF 质膜的胞啃作用,从血液颗粒中获取脂质并将其转移给 PDAC 细胞;该过程需要 CAF 表达的磷脂爬行酶 anoctamin 6(ANO6),以促进 PDAC 细胞存活。癌细胞与 CAF 形成突触样接触,经 Orai 通道诱导 CAF 胞质钙内流,激活 ANO6,驱动 CAF 膜上磷脂酰丝氨酸暴露,从而启动胞啃作用并向 PDAC 细胞转移膜脂质,包括胆固醇。这种依赖 ANO6 的磷脂酰丝氨酸外翻也通过胞啃作用支持 CAF 介导的对细胞毒性 T 细胞的免疫抑制。阻断 ANO6 可拮抗肿瘤生长,部分通过破坏向癌细胞输送胆固醇,并减弱免疫抑制,表明 ANO6 是 PDAC 的候选治疗靶点。
3其他实体瘤 (60篇)
临床研究 (7篇)
The genomic characterization of cancers has considerably advanced research and clinical practice. However, critical gaps remain, including limited knowledge of tumor profiles in rare cancers and populations understudied in genomic research and insufficient integration of genomic, clinical and epidemiologic data. This Perspective highlights the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network, established by the US National Cancer Institute to address knowledge gaps in rare and understudied cancers. PE-CGS comprises five research centers supported by a coordinating center and guided by an external advisory panel. Collaborations across PE-CGS are grounded in shared values of participant-centeredness, engagement, access, collaboration and innovation. Activities emphasize participant engagement throughout the research process, including the return of results and collection of clinical and epidemiologic data alongside paired tumor/germline sequencing. PE-CGS demonstrates how engagement, return of results and comprehensive data collection can be integrated to support participant-centered cancer genomics research and accelerate research in rare and understudied cancers.
中文摘要:癌症的基因组特征描述已显著推动研究和临床实践。然而仍存在关键缺口,包括对罕见癌症及基因组研究中代表性不足人群的肿瘤图谱了解有限,以及基因组、临床和流行病学数据整合不足。该观点文章介绍美国国家癌症研究所建立的参与者参与与癌症基因组测序(PE-CGS)网络,以弥补罕见和代表性不足癌症中的知识缺口。PE-CGS由五个研究中心组成,由一个协调中心支持,并由外部咨询小组指导。PE-CGS内部的合作以参与者中心、参与、可及、协作和创新等共同价值观为基础。相关活动强调在研究全过程中促进参与者参与,包括返还结果,以及在配对肿瘤/胚系测序之外收集临床和流行病学数据。PE-CGS展示了如何将参与、结果返还和全面数据收集整合起来,以支持以参与者为中心的癌症基因组研究,并加速罕见和代表性不足癌症的研究。
There is an urgent global need for affordable, large-scale health screening to enhance preventive care in the ageing population. Using low-cost, non-invasive retinal photographs and leveraging large foundation models, we developed a deep learning-based biomarker, Retinal Mortality Equivalent (RetiME), that directly mapped retinal features to individual mortality risk. Trained on a European cohort and externally validated across three independent external cohorts spanning Southeast Asia, Eurasia and North America, RetiME showed robust associations with all-cause and cause-specific mortality and predicted the incidence of a wide range of systemic and ocular diseases. Crucially, beyond static risk estimation, RetiME re-timed mortality risk by reconstructing personalized lifespan trajectories that were associated with observed mortality outcomes (for example, age of death). Clustering of these trajectories revealed distinct mortality patterns, spanning cancer-predominant, cardiometabolic and neurodegenerative risks, reflecting diverse ageing pathways captured by RetiME. Interpretability analyses showed that RetiME captures diverse biological and retinal features underlying mortality risk. Genome-wide analyses further identified genetic loci associated with RetiME. Collectively, these findings support further evaluation of retinal imaging and trajectory modelling as one component of a comprehensive assessment of mortality risk.
中文摘要:全球亟需可负担的大规模健康筛查,以加强老龄人口的预防保健。利用低成本、非侵入性的视网膜照片并结合大型基础模型,我们开发了深度学习生物标志物视网膜死亡等效指标RetiME,将视网膜特征直接映射到个体死亡风险。RetiME在欧洲队列中训练,并在覆盖东南亚、欧亚大陆和北美的三个独立外部队列中验证,与全因死亡和特定原因死亡均表现出稳健关联,并能预测多种系统性疾病和眼部疾病的发生。除静态风险评估外,RetiME通过重建个体化寿命轨迹重新定位死亡风险的时间,这些轨迹与观察到的死亡结局相关,例如死亡年龄。对这些轨迹进行聚类显示出不同的死亡模式,涵盖以癌症为主、心脏代谢和神经退行性风险,反映了RetiME捕捉到的多样衰老路径。可解释性分析显示,RetiME捕捉到死亡风险背后的多种生物学和视网膜特征。全基因组分析进一步识别出与RetiME相关的遗传位点。这些发现支持进一步评估视网膜成像和轨迹建模,将其作为死亡风险综合评估的一个组成部分。
Molecular Tumor Boards (MTBs) are increasingly recognized as key instruments for integrating genomic data into clinical decision-making in precision oncology. While evidence suggests that MTBs may improve patient outcomes, their implementation across European healthcare systems remains heterogeneous. This scoping review aims to explore challenges and facilitators of MTB implementation, focusing on feasibility, acceptability, equity, and resource use. We conducted a literature search in PubMed, Embase and Web of Science up to 30 June 2026 to identify studies addressing implementation aspects of MTBs in Europe. Eligible studies included any design discussing feasibility, acceptability, equity, or resource use. Statements were extracted and coded using a hierarchical analytical framework based on domains, themes, and subthemes. Statements were classified as challenges or facilitators. One hundred and six studies were included out of 3307 studies identified. Most studies addressed feasibility (87.7%), followed by equity (47.2%), resource use (44.3%), and acceptability (32.1%). A total of 466 statements were extracted, divided between challenges (43.1%) and facilitators (56.9%). Feasibility challenges included technical and organizational barriers, particularly delays in turnaround time, lack of standardized workflows, and limited interoperability of digital systems. Facilitators included workflow optimization, multidisciplinary coordination, standardized procedures, and decision-support tools. Acceptability challenges involved limited genomic knowledge and readiness among healthcare professionals and concerns regarding the clinical benefits and potential risks of genomic testing among patients, while education and training emerged as key facilitators. Equity challenges included geographical disparities, limited access to clinical trials, and inequalities in access to molecular technologies across countries and healthcare centers; virtual MTBs, regional networks, and centralized services were identified as potential facilitators. Resource use challenges were mainly related to the costs of genomic testing and targeted therapies and uncertainties in reimbursement, whereas facilitators included declining sequencing costs, dedicated funding, and structured reimbursement pathways. MTB implementation across Europe remains heterogeneous and is influenced by interconnected organizational, technical, educational, equity, and economic factors. Standardized processes, interoperable digital infrastructures, workforce training, equitable access, and sustainable financing may be key to supporting the integration and scalability of MTBs into routine oncology care.
中文摘要:分子肿瘤委员会(MTB)日益被视为将基因组数据纳入精准肿瘤学临床决策的关键工具。已有证据提示MTB可能改善患者结局,但其在欧洲各医疗体系中的实施仍不均衡。本范围综述旨在探讨MTB实施的挑战与促进因素,重点关注可行性、可接受性、公平性和资源使用。我们检索了PubMed、Embase和Web of Science截至2026年6月30日的文献,以识别涉及欧洲MTB实施方面的研究。纳入研究可为任何设计,但需讨论可行性、可接受性、公平性或资源使用。我们提取陈述,并依据由领域、主题和亚主题构成的分层分析框架进行编码。陈述被归类为挑战或促进因素。在3307项识别出的研究中纳入106项。多数研究涉及可行性(87.7%),其次为公平性(47.2%)、资源使用(44.3%)和可接受性(32.1%)。共提取466条陈述,其中挑战占43.1%,促进因素占56.9%。可行性挑战包括技术和组织障碍,尤其是周转时间延迟、缺乏标准化工作流程、数字系统互操作性有限。促进因素包括工作流程优化、多学科协调、标准化程序和决策支持工具。可接受性挑战涉及医疗专业人员基因组知识和准备不足,以及患者对基因组检测临床获益和潜在风险的担忧;教育和培训是关键促进因素。公平性挑战包括地理差异、临床试验可及性有限,以及不同国家和医疗中心在分子技术可及性方面的不平等;虚拟MTB、区域网络和集中化服务被认为是潜在促进因素。资源使用挑战主要与基因组检测和靶向治疗成本及报销不确定性有关,促进因素包括测序成本下降、专项资助和结构化报销路径。欧洲MTB实施仍呈异质性,并受组织、技术、教育、公平和经济因素相互交织的影响。标准化流程、可互操作的数字基础设施、人员培训、公平可及和可持续融资可能对支持MTB融入常规肿瘤诊疗并实现可扩展性至关重要。
Spine and pelvis diseases impair motor control through pain and neurological dysfunction, resulting in characteristic gait abnormalities. However, existing clinical screening and initial triage rely on static imaging, which overlooks gait patterns and limits efficiency for the primary assessment of these diseases. To enhance efficiency and enable clinically aligned diagnostics, we utilize gait videos and propose a hierarchical diagnostic model for spine and pelvis diseases. Based on gait videos, our method progresses from disease-region localization to pathological characterization, explicitly mimicking the clinical diagnostic process. To capture dynamic gait features, we leverage a Spatiotemporal Transformer that jointly models structural dependencies among body regions and motion rhythms. To ensure diagnostic coherence, we design a clinically inspired Tree Hierarchy Classifier that integrates region localization and pathology assessment, while preventing incompatible cross-level predictions. We collected clinical gait videos from 419 patients to train and validate our proposed model. At the first diagnostic level, the model distinguishes cervical/thoracic from lumbar/pelvis diseases, achieving an accuracy of 76% and an AUC of 85%. The second diagnostic level performs pathological characterization, further classifying cases into tumor and non-tumor subtypes across these regions. We further provide clinical interpretability via spatiotemporal attention visualizations, revealing that the model captures gait patterns consistent with established pathophysiological mechanisms. By aligning gait patterns with the dynamic functional impact of disease, we demonstrate the potential of gait video analysis as an efficient approach for the primary screening of spine and pelvis diseases.
中文摘要:脊柱与骨盆疾病通过疼痛和神经功能障碍损害运动控制,导致具有特征性的步态异常。现有临床筛查和初诊分诊依赖静态影像,忽视步态模式,限制了这些疾病初级评估的效率。为提高效率并实现与临床一致的诊断,我们利用步态视频,提出一种脊柱与骨盆疾病的分层诊断模型。基于步态视频,该方法从疾病区域定位推进到病理特征刻画,明确模拟临床诊断过程。为捕捉动态步态特征,我们采用时空Transformer,联合建模身体区域间的结构依赖与运动节律。为保证诊断一致性,我们设计受临床启发的树状层级分类器,整合区域定位与病理评估,同时防止不相容的跨层级预测。我们收集419例患者的临床步态视频以训练和验证所提模型。在第一诊断层级,模型区分颈/胸段与腰/骨盆疾病,准确率76%,AUC 85%。第二诊断层级进行病理特征刻画,进一步将这些区域的病例分为肿瘤与非肿瘤亚型。我们通过时空注意力可视化提供临床可解释性,显示模型捕捉到与已知病理生理机制一致的步态模式。通过将步态模式与疾病的动态功能影响对齐,我们展示步态视频分析作为脊柱与骨盆疾病初级筛查高效方法的潜力。
Flat head/neck pigmented macules can be diagnostically challenging. To assess the impact of reflectance confocal microscopy (RCM) integration to dermoscopic triage of equivocal lesions. Prospective multicenter study of equivocal flat macules. Lesions suspicious or discordant were biopsied/excised; double-negative lesions were followed ≥1 year. Histopathology served as reference standard. A total of 2006 lesions from 801 patients (mean age 66.2 years) were evaluated. After dermoscopy-RCM integration, 236/2006 (11.8%) lesions were managed as malignant (226 biopsied/excised; 10 noninvasively treated: 8 basal cell carcinoma [BCC] and 2 lentigo maligna [LM]). Twenty-six lesions changed at follow-up and were removed, with 4 malignancies (0.4%; 3 LM, 1 BCC). Histology (n = 252) confirmed 114 malignancies (62 LM/lentigo maligna melanoma [LMM]; 52 BCC/squamous cell carcinoma [SCC]). Dermoscopy detected 54.8% of LM/LMM and 90.4% of BCC/SCC; RCM correctly diagnosed 91.9% of LM/LMM and 94.2% of BCC/SCC. Verification and selection biases and follow-up losses. Integrating RCM significantly improves LM/LMM sensitivity detection and specificity for benign lesions compared to dermoscopy alone, minimizing overtreatment and missed malignancies. Although a small residual risk of missed malignancy persists, the combined approach offers a highly safe, noninvasive pathway for managing equivocal lesions in cosmetically sensitive areas.
中文摘要:头颈部平坦色素性斑片的诊断常较困难。评估将反射式共聚焦显微镜(RCM)整合进皮肤镜分诊对不确定病变的影响。这项前瞻性多中心研究纳入平坦且诊断不确定的斑片。对可疑或皮肤镜与RCM结果不一致的病变进行活检或切除;双阴性病变随访至少1年。以组织病理学为参考标准。共评估801例患者的2006个病变,平均年龄66.2岁。皮肤镜与RCM整合后,236/2006(11.8%)个病变按恶性处理(226个活检或切除;10个接受无创治疗:8个基底细胞癌,2个恶性雀斑样痣)。随访中26个病变发生变化并切除,其中4个为恶性(0.4%;3个恶性雀斑样痣,1个基底细胞癌)。组织学检查(n=252)证实114个恶性病变(62个恶性雀斑样痣/恶性雀斑样黑素瘤;52个基底细胞癌/鳞状细胞癌)。皮肤镜检出54.8%的恶性雀斑样痣/恶性雀斑样黑素瘤和90.4%的基底细胞癌/鳞状细胞癌;RCM正确诊断91.9%的恶性雀斑样痣/恶性雀斑样黑素瘤和94.2%的基底细胞癌/鳞状细胞癌。研究存在验证偏倚、选择偏倚和随访失访。与单用皮肤镜相比,整合RCM明显提高恶性雀斑样痣/恶性雀斑样黑素瘤的检出敏感性和良性病变的特异性,减少过度治疗和漏诊恶性病变。尽管仍有少量漏诊恶性病变的残余风险,联合方案为美容敏感部位的不确定病变提供了高度安全的无创管理路径。
Tumor necrosis factor (TNF) is a key driver of intestinal epithelial inflammation. The baculoviral inhibitor of apoptosis protein repeat-containing 3 (BIRC3) gene encodes the cellular inhibitor of apoptosis protein 2 (cIAP2), a known regulator of TNF signaling. Although genetic variants in components of the TNF signaling pathway have been reported, no human BIRC3 variants have been previously identified. We screened exomes obtained from Crohn's disease (CD) patients from multiple centers for BIRC3 variants. We used cellular, mouse organoids, induced pluripotent stem cells-derived intestinal organoids, knock-in and knockout mouse models, and knockout zebrafish, as well as transcriptome analysis of various samples to determine pathogenicity of BIRC3 variants. Rare and damaging BIRC3 variants were identified in 14 patients from 10 unrelated families with CD diagnosed between infancy and adulthood. Functional studies showed that BIRC3 deficiency caused impaired receptor-interacting protein kinase 1 (RIPK1) ubiquitylation, leading to RIPK1 autophosphorylation resulting in increased epithelial cell death. The p.H312Y cIAP2 variant identified in both our index and in another independent patient was mislocalizaed, and a knock-in mouse model of this BIRC3 variant (cIAP2H312Y/+) had exacerbation of chemically induced colitis, whereas ciap1-/+ zebrafish developed spontaneous colitis. Transcriptome analysis of mice organoids and zebrafish showed that BIRC3 deficiency led to inappropriate sustained activation of TNF-responsiveness genes in the absence of stimuli. Small molecule pharmacologic inhibition of RIPK1 or caspases attenuated intestinal inflammation in BIRC3-deficient intestinal organoids and cIAP2H312Y/+ mice. We establish BIRC3 deficiency as a cause of monogenic CD in both pediatric- and adult-onset patients and identify RIPK1 as a therapeutic target.
中文摘要:肿瘤坏死因子(TNF)是肠道上皮炎症的关键驱动因素。含杆状病毒凋亡抑制蛋白重复序列3(BIRC3)基因编码细胞凋亡抑制蛋白2(cIAP2),后者是TNF信号通路的已知调控因子。尽管TNF信号通路组分的遗传变异已有报道,但此前未发现人类BIRC3变异。我们从多中心克罗恩病(CD)患者的外显子组中筛查BIRC3变异。我们利用细胞、小鼠类器官、诱导多能干细胞来源的肠道类器官、敲入和敲除小鼠模型、敲除斑马鱼,以及多种样本的转录组分析,确定BIRC3变异的致病性。在10个无亲缘关系的家系、14例婴儿期至成年期确诊的CD患者中鉴定出罕见且有害的BIRC3变异。功能研究显示,BIRC3缺陷导致受体相互作用蛋白激酶1(RIPK1)泛素化受损,引起RIPK1自身磷酸化,进而增加上皮细胞死亡。在我们的先证者及另一名独立患者中均发现的p.H312Y cIAP2变异存在定位异常,该BIRC3变异敲入小鼠模型(cIAP2H312Y/+)在化学诱导结肠炎中表现加重,而ciap1-/+斑马鱼发生自发性结肠炎。小鼠类器官和斑马鱼的转录组分析显示,BIRC3缺陷导致在无刺激情况下TNF反应基因持续异常激活。用小分子药物抑制RIPK1或caspase可减轻BIRC3缺陷肠道类器官和cIAP2H312Y/+小鼠的肠道炎症。我们确立BIRC3缺陷是儿童期和成年期发病的单基因CD的病因,并确定RIPK1为治疗靶点。
Persistent fever after initiating intravenous antibiotics is common in hospitalized patients with cancer and often leads to additional imaging and antimicrobial escalation. Early identification of patients unlikely to remain febrile could provide additional information during clinical reassessment. We developed and externally validated machine learning models to predict persistent fever 48-72 h after antibiotic initiation using electronic health records from two academic hospitals. Adult cancer patients with fever within 24-48 h of treatment were included. Models incorporated demographics, comorbidities, laboratory results, vital signs, and temperature patterns. The best-performing model achieved an AUROC of 0.82 (95% CI 0.79-0.84) internally and 0.78 (95% CI 0.77-0.79) externally. Temperature-related variables were the dominant predictors. Decision curve analysis demonstrated positive net benefit across much of the evaluated threshold range. Retrospective assessment suggested that approximately one quarter of antibiotic escalations and chest CT scans occurred in patients correctly predicted not to remain febrile, highlighting the potential contextual value of fever predictions. These findings indicate that short-term fever persistence can be predicted with clinically meaningful accuracy using routine data. However, clinical use should be limited to an adjunctive role rather than standalone rule-out decision-making, and prospective studies are required to evaluate safety, clinician uptake, and real-world impact.
中文摘要:在住院癌症患者中,开始静脉抗生素后持续发热较常见,并常导致额外影像学检查和抗菌药物升级。早期识别不太可能持续发热的患者,可为临床再评估提供额外信息。我们使用两家学术型医院的电子健康记录,开发并外部验证了预测抗生素开始后48-72小时持续发热的机器学习模型。纳入治疗开始后24-48小时内出现发热的成年癌症患者。模型纳入人口学特征、合并症、实验室结果、生命体征和体温模式。表现最佳模型内部AUROC为0.82(95% CI 0.79-0.84),外部为0.78(95% CI 0.77-0.79)。体温相关变量是最主要预测因子。决策曲线分析显示,在多数评估阈值范围内具有正净获益。回顾性评估提示,约四分之一的抗菌药物升级和胸部CT检查发生在被正确预测为不会持续发热的患者中,显示发热预测可能具有情境价值。这些结果表明,利用常规数据可以以具有临床意义的准确度预测短期发热持续;但临床使用应限于辅助作用,不能作为独立的排除性决策,且需要前瞻性研究评估安全性、临床医生接受度和实际影响。
基础研究 (53篇)
TKIs (tyrosine kinase inhibitors) have transformed cancer therapy; however, cardiotoxicity remains a frequent adverse effect with variable susceptibility among patients. For sunitinib, a commonly prescribed TKI, the molecular programs and functional features underlying this variability are not well defined, and clinically actionable predictors of cardiotoxicity risk remain lacking. To investigate interindividual variability in sunitinib-induced cardiotoxic responses, we implemented the Cell Village platform consisting of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from 20 healthy donors. Pooled iPSCs were differentiated into cardiomyocytes, treated with sunitinib for 72 hours, followed by harvesting for single-nucleus RNA sequencing. Donor identity was determined using single nucleotide polymorphism-based demultiplexing. Additionally, individual line-specific transcriptomic responses to sunitinib were integrated with quantitative functional phenotyping (including contractility, electrophysiology, and recovery efficacy following tocotrienol treatment) in iPSC-CMs differentiated from a subset of 10 lines. Sunitinib induced a robust global transcriptional response characterized by dysregulation of tyrosine kinase signaling, cytoskeletal organization, ion channels, and calcium-handling pathways. Although the pathway-level changes were shared, individual donor lines displayed heterogeneity in both gene expression patterns and functional impairment. Across functional parameters, relaxation velocity was the most consistently correlated with toxicity severity. Integration of each iPSC line's functional data with the corresponding transcriptomic signatures identified gene modules related to calcium handling and structural organization strongly correlated with donor-specific toxicity and recovery indices. Pharmacological validation using tocotrienol demonstrated partial, donor-dependent improvement of sunitinib-related iPSC-CM impairments. This proof-of-concept study establishes a scalable, donor-resolved platform that links pooled transcriptomic profiling with functional toxicity and recovery phenotypes in human cardiomyocytes. By linking molecular perturbations to functional outcomes across genetically diverse backgrounds, this approach provides a framework for dissecting interindividual variability in TKI-associated cardiotoxicity. More broadly, it provides a foundation for extending population-scale cardiotoxicity assessment to additional drugs and protective interventions.
中文摘要:酪氨酸激酶抑制剂改变了肿瘤治疗格局,但心脏毒性仍是常见不良效应,且患者易感性差异明显。对于常用酪氨酸激酶抑制剂舒尼替尼,这种差异背后的分子程序和功能特征尚不明确,临床可操作的心脏毒性风险预测指标仍然缺乏。为研究舒尼替尼诱导心脏毒性反应的个体间差异,该研究采用Cell Village平台,纳入来自20名健康供者的人诱导多能干细胞来源心肌细胞。将混合培养的诱导多能干细胞分化为心肌细胞,经舒尼替尼处理72小时后收获并进行单核RNA测序,通过基于单核苷酸多态性的去多重分析确定供者身份。随后,将10株细胞系来源心肌细胞的株特异性转录组反应与定量功能表型整合,功能表型包括收缩性、电生理以及生育三烯酚处理后的恢复效果。舒尼替尼引发了显著的全局转录反应,表现为酪氨酸激酶信号、细胞骨架组织、离子通道和钙处理通路失调。通路层面的变化在各供者间共有,但不同供者细胞系在基因表达模式和功能损伤上表现出异质性。在各功能参数中,松弛速度与毒性严重程度的相关性最为一致。将每株诱导多能干细胞系的功能数据与相应转录组特征整合后,识别出与钙处理和结构组织相关的基因模块,这些模块与供者特异性毒性和恢复指标高度相关。生育三烯酚的药理学验证显示,舒尼替尼相关心肌细胞损伤可获得部分改善,且改善程度依赖供者。该概念验证研究建立了一个可扩展、可分辨供者的平台,将混合样本转录组分析与人心肌细胞的功能性毒性和恢复表型联系起来。通过在不同遗传背景中连接分子扰动与功能结局,该方法为解析酪氨酸激酶抑制剂相关心脏毒性的个体间差异提供了框架,也为将群体规模心脏毒性评估扩展到其他药物和保护性干预奠定了基础。
Abdominal aortic aneurysms (AAAs) are a life-threatening cardiovascular disease for which there is a lack of therapy preventing aortic rupture. During AAA formation, pathological vascular remodeling is driven by an imbalance of proinflammatory and anti-inflammatory macrophage responses, and mechanisms regulating macrophage-mediated inflammation remain undefined. Recent evidence suggests that males absent on the first (MOF), a histone acetyltransferase, can play a critical role in establishing macrophage phenotype and modulating innate immune response. Single-cell RNA sequencing analysis of human AAAs and control tissues was performed to analyze MOF expression in aortic monocyte/macrophages and the inflammatory immune response. Mice underwent 2 murine AAA models: either Ang II (angiotensin II) or topical porcine pancreatic elastase. To investigate the role of MOF in AAA development, targeted inhibition was performed with MG-149 administration or in mice genetically deficient in macrophage-specific MOF (Moff/fLyz2Cre+). Finally, flow cytometry and chromatin immunoprecipitation were conducted to analyze macrophage phenotype and levels of histone (H) lysine (K) acetylation (H4K16ac) in human and murine AAA macrophages. Using single-cell RNA sequencing of human AAA tissues and multiple murine AAA models, we identified that MOF is increased in aortic monocyte/macrophages associated with upregulation of inflammatory transcriptional programs. Mechanistically, TNF-α (tumor necrosis factor alpha) signaling promotes the induction of MOF, which in turn induces NF-κB (nuclear factor kappa-light-chain-enhancer of activated B)-mediated inflammatory gene transcription by increasing the activating H4K16ac mark on gene promoters in infiltrating aortic macrophages. In vivo targeted inhibition of the MOF pathway, with myeloid-specific genetic depletion (Moff/fLyz2Cre+) or pharmacological inhibition in the elastase- and angiotensin II-induced AAA model, preserved macrophage function, decreased elastin fragmentation, attenuated aortic inflammation, and markedly reduced AAA development. Our study provides important evidence that MOF regulates macrophage phenotypic function and inflammation during human and murine AAA development. Targeting the MOF pathway affords the opportunity to prevent pathological macrophage infiltration within the aortic wall and potentially limit AAA development.
中文摘要:腹主动脉瘤(AAA)是危及生命的心血管疾病,目前缺乏预防主动脉破裂的治疗。AAA形成过程中,病理性血管重塑由促炎与抗炎巨噬细胞反应失衡驱动,调控巨噬细胞介导炎症的机制尚未明确。近期证据提示组蛋白乙酰转移酶MOF(males absent on the first)在决定巨噬细胞表型和调节固有免疫反应中起关键作用。研究对人AAA与对照组织进行单细胞RNA测序,分析主动脉单核/巨噬细胞中MOF表达及炎症免疫反应。小鼠接受两种AAA模型:血管紧张素II(Ang II)或局部猪胰弹性蛋白酶。为探讨MOF在AAA发展中的作用,采用MG-149给药进行靶向抑制,或使用巨噬细胞特异性MOF基因缺陷小鼠(Moff/fLyz2Cre+)。最后用流式细胞术和染色质免疫沉淀分析人和小鼠AAA巨噬细胞表型及组蛋白H4赖氨酸16乙酰化(H4K16ac)水平。通过对人AAA组织和多种小鼠AAA模型进行单细胞RNA测序,发现主动脉单核/巨噬细胞中MOF升高,并与炎症转录程序上调相关。机制上,TNF-α信号促进MOF诱导,MOF通过增加浸润主动脉巨噬细胞基因启动子上的活化型H4K16ac标记,进而诱导NF-κB介导的炎症基因转录。在弹性蛋白酶和Ang II诱导的AAA模型中,采用髓系特异性基因缺失(Moff/fLyz2Cre+)或药物抑制MOF通路进行体内靶向抑制,可保留巨噬细胞功能、减少弹性蛋白断裂、减轻主动脉炎症并显著降低AAA形成。研究提供重要证据表明MOF调控人和小鼠AAA发展中的巨噬细胞表型功能和炎症。靶向MOF通路有机会阻止主动脉壁内病理性巨噬细胞浸润,并可能限制AAA发展。
Biliary tract cancer (BTC) comprises a family of rare malignancies subclassified by anatomy and pathology. However, this classification scheme may obscure shared biology and limit patient stratification. Here, we tested whether BTC heterogeneity can be explained by coherent latent axes and evaluated the potential to unify diverse clinical and genomic factors under a tractable biological framework. Whole-genome and transcriptome sequencing was performed on 180 tumors enriched for tumor cells by laser capture microdissection to identify shared programs in BTC. Network integration across transcriptomic classes identified two consensus cancer subtypes (CCS). The CCS segregated with anatomical location of primary tumor, and gene expression marker analyses suggested that subtypes reflect tumor cell of origin differences. The CCS displayed strikingly divergent molecular landscapes, explaining more variance than anatomical location of the primary tumor. CCS-B tumors were mutationally loaded with clock-like and APOBEC signatures and extrachromosomal DNA, whereas CCS-A tumors were characterized by chromosome-arm deletions. This approach showed that harnessing the genomic and transcriptomic diversity of BTC provides insights into shared biology and improves stratification.
中文摘要:胆道癌(BTC)是一组按解剖部位和病理学亚分类的罕见恶性肿瘤。这种分类方案可能掩盖共享的生物学特征,并限制患者分层。对BTC异质性是否可由一致的潜在轴解释进行了检验,并评估在可操作的生物学框架下统一多种临床与基因组因素的潜力。对180例经激光捕获显微切割富集肿瘤细胞的肿瘤进行全基因组和转录组测序,以识别BTC中的共享程序。跨转录组类别的网络整合识别出两个共识癌症亚型(CCS)。CCS与原发肿瘤的解剖部位相关,基因表达标记分析提示亚型反映肿瘤细胞起源差异。CCS呈现显著不同的分子景观,其对变异的解释度高于原发肿瘤解剖部位。CCS-B肿瘤突变负荷较高,伴时钟样和APOBEC特征及染色体外DNA,而CCS-A肿瘤以染色体臂缺失为特征。该方法表明,利用BTC的基因组和转录组多样性有助于理解共享生物学并改善分层。
Genetic perturbation-induced transcriptional reprogramming drastically remodels tumor cellular phenotypes and tumor microenvironment crosstalk. Unraveling the heterogeneous cellular responses to genetic perturbations is essential for the mechanistic dissection of tumors and the discovery of therapeutic targets. Here, we present iGPSC-DB (https://bio-bigdata.hrbmu.edu.cn/iGPSC-DB), a database designed to infer connections between tumor microenvironmental cells and diverse genetic perturbation events and to dissect the heterogeneous cellular responses to these perturbations. iGPSC-DB curates associations linking 178 114 perturbation events that target 7407 genes to 9 249 080 single cells from 1580 samples across 88 cancer types. iGPSC-DB also provides seven user-friendly tools for retrieving and analyzing: (i) inferred associations between genetic perturbation events and cells/cell types; (ii) the inferred perturbation-associated effects of perturbations on cellular functions, developmental trajectories, and cell-cell communication within the tissue microenvironment; (iii) the combined effects of different perturbations on cells, facilitating the design of combination therapeutic regimens; (iv) the impact of different perturbations on the differentiation trajectories and functional states of malignant cells; and (v) the association between perturbed target genes and clinical survival outcomes. iGPSC-DB will serve as a valuable resource to advance single-cell-resolution research on gene functions, regulatory mechanisms, and the discovery of tumor therapeutic targets.
中文摘要:遗传扰动诱导的转录重编程会显著重塑肿瘤细胞表型以及肿瘤微环境中的相互作用。解析细胞对遗传扰动的异质性响应,对肿瘤机制剖析和治疗靶点发现至关重要。iGPSC-DB(https://bio-bigdata.hrbmu.edu.cn/iGPSC-DB)是一个用于推断肿瘤微环境细胞与多种遗传扰动事件之间联系、并解析细胞对这些扰动异质性响应的数据库。iGPSC-DB整理了178114个靶向7407个基因的扰动事件与来自1580份样本、覆盖88种癌症类型的9249080个单细胞之间的关联。该数据库提供7个易用工具,用于检索和分析:遗传扰动事件与细胞或细胞类型之间的推断关联;扰动对组织微环境中细胞功能、发育轨迹和细胞间通讯的推断相关效应;不同扰动对细胞的联合效应,以辅助联合治疗方案设计;不同扰动对恶性细胞分化轨迹和功能状态的影响;受扰动靶基因与临床生存结局之间的关联。iGPSC-DB可作为重要资源,推动基因功能、调控机制的单细胞分辨率研究以及肿瘤治疗靶点发现。
The vascular endothelial growth factor (VEGF) ligand and its main receptor VEGFR2 are considered to be essential for endothelial differentiation, proliferation, sprouting and survival1. Blood vessels cannot form in growing embryos or tissues when VEGF-VEGFR2 signalling is compromised in all cells2,3. The anti-VEGF antibody, which can block angiogenesis in cancer, wound healing or ischaemic diseases, is among the most widely used antibodies in the clinic. However, vascular resistance to anti-VEGF therapy has been reported4,5. Here we used iFlpMosaics and iSuRe-HadCre to induce and track genetic mosaics of endothelial cells (ECs) lacking VEGFR2 during the entire embryonic and postnatal development. These Vegfr2-knockout (Vegfr2KO) ECs adapted, proliferated normally and competed with wild-type cells over time, eventually forming a substantial portion of the vascular network in most organs. Vegfr2KO ECs could not sprout during the first wave of angiogenesis in most tissues, because this process is highly VEGF-dependent and favours growth and mobilization of wild-type ECs. However, owing to their inability to respond to VEGF, Vegfr2KO ECs became dominant in veins, which represented a long-term and continuous source of ECs for subsequent waves of VEGF-independent angiogenesis. Comparative single-cell RNA sequencing analysis of ECs with acute and long-term loss of VEGFR2 identified both common and organ-specific molecular mechanisms of adaptation and resistance to VEGF signalling loss. These included significant endothelial venousization and upregulation of ligands for VEGFR1 and VEGFR3. VEGFR1 only partially compensated for VEGFR2 loss in capillary ECs, whereas VEGFR3 compensated only in arterial ECs. Loss of the three VEGF receptors did not compromise venous growth. Notably, loss of the master regulator of venous development, NR2F2 (also known as COUP-TFII), significantly compromised expansion of Vegfr2KO ECs. This work has implications for our understanding of the role of VEGF receptors in angiogenesis and demonstrates venousization as a mechanism of adaptation and resistance to VEGF signalling loss during angiogenesis.
中文摘要:血管内皮生长因子(VEGF)配体及其主要受体VEGFR2被认为对内皮细胞分化、增殖、出芽和存活不可或缺。当所有细胞中的VEGF-VEGFR2信号受损时,发育中的胚胎或组织无法形成血管。抗VEGF抗体可阻断癌症、伤口愈合或缺血性疾病中的血管生成,是临床最广泛使用的抗体之一。然而,已有报道血管对抗VEGF治疗产生抵抗。本研究使用iFlpMosaics和iSuRe-HadCre在整个胚胎期和出生后发育过程中诱导并追踪缺乏VEGFR2的内皮细胞遗传嵌合体。这些Vegfr2敲除内皮细胞能够适应、正常增殖,并随时间与野生型细胞竞争,最终在多数器官中形成相当一部分血管网络。在多数组织的第一波血管生成中,Vegfr2敲除内皮细胞不能出芽,因为该过程高度依赖VEGF,并有利于野生型内皮细胞的生长和动员。然而,由于无法对VEGF作出响应,Vegfr2敲除内皮细胞在静脉中占据优势,成为后续不依赖VEGF的血管生成波的长期、持续内皮细胞来源。对急性与长期丧失VEGFR2的内皮细胞进行比较单细胞RNA测序分析,识别出适应和抵抗VEGF信号丧失的共同及器官特异性分子机制,包括显著的内皮静脉化和VEGFR1、VEGFR3配体上调。VEGFR1仅在毛细血管内皮细胞中部分代偿VEGFR2缺失,而VEGFR3仅在动脉内皮细胞中代偿。三种VEGF受体缺失并未损害静脉生长。静脉发育主调控因子NR2F2(又称COUP-TFII)缺失显著损害Vegfr2敲除内皮细胞的扩增。这项工作有助于理解VEGF受体在血管生成中的作用,并表明静脉化是血管生成过程中适应和抵抗VEGF信号丧失的一种机制。
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal and treatment-refractory malignancies worldwide, largely driven by its uniquely desmoplastic and highly innervated microenvironment. Given the striking incidence of perineural invasion and its profound correlation with intractable cancer pain and early recurrence, tumor-nervous system crosstalk has emerged as a pivotal driver of PDAC progression. Neural components-including neurotransmitters, neurotrophic factors, axon guidance molecules, and specific sensory and autonomic networks (e.g., dorsal root ganglia and sympathetic nerves)-do not merely act as passive conduits, but actively orchestrate tumor genesis, metastasis, and immune evasion. Crucially, this neuro-stromal crosstalk actively drives chemoresistance by facilitating the dual-effect remodeling of tumor energy metabolism and detoxification networks. In this comprehensive review, we decode the multidimensional molecular mechanisms and reciprocal signaling cascades underpinning tumor-nervous system crosstalk. We critically evaluate the translational challenges of applying neurotherapy in clinical practice, encompassing mechanistic pleiotropy, neural plasticity, and visceral safety risks. Furthermore, by synthesizing emerging clinical trials targeting neurotransmitter axes, dorsal root ganglia, and neurotrophic signaling, we provide a forward-looking roadmap for integrating precision neuro-oncology with standard regimens to simultaneously alleviate cancer pain and overcome therapeutic resistance in PDAC.
中文摘要:胰腺导管腺癌(PDAC)仍是全球最致命且最难治的恶性肿瘤之一,主要原因在于其独特的促结缔组织增生和高度神经支配的微环境。鉴于神经周围侵犯发生率高,且与难治性癌痛和早期复发密切相关,肿瘤-神经系统串扰已成为PDAC进展的关键驱动因素。神经成分——包括神经递质、神经营养因子、轴突导向分子以及特定感觉和自主神经网络(如背根神经节和交感神经)——并非被动通道,而是主动编排肿瘤发生、转移和免疫逃逸。关键在于,这种神经-基质串扰通过促进肿瘤能量代谢与解毒网络的双重效应重塑,主动驱动化疗耐药。在这篇综合综述中,我们解析肿瘤-神经系统串扰的多维分子机制和相互信号级联。我们批判性评估神经疗法在临床实践中应用的转化挑战,涵盖机制多效性、神经可塑性和内脏安全性风险。通过综合靶向神经递质轴、背根神经节和神经营养信号的新兴临床试验,我们为将精准神经肿瘤学与标准方案整合提供前瞻性路线图,以同时缓解癌痛并克服PDAC治疗耐药。
Noncoding sequences comprise most of the human genome; however, their functional significance remains largely elusive. Using CRISPR tiling mutagenesis with near-PAMless, high-fidelity SpRY-Cas9, we mapped the fitness landscape of an entire human gene, the 10-kb MYC locus, at base-pair resolution. This unbiased interrogation revealed that 67% of functionally essential base pairs are noncoding. Essential noncoding base pairs are under strong constraint in the human population but show limited evolutionary conservation across species. Within this landscape, we identified an ultraconserved noncoding RNA element in the 3' untranslated region (UTR) that promotes perinuclear localization of MYC mRNA and nuclear localization of MYC protein through interaction with hnRNP L. Steric-blocking antisense oligonucleotides (ASOs) targeting this element selectively eliminate diverse MYC-dependent cancer cells and inhibit growth of patient-derived tumor organoids. Together, these findings establish noncoding sequences as major carriers of functional genetic information and identify a therapeutically actionable RNA element whose targeting disrupts MYC-driven cancer.
中文摘要:非编码序列占人类基因组的大部分,其功能意义仍多不明确。利用近乎不受PAM限制的高保真SpRY-Cas9进行CRISPR平铺诱变,我们在碱基对分辨率上绘制了整个人类基因即10 kb MYC位点的适应性图谱。无偏解析显示,67%的功能必需碱基对为非编码碱基对。必需非编码碱基对在人群中受到强约束,但跨物种进化保守性有限。在该图谱中,我们发现3'非翻译区存在一个超保守非编码RNA元件,它通过与hnRNP L相互作用促进MYC mRNA的核周定位及MYC蛋白的核定位。靶向该元件的空间位阻反义寡核苷酸可选择性地清除多种依赖MYC的癌细胞,并抑制患者来源肿瘤类器官的生长。这些结果确立非编码序列是功能性遗传信息的主要载体,并识别出一个可治疗干预的RNA元件,靶向该元件可破坏MYC驱动的癌症。
Osteosarcoma remains challenging due to incomplete tumor resection, local recurrence, and limited immunostimulatory efficacy of current microwave (MW)-based therapies. Here, we develop a multifunctional theranostic nanoplatform, GPC3@TTBC, by conjugating an osteosarcoma-targeting anti-GPC3 peptide onto aggregation-induced emission (AIE) nanoparticles. GPC3@TTBC enables selective tumor accumulation and high-contrast near-infrared fluorescence imaging, allowing precise tumor margin delineation and superior tumor-to-background resolution compared with clinically used dyes, including effective visualization in patient-derived xenograft models. Upon MW irradiation, lysosome-localized GPC3@TTBC generates robust nonthermal reactive oxygen species (ROS) through enhanced charge separation and electron transfer, resulting in substantial tumor cell apoptosis while simultaneously inducing a prominent immunogenic senescence-associated phenotype and senescence-associated secretory phenotype (SASP) response. Importantly, MW + GPC3@TTBC suppressed tumor cell migration and invasion in vitro and reduced pulmonary metastatic lesions in vivo. Meanwhile, the SASP promoted dendritic cell maturation and cytotoxic T lymphocyte activation, thereby enhancing antitumor immune responses and remodeling the tumor immune microenvironment. Beyond tumor eradication, GPC3@TTBC facilitates osteogenic microenvironment reconstruction and bone regeneration after tumor clearance, while exhibiting favorable biosafety. Collectively, GPC3@TTBC integrates targeted fluorescence-guided imaging, MW-enhanced ROS generation, immunogenic senescence induction, and bone regeneration, providing a comprehensive theranostic strategy for precise osteosarcoma treatment.
中文摘要:骨肉瘤因肿瘤切除不彻底、局部复发以及现有微波治疗免疫刺激效果有限而仍具挑战。我们通过将靶向骨肉瘤的抗GPC3肽偶联到聚集诱导发光(AIE)纳米颗粒上,构建了多功能诊疗纳米平台GPC3@TTBC。GPC3@TTBC可实现选择性肿瘤蓄积和高对比度近红外荧光成像,能够精确勾画肿瘤边界,与临床所用染料相比具有更优的肿瘤/背景分辨率,并在患者来源异种移植模型中实现有效可视化。微波照射后,定位于溶酶体的GPC3@TTBC通过增强的电荷分离和电子转移产生强烈的非热活性氧(ROS),导致大量肿瘤细胞凋亡,同时诱导显著的免疫原性衰老相关表型及衰老相关分泌表型(SASP)反应。MW + GPC3@TTBC在体外抑制肿瘤细胞迁移和侵袭,并在体内减少肺部转移灶。SASP促进树突状细胞成熟和细胞毒性T淋巴细胞活化,从而增强抗肿瘤免疫反应并重塑肿瘤免疫微环境。除清除肿瘤外,GPC3@TTBC还促进肿瘤清除后的成骨微环境重建和骨再生,并表现出良好的生物安全性。GPC3@TTBC整合了靶向荧光引导成像、微波增强ROS生成、免疫原性衰老诱导和骨再生,为骨肉瘤精准治疗提供了综合诊疗策略。
Inositol-requiring enzyme 1α (IRE1α) and the downstream spliced form of X-Box Binding Protein 1 (XBP1s) have been identified as tumor promotors. However, how IRE1α-XBP1s signaling affects tumor progression in a non-cell autonomous manner remains unclear. Here we show that the hepatocyte IRE1α-XBP1s axis unexpectedly inhibits liver metastasis by confining local metainflammation. Genetic ablation of IRE1α or XBP1 in mouse hepatocytes exacerbates liver metastasis due to the accumulation of inflammatory monocytes (IMs). Mechanistically, a non-canonical Forkhead box O1 (FoxO1)-glutamine synthetase (GS) pathway endows the IRE1α- or XBP1-null hepatocytes with the metabolic activity to secrete glutamine, which is necessary and sufficient for IM fitness. Reintroduction of hepatocyte XBP1s or blockade of glutamine metabolism effectively reduces IMs and mitigates disease progression. Importantly, clinical patient survival with liver metastases positively correlates with hepatocyte XBP1s expression. Our study defines a paradigm of hepatocyte-IM interaction that can be leveraged to treat liver metastasis.
中文摘要:肌醇需求酶1α(IRE1α)及其下游X盒结合蛋白1剪接型(XBP1s)已被认定为促肿瘤因子。然而,IRE1α-XBP1s信号如何以非细胞自主方式影响肿瘤进展仍不清楚。本研究发现,肝细胞IRE1α-XBP1s轴通过限制局部代谢性炎症,意外地抑制肝转移。小鼠肝细胞中IRE1α或XBP1的遗传缺失会因炎性单核细胞(IMs)积聚而加重肝转移。机制上,一条非经典叉头框O1(FoxO1)-谷氨酰胺合成酶(GS)通路使IRE1α或XBP1缺失的肝细胞获得分泌谷氨酰胺的代谢能力,而谷氨酰胺对IMs的适应状态是必要且充分的。重新引入肝细胞XBP1s或阻断谷氨酰胺代谢可有效减少IMs并缓解疾病进展。临床肝转移患者的生存与肝细胞XBP1s表达呈正相关。该研究定义了肝细胞-IM相互作用的一种范式,可用于治疗肝转移。
Cancer cachexia is a multifactorial syndrome characterized by progressive skeletal muscle wasting that impairs quality of life, limits responses to anticancer therapies, and increases mortality. Although excessive protein degradation has traditionally been viewed as a primary driver of muscle loss, cachectic muscle undergoes broader disruptions in proteostasis involving protein turnover, organelle quality control, stress adaptation, metabolism, and regenerative capacity. Accumulating evidence suggests that diverse tumor- and host-derived signals converge on interconnected transcriptional networks that coordinate these processes. Rather than functioning independently, transcription factors integrate inflammatory, metabolic, hormonal, and cellular-stress signals to orchestrate catabolic, stress-responsive, anabolic, and regenerative programs, with effects that vary with disease stage and cellular context. Importantly, these transcriptional responses are not uniformly pathological but can represent causal, adaptive, or compensatory programs. Epigenetic, post-transcriptional, and post-translational mechanisms add further regulatory layers that shape the activation and magnitude of these transcriptional programs. Emerging single-cell and multi-omic approaches have further revealed myofiber- and cell-specific regulatory networks that contribute to the heterogeneous response of skeletal muscle to tumor growth. In this review, we propose that transcriptional reprogramming represents a central integrative mechanism through which diverse catabolic signals remodel skeletal muscle proteostasis, and we examine how network-level regulation contributes to muscle adaptation and wasting in cancer cachexia. Defining which regulatory programs are causal, maladaptive, adaptive, or compensatory may reveal more precise biomarkers and therapeutic targets for preserving skeletal muscle mass and function in patients with cancer cachexia.
中文摘要:癌症恶病质是一种多因素综合征,以进行性骨骼肌消耗为特征,会损害生活质量、限制抗肿瘤治疗反应并增加死亡率。传统上,蛋白质过度降解被视为肌肉丢失的主要驱动因素,但恶病质肌肉中存在更广泛的蛋白质稳态紊乱,涉及蛋白质周转、细胞器质量控制、应激适应、代谢和再生能力。越来越多证据表明,多种肿瘤来源和宿主来源信号汇聚于相互连接的转录网络,协调上述过程。转录因子并非独立发挥作用,而是整合炎症、代谢、激素和细胞应激信号,编排分解代谢、应激反应、合成代谢和再生程序,其效应随疾病阶段和细胞环境而变化。这些转录反应并非一律病理性,也可能代表因果性、适应性或代偿性程序。表观遗传、转录后和翻译后机制增加了额外调控层,影响这些转录程序的激活和幅度。新兴的单细胞和多组学方法进一步揭示了肌纤维特异性和细胞特异性调控网络,这些网络参与骨骼肌对肿瘤生长的异质性反应。文章提出,转录重编程是多种分解代谢信号重塑骨骼肌蛋白质稳态的核心整合机制,并探讨网络层面的调控如何参与癌症恶病质中的肌肉适应和消耗。明确哪些调控程序属于因果性、适应不良性、适应性或代偿性,可能揭示更精确的生物标志物和治疗靶点,用于保留癌症恶病质患者的骨骼肌质量和功能。
Understanding the molecular grammar of liquid-liquid phase separation has enabled rational design of peptide coacervates as intracellular therapeutic carriers with tunable viscoelasticity, controlled cargo partitioning, and enhanced cellular uptake. However, sequence-level determinants governing coacervate disassembly remain poorly characterized. Encoding protease-recognition motifs within phase-separating peptides offers controlled, localized catalytic disassembly without requiring global perturbation via macroscopic triggers such as pH, ionic strength, temperature, or redox potential. Yet, enzymatic cleavage of coacervates is spatially biased and constrained by limited enzyme partitioning, restricted substrate accessibility, and altered kinetics relative to the dilute phase. Here, we test whether the lysosomal protease cathepsin B (CatB)─often upregulated in cancer cells─acts on coacervates assembled from phase-separating peptides encoding CatB-recognition motifs to enable intracellular cargo release in cancer cells. Common CatB-recognition motifs (GFLG and EVCit), developed for linker-based delivery systems under dilute conditions, preserved phase separation but exhibited poor CatB-triggered cleavage and cargo release. In contrast, a de novo motif, FRFV, designed from CatB subsite preferences, retained catalytic activity as confirmed by mass spectrometry and enabled protease-triggered cargo release in vitro and in cancer cells. Thus, protease-recognition motifs require reevaluation within dense-phase architectures to enable efficient intracellular cargo release through coacervate disassembly.
中文摘要:理解液-液相分离的分子语法,使肽凝聚层可作为胞内治疗载体被理性设计,并具备可调黏弹性、可控货物分配和增强的细胞摄取。然而,控制凝聚层解聚的序列层面决定因素仍不清楚。在相分离肽中编码蛋白酶识别基序,可实现受控、局部的催化性解聚,而无需通过pH、离子强度、温度或氧化还原电位等宏观触发条件造成全局扰动。但凝聚层的酶切具有空间偏向,并受酶分配有限、底物可及性受限以及与稀相相比动力学改变的限制。这里检验溶酶体蛋白酶组织蛋白酶B(CatB)——在癌细胞中常上调——是否作用于由编码CatB识别基序的相分离肽组装而成的凝聚层,从而在癌细胞中实现胞内货物释放。为稀溶液条件下基于连接子的递送系统开发的常见CatB识别基序(GFLG和EVCit)保留了相分离,但CatB触发的切割和货物释放很差。相反,依据CatB亚位点偏好设计的从头基序FRFV保留了催化活性(质谱确认),并在体外和癌细胞中实现了蛋白酶触发的货物释放。因此,蛋白酶识别基序需要在致密相结构中重新评估,才能通过凝聚层解聚实现高效的胞内货物释放。
Circadian rhythms are endogenous, approximately 24-hour oscillations that align physiology and behavior with the environmental light-dark cycle and support homeostasis. In mammals, the suprachiasmatic nucleus (SCN) serves as the central circadian pacemaker, but its neuronal projections are restricted to a relatively small set of hypothalamic targets. The hypothalamic paraventricular nucleus (PVN) is an important downstream integrative node that receives direct and indirect temporal signals from the SCN and integrates them with metabolic, visceral, stress-related, and limbic inputs. Through functionally distinct neuroendocrine, autonomic, and central-projecting neuronal populations, the PVN contributes to the temporal regulation of hypothalamic-pituitary-adrenal axis activity, glucose metabolism, feeding behavior, nociceptive sensitivity, and cardiovascular function. Cell-type-specific genetic and transcriptomic studies further indicate that PVN neuronal populations exhibit distinct clock-related molecular programs. Studies predominantly in nocturnal rodent models have linked disruption of PVN clocks or rhythmic output to aging-associated decline, metabolic dysfunction, altered tumor immunity, neurodegenerative disease, and pain-related phenotypes. Human post-mortem studies have reported heterogeneous PVN changes in Alzheimer's disease, but direct evidence of PVN clock or SCN-PVN circuit dysfunction in humans remains limited. This review integrates circuit-, cellular-, and molecular-level evidence for the PVN's role in circadian regulation, evaluates interventions spanning timed drug delivery, meal timing, light exposure, and PVN-focused experimental manipulation, and outlines the challenges of translating preclinical findings into clinical practice.
中文摘要:昼夜节律是内源性的、约24小时的振荡,使生理与行为同环境明暗周期保持一致并支持稳态。在哺乳动物中,视交叉上核(SCN)是中枢昼夜节律起搏器,但其神经元投射仅局限于相对较少的下丘脑靶点。下丘脑室旁核(PVN)是重要的下游整合节点,接收来自SCN的直接和间接时间信号,并将其与代谢、内脏、应激相关及边缘系统输入整合。通过功能不同的神经内分泌、自主神经和中枢投射神经元群体,PVN参与下丘脑-垂体-肾上腺轴活动、糖代谢、进食行为、痛觉敏感性和心血管功能的时间调控。细胞类型特异性的遗传学和转录组学研究进一步表明,PVN神经元群体具有不同的时钟相关分子程序。主要在夜行性啮齿动物模型中进行的研究已将PVN时钟或节律性输出的破坏与衰老相关衰退、代谢功能障碍、肿瘤免疫改变、神经退行性疾病和疼痛相关表型联系起来。人类尸检研究报告了阿尔茨海默病中PVN存在异质性改变,但PVN时钟或SCN-PVN环路功能障碍在人类中的直接证据仍然有限。该综述整合了环路、细胞和分子层面的证据,以说明PVN在昼夜节律调控中的作用,评估了定时给药、进餐时间、光照暴露和以PVN为重点的实验性操作等干预措施,并概述了将临床前发现转化为临床实践所面临的挑战。
Unlike most tissue-resident cells that inhabit relatively homeostatic mechanical microenvironments, immune cells encounter diverse mechanical cues as they circulate throughout the body and transmigrate across tissue barriers. Mechanical stimuli have emerged as fundamental upstream regulators of both innate and adaptive immune responses. Mechanotransduction processes governed by core biomechanical sensors and effectors, including Piezo1, TRPV4, and YAP/TAZ, have recently attracted escalating research attention across immunological and mechanobiological fields. Notably, cellular mechanosensing is intrinsically context-dependent, shaped by the interplay between local mechanical properties and biochemical cues within tissue microenvironments. As a result, mechanoregulated immune phenotypes and functional outputs are highly sensitive to the experimental configurations of preclinical models. In contrast to previous reviews that mainly outline mechanotransduction signaling cascades, this review systematically categorizes prevalent biomechanical research platforms, detailing their technical specifications and key parametric characteristics, while contextualizing the mechanical regulation of immune behaviors within specific experimental frameworks. STATEMENT OF SIGNIFICANCE: Mechanoimmunology has revealed that mechanical forces are fundamental regulators of immune cell function, yet the field is plagued by contradictory findings arising from inconsistent platform parameterization. This review provides the first systematic classification of five major biomechanical research platforms - 2D hydrogel systems, 3D matrix models, microfluidic devices, single-molecule force spectroscopy, and in vivo genetic models - detailing their technical specifications, parametric boundaries, and experimental contexts. By anchoring immune mechanobiological conclusions to specific platform parameters, we establish a framework for resolving apparent phenotypic contradictions and standardizing cross-study comparisons. This context-aware approach directly informs the rational design of immunomodulatory biomaterials with tunable mechanical properties, bridging biomaterials engineering and immune cell biology for applications in tissue repair, cancer immunotherapy, and regenerative medicine.
中文摘要:与大多数处于相对稳态机械微环境中的组织驻留细胞不同,免疫细胞在全身循环并跨组织屏障迁移时会遇到多种机械信号。机械刺激已成为先天性和适应性免疫反应的基本上游调控因素。由Piezo1、TRPV4和YAP/TAZ等核心生物力学感受器和效应器介导的机械转导过程,近年来在免疫学和力学生物学领域受到越来越多的关注。细胞机械感知本质上依赖具体情境,受组织微环境中局部力学性质与生化信号相互作用的影响。因此,机械调控的免疫表型和功能输出对临床前模型的实验配置高度敏感。与以往主要概述机械转导信号级联的综述不同,本综述系统梳理常见生物力学研究平台,详述其技术规格和关键参数特征,并将免疫行为的机械调控置于具体实验框架中讨论。意义声明:机械免疫学已揭示机械力是免疫细胞功能的基本调控因素,但该领域受平台参数化不一致所导致的矛盾结果困扰。本综述首次对五类主要生物力学研究平台——二维水凝胶系统、三维基质模型、微流控装置、单分子力谱和体内遗传模型——进行系统分类,详述其技术规格、参数边界和实验情境。通过将免疫机械生物学结论锚定到具体平台参数,我们建立了一个框架,用于解释表观表型矛盾并规范跨研究比较。这种情境感知方法直接指导具有可调力学性质的免疫调节生物材料的合理设计,连接生物材料工程与免疫细胞生物学,服务于组织修复、癌症免疫治疗和再生医学应用。
RNAactDrug 2.0 (available at https://bio-bigdata.hrbmu.edu.cn/RNAactDrug or https://bio-datamining.hrbmu.edu.cn/RNAactDrug) is an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets. We have updated the RNAactDrug 2.0 database with significantly expanded data and improved features, including (i) ∼30 000 drugs, 38 908 RNA molecules, and 22 800 375 drug-RNA associations from large-scale pharmacogenomic databases, covering four molecular layers: expression, copy number variation (CNV), mutation, and methylation; (ii) 11 099 cases from The Cancer Genome Atlas across 33 cancer types are integrated to support clinical and pan-cancer analyses of drug sensitivity-associated RNA features; (iii) ∼3.8 million cells from >200 single-cell RNA sequencing datasets, spanning 34 cancer types and 38 tissues, enable analysis of cell type-specific patterns and intratumoral heterogeneity; (iv) 26 440 enhancers and 788 444 drug-enhancer associations, combined with potential target prediction, provide an exploratory epigenetic regulatory dimension; (v) enhanced search and browsing functionalities, together with seven tools for functional annotation, pan-cancer analysis, tumor microenvironment profiling, single-cell trajectory and CNV analysis, and enhancer-related analyses. In summary, RNAactDrug 2.0 is a crucial resource for the multi-omics dissection of drug sensitivity-associated molecules, providing important support for the discovery of drug resistance biomarkers and the advancement of personalized therapeutic strategies.
中文摘要:RNAactDrug 2.0(访问地址为 https://bio-bigdata.hrbmu.edu.cn/RNAactDrug 或 https://bio-datamining.hrbmu.edu.cn/RNAactDrug)是一个更新后的资源,用于系统探索多组学数据集中与药物敏感性相关的分子特征。该数据库在数据和功能上均有明显扩展,包括:(i) 来自大规模药物基因组学数据库的约30000种药物、38908个RNA分子和22800375个药物-RNA关联,覆盖表达、拷贝数变异、突变和甲基化四个分子层面;(ii) 整合癌症基因组图谱中33种癌症类型的11099例病例,支持药物敏感性相关RNA特征的临床分析和泛癌分析;(iii) 纳入来自200余个单细胞RNA测序数据集的约380万个细胞,覆盖34种癌症类型和38种组织,可分析细胞类型特异性模式与瘤内异质性;(iv) 26440个增强子和788444个药物-增强子关联,结合潜在靶点预测,提供探索性的表观遗传调控维度;(v) 增强的检索与浏览功能,以及7个工具,用于功能注释、泛癌分析、肿瘤微环境刻画、单细胞轨迹与拷贝数变异分析及增强子相关分析。RNAactDrug 2.0是多组学解析药物敏感性相关分子的重要资源,为发现耐药生物标志物和推进个体化治疗策略提供支持。
Alveolar rhabdomyosarcoma (aRMS) is a fusion-driven pediatric cancer with poor survival and limited therapeutic options. To uncover novel vulnerabilities, we used complex-Map functional genomic data, identifying CDK8 as a dependency in aRMS. Both CDK8 knockout and pharmacologic inhibition impaired tumor cell growth and induced myogenic differentiation in vitro and in vivo. Compared with genetic loss, CDK8 pharmacologic inhibition induced more dynamic transcriptional changes. With a genome-scale CRISPR-Cas9 drug modifier screen, we determined that the maximal antitumor activity of the CDK8 inhibitor requires the presence of the Mediator kinase module, including CDK8, and transcriptional cooperation with the SAGA complex. We further identified SIX4 as a key transcription factor mediating CDK8 inhibitor-induced transcriptional activation of myogenic differentiation genes and impaired tumor proliferation. These findings suggest a distinct gain-of-function mechanism of the CDK8 inhibitor and establish a strong rationale for CDK8 inhibition as a differentiation-inducing therapeutic strategy in aRMS. We provide a framework for uncovering therapeutic targets by network-based analysis of functional genomic screens. We identify CDK8 as a druggable target in aRMS and determine that CDK8 inhibition drives myogenic differentiation and impairs tumor progression via a collaborative mechanism involving the Mediator kinase module, SAGA complex, and SIX4. See related commentary by Stevens and Hatley, p. 2210.
中文摘要:腺泡型横纹肌肉瘤(aRMS)是一种由融合基因驱动的儿童肿瘤,生存率低、治疗手段有限。为寻找新的可干预弱点,研究者利用复合Map功能基因组数据,将CDK8确定为aRMS的依赖因子。CDK8敲除与药物抑制均可在体外和体内削弱肿瘤细胞生长并诱导肌源性分化。与基因缺失相比,CDK8药物抑制引起的转录变化更具动态性。借助全基因组CRISPR-Cas9药物修饰筛选,发现CDK8抑制剂的最大抗肿瘤活性需要Mediator激酶模块(含CDK8)的存在,并与SAGA复合物的转录协同有关。SIX4被确定为介导CDK8抑制剂诱导肌源性分化基因转录激活及肿瘤增殖受损的关键转录因子。这些结果提示CDK8抑制剂具有一种独特的增益功能机制,为以CDK8抑制作为分化诱导治疗策略提供了有力依据。研究还给出了通过功能基因组筛选的网络分析发现治疗靶点的框架。CDK8被确定为aRMS中可成药的靶点,其抑制通过Mediator激酶模块、SAGA复合物与SIX4协同的机制驱动肌源性分化并阻碍肿瘤进展。相关评论见Stevens与Hatley,第2210页。
Tumour-derived extracellular vesicles (EVs) or exosomes are critical mediators of the cancer-immune system crosstalk, yet the mechanisms by which they reprogram neutrophil function in vivo remain insufficiently characterised. Here, we identify the serine protease inhibitor Serpin A1 as a predominant cargo component of small EVs (sEVs) released by head and neck cancer cels (HNC) and show that this molecule is both necessary and sufficient to confer a stable pro-tumoural programming of neutrophils. Uptake of Serpin A1-enriched sEVs elicits extensive proteomic remodelling in neutrophils including activation of STAT3 signalling, leading to sustained induction of PD-L1, increased Arginase 1 production and prolonged neutrophil lifespan. Functionally, these reprogrammed neutrophils acquire a capacity to drive epithelial-mesenchymal transition in tumour cells, and to impose exhaustion of T cells via metabolic restriction and arginine depletion, leading to their reduced cytotoxicity. Genetic ablation of Serpin A1 from tumour-derived sEVs or pharmacologic inhibition of serpin-STAT3 axis restores neutrophil anti-tumour functions. Collectively, these findings delineate a Serpin A1-STAT3/Arginase 1 as an important signalling pathway through which tumour-derived sEVs promote neutrophil-dependent immune suppression and tumour progression, and highlight EV-associated serpins as potential targets for future therapeutic intervention in cancer.
中文摘要:肿瘤来源的细胞外囊泡(EVs)或外泌体是肿瘤与免疫系统相互作用的重要介质,但其在体内重编程中性粒细胞功能的机制仍未被充分阐明。本研究发现,丝氨酸蛋白酶抑制剂 Serpin A1 是头颈癌细胞释放的小细胞外囊泡(sEVs)中的主要货物成分,并且该分子对于赋予中性粒细胞稳定的促肿瘤程序既必要又充分。摄取富含 Serpin A1 的 sEVs 会引发中性粒细胞广泛的蛋白质组重塑,包括激活 STAT3 信号,导致 PD-L1 持续诱导、Arginase 1 生成增加以及中性粒细胞寿命延长。在功能上,这些被重编程的中性粒细胞获得驱动肿瘤细胞发生上皮-间质转化的能力,并通过代谢限制和精氨酸耗竭促使 T 细胞耗竭,从而降低其细胞毒性。从肿瘤来源 sEVs 中基因敲除 Serpin A1,或药物抑制 serpin-STAT3 轴,可恢复中性粒细胞的抗肿瘤功能。这些结果勾勒出 Serpin A1-STAT3/Arginase 1 是一条重要信号通路,肿瘤来源 sEVs 通过该通路促进中性粒细胞依赖性免疫抑制和肿瘤进展,并提示 EV 相关 serpins 可作为未来癌症治疗干预的潜在靶点。
The straightforward one-step wet-chemical approach represents a promising strategy for the preparation of ultrasmall gadolinium oxide nanoparticles (GdONs) featuring high T1 relaxivity and excellent aqueous dispersion stability. However, achieving specificity for conventional GdONs still requires multi-step modifications with targeting molecules, introducing uncertainty into their application prospects. Herein, rutin (Ru)-coated ultrasmall GdONs (Gd@Ru) possessing both high T1 relaxivity and glucose transporter (GLUT)-overexpressing tumor-targeted magnetic resonance imaging (MRI) capability were successfully prepared via a one-step wet-chemical method. Among all the as-prepared Gd@Ru, Gd@Ru-5 with the lowest Gd content (∼3.8 wt% Gd, as determined by EDS) exhibits the smallest crystalline size (∼ 1.8 nm) and hydrodynamic diameter (∼ 4.0 nm), achieving the highest T1 relaxivity (40.4 mM- 1s- 1 at 1.5 T) along with exceptional stability. Moreover, Gd@Ru-5 showed satisfactory biosafety and excellent magnetic resonance angiography (MRA) performance in SD rats and New Zealand rabbits, as well as effective targeted imaging of GLUT-overexpressing 4T1 breast tumors. Overall, we present a facile one-step wet-chemical strategy for fabricating ultrasmall GdONs that integrate high T1 relaxivity, excellent MRA performance, and tumor-targeted MRI capability.
中文摘要:一步湿化学法为制备具有高T1弛豫率和优良水分散稳定性的超小氧化钆纳米颗粒(GdONs)提供了有前景的策略。常规GdONs要获得靶向特异性仍需多步修饰靶向分子,这给其应用前景带来不确定性。本工作通过一步湿化学法成功制备了芦丁(Ru)包覆的超小GdONs(Gd@Ru),其同时具备高T1弛豫率和靶向葡萄糖转运体(GLUT)过表达肿瘤的磁共振成像(MRI)能力。在所制备的Gd@Ru中,Gd@Ru-5的Gd含量最低(EDS测定约为3.8 wt% Gd),晶粒尺寸最小(约1.8 nm),流体力学直径最小(约4.0 nm),并达到最高T1弛豫率(1.5 T下为40.4 mM⁻¹s⁻¹),同时具有优异稳定性。Gd@Ru-5在SD大鼠和新西兰兔中表现出满意的生物安全性和良好的磁共振血管成像(MRA)性能,并对GLUT过表达的4T1乳腺癌实现了有效靶向成像。整体上,我们提出了一种简便的一步湿化学策略,用于制备集高T1弛豫率、良好MRA性能和肿瘤靶向MRI能力于一体的超小GdONs。
Exosomes are central mediators of intercellular communication in the tumor microenvironment, transferring proteins, lipids, metabolites, and nucleic acids that regulate cancer progression. Recent advances in multi-omics and extracellular vesicle profiling have revealed substantial molecular and functional heterogeneity, extending beyond classical membrane-bound exosomes to nonmembranous extracellular nanoparticles such as exomeres and supermeres. Here, we provide a pan-cancer synthesis of exosome biology, integrating mechanisms of biogenesis, cargo sorting, and secretion with emerging concepts of extracellular nanoparticle diversity. We examine how tumor-derived exosomes remodel local and distant microenvironments by promoting angiogenesis, metabolic reprogramming, immune suppression, premetastatic niche formation, and cancer-associated cachexia. We also discuss the relative contributions of active organotropic targeting and passive spatiotemporal accumulation to metastatic dissemination, together with tissue-specific mechanisms governing endothelial barrier crossing, myeloid-cell reprogramming, and intercellular network integration. Clinically, we evaluate exosome-based liquid biopsy, molecular subtyping, engineered delivery systems, and strategies that inhibit endogenous vesicle production or circulation. Finally, we outline key translational challenges, including single-vesicle heterogeneity, limited intravital tracking, and the absence of standardized cGMP manufacturing and analytical frameworks across diverse tumor types and clinically relevant biological contexts worldwide. This review defines a roadmap for exosome-guided precision oncology.
中文摘要:外泌体是肿瘤微环境中细胞间通讯的核心介质,可转运蛋白质、脂质、代谢物与核酸,调控肿瘤进展。多组学与细胞外囊泡分析技术的进步揭示出显著的分子与功能异质性,其范围已超出经典膜结合外泌体,延伸至exomeres、supermeres等非膜性细胞外纳米颗粒。本文在泛癌种层面整合外泌体生物学,把生成、货物分选与分泌机制同细胞外纳米颗粒多样性这一新兴认识相结合,考察肿瘤来源外泌体如何通过促进血管生成、代谢重编程、免疫抑制、转移前微环境形成以及癌症相关恶病质,重塑局部与远端微环境;并讨论主动器官趋向性靶向与被动时空蓄积在转移播散中的相对贡献,以及调控内皮屏障穿越、髓系细胞重编程与细胞间网络整合的组织特异性机制。临床层面评估基于外泌体的液体活检、分子分型、工程化递送系统,以及抑制内源性囊泡产生或循环的策略。文章亦概述关键转化难题,包括单囊泡异质性、活体追踪手段有限,以及在全球不同肿瘤类型与临床相关生物学情境中缺乏标准化的cGMP生产与分析框架。本综述为外泌体引导的精准肿瘤学勾勒出路线图。
Metastasis is the primary cause of mortality in cancer including lung adenocarcinoma (LUAD), yet the underlying mechanisms remain incompletely understood. Preferentially expressed antigen of melanoma (PRAME), a cancer-testis antigen, displays context-dependent functions across malignancies, but its biological role in LUAD metastasis has not been clearly defined. Here, we demonstrate that the significantly upregulated PRAME in metastatic LUAD directly interacts with the m6A methyltransferase METTL3 and promotes its K63-linked non-proteolytic ubiquitination. This modification occurs at lysine 235 of METTL3, increases its protein stability and facilitates METTL3 interaction with METTL14 and WTAP. Consequently, m6A modification of TGFB2 mRNA and activation of the TGF-β signaling pathway are enhanced, which is essential for PRAME-driven pro-metastatic effects both in vitro and in vivo. Clinically, PRAME expression positively correlates with METTL3 protein abundance and TGF-β pathway activation, and is robustly associated with poor clinical outcomes. Taken together, our findings identify K63-linked ubiquitination as a previously unrecognized post-translational modification of METTL3 and underscore the importance of the PRAME/METTL3/TGF-β axis in LUAD metastasis, providing mechanistic insights and potential therapeutic targets for this malignancy.
中文摘要:转移是包括肺腺癌(LUAD)在内的癌症最主要的致死原因,其背后的机制仍未完全阐明。黑色素瘤优先表达抗原(PRAME)是一种癌睾抗原,在不同恶性肿瘤中表现出依赖于背景的功能,而它在肺腺癌转移中的生物学作用尚未明确。研究发现,转移性肺腺癌中显著上调的PRAME可直接与m6A甲基转移酶METTL3结合,并促进其K63连接的非降解性泛素化。该修饰发生在METTL3的第235位赖氨酸,可提高其蛋白稳定性,并促进METTL3与METTL14及WTAP的结合。随之TGFB2 mRNA的m6A修饰与TGF-β信号通路激活增强,这一环节是PRAME在体外与体内发挥促转移效应所必需的。临床上,PRAME表达与METTL3蛋白丰度及TGF-β通路激活呈正相关,并与不良临床结局密切相关。上述结果将K63连接泛素化识别为METTL3一种此前未被认识到的翻译后修饰,并提示PRAME/METTL3/TGF-β轴在肺腺癌转移中具有重要作用,为该恶性肿瘤提供了机制层面的认识与潜在治疗靶点。
Despite two decades of intensive molecular engineering, the clinical translation of proteolysis-targeting chimeras (PROTACs) remains constrained by a fundamental paradox: high in vitro potency often fails to translate into in vivo efficacy due to poor pharmacokinetics (PK)/pharmacodynamics (PD) profiles and uncontrolled biodistribution. This review departs from conventional narratives centered on potency by introducing a framework focused on drug fate that explicitly connects the absorption, distribution, metabolism, excretion (ADME), and tumor targeting of PROTACs with the rational design of advanced delivery systems. We first dissect the primary physiological barriers that undermine PROTAC performance in vivo, including rapid clearance, suboptimal tissue penetration, and off-target accumulation. Furthermore, we argue that efficient delivery must be engineered from the ground up based on how PROTACs behave inside the body. To this end, we systematically evaluate three tiers of delivery platforms, comprising small molecule prodrugs, macromolecular carriers, and systems based on nanoparticles, with particular emphasis on how each platform can be optimized to overcome specific PK/PD bottlenecks. Crucially, we propose a performance-by-design roadmap that integrates molecular-level innovations with nanoscale delivery engineering, shifting the field's focus from in vitro degradation potency toward predictable in vivo outcomes. By providing rational design principles grounded in the real-world fate of PROTACs, this review offers a timely paradigm shift that aims to accelerate clinical candidate development and unlock the full therapeutic potential of targeted protein degradation (TPD) in cancer.
中文摘要:尽管经过二十年的密集分子工程改造,蛋白降解靶向嵌合体(PROTACs)的临床转化仍受一个根本性矛盾制约:高体外活性常因药代动力学(PK)/药效动力学(PD)性质不佳和生物分布失控而难以转化为体内疗效。本综述不再沿用以活性为中心的常规叙述,而是引入以药物体内命运为核心的框架,将PROTACs的吸收、分布、代谢、排泄(ADME)及肿瘤靶向与先进递送系统的理性设计明确联系起来。文章先剖析削弱PROTAC体内表现的主要生理屏障,包括快速清除、组织渗透不足和脱靶蓄积。进一步提出,高效递送必须基于PROTAC在体内的实际行为从底层进行工程化设计。为此,系统评估三类递送平台,包括小分子前药、大分子载体和纳米颗粒系统,重点讨论各平台如何优化以克服特定PK/PD瓶颈。文章提出以性能为导向的设计路线图,将分子层面创新与纳米尺度递送工程整合,推动该领域从体外降解活性转向可预测的体内结果。通过提供基于PROTAC真实体内命运的理性设计原则,本综述给出及时的范式转变,旨在加速临床候选药物开发并释放靶向蛋白降解(TPD)在癌症治疗中的全部潜力。
CAR signaling instructs divergent metabolic reprogramming and functional fates in αβ and γδ T cells.
γδ T-cell-based immunotherapies have become relevant as alternatives to conventional αβ T-cell products, with preclinical data demonstrating tumor burden reduction and the mitigation of tumor-induced tissue damage. Given that most CAR constructs have been optimized for αβ T cells, we hypothesized that distinct T-cell types may require tailored CAR architectures to achieve optimal function. To test this hypothesis, we conducted a systematic comparative analysis of γδ and αβ T cells transduced with a second-generation PSCA-targeting CAR (PSCA-8t28z). We found that although γδ and αβ CAR-T cells exhibit comparable levels of cytotoxicity, they differ phenotypically. Through a system-level phosphoproteomic analysis, we identified 307 phosphosites whose abundance differed between γδ and αβ CAR-T cells. Pathway enrichment analysis placed glycolysis/gluconeogenesis and TCR signaling within the top significantly overrepresented signaling networks. The results of functional validation studies confirmed that γδ CAR-T cells have lower glycolytic and oxidative phosphorylation capacity than αβ-CAR-T cells do and weaker activation of activator protein 1 (AP-1). Notably, we identified thioredoxin-interacting protein (TXNIP) as a potential actionable target to enhance γδ CAR-T-cell metabolism. Finally, we designed a new synthetic costimulatory receptor that potentiates AP-1 activation, resulting in improved in vivo persistence. These results highlight the fundamental biological differences between γδ and αβ T cells and support the development of cell type-specific receptor engineering strategies to maximize γδ CAR-T-cell function and therapeutic benefit.
中文摘要:基于γδ T细胞的免疫疗法已成为传统αβ T细胞产品的相关替代方案,临床前数据表明其可减轻肿瘤负荷并缓解肿瘤引起的组织损伤。鉴于大多数CAR构建体是针对αβ T细胞优化的,我们假设不同T细胞类型可能需要定制的CAR结构以实现最佳功能。为检验这一假设,我们对转导了靶向PSCA的第二代CAR(PSCA-8t28z)的γδ和αβ T细胞进行了系统比较分析。我们发现,尽管γδ和αβ CAR-T细胞表现出相当的细胞毒性水平,但它们的表型不同。通过系统级磷酸化蛋白质组分析,我们鉴定出307个在γδ和αβ CAR-T细胞之间丰度不同的磷酸化位点。通路富集分析将糖酵解/糖异生和TCR信号传导列为最显著过度代表的信号网络。功能验证研究结果证实,与αβ CAR-T细胞相比,γδ CAR-T细胞的糖酵解和氧化磷酸化能力较低,激活蛋白1(AP-1)的激活较弱。我们鉴定出硫氧还蛋白相互作用蛋白(TXNIP)作为增强γδ CAR-T细胞代谢的潜在可操作靶点。我们还设计了一种新的合成共刺激受体,可增强AP-1激活,从而改善体内持久性。这些结果突显了γδ和αβ T细胞之间的基本生物学差异,并支持开发细胞类型特异性受体工程策略,以最大化γδ CAR-T细胞功能和治疗获益。
Meteorin-like (Metrnl) is a newly discovered multifunctional secreted protein widely expressed in various tissues such as adipose tissue, skeletal muscle, and epithelial barrier tissues. This review systematically summarizes current knowledge of Metrnl, detailing its molecular characteristics, structure, cellular sources, inducers, receptors, and the complex signaling pathways and network. Metrnl has been identified as a pleiotropic protein with multiple effects, including enhancing insulin sensitivity, modulating lipid metabolism, promoting neurogenesis, reducing inflammation and oxidative stress, regulating tumor immunity, and potentiating angiogenesis and tissue repair. In metabolic and endocrine disorders, cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, skin diseases, autoimmune diseases, and nervous system diseases, and other pathological processes, the expression of Metrnl shows tissue-specific and disease stage-dependent changes, underscoring its potential as a biomarker or novel therapeutic target. However, the expression characteristics and biological functions of Metrnl in some diseases are controversial, and its tissue-specific role has not been fully elucidated. This review integrates clinical cohort studies and animal model results targeting Metrnl and its receptors. On this basis, we propose that Metrnl should be regarded as a stress-responsive immunometabolic molecule rather than a static disease biomarker. The research on targeted intervention in Metrnl is currently in the preclinical stage and has not yet progressed to clinical trials, and its clinical application value in specific diseases needs to be verified by large-scale stratified cohort analysis. This article aims to provide theoretical clues and novel insights for understanding Metrnl as a potential biomarker and therapeutic target.
中文摘要:Metrnl 是一种新发现的多功能分泌蛋白,广泛表达于脂肪组织、骨骼肌和上皮屏障组织等多种组织。该综述系统梳理了 Metrnl 的分子特征、结构、细胞来源、诱导因素、受体以及复杂的信号通路和调控网络。Metrnl 已被认定具有多效性,可增强胰岛素敏感性、调节脂质代谢、促进神经发生、减轻炎症和氧化应激、调控肿瘤免疫,并增强血管生成和组织修复。在代谢与内分泌疾病、心脑血管疾病、呼吸系统疾病、胃肠道疾病、皮肤疾病、自身免疫性疾病、神经系统疾病及其他病理过程中,Metrnl 的表达呈组织特异性和疾病阶段依赖性变化,提示其作为生物标志物或新治疗靶点的潜力。不过,Metrnl 在某些疾病中的表达特征和生物学功能仍存在争议,其组织特异性作用尚未完全阐明。该综述整合了以 Metrnl 及其受体为靶点的临床队列研究和动物模型结果,并据此提出应将 Metrnl 视为应激反应性免疫代谢分子,而非静态的疾病生物标志物。目前针对 Metrnl 的靶向干预研究处于临床前阶段,尚未进入临床试验,其在特定疾病中的临床价值仍需大规模分层队列分析验证。文章旨在为理解 Metrnl 作为潜在生物标志物和治疗靶点提供理论线索和新思路。
Lung metastasis is a major cause of cancer-related mortality, and the pre-metastatic niche (PMN) provides a window for early intervention. Here, transcriptomic profiling of pre-metastatic lungs in a subcutaneous B16-F10 melanoma model identified S100a8 and S100a9 as strongly upregulated PMN-associated genes. Exploratory TCGA analyses further linked high S100A8 or S100A9 expression with poorer overall survival in selected cancer types, although most associations were attenuated after multivariable adjustment. To evaluate these molecules as vaccine targets, we engineered recombinant fusion proteins linking mouse S100A8, S100A9, or tandem S100A8/A9 to a hypervariable-region-deleted flagellin (FliCΔHP) that retains Toll-like receptor 5 agonist activity. All three fusion proteins broke immune tolerance and elicited high-titer antigen-specific IgG responses, whereas only FliCΔHP-A9 significantly reduced experimental pulmonary metastasis in both male and female mice. Among the analyzed animals, anti-S100A9 IgG titers were inversely associated with metastatic burden. Immune serum inhibited S100A9-driven B16-F10 migration in vitro, and passive transfer of FliCΔHP-A9 immune serum reduced lung metastatic burden in naïve recipients, supporting an important contribution of humoral immunity to protection. Vaccination was also associated with lower pulmonary S100a8/S100a9 expression, reduced granulocytic and monocytic myeloid-derived suppressor cell accumulation, increased CD8+ T-cell frequencies, and an IFN-γ/IL-12-enriched pulmonary immune environment. Collectively, these findings identify S100A9 as an effective vaccine target in this experimental setting and suggest that S100A9-directed humoral immunity is accompanied by remodeling of the pulmonary immune microenvironment. Validation in spontaneous metastasis models and translational systems will be required to define the broader therapeutic potential of FliCΔHP-A9.
中文摘要:肺转移是癌症相关死亡的主要原因,前转移生态位为早期干预提供了窗口。对皮下B16-F10黑色素瘤模型前转移肺组织进行转录组分析,发现S100a8和S100a9是明显上调的前转移生态位相关基因。探索性TCGA分析进一步显示,在部分癌种中S100A8或S100A9高表达与总生存较差相关,但多变量校正后多数关联减弱。为评估这些分子作为疫苗靶点,研究构建了将小鼠S100A8、S100A9或串联S100A8/A9与保留Toll样受体5激动活性的超变区缺失鞭毛蛋白FliCΔHP连接的重组融合蛋白。三种融合蛋白均打破免疫耐受并诱导高滴度抗原特异性IgG应答,但仅FliCΔHP-A9在雄性和雌性小鼠中均显著减少实验性肺转移。在受检动物中,抗S100A9 IgG滴度与转移负荷呈负相关。免疫血清在体外抑制S100A9驱动的B16-F10迁移,被动转移FliCΔHP-A9免疫血清可降低未免疫受体的肺转移负荷,支持体液免疫对保护的重要贡献。接种还伴随肺组织S100a8/S100a9表达降低、粒细胞性和单核细胞性髓源性抑制细胞积聚减少、CD8+ T细胞频率升高以及IFN-γ/IL-12富集的肺部免疫环境。这些结果表明,在该实验体系中S100A9是有效疫苗靶点,并提示靶向S100A9的体液免疫伴随肺部免疫微环境重塑。仍需在自发性转移模型和转化体系中验证,以确定FliCΔHP-A9更广泛的治疗潜力。
Mushroom-derived (1→3),(1→6)-β-D-glucans exhibit diverse biological activities, including effects relevant to cancer research, which may be modulated through chemical modification. In the present study, sequential hydroxypropylations were performed on a highly purified (1→3),(1→6)-β-D-glucan (NM-Glc) from the mushroom Lactarius quieticolor to generate derivatives with distinct structural characteristics (HP1 and HP2). The derivatives were characterized by NMR, GC-MS, and SEC-MALS-RI, which suggested preferential hydroxypropyl substitution at the O-6 and O-4 positions. Each sample (NM-Glc (unmodified glucan; Mw 1.26 × 105 g.mol-1), HP1 (Mw 4.02 × 104 g.mol-1, MS: 0.70, DSFrac: 0.38, DSSub: 0.57), and HP2 (Mw 5.66 × 104 g.mol-1, MS: 0.94, DSFrac: 0.47, DSSub: 0.83) was evaluated for its biological effects on B16-F10 murine melanoma cells at 10, 100, and 1000 μg.mL-1. NM-Glc did not exhibit significant cytotoxicity toward tumor cells under the evaluated conditions, whereas the hydroxypropyl-modified glucans exhibited cytotoxicity at 100 and 1000 μg.mL-1 and reduced cell adhesion to the substrate (observed only for HP2 at 1000 μg.mL-1). Acridine orange/ethidium bromide (AO/EB) staining revealed an increased proportion of apoptotic-like cells following treatment with HP1 and HP2, with HP2 producing the most pronounced effects. Therefore, hydroxypropylation is a promising strategy to generate (1→3),(1→6)-β-D-glucans capable of reducing melanoma cell viability in vitro.
中文摘要:蘑菇来源的(1→3),(1→6)-β-D-葡聚糖具有多种生物活性,其中包括与肿瘤研究相关的效应,这些效应可通过化学修饰加以调节。本研究对来自蘑菇Lactarius quieticolor的高纯度(1→3),(1→6)-β-D-葡聚糖NM-Glc进行连续羟丙基化,生成结构特征不同的衍生物HP1和HP2。通过NMR、GC-MS和SEC-MALS-RI表征,结果提示羟丙基取代优先发生在O-6和O-4位。各样品包括未修饰葡聚糖NM-Glc(Mw 1.26×10^5 g·mol⁻¹)、HP1(Mw 4.02×10^4 g·mol⁻¹,MS 0.70,DSFrac 0.38,DSSub 0.57)和HP2(Mw 5.66×10^4 g·mol⁻¹,MS 0.94,DSFrac 0.47,DSSub 0.83),在10、100和1000 μg·mL⁻¹浓度下评估其对B16-F10小鼠黑色素瘤细胞的生物学作用。在所评估条件下,NM-Glc未表现出明显细胞毒性,而羟丙基修饰葡聚糖在100和1000 μg·mL⁻¹时具有细胞毒性,并降低细胞对基质的黏附,后者仅在HP2 1000 μg·mL⁻¹时观察到。吖啶橙/溴化乙锭染色显示,HP1和HP2处理后凋亡样细胞比例增加,HP2作用最明显。因此,羟丙基化是生成可在体外降低黑色素瘤细胞活力的(1→3),(1→6)-β-D-葡聚糖的有前景策略。
Ferroptosis, an iron-dependent cell death, emerged as a new therapeutic approach to treat diseases such as cancer or diabetes. Several pathological conditions are characterized by the appearance of chronic hypoxia, which is known to attract immune cells, especially monocytes and macrophages. Therefore, we investigated how chronic hypoxia affects ferroptosis in primary human macrophages and THP-1 cells. Chronic but not acute hypoxia sensitized cells towards ferroptosis, in line with elevated cellular as well as mitochondrial lipid peroxides, and mitochondrial ROS. Time kinetics revealed an earlier increase in lipid peroxidation under chronic hypoxia compared to normoxia, which was followed by mitochondrial lipid peroxidation and mitochondrial ROS. Mechanistically, and in contrast to normoxia and/or acute hypoxia, chronic hypoxia diminished nuclear abundance and activity of the antioxidant transcription factor NRF2. Consequently, NRF2 target gene expression, including ferroptosis suppressor protein 1 (FSP1), decreased. Inhibition or knockdown of FSP1 mimicked the ferroptosis-sensitizing effect of chronic hypoxia. To causatively link decreased NRF2 activity to increased ferroptosis under hypoxia, we inhibited KEAP1, which preserved NRF2 activity, increased FSP1 expression, and decreased ferroptosis. Our data provides novel insights into NRF2 regulation under chronic hypoxia linked to FSP1 expression and ferroptosis sensitivity of primary human macrophages.
中文摘要:铁死亡是一种依赖铁的细胞死亡方式,已成为治疗癌症或糖尿病等疾病的新思路。多种病理状态会出现慢性缺氧,而慢性缺氧会招募免疫细胞,尤其是单核细胞和巨噬细胞。因此,我们研究慢性缺氧如何影响原代人巨噬细胞和THP-1细胞中的铁死亡。慢性缺氧而非急性缺氧使细胞对铁死亡更敏感,这与细胞及线粒体脂质过氧化物和线粒体ROS升高一致。时间动力学显示,与常氧相比,慢性缺氧下脂质过氧化升高更早,随后出现线粒体脂质过氧化和线粒体ROS。机制上,与常氧和/或急性缺氧不同,慢性缺氧降低抗氧化转录因子NRF2的核内丰度和活性。因此,NRF2靶基因表达下降,包括铁死亡抑制蛋白1(FSP1)。抑制或敲低FSP1可模拟慢性缺氧对铁死亡的增敏作用。为将NRF2活性下降与缺氧下铁死亡增加建立因果联系,我们抑制KEAP1,从而维持NRF2活性、提高FSP1表达并减少铁死亡。我们的数据为慢性缺氧下NRF2调控及其与FSP1表达和原代人巨噬细胞铁死亡敏感性的联系提供了新见解。
Head and neck cancers (HNCs) are characterized by substantial genetic, epigenetic, transcriptional, and microenvironmental heterogeneity, which contributes to variable responses and limited durability of non-coding RNA (ncRNA)-based therapies. Although previous reviews have extensively catalogued dysregulated miRNAs, lncRNAs, and circRNAs in HNC, less attention has been paid to how tumor heterogeneity dynamically reshapes ncRNA-target relationships and therapeutic responses. Here, we introduce heterogeneity-driven target drift as a conceptual framework linking multidimensional tumor heterogeneity to ncRNA therapeutic instability. We first examine the molecular mechanisms by which genetic variation, alternative polyadenylation, epigenetic remodeling, viral status, and the tumor microenvironment shape heterogeneous ncRNA functions. We then analyze three major translational barriers: heterogeneous drug delivery, context-dependent target engagement, and microenvironmental interference and resistant subclones. Finally, we discuss actionable precision strategies, including heterogeneity-informed diagnostics, targeted and stimuli-responsive delivery, CRISPR-based ncRNA editing, intercellular therapeutic circuits, APA-directed interventions, and multimodal combinations. We propose a heterogeneity-aware framework integrating dynamic molecular profiling, individualized target selection, adaptive treatment design, and clinically scalable delivery to improve the predictability and durability of ncRNA therapies in HNC.
中文摘要:头颈癌(HNCs)具有显著的遗传、表观遗传、转录及微环境异质性,这种异质性导致非编码RNA(ncRNA)治疗应答不一且疗效难以持久。既往综述已系统梳理HNC中失调的miRNA、lncRNA和circRNA,但对肿瘤异质性如何动态重塑ncRNA与靶点关系及治疗反应关注不足。本文提出「异质性驱动的靶点漂移」这一概念框架,将多维肿瘤异质性与ncRNA治疗不稳定性联系起来。我们考察遗传变异、选择性多聚腺苷酸化、表观遗传重塑、病毒状态和肿瘤微环境塑造ncRNA功能异质性的分子机制,并分析三类转化障碍:药物递送异质性、依赖背景的靶点结合、微环境干扰与耐药亚克隆。可操作的精准策略包括基于异质性的诊断、靶向及刺激响应型递送、基于CRISPR的ncRNA编辑、细胞间治疗回路、针对APA的干预和多模式联合。我们提出一个异质性感知框架,整合动态分子谱分析、个体化靶点选择、适应性治疗设计和临床可扩展递送,以提高HNC中ncRNA治疗的可预测性和持久性。
Traditional two-dimensional (2D) cell cultures fail to capture the structural, mechanical, and biochemical complexity of living tissues, prompting a major paradigm shift toward three-dimensional (3D) cell culture models. 3D systems faithfully replicate in vivo physiological architectures, dynamic cell-to-cell contacts, and extracellular matrix (ECM) interactions, bridging a critical gap in preclinical studies by predicting human therapeutic responses more accurately. This review explores the technological evolution from simple multicellular tumor spheroids to sophisticated microphysiological networks. Scaffold-free methods-including the hanging drop, low-adherent plates, magnetic levitation, and dynamic bioreactors-efficiently recreate the pathophysiological oxygen, nutrient, and metabolic gradients characteristic of solid tumor zonation and drug-resistance pathways. Conversely, scaffold-based systems leverage hydrogels, synthetic polymers, and decellularized matrices to dissect the biomechanics of matrix stiffness and mechanotransduction. At a higher tier of biological fidelity, patient-derived organoids preserve cellular heterogeneity, native tissue polarity, and accurate patient-specific mutational profiles, serving as critical pipelines for personalized medicine and precision drug screening. Furthermore, the integration of advanced microfluidic technologies has facilitated the engineering of tumor-, organ-, and multi-organ body-on-a-chip platforms. These microphysiological systems reconstruct dynamic fluid flow, functional tissue-vascular interfaces, physiological barriers (such as the blood-brain barrier), and systemic pharmacokinetic/pharmacodynamic (ADME) drug profiles. Beyond deepening mechanistic insights into oncology, these interconnected 3D models provide highly ethical, predictive, and cost-effective alternatives to animal experimentation in strict alignment with the 3Rs principles. Ultimately, these complementary 3D culture technologies are transforming oncology into a highly predictive, patient-tailored discipline.
中文摘要:传统二维细胞培养无法捕捉活体组织的结构、力学和生化复杂性,推动向三维细胞培养模型的重大范式转变。三维系统可忠实复现体内生理结构、动态细胞间接触和细胞外基质相互作用,通过更准确预测人体治疗反应,弥补临床前研究的关键缺口。本综述梳理从简单多细胞肿瘤球到复杂微生理网络的技术演进。无支架方法包括悬滴法、低黏附板、磁悬浮和动态生物反应器,可有效重建实体瘤分区和耐药通路所特有的病理生理性氧、营养和代谢梯度。支架系统利用水凝胶、合成聚合物和脱细胞基质,解析基质刚度和机械转导的生物力学。在更高生物保真度层面,患者来源类器官保留细胞异质性、天然组织极性和准确的患者特异性突变谱,成为个性化医疗和精准药物筛选的重要管道。先进微流控技术的整合促进了肿瘤、器官和多器官人体芯片平台的构建。这些微生理系统重建动态流体流动、功能性组织-血管界面、生理屏障(如血脑屏障)以及系统性药代动力学/药效学(ADME)药物特征。除深化肿瘤学机制认识外,这些互联三维模型提供符合3Rs原则的高度伦理、可预测且成本有效的动物实验替代方案。最终,这些互补的三维培养技术正将肿瘤学转变为高度可预测、以患者为中心的学科。
Myelosuppression is a common and dose-limiting severe complication in tumor radiotherapy and chemotherapy. The disruption of hematopoietic microenvironment homeostasis mediated by bone marrow mesenchymal stem cells (BMSCs) may be one of the important pathological factors for its persistent non-healing. Traditional Chinese medicine (TCM) can regulate BMSCs function through multi-target and multi-pathway mechanisms, reshape the hematopoietic microenvironment, and support hematopoietic regeneration. This article systematically explains the network mechanisms by which BMSCs regulate hematopoiesis and the pathological mechanisms by which factors like radiotherapy and chemotherapy damage BMSCs. It explores how active ingredients in Chinese medicine can restore BMSCs function and remodel the hematopoietic microenvironment by regulating differentiation and enhancing paracrine effects, suggesting that shifting treatment strategies from "protecting the seeds" to "remodeling the soil" might be a promising direction. At the same time, it summarizes the potential application value of nano-targeted delivery to improve bone marrow homing efficiency of active ingredients and other new technology research progress. Although most studies are still at the preclinical stage, these findings suggest the potential value of TCM in treating myelosuppression and provide ideas and directions for using single-cell multi-omics to identify abnormal BMSCs subpopulations and their molecular targets, developing intelligent drug delivery systems, and conducting clinical translational research.
中文摘要:骨髓抑制是肿瘤放疗和化疗中常见且限制剂量的严重并发症。骨髓间充质干细胞(BMSCs)介导的造血微环境稳态破坏,可能是其持续不愈的重要病理因素之一。中药可通过多靶点、多通路机制调控BMSCs功能,重塑造血微环境,支持造血再生。该文系统阐述BMSCs调控造血的网络机制,以及放疗、化疗等因素损伤BMSCs的病理机制,探讨中药活性成分通过调节分化和增强旁分泌作用恢复BMSCs功能、重塑造血微环境的途径,提出将治疗策略从「保护种子」转向「重塑土壤」可能是有前景的方向。同时总结纳米靶向递送提高活性成分骨髓归巢效率等新技术研究进展的潜在应用价值。尽管多数研究仍处于临床前阶段,这些发现提示中药治疗骨髓抑制的潜在价值,并为利用单细胞多组学识别异常BMSCs亚群及其分子靶点、开发智能药物递送系统、开展临床转化研究提供思路和方向。
Melanoma therapies can produce substantial tumor regression without durable control, raising two separable questions: how efficiently tumor cells are eliminated and whether therapy-induced death supports immune recognition. This review examines whether melanocytic-lineage redox biology and site-selective protein S-nitrosylation help connect these outcomes. We distinguish mechanisms demonstrated directly in melanoma from mechanistic precedents in other systems and from hypotheses that require validation. In melanocytic cells, active pigment-forming chemistry can support a nitric oxide synthase (NOS)-active state. In melanoma, S-nitrosylation has been linked to MAPK persistence during MEK inhibition, TSC2-dependent mTOR activation, and NOS1-dependent suppression of interferon programs through HDAC2 and IRF7. Pharmacological S-nitrosylation blockade also increases ER stress signaling, calreticulin exposure, HMGB1 release, immune cell recruitment, and tumor control, but these observations do not establish a site-specific effect on the immunological quality of cell death. We therefore propose a two-gate framework in which S-nitrosylation may regulate both susceptibility to irreversible death and the signaling competence of dying cells. Establishing this model will require quantitative site occupancy, cell type-resolved nitrosoproteomics, causal site replacement, and immune assays that distinguish altered signaling from simply increased cell killing. The available evidence supports selective interrogation of causal S-nitrosylation nodes rather than indiscriminate suppression of NO biology.
中文摘要:黑色素瘤治疗可出现显著肿瘤退缩,却难以获得持久控制,由此提出两个可分开的问题:肿瘤细胞被清除的效率如何,以及治疗诱导的死亡是否支持免疫识别。本综述考察黑色素细胞谱系氧化还原生物学与位点选择性蛋白S-亚硝基化是否有助于连接这些结局。我们将直接在黑色素瘤中证实的机制、其他系统中的机制先例以及尚待验证的假说加以区分。在黑色素细胞中,活跃的色素形成化学可支持一氧化氮合酶(NOS)活跃状态。在黑色素瘤中,S-亚硝基化与MEK抑制期间MAPK持续存在、TSC2依赖的mTOR激活,以及NOS1依赖地通过HDAC2和IRF7抑制干扰素程序有关。药理学阻断S-亚硝基化还可增强内质网应激信号、钙网蛋白暴露、HMGB1释放、免疫细胞募集和肿瘤控制,但这些观察并未确立对细胞死亡免疫学质量的位点特异性效应。因此,我们提出一个双闸门框架,其中S-亚硝基化可能同时调节对不可逆死亡的易感性和濒死细胞的信号传导能力。建立该模型需要定量位点占据、细胞类型分辨的亚硝基化蛋白质组学、因果性位点替换,以及能够区分信号改变与单纯细胞杀伤增加的免疫实验。现有证据支持对因果性S-亚硝基化节点进行选择性探究,而非不加区分地抑制NO生物学。
Therapy resistance remains a major cause of relapse and cancer-related mortality, arising from dynamic interactions between tumor-intrinsic programs and microenvironmental constraints. Genetic and epigenetic alterations, transcriptional rewiring, metabolic adaptation, extracellular matrix signalling, hypoxia and limited drug penetration shape resistant phenotypes and therapeutic failure. Accurately modelling these processes is essential for identifying actionable resistance mechanisms and guide patient treatment. Conventional 2D cultures provide valuable mechanistic insights and scalable drug screening platforms, but fail to recapitulate the spatial organization, diffusion gradients and heterogeneous drug exposure characteristic of solid tumors. In contrast, advanced 3D preclinical models capture key aspects of tumor architecture and microenvironmental complexity that influence therapy response and resistance evolution. This review provides a comparative analysis of current 3D cancer models and proposes a conceptual framework linking mechanisms of therapeutic adaptation to the experimental platforms that most faithfully recapitulate them, with particular emphasis on patient-derived organoids (PDOs). By retaining clinically relevant features of the tumor of origin, PDOs enable the investigation of resistance evolution in both treatment-naïve and clinically treated tumors, as well as modelling experimentally acquired resistance through controlled therapeutic selection. These features enable mechanistic studies with high translational relevance, while supporting the development of precision oncology strategies. Finally, we propose practical recommendations for experimental design, model selection and reporting to improve reproducibility and facilitate cross-study comparisons. Collectively, advanced 3D cancer models represent a promising translational framework for uncovering mechanisms of therapy resistance and identifying actionable vulnerabilities that may guide more effective and personalized treatment strategies.
中文摘要:治疗耐药仍是复发和癌症相关死亡的主要原因,源于肿瘤内在程序与微环境约束之间的动态相互作用。遗传和表观遗传改变、转录重编程、代谢适应、细胞外基质信号、缺氧和药物渗透受限塑造耐药表型并导致治疗失败。准确模拟这些过程对于识别可干预的耐药机制和指导患者治疗至关重要。传统2D培养提供有价值的机制见解和可扩展的药物筛选平台,但无法再现实体瘤的空间组织、扩散梯度和异质性药物暴露。相较之下,先进3D临床前模型捕捉影响治疗反应和耐药演化的肿瘤结构和微环境复杂性的关键方面。当前3D癌症模型得到比较分析,并提出一个概念框架,将治疗适应机制与最能忠实再现这些机制的实验平台联系起来,特别强调患者来源类器官(PDOs)。通过保留原发肿瘤的临床相关特征,PDOs能够研究初治和临床治疗肿瘤中的耐药演化,并通过受控治疗选择模拟实验获得的耐药。这些特征使机制研究具有高转化相关性,同时支持精准肿瘤学策略的开发。在实验设计、模型选择和报告方面,作者提出实用建议,以提高可重复性并促进跨研究比较。总体而言,先进3D癌症模型代表一个有前景的转化框架,用于揭示治疗耐药机制并识别可干预的脆弱点,可能指导更有效和个性化的治疗策略。
Pancreatic neuroendocrine neoplasms (PNENs) arise from neuroendocrine cells of the pancreas. Therapeutic options are limited for patients with advanced disease and the molecular mechanisms that drive PNEN progression remain elusive. The Notch pathway regulates cell fate, proliferation, cell-cell communication, and survival in multicellular organisms. Dysregulation of one pathway member, Notch1, has been linked to the development and growth of several cancers; however, the role of Notch1 signaling in PNENs is not defined. Notch1 expression was evaluated in normal adult pancreas and PNENs using publicly available single-cell RNA sequencing data from the Human Protein Atlas and immunohistochemistry on PNEN tissue microarrays. A CRISPR/Cas9-mediated knockout of Notch1 was generated in a PNEN cell line ('BON'). The functional impact of Notch1 loss was assessed through proliferation assays, cell cycle analysis, bulk transcriptomics, and Seahorse metabolic flux assays. In vivo tumor growth was evaluated using subcutaneous xenografts, and global proteomic profiling was performed on resected tumors. Notch1 was found to be absent in normal adult pancreatic neuroendocrine cells but was re-expressed in 39-45% of primary and metastatic PNENs. Genetic deletion of Notch1 significantly reduced PNEN cell proliferation in both 2D and 3D conditions, induced G1 cell cycle arrest, and slowed xenograft tumor growth. We also found that Notch1 regulates proliferation and cellular bioenergetic pathways in PNEN cells. Our findings reveal a role for Notch1 in supporting proliferation and bioenergetics in a PNEN cell line, providing new insights into its potential oncogenic function and contribution to PNEN pathobiology.
中文摘要:胰腺神经内分泌肿瘤(PNENs)起源于胰腺神经内分泌细胞。晚期患者治疗选择有限,驱动PNEN进展的分子机制仍不清楚。Notch通路在多细胞生物中调控细胞命运、增殖、细胞间通讯和存活。通路成员Notch1的失调与多种癌症的发生和生长相关;但Notch1信号在PNEN中的作用尚未明确。研究利用Human Protein Atlas公开的单细胞RNA测序数据以及PNEN组织芯片的免疫组化,评估正常成人胰腺和PNEN中的Notch1表达。在PNEN细胞系「BON」中构建CRISPR/Cas9介导的Notch1敲除。通过增殖实验、细胞周期分析、批量转录组学和Seahorse代谢流分析评估Notch1缺失的功能影响。采用皮下异种移植评估体内肿瘤生长,并对切除肿瘤进行整体蛋白质组学分析。结果发现正常成人胰腺神经内分泌细胞中Notch1缺失,但在39-45%的原发性和转移性PNEN中重新表达。Notch1基因缺失在二维和三维条件下均显著降低PNEN细胞增殖,诱导G1细胞周期阻滞,并减缓异种移植肿瘤生长。还发现Notch1调控PNEN细胞的增殖和细胞生物能量通路。这些发现揭示Notch1在PNEN细胞系中支持增殖和生物能量代谢的作用,为其潜在致癌功能及对PNEN病理生物学的贡献提供新认识。
Osteosarcoma (OS) is an aggressive bone malignancy with poor outcomes in recurrent and metastatic disease. Although ferroptosis represents as a promising therapeutic strategy, its regulation in OS remains incompletely understood. Here, we identified STK25 as a regulator of ferroptosis susceptibility and tumor growth in OS. Transcriptomic analysis of paired parental and multidrug-resistant OS cell lines identified lower STK25 expression in the resistant derivatives. In a retrospective tissue microarray, low tumor STK25 expression was associated with a lower histological tumor necrosis rate after neoadjuvant chemotherapy and shorter survival. Mechanistically, METTL3 overexpression reduced STK25 reporter activity and accelerated STK25 mRNA decay in an m6A-site-dependent manner. STK25 depletion was accompanied by reduced Hippo pathway activity, increased YAP nuclear localization, and increased GPX4 expression, whereas STK25 restoration increased LATS1 and YAP phosphorylation, reduced GPX4 expression and sensitized OS cells to ferroptosis. GPX4 re-expression partially rescued cell viability and oxidative-stress phenotypes induced by STK25 overexpression, supporting GPX4 as a functional downstream effector. In xenografts, STK25 overexpression significantly suppressed tumor growth and increased ferroptosis-associated changes. These findings support an METTL3-STK25-YAP-GPX4 regulatory model that links epitranscriptomic control to ferroptosis susceptibility in OS and warrants further preclinical and prospective clinical validation.
中文摘要:骨肉瘤(OS)是一种侵袭性骨恶性肿瘤,复发和转移性疾病结局较差。铁死亡是有前景的治疗策略,但其在骨肉瘤中的调控仍不完全清楚。本研究发现 STK25 是骨肉瘤铁死亡易感性和肿瘤生长的调节因子。对配对亲本和多药耐药骨肉瘤细胞系进行转录组分析,发现耐药衍生细胞中 STK25 表达较低。在一项回顾性组织芯片中,肿瘤 STK25 低表达与新辅助化疗后组织学肿瘤坏死率较低和生存期较短相关。机制上,METTL3 过表达以 m6A 位点依赖方式降低 STK25 报告基因活性并加速 STK25 mRNA 衰减。STK25 缺失伴随 Hippo 通路活性降低、YAP 核定位增加和 GPX4 表达升高,而 STK25 恢复则增加 LATS1 和 YAP 磷酸化,降低 GPX4 表达,并使骨肉瘤细胞对铁死亡敏感。GPX4 再表达部分挽救 STK25 过表达诱导的细胞活力和氧化应激表型,支持 GPX4 是功能性下游效应因子。在异种移植瘤中,STK25 过表达显著抑制肿瘤生长并增加铁死亡相关变化。这些发现支持 METTL3-STK25-YAP-GPX4 调控模型,将表观转录组控制与骨肉瘤铁死亡易感性联系起来,值得进一步开展临床前和前瞻性临床验证。
CCT2, a vital subunit of the chaperonin-containing TCP-1 (CCT) complex, has emerged as a critical regulator of protein homeostasis and cancer progression. In this study, we highlight the essential role of CCT2 in head and neck squamous cell carcinoma (HNSCC), where it is overexpressed and strongly associated with poor prognosis, advanced clinical stages, and aggressive tumor behavior. Mechanistically, CCT2 interacts with and stabilizes the oncogenic c-Myc protein to drive tumor cell proliferation, migration, and invasion. Furthermore, CCT2 contributes to cisplatin resistance by regulating c-Myc-dependent pathways and cell cycle-related proteins. Notably, apoptotic vesicles derived from drug-resistant tumor cells transfer CCT2 to neighboring cells, further enhancing chemoresistance. These findings position CCT2 as a key driver of HNSCC progression and c-Myc-mediated oncogenic pathways, presenting it as a promising therapeutic target for overcoming drug resistance and improving treatment outcomes in HNSCC patients.
中文摘要:CCT2 是含 TCP-1 的伴侣蛋白(CCT)复合体的重要亚基,已成为蛋白稳态与肿瘤进展的关键调控因子。本工作聚焦 CCT2 在头颈鳞状细胞癌(HNSCC)中的作用,其在肿瘤中表达上调,并与不良预后、较晚的临床分期及侵袭性肿瘤行为密切相关。机制上,CCT2 与致癌蛋白 c-Myc 相互作用并使其稳定,从而推动肿瘤细胞增殖、迁移与侵袭。CCT2 还通过调控 c-Myc 依赖的通路及细胞周期相关蛋白参与顺铂耐药。耐药肿瘤细胞来源的凋亡囊泡可将 CCT2 转移至邻近细胞,进一步增强化疗耐药。这些结果将 CCT2 定位为 HNSCC 进展及 c-Myc 介导致癌通路的关键驱动因子,也提示其作为克服耐药、改善 HNSCC 患者治疗结局的潜在治疗靶点。
Neuroendocrine carcinoma of the cervix (NECC) represents a highly aggressive cervical cancer subtype with a poorly characterized tumor immune microenvironment (TIME) and unclear oncogenic mechanisms. Herein, through scRNA-seq analysis, we identified neuronal progenitor cells (NPCs) exhibiting high expression of NECC markers (SYN/INSM1) as putative malignant cells, and delineated three distinct NPC states along their developmental trajectory. Notably, we observed extensive infiltration of both naïve and exhausted T cells, collaboratively shaping an immunosuppressive TIME. Cellular communication analysis discovered DLL3's interaction with NOTCH2 on NPCs and NOTCH1/2 on tumor-infiltrating lymphocytes, with spatial relationships validated by multicolor immunohistochemistry staining. Functional experiments demonstrated that DLL3 promoted tumor cell proliferation and invasion, whereas co-culture assays revealed that DLL3 contributed to T cell exhaustion and impaired T cell activation, collectively proving DLL3 as a central molecular hub coordinating both malignant progression and immunosuppression. Moreover, we verified heightened and specific DLL3 expression in NECC tissues through immunohistochemistry staining, underscoring DLL3 as a promising therapeutic target for NECC. Significantly, we not only innovatively established NECC-derived organoids replicating cellular morphology, neuroendocrine differentiation features, and genetic characteristics of parental tumors, but also co-cultured organoids with tumor-infiltrating lymphocytes to assess the therapeutic efficacy of AMG757 targeting DLL3. Remarkably, the combination of AMG757 targeting DLL3 with chemotherapy (etoposide + cisplatin) induced substantial T cell aggregation and activation and heightened immunogenic cell death, offering novel insights into NECC treatment. Overall, the study provides comprehensive insights into NECC TIME and tailored therapeutic approaches beyond traditional therapy for NECC.
中文摘要:宫颈神经内分泌癌(NECC)是侵袭性很强的宫颈癌亚型,其肿瘤免疫微环境(TIME)特征尚不清晰,致癌机制也未明确。通过单细胞RNA测序分析,鉴定出高表达NECC标志物SYN/INSM1的神经祖细胞(NPCs)为推定恶性细胞,并沿发育轨迹划分出三种不同的NPC状态。观察到初始T细胞与耗竭T细胞广泛浸润,共同塑造免疫抑制性TIME。细胞通讯分析发现DLL3与NPCs上的NOTCH2以及肿瘤浸润淋巴细胞上的NOTCH1/2存在相互作用,多重免疫组化染色验证了其空间关系。功能实验显示DLL3促进肿瘤细胞增殖和侵袭,共培养实验显示DLL3促进T细胞耗竭并削弱T细胞活化,共同证明DLL3是协调恶性进展与免疫抑制的核心分子枢纽。免疫组化染色验证NECC组织中DLL3表达升高且具有特异性,提示DLL3是NECC有前景的治疗靶点。研究创新性建立了NECC来源类器官,可复现亲本肿瘤的细胞形态、神经内分泌分化特征和遗传特征,并将类器官与肿瘤浸润淋巴细胞共培养,以评估靶向DLL3的AMG757的治疗疗效。靶向DLL3的AMG757联合化疗(依托泊苷+顺铂)可诱导明显的T细胞聚集与活化,并增强免疫原性细胞死亡,为NECC治疗提供新思路。该研究为NECC的TIME及超越传统治疗的个体化治疗策略提供了较全面的认识。
Chronic inorganic arsenic (iAs) exposure affects > 220 million people worldwide and skin cancer is a hallmark of long-term iAs exposure. Limited information exists regarding arsenic methylation by human keratinocytes and how methylation influences skin carcinogenesis. Inorganic arsenite (iAsIII) and its methylated metabolites disrupt diverse zinc finger proteins, leading to differential toxicity patterns. We examined arsenic methylation capacity in non-malignant human keratinocytes and interrogated proteomic remodeling across three stages of iAsIII induced malignant transformation using the well-established preclinical HaCaT model. Arsenic methylation was assessed by hydride generation cryotrapping inductively coupled-mass spectrometry and global proteomic changes were analyzed by tandem-mass tagging liquid chromatography-tandem mass spectrometry. Primary, hTERT-immortalized and HaCaT human keratinocytes exhibited negligible arsenic methylation, with iAsIII comprising at least 98.5% of total intracellular arsenic, attributable to minimal expression of arsenite methyltransferase. Proteomic profiling identified over 275 differentially expressed proteins at each stage of transformation, including multiple zinc finger proteins implicated in cell cycle control, RNA metabolism, and genome stability. Ingenuity® Pathway Analysis revealed progressive, coordinated disruption of cancer-associated pathways and regulatory networks over the transformation timeline, including zinc-coordinating upstream regulators that may explain widespread pathway dysregulation. Collectively, our findings suggest that iAsIII promotes skin carcinogenesis by disrupting C3H1- and C4-type zinc finger protein-centered regulatory networks that coordinate cancer-associated signaling and metabolic pathways in human keratinocytes, highlighting key candidates for future mechanistic studies.
中文摘要:慢性无机砷暴露影响全球超过2.2亿人,皮肤癌是长期无机砷暴露的标志性结局。人角质形成细胞对砷的甲基化能力及其对皮肤致癌过程的影响仍知之有限。无机亚砷酸盐(iAsIII)及其甲基化代谢物会干扰多种锌指蛋白,导致不同的毒性模式。研究检测了非恶性人角质形成细胞的砷甲基化能力,并利用成熟的临床前HaCaT模型,分析iAsIII诱导恶性转化三个阶段的蛋白质组重塑。砷甲基化采用氢化物发生-冷阱捕获-电感耦合等离子体质谱评估,全局蛋白质组变化采用串联质量标签液相色谱-串联质谱分析。原代、hTERT永生化及HaCaT人角质形成细胞的砷甲基化几乎检测不到,iAsIII占细胞内总砷至少98.5%,这与亚砷酸盐甲基转移酶表达极低有关。蛋白质组分析在每个转化阶段鉴定出超过275个差异表达蛋白,包括多种参与细胞周期控制、RNA代谢和基因组稳定性的锌指蛋白。Ingenuity通路分析显示,癌症相关通路和调控网络在转化时间线上呈进行性、协同性紊乱,其中包括锌配位上游调控因子,这可能解释广泛的通路失调。这些结果提示,iAsIII通过扰乱以C3H1型和C4型锌指蛋白为中心、协调癌症相关信号与代谢通路的调控网络,促进人角质形成细胞的皮肤致癌过程,并为后续机制研究提供了关键候选对象。
Wearable sensors show value in dynamic disease monitoring but face the challenge in efficiently detecting low-abundance biomarkers from trace skin interstitial fluid (ISF). Herein, we proposed an active microneedle sensor integrated with micromotors for highly sensitive, dynamic monitoring of trace tumor markers carcinoembryonic antigen (CEA) in ISF. The sensor employed a core-shell structured hydrogel microneedle array. The shell provided mechanical strength for minimally invasive skin penetration, while the water-soluble core dissolved upon contact with ISF, releasing self-propelled micromotors. These micromotors generated hydrogen bubbles that drove antibody-functionalized magnetic carriers, enhancing the capture efficiency of CEA and overcoming the limitations inherent in traditional passive diffusion modes. Following capture, the magnetic complexes bound with CEA were concentrated onto the surface of a screen-printed electrode, where quantitative detection was achieved by monitoring variations in the electrochemical current response. The in vivo results showed that the sensor could detect an early electrochemical response associated with tumor progression as early as day 2 after LLC-GFP-LUC cell inoculation, and the current signal showed a progressive decline with tumor development. By day 5, a significant increase in CEA concentration was measured by ELISA, while tumor volume remained undetectable by conventional physical methods. This micromotor-integrated sensor can provide early detection signals within a time window where traditional methods are unable to detect, offering a promising minimally invasive tool for monitoring tumor progression and evaluating treatment efficacy.
中文摘要:可穿戴传感器在疾病动态监测中具有价值,但如何从微量皮肤间质液中高效检测低丰度生物标志物仍面临挑战。为此,我们提出一种集成微电机的主动式微针传感器,用于高灵敏、动态监测间质液中的微量肿瘤标志物癌胚抗原(CEA)。该传感器采用核壳结构水凝胶微针阵列。壳层为微创皮肤穿刺提供机械强度,水溶性核心在接触间质液后溶解并释放自驱动微电机。这些微电机产生氢气泡,驱动抗体功能化磁性载体,提高CEA捕获效率,克服传统被动扩散模式的固有局限。捕获后,与CEA结合的磁性复合物被富集到丝网印刷电极表面,通过监测电化学电流响应变化实现定量检测。体内结果显示,该传感器最早可在LLC-GFP-LUC细胞接种后第2天检测到与肿瘤进展相关的早期电化学响应,电流信号随肿瘤发展呈逐步下降。至第5天,ELISA测得CEA浓度显著升高,而传统物理方法仍无法检测到肿瘤体积。这种集成微电机的传感器可在传统方法无法检测的时间窗内提供早期检测信号,为监测肿瘤进展和评估治疗效果提供有前景的微创工具。
DNA methylation, particularly 5-methylcytosine (5 mC), is a key epigenetic modification involved in the regulation of gene expression and genomic stability, and has emerged as a promising biomarker for early cancer screening and molecular stratification. CRISPR-Cas12a systems have been increasingly exploited to convert methylation-associated sequence information into detectable signals owing to their programmability and collateral cleavage-mediated signal amplification. However, many CRISPR-based assays remain constrained by the high background and relatively slow response kinetics of conventional fluorophore-quencher reporters. To overcome these limitations, we developed a cleavage-responsive DNA-templated silver nanocluster (DNA/AgNC) reporter that translates Cas12a trans-cleavage activity into a green-to-red ratiometric fluorescence shift. In this design, the AgNC-templating DNA scaffold itself serves as an enzymatically cleavable signal transducer, rather than relying on a terminal fluorophore-quencher pair. Compared with a representative F-ssDNA-Q reporter, the DNA/AgNC reporter exhibited stronger apparent association with Cas12a and an approximately two-fold improvement in apparent catalytic efficiency. When incorporated into an MSRE-RPA-Cas12a workflow, the platform achieved a limit of detection of 74.5 aM, while completing the Cas12a reporting step within 30 min. Coupling this assay with a miniaturized optoelectronic device further enabled spatially resolved profiling of five genomic loci, with relative errors of approximately 5%. Overall, this strategy establishes a ratiometric reporter format for CRISPR-based DNA methylation profiling and offers potential for point-of-care epigenetic biosensing.
中文摘要:DNA甲基化,尤其是5-甲基胞嘧啶(5 mC),是参与基因表达调控与基因组稳定性维持的重要表观遗传修饰,已成为早期癌症筛查与分子分层中有前景的生物标志物。CRISPR-Cas12a系统具有可编程性与附带切割介导的信号放大能力,被越来越多地用于把甲基化相关序列信息转化为可检测信号。但许多基于CRISPR的检测仍受常规荧光基团-淬灭基团报告探针背景高、响应动力学较慢的限制。为克服这些限制,作者构建了一种切割响应型DNA模板银纳米簇(DNA/AgNC)报告探针,可将Cas12a的反式切割活性转化为绿到红的比率型荧光变化。该设计中,充当AgNC模板的DNA骨架本身即为可被酶切切的信号转换元件,不依赖末端荧光基团-淬灭基团对。与代表性的F-ssDNA-Q报告探针相比,DNA/AgNC报告探针与Cas12a的表观结合更强,表观催化效率提升约两倍。将其整合进MSRE-RPA-Cas12a流程后,平台检出限为74.5 aM,Cas12a报告步骤可在30分钟内完成。该检测与小型化光电装置联用,还可对五个基因组位点进行空间分辨的谱型分析,相对误差约为5%。该策略为基于CRISPR的DNA甲基化谱型分析建立了比率型报告探针形式,并有望用于床旁表观遗传生物传感。
Exosomes derived from bone marrow mesenchymal stem cells (BMSCs) represent a promising cell-free strategy for intervertebral disc degeneration (IDD). Here, we obtained oxidative stress-preconditioned exosomes (O-Exos) from BMSCs exposed to low-concentration hydrogen peroxide. Compared with exosomes from untreated cells (N-Exos), O-Exos more effectively delayed nucleus pulposus (NP) cell senescence and attenuated IDD in vitro and in vivo. The superior effects of O-Exos were associated with restoration of mitophagy and improved mitochondrial homeostasis in TNF/TNF-α-treated NP cells. BMF (Bcl2 modifying factor) was identified as a functionally relevant downstream target suppressed by O-Exos, and Bmf deficiency promoted mitophagy and alleviated IDD. Further analyses showed that O-Exos relieved the inhibitory effect of BMF on BCL2L13-LC3B coupling, thereby restoring mitophagy. In addition, exosomal Mir29a-3p was required for BMF suppression and the superior activity of O-Exos. Together, these findings identify oxidative stress preconditioning as an effective strategy to enhance exosome potency against IDD.Abbreviations: ACAN: aggrecan; BCL2L13: BCL2 like 13; BMF: Bcl2 modifying factor; BMSCs: bone marrow mesenchymal stem cells; BNIP3: BCL2 interacting protein 3; CDKN1A: cyclin dependent kinase inhibitor 1A; CDKN2A: cyclin dependent kinase inhibitor 2A; COL2A1: collagen type II alpha 1 chain; DHI: disc height index; FUNDC1: FUN14 domain containing 1; H2O2: hydrogen peroxide; IDD: intervertebral disc degeneration; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MMP3: matrix metallopeptidase 3; MRI: nuclear magnetic resonance imaging; N-Exos: exosomes derived from untreated BMSCs; NP: nucleus pulposus; O-Exos: exosomes derived from H2O2-preconditioned BMSCs; OCR: oxygen consumption rate; PINK1: PTEN induced kinase 1; PRKN: parkin RBR E3 ubiquitin protein ligase; ROS: reactive oxygen species; RT-qPCR: reverse transcription quantitative polymerase chain reaction; SA-GLB1/β-gal: senescence-associated galactosidase beta 1; TEM: transmission electron microscopy; TNF/TNF-alpha: tumor necrosis factor; TOMM20: translocase of outer mitochondrial membrane 20; TP53: tumor protein p53; WT: wild type.
中文摘要:来自骨髓间充质干细胞(BMSCs)的外泌体是治疗椎间盘退变(IDD)的有前景的无细胞策略。本研究用低浓度过氧化氢处理BMSCs,获得氧化应激预处理外泌体(O-Exos)。与未处理细胞来源外泌体(N-Exos)相比,O-Exos在体外和体内更有效延缓髓核(NP)细胞衰老并减轻IDD。O-Exos的优越效应与恢复TNF/TNF-α处理NP细胞中的线粒体自噬、改善线粒体稳态相关。BMF被鉴定为O-Exos抑制的功能相关下游靶点,Bmf缺失促进线粒体自噬并减轻IDD。进一步分析显示,O-Exos缓解BMF对BCL2L13-LC3B偶联的抑制作用,从而恢复线粒体自噬。外泌体Mir29a-3p是BMF抑制和O-Exos优越活性所必需的。这些发现确定氧化应激预处理是增强外泌体抗IDD效力的有效策略。
Paternal pre-conceptual exposure to pathogenic infection can alter offspring phenotypes via changes to sperm epigenetics, including small non-coding RNAs (ncRNAs). This phenomenon occurs even in the absence of infection when pathogen mimetics trigger paternal immune activation (PIA). While this implicates a shared component of the immune response, the specific mechanisms responsible remain unknown. Cytokines are a key component of innate immunity and are highly upregulated following exposure to both pathogens and their mimetics. Here we investigate whether paternal administration of the pro-inflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) recapitulates alterations to sperm small ncRNAs and offspring phenotypic changes from other models of PIA. C57BL/6J male mice were administered a single dose of IL-1β, TNF-α, or vehicle, prior to mating with naïve female mice, to produce offspring. Offspring from IL-1β-treated fathers exhibited altered fasting responses and female-specific alterations to stress-coping behavior. In response to paternal TNF-α, male offspring showed increased anxiety-like behavior. Analysis of paternal sperm small ncRNA revealed that IL-1β significantly downregulated several transfer RNA-derived small RNAs (tsRNAs) and P-element-induced wimpy testis (PIWI)-interacting RNA (piRNA) clusters. Surprisingly, paternal TNF-α only slightly altered small ncRNAs, downregulating a single piRNA cluster. These results partially recapitulate offspring phenotypic changes following paternal exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, in a COVID-19 mouse model) and polyinosinic:polycytidylic acid (poly I:C, a viral mimetic). Ultimately, we provide the first evidence that cytokines have intergenerational effects on brain and behavior, and that they contribute to altered offspring phenotypes in viral-like PIA. This study demonstrates that paternal cytokines are causally involved in a mechanism of epigenetic inheritance following PIA, and highlights the importance of PIA as a pre-conceptual factor that may modulate offspring health, including risk of neuropsychiatric disorders.
中文摘要:父代在受孕前的病原体感染暴露,可通过改变精子表观遗传(包括小非编码RNA)影响子代表型。即使没有实际感染,只要病原体类似物触发父代免疫激活(PIA)也会出现这一现象。这提示免疫反应中存在共同成分,但具体机制仍不清楚。细胞因子是天然免疫的关键组分,在接触病原体及其类似物后高度上调。本研究考察父代给予促炎细胞因子白细胞介素-1β(IL-1β)与肿瘤坏死因子-α(TNF-α)能否重现其他PIA模型中所见的精子小非编码RNA改变与子代表型变化。C57BL/6J雄鼠在与未接触过处理的雌鼠交配前接受单剂IL-1β、TNF-α或溶剂对照,以产生子代。IL-1β处理雄鼠的子代出现空腹反应改变,雌性子代还出现应激应对行为的改变。父代接受TNF-α后,雄性子代焦虑样行为增加。父代精子小非编码RNA分析显示,IL-1β显著下调若干转运RNA衍生小RNA(tsRNA)及P元件诱导的wimpy testis(PIWI)互作RNA(piRNA)簇。TNF-α对精子小非编码RNA影响很小,仅下调一个piRNA簇。这些结果部分重现了父代暴露于严重急性呼吸综合征冠状病毒2(SARS-CoV-2,COVID-19小鼠模型)及聚肌苷酸-聚胞苷酸(poly I:C,一种病毒类似物)后子代的表型变化。研究首次提供证据表明细胞因子对脑与行为具有跨代影响,并参与病毒样PIA所致子代表型改变。该研究说明父代细胞因子因果性参与PIA后的表观遗传传代机制,并凸显PIA作为受孕前因素可能调节子代健康(包括神经精神障碍风险)的重要性。
Therapy resistance remains a central barrier to durable clinical benefit across cancer types, limiting the long-term efficacy of chemotherapy, targeted therapies, and immunotherapy. Although genetic alterations contribute to resistance, increasing evidence indicates that epigenetic regulation and non-genetic cellular plasticity are primary drivers of drug-tolerant and relapse-initiating states. In this review, we propose a multi-layered framework in which chromatin-level regulation, RNA-mediated control, and higher-order genome organization collectively reprogram transcriptional landscapes, enable lineage and phenotypic plasticity, and sustain persister cell populations under therapeutic pressure. This integrative perspective moves beyond cataloging individual mechanisms to highlight how coordinated epigenetic networks drive adaptive resistance. We further summarize recent translational advances in epigenetic therapies, including inhibitors targeting DNA methyltransferases, histone deacetylases, histone and RNA methyltransferases, and chromatin readers, with an emphasis on rational combination strategies designed to restore drug sensitivity and delay resistance acquisition. Finally, we discuss key challenges, including distinguishing causal from passenger epigenetic alterations, managing on-target and off-target toxicities, and developing robust predictive biomarkers. We also outline future directions, including single-cell and spatial multi-omics-guided precision medicine, real-time tracking of epigenetic state transitions, and adaptive, mechanism-informed combination strategies aimed at constraining cellular plasticity and preventing resistance evolution.
中文摘要:治疗耐药仍是多种癌症获得持久临床获益的核心障碍,限制了化疗、靶向治疗和免疫治疗的长期疗效。遗传改变参与耐药,但越来越多证据表明,表观遗传调控和非遗传性细胞可塑性是药物耐受状态和复发起始状态的主要驱动因素。本综述提出一个多层框架:染色质水平调控、RNA介导的控制和高级基因组组织共同重编程转录景观,促成谱系与表型可塑性,并在治疗压力下维持持留细胞群体。这一整合视角不止于罗列单一机制,而是强调协同的表观遗传网络如何驱动适应性耐药。文章进一步总结表观遗传治疗的最新转化进展,包括靶向DNA甲基转移酶、组蛋白去乙酰化酶、组蛋白和RNA甲基转移酶以及染色质阅读器的抑制剂,重点讨论旨在恢复药物敏感性并延缓耐药获得的理性联合策略。最后讨论关键挑战,包括区分因果性表观遗传改变与伴随性改变、管理在靶和脱靶毒性、开发稳健的预测性生物标志物,并展望未来方向,包括单细胞和空间多组学引导的精准医学、表观遗传状态转变的实时追踪,以及以限制细胞可塑性、阻止耐药演化为目标的适应性、机制导向联合策略。
Exosomes serve as stable liquid-biopsy biomarkers for early cancer detection due to their molecular resemblance to parent cells. Here, a magnetic enrichment-assisted surface plasmon resonance (SPR) assay is developed based on Zr/Ce-MOF@Fe3O4 core-satellite nanocomposites for sensitive exosome analysis. The Zr/Ce-MOF is constructed with Zr as the metal node and doped with Ce, exhibiting intrinsic oxidase-like activity through the Ce3+/Ce4+ redox cycle. It catalyzes the oxidation of 3,3',5,5'-tetramethylbenzidine without exogenous H2O2, generating a high-refractive-index precipitate that significantly amplifies the SPR signal. The Zr-O-P coordination enables selective capture of phospholipid membranes on exosomes, while Fe3O4 satellites facilitate rapid magnetic enrichment and separation. To further improve specificity and antifouling performance, single-walled carbon nanotube interlayers pre-functionalized with PD-L1 targeting peptides were integrated onto the sensor chip, enabling selective recognition of magnetically enriched PD-L1+ exosomes. The combined refractive-index increase from the nanocomposite and the TMB deposition leads to enhanced SPR responses. Under optimized conditions, the assay achieves a detection limit of 2.16 particles mL-1 (S/N = 3) over a linear range of 102-107 particles mL-1. The total analysis time is within 40 min, and the method shows consistent differentiation between serum samples from cancer patients and healthy donors. This approach provides a practical strategy for the analysis of low abundance exosomal biomarkers.
中文摘要:外泌体因分子特征与亲代细胞相似,可作为稳定的液体活检标志物用于癌症早期检测。本研究构建了基于Zr/Ce-MOF@Fe3O4核-卫星纳米复合物的磁富集辅助表面等离子体共振(SPR)分析方法,用于灵敏检测外泌体。Zr/Ce-MOF以Zr为金属节点并掺杂Ce,通过Ce3+/Ce4+氧化还原循环表现出内在的类氧化酶活性,可在不外加H2O2的情况下催化3,3',5,5'-四甲基联苯胺氧化,生成高折射率沉淀并显著放大SPR信号。Zr-O-P配位使材料能够选择性捕获外泌体上的磷脂膜,Fe3O4卫星结构有助于快速磁富集与分离。为提高特异性和抗污染性能,传感器芯片引入经PD-L1靶向肽预功能化的单壁碳纳米管夹层,可选择性识别磁富集后的PD-L1+外泌体。纳米复合物带来的折射率升高与TMB沉积共同增强SPR响应。优化条件下,该方法在10^2-10^7 particles mL^-1线性范围内检测限为2.16 particles mL^-1(S/N=3),总分析时间在40 min以内,并能一致区分癌症患者与健康供者血清样本。该策略为低丰度外泌体标志物分析提供了实用方法。
Pyruvate kinase M2 (PKM2) serves as a crucial metabolic biomarker for tumor progression; however, distinguishing PKM2 from its highly homologous isoform PKM1 and dynamically monitoring its oligomeric state in living systems remain formidable challenges. Herein, we present two novel near-infrared (NIR) fluorescent probes, YL1 and YL2, designed by conjugating the PKM2-specific allosteric activator TEPP-46 with a green fluorescent protein (GFP)-chromophore-derived molecular rotor. Operating through a twisted intramolecular charge transfer (TICT) mechanism, these probes exhibit a highly sensitive "turn-on" NIR fluorescence response upon specific binding within the hydrophobic allosteric pocket of PKM2, which restricts their intramolecular rotation. Both probes demonstrate exceptional isoform selectivity over PKM1 and various biological interferents, boasting low detection limits (180 nM for YL1 and 210 nM for YL2) alongside ultra-fast, second-scale binding kinetics. Significantly, YL1 and YL2 function as potent fluorogenic agonists, effectively promoting the allosteric re-assembly of tumor-associated, inactive PKM2 dimers into active tetramers, thereby restoring pyruvate kinase activity. In live-cell imaging, the probes selectively illuminate PKM2-overexpressing cancer cells (HeLa, A549, and 4T1) with high contrast while remaining virtually silent in normal cells (HK-2, MCF-10A). Furthermore, their integration with flow cytometry facilitates rapid, quantitative, and high-throughput screening of malignant cell populations. Finally, in vivo imaging successfully visualizes tumor lesions in mouse models with high signal-to-noise ratios and deep tissue penetration. This multifunctional probe platform seamlessly integrates precision imaging, enzyme activation, and high-throughput cytometric screening, offering a powerful theranostic strategy for tracking metabolic reprogramming and facilitating early cancer diagnosis.
中文摘要:丙酮酸激酶M2(PKM2)是肿瘤进展的重要代谢生物标志物,但将其与高度同源的PKM1亚型区分,并在活体系统中动态监测其寡聚状态仍十分困难。为此,研究设计了两类新型近红外荧光探针YL1和YL2,将PKM2特异性变构激活剂TEPP-46与绿色荧光蛋白发色团衍生的分子转子偶联。探针通过扭曲分子内电荷转移机制工作,在特异性结合PKM2疏水变构口袋后限制分子内旋转,产生高灵敏的开启型近红外荧光响应。两种探针对PKM1及多种生物干扰物均表现出优异的亚型选择性,检测限低(YL1为180 nM,YL2为210 nM),结合动力学达到秒级且速度极快。YL1和YL2还可作为有效的荧光激动剂,促使肿瘤相关失活PKM2二聚体发生变构重组装为活性四聚体,从而恢复丙酮酸激酶活性。在活细胞成像中,探针以高对比度选择性点亮PKM2高表达的癌细胞(HeLa、A549和4T1),而在正常细胞(HK-2、MCF-10A)中几乎无信号。将其与流式细胞术结合,可快速、定量、高通量筛选恶性细胞群。在体内成像中,探针在小鼠模型中成功显示肿瘤病灶,具有高信噪比和深部组织穿透能力。该多功能探针平台将精准成像、酶激活与高通量细胞术筛选整合在一起,为追踪代谢重编程和推动癌症早期诊断提供了有力的诊疗策略。
Organoids have become mainstay tools for drug discovery and personalized medicine. High-throughput imaging readouts for drug screening of tumor organoids are of particular interest as organoid-level quantification of responses provides insights into heterogeneity, which is relevant for predicting therapeutic efficacy and anticipating emergence of resistance. However, screening extracellular matrix (ECM)-embedded organoids remains technically challenging. Standard methods with manual cell seeding in thick ECM constructs impede imaging efficiency, whereas bulk endpoint assays are easy to implement but fail to resolve single-organoid-level drug response data. Here we present a protocol to bioprint cells within a temperature-sensitive ECM in thin, flat, square-shaped patterns in 96-well plates to establish three-dimensional (3D) cultures for efficient, high-throughput, time-resolved quantitative phase imaging at single-organoid resolution. Quantitative phase imaging of 3D-bioprinted organoids using high-speed live cell interferometry coupled with machine learning analyses enables label-free quantification of biomass, growth kinetics and drug response profiles of thousands of individual organoids per experiment. We demonstrate that the protocol can be leveraged to automatically generate plates containing thousands of organoids for high-throughput imaging and drug screening experiments, quantify growth and drug response heterogeneity, resolve rare phenotypes and identify predictive features of drug response profiles for fundamental studies and therapeutic decision-making. This protocol can be completed in 2 weeks or less and can be adapted to organoids derived from a variety of cell sources and to alternative screening paradigms. The protocol requires familiarity with coding and experience with 3D cell culture, optical assembly and software installation.
中文摘要:类器官已成为药物发现和个性化医疗的主要工具。肿瘤类器官药物筛选的高通量成像读出尤其受关注,因为类器官水平的反应定量可揭示异质性,这对于预测治疗疗效和预判耐药出现具有意义。然而,对包埋于细胞外基质(ECM)中的类器官进行筛选在技术上仍具挑战。采用人工接种细胞于厚ECM构建物中的标准方法会阻碍成像效率,而批量终点检测易于实施却无法解析单类器官水平的药物反应数据。这里介绍一种方案:在96孔板内将细胞生物打印于温度敏感型ECM中,形成薄、平、方形的图案,建立三维(3D)培养,从而以单类器官分辨率进行高效、高通量、时间分辨的定量相位成像。利用高速活细胞干涉测量结合机器学习分析对3D生物打印类器官进行定量相位成像,可在每次实验中无标记地定量数千个独立类器官的生物量、生长动力学和药物反应谱。我们证明该方案可用于自动生成包含数千个类器官的孔板,用于高通量成像和药物筛选实验,定量生长和药物反应异质性,分辨稀有表型,并识别药物反应谱的预测特征,服务于基础研究和治疗决策。该方案可在2周或更短时间内完成,并可适配来自多种细胞来源的类器官及替代筛选范式。方案要求熟悉编程,并具备3D细胞培养、光学组装和软件安装经验。
In 2025, the U.S. Food and Drug Administration (FDA) continued to advance therapeutic innovation by approving a diverse range of novel drugs. According to the FDA's 2025 Novel Drug Approvals list, 46 new drugs received approval, including both new chemical entities such as Ziftomenib, Sevabertinib, Zoliflodacin, and Gepotidacin, as well as new biologics. These approvals cover a wide range of therapeutic areas, including oncology, rare genetic diseases, infectious diseases, cardiovascular diseases, and immunomodulation. A significant proportion of the approved products navigated accelerated or priority review pathways, reflecting their potential impact on unmet medical needs. This review provides a comprehensive overview of the synthetic routes and clinical applications of FDA-approved small-molecule drugs in 2025, aiming to inspire future development in drug discovery.
中文摘要:2025年,美国食品药品监督管理局(FDA)持续推动治疗创新,批准了多种新药。根据FDA的2025年新药批准清单,共有46种新药获批,包括Ziftomenib、Sevabertinib、Zoliflodacin和Gepotidacin等新化学实体,也包括新生物制品。这些批准覆盖肿瘤、罕见遗传病、感染性疾病、心血管疾病和免疫调节等多个治疗领域。获批产品中有相当比例通过加速审评或优先审评通道,反映出其对未满足医疗需求的潜在影响。本综述全面概述2025年FDA批准的小分子药物的合成路线与临床应用,旨在为药物发现领域的后续开发提供启发。
Metabolic reprogramming, particularly enhanced lipid anabolism, is a hallmark of oral squamous cell carcinoma (OSCC), yet effective therapies targeting this process remain lacking. Here, we identify concurrent activation of acetyl-CoA synthetase 2 (ACSS2) and ATP-citrate lyase (ACLY) as a cooperative metabolic driver of OSCC progression. Whereas previous efforts have focused on single-enzyme inhibition, we show that ACSS2 and ACLY form a compensatory network that sustains lipid anabolism and drives OSCC progression, providing a rationale for their dual inhibition. Integrative transcriptomic and lipidomic analyses reveal a metabolically aggressive OSCC subset defined by concurrent ACSS2 and ACLY upregulation, which was associated with poor clinical outcomes. Dual inhibition of ACSS2 and ACLY depleted acetyl-CoA, suppressed lipogenesis, and impaired tumor growth in vitro and in vivo. We further identified S8588, a quinoxaline-based small molecule, as a dual-target degrader that induces ubiquitin-proteasome-dependent degradation of both ACSS2 and ACLY, thereby blocking OSCC proliferation. Mechanistically, S8588 directly binds key residues of both enzymes, promoting their proteasomal turnover. Supplementation with acetate and citrate reverses its anti-tumor effect, confirming acetyl-CoA depletion as the primary mechanism. Collectively, our findings establish ACSS2/ACLY co-activation as a therapeutic vulnerability in OSCC and nominate S8588 as a promising dual-target therapeutic to dismantle metabolic adaptability for improved treatment.
中文摘要:代谢重编程,尤其脂质合成增强,是口腔鳞状细胞癌(OSCC)的标志,但针对这一过程的有效治疗仍缺乏。研究识别乙酰辅酶A合成酶2(ACSS2)与ATP-柠檬酸裂解酶(ACLY)同时激活是OSCC进展的协同代谢驱动因素。既往工作多聚焦单酶抑制,本研究表明ACSS2和ACLY形成补偿网络,维持脂质合成并推动OSCC进展,为双重抑制提供依据。整合转录组和脂质组分析揭示一个以ACSS2和ACLY同时上调为特征的代谢侵袭性OSCC亚群,与不良临床结局相关。双重抑制ACSS2和ACLY耗竭乙酰辅酶A,抑制脂质合成,并在体外和体内削弱肿瘤生长。进一步鉴定S8588,一种基于喹喔啉的小分子,作为双靶点降解剂,诱导ACSS2和ACLY经泛素-蛋白酶体依赖性降解,从而阻断OSCC增殖。机制上,S8588直接结合两种酶的关键残基,促进其蛋白酶体周转。补充乙酸盐和柠檬酸盐可逆转其抗肿瘤作用,证实乙酰辅酶A耗竭是主要机制。总体,这些发现确立ACSS2/ACLY共激活是OSCC的治疗脆弱点,并提示S8588是有前景的双靶点治疗药物,可破坏代谢适应性以改善治疗。
Radiotherapy combined with immunotherapy has emerged as a promising therapeutic strategy across multiple cancer types. However, despite encouraging findings from selected clinical trials, most radioimmunotherapy studies have shown only limited or even negative results, highlighting important biological barriers that limit therapeutic efficacy. Accumulating evidence suggests that radiotherapy induces phenotypic and functional changes in immune cells that resemble key features of age-related immunosenescence, including thymic involution, persistent low-grade inflammation, impaired immune reconstitution, and the accumulation of senescent cells. In this review, we systematically characterize this radiation-induced immunosenescence and distinguish it from physiological immunosenescence. We further introduce the concept of "radiation-induced immunosenescence mimicry," which we propose that this mimicry may represent a critical and previously underappreciated obstacle limiting the efficacy of current radioimmunotherapy. We summarize current evidence describing the impact of radiotherapy on immunosenescence and propose a stratification framework based on baseline immune reserve, radiation field and dose, lymphoid organ exposure, and other clinically relevant variables. Building on this framework, we discuss emerging strategies designed to target radiation-induced immunosenescence mimicry in combination with immunotherapy, together with relevant clinical investigations. Finally, we propose personalized diagnostic and therapeutic approaches for the future clinical integration of radiotherapy and immunotherapy, with the aim of overcoming the current dilemma of combined radioimmunotherapy and improving patient outcomes.
中文摘要:放疗联合免疫治疗已成为跨多种癌种的有前景的治疗策略。然而,尽管部分临床试验结果令人鼓舞,多数放疗免疫治疗研究仅显示有限甚至阴性结果,提示存在限制疗效的重要生物学屏障。越来越多证据表明,放疗可引起免疫细胞表型和功能改变,这些改变类似年龄相关免疫衰老的关键特征,包括胸腺退化、持续性低度炎症、免疫重建受损以及衰老细胞积累。我们系统描述这种放疗诱导的免疫衰老,并将其与生理性免疫衰老区分。我们进一步提出「放疗诱导的免疫衰老拟态」概念,认为这种拟态可能是限制当前放疗免疫治疗疗效的关键且此前未被充分认识的障碍。我们总结描述放疗对免疫衰老影响的现有证据,并提出基于基线免疫储备、照射野与剂量、淋巴器官暴露及其他临床相关变量的分层框架。在此框架基础上,讨论针对放疗诱导免疫衰老拟态并与免疫治疗联合的新兴策略及相关临床研究。最后,我们提出未来临床整合放疗与免疫治疗的个体化诊断和治疗路径,以期克服当前放疗免疫治疗联合的困境并改善患者结局。
Aberrant glycolysis and lactate accumulation are hallmarks of solid tumors, yet how tumor-derived lactate contributes to tumor progression has not been fully defined. This study intends to examine the role of glycolysis in lung adenocarcinoma (LUAD) growth and immunosuppression, and to explore the underpinning mechanisms. Syngeneic Lewis lung carcinoma models and autochthonous KrasLSL-G12D LUAD mice were used. Glycolysis was inhibited by 2-DG or LDH knockdown, followed by tumor growth and immune-cell composition assessments. Therapeutic anti-IL-35 blockade and CD8+ T depletion were performed using neutralizing antibodies. Chitinase 3-like 1 (CHI3L1) expression, regulatory B cell (Breg) polarization, and B-cell-mediated T-cell suppression were assessed by flow cytometry, RNA sequencing, qPCR, ELISA, immunohistochemistry, and co-culture assays. CUT&Tag, chromatin immunoprecipitation, co-immunoprecipitation, and cell-free transferase assays were used to define the lactylation mechanism. Glycolysis restriction suppressed tumor growth and metastatic colonization, reduced CD1dhiCD5+IL-35+ Bregs, and restored GZMB+CD8+ T cells. CHI3L1 was markedly downregulated after glycolysis inhibition, whereas recombinant CHI3L1 restored IL-13Rα2+ Breg polarization and impaired CD8+ T-cell responses through STAT3 activation. Lactate increased H3K9 lactylation and CHI3L1 expression, while glycolysis inhibition reduced H3K9la enrichment at the Chi3l1 promoter. HBO1 directly catalyzed H3K9 lactylation and promoted CHI3L1 production. Genetic or pharmacological HBO1 blockade reduced Bregs, enhanced cytotoxic T-cell activity, and improved the efficacy of anti-PD-1 therapy. This study demonstrates the participation of an HBO1-H3K9la-CHI3L1–IL-13Rα2-STAT3 axis in tumor glycolysis-established Breg polarization and CD8+ T dysfunction. Targeting HBO1 may provide a strategy to enhance the efficacy of PD-1 blockade in LUAD.
中文摘要:实体瘤的特征是糖酵解异常和乳酸蓄积,但肿瘤来源的乳酸如何推动肿瘤进展仍未完全明确。本工作考察糖酵解在肺腺癌(LUAD)生长与免疫抑制中的作用及其机制。研究采用同基因Lewis肺癌模型与自发KrasLSL-G12D LUAD小鼠,以2-DG或敲低LDH抑制糖酵解,随后评估肿瘤生长和免疫细胞组成;用中和抗体进行抗IL-35阻断与CD8+ T细胞清除;通过流式细胞术、RNA测序、qPCR、ELISA、免疫组化及共培养实验检测CHI3L1表达、调节性B细胞(Breg)极化与B细胞介导的T细胞抑制;用CUT&Tag、染色质免疫沉淀、免疫共沉淀及无细胞转移酶实验明确乳酸化机制。限制糖酵解可抑制肿瘤生长与转移定植,减少CD1dhiCD5+IL-35+ Breg,并恢复GZMB+CD8+ T细胞。糖酵解抑制后CHI3L1明显下调,而重组CHI3L1经STAT3激活重建IL-13Rα2+ Breg极化并削弱CD8+ T细胞应答。乳酸增加H3K9乳酸化与CHI3L1表达,糖酵解抑制则降低Chi3l1启动子处H3K9la富集。HBO1直接催化H3K9乳酸化并促进CHI3L1产生。遗传或药物阻断HBO1可减少Breg、增强细胞毒性T细胞活性,并提升抗PD-1治疗的疗效。上述结果提示HBO1-H3K9la-CHI3L1–IL-13Rα2-STAT3轴参与肿瘤糖酵解所建立的Breg极化与CD8+ T细胞功能障碍,靶向HBO1或可成为增强LUAD中PD-1阻断疗效的策略。
Tumor-associated macrophages (TAMs) are critical drivers in melanoma growth and metastasis orchestrating complex cellular interactions within the tumor microenvironment (TME). While the RNA-binding protein heterogeneous nuclear ribonucleoprotein C1/C2 (hnRNP C) has been linked to melanoma progression and immune evasion, its specific role in macrophage-tumor communication and TME remodeling remains poorly understood. Multiple publicly available melanoma datasets (TCGA-SKCM, GSE8401, GSE46517, and single-cell RNA sequencing) were analyzed to map hnRNP C-associated signaling pathways, and macrophage-tumor interactions. Ligand-receptor cell communication analysis was used to characterize networks within the TME. Functional studies were conducted in melanoma cell lines (Buf1379, Buf1402, Buf836) following siRNA-mediated hnRNP C knockdown using wound healing and trans-well assays to assess cell migration and invasion. Macrophage-tumor interactions were comprehensively studied via trans-well co-culture models, flow cytometry, cytokine profiling, and recombinant CXCL10 stimulation assays. Protein-level validation and clinical relevance were assessed using multicohort datasets and immunohistochemistry. Elevated hnRNP C expression significantly enhanced melanoma cell migration, invasion, and epithelial-mesenchymal transition (EMT)-associated programs. Mechanistically, hnRNP C-high melanoma cells secreted increased levels of the macrophage migration inhibitory factor (MIF), which reprogrammed macrophages toward an interferon-associated TAM (IFN-TAM) phenotype. Moreover, CXCL10 via CXCR3 activation upregulated hnRNP C expression in melanoma cells establishing a bidirectional feedback loop. Single-cell transcriptomic analyses confirmed enriched MIF-mediated signaling between macrophages and melanoma cells. Spatially, this macrophage-derived CXCL10/CXCR3-hnRNP C-MIF signaling axis promoted macrophage remodeling and drove metastatic tumor states. A three-gene prognostic signature (hnRNP C-MIF-CXCR3) showed robust predictive performance across independent melanoma cohorts and strongly correlated with tumor stage, metastatic status, and overall survival. Protein-level validation confirmed elevated hnRNP C and MIF expression in melanoma tissues compared with normal skin. This study identifies a novel macrophage-tumor signaling circuit in melanoma, wherein CXCL10/CXCR3-driven hnRNP C activation promotes MIF-mediated macrophage reprogramming and subsequent metastatic progression. The identified three-gene signature provides a clinically relevant prognostic biomarker and highlights hnRNP C as a promising therapeutic target for disrupting macrophage-driven tumor progression.
中文摘要:肿瘤相关巨噬细胞(TAMs)是黑色素瘤生长和转移的重要驱动因素,在肿瘤微环境(TME)内协调复杂的细胞相互作用。RNA结合蛋白异质核核糖核蛋白C1/C2(hnRNP C)与黑色素瘤进展和免疫逃逸相关,但其在巨噬细胞-肿瘤细胞通讯及TME重塑中的具体作用仍不清楚。分析多个公开黑色素瘤数据集(TCGA-SKCM、GSE8401、GSE46517及单细胞RNA测序),以绘制hnRNP C相关信号通路和巨噬细胞-肿瘤相互作用;采用配体-受体细胞通讯分析刻画TME内网络。在黑色素瘤细胞系(Buf1379、Buf1402、Buf836)中经siRNA介导hnRNP C敲低后,用划痕愈合和Transwell实验评估细胞迁移与侵袭。通过Transwell共培养模型、流式细胞术、细胞因子谱分析和重组CXCL10刺激实验系统研究巨噬细胞-肿瘤相互作用。使用多队列数据集和免疫组化评估蛋白水平验证及临床相关性。hnRNP C表达升高显著增强黑色素瘤细胞迁移、侵袭及上皮-间质转化(EMT)相关程序。机制上,hnRNP C高表达黑色素瘤细胞分泌更多巨噬细胞移动抑制因子(MIF),将巨噬细胞重编程为干扰素相关TAM(IFN-TAM)表型。CXCL10经CXCR3激活上调黑色素瘤细胞hnRNP C表达,形成双向反馈环路。单细胞转录组分析证实巨噬细胞与黑色素瘤细胞间MIF介导的信号富集。空间上,巨噬细胞来源的CXCL10/CXCR3-hnRNP C-MIF信号轴促进巨噬细胞重塑并驱动转移性肿瘤状态。由hnRNP C-MIF-CXCR3组成的三基因预后特征在独立黑色素瘤队列中显示稳健预测性能,并与肿瘤分期、转移状态和总生存强相关。蛋白水平验证显示黑色素瘤组织中hnRNP C和MIF表达高于正常皮肤。该研究识别出黑色素瘤中新的巨噬细胞-肿瘤信号环路:CXCL10/CXCR3驱动的hnRNP C激活促进MIF介导的巨噬细胞重编程及后续转移进展。所识别的三基因特征提供具有临床相关性的预后生物标志物,并提示hnRNP C是阻断巨噬细胞驱动肿瘤进展的潜在治疗靶点。
Trained immunity is tightly regulated by metabolic and epigenetic reprogramming, yet how these changes are orchestrated at the chromatin level to establish long-term innate immune memory is not fully understood. Here, we show that induction of trained immunity elevates nuclear levels of nicotinamide adenine dinucleotide (NAD+), which directly binds to KDM5A demethylase and inhibits its activity, thereby sustaining H3K4me3 (histone H3 lysine 4 trimethylation) levels and chromatin accessibility at inflammatory gene promoters to enhance "memory" responsiveness upon restimulation. Genetic deletion or pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme for NAD+ synthesis, impaired trained immunity and associated antitumor activity. Nicotinamide mononucleotide (NMN) supplementation rescued defective trained immunity-mediated antitumor activity in NAMPT-deficient and aged mice. In human cancer, NAMPT expression in myeloid cells correlated with an inflammatory tumor microenvironment. Our findings identify KDM5A as a nuclear NAD+ sensor that orchestrates histone methylation and chromatin accessibility required for trained immunity.
中文摘要:训练免疫受代谢与表观遗传重编程的严格调控,但这些改变如何在染色质层面被协调以建立长期天然免疫记忆仍不完全清楚。本研究发现,训练免疫的诱导提高核内烟酰胺腺嘌呤二核苷酸(NAD+)水平,NAD+直接结合KDM5A去甲基化酶并抑制其活性,从而维持炎症基因启动子处的H3K4me3(组蛋白H3第4位赖氨酸三甲基化)水平和染色质可及性,增强再刺激时的「记忆」反应。遗传性敲除或药理学抑制烟酰胺磷酸核糖转移酶(NAMPT,NAD+合成的限速酶)会削弱训练免疫及其相关抗肿瘤活性。补充烟酰胺单核苷酸(NMN)可挽救NAMPT缺陷小鼠和老年小鼠中受损的训练免疫介导抗肿瘤活性。在人类癌症中,髓系细胞的NAMPT表达与炎症性肿瘤微环境相关。这些结果确定KDM5A是核内NAD+感受器,协调训练免疫所需的组蛋白甲基化和染色质可及性。
Sprouting angiogenesis is critical for embryogenesis, wound healing, and tumor growth. Here, we show that the liquid crystal framework, which has recently been leveraged to study various morphogenetic events, provides unique insight into angiogenic sprouting. In response to vascular endothelial growth factor, a potent proangiogenic factor, endothelial cells cultured on the surfaces of soft collagen hydrogels form elongated cell streams that coexist with more polygonal cell regions. Angiogenic sprouting initiates preferentially at cell stream tips, where nematic order gradients are most pronounced. We demonstrate that cell streams are associated with large traction forces that lead to three-dimensional deformations of the underlying hydrogel and that stream formation results from a delicate balance between microtubule polymerization and actomyosin contractility. Last, we show that active control of nematic order allows modulation of sprout formation, highlighting the key role of endothelial cell orientation gradients in angiogenic sprouting and paving the way for new therapeutic avenues.
中文摘要:出芽性血管生成对胚胎发生、伤口愈合和肿瘤生长至关重要。研究发现,近来被用于研究多种形态发生事件的液晶框架,可为血管生成性出芽提供独特认识。在血管内皮生长因子这一强效促血管生成因子作用下,培养于柔软胶原水凝胶表面的内皮细胞形成拉长的细胞流,并与较多多边形细胞区域共存。血管生成性出芽优先发生于细胞流尖端,此处的向列序梯度最为显著。细胞流伴随较大的牵引力,可引起下方水凝胶的三维变形;细胞流的形成源于微管聚合与肌动球蛋白收缩性之间的精细平衡。对向列序的主动控制能够调节出芽形成,凸显内皮细胞取向梯度在血管生成性出芽中的关键作用,并为新的治疗途径奠定基础。
Chimeric RNAs are a class of molecules defined as RNA transcripts containing genetic information for multiple genes. While their expression patterns across tissue types and disease states have been well documented, the biological function of these transcripts remains poorly understood. In this study, we developed an integrative prediction pipeline to establish an atlas of 569,640 chimeric RNAs across 1019 cancer cell lines. Leveraging this resource, we performed a systematic functional dependency screen by integrating our predictions with perturbation datasets from The Cancer Dependency Map project. This approach moves beyond prediction to identifying high-confidence functional chimeric RNAs essential for cellular processes, including a subset of recurrent chimeric transcripts generated by cis-splicing of adjacent genes. We demonstrate that depletion of selected candidate chimeras disrupts cell cycle progression and cellular fitness and that these transcripts are frequently dysregulated in primary breast tumors. Together, these results demonstrate that chimeric RNAs constitute a previously underappreciated layer of gene expression, expanding the functional genome beyond conventional genetics.
中文摘要:嵌合RNA是一类含有多个基因遗传信息的RNA转录本。其在不同组织类型和疾病状态中的表达模式已有充分记录,但这些转录本的生物学功能仍知之甚少。本研究开发了一套整合预测流程,在1019个癌细胞系中建立了包含569,640条嵌合RNA的图谱。利用该资源,我们将预测结果与癌症依赖图谱项目的扰动数据集整合,开展了系统性功能依赖筛选。该方法超越预测,识别出对细胞过程必不可少的高置信度功能性嵌合RNA,包括由相邻基因顺式剪接产生的一组复发性嵌合转录本。我们证明,敲低选定的候选嵌合RNA会破坏细胞周期进程和细胞适应性,这些转录本在原发乳腺肿瘤中频繁失调。这些结果共同表明,嵌合RNA构成了一个此前未被充分重视的基因表达层面,将功能基因组扩展到传统遗传学之外。
Epilepsy is increasingly viewed as a systemic disorder in which recurrent seizures intersect with vascular, autonomic, respiratory, and cardiac processes to influence cardiovascular vulnerability. Seizure-related neuroinflammation involves multiple interacting mediator pathways, including HMGB1/TLR4-RAGE signaling, inflammasome/IL-1β activation, IL-6/IL-6R-gp130 signaling, albumin/TGF-β signaling following blood-brain barrier (BBB) disruption, and tumor necrosis factor-alpha (TNF-α)/TNF receptor (TNFR) signaling. Within this inflammatory network, TNF/TNFR signaling represents a mechanistically distinct and translationally relevant framework for examining how immune activation intersects with endothelial-barrier dysfunction, neurovascular unit injury, autonomic disturbance, inflammatory communication across neural and cardiovascular compartments, and cardiac vulnerability. This review integrates direct evidence from epilepsy studies with mechanistic insights from related experimental studies of BBB injury, myocardial ischemia-reperfusion injury, cardioprotection, and brain-heart communication. TNF biology is determined by ligand form, receptor subtype, cellular compartment, and disease context. Soluble TNF preferentially engages TNFR1-associated inflammatory and injury-amplifying pathways, whereas transmembrane TNF/TNFR2 signaling may support regulatory or reparative responses in selected settings. In epilepsy, seizure-associated inflammation, BBB dysfunction, glial activation, and autonomic imbalance may interact to increase susceptibility to arrhythmogenic stress, myocardial injury, adverse cardiac remodeling, and cardiorespiratory instability relevant to sudden unexpected death in epilepsy (SUDEP). However, epilepsy-specific evidence directly linking TNF/TNFR signaling to cardiovascular outcomes remains limited, and many mechanistic connections currently rely on converging evidence from neurovascular and cardiovascular research. Future studies should integrate compartment-resolved inflammatory profiling with autonomic, respiratory, electrocardiographic, and cardiac phenotyping to distinguish inflammatory signatures of disease severity from modifiable contributors to cardiovascular risk. Such approaches may enable phenotype-specific strategies to better understand and ultimately mitigate the brain-heart consequences of epilepsy.
中文摘要:癫痫正日益被视为一种系统性疾病,其反复发作与血管、自主神经、呼吸及心脏过程相互交织,从而影响心血管易感性。癫痫发作相关神经炎症涉及多条相互作用的介质通路,包括HMGB1/TLR4-RAGE信号、炎症小体/IL-1β激活、IL-6/IL-6R-gp130信号、血脑屏障破坏后的白蛋白/TGF-β信号以及肿瘤坏死因子α(TNF-α)/TNF受体(TNFR)信号。在这一炎症网络中,TNF/TNFR信号提供了一个机制上独特且具有转化相关性的框架,用于考察免疫激活如何与内皮屏障功能障碍、神经血管单元损伤、自主神经紊乱、神经与心血管 compartments 之间的炎症通讯以及心脏易感性相交汇。本综述整合癫痫研究的直接证据与血脑屏障损伤、心肌缺血再灌注损伤、心脏保护及脑-心通讯等相关实验研究的机制见解。TNF生物学由配体形式、受体亚型、细胞区室和疾病背景决定。可溶性TNF优先启动TNFR1相关的炎症与损伤放大通路,而跨膜TNF/TNFR2信号在特定情形下可能支持调节性或修复性反应。在癫痫中,发作相关炎症、血脑屏障功能障碍、胶质激活和自主神经失衡可能相互作用,增加对致心律失常应激、心肌损伤、不良心脏重构以及与癫痫猝死(SUDEP)相关的心肺不稳定的易感性。然而,直接将TNF/TNFR信号与心血管结局联系起来的癫痫特异性证据仍有限,许多机制联系目前依赖神经血管与心血管研究的汇聚证据。未来研究应将区室分辨的炎症谱分析与自主神经、呼吸、心电图及心脏表型分析相结合,以区分疾病严重度的炎症特征与可干预的心血管风险贡献因素。这类方法可能促成表型特异性策略,以更好地理解并最终减轻癫痫的脑-心后果。
The GDF15-GFRAL-RET neuroendocrine axis is a key regulator of body-weight homeostasis and metabolic control. GFRAL, a hindbrain-restricted receptor for the stress-responsive cytokine GDF15, signals by assembling a ternary complex with GDF15 and the tyrosine kinase RET. Pathological hyperactivation of this axis drives disease-associated weight loss, including cancer-associated cachexia. Here, we report a GFRAL-binding and GDF15-GFRAL pathway-blocking antibody (GB2Ab) and its humanized lead with potent preclinical efficacy. The GB2Ab Fab-GFRAL D3 crystal structure reveals an induced-fit mechanism in which GB2Ab sterically occludes the GFRAL-RET interface and remodels the primary RET CLD1-CLD2 binding site, providing a structural basis for high-affinity binding, slow dissociation, and potent antagonism. Structure-guided humanization preserves high-affinity and cross-reactivity. The humanized antibody reaches the area postrema, attenuates GDF15-evoked neural activation, ameliorates cachectic phenotypes, and suppresses sympathetic preganglionic activity in an orthotopic cancer cachexia model, establishing receptor-centric GDF15-GFRAL-RET antagonism as a promising strategy for cancer-associated cachexia and other GDF15-driven diseases.
中文摘要:GDF15-GFRAL-RET 神经内分泌轴是体重稳态和代谢控制的关键调节通路。GFRAL 是应激反应性细胞因子 GDF15 的后脑限制性受体,通过与 GDF15 及酪氨酸激酶 RET 组装三元复合物传递信号。该轴的病理性过度激活驱动疾病相关体重下降,包括癌症相关恶病质。研究报告一种结合 GFRAL 并阻断 GDF15-GFRAL 通路的抗体 GB2Ab 及其人源化先导分子,二者在临床前模型中具有强效作用。GB2Ab Fab-GFRAL D3 晶体结构揭示诱导契合机制:GB2Ab 在空间上遮蔽 GFRAL-RET 界面,并重塑 RET 主要 CLD1-CLD2 结合位点,为高亲和力结合、缓慢解离和强效拮抗提供结构基础。结构引导的人源化保留了高亲和力和交叉反应性。人源化抗体可到达最后区,减弱 GDF15 诱发的神经激活,改善恶病质表型,并在原位癌症恶病质模型中抑制交感节前活动,确立以受体为中心的 GDF15-GFRAL-RET 拮抗作为癌症相关恶病质及其他 GDF15 驱动疾病的有前景策略。
4肿瘤基础/转化 (55篇)
临床研究 (3篇)
Choroid plexus tumours (CPTs) are rare intraventricular brain neoplasms derived from choroid plexus epithelium, predominantly affecting young children. They include benign choroid plexus papilloma (CPP), atypical CPP (aCPP), and malignant choroid plexus carcinoma (CPC) and segregate into three DNA-methylation subgroups: paediatric A (pedA), paediatric B (pedB), and adult. To resolve subtype-specific biology, we performed single-nucleus RNA sequencing on 43 CPTs and integrated 12 non-neoplastic foetal, paediatric, and adult choroid plexus references, complemented by spatial transcriptomics in a subset of 16 tumour sections and 2 normal choroid plexus samples. Tumour embeddings and correlation analyses demonstrated that CPTs cluster by methylation subtype rather than WHO grade, revealing epigenetically driven relationships despite divergent histology. We identified 10 tumour metaprograms spanning epithelial differentiation, ciliogenesis, proliferation, extra cellular matrix remodelling, and stress responses. PedA and adult tumours showed relatively homogeneous program distribution dominated by differentiation or ciliation states, whereas pedB tumours exhibited marked heterogeneity with selective enrichment of hypoxia, interferon signalling, early stress response, and TGF-β signalling. Spatial mapping revealed consistent anticorrelation of these programs with ciliogenesis and differentiation programs, suggesting stress-associated dedifferentiation. Elevated stress and hypoxia scores correlated with poorer survival. PedB tumours showed enrichment of interferon- and lipid-associated myeloid populations, that carried pro-angiogenic signatures. They were spatially co-localised with hypoxic and interferon I expressing tumour areas, that were predicted to interact with myeloid cells via immunosuppressive cues, shaping a pro-angiogenic, pro-tumour environment. This study identifies stress- and hypoxia-associated dedifferentiation programs that are selectively enriched in pedB tumours, correlate with poor clinical outcome, and antagonise multiciliogenesis and epithelial differentiation. Their spatial co-localisation with immunosuppressive, pro-angiogenic macrophage populations links developmental arrest to microenvironmental remodelling and aggressive behaviour. These findings provide a biologically grounded framework for risk stratification and highlight hypoxia, angiogenesis and macrophage polarisation as candidate therapeutic targets in high-risk CPTs.
中文摘要:脉络丛肿瘤(CPTs)是起源于脉络丛上皮的罕见脑室内肿瘤,主要累及幼儿,包括良性脉络丛乳头状瘤(CPP)、非典型CPP(aCPP)和恶性脉络丛癌(CPC),并分为儿童A型(pedA)、儿童B型(pedB)和成人型三个DNA甲基化亚组。为解析亚型特异性生物学,我们对43例CPT进行了单核RNA测序,并整合12例非肿瘤性胎儿、儿童和成人脉络丛参考样本,同时对16个肿瘤切片和2个正常脉络丛样本进行了空间转录组分析。肿瘤样本嵌入表示与相关性分析显示,CPT按甲基化亚型而非WHO分级聚类,尽管组织学差异明显,仍揭示出表观遗传驱动的关系。我们识别出10种肿瘤元程序,涵盖上皮分化、纤毛发生、增殖、细胞外基质重塑和应激反应。pedA和成人型肿瘤的程序分布相对均一,以分化或纤毛化状态为主;pedB肿瘤则表现出明显异质性,选择性富集缺氧、干扰素信号、早期应激反应和TGF-β信号。空间定位显示这些程序与纤毛发生和分化程序呈一致负相关,提示应激相关去分化。应激和缺氧评分升高与较差生存相关。pedB肿瘤富集干扰素相关和脂质相关髓系细胞群,这些细胞群携带促血管生成特征,并与缺氧及表达I型干扰素的肿瘤区域空间共定位;预测这些区域通过免疫抑制信号与髓系细胞相互作用,塑造促血管生成、促肿瘤的环境。该研究识别出应激和缺氧相关去分化程序,这些程序在pedB肿瘤中选择性富集,与不良临床结局相关,并拮抗多纤毛发生和上皮分化。它们与免疫抑制、促血管生成巨噬细胞群的空间共定位,将发育停滞与微环境重塑及侵袭性行为联系起来。这些发现为风险分层提供了有生物学依据的框架,并提示缺氧、血管生成和巨噬细胞极化可作为高危CPT的候选治疗靶点。
Hepatocellular carcinoma (HCC) exhibits substantial molecular heterogeneity, complicating treatment selection and clinical management. We developed an artificial intelligence-based histopathological framework to predict HCC biological characteristics from routine hematoxylin and eosin (H&E)-stained slides. Using The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) cohort, transcriptomic phenotypes associated with angiogenesis, stemness, and autophagy were identified through gene set analysis, differential expression analysis, and consensus clustering, and evaluated for overall survival and drug sensitivity. Whole-slide images were processed into 224 × 224-pixel tumor tiles for phenotype prediction using feature extraction (UNI, ResNet50, CTrans, GigaPath, and Virchow2) combined with classic multiple instance learning and clustering-constrained attention-based multiple instance learning.. Models were externally validated at Renmin Hospital of Wuhan University and Tongji Hospital. Interpretability was assessed using attention heatmaps, and predictions were evaluated against molecular markers and tumor differentiation grades. Unsupervised clustering identified two subgroups per phenotype, with significant difference in survival (all p < 0.004) and sensitivities to sorafenib or transcatheter arterial chemoembolization (all p < 0.0001). The tumor detection model achieved an area under the receiver operating characteristic curve (AUC) of 97.53%. The phenotype prediction models achieved internal optimal AUCs of 85.51%-91.05% and accuracies of 79.63%-88.89%. External optimal AUCs were 70.94%, 88.64%, and 91.17% for angiogenesis, stemness, and autophagy, with accuracies of 62.00%, 78.00%, and 84.00%, respectively. Attention heatmaps revealed distinct morphological features among subgroups, including neovascularization, increased nuclear-to-cytoplasmic ratios, and cytoplasmic vacuolization. Model predictions showed concordance with CD31/CD105 (κ = 0.398-0.432), CD133/LGR5 (κ = 0.428-0.629), Beclin-1/p62-LC3B (κ = 0.592-0.762) (all p < 0.05), and tumor differentiation grade (κ = - 0.167 to - 0.175, p < 0.05). This proof-of-concept AI framework predicted transcriptome-defined HCC phenotypes from routine histology, with predictions associated with prognosis and therapeutic response. It may provide a cost-effective approach for assessing HCC heterogeneity and complement molecular profiling.
中文摘要:肝细胞癌(HCC)存在显著分子异质性,使治疗选择和临床管理复杂化。我们开发了一个基于人工智能的组织病理学框架,从常规苏木精-伊红(H&E)染色切片预测HCC生物学特征。利用TCGA-LIHC队列,通过基因集分析、差异表达分析和共识聚类识别与血管生成、干性和自噬相关的转录组表型,并评估总生存和药物敏感性。全切片图像处理为224×224像素肿瘤图块,用于表型预测,采用特征提取(UNI、ResNet50、CTrans、GigaPath和Virchow2)结合经典多实例学习和聚类约束注意力多实例学习。模型在武汉大学人民医院和同济医院进行外部验证。使用注意力热图评估可解释性,并将预测与分子标志物和肿瘤分化分级比较。无监督聚类为每个表型识别两个亚组,生存差异显著(所有p<0.004),对索拉非尼或经导管动脉化疗栓塞敏感性差异显著(所有p<0.0001)。肿瘤检测模型受试者工作特征曲线下面积(AUC)为97.53%。表型预测模型内部最佳AUC为85.51%-91.05%,准确率为79.63%-88.89%。血管生成、干性和自噬的外部最佳AUC分别为70.94%、88.64%和91.17%,准确率分别为62.00%、78.00%和84.00%。注意力热图显示亚组间形态学特征不同,包括新生血管形成、核质比增高和细胞质空泡化。模型预测与CD31/CD105(κ=0.398-0.432)、CD133/LGR5(κ=0.428-0.629)、Beclin-1/p62-LC3B(κ=0.592-0.762)(均p<0.05)及肿瘤分化分级(κ=-0.167至-0.175,p<0.05)一致。该概念验证AI框架从常规组织学预测转录组定义的HCC表型,预测与预后和治疗反应相关。它可能提供一种成本效益较高的方法评估HCC异质性并补充分子分型。
Ambient air pollutants have been associated with increased risks of mortality and chronic diseases; however, population-based evidence on their shared versus pollutant- and outcome-specific molecular mechanisms remains unclear. Leveraging proteomics data from 48,645 participants in the UK Biobank, we characterized proteomic signatures related to overall and individual air pollutants, including particulate matter (PM2.5 and PM10), nitrogen dioxide (NO2) and nitrogen oxides (NOx), and examined their associations with risks of mortality and major chronic diseases. Subsequently, we investigated potential mediating proteins underlying these associations to determine relevant biological mechanisms through functional annotation analyses. Plasma proteins jointly associated with four air pollutants were commonly enriched in immune regulatory pathways, while proteins uniquely associated with PM2.5, PM10, NO2, and NOx were enriched in pollutant-specific pathways of vascular dysfunction, DNA damage, apoptosis signaling, and extracellular matrix remodeling, respectively. Proteomic signatures of air pollutants captured biological processes underlying mortality and major chronic diseases. Mediation analyses and Mendelian randomization identified mediating proteins causally associated with their respective health outcomes, highlighting shared mechanisms of inflammation and immune response as well as outcome-specific pathways such as vascular remodeling for cardiovascular disease, oxidative stress for chronic kidney disease, and cell adhesion for dementia. Specifically, cell-type and tissue enrichment annotation revealed outcome-relevant specificity of advanced glycosylation end product-specific receptor (AGER) for chronic respiratory disease and lung cancer. This study dissects the relationship between ambient air pollutants and adverse health outcomes by revealing both shared and divergent mechanisms and representing potential targets such as AGER for disease prevention and therapeutic intervention.
中文摘要:环境空气污染物与死亡和慢性疾病风险升高相关,但其共同及污染物和结局特异性分子机制的人群证据仍不清楚。基于英国生物银行48,645名参与者的蛋白质组学数据,我们刻画了与总体及单一空气污染物相关的蛋白质组特征,污染物包括细颗粒物(PM2.5和PM10)、二氧化氮(NO2)和氮氧化物(NOx),并检验这些特征与死亡和主要慢性疾病风险的关联。随后,我们分析这些关联背后的潜在中介蛋白,并通过功能注释分析探讨相关生物学机制。与四种空气污染物共同相关的血浆蛋白主要富集于免疫调节通路,而与PM2.5、PM10、NO2和NOx分别独特相关的蛋白则分别富集于血管功能障碍、DNA损伤、凋亡信号和细胞外基质重塑等污染物特异性通路。空气污染物的蛋白质组特征反映了死亡和主要慢性疾病背后的生物学过程。中介分析和孟德尔随机化识别出与各自健康结局存在因果关联的中介蛋白,揭示炎症和免疫反应的共同机制,以及结局特异性通路,如心血管疾病的血管重塑、慢性肾病的氧化应激和痴呆的细胞黏附。具体而言,细胞类型和组织富集注释显示晚期糖基化终末产物特异性受体(AGER)对慢性呼吸系统疾病和肺癌具有结局相关特异性。本研究通过揭示共同和分化机制,解析环境空气污染物与不良健康结局的关系,并提出AGER等潜在靶点用于疾病预防和治疗干预。
基础研究 (52篇)
Transcriptional regulation is fundamental to vascular homeostasis, ensuring vessel stability and function. Disruption of this regulation underlies pathological angiogenesis in cancer and vascular malformations. While RUNX3 (Runt-related transcription factor 3), a Runt-domain transcription factor, is established as a tumor suppressor and regulator of lymphocyte development, its role in endothelial cells has remained unknown. To define the vascular function of RUNX3, we generated endothelial-specific RUNX3 knockout mice and analyzed postnatal retinal angiogenesis and oxygen-induced retinopathy. Mechanistic insights were obtained through assay for transposase-accessible chromatin with high-throughput sequencing data analysis, coimmunoprecipitation, proximity ligation assay, electrophoretic mobility shift assay, and chromatin immunoprecipitation followed by quantitative real-time polymerase chain reaction (ChIP-qPCR). Loss of endothelial RUNX3 induced hypersprouting angiogenesis with excessive tip cell formation and reduced DLL4 (delta-like ligand 4) expression. RUNX3 deficiency disrupted vascular integrity by lowering VE-cadherin (vascular endothelial cadherin) and claudin-5 levels, while increasing ICAM1 (intercellular adhesion molecule 1) expression, retinal hemorrhage, and leukocyte infiltration. In the oxygen-induced retinopathy model, endothelial RUNX3 deletion aggravated pathological neovascularization. Mechanistically, RUNX3 cooperated with ERG (ETS-related gene) at ETS:RUNX motifs to regulate genes controlling sprouting (DLL4), junctional stability (CDH5, CLDN5), and leukocyte adhesion (ICAM1). RUNX3 formed complexes with ERG, p300, and HDAC3 (histone deacetylase 3), and proximity ligation assays showed that these interactions were enriched in the nucleus upon VEGF-A (vascular endothelial growth factor-A) stimulation. ChIP-qPCR further demonstrated that RUNX3 was required for the recruitment of these coregulators to target loci. Through differential coregulator engagement, RUNX3 functioned bidirectionally, acting as a transcriptional activator of CDH5, CLDN5, and DLL4 while serving as a repressor of ICAM1. Consistently, single-cell transcriptome analysis of human arteriovenous malformations revealed dysregulated RUNX3 and target gene expression, underscoring translational relevance. This study provides the first evidence that RUNX3 is a pivotal transcriptional coordinator in endothelial cells. By integrating ERG and chromatin regulators at ETS:RUNX motifs, RUNX3 safeguards the balance between angiogenic activation and vascular stability. These findings establish RUNX3 as a gatekeeper of endothelial transcriptional identity and highlight its potential as a therapeutic target in pathological angiogenesis.
中文摘要:转录调控是血管稳态的基础,保障血管稳定性和功能。该调控紊乱是癌症病理性血管生成和血管畸形的根源。RUNX3(Runt相关转录因子3)是一种Runt结构域转录因子,已被确立为抑癌因子和淋巴细胞发育调控因子,但其在内皮细胞中的作用仍不清楚。为明确RUNX3的血管功能,我们构建了内皮特异性RUNX3敲除小鼠,并分析出生后视网膜血管生成和氧诱导视网膜病变。机制研究通过ATAC-seq数据分析、免疫共沉淀、邻近连接实验、电泳迁移率变动实验以及染色质免疫沉淀后实时定量PCR(ChIP-qPCR)获得。内皮RUNX3缺失诱导过度出芽的血管生成,表现为尖端细胞形成过多和DLL4(delta样配体4)表达降低。RUNX3缺陷通过降低VE-cadherin(血管内皮钙黏蛋白)和claudin-5水平、增加ICAM1(细胞间黏附分子1)表达、视网膜出血和白细胞浸润,破坏血管完整性。在氧诱导视网膜病变模型中,内皮RUNX3缺失加重病理性新生血管。机制上,RUNX3与ERG(ETS相关基因)在ETS:RUNX基序上协同调控控制出芽(DLL4)、连接稳定性(CDH5、CLDN5)和白细胞黏附(ICAM1)的基因。RUNX3与ERG、p300和HDAC3(组蛋白去乙酰化酶3)形成复合物,邻近连接实验显示VEGF-A(血管内皮生长因子-A)刺激后这些相互作用在细胞核内富集。ChIP-qPCR进一步表明RUNX3是将这些共调控因子招募至靶位点所必需的。通过差异性共调控因子参与,RUNX3发挥双向作用:作为CDH5、CLDN5和DLL4的转录激活因子,同时作为ICAM1的抑制因子。与此一致,对人动静脉畸形的单细胞转录组分析显示RUNX3及其靶基因表达失调,提示转化相关性。该研究首次证明RUNX3是内皮细胞中的关键转录协调因子。通过在ETS:RUNX基序整合ERG和染色质调控因子,RUNX3维护血管生成激活与血管稳定之间的平衡。这些发现确立RUNX3为内皮转录身份守门因子,并突出其作为病理性血管生成治疗靶点的潜力。
Circulating tumor cells (CTCs) are valuable liquid biopsy markers for assessing tumor heterogeneity, monitoring minimal residual disease (MRD), and guiding personalized therapy. However, their rarity in blood and phenotypic changes during epithelial-mesenchymal transition (EMT) limit reliable detection. Electrochemical interfacial biosensors offer a promising solution due to their high sensitivity, miniaturization potential, and compatibility with microfluidics. This review summarizes recent advances in nanomaterial-enabled electrochemical CTC biosensing, focusing on interface engineering, signal transduction, and clinical translation. We highlight strategies such as multivalent recognition, engineered nanotopography, antifouling interfaces, and stimulus-responsive release that enhance CTC capture in whole blood. We also discuss nanozyme-based amplification, ratiometric calibration, and multiplexed electrochemical detection for phenotypic profiling beyond simple enumeration. Finally, we outline key translational requirements, including standardized benchmarking, clinical cohort validation, and artificial intelligence (AI)-assisted data analysis. Integrating nanostructured interfaces with multiplexed detection and standardized whole-blood validation may accelerate electrochemical CTC analysis toward routine, phenotype-aware liquid biopsy.
中文摘要:循环肿瘤细胞(CTCs)是评估肿瘤异质性、监测微小残留病(MRD)和指导个体化治疗的重要液体活检标志物。其在外周血中数量稀少,且上皮-间质转化(EMT)过程中表型发生变化,限制了可靠检测。电化学界面生物传感器具有高灵敏度、易于小型化并与微流控兼容等优势,提供了有前景的解决途径。本综述总结纳米材料赋能电化学CTC生物传感的最新进展,聚焦界面工程、信号转导和临床转化。重点介绍多价识别、工程化纳米拓扑结构、抗污染界面和刺激响应释放等策略,这些策略可增强全血中的CTC捕获。也讨论基于纳米酶的信号放大、比率校准和多路电化学检测,用于超越单纯计数的表型分析。最后概述关键转化需求,包括标准化基准测试、临床队列验证和人工智能(AI)辅助数据分析。将纳米结构界面与多路检测及标准化全血验证相结合,可能推动电化学CTC分析走向常规、表型感知的液体活检。
Extrachromosomal DNA (ecDNA) is a key element driving the malignant progression of tumors. Since ecDNA lacks canonical high-order chromatin compaction, how it maintains structural and functional stability in highly oxidizing tumor environments remains unclear. Using metabolomics, biochemistry, and imaging assays in human cancer cells and mouse models, we herein show that ecDNA hub establishes an active electrochemical environment, which drives the reduction of oxidized glutathione (GSSG) to reduced glutathione (GSH) through a non-enzymatic mechanism. GSH forms a protective "cloud" around ecDNA hubs, shielding ecDNA from damage and sustaining oncogene expression. Lastly, using spermidine, which disrupts the interfacial environment of ecDNA hubs, we found that affecting the redox balance of ecDNA hubs drives tumor death. This study uncovers a non-enzymatic function of ecDNA hubs that establishes a self-reinforcing maintenance loop to regulate spatial redox environments, revealing an electrochemical environment-dependent redox-regulation strategy in cancer biology.
中文摘要:染色体外DNA(ecDNA)是驱动肿瘤恶性进展的关键元件。由于ecDNA缺乏经典的高阶染色质压缩结构,其如何在高度氧化的肿瘤环境中维持结构与功能稳定仍不清楚。我们在人癌细胞和小鼠模型中采用代谢组学、生物化学和成像分析,发现ecDNA枢纽建立活跃的电化学环境,通过非酶机制驱动氧化型谷胱甘肽(GSSG)还原为还原型谷胱甘肽(GSH)。GSH在ecDNA枢纽周围形成保护性「云」,使ecDNA免受损伤并维持癌基因表达。最后,使用可破坏ecDNA枢纽界面环境的亚精胺,我们发现影响ecDNA枢纽的氧化还原平衡可驱动肿瘤死亡。该研究揭示ecDNA枢纽的一种非酶功能,即建立自我强化的维持环路以调控空间氧化还原环境,展现了癌症生物学中依赖电化学环境的氧化还原调控策略。
Met1-linked ubiquitin chains (Met1-Ub), synthesized by the linear ubiquitin chain assembly complex (LUBAC) and disassembled by the deubiquitinase OTULIN, regulate inflammatory signaling and cell death. OTULIN activity prevents tumor necrosis factor (TNF)-driven autoinflammatory pathology and embryonic lethality, but the role of the direct OTULIN-LUBAC interaction remains unclear. Here, we show that mice harboring a point mutation in the OTULIN peptide:N-glycanase/UBA- or UBX-containing proteins (PUB)-interacting motif (OTULINY56A), which disrupts LUBAC binding, are viable without spontaneous pathology but are highly sensitive to TNF-induced toxicity and TNF-mediated immunopathology during Listeria monocytogenes infection. Mechanistically, the OTULIN-LUBAC interaction prevents Met1-linked autoubiquitination, thereby limiting LUBAC activity and Met1-Ub conjugation on non-LUBAC substrates. Disrupting the OTULIN-LUBAC interaction increased Met1-Ub accumulation at the TNF receptor signaling complex, which stabilized the signaling complex, increased nuclear factor-kappa B (NF-κB) signaling, and, unlike loss of OTULIN or its activity, protected from TNF-induced apoptosis. Collectively, we identify the OTULIN-LUBAC interaction as a critical brake restricting LUBAC function and Met1-Ub-dependent signaling.
中文摘要:Met1连接泛素链由线性泛素链组装复合物LUBAC合成,并由去泛素化酶OTULIN解聚,参与调控炎症信号与细胞死亡。OTULIN活性可防止肿瘤坏死因子TNF驱动的自身炎症性病理和胚胎致死,但OTULIN与LUBAC直接相互作用的作用仍不清楚。本研究报告,携带OTULIN肽:N-聚糖酶/UBA或UBX蛋白PUB相互作用基序点突变OTULINY56A的小鼠可存活且无自发病理,但该突变破坏LUBAC结合后,小鼠对TNF诱导的毒性以及单核细胞增生李斯特菌感染期间TNF介导的免疫病理高度敏感。机制上,OTULIN-LUBAC相互作用可防止Met1连接的自泛素化,从而限制LUBAC活性及非LUBAC底物上的Met1-Ub缀合。破坏OTULIN-LUBAC相互作用会增加TNF受体信号复合物处的Met1-Ub积累,稳定该信号复合物,增强核因子κB信号,并且不同于OTULIN缺失或活性丧失,可保护细胞免受TNF诱导的凋亡。总体而言,该研究将OTULIN-LUBAC相互作用确定为限制LUBAC功能和Met1-Ub依赖信号的关键刹车。
The fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling pathway is essential for maintaining physiological homeostasis, and its dysregulation is implicated in the pathogenesis of numerous diseases. FGF-binding proteins (FGFBPs) constitute a family of secreted proteins that modulate the bioavailability of FGF ligands, thereby fine-tuning FGF signaling output in a context-specific manner. Emerging evidence indicates that FGFBPs regulate diverse physiological processes, including embryonic development, tissue repair, and metabolic homeostasis, while dysregulation of these members is closely associated with various diseases, particularly malignancies. Nevertheless, their precise functional roles in physiological homeostasis and oncogenesis, as well as the underlying molecular mechanisms governing these functions, remain incompletely characterized. This review systematically summarizes the physiological functions of FGFBPs, with a focused analysis of their context-dependent roles in diverse types of cancer. We further discuss their emerging potential as prognostic biomarkers and therapeutic implications. A deeper mechanistic understanding of FGFBPs is expected to advance insights into the molecular underpinnings of both physiological homeostasis and tumorigenesis, thereby informing the rational development of novel diagnostic biomarkers and precise therapeutic intervention strategies.
中文摘要:成纤维细胞生长因子(FGF)/FGF受体(FGFR)信号通路对维持生理稳态至关重要,其失调参与多种疾病的发病过程。FGF结合蛋白(FGFBPs)是一类分泌蛋白,可调节FGF配体的生物利用度,从而以情境依赖的方式精细调控FGF信号输出。新近证据显示,FGFBPs参与胚胎发育、组织修复和代谢稳态等多种生理过程,而其失调与多种疾病尤其是恶性肿瘤密切相关。不过,这些成员在生理稳态和肿瘤发生中的确切功能作用及其分子机制仍未得到充分阐明。本综述系统总结FGFBPs的生理功能,重点分析其在不同癌种中依赖情境的作用,并讨论其作为预后生物标志物和治疗靶点的新兴潜力。更深入地理解FGFBPs的机制有望增进对生理稳态与肿瘤发生分子基础的认识,并为合理开发新型诊断标志物和精准治疗干预策略提供依据。
Basophils are rare cells best known for their role in allergy but their contribution to cancer remains poorly understood. Here, we found that basophils suppress early lung metastatic seeding in mice by enhancing antitumor CD8+ T cell immunity through inhibition of regulatory T (Treg) cells. Basophils restrain Treg cells through two complementary mechanisms: mast cell protease 8-mediated cleavage of interleukin-2 receptor α and histamine-mediated activation of the histamine H1 receptor (HRH1). HRH1 blockade with loratadine abolished Treg cell suppression and accelerated metastatic seeding in mice. In a prospective double-blind crossover trial of loratadine versus placebo enrolling 40 healthy volunteers ( IRCT20170608034390N14 ), circulating Treg cell frequency (primary outcome) increased following loratadine. Higher blood basophil counts predicted improved survival across human cancers and integrative multiomic analyses identified conserved quiescent (B0) and tumor-associated (B1) basophil states, with B0 predicting favorable outcomes. These findings identify basophils as regulators of early metastatic progression and highlight the basophil-Treg cell axis as a potential therapeutic target.
中文摘要:嗜碱性粒细胞是罕见细胞,最为人所知的作用在过敏反应中,但其对癌症的贡献仍了解甚少。研究发现,嗜碱性粒细胞通过抑制调节性T(Treg)细胞增强抗肿瘤CD8+ T细胞免疫,从而抑制小鼠早期肺转移灶的定植。嗜碱性粒细胞通过两种互补机制限制Treg细胞:肥大细胞蛋白酶8介导的白细胞介素-2受体α裂解,以及组胺介导的组胺H1受体(HRH1)激活。用氯雷他定阻断HRH1可消除对Treg细胞的抑制并加速小鼠转移灶定植。在一项纳入40名健康志愿者的氯雷他定与安慰剂前瞻性双盲交叉试验(IRCT20170608034390N14)中,氯雷他定后循环Treg细胞频率(主要结局)升高。较高的外周血嗜碱性粒细胞计数预测多种人类癌症的生存改善,整合多组学分析识别出保守的静息(B0)和肿瘤相关(B1)嗜碱性粒细胞状态,其中B0预测良好结局。这些发现确定嗜碱性粒细胞是早期转移进展的调节者,并提示嗜碱性粒细胞-Treg细胞轴可作为潜在治疗靶点。
E2F3 is a central regulator of cell cycle progression, development, differentiation, and oncogenesis. Alternative promoter usage generates two major homologous isoforms, E2F3A and E2F3B, differing only at their N-termini. Although E2F3A is traditionally considered an activator and E2F3B a repressor of transcription, studies suggest that both isoforms have overlapping and isoform-specific functions, shaped by differences in temporal expression, protein stability, and target gene specificity. In this review, we examine how E2F3A and E2F3B contribute to proliferation, differentiation, and cancer. We also discuss contradictions and limitations in experimental approaches that have complicated the interpretation of these functions. Finally, we explore how clarifying these roles could help resolve long-standing questions in cell cycle regulation, differentiation, and cancer, where E2F3 plays a major role.
中文摘要:E2F3 是细胞周期进程、发育、分化和肿瘤发生的核心调控因子。可变启动子使用产生两个主要同源异构体 E2F3A 和 E2F3B,二者仅在 N 端不同。传统上认为 E2F3A 是转录激活因子、E2F3B 是转录抑制因子,但研究提示两个异构体既有重叠功能也有异构体特异性功能,这些功能受表达时相、蛋白稳定性和靶基因特异性差异影响。综述审视 E2F3A 与 E2F3B 如何参与增殖、分化和癌症。也讨论实验方法中的矛盾与局限,这些因素使上述功能的解释复杂化。最后探讨明确这些作用如何帮助解决细胞周期调控、分化和癌症中长期存在的问题,E2F3 在这些过程中发挥重要作用。
Resistance to therapeutic interventions contributes to poor long-term cancer patient outcomes. Adaptation to therapy, a common mechanism of drug resistance involving drug-induced activation of pro-survival oncogenic processes, poses a challenge for the implementation of effective precision therapies. Here, we addressed this challenge using the TargetScore network modeling method to nominate combination therapies that block adaptive responses in breast cancer. TargetScore identified therapeutically actionable adaptive responses as drug-induced concurrent changes in phospho-proteins connected within a signaling network. To study how apoptotic stress rewires cancer cells and uncover therapeutically actionable oncogenic dependencies, breast cancer cells were perturbed with inhibitors of anti-apoptotic mediators, particularly MCL1. TargetScore and phosphoproteomics analyses revealed the short-term (i.e., days) stress and long-term (i.e., months) acquired drug resistance to inhibitors of anti-apoptotic mediators. TargetScore predicted concurrent activation of growth and DNA repair pathways as cells evolved to resist apoptotic targeting. Validation of the predictions demonstrated strong responses to PARP1/2 and SHP2 inhibitor combination in vitro and in vivo. In genetically engineered mouse models, PARP1/2 and SHP2 co-targeting led to near-complete tumor eradication and durable responses with significant survival benefit, laying the groundwork for clinical evaluation. Functional proteomics and perturbation biology analyses proposed a mechanism of response to PARP1/2 and SHP2 co-targeting associated with molecular markers of DNA damage response, replication stress, and cell cycle arrest. This study demonstrates that TargetScore may advance precision oncology by matching drug combinations to molecular signatures and dependencies revealed under therapeutic stress.
中文摘要:治疗抵抗导致癌症患者长期预后不佳。治疗适应是耐药的常见机制,涉及药物诱导的促生存致癌过程激活,给有效精准治疗的实施带来挑战。为此,采用 TargetScore 网络建模方法提名可阻断乳腺癌适应性反应的联合治疗。TargetScore 将治疗上可干预的适应性反应界定为信号网络内相连磷酸化蛋白在药物作用下发生的同步变化。为研究凋亡应激如何重编程癌细胞并揭示可干预的致癌依赖,用抗凋亡介质抑制剂(尤其 MCL1 抑制剂)处理乳腺癌细胞。TargetScore 与磷酸化蛋白质组分析揭示了细胞对这类抑制剂的短期(数天)应激反应和长期(数月)获得性耐药。TargetScore 预测,细胞在进化出抵抗凋亡靶向的过程中,生长通路与 DNA 修复通路同步激活。验证显示,PARP1/2 与 SHP2 抑制剂联合在体外和体内均产生强反应。在基因工程小鼠模型中,共同靶向 PARP1/2 与 SHP2 使肿瘤接近完全清除,并带来持久缓解和显著生存获益,为临床评估奠定基础。功能蛋白质组学与扰动生物学分析提出,对 PARP1/2 与 SHP2 共同靶向的反应机制与 DNA 损伤应答、复制应激和细胞周期阻滞的分子标志相关。该研究表明,TargetScore 可依据治疗应激下显现的分子特征和依赖关系匹配药物组合,从而推进精准肿瘤学。
Maladaptive vascular remodeling is a hallmark of pulmonary hypertension (PH), and therapeutic strategies directly targeting the pathological activity of smooth muscle cells remain limited. Metabolic and epigenetic dysregulation are established drivers of PH, and lysine lactylation has emerged as a novel posttranslational modification implicated in diverse diseases; however, its direct contribution to PH progression remains undefined. Integrated lactylomic and proteomic profiling was performed in hypoxic human pulmonary arterial smooth muscle cells. The functional role of ALDOA (aldolase A) lactylation at lysine 42 (K42) was assessed using site-specific mutant virus and smooth muscle cell-specific inducible ALDOA knockout mice in 2 established PH models: SU5416+hypoxia in mice and monocrotaline in rats. We identified ALDOA as a prominent lactylation target in hypoxic pulmonary arterial smooth muscle cells, with K42 lactylation consistently elevated in primary pulmonary arterial smooth muscle cells derived from PH rodent models and human PH tissues. Mechanistically, AARS1 (alanyl-tRNA synthetase 1)-mediated ALDOA K42 lactylation enhanced its binding to γ-actin, independent of glycolytic activity. This lactylation-enhanced interaction promoted F-actin polymerization and activated YAP (Yes-associated protein) signaling via LATS1 (large tumor suppressor kinase 1) inhibition, thereby driving pulmonary arterial smooth muscle cell proliferation and phenotypic switching. Moreover, YAP/TEAD4 (TEA domain transcription factor 4)-mediated transcriptional upregulation of AARS1 established a positive feedback loop reinforcing ALDOA K42 lactylation under hypoxia. In vivo, ALDOA inducible knockout or reconstitution with the lactylation-deficient K42R (lysine 42 mutant to arginine) mutant attenuated experimental PH progression, with suppressed F-actin/YAP activation and reduced vascular remodeling. Furthermore, competitive inhibition of lactylation through β‑alanine reduced ALDOA K42 lactylation and ameliorated vascular remodeling in ALDOA-overexpressing rodent PH models. Translationally, pharmacological disruption of the ALDOA/γ-actin interaction by raltegravir suppressed cytoskeletal reorganization and YAP signaling, mitigating PH progression in both mouse and rat models. AARS1-mediated ALDOA K42 lactylation drives pulmonary vascular remodeling through a mechanism independent of ALDOA's catalytic activity, promoting F-actin polymerization and YAP activation. Precision targeting of this modification selectively inhibits pathological signaling while preserving metabolic homeostasis, highlighting a translational potential for precision intervention in PH.
中文摘要:适应不良的血管重塑是肺动脉高压(PH)的标志,直接针对平滑肌细胞病理活性的治疗策略仍有限。代谢与表观遗传失调是PH的已确立驱动因素,赖氨酸乳酰化作为一种新型翻译后修饰已涉及多种疾病,但其对PH进展的直接作用尚未明确。研究在缺氧人肺动脉平滑肌细胞中开展整合乳酰化组与蛋白质组分析。利用位点特异性突变病毒和平滑肌细胞特异性可诱导ALDOA敲除小鼠,在两种已建立的PH模型(小鼠SU5416+缺氧模型和大鼠野百合碱模型)中评估ALDOA(醛缩酶A)赖氨酸42(K42)乳酰化的功能作用。研究发现ALDOA是缺氧肺动脉平滑肌细胞中显著的乳酰化靶点,K42乳酰化在PH啮齿动物模型来源的原代肺动脉平滑肌细胞及人PH组织中持续升高。机制上,AARS1(丙氨酰-tRNA合成酶1)介导的ALDOA K42乳酰化增强其与γ-肌动蛋白结合,且不依赖糖酵解活性。这种乳酰化增强的相互作用促进F-肌动蛋白聚合,并通过抑制LATS1(大肿瘤抑制激酶1)激活YAP(Yes相关蛋白)信号,从而驱动肺动脉平滑肌细胞增殖和表型转换。YAP/TEAD4(TEA结构域转录因子4)介导的AARS1转录上调形成正反馈环路,在缺氧下强化ALDOA K42乳酰化。体内,ALDOA可诱导敲除或用乳酰化缺陷型K42R(赖氨酸42突变为精氨酸)突变体重建可减轻实验性PH进展,并抑制F-肌动蛋白/YAP激活、减少血管重塑。通过β-丙氨酸竞争性抑制乳酰化可降低ALDOA K42乳酰化,并改善ALDOA过表达啮齿动物PH模型的血管重塑。转化层面,用拉替拉韦药理学破坏ALDOA/γ-肌动蛋白相互作用可抑制细胞骨架重排和YAP信号,减轻小鼠和大鼠模型的PH进展。AARS1介导的ALDOA K42乳酰化通过不依赖ALDOA催化活性的机制驱动肺血管重塑,促进F-肌动蛋白聚合和YAP激活。精准靶向该修饰可选择性抑制病理信号并保留代谢稳态,显示PH精准干预的转化潜力。
Metastatic cancer cells must adapt to the physical properties of distant tissues, yet the consequences of such mechanical adaptation for immune surveillance remain poorly understood. In Immunity, Elbanna and colleagues reveal an unexpected trade-off between mechanical fitness and immune vulnerability: Environmental rigidity induces cancer cell stiffening, enabling robust colonization of rigid bone in the absence of effective cytotoxic immunity. However, this mechanically adapted state also increases susceptibility to cytotoxic lymphocytes, allowing immunosurveillance to preferentially eliminate stiffened cancer cells and suppress bone metastasis in immunocompetent hosts. SPP1 contributes to this environmentally induced mechanical adaptation and its associated immune vulnerability. This study also highlights a broader mechanical dialogue between the metastatic niche, cancer cells, and the immune system, in which adaptation to one physical constraint may create vulnerability to another. Mechanistically, cancer cell mechanics may represent more than a consequence of tumor progression-it may constitute an actionable determinant of immune susceptibility. Manipulating the mechanical state of cancer cells could therefore complement strategies aimed at enhancing immune cell function. The study raises the intriguing possibility that the very adaptation that enables cancer cells to establish themselves within a rigid metastatic niche may simultaneously expose a therapeutically exploitable mechanical vulnerability to immune surveillance.
中文摘要:转移性癌细胞必须适应远处组织的物理属性,但这种机械适应对免疫监视的影响仍所知甚少。在《Immunity》上,Elbanna 及其同事揭示了一种出人意料的权衡:机械适应性与免疫易感性之间的取舍。环境硬度诱导癌细胞变硬,使其在缺乏有效细胞毒性免疫的情况下得以在坚硬的骨组织中稳固定植。然而,这种机械适应状态同时提高了癌细胞对细胞毒性淋巴细胞的易感性,使免疫监视能够优先清除变硬的癌细胞,并在免疫功能正常的宿主体内抑制骨转移。SPP1 参与了这种由环境诱导的机械适应及其相关的免疫易感性。该研究还凸显了转移龛、癌细胞与免疫系统之间更广泛的机械对话:对某一种物理约束的适应可能造成对另一种约束的易感。在机制层面,癌细胞的力学特性或许不只是肿瘤进展的结果,还可能是决定免疫易感性的可干预因素。因此,调控癌细胞的机械状态可与增强免疫细胞功能的策略相辅相成。该研究提出了一个引人关注的可能:使癌细胞得以在坚硬转移龛中立足的那种适应,同时也暴露出一种可被治疗利用的、针对免疫监视的机械弱点。
Chronic stress is increasingly recognized as a driver of cancer metabolism, highlighting the need to elucidate the mechanism linking chronic stress to metabolic reprogramming. In this study, we performed untargeted metabolomics on serum samples from patients with esophageal squamous cell carcinoma (ESCC) and integrated the results with clinical and stress-related assessments, revealing pentose phosphate pathway (PPP) enrichment accompanied by elevated epinephrine levels in patients with stress-associated features. A β2-adrenergic receptor (ADRB2) activated by chronic stress stabilized MYC-binding protein (MYCBP) by competitively displacing VHL, thereby enhancing MYC transcriptional activity and upregulating key PPP enzymes, including G6PD and TKT. Unexpectedly, stress-associated stimulation not only activated ADRB2 signaling but also increased ADRB2 protein abundance. Mechanistically, stress exposure enhanced RNA guanine-7 methyltransferase (RNMT)-dependent N7-methylguanosine (m7G) cap modification of ADRB2 mRNA, thereby increasing its translational efficiency. Together, these findings define an RNMT-ADRB2-MYCBP-PPP axis that integrates epitranscriptomic regulation with adrenergic signaling to promote metabolic reprogramming and malignant progression in ESCC. The stress-associated RNA modification-metabolism circuitry comprises potential therapeutic targets to overcome stress-associated ESCC progression. Stress-associated signaling promotes esophageal squamous cell carcinoma progression through RNMT-dependent m7G cap modification of ADRB2 mRNA, enhancing adrenergic signaling, stabilizing MYCBP, and activating MYC-driven pentose phosphate pathway reprogramming.
中文摘要:慢性应激日益被视为癌症代谢的驱动因素,因此需要阐明慢性应激与代谢重编程之间的机制联系。本研究对食管鳞状细胞癌(ESCC)患者血清样本进行非靶向代谢组学分析,并将结果与临床及应激相关评估整合,发现具有应激相关特征的患者存在磷酸戊糖途径(PPP)富集并伴肾上腺素水平升高。慢性应激激活的β2肾上腺素能受体(ADRB2)通过竞争性置换VHL稳定MYC结合蛋白(MYCBP),从而增强MYC转录活性并上调G6PD和TKT等关键PPP酶。出乎意料的是,应激相关刺激不仅激活ADRB2信号,还增加ADRB2蛋白丰度。机制上,应激暴露增强RNA鸟嘌呤-7甲基转移酶(RNMT)依赖的ADRB2 mRNA N7-甲基鸟苷(m7G)帽修饰,进而提高其翻译效率。这些发现界定了一条RNMT-ADRB2-MYCBP-PPP轴,将表观转录组调控与肾上腺素能信号整合,促进ESCC代谢重编程和恶性进展。应激相关RNA修饰-代谢回路包含可用于克服应激相关ESCC进展的潜在治疗靶点。应激相关信号通过RNMT依赖的ADRB2 mRNA m7G帽修饰促进食管鳞状细胞癌进展,增强肾上腺素能信号,稳定MYCBP,并激活MYC驱动的磷酸戊糖途径重编程。
Primary and metastatic lesions share similar biological properties despite existing in different microenvironments. A better understanding of the mechanisms underlying the maintenance of phenotypic homogeneity in heterogeneous microenvironments could help identify strategies for suppressing metastasis. In this study, we found that mechanical memory enabled tumor cells to resist biomechanical stress and sustain malignant traits. Matrix stiffness activated the RhoA-ROCK1 signaling pathway, leading to actin cytoskeletal remodeling and suppression of mitochondrial fission. The dysregulation of mitochondrial dynamics enhanced fatty acid β-oxidation, leading to the accumulation of acetyl coenzyme A and subsequent histone hyperacetylation. The stiffness-mediated epigenetic reprogramming was mitotically heritable, allowing progeny cells to retain a proliferative advantage after detachment from stiff environments. Inhibition of RhoA-ROCK1 disrupted mechanical memory, thereby reducing metastasis. These findings suggest that targeting mechanical memory may be a strategy for preventing metastasis. Matrix stiffness induces metabolic and epigenetic rewiring that creates a lasting memory in cancer cells that supports metastasis, revealing mechanical memory as a potential target for metastasis prevention. See related commentary by Kilian, p. 5313.
中文摘要:原发灶与转移灶处于不同微环境,却具有相似的生物学特性。更深入理解异质微环境中表型同质性得以维持的机制,有助于发现抑制转移的策略。研究发现,机械记忆使肿瘤细胞能够抵抗生物力学应激并维持恶性特征。基质硬度激活RhoA-ROCK1信号通路,引起肌动蛋白细胞骨架重塑并抑制线粒体分裂。线粒体动力学失调增强脂肪酸β氧化,导致乙酰辅酶A积累,随后发生组蛋白超乙酰化。硬度介导的表观遗传重编程可经有丝分裂遗传,使子代细胞在脱离硬基质环境后仍保留增殖优势。抑制RhoA-ROCK1可破坏机械记忆,从而减少转移。这些结果提示,靶向机械记忆可能是预防转移的策略。基质硬度诱导代谢与表观遗传重编程,在癌细胞中形成持久记忆并支持转移,表明机械记忆是预防转移的潜在靶点。参见Kilian的相关评论,第5313页。
Tumor evolution is driven not only by genetic alterations but also by the capacity of cancer cells to adapt to dynamic microenvironmental stresses. Emerging evidence indicates that metabolic constraints can remodel the extracellular matrix (ECM), extending stress adaptation beyond cell-intrinsic programs. Importantly, stress-induced changes in ECM composition, organization and mechanics may persist beyond the initiating stimulus and influence subsequent cell-matrix signaling. We refer to this proposed persistence of stress-associated extracellular changes as"ECM encoding", a form of physicochemical information storage that is mechanistically distinct from genetic memory or cell-intrinsic epigenetic stabilization. Here, we critically review the ECM-integrin axis as a signaling interface linking metabolic stress, redox adaptation and transcriptional plasticity. Metabolic pressures, including hypoxia, nutrient limitation and isolation stress, reshape ECM composition, mechanics and ligand availability, thereby reprogramming integrin signaling. Through focal adhesions, cytoskeletal tension and nuclear mechanotransduction, integrin-dependent signals can influence chromatin accessibility and converge with stress-responsive networks involving YAP/TAZ, ATF4, HIF, NRF2, STAT3 and NF-κB. In parallel, matrix-dependent regulation of mitochondrial reactive oxygen species production and NRF2-mediated antioxidant responses may provide mechanisms linking extracellular cues to redox adaptation. These interconnected processes can promote phenotypic plasticity associated with stemness, dormancy, metastasis, immune evasion and therapeutic resistance, although their relative contributions vary across tumor types and experimental contexts. Finally, we evaluate the therapeutic potential of targeting the ECM-integrin-redox network while considering signaling redundancy, previous clinical setbacks, and the need for biomarker-guided patient selection.
中文摘要:肿瘤进化不仅由基因改变驱动,也取决于癌细胞适应动态微环境应激的能力。越来越多证据表明,代谢限制可重塑细胞外基质(ECM),使应激适应超出细胞内在程序。重要的是,应激诱导的ECM组成、组织和力学变化可能在初始刺激消退后持续存在,并影响后续细胞-基质信号传导。我们将这种应激相关细胞外变化持续存在的设想称为「ECM编码」,这是一种物理化学信息储存形式,在机制上不同于遗传记忆或细胞内在表观遗传稳定化。这里批判性审视ECM-整合素轴作为连接代谢应激、氧化还原适应和转录可塑性的信号界面。缺氧、营养限制和分离应激等代谢压力重塑ECM组成、力学和配体可用性,从而重编程整合素信号。通过黏着斑、细胞骨架张力和核机械转导,整合素依赖信号可影响染色质可及性,并与涉及YAP/TAZ、ATF4、HIF、NRF2、STAT3和NF-κB的应激响应网络汇聚。同时,基质依赖的线粒体活性氧产生调控和NRF2介导的抗氧化反应可能提供将细胞外线索与氧化还原适应联系起来的机制。这些相互关联的过程可促进与干性、休眠、转移、免疫逃逸和治疗耐药相关的表型可塑性,但其相对贡献因肿瘤类型和实验背景而异。同时评估靶向ECM-整合素-氧化还原网络的治疗潜力,并考虑信号冗余、既往临床挫折以及生物标志物指导患者选择的必要性。
Epithelial-to-mesenchymal transition (EMT) regulates tumor progression, metastasis and resistance to therapy. EMT encompasses a continuum of tumor states displaying different functions. The precise dialog between the tumor microenvironment and the different EMT states remains poorly understood. Using single-cell and spatial transcriptomics of mouse skin tumors, we uncover that different EMT states are associated with different niches. Neutrophils are more abundant in niches associated with hybrid EMT and secreted oncostatin M, which partially activates EMT while sustaining the epithelial program, promoting hybrid EMT states and metastasis formation. Macrophages are more abundant in niches associated with more advanced EMT states, which, together with other stromal cells, express TGFβ1 that promotes the late EMT state. Oncostatin M and TGFβ1 function in a feed-forward manner by creating distinct inflammatory niches to maintain specific EMT states. Together, our results reveal that distinct niches are associated with specific EMT states and that signaling pathways sustain their own niche's identity by recruiting specific myeloid cell populations.
中文摘要:上皮–间质转化(EMT)调控肿瘤进展、转移和治疗耐药。EMT 涵盖一系列功能各异的肿瘤状态。肿瘤微环境与不同 EMT 状态之间的精确对话仍不清楚。利用小鼠皮肤肿瘤的单细胞与空间转录组学,我们发现不同的 EMT 状态与不同的生态位相关联。中性粒细胞在混合型 EMT 相关的生态位中更丰富,其分泌的抑瘤素 M 可部分激活 EMT,同时维持上皮程序,促进混合型 EMT 状态与转移形成。巨噬细胞在更晚期 EMT 状态相关的生态位中更丰富,它们与其他基质细胞共同表达 TGFβ1,推动晚期 EMT 状态。抑瘤素 M 与 TGFβ1 以前馈方式发挥作用,通过形成不同的炎性生态位来维持特定的 EMT 状态。上述结果揭示,不同生态位与特定 EMT 状态相对应,信号通路通过募集特定髓系细胞群体来维持各自生态位的身份。
In vivo continuous eradication of circulating tumor cells (CTCs) following chemotherapy represents a promising strategy to prevent cancer recurrence and metastasis, but remains a practical challenge. Here, we propose a bioligand-assisted in vivo therapy for dynamic check and hemo clearance of CTCs, termed the "Black-hole" system. Inspired by hemopurification, the Black-hole system integrates a peristaltic pump to maintain continuous blood flow, a functionalized microfluidic reservoir for CTCs sustained capture, and flexible tubing with needles for in vivo blood withdrawal and reinfusion. In this system, blood is drawn from the left carotid artery, passes through the microfluidic reservoir to selectively withhold CTCs, and is subsequently reinfused into the right jugular vein. Demonstration in a live tumor-bearing mouse model demonstrated the biosafety and efficacy of the system for single-pass, in vivo CTCs elimination. No significant morphological alterations were observed in major organs after the Black-hole system therapy. Notably, mice receiving the Black-hole therapy following paclitaxel chemotherapy exhibited a 50% survival rate, along with a 16.7% reduction in overall tumor recurrence. We expect the Black-hole system to become a safe and effective adjuvant therapy for postoperative cancer management.
中文摘要:化疗后体内持续清除循环肿瘤细胞(CTCs)是预防癌症复发和转移的有前景策略,但实际应用仍有挑战。我们提出一种生物配体辅助的体内治疗策略,用于动态检查并血液清除CTCs,称为「Black-hole」系统。受血液净化启发,该系统整合蠕动泵维持连续血流、功能化微流控储液器持续捕获CTCs,以及带针柔性管路用于体内取血和回输。系统中血液从左颈动脉引出,经过微流控储液器选择性截留CTCs,随后回输至右颈静脉。在荷瘤活体小鼠模型中的演示显示,该系统单次循环体内清除CTCs具有生物安全性和有效性。Black-hole系统治疗后主要器官未见明显形态学改变。接受紫杉醇化疗后给予Black-hole治疗的小鼠生存率为50%,总体肿瘤复发减少16.7%。我们期望Black-hole系统成为术后癌症管理安全有效的辅助治疗。
Micro- and nanoplastics have been found in tumors throughout the human body, from the gut and lung to the brain and prostate, and laboratory work ties them to inflammation, DNA damage, and other cancer-related changes. But nearly all that evidence is either associative or drawn from animals and cells. Researchers say a causal verdict will require studies that measure exposure before disease appears, a bar the field has not yet cleared.
中文摘要:微塑料和纳米塑料已在人体多处肿瘤中被检出,从肠道、肺到脑和前列腺;实验室研究把它们与炎症、DNA损伤及其他癌症相关改变联系起来。但这些证据几乎全部是关联性的,或来自动物与细胞。研究者表示,要作出因果判断,需要在疾病出现之前测量暴露,而该领域尚未达到这一标准。
Radioresistance severely compromises radiotherapy efficacy for lung adenocarcinoma (LUAD), yet the intrinsic heterogeneity of cellular radioresponses among isogenic tumor cells remains poorly characterized. Here, we integrated single-cell RNA sequencing (scRNA-seq) and single-cell assay for transposase-accessible chromatin with high-throughput sequencing (scATAC-seq) to dissect the transcriptional and regulatory landscape underlying heterogeneous radioresponses in single-cell-derived LUAD cells following 6 Gy γ-ray irradiation. We found that isogenic LUAD cells harbored intrinsic molecular determinants for divergent radiosensitivity and displayed heterogeneous radioresponsiveness upon irradiation. A radiation-associated transcriptional cell state, coupled with DNA damage repair, apoptosis, and cell cycle regulation, emerged at 6 h post-irradiation. Inhibition of lysine demethylase 4B (KDM4B) enhanced LUAD radiosensitivity by intensifying DNA damage, whereas reduced expression of cyclin B1 (CCNB1) and DNA topoisomerase IIα (TOP2A) potentially contributed to radiation-triggered G2/M arrest. Notably, the radiation-associated regulatory cell state emerged earlier than radiation-induced transcriptional cell state. RNA polymerase II subunit A (POLR2A) functioned as a core regulator in high-responsive LUAD cells. Based on these findings, we proposed a hypothesis for the radiosensitization of LUAD cells. Collectively, this study provides multilayer mechanistic insights into LUAD radioresponse heterogeneity and yields actionable molecular candidates for developing improved radiosensitization strategies to advance precise radiotherapy for LUAD.
中文摘要:放射抵抗严重削弱肺腺癌(LUAD)的放疗疗效,但同基因肿瘤细胞之间细胞放射反应的内在异质性仍缺乏充分刻画。本研究整合单细胞RNA测序(scRNA-seq)与高通量单细胞转座酶可及性染色质检测(scATAC-seq),解析单细胞来源LUAD细胞接受6 Gy γ射线照射后异质性放射反应背后的转录与调控图谱。研究发现,同基因LUAD细胞具有导致放射敏感性差异的内在分子决定因素,并在照射后表现出异质性放射反应性。照射后6小时出现一种与放射相关的转录细胞状态,并伴随DNA损伤修复、凋亡和细胞周期调控。抑制赖氨酸去甲基化酶4B(KDM4B)可通过加剧DNA损伤增强LUAD放射敏感性,而细胞周期蛋白B1(CCNB1)和DNA拓扑异构酶IIα(TOP2A)表达降低可能促进放射触发的G2/M阻滞。放射相关调控细胞状态早于放射诱导的转录细胞状态出现。RNA聚合酶II亚基A(POLR2A)在高反应性LUAD细胞中作为核心调控因子发挥作用。基于这些发现,提出LUAD细胞放射增敏的假说。这些结果从多层机制层面揭示LUAD放射反应异质性,并为开发改进的放射增敏策略、推进LUAD精准放疗提供可操作的分子候选。
Here we present AmpliconSuite, a toolkit for focal amplification analysis from cancer whole-genome sequencing that identifies extrachromosomal DNA (ecDNA), breakage-fusion-bridges and other amplification modes. Its ecContext module categorizes ecDNA structures to understand formation mechanisms. Validation across 175 metaphase fluorescence in situ hybridization-probed genes in 72 models demonstrated accurate predictions. Analysis of 6,506 patient pan-cancer samples revealed ecDNA-mediated oncogene co-amplification preferences. To democratize data sharing, we created AmpliconRepository, a community-contributable platform, enabling investigation of results across >15,000 publicly hosted samples.
中文摘要:AmpliconSuite 是一套用于癌症全基因组测序中局灶性扩增分析的工具包,可识别染色体外 DNA(ecDNA)、断裂-融合-桥及其他扩增模式。其 ecContext 模块对 ecDNA 结构进行分类,以理解其形成机制。在 72 个模型中对 175 个经中期荧光原位杂交探针检测的基因进行验证,显示出准确的预测能力。对 6,506 例泛癌患者样本的分析揭示了 ecDNA 介导的癌基因共扩增偏好。为促进数据共享,建立了社区可贡献平台 AmpliconRepository,可对超过 15,000 例公开托管样本的结果进行研究。
Atherosclerosis remains a leading cause of cardiovascular mortality, driven by macrophage dysfunction and necrotic core expansion. Ferroptosis, an iron-dependent cell death, is a critical driver of plaque instability; however, pharmacological interventions targeting ferroptosis remain scarce. Lentinan (LNT), a bioactive β-(1,3)-glucan extracted from shiitake mushrooms, exhibits potent antioxidant properties but its potential role in the modulation of macrophage ferroptosis remains unexplored. We investigated the therapeutic potential and molecular mechanisms of action of LNT in atherosclerosis. LNT administration significantly attenuated atherosclerotic progression in mice. Specifically, LNT mitigated macrophage ferroptosis by enhancing glutathione homeostasis and reducing lipid peroxidation. Notably, these protective effects were significantly abrogated in mice deficient in solute carrier family 7 member 11 (SLC7A11), indicating that the effect of LNT is dependent on this molecule. We found that LNT directly binds to far upstream binding protein 1 (FUBP1) and that T559 is required for FUBP1 O-GlcNAcylation and subsequent nuclear translocation. In the nucleus, FUBP1 binds to tumor protein p53 (Tp53), thereby relieving the transcriptional repression of SLC7A11. The resulting activation of the SLC7A11 signaling axis not only inhibits ferroptosis but also promotes scavenger receptor B type 1 (SR-B1)-mediated cholesterol efflux. These findings highlight LNT as a novel modulator of the FUBP1/Tp53/SLC7A11 axis, offering a promising natural therapeutic strategy to stabilize atherosclerotic plaques.
中文摘要:动脉粥样硬化仍是心血管死亡的主要原因,其发生与巨噬细胞功能障碍和坏死核心扩大有关。铁死亡是一种铁依赖性细胞死亡,是斑块不稳定的关键驱动因素;但靶向铁死亡的药物干预仍较少。香菇多糖(LNT)是从香菇中提取的具有生物活性的β-(1,3)-葡聚糖,具有较强抗氧化特性,但其调控巨噬细胞铁死亡的潜在作用尚未被探索。我们研究了LNT在动脉粥样硬化中的治疗潜力及分子作用机制。给予LNT可显著减轻小鼠动脉粥样硬化进展。具体而言,LNT通过增强谷胱甘肽稳态和减少脂质过氧化来减轻巨噬细胞铁死亡。这些保护作用在溶质载体家族7成员11(SLC7A11)缺陷小鼠中显著减弱,表明LNT的作用依赖该分子。我们发现LNT直接结合远端上游结合蛋白1(FUBP1),且T559是FUBP1 O-GlcNAc糖基化及随后核转位所必需。在细胞核中,FUBP1结合肿瘤蛋白p53(Tp53),从而解除对SLC7A11的转录抑制。由此激活的SLC7A11信号轴不仅抑制铁死亡,还促进B类清道夫受体1(SR-B1)介导的胆固醇外流。这些发现表明LNT是FUBP1/Tp53/SLC7A11轴的新型调节剂,为稳定动脉粥样硬化斑块提供了一种有前景的天然治疗策略。
Tumors persist under sustained redox stress by coupling increased reactive-species production to antioxidant buffering, metabolic plasticity and multicellular support. This creates therapeutic vulnerabilities whose tractability depends on the biological state of the exposed compartment. Here, we frame redox nanomedicine as state-matched manipulation of oxidant flux, antioxidant buffering, oxygen and substrate availability, localization, duration and spatial coverage. We propose that therapeutic outcome emerges from chemistry, exposure and the presence of an executable redox dependency together with the machinery required for adaptation, apoptosis, ferroptosis, pyroptosis or cuproptosis. Redox perturbations also propagate through immune, vascular, stromal and metabolic compartments, generating both therapeutic benefits and liabilities. We therefore integrate redox-state dependence, cell-fate assignment, multicompartment effects and translational target engagement into a unified framework. A state-matched development strategy begins with a defined biological dependency, measures local exposure and target engagement, and uses pharmacokinetic, safety and biomarker data to refine product design and patient selection. This framework positions redox nanomedicine as mechanistically testable control of tumor redox states within a defined therapeutic window.
中文摘要:肿瘤在持续氧化还原应激下通过将活性物质产生增加与抗氧化缓冲、代谢可塑性和多细胞支持相耦联而得以存续。这形成了治疗易感性,其可干预性取决于暴露区室的生物学状态。在此,我们将氧化还原纳米医学界定为对氧化剂通量、抗氧化缓冲、氧与底物可利用性、定位、持续时间及空间覆盖进行状态匹配式操控。我们提出,治疗结局源于化学性质、暴露以及可执行的氧化还原依赖性与适应、凋亡、铁死亡、焦亡或铜死亡所需机制的同时存在。氧化还原扰动还会经免疫、血管、基质和代谢区室传播,既产生治疗获益也带来治疗风险。因此,我们将氧化还原状态依赖性、细胞命运指定、多区室效应和转化靶点参与整合为一个统一框架。状态匹配的开发策略始于明确的生物学依赖性,测定局部暴露和靶点参与,并利用药代动力学、安全性和生物标志物数据来优化产品设计与患者选择。该框架将氧化还原纳米医学定位为在限定治疗窗内对肿瘤氧化还原状态进行机制上可检验的调控。
Ferroptosis is an iron-dependent form of cell death involved in cancer, ischemia-reperfusion injury, inflammation, and neurodegeneration. It can be triggered in two ways: class 1 inhibitors such as erastin block system xc-, the cystine/glutamate antiporter composed of xCT and 4F2hc/CD98, causing glutathione depletion, whereas class 2 inhibitors such as RSL3 directly inhibit glutathione peroxidase 4, causing lipid peroxidation. Ferroptotic cell death is suppressed by radical-trapping antioxidants like ferrostatin-1. We investigated the effects of erastin and RSL3 on Drosophila melanogaster lifespan, iron metabolism, and lipid composition. Erastin and RSL3 dose- and diet-dependently shortened lifespan which was rescued by ferrostatin-1. Erastin increased the Fe2+/Fe3+ ratio and reduced ferritin-bound iron, and RSL3 remodeled lipid composition consistent with lipid peroxidation. Both effects occurred only in male w1118 flies although both sexes had similarly reduced lifespans. Total glutathione was unchanged by erastin; notably, the fly GPX4 ortholog Gtpx is a non-selenocysteine, thioredoxin-dependent peroxidase. Complete Gtpx knockout caused early lethality mirroring the embryonic lethality of constitutive GPX4 knockout in mice but was not affected by ferrostatin-1. Flies also lack a clearly defined xCT ortholog. Together, these results establish male w1118 flies as a suitable in vivo ferroptosis model and point to glutathione-independent actions of erastin.
中文摘要:铁死亡是一种铁依赖性细胞死亡形式,参与癌症、缺血再灌注损伤、炎症和神经退行性变。它可由两类方式触发:erastin等1类抑制剂阻断由xCT和4F2hc/CD98组成的胱氨酸/谷氨酸逆向转运体system xc-,造成谷胱甘肽耗竭;RSL3等2类抑制剂直接抑制谷胱甘肽过氧化物酶4,引起脂质过氧化。铁死亡性细胞死亡可被ferrostatin-1等自由基捕获型抗氧化剂抑制。我们研究了erastin和RSL3对黑腹果蝇寿命、铁代谢和脂质组成的影响。erastin和RSL3以剂量和饮食依赖的方式缩短寿命,ferrostatin-1可挽救这一效应。erastin提高Fe2+/Fe3+比值并减少铁蛋白结合铁,RSL3重塑脂质组成,符合脂质过氧化的表现。这两种效应仅出现在雄性w1118果蝇中,尽管两性寿命下降程度相似。erastin未改变总谷胱甘肽;果蝇GPX4直系同源物Gtpx是一种不含硒代半胱氨酸、依赖硫氧还蛋白的过氧化物酶。Gtpx完全敲除导致早期致死,与小鼠组成性GPX4敲除的胚胎致死相似,但不受ferrostatin-1影响。果蝇也缺乏明确界定的xCT直系同源物。这些结果确立雄性w1118果蝇作为合适的体内铁死亡模型,并提示erastin具有不依赖谷胱甘肽的作用。
Cisplatin resistance in hepatoblastoma (HB) is a major therapeutic barrier. Emerging evidence suggests that cancer cells can activate DNA double-strand break repair pathways to evade chemotherapy-induced apoptosis and sustain stemness; however, the mechanisms underlying cisplatin resistance in HB remain poorly understood. Here, we identified the neuronal protein BEX4 as a key mediator of cisplatin resistance. BEX4 was aberrantly overexpressed in HB cells and maintained a stem-like state. Mechanistically, BEX4 bound to and stabilized the core nonhomologous end-joining (NHEJ) factor X-ray repair cross-complementing protein 5 (XRCC5), thereby promoting NHEJ activity and contributing to cisplatin resistance. DNA damage induced ataxia telangiectasia mutated kinase (ATM)-dependent phosphorylation of BEX4 at Thr107, promoting transient dissociation of the BEX4-XRCC5 complex and facilitating XRCC5 recruitment to DNA damage sites. BEX4-driven NHEJ enhances DNA damage repair, potentially contributing to genomic instability, stemness, and chemoresistance. Building on these mechanistic findings, we identified a small-molecule compound, F35-303, which disrupted the BEX4-XRCC5 interaction, suppressed NHEJ activity, and restored cisplatin sensitivity in resistant preclinical models. Our findings identify BEX4 as a key mediator of cisplatin resistance in HB and suggest that targeting the BEX4-XRCC5 interaction with F35-303 may provide a new therapeutic strategy for overcoming chemoresistance in HB and a mechanistic framework for understanding adaptive chemoresistance.
中文摘要:顺铂耐药是肝母细胞瘤(HB)治疗的主要障碍。越来越多证据提示,癌细胞可激活DNA双链断裂修复通路,逃避化疗诱导的凋亡并维持干性;但HB顺铂耐药机制仍不清楚。我们鉴定神经元蛋白BEX4是顺铂耐药的关键介导因子。BEX4在HB细胞中异常高表达并维持类干状态。机制上,BEX4结合并稳定核心非同源末端连接(NHEJ)因子X射线修复交叉互补蛋白5(XRCC5),促进NHEJ活性并导致顺铂耐药。DNA损伤诱导共济失调毛细血管扩张突变激酶(ATM)依赖的BEX4 Thr107磷酸化,促使BEX4-XRCC5复合物短暂解离,并促进XRCC5募集至DNA损伤位点。BEX4驱动的NHEJ增强DNA损伤修复,可能促成基因组不稳定、干性和化疗耐药。基于这些机制发现,我们找到小分子化合物F35-303,可破坏BEX4-XRCC5相互作用、抑制NHEJ活性,并在耐药临床前模型中恢复顺铂敏感性。研究结果确定BEX4是HB顺铂耐药的关键介导因子,并提示以F35-303靶向BEX4-XRCC5相互作用可能为克服HB化疗耐药提供新治疗策略,也为理解适应性化疗耐药提供机制框架。
Cancer stem cells (CSCs) drive tumor recurrence, metastasis, and therapeutic resistance.Rather than exhibiting a uniform glycolytic phenotype, CSCs occupy tumor- and state-dependent metabolic configurations ranging from glycolysisdominant to oxidative phosphorylation(OXPHOS)-dependent and hybrid states. In hypoxic and hypoxia-inducible factor-1α(HIF-1α)-active CSC subpopulations, aerobic glycolysis can support stemness, treatment resistance, and immune evasion by increasing glucose consumption, lactate production, and microenvironmental acidification. Accordingly, the HIF-Warburg axis represents an actionable but context-dependent metabolic vulnerability. This review systematically examines nanodrug design strategies targeting the HIF-Warburg axis, spanning four regulatory levels: (1) Direct inhibition of HIF-1α expression via nanocarriers delivering siRNA or oxygen-releasing particles; (2) Inhibition of glycolysis through nanoscale inhibitors targeting HK2, LDHA, and PDK1; (3) Substrate deprivation by targeting GLUT1 or employing glucose oxidase; and (4) Lactate neutralization and pH-responsive nanosystems to reverse the acidic microenvironment, reactivate immune responses, and achieve metabolic-immune synergistic therapy. This review synthesizes interactions among CSCs, the Warburg effect, HIF-1α signaling, and immune evasion mechanisms, and highlights emerging nanotherapeutic strategies that exploit these vulnerabilities to improve cancer treatment outcomes, offering significant promise for advancing precision cancer therapy.
中文摘要:癌症干细胞(CSCs)驱动肿瘤复发、转移和治疗耐药。CSCs并非表现统一的糖酵解表型,而是呈现依赖肿瘤类型和状态变化的代谢配置,从糖酵解主导到依赖氧化磷酸化(OXPHOS)及混合状态。在缺氧且缺氧诱导因子-1α(HIF-1α)活跃的CSC亚群中,有氧糖酵解可通过增加葡萄糖消耗、乳酸生成和微环境酸化来支持干性、治疗耐药和免疫逃逸。因此,HIF-Warburg轴是一个可干预但依赖情境的代谢脆弱点。本综述系统考察靶向HIF-Warburg轴的纳米药物设计策略,涵盖四个调控层面:(1)通过纳米载体递送siRNA或释氧颗粒直接抑制HIF-1α表达;(2)通过靶向HK2、LDHA和PDK1的纳米抑制剂抑制糖酵解;(3)通过靶向GLUT1或使用葡萄糖氧化酶实现底物剥夺;(4)乳酸中和及pH响应纳米系统逆转酸性微环境、重新激活免疫反应并实现代谢-免疫协同治疗。本综述整合CSCs、Warburg效应、HIF-1α信号与免疫逃逸机制之间的相互作用,并强调利用这些脆弱点改善癌症治疗结局的新兴纳米治疗策略,为推进精准癌症治疗提供重要前景。
The TLR4/MyD88 signaling axis serves as a central hub linking microbial- and damage-associated molecular patterns to oncogenic inflammation. Upon ligand engagement, MyD88 orchestrates two major downstream branches, including the canonical NF-κB pathway, which drives transcriptional programs for cell survival, proliferation, angiogenesis, and metastasis, and the NLRP3 inflammasome, which amplifies IL-1β/IL-18 release and pyroptosis. While these branches have been extensively studied individually, their integrated roles and crosstalk remain underexplored in cancer. Recent advances show that NF-κB provides the essential signal 1 for NLRP3 priming, yet the two pathways exert cell-type- and tumor-stage-dependent, sometimes opposing effects on tumor progression, therapy resistance, and anti-tumor immunity. We highlight cancer-type and cell-type specificity, microbiome influences, and emerging therapeutic opportunities targeting TLR4, NF-κB, and NLRP3 individually or in combination. This unified framework positions the TLR4/MyD88 axis as a high-value target for precision oncology and underscores the need for pathway-selective inhibitors to harness its divergent outputs.
中文摘要:TLR4/MyD88信号轴是连接微生物相关分子模式和损伤相关分子模式与致癌性炎症的中心枢纽。配体结合后,MyD88协调两条主要下游分支:经典NF-κB通路驱动细胞存活、增殖、血管生成和转移相关转录程序;NLRP3炎症小体则放大IL-1β/IL-18释放与细胞焦亡。这两条分支虽已被分别广泛研究,但其在癌症中的整合作用与交互仍认识不足。近期进展显示,NF-κB为NLRP3致敏提供必需的信号1,但两条通路对肿瘤进展、治疗抵抗和抗肿瘤免疫的影响具有细胞类型与肿瘤阶段依赖性,有时甚至相反。文中强调癌种与细胞类型特异性、微生物组影响,以及靶向TLR4、NF-κB和NLRP3单用或联用的新兴治疗机会。这一统一框架将TLR4/MyD88轴定位为精准肿瘤学的高价值靶点,并强调需要通路选择性抑制剂以利用其不同输出。
PBK/TOPK is a serine/threonine kinase belonging to the mitogen-activated protein kinase kinase family, involved in the regulation of cell survival, proliferation, growth, apoptosis, and inflammation response. It is overexpressed in various malignant tumors and participates in chromosome condensation, mitotic progression, and cytokinesis. Aberrant activation of PBK may promote tumor-cell proliferation, survival, local invasion, and metastasis, whereas depletion or inhibition of PBK induces mitotic defects and cytokinesis failure, thereby suppressing tumor-cell growth. These findings support PBK as a molecular target with clear pathological relevance in cancer therapy, although its dysregulated expression extends beyond malignancy. Studies have shown that PBK is also expressed in normal proliferating cells, such as neural progenitor cells and spermatogenic cells, and is markedly upregulated under pathological conditions in cardiac, cerebral, and renal tissues. By regulating key physiological processes, including cell proliferation and self-renewal, it plays a pivotal role in maintaining tissue homeostasis and facilitating injury repair. This review compares PBK kinase inhibition with expression silencing and targeted protein degradation, emphasizing the potential advantages of reversible and dose-titratable catalytic modulation while recognizing that kinase-independent PBK functions may require protein-level depletion. By summarizing the development of PBK inhibitors, this review further suggests that activity-based inhibition may offer superior pharmacological controllability, reversibility, dose adjustability, and translational potential compared with expression-silencing strategies such as RNA interference.
中文摘要:PBK/TOPK 是丝裂原活化蛋白激酶激酶家族的丝氨酸/苏氨酸激酶,参与细胞存活、增殖、生长、凋亡与炎症反应的调控。它在多种恶性肿瘤中过度表达,并参与染色体凝缩、有丝分裂进程和胞质分裂。PBK 异常激活可促进肿瘤细胞增殖、存活、局部侵袭与转移,而敲低或抑制 PBK 会引起有丝分裂缺陷和胞质分裂失败,从而抑制肿瘤细胞生长。这些结果支持把 PBK 看作肿瘤治疗中具有明确病理相关性的分子靶点,但其表达失调并不限于恶性肿瘤。研究显示 PBK 也表达于神经祖细胞、精原细胞等正常增殖细胞,并在心脏、脑和肾脏组织的病理状态下明显上调。通过调控细胞增殖与自我更新等关键生理过程,它在维持组织稳态和促进损伤修复中起重要作用。本综述将 PBK 激酶抑制与表达沉默、靶向蛋白降解进行比较,强调可逆且剂量可滴定的催化活性调控所具有的潜在优势,同时指出不依赖激酶活性的 PBK 功能可能需要蛋白水平的清除。通过总结 PBK 抑制剂的研发进展,综述进一步提出,与 RNA 干扰等表达沉默策略相比,基于活性的抑制在药理学可控性、可逆性、剂量可调性及转化潜力方面可能更具优势。
Endometriosis is a chronic, estrogen-dependent inflammatory disease that, despite its benign histology, displays several cancer-relevant features, including clonal expansion, somatic alteration-associated lesion evolution, tissue invasion, apoptosis resistance, immune evasion, angiogenesis, fibrosis, and metabolic adaptation. These features are particularly important in ovarian endometriosis, where recurrent hemorrhage, iron-driven oxidative stress, and chronic inflammatory remodeling may promote malignant transformation. This review examines endometriosis through an oncologic framework by integrating current evidence on disease initiation, clonal lesion evolution, and the peritoneal, ovarian, and deep-infiltrating microenvironments. We discuss how epithelial, stromal, immune, endothelial, mesothelial, and neural components cooperate to support lesion survival, dissemination, vascularization, fibrosis, neuroinflammation, and treatment resistance. Particular attention is given to cancer-associated molecular programs, including PI3K-AKT-mTOR, RAS-MAPK, WNT/β-catenin, hypoxia, oxidative-stress, inflammatory, and epigenetic signaling, and their relationship to endometriosis-associated ovarian cancer. We also critically evaluate animal models, organoids, three-dimensional scaffolds, and microfluidic systems for their ability to reproduce lesion heterogeneity, microenvironmental interactions, therapeutic responses, and malignant progression. Finally, we assess current and emerging therapeutic strategies, emphasizing non-hormonal interventions directed against inflammatory, immune, fibrotic, angiogenic, metabolic, and oncogenic vulnerabilities, together with biomarker-guided and fertility-sparing approaches. Viewing endometriosis as a cancer-relevant inflammatory and clonal disease may reveal actionable mechanisms for precision treatment and interception of endometriosis-associated malignancy.
中文摘要:子宫内膜异位症是一种慢性、雌激素依赖性炎症性疾病,组织学虽为良性,却表现出多种与癌症相关的特征,包括克隆性扩增、体细胞改变相关的病灶演化、组织侵袭、凋亡抵抗、免疫逃逸、血管生成、纤维化和代谢适应。这些特征在卵巢子宫内膜异位症中尤为重要,反复出血、铁驱动的氧化应激和慢性炎症重塑可能促进恶变。本综述以肿瘤学框架审视子宫内膜异位症,整合疾病起始、克隆性病灶演化以及腹膜、卵巢和深部浸润微环境方面的现有证据。讨论上皮、间质、免疫、内皮、间皮和神经成分如何协同支持病灶存活、播散、血管化、纤维化、神经炎症和治疗抵抗。重点讨论癌症相关分子程序,包括PI3K-AKT-mTOR、RAS-MAPK、WNT/β-catenin、缺氧、氧化应激、炎症和表观遗传信号,以及它们与子宫内膜异位症相关卵巢癌的关系。也批判性评估动物模型、类器官、三维支架和微流控系统在重现病灶异质性、微环境相互作用、治疗反应和恶性进展方面的能力。治疗层面,评估当前和新兴治疗策略,强调针对炎症、免疫、纤维化、血管生成、代谢和致癌脆弱性的非激素干预,以及生物标志物引导和保留生育力的方法。将子宫内膜异位症视为一种与癌症相关的炎症性和克隆性疾病,可能揭示用于精准治疗和拦截子宫内膜异位症相关恶性肿瘤的可操作机制。
Atherosclerosis (AS) is the main pathological basis of cardiovascular diseases, and its pathogenesis and treatment strategies remain major challenges. Recent advances in single-cell RNA sequencing and lineage tracing have revealed that vascular smooth muscle cells (VSMCs) are not merely passive structural components of atherosclerotic plaques, but highly plastic participants that undergo clonal expansion, phenotypic modulation, and transdifferentiation into functionally diverse cell states. These findings have prompted the emergence of an "athero-oncology" framework, which explores selected tumor-like cellular programs in VSMCs during AS without equating atherosclerosis with cancer. In this review, we summarize the evidence supporting VSMC-derived clonal expansion and phenotypic diversification in atherosclerotic lesions and discuss key mechanisms involved in this process, including proliferative expansion and survival programs, metabolic reprogramming, epigenetic regulation, DNA damage and genomic stress, VSMC senescence, pathological angiogenesis, and remodeling of the inflammatory and immune microenvironment. We further highlight shared signaling pathways between VSMC-driven plaque remodeling and tumor biology, while emphasizing fundamental differences between AS and malignant disease in growth limitation, mutational burden, metastatic potential, and clinical behavior. Finally, we discuss oncology-inspired therapeutic opportunities and boundaries, including pathway-level targeting of proliferative, metabolic, epigenetic, and inflammatory programs, as well as the risks of directly repurposing anticancer therapies for chronic vascular disease. This framework may provide new insights into vascular biology and therapeutic development.
中文摘要:动脉粥样硬化(AS)是心血管疾病的主要病理基础,其发病机制和治疗策略仍面临重大挑战。单细胞RNA测序和谱系追踪的进展显示,血管平滑肌细胞(VSMCs)并非动脉粥样硬化斑块中被动的结构成分,而是具有高度可塑性的参与者,可发生克隆扩增、表型调节并转分化为功能多样的细胞状态。这些发现促成了「动脉粥样硬化-肿瘤学」框架的出现,该框架探讨AS中VSMCs的某些肿瘤样细胞程序,但并不将动脉粥样硬化等同于癌症。本综述总结支持动脉粥样硬化病变中VSMC来源克隆扩增和表型多样化的证据,讨论该过程涉及的关键机制,包括增殖性扩增与存活程序、代谢重编程、表观遗传调控、DNA损伤与基因组应激、VSMC衰老、病理性血管生成以及炎症和免疫微环境重塑。进一步突出VSMC驱动斑块重塑与肿瘤生物学之间的共享信号通路,同时强调AS与恶性肿瘤在生长限制、突变负荷、转移潜能和临床行为方面的根本差异。最后讨论受肿瘤学启发的治疗机会与边界,包括对增殖、代谢、表观遗传和炎症程序的通路层面靶向,以及将抗癌疗法直接重新用于慢性血管疾病的风险。该框架可能为血管生物学和治疗开发提供新见解。
Cancer stem cells (CSCs) contribute to therapeutic resistance, metastatic progression, and tumor recurrence, yet the metabolic pathways that sustain their survival remain incompletely understood. Here, we identify 3-mercaptopyruvate sulfurtransferase (3-MST), a hydrogen sulfide-producing enzyme encoded by MPST, as a metabolic dependency of colorectal CSCs. 3-MST expression was increased in human colorectal tumors and cancer cell lines and strongly correlated with proliferative capacity. HCT116-derived CSCs exhibited elevated 3-MST expression, increased hydrogen sulfide and reactive sulfur species production, altered membrane rigidity, and a metabolically restrained phenotype characterized by low basal oxidative phosphorylation and glycolysis. Genetic depletion of 3-MST preferentially impaired CSC proliferation, spheroid formation, stem-like properties, and migration, with less pronounced effects in differentiated parental cells. Pharmacological inhibition of 3-MST reproduced these effects across CSCs derived from several colorectal cancer cell lines and induced near-complete suppression of mitochondrial respiration and glycolytic activity. 3-MST inhibition also increased membrane fluidity, promoted cell death, and reduced CSC-derived tumor growth in mice. Integrated transcriptomic, proteomic, metabolomic, and lipidomic analyses demonstrated coordinated disruption of mitochondrial carbon metabolism, respiratory-chain maintenance, lipid desaturation, and membrane phospholipid homeostasis. These changes were accompanied by accumulation of free fatty acids and diacylglycerols and activation of antioxidants, integrated stress-response, endoplasmic-reticulum-stress, apoptotic, and p53-associated pathways. Ferroptosis-related molecular signatures were also enriched. These findings identify 3-MST as a critical regulator of colorectal CSC bioenergetics and membrane homeostasis and reveal a therapeutically exploitable metabolic vulnerability in treatment-resistant colorectal cancer.
中文摘要:肿瘤干细胞(CSCs)参与治疗抵抗、转移进展和肿瘤复发,但维持其存活的代谢通路仍未完全阐明。3-巯基丙酮酸硫转移酶(3-MST)是由MPST编码的产硫化氢酶,可作为结直肠CSCs的代谢依赖。3-MST在人类结直肠肿瘤和癌细胞系中表达升高,并与增殖能力密切相关。HCT116来源的CSCs表现出3-MST表达升高、硫化氢和活性硫物种生成增加、膜刚性改变,以及基础氧化磷酸化和糖酵解均较低的代谢受限表型。基因敲低3-MST优先损害CSC的增殖、球体形成、干性特征和迁移,对分化的亲本细胞影响较弱。药理学抑制3-MST在多种结直肠癌细胞系来源的CSCs中重现这些效应,并几乎完全抑制线粒体呼吸和糖酵解活性。抑制3-MST还增加膜流动性、促进细胞死亡,并减少小鼠中CSC来源的肿瘤生长。整合转录组学、蛋白质组学、代谢组学和脂质组学分析显示,线粒体碳代谢、呼吸链维持、脂质去饱和和膜磷脂稳态受到协同破坏。这些变化伴随游离脂肪酸和二酰甘油积累,以及抗氧化、整合应激反应、内质网应激、凋亡和p53相关通路的激活。铁死亡相关分子特征也出现富集。这些发现将3-MST确定为结直肠CSC生物能量学和膜稳态的关键调节因子,并揭示了治疗抵抗性结直肠癌中可利用的代谢脆弱性。
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited therapeutic options. Here, we identify long-chain acyl-CoA synthetase 5 (ACSL5) as a key oncogenic driver and prognostic biomarker in PDAC. Combined transcriptomic analysis of 51 PDAC samples and three public databases (GSE183795, GSE28735, GSE62452) reveals that ACSL5 is markedly upregulated in PDAC, and its overexpression is significantly associated with shorter patient survival and high diagnostic accuracy (AUC = 0.899), suggesting robust diagnostic potential. Functional assays demonstrate that ACSL5 promotes PDAC cell proliferation, migration, and tumor growth while inhibiting apoptosis. Mechanistically, ACSL5 activates the JAK1-STAT1 signaling pathway, leading to transcriptional upregulation of oligoadenylate synthetase-like protein (OASL). The ACSL5-OASL axis concurrently suppresses PINK1/Parkin-mediated mitophagy and enhances ferroptosis resistance by modulating GPX4, SLC7A11, and ACSL4 expression. Notably, the mitophagy activator CCCP effectively reverses ACSL5-driven tumor progression and restores ferroptosis sensitivity. Our findings establish ACSL5 as a promising diagnostic and therapeutic target and reveal that targeting mitophagy represents a potential strategy for ACSL5-high PDAC.
中文摘要:胰腺导管腺癌(PDAC)致死率高,治疗选择有限。研究将长链酰基辅酶A合成酶5(ACSL5)鉴定为PDAC的关键致癌驱动因子和预后生物标志物。对51例PDAC样本及三个公共数据库(GSE183795、GSE28735、GSE62452)的联合转录组分析显示,ACSL5在PDAC中明显上调,其过表达与患者生存期缩短显著相关,并具有较高诊断准确性(AUC=0.899),提示较好的诊断潜力。功能实验表明,ACSL5促进PDAC细胞增殖、迁移和肿瘤生长,同时抑制凋亡。机制上,ACSL5激活JAK1-STAT1信号通路,导致寡腺苷酸合成酶样蛋白(OASL)转录上调。ACSL5-OASL轴同时抑制PINK1/Parkin介导的线粒体自噬,并通过调节GPX4、SLC7A11和ACSL4表达增强铁死亡抵抗。线粒体自噬激活剂CCCP可有效逆转ACSL5驱动的肿瘤进展并恢复铁死亡敏感性。研究结果确立ACSL5作为有前景的诊断和治疗靶点,并揭示靶向线粒体自噬可能是ACSL5高表达PDAC的潜在策略。
Leptomeningeal metastases are devastating complications of advanced HER2+ breast cancer, with limited therapeutic options. We developed a xenograft model of human HER2+ breast cancer cell line JIMT1-BR3-LM4 leptomeningeal colonization by four iterative cycles of intrathecal injection. The model reliably produced leptomeningeal lesions in brain and spinal cord and tumor cells in the CSF, as confirmed by endpoints of BLI, MRI, pathologic analysis and immunofluorescent staining. Upon RNA-seq, the LM model exhibited significant transcriptional changes as compared to the starting brain-tropic line. In a preclinical experiment, two doses of trastuzumab deruxtecan (T-DXd) were compared to human IgG, trastuzumab (T), nab-paclitaxel (nab-P) and T + nab-P for leptomeningeal metastasis. T-DXd demonstrated efficacy in terms of BLI imaging of the brain (P < 0.0001) and spine (P = 0.008), leptomeningeal lesion number and size in the brain (P = 0.06); efficacy was dose-dependent. T-DXd 10 mg/kg reduced leptomeningeal tumor Ki67 positivity (P = 0.0008) and increased apoptosis (P < 0.0001). In the brain, a comparison of leptomeningeal and parenchymal lesion number showed a reduction by T-DXd of 53% and 72%, respectively, compared to human IgG, with comparable effects on tumor proliferation and apoptosis. T-DXd also extended median survival to 38 days compared with 20 -24 days in control IgG or T + nab-P, with some mice surviving beyond 60 days (P = 0.003). These findings support ongoing clinical translation of T-DXd for HER2+ leptomeningeal metastasis and highlight the value of this model for future therapeutic development.
中文摘要:软脑膜转移是晚期HER2阳性乳腺癌的严重并发症,治疗选择有限。研究通过四轮迭代鞘内注射,建立了人HER2阳性乳腺癌细胞系JIMT1-BR3-LM4软脑膜定植的异种移植模型。该模型可在脑和脊髓中稳定产生软脑膜病灶,并在脑脊液中检出肿瘤细胞,经生物发光成像、磁共振成像、病理分析和免疫荧光染色终点确认。RNA测序显示,与起始脑趋向性细胞系相比,该软脑膜转移模型出现显著转录变化。在临床前实验中,将两剂曲妥珠单抗德鲁替康(T-DXd)与人IgG、曲妥珠单抗、白蛋白结合型紫杉醇及曲妥珠单抗联合白蛋白结合型紫杉醇用于软脑膜转移进行比较。T-DXd在脑部生物发光成像(P < 0.0001)和脊柱成像(P = 0.008)、脑内软脑膜病灶数量和大小(P = 0.06)方面显示疗效,且疗效呈剂量依赖性。T-DXd 10 mg/kg降低软脑膜肿瘤Ki67阳性率(P = 0.0008)并增加凋亡(P < 0.0001)。在脑内,比较软脑膜与脑实质病灶数量显示,与人IgG相比,T-DXd分别使病灶减少53%和72%,对肿瘤增殖和凋亡的影响相当。T-DXd还将中位生存期延长至38天,而对照IgG或曲妥珠单抗联合白蛋白结合型紫杉醇组为20至24天,部分小鼠生存超过60天(P = 0.003)。这些结果支持T-DXd用于HER2阳性软脑膜转移的持续临床转化,并凸显该模型对未来治疗开发的价值。
Considerable progress in oncology has substantially reduced cancer-related mortality, as reflected by the growing number of cancer survivors. In this context, the management of adverse events associated with cancer treatments has become even more important. Small-molecule VEGFR inhibitors are associated with clinically relevant cardiovascular and hepatic adverse events, including arrhythmias, heart failure, liver enzyme elevations, and hepatic failure. This review integrates the clinical profiles, organ-specific mechanisms, and shared biological pathways underlying VEGFR inhibitor-associated cardiotoxicity and hepatotoxicity. Clinical evidence primarily supports parallel cardiovascular and hepatic toxicities, whereas experimental studies identify convergent mechanisms involving endothelial injury, oxidative stress, mitochondrial dysfunction, inflammation, autophagy dysregulation, apoptosis, and metabolic disturbance. Direct evidence of cross-organ propagation was not identified in the reviewed literature, and the proposed cardio-hepatic relationship should therefore be considered a testable framework rather than an established mechanism. Particular attention is given to ageing-related susceptibility, including reduced cardiovascular and hepatic reserve, frailty, multimorbidity, and polypharmacy, which may modify treatment tolerance and monitoring needs. We also critically evaluate candidate preventive and therapeutic strategies and identify the evidence required for their clinical translation. By separating established clinical observations from mechanistic hypotheses, this review provides an evidence-graded framework for interpreting VEGFR inhibitor-associated toxicity, refining risk-adapted surveillance, directing future studies of cardio-hepatic interactions and guiding the development and validation of targeted mitigation strategies aimed at safer cancer treatment.
中文摘要:肿瘤学取得的显著进展大幅降低了癌症相关死亡率,癌症生存者数量不断增加也反映了这一点。在此背景下,管理抗癌治疗相关不良事件变得更加重要。小分子VEGFR抑制剂与具有临床意义的心血管和肝脏不良事件相关,包括心律失常、心力衰竭、肝酶升高和肝衰竭。本综述整合了VEGFR抑制剂相关心脏毒性和肝毒性的临床特征、器官特异性机制及共同生物学通路。临床证据主要支持心血管毒性与肝毒性并行发生,实验研究则发现二者存在汇聚机制,涉及内皮损伤、氧化应激、线粒体功能障碍、炎症、自噬失调、凋亡和代谢紊乱。所综述文献未发现跨器官传播的直接证据,因此所提出的心-肝关系应视为可检验的框架,而非已确立的机制。特别关注衰老相关易感性,包括心血管和肝脏储备下降、衰弱、多病共存和多重用药,这些因素可能改变治疗耐受性和监测需求。还批判性评估候选预防和治疗策略,并明确其临床转化所需的证据。通过区分已确立的临床观察与机制假说,本综述提供循证分级框架,用于解读VEGFR抑制剂相关毒性、完善风险适配监测、指导心-肝相互作用的未来研究,以及引导旨在提高癌症治疗安全性的靶向缓解策略的开发与验证。
psiTPTE22-HERV is a human-specific gene with unexplored functions. This study investigated its regulation, molecular mechanism, and clinical significance in gastric cancer. psiTPTE22-HERV expression was consistently down-regulated in primary tumors and cancer cell lines across various cancer types, including gastric cancer, as indicated by TCGA data and quantitative PCR analysis. Its down-regulation in gastric cancer cells is mediated by promoter methylation, confirmed through bisulfite genomic sequencing, with expression restored following demethylation treatment. A progressive reduction in psiTPTE22-HERV expression was observed from normal stomach mucosa to adjacent non-tumor tissues and primary tumors, along with increased methylation. psiTPTE22-HERV inhibited cancer cell viability, clonogenicity, cell cycle progression, migration, and invasion while promoting apoptosis. It also suppressed subcutaneous tumor growth and distant metastasis in mice. Transcriptomic analysis revealed that psiTPTE22-HERV disrupted PI3K/AKT/mTOR signaling. Western blotting confirmed that psiTPTE22-HERV reduced protein levels of PI3K, p-AKT, and mTOR. This led to the down-regulation of EIF4E and EIF4EBP1, oncogenic protein synthesis genes and effectors of mTOR signaling, as well as p-EIF4EBP1(Thr70), which is regulated by mTOR. Notably, psiTPTE22-HERV expression was inversely correlated with EIF4E, EIF4EBP1, and p-EIF4EBP1 (Thr70) in gastric tumors (all P < 0.001). Multivariate analysis revealed that psiTPTE22-HERV expression in primary gastric tumors independently predicted survival (P = 0.027). Kaplan-Meier survival analysis showed that low psiTPTE22-HERV expression was associated with shortened survival in gastric cancer patients (P = 0.0009). Overall, psiTPTE22-HERV plays a tumor-suppressive role by inhibiting the PI3K/AKT/mTOR/EIF4E pathway, and its down-regulation serves as an independent marker for poor prognosis in gastric cancer patients.
中文摘要:psiTPTE22-HERV 是一个人类特异性基因,其功能尚未被阐明。本研究探讨了它在胃癌中的表达调控、分子机制与临床意义。TCGA 数据与定量 PCR 分析显示,psiTPTE22-HERV 在多种癌种(含胃癌)的原发肿瘤与癌细胞系中持续低表达。亚硫酸氢盐基因组测序证实,胃癌细胞中该基因的低表达由启动子甲基化介导,去甲基化处理后表达恢复。从正常胃黏膜到癌旁非肿瘤组织再到原发肿瘤,psiTPTE22-HERV 表达逐步降低,甲基化程度同步升高。psiTPTE22-HERV 可抑制癌细胞活力、克隆形成、细胞周期进程、迁移与侵袭,并促进凋亡;在小鼠体内它同样抑制皮下肿瘤生长与远处转移。转录组分析显示 psiTPTE22-HERV 干扰 PI3K/AKT/mTOR 信号通路。蛋白免疫印迹证实 psiTPTE22-HERV 降低 PI3K、p-AKT 与 mTOR 的蛋白水平,进而下调 mTOR 信号通路的效应分子、致癌蛋白合成基因 EIF4E 与 EIF4EBP1 以及受 mTOR 调控的 p-EIF4EBP1(Thr70)。在胃肿瘤中,psiTPTE22-HERV 表达与 EIF4E、EIF4EBP1、p-EIF4EBP1(Thr70) 呈负相关(均 P < 0.001)。多因素分析显示,原发胃肿瘤中 psiTPTE22-HERV 表达可独立预测生存(P = 0.027)。Kaplan-Meier 生存分析显示,psiTPTE22-HERV 低表达与胃癌患者生存期缩短相关(P = 0.0009)。psiTPTE22-HERV 通过抑制 PI3K/AKT/mTOR/EIF4E 通路发挥抑癌作用,其表达下调可作为胃癌患者预后不良的独立标志物。
Microtubule glutamylation is a dynamic post-translational modification that involves the addition of glutamate chains to tubulin, a process crucial for reshaping the biochemical interface of microtubules. This modification orchestrates an array of vital cellular functions, including cell division, neuronal development, and ciliary biology. We first delineate the molecular machinery by which glutamylation governs successive stages of cell division, encompassing centrosome-driven spindle assembly, spindle pole integrity maintenance, and the coordination of late mitotic events for faithful chromosome segregation and cytokinesis. We then examine how the dysregulation of this system drives oncogenesis. This includes loss-of-function perturbations, such as the downregulation of the tumor-suppressive enzyme TTLL11, which promotes chromosomal instability, as well as gain-of-function events involving oncogenic glutamylases like TTLL4, TTLL6, and TTLL12, which reprogram cytoskeletal dynamics to fuel proliferation, metastasis, and therapy resistance. Finally, we evaluate the resulting therapeutic landscape, discussing evolving strategies from metabolic intervention and direct enzyme inhibition to cutting-edge modalities like targeted protein degradation and synthetic biology for precision correction. Our analysis positions the glutamylation pathway not only as a fundamental regulator of cell division but also as a promising and multifaceted target for novel cancer therapeutics.
中文摘要:微管谷氨酰化是在微管蛋白上添加谷氨酸链的动态翻译后修饰,对重塑微管的生化界面至关重要。该修饰协调细胞分裂、神经元发育、纤毛生物学等一系列关键细胞功能。谷氨酰化调控细胞分裂连续阶段的分子机制得到系统梳理,涵盖中心体驱动的纺锤体组装、纺锤体极完整性的维持,以及晚期有丝分裂事件对染色体忠实分离和胞质分裂的协调。该系统的失调如何驱动肿瘤发生也一并讨论:功能缺失性扰动如抑癌酶TTLL11下调促进染色体不稳定,功能获得性事件则涉及TTLL4、TTLL6、TTLL12等致癌性谷氨酰化酶,它们重编程细胞骨架动力学,助长增殖、转移和治疗耐药。相应的治疗格局随之展开,从代谢干预、直接酶抑制到靶向蛋白降解与合成生物学精准校正等新兴手段均有评述。谷氨酰化通路由此被视为细胞分裂的基础调控环节,也是新型肿瘤治疗中颇具前景的多层面靶点。
Epigenetic mechanisms represented by N6-methyladenosine (m6A) modifications and circular RNAs (circRNAs) regulate chemotherapy resistance in prostate cancer (PCa). Here, we stuided the role of m6A-modified circLPAR3 in assisting docetaxel (DTX) resistance in PCa and the mechanism of its regulatory function. The expression of circLPAR3 was higher in all three drug-resistant cell lines than in the corresponding parental cell lines and was mainly localized in the cytoplasm. The m6A modification and stability enhancement of circLPAR3 by the METTL3/IGF2BP2 axis was primarily determined by expression assays, stability assays, and mass spectrometry. Functionally, circLPAR3 reduced the sensitivity of PCa cells to DTX and promoted PCa proliferation in a DTX environment. In addition, circLPAR3 reduced cytotoxicity by inhibiting the DTX-induced ferroptosis effect. Mechanistically, circLPAR3 downregulated the expression of CHAC1, an emerging driver of ferroptosis. PCBP2 was identified as a mediating RNA-binding protein between circLPAR3 and CHAC1. On the one hand, it shares a very high binding phase with circLPAR3 without interfering with each other's expression; on the other hand, it increases mRNA stability by binding to the 3' UTR of CHAC1, which is interfered by circLPAR3. In conclusion, m6A-modified circLPAR3 inhibits CHAC1 expression by competitively binding to PCBP2, ultimately conferring docetaxel resistance to PCa.
中文摘要:以N6-甲基腺苷(m6A)修饰和环状RNA(circRNA)为代表的表观遗传机制调控前列腺癌(PCa)的化疗耐药。本研究探讨m6A修饰的circLPAR3在前列腺癌多西他赛(DTX)耐药中的作用及其调控机制。circLPAR3在三种耐药细胞系中的表达均高于相应亲本细胞系,且主要定位于细胞质。通过表达检测、稳定性检测和质谱分析,主要确定了METTL3/IGF2BP2轴对circLPAR3的m6A修饰及稳定性增强作用。功能上,circLPAR3降低前列腺癌细胞对DTX的敏感性,并在DTX环境中促进前列腺癌细胞增殖。circLPAR3还通过抑制DTX诱导的铁死亡效应降低细胞毒性。机制上,circLPAR3下调CHAC1表达,CHAC1是铁死亡的新兴驱动因子。PCBP2被鉴定为介导circLPAR3与CHAC1之间作用的RNA结合蛋白。一方面,它与circLPAR3具有很高的结合相位,且互不干扰彼此表达;另一方面,它通过与CHAC1的3' UTR结合提高mRNA稳定性,而这一作用受到circLPAR3干扰。由此,m6A修饰的circLPAR3通过竞争性结合PCBP2抑制CHAC1表达,最终赋予前列腺癌多西他赛耐药。
N6-methyladenosine (m6A) is the most common post-transcriptional modification in mRNA, playing a crucial role in cancer development by modulating RNA stability, translation, and nuclear export. As the first discovered m6A demethylase, FTO catalyzes m6A demethylation in a Fe2+/α-KG-dependent manner, functioning as either an oncogene or a tumor suppressor to mediate cancer progression via reducing m6A levels and thereby modulating RNA metabolism. Numerous studies have elucidated the mechanisms by which upstream regulators affect FTO expression, as well as the post-translational modifications that impact its protein stability, translocation, and degradation. Moreover, inhibitors targeting FTO demonstrate significant therapeutic potential. In this review, we summarize recent research on the role and regulatory manner of FTO in gastrointestinal cancer and discuss its potential clinical application in cancer therapy.
中文摘要:N6-甲基腺苷(m6A)是mRNA中最常见的转录后修饰,通过调节RNA稳定性、翻译和核输出,在肿瘤发生发展中起关键作用。FTO是最早发现的m6A去甲基化酶,以Fe2+/α-KG依赖方式催化m6A去甲基化,可通过降低m6A水平并调节RNA代谢,发挥癌基因或抑癌基因作用,介导肿瘤进展。大量研究阐明了上游调控因子影响FTO表达的机制,以及影响其蛋白稳定性、转位和降解的翻译后修饰。靶向FTO的抑制剂显示出显著治疗潜力。该综述总结FTO在胃肠道肿瘤中作用及调控方式的最新研究,并讨论其在肿瘤治疗中的潜在临床应用。
Therapeutic resistance continues to be a significant challenge in cancer treatment, often leading to tumor recurrence, metastasis, and limited therapeutic efficacy despite advancements in chemotherapy and radiotherapy. This resistance arises from complex molecular mechanisms that are influenced by various factors, including genetic alterations, epigenetic modifications, and cellular signaling. Recently, lncRNAs, a subclass of non-coding RNAs, have gained prominence for their essential role in driving cancer progression and mediating resistance to therapy. The resistance phenotype is shaped by lncRNAs through the regulation of key signaling pathways, DNA repair mechanisms, and cellular survival processes. For example, lncRNAs such as HOTAIR and MALAT1 are involved in the regulation of PI3K/AKT, EMT, and DNA repair pathways, and influence cell proliferation, apoptosis, and metastasis. These findings underscore the potential of lncRNAs as therapeutic targets. Targeting lncRNA-mediated pathways offers a promising approach to overcome resistance and enhance the efficacy of existing therapies. This review provides an in-depth analysis of the molecular mechanisms by which lncRNAs mediate resistance in various cancers, such as gastric cancer, lung cancer, breast cancer, and hepatocellular carcinoma. By focusing on the therapeutic potential of lncRNAs, we propose new avenues for overcoming resistance and improving treatment outcomes in cancer therapy.
中文摘要:治疗耐药仍是癌症治疗中的重大难题,即便化疗和放疗取得进展,肿瘤复发、转移和治疗效果受限仍常随之出现。这种耐药由复杂分子机制造成,并受基因改变、表观遗传修饰和细胞信号传导等多种因素影响。近年来,长链非编码RNA(lncRNA)作为非编码RNA的一个亚类受到关注,其在推动癌症进展和介导治疗耐药中具有重要作用。lncRNA通过调控关键信号通路、DNA修复机制和细胞存活过程塑造耐药表型。例如,HOTAIR和MALAT1等lncRNA参与PI3K/AKT、EMT和DNA修复通路的调控,并影响细胞增殖、凋亡和转移。这些发现凸显lncRNA作为治疗靶点的潜力。靶向lncRNA介导的通路为克服耐药、提高现有疗法疗效提供了有希望的途径。本综述深入分析lncRNA在胃癌、肺癌、乳腺癌和肝细胞癌等多种癌症中介导耐药的分子机制。围绕lncRNA的治疗潜力,我们提出克服耐药并改善癌症治疗结局的新方向。
Atypical teratoid rhabdoid tumor (ATRT) is the most common malignant brain tumor in infants. ATRT is associated with inactivation/deletion of SMARCB1, a member of the SWI/SNF chromatin remodeling complex. SMARCB1 loss contributes to tumorigenicity by compromising SWI/SNF activity at specific loci associated with the CoREST repressor complex, which regulates transcription at critical gene promoters and enhancers. We therefore explored the role of the CoREST repressor complex in ATRT. We evaluated the effects of the bifunctional LSD1/HDAC1/2 small molecule CoREST inhibitor, corin, on ATRT tumor cell growth, apoptosis, differentiation, gene expression, and chromatin accessibility. Corin inhibited the growth of ATRT cells regardless of their epigenetic subgroup. Corin caused increased tumor cell apoptosis and differentiation. ATAC-seq showed increased chromatin accessibility in corin-treated ATRT cells, with changes seen at genes associated with neuronal differentiation and synaptic function. RNA-seq confirmed increased expression of neuronal differentiation genes in ATRT cells treated with corin. Knockdown of RCOR2 phenocopied the effects of corin and desensitized the cells to the drug, confirming corin specificity to the CoREST complex. Corin suppressed orthotopic ATRT tumor growth, leading to significant extension of lifespan in ATRT mouse models. Corin caused increased histone acetylation (H3K9ac) and methylation (H3K4Me1) in ATRT orthotopic xenografts, consistent with on-target pharmacodynamics. The CoREST inhibitor, corin, suppressed tumor growth, induced differentiation, and promoted apoptosis in ATRT, leading to significantly increased survival of mice bearing ATRT orthotopic xenografts. Our results suggest a potential application of CoREST complex inhibitors in patients with ATRT.
中文摘要:非典型畸胎样横纹肌样肿瘤(ATRT)是婴儿中最常见的恶性脑肿瘤。ATRT与SMARCB1失活或缺失相关,SMARCB1是SWI/SNF染色质重塑复合物成员。SMARCB1缺失使与CoREST抑制复合物相关的特定位点SWI/SNF活性受损,从而促进致瘤性;CoREST复合物调控关键基因启动子和增强子的转录。因此,我们探讨CoREST抑制复合物在ATRT中的作用,评估双功能LSD1/HDAC1/2小分子CoREST抑制剂corin对ATRT肿瘤细胞生长、凋亡、分化、基因表达和染色质可及性的影响。corin抑制不同表观遗传亚型ATRT细胞的生长,并引起肿瘤细胞凋亡和分化增加。ATAC-seq显示,corin处理的ATRT细胞染色质可及性增加,变化见于与神经元分化和突触功能相关的基因。RNA-seq证实,corin处理的ATRT细胞中神经元分化基因表达增加。敲低RCOR2可重现corin的效应,并使细胞对药物敏感性降低,证实corin对CoREST复合物的特异性。corin抑制原位ATRT肿瘤生长,使ATRT小鼠模型寿命显著延长。corin使原位ATRT异种移植瘤中组蛋白乙酰化(H3K9ac)和甲基化(H3K4Me1)增加,符合靶点药效学。CoREST抑制剂corin在ATRT中抑制肿瘤生长、诱导分化并促进凋亡,显著提高携带ATRT原位异种移植瘤小鼠的生存。结果提示CoREST复合物抑制剂在ATRT患者中的潜在应用。
Transcription factors (TFs) occupy a central position in cancer biology, functioning as master regulators that translate genetic, epigenetic and environmental cues into cell fate decisions, proliferation, survival, and therapy response. Historically deemed "undruggable" owing to their lack of catalytic sites, conformational flexibility, and engagement in broad protein-DNA and protein-protein interfaces, TFs were long considered beyond the reach of conventional pharmacology. Over the past decades, advances in structural biology, chemical biology, epigenetics, and nucleic acid therapeutics have begun to overcome these challenges, revealing actionable vulnerabilities within TF networks. This review synthesizes current understanding of TF function in tumorigenesis, moving from mechanistic insights at the level of individual TFs to the higher-order organization of transcriptional regulatory networks. It further assesses emerging therapeutic strategies aimed at perturbing aberrant TF activity, encompassing direct inhibition, targeted protein degradation, modulation of TF-cofactor interactions, and nucleic acid-based interventions. We further highlight exemplary TFs and their typical targeting strategies, including Myelocytomatosis oncogene (MYC), Signal transducer and activator of transcription 3 (STAT3), Catenin beta-1 (β-catenin), Yes-associated protein/Transcriptional coactivator with PDZ-binding motif/Transcriptional enhanced associate domain (YAP/TAZ/TEAD), Estrogen receptor/Androgen receptor (ER/AR), and Phosphatase and tensin homolog/Protein kinase B/Forkhead box O (PTEN/AKT/FOXO), which illustrating mechanistic understanding of transcriptional regulation drives therapeutic development and enables genomics-guided precision oncology. By unifying mechanistic insight with pharmacological innovation, we aim to provide a conceptual framework for targeting the transcriptional architecture of cancer and charting paths toward next-generation transcription-directed therapies.
中文摘要:转录因子在肿瘤生物学中处于核心位置,作为主调控因子把遗传、表观遗传和环境线索转化为细胞命运决定、增殖、存活与治疗反应。由于缺乏催化位点、构象灵活,并参与广泛的蛋白-DNA和蛋白-蛋白界面,转录因子长期被视为「不可成药」,超出传统药理学可达范围。过去数十年,结构生物学、化学生物学、表观遗传学和核酸治疗的进展开始克服这些障碍,揭示转录因子网络内可干预的脆弱点。本综述整合当前对转录因子在肿瘤发生中功能的理解,从单个转录因子的机制认识推进到转录调控网络的高阶组织。文章进一步评估旨在扰动异常转录因子活性的新兴治疗策略,包括直接抑制、靶向蛋白降解、调节转录因子与辅因子相互作用以及基于核酸的干预。文章还重点介绍代表性转录因子及其典型靶向策略,涵盖髓细胞瘤病癌基因MYC、信号转导与转录激活因子3 STAT3、β-连环蛋白、YAP/TAZ/TEAD、雌激素受体/雄激素受体以及PTEN/AKT/FOXO,说明对转录调控的机制理解如何推动治疗开发并支持基因组学指导的精准肿瘤学。通过把机制认识与药理学创新结合起来,文章旨在提供靶向肿瘤转录架构的概念框架,并勾勒迈向下一代转录导向治疗的路径。
Pancreatic ductal adenocarcinoma (PDAC) exhibits profound therapy resistance driven by lysosome-dependent nutrient recycling, metabolic adaptation, and stress tolerance. Current lysosome targeting agents such as chloroquine (CQ)/hydroxychloroquine (HCQ) show limited efficacy due to transient activity and dose-limiting-toxicities. To overcome these limitations, we developed lysostilbenes, a new class of hybrid small molecules combining the CQ pharmacophore with lysosome-disrupting stilbene analogs. Stilbene pharmacophore is the core structural component of resveratrol. Among the synthesized hybrids, lysostilbene-4 emerged as the lead candidate, demonstrating ~30-40-fold greater cytotoxicity against PDAC cells than parent compounds, while sparing nonmalignant cells. At nanomolar concentrations, lysostilbene-4 induced rapid, irreversible lysosomal membrane permeabilization (LMP), initiating a lysosome mitochondria apoptotic cascade via CTSB (cathepsin B) release, BID cleavage, BAX activation, and caspase-mediated apoptosis. In parallel, it abrogated lysosomal recovery by significantly reducing repair, lysophagy, autophagosome maturation, and uncoupling TFEB-driven transcriptional programs from effective lysosome biogenesis. Reduced TFEB mRNA expression correlated with poor overall-survival and disease-free-survival across multiple cancer patients, with a particularly strong association in pancreatic cancer patients. Using TFEB+/+ and TFEB-/- knockout pancreatic cancer cells we establish that lysostilbene-4 exerts severe cytotoxicity by inducing persistent lysosomal-damage and disrupting autophagosome-lysosome assembly, with vulnerability further amplified in TFEB-deficient cells. This finding underscores TFEB as a key determinant of lysosomal-resilience and a potential predictive biomarker. Importantly, lysostilbene-4 was well tolerated in preclinical mouse-models at supra-therapeutic doses without systemic-toxicity. These findings position lysostilbene-4 as a first-in-class lysosome-targeting therapeutic that enforces sustained lysosomal collapse while compromising adaptive recovery-mechanisms, providing a mechanistically precise and safe strategy against PDAC.Abbreviations: ALG: autophagy-lysosome genes; AMPK: AMP-activated protein kinase; CASM: conjugation of ATG8s to single membranes; CTSB: cathepsin B; LGALS3: galectin 3; LMP: lysosomal membrane permeabilization; LS: lysostilbene; MTOR: mechanistic target of rapamycin kinase; PDAC: pancreatic ductal adenocarcinoma; TCGA: The Cancer Genome Atlas; TFEB: transcription factor EB; ULK1: unc-51 like autophagy activating kinase 1.
中文摘要:胰腺导管腺癌(PDAC)因依赖溶酶体的营养回收、代谢适应和应激耐受而表现出显著治疗抵抗。现有溶酶体靶向药物如氯喹(CQ)/羟氯喹(HCQ)因作用短暂和剂量限制性毒性而疗效有限。为克服这些限制,我们开发了lysostilbenes,一类将CQ药效团与破坏溶酶体的二苯乙烯类似物结合的新型杂合小分子。二苯乙烯药效团是白藜芦醇的核心结构组分。在合成的杂合分子中,lysostilbene-4成为先导候选物,对PDAC细胞的细胞毒性比母体化合物高约30-40倍,同时对非恶性细胞影响较小。在纳摩尔浓度下,lysostilbene-4诱导快速、不可逆的溶酶体膜通透化(LMP),通过CTSB(组织蛋白酶B)释放、BID切割、BAX激活和caspase介导的凋亡启动溶酶体-线粒体凋亡级联。与此同时,它通过显著降低修复、溶酶体自噬、自噬体成熟,并使TFEB驱动的转录程序与有效溶酶体生物合成解耦,削弱溶酶体恢复。TFEB mRNA表达降低与多种癌症患者的总生存期和无病生存期较差相关,在胰腺癌患者中关联尤其强。使用TFEB+/+和TFEB-/-敲除胰腺癌细胞,我们确定lysostilbene-4通过诱导持续溶酶体损伤和破坏自噬体-溶酶体组装产生严重细胞毒性,TFEB缺陷细胞中的脆弱性进一步放大。这一发现强调TFEB是溶酶体韧性的关键决定因素和潜在预测生物标志物。lysostilbene-4在临床前小鼠模型中以超治疗剂量耐受良好,无全身毒性。这些发现将lysostilbene-4定位为同类首个溶酶体靶向治疗药物,可强制持续溶酶体崩溃并削弱适应性恢复机制,为PDAC提供机制精确且安全的策略。缩写:ALG:自噬-溶酶体基因;AMPK:AMP活化蛋白激酶;CASM:ATG8s与单膜结合;CTSB:组织蛋白酶B;LGALS3:半乳糖凝集素3;LMP:溶酶体膜通透化;LS:lysostilbene;MTOR:雷帕霉素激酶机制靶点;PDAC:胰腺导管腺癌;TCGA:癌症基因组图谱;TFEB:转录因子EB;ULK1:unc-51样自噬激活激酶1。
Intercellular mitochondria transfer has emerged as a new form of cell-to-cell communication with profound consequences for cellular fate. A growing body of evidence defines mitochondria transfer between cells as a new pathological program in which cancer cells appropriate functional mitochondria from donor cells, thereby co-opting conserved physiological mechanisms of energy allocation to gain bioenergetic and phenotypic advantages. Our recent work demonstrates the prevalence of mitochondria transfer at the nerve-cancer interface, with neurons, though not exclusively, serving as a prominent source of the organelle. This suggests an unrecognized role of the nervous system in systemic energy redistribution and indicates that tumors may exploit this ancient, physiologically grounded mechanism to fuel progression and metastasis.
中文摘要:细胞间线粒体转移已成为一种新的细胞间通讯方式,对细胞命运产生深远影响。越来越多证据将细胞间线粒体转移界定为一种新的病理程序:癌细胞从供体细胞获取功能性线粒体,从而挪用能量分配这一保守生理机制,获得生物能量与表型优势。近期工作显示,线粒体转移在神经与癌交界处较为普遍,神经元虽非唯一来源,却是该细胞器的重要供体。这提示神经系统在全身能量再分配中具有尚未被认识的作用,也提示肿瘤可能利用这一古老且具有生理基础的过程,为进展和转移提供能量支持。
IFNG (interferon gamma)-activated macrophages contribute to accelerated clearance of platelets and excessive secretion of inflammatory cytokines in immune thrombocytopenia (ITP). In this study, we identified two distinct subpopulations of activated macrophages: phagocytic macrophages (M[IFNG]p), which predominantly exhibit phagocytic activity, and inflammatory macrophages (M[IFNG]i), characterized by their pro-inflammatory capacity. The M(IFNG)p and M(IFNG)i subsets were functionally disturbed in patients with ITP. Chaperone-mediated autophagy (CMA) deficiency in macrophages was discovered in ITP and has been reported to induce sustained inflammation. Furthermore, CMA interference enhanced pro-inflammatory function rather than phagocytic activity of macrophages in vitro. In parallel, macrophage-specific conditional lamp2a (lysosome associated membrane protein 2A) knockout mice exhibited expansion and excessive cytokine release of M(IFNG)i. Restoring CMA restrains M(IFNG)i subset and reprograms M(IFNG)p subset via ALDH2 (aldehyde dehydrogenase 2 family member) in ITP. Here, anti-ITGB3/CD61 immune-sensitized splenocytes were transferred into severe combined immunodeficient mice to establish an active murine model of ITP. CMA activation diminished the pro-inflammatory and phagocytic activity of activated macrophages and ameliorated thrombocytopenia in ITP mice. MeRIP-sequencing identified PTEN (phosphatase and tensin homolog) as a crucial activator for LAMP2A, exhibiting decreased m6A methylation and subsequent downregulation, which indicated a potential mechanism underlying CMA deficiency in activated macrophages. In conclusion, restoring CMA restrains the M(IFNG)i subset and reprograms the M(IFNG)p subset via ALDH2 to raise platelet counts in ITP. Targeting CMA in activated primary human macrophages presents a promising therapeutic strategy to rapidly and sustainably increase platelet counts and restore immune balance in ITP.Abbreviation ALDH2: aldehyde dehydrogenase 2 family member; ALKBH5: alkB homolog 5, RNA demethylase; CCL: C-C motif chemokine ligand; CMA: chaperone-mediated autophagy; CSF1/M-CSF: colony stimulating factor 1; CUT&Tag: Cleavage Under Targets and Tagmentation; CXCL: C-X-C motif chemokine ligand; FBS: fetal bovine serum; FCGR/FcγR: Fc gamma receptor; HLA-DR: major histocompatibility complex, class II, DR; IFNG/IFN-γ: interferon gamma; IGF2R: insulin like growth factor 2 receptor; IL: interleukin; ITP: immune thrombocytopenia; LAMP2A: lysosome associated membrane protein 2A; m6A: N6-methyladenosine; MeRIP-seq: methylated RNA immunoprecipitation sequencing; METTL3: methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit; MFI: mean fluorescence intensity; mRNA: messenger RNA; NFE2L2/NRF2: NFE2 like bZIP transcription factor 2; NLRP3: NLR family pyrin domain containing 3; NOS2/iNOS: nitric oxide synthase 2; PBMCs: peripheral blood mononuclear cells; PTEN: phosphatase and tensin homolog; PYCARD: PYD and CARD domain containing; STAT: signal transducer and activator of transcription; Th1: T-helper 1; TNF: tumor necrosis factor; WTAP: WT1 associated protein.
中文摘要:IFNG(干扰素γ)激活的巨噬细胞促进免疫性血小板减少症(ITP)中血小板清除加速和炎症细胞因子过度分泌。本研究识别出两种不同的活化巨噬细胞亚群:吞噬性巨噬细胞(M[IFNG]p),以吞噬活性为主;炎症性巨噬细胞(M[IFNG]i),以促炎能力为特征。ITP患者的M(IFNG)p和M(IFNG)i亚群功能紊乱。ITP中发现巨噬细胞分子伴侣介导的自噬(CMA)缺陷,而CMA缺陷已被报道可诱导持续性炎症。体外干扰CMA增强巨噬细胞的促炎功能而非吞噬活性。同时,巨噬细胞特异性条件性lamp2a(溶酶体相关膜蛋白2A)敲除小鼠显示M(IFNG)i扩增和细胞因子过度释放。恢复CMA通过ALDH2(乙醛脱氢酶2家族成员)抑制M(IFNG)i亚群并重编程M(IFNG)p亚群。将抗ITGB3/CD61免疫致敏的脾细胞转移至重症联合免疫缺陷小鼠,建立活动性ITP小鼠模型。CMA激活降低活化巨噬细胞的促炎和吞噬活性,并改善ITP小鼠的血小板减少。MeRIP测序鉴定PTEN(磷酸酶和张力蛋白同源物)为LAMP2A的关键激活因子,其m6A甲基化降低并随后下调,提示活化巨噬细胞CMA缺陷的潜在机制。恢复CMA通过ALDH2抑制M(IFNG)i亚群并重编程M(IFNG)p亚群,提高ITP血小板计数。靶向活化原代人巨噬细胞中的CMA是快速持续提高血小板计数并恢复ITP免疫平衡的有前景治疗策略。
Bisphosphonates (BPs) are the most widely used anti-resorptive agents and first-line drugs for managing bone-related diseases, such as osteoporosis, Paget disease of bone, and bone metastatic cancer. BPs are known to inhibit osteoclasts' functions, and recent studies have highlighted the importance of macroautophagy/autophagy in osteoclasts. However, the involvement of autophagy in BP-mediated inhibition of osteoclast functions remains unclear. In this study, we showed that BPs inhibit the bone resorptive functions of osteoclasts by blocking autophagy. At the non-apoptotic doses, zoledronic acid (ZOL) inhibited autophagy by blocking autophagic flux and delaying the degradation of autophagy-related proteins. ZOL also prevented the cleavage and secretion of secretory proteins such as CTSK, ACP5/TRAP, and MMP9 essential for bone resorption. Mechanistically, ZOL inhibits the prenylation of the RAB7 small GTPase, a key protein that is required for autolysosome formation. In vivo studies showed that osteoclast-specific rab7 conditional knockout mice exhibited osteopetrotic phenotypes. These findings provide insights into how BPs disrupt osteoclast function by blocking autophagy and suggest that targeting autophagy in osteoclasts could be a potential therapeutic approach for bone-related diseases.Abbreviations: ACP5/TRAP: acid phosphatase 5, tartrate resistant, ATG: autophagy related, 54 BafA1: bafilomycin A1, BECN1: beclin 1, BMM: bone marrow-derived macrophage, CQ: 55 chloroquine, CSF1/M-CSF: colony stimulating factor 1, CTSK: cathepsin K, CTX-I: C-terminal 56 telopeptide of type I collagen, FPPS: farnesyl pyrophosphate synthase, GFP: green fluorescent 57 protein, GGTI: geranylgeranyltransferase I inhibitor, LAMP1: lysosome associated membrane 58 protein 1, MAP1LC3/LC3: microtubule associated protein 1 light chain 3, MMP9: matrix 59 metallopeptidase 9, N-BPs: nitrogen-containing bisphosphonates, P1NP: procollagen type I N- 60 terminal propeptide, PGGT1B: protein geranylgeranyl transferase type I subunit beta, RABGGTB: 61 Rab geranylgeranyltransferase subunit beta, RFP: red fluorescent protein, SQSTM1/p62: 62 sequestosome 1, TNFSF11/RANKL: TNF superfamily member 11, ZOL: zoledronic acid.
中文摘要:双膦酸盐(BPs)是使用最广泛的抗骨吸收药物,也是治疗骨质疏松、Paget骨病和骨转移癌等骨相关疾病的一线药物。已知BPs可抑制破骨细胞功能,近期研究强调巨自噬/自噬在破骨细胞中的重要性。但自噬是否参与BP介导的破骨细胞功能抑制仍不清楚。研究显示,BPs通过阻断自噬抑制破骨细胞的骨吸收功能。在非凋亡剂量下,唑来膦酸(ZOL)通过阻断自噬流并延迟自噬相关蛋白降解来抑制自噬。ZOL还阻止骨吸收必需的分泌蛋白如CTSK、ACP5/TRAP和MMP9的剪切与分泌。机制上,ZOL抑制RAB7小GTP酶的异戊二烯化,RAB7是自噬溶酶体形成所需的关键蛋白。体内研究显示,破骨细胞特异性rab7条件性敲除小鼠表现出骨硬化表型。这些发现揭示了BPs如何通过阻断自噬破坏破骨细胞功能,并提示靶向破骨细胞自噬可能成为骨相关疾病的潜在治疗策略。缩写:ACP5/TRAP:抗酒石酸酸性磷酸酶5;ATG:自噬相关;BafA1:巴弗洛霉素A1;BECN1:beclin 1;BMM:骨髓来源巨噬细胞;CQ:氯喹;CSF1/M-CSF:集落刺激因子1;CTSK:组织蛋白酶K;CTX-I:I型胶原C端端肽;FPPS:法尼基焦磷酸合酶;GFP:绿色荧光蛋白;GGTI:香叶基香叶基转移酶I抑制剂;LAMP1:溶酶体相关膜蛋白1;MAP1LC3/LC3:微管相关蛋白1轻链3;MMP9:基质金属蛋白酶9;N-BPs:含氮双膦酸盐;P1NP:I型前胶原N端前肽;PGGT1B:蛋白香叶基香叶基转移酶I亚基β;RABGGTB:Rab香叶基香叶基转移酶亚基β;RFP:红色荧光蛋白;SQSTM1/p62:螯合体1;TNFSF11/RANKL:TNF超家族成员11;ZOL:唑来膦酸。
Sensitive circulating tumor DNA (ctDNA) analysis is increasingly important for mutation monitoring and molecular stratification in cancer management, yet most current approaches depend on complex signal transducers, fluorescent labels and sophisticated instrumentation. Here, we present an amplification byproduct-induced nanozyme suppression (ABINS) strategy that uses amplification byproducts as functional signals for colorimetric ctDNA detection. By coupling exponential amplification reaction (EXPAR) with Cu3(PO4)2 microflower nanozymes (Cu3(PO4)2 MFs), pyrophosphate (PPi) generated during amplification selectively inhibits the peroxidase-like activity of the nanozymes, resulting in a straightforward signal-off visual readout. This assay enables highly sensitive detection of KRAS G12D ctDNA at the femtomolar level and effectively discriminates target mutants from wild-type sequences. Furthermore, as a proof-of-concept, the sensing paradigm reliably discriminated KRAS-mutant patients from healthy donors in clinical plasma samples, showing good agreement with PCR-based analysis. The ABINS strategy provides a simple amplification-coupled and label-free colorimetric approach for mutation-associated ctDNA analysis, while broader validation in larger clinical cohorts and more representative ctDNA models will still be needed to further define its practical performance.
中文摘要:敏感的循环肿瘤DNA(ctDNA)分析在癌症管理中的突变监测和分子分层中日益重要,但当前多数方法依赖复杂信号转换器、荧光标记和精密仪器。我们提出一种扩增副产物诱导的纳米酶抑制(ABINS)策略,利用扩增副产物作为功能信号进行比色ctDNA检测。通过将指数扩增反应(EXPAR)与Cu3(PO4)2微花纳米酶(Cu3(PO4)2 MFs)耦合,扩增过程中产生的焦磷酸(PPi)选择性抑制纳米酶的类过氧化物酶活性,形成直接的信號关闭型可视化读出。该方法可检测飞摩尔水平的KRAS G12D ctDNA,并有效区分目标突变与野生型序列。作为概念验证,该传感范式在临床血浆样本中可靠区分KRAS突变患者与健康供者,与基于PCR的分析显示良好一致性。ABINS策略为突变相关ctDNA分析提供了一种简单的扩增耦合、无标记比色方法,但仍需在更大临床队列和更具代表性的ctDNA模型中开展更广泛验证,以进一步确定其实际性能。
Endothelial dysfunction is a critical determinant of sepsis-associated organ injury, often driven by its interaction with overactivated immune cells. Neutrophils, the dominant early responders in sepsis, contribute to endothelial barrier disruption, yet the underlying metabolic and epigenetic mechanisms remain poorly understood. Here, we observed elevated intracellular lactate levels in neutrophils from septic patients which correlated with organ dysfunction and systemic inflammatory markers. Mechanistically, lactate-induced histone H3K18 lactylation (H3K18la) enhanced ATG7/GSA7 (autophagy related 7) transcription, initiating a non-degradative, secretory autophagy program. This facilitated the extracellular release of IL1B/IL-1B (interleukin 1 beta), a key driver of endothelial dysfunction. Interference of lactate production, ATG7 expression or IL1B signaling alleviated endothelial dysfunction in vitro. In vivo, myeloid-specific deletion of the lactylation writer EP300/p300 (EP300 lysine acetyltransferase) mitigated pulmonary endothelial dysfunction and lung injury. Additionally, the stress-responsive transcription factor ATF4/CREB-2 (activating transcription factor 4) was found to directly interact with both EP300 and H3K18la, amplifying H3K18la-driven ATG7 transcription. Our findings uncover a metabolically driven, epigenetically regulated secretory autophagy pathway in neutrophils that mediates endothelial dysfunction. Our study provides mechanistic insights into neutrophil-endothelial crosstalk in sepsis and identifies EP300, ATG7, and IL1B as potential therapeutic targets for sepsis.Abbreviations: ALI: acute lung injury; ANOVA: analysis of variance; ATF4/CREB-2: activating transcription factor 4; ATG7/GSA7: autophagy related 7; ATP: adenosine triphosphate; BafA1: bafilomycin A1; BMDN: bone marrow-derived neutrophil; C-CASP1: cleaved-caspase 1; CDH5/CD144: cadherin 5; CRP/PTX1: C-reactive protein; CST3: cystatin C; CXCL8/IL-8: C-X-C motif chemokine ligand 8; DAPI: 4',6-diamidino-2-phenylindole; DEG: differentially expressed gene; dHL-60: dimethyl sulfoxide-differentiated HL-60 cell; DMSO: dimethyl sulfoxide; ELISA: enzyme-linked immunosorbent assay; EP300/p300: EP300 lysine acetyltransferase; GOT1/AST: glutamic-oxaloacetic transaminase 1; GPT/ALT: glutamic - pyruvic transaminase; GSDMD-N: gasdermin D N-terminal; H&E: hematoxylin and eosin; H3K18la: histone H3K18 lactylation; HRP: horseradish peroxidase; ICU: intensive care unit; IHC: immunohistochemistry; IL1B/IL-1B: interleukin 1 beta; IL1R1/CD121A: interleukin 1 receptor type 1; IL6/IL-6: interleukin 6; KEGG: Kyoto Encyclopedia of Genes and Genomes; LAMP1/CD107a: lysosome associated membrane protein 1; LDHA: lactate dehydrogenase A; LPS: lipopolysaccharide; 3-MA: 3-methyladenine; NLRP3/NALP3: NLR family pyrin domain containing 3; PBS: phosphate-buffered saline; PCT: procalcitonin; PMN: peripheral neutrophils; Rapa: rapamycin; RNA-seq: RNA-sequencing; SERPINE1/PAI1: serpin family E member 1; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; SOFA: Sequential Organ Failure Assessment; SQSTM1/p62: sequestosome 1; TEM: transmission electron microscopy; TNF/TNF-alpha: tumor necrosis factor; panKla: pan-histone lactylation; VCAM1/CD106: vascular cell adhesion molecule 1.
中文摘要:内皮功能障碍是脓毒症相关器官损伤的重要决定因素,常由内皮细胞与过度活化的免疫细胞相互作用所驱动。中性粒细胞是脓毒症早期主要的应答细胞,参与破坏内皮屏障,但其代谢和表观遗传机制仍不清楚。我们观察到脓毒症患者中性粒细胞内乳酸水平升高,并与器官功能障碍和全身炎症标志物相关。机制上,乳酸诱导的组蛋白H3K18乳酰化(H3K18la)增强ATG7/GSA7(自噬相关7)转录,启动非降解性分泌性自噬程序。该程序促进IL1B/IL-1B(白细胞介素1β)释放到细胞外,而IL1B是内皮功能障碍的关键驱动因子。干预乳酸产生、ATG7表达或IL1B信号均可在体外减轻内皮功能障碍。体内实验中,髓系特异性敲除乳酰化写入因子EP300/p300(EP300赖氨酸乙酰转移酶)可减轻肺内皮功能障碍和肺损伤。应激反应转录因子ATF4/CREB-2(激活转录因子4)被发现在直接与EP300和H3K18la相互作用,放大H3K18la驱动的ATG7转录。我们的发现揭示中性粒细胞中一条代谢驱动、表观遗传调控的分泌性自噬通路介导内皮功能障碍。该研究为脓毒症中中性粒细胞与内皮细胞交互提供了机制见解,并将EP300、ATG7和IL1B确定为脓毒症的潜在治疗靶点。
Current DNA structural analysis methods, such as X-ray crystallography, NMR, Circular Dichroism (CD) spectrometry, and Electron Microscopy (EM) provide accurate analysis of DNA structures; however, these methods are limited in their applicability due to their high cost, large size, and complexity of operation. To combat this, we invented Elliptical Dichroism Spectrometer (EDS), which is lower in cost, smaller in size, and handy for DNA structural analysis. Previously, we validated its use as a protein secondary structural analysis instrument with clinical potential for noninvasive cancer detection. Here, we validate EDS for DNA structural analysis using well-established fluorescence assays and circular dichroism spectroscopy. EDS demonstrates strong potential as a label-free alternative method for analyzing diverse DNA structures, including simple hairpins, complex G-quadruplexes, and various DNA origami architectures. Furthermore, EDS demonstrates proof-of-concept in biologically relevant systems for detecting diseases associated with DNA damage.
中文摘要:当前DNA结构分析方法如X射线晶体学、核磁共振、圆二色光谱和电子显微镜可对DNA结构进行准确分析,但成本高、体积大、操作复杂,限制了应用范围。为此,我们研制了椭圆二色光谱仪(EDS),其成本更低、体积更小,便于进行DNA结构分析。此前,我们已证明其作为蛋白质二级结构分析仪器使用,并具有用于无创癌症检测的临床潜力。在本研究中,我们利用成熟的荧光测定和圆二色光谱验证EDS用于DNA结构分析。EDS在分析多种DNA结构方面显示出作为无标记替代方法的较强潜力,包括简单发夹结构、复杂G-四链体以及多种DNA折纸结构。此外,EDS在与DNA损伤相关疾病的检测中于生物学相关系统内展示了概念验证。
Single-cell analysis of circulating tumor cells (CTCs) holds significant potential for elucidating tumor metastasis mechanisms, improving prognosis assessment, and advancing precision therapeutics. Microfluidic chips have emerged as essential tools for isolating and enriching CTCs. However, existing microfluidic techniques have limited capability to achieve in situ functional characterization of single CTCs. Moreover, most current systems ignore CTC co-capture, obscuring the inherent heterogeneity of individual CTCs. In this study, we developed a novel integrated microfluidic chip for CTC enrichment, single-cell capture, and migration and molecular heterogeneity. On the chip, a spiral inertial structure enables label-free CTC enrichment, while a symmetrical branching network and double-cross-shaped micropillars achieve high-throughput, high-efficiency single-cell capture. The platform allows in situ establishment of a spatial concentration gradient to quantitatively analyze single-CTC migration, coupled with immunofluorescence detection of epithelial-mesenchymal transition (EMT)-related markers. Experimental results demonstrate that the chip achieved a capture rate exceeding 80%, with a single-cell capture efficiency of over 70%. This integrated chip enables a direct single-cell resolution correlation between the migratory capacity and EMT phenotype of CTCs. Analysis of blood samples from 11 colorectal cancer patients reveals that both the migration speed of CTCs and the proportion of migratory CTCs are significantly higher in patients with metastatic disease. The integrated platform correlates the dynamic migratory function with static molecular phenotypes at single-cell resolution, offering a new method for investigating CTC heterogeneity in tumor metastasis.
中文摘要:循环肿瘤细胞(CTC)的单细胞分析有助于阐明肿瘤转移机制、改进预后评估并推动精准治疗。微流控芯片已成为分离和富集CTC的重要工具,但现有微流控技术在单CTC原位功能表征方面能力有限,且多数系统忽视CTC的共捕获,掩盖了单个CTC的固有异质性。研究构建了一种新型集成微流控芯片,用于CTC富集、单细胞捕获以及迁移和分子异质性分析。芯片上的螺旋惯性结构实现无标记CTC富集,对称分支网络和双十字形微柱实现高通量、高效率的单细胞捕获。该平台可在原位建立空间浓度梯度,对单CTC迁移进行定量分析,并结合免疫荧光检测上皮-间质转化(EMT)相关标志物。实验结果显示,芯片捕获率超过80%,单细胞捕获效率超过70%。该集成芯片能够在单细胞分辨率下直接关联CTC的迁移能力与EMT表型。对11例结直肠癌患者血液样本的分析显示,转移患者的CTC迁移速度和迁移性CTC比例均显著更高。该集成平台在单细胞分辨率下将动态迁移功能与静态分子表型相关联,为研究肿瘤转移中的CTC异质性提供了新方法。
Monitoring therapeutic response is essential for improving the precision and efficacy of photodynamic therapy (PDT), yet quantitative and real-time evaluation remain challenging. Herein, we report a programmable DNA nanotube-based dual-mode biosensing platform for monitoring PDT-induced apoptosis through complementary fluorescence and electrochemical signals. In this system, methylene blue (MB) functions as a multifunctional component, simultaneously acting as a photosensitizer, near-infrared imaging probe, and electrochemical reporter. A caspase-3-responsive peptide is integrated into the DNA nanotube scaffold, enabling apoptosis-triggered fluorescence activation. Caspase-3 activation triggers peptide cleavage, resulting in fluorescence recovery and enhanced electrochemical signals, with limits of detection (LOD) of 0.786 ng/mL for the fluorescence method and 0.622 ng/mL for square-wave voltammetry (SWV). Gold nanoparticles incorporated into the DNA nanotube further catalyze endogenous H2O2 decomposition to generate oxygen, alleviating tumor hypoxia and enhancing PDT efficacy. The platform demonstrated accurate dual-mode detection capability in complex biological samples. These results demonstrate that the programmable DNA nanotube-based platform enables synchronized electrochemical and fluorescence biosensing through a shared caspase-3-responsive mechanism, thereby allowing real-time therapeutic feedback during photodynamic therapy.
中文摘要:监测治疗反应对于提高光动力治疗(PDT)的精准性和疗效至关重要,但定量、实时评估仍具挑战。报道了一种可编程DNA纳米管双模式生物传感平台,通过互补的荧光与电化学信号监测PDT诱导的细胞凋亡。在该系统中,亚甲蓝(MB)作为多功能组分,同时充当光敏剂、近红外成像探针和电化学报告分子。将caspase-3响应肽整合到DNA纳米管支架中,可实现凋亡触发的荧光激活。caspase-3激活引发肽切割,导致荧光恢复和电化学信号增强,荧光法和方波伏安法(SWV)的检测限(LOD)分别为0.786 ng/mL和0.622 ng/mL。掺入DNA纳米管的金纳米颗粒进一步催化内源性H2O2分解产生氧气,缓解肿瘤缺氧并增强PDT疗效。该平台在复杂生物样本中表现出准确的双模式检测能力。这些结果表明,基于可编程DNA纳米管的平台通过共享的caspase-3响应机制实现电化学与荧光生物传感同步,从而在光动力治疗期间提供实时治疗反馈。
Wee kinases, including Wee1, Myt1 (PKMYT1) and Wee2, serve as critical regulators of the DNA damage response by inhibiting the G2/M transition and have attracted increasing attention as a targetable vulnerability in TP53-deficient cancers. Wee1 is the fastest progressing member in clinical research, and its inhibitors such as AZD-1775 and ZN-c3 are under clinical evaluation. Because toxicity and resistance persist with existing agents, research is moving toward newer strategies such as protein degradation technologies. Proceeding from sequence and structure, we, for the first time, use chemoinformatics to delineate the chemical space of the Wee1 binding pocket and classify reported inhibitors into three pocket engagement types, thereby constructing a high-resolution pocket map and an anchorable Markush for designing inhibitors with high selectivity and activity. We further summarize design principles for targeted degradation of Wee1 and outline combination strategies grounded in synthetic lethality, and we curate recent preclinical and ongoing clinical advances with discussion of biomarker-guided enrollment and dosing schedules. By linking structural mechanisms to pharmacology and clinical placement, this review provides an actionable framework for next-generation Wee1-directed drug design and translation in oncology.
中文摘要:Wee激酶包括Wee1、Myt1(PKMYT1)和Wee2,通过抑制G2/M转换成为DNA损伤反应的关键调控因子,并作为TP53缺陷型癌症的可靶向脆弱点受到越来越多关注。Wee1是临床研究进展最快的成员,AZD-1775和ZN-c3等抑制剂正在临床评估。现有药物仍存在毒性和耐药问题,研究正转向蛋白降解技术等更新策略。从序列和结构出发,我们首次利用化学信息学刻画Wee1结合口袋的化学空间,将已报道抑制剂分为三类口袋结合方式,由此构建高分辨率口袋图谱和可锚定的马库什结构,用于设计高选择性和高活性抑制剂。进一步总结Wee1靶向降解的设计原则,概述基于合成致死的联合策略,并整理近期临床前和正在进行的临床进展,讨论生物标志物指导入组与给药方案。通过将结构机制与药理学及临床定位相联系,该综述为下一代Wee1导向的药物设计及肿瘤学转化提供可操作框架。
Hypoxia-inducible factor 3 alpha (HIF-3α) has long been considered a minor, inhibitory branch of the HIF pathway. However, accumulating evidence suggests that HIF-3α is a context-dependent regulator with transcriptional activator and dominant-negative functions. The human HIF3A locus undergoes extensive alternative splicing, yielding at least eight to ten protein isoforms. In contrast, the mouse Hif3a gene produces only three major variants. This creates substantial species divergence in isoform architecture and expression. Full-length human isoforms, such as HIF-3α1, HIF-3α2, and HIF-3α9, are bona fide transcription factors that regulate both canonical and non-canonical hypoxic targets, including EPO, LC3C, REDD1, SQRDL, and IGFBP-1. In contrast, truncated variants, such as HIF-3α4, antagonize HIF-1/2-dependent angiogenic and metabolic programs in a tissue-specific manner. Mouse models demonstrate that canonical HIF-3α integrates developmental and redox cues in the lungs, heart, and metabolism. Furthermore, human HIF3A methylation and isoform-specific expression have been linked to obesity, liver dysfunction, diabetes, chronic lung disease, neurodegeneration, and cancer. Full-length isoforms often promote tumor growth and metastasis (e.g., in colorectal and pancreatic cancers), whereas truncated isoforms constrain angiogenesis or stabilize oncogenic HIF-2α in certain contexts. In this review, we integrate these findings into an isoform-resolved, cross-species framework that distinguishes experimentally validated HIF-3α functions from indirect associations and proposed redox mechanisms. We propose that HIF-3α acts less as a single hypoxia transcription factor and more as an isoform-specific rheostat that shapes acute, chronic, and redox-stressed states. Finally, we outline the need for long-read transcriptomics, isoform-specific assays, evidence-stratified disease models, and targeted modulation of individual HIF-3α variants to translate this complexity into therapeutic strategies for redox-driven human diseases.
中文摘要:缺氧诱导因子3α(HIF-3α)长期被视为HIF通路中次要的抑制性分支。已有证据显示,HIF-3α是按环境发挥作用的调节因子,兼具转录激活和显性负性功能。人HIF3A基因座发生广泛可变剪接,至少产生8至10种蛋白异构体;小鼠Hif3a基因仅产生3种主要变体,造成异构体结构和表达上的显著种属差异。全长人异构体如HIF-3α1、HIF-3α2和HIF-3α9是真正的转录因子,调控经典与非经典缺氧靶点,包括EPO、LC3C、REDD1、SQRDL和IGFBP-1。截短变体如HIF-3α4则以组织特异方式拮抗HIF-1/2依赖的血管生成和代谢程序。小鼠模型显示,经典HIF-3α整合肺、心脏和代谢中的发育与氧化还原信号。人HIF3A甲基化及异构体特异性表达与肥胖、肝功能异常、糖尿病、慢性肺病、神经退行性疾病和癌症相关。全长异构体常促进肿瘤生长和转移(如结直肠癌和胰腺癌),截短异构体在某些情境下限制血管生成或稳定致癌性HIF-2α。本综述将这些发现整合为按异构体分辨、跨物种的框架,区分实验验证的HIF-3α功能与间接关联及推测的氧化还原机制。HIF-3α更像按异构体发挥作用的变阻器,塑造急性、慢性和氧化还原应激状态,而非单一缺氧转录因子。并指出需要长读长转录组学、异构体特异性检测、按证据分层的疾病模型以及针对单个HIF-3α变体的靶向调控,以将这种复杂性转化为氧化还原驱动人类疾病的治疗策略。
LUAD exhibits diversity in the mechanisms of angiogenesis and the tumor environment's responses to anti-VEGF therapy, while the tumor-cell-intrinsic mechanisms that prevent vascularization are not well understood. SCGB3A2 (secretoglobin 3A2; HIN-2/UGRP1) is a club/secretory marker of pulmonary adenocarcinoma without established angiogenic function. By using an unsupervised integration approach of two public LUAD single-cell RNA-seq cohorts, we described a SCGB3A2-high malignant epithelial state characterized by an angiogenesis-low phenotype as indicated by the low presence of VEGFA, hypoxic conditions, and a low epithelial-mesenchymal transition (EMT), along with a secretory/anti-inflammatory program, which was confirmed in independent bulk cohorts (TCGA-LUAD, GSE72094) showing that SCGB3A2-high tumors experienced lower instances of angiogenesis, hypoxia, and scores related to EMT/invasion. Using spatial transcriptomics, we positioned SCGB3A2-high tumor cells next to endothelial cells and identified a spatially inferred VEGFA/B-FLT1 interaction pattern. In A549 and NCI-H1975 cells, conditioned medium from SCGB3A2-overexpressing cells contained higher levels of extracellular PGK2-immunoreactive signal and angiostatin and was associated with reduced HUVEC tube formation and VEGFR2 phosphorylation. Thus, SCGB3A2 is a marker for LUAD tumors characterized by low levels of angiogenesis, which is associated with an extracellular PGK2/angiostatin signal.
中文摘要:肺腺癌的血管生成机制及肿瘤环境对抗VEGF治疗的反应存在差异,而阻止血管化的肿瘤细胞内在机制尚不清楚。SCGB3A2(secretoglobin 3A2;HIN-2/UGRP1)是肺腺癌的club/分泌型标志物,其血管生成功能尚未确立。通过对两个公开肺腺癌单细胞RNA测序队列进行无监督整合,我们描述了一种SCGB3A2高表达的恶性上皮状态,该状态以低血管生成表型为特征,表现为VEGFA少、缺氧水平低、上皮-间质转化(EMT)低,并伴随分泌/抗炎程序;这一特征在独立bulk队列(TCGA-LUAD、GSE72094)中得到确认,SCGB3A2高表达肿瘤的血管生成、缺氧及EMT/侵袭相关评分较低。利用空间转录组学,我们将SCGB3A2高表达肿瘤细胞定位在内皮细胞邻近区域,并识别出空间推断的VEGFA/B-FLT1相互作用模式。在A549和NCI-H1975细胞中,SCGB3A2过表达细胞的条件培养基含有更高水平的细胞外PGK2免疫反应信号和血管抑素,并与HUVEC成管减少及VEGFR2磷酸化降低相关。因此,SCGB3A2是低血管生成肺腺癌肿瘤的标志物,并与细胞外PGK2/血管抑素信号相关。
Chronic stress is associated with increased risk of breast cancer metastasis and poor clinical outcomes; however, the underlying mechanisms remain incompletely understood. Here, we demonstrated that chronic stress elevates lactate levels in the tumor microenvironment, thereby promoting lactylation of metastasis associated 1 family member 2 (MTA2) at lysine 460. Mechanistically, chronic stress not only enhances lactate metabolism within the tumor microenvironment, providing sufficient substrate for lactylation, but also activates the β2-adrenergic receptor (β2-AR)/PKA signaling axis, leading to P300 phosphorylation and cooperatively facilitating MTA2 lactylation. This modification weakens the interaction between MTA2 and RBBP7, resulting in destabilization of the nucleosome remodelling and histone deacetylase (NuRD) complex and impaired transcriptional repression. This is accompanied by increased H3K9 acetylation and upregulation of genes associated with both tumor progression and metastasis, including MMP16, NRP1, and VCAM1. Importantly, a cell-penetrating peptide specifically targeting MTA2 lactylation effectively inhibits breast tumor growth and reduces lung metastatic burden in chronic stress models. Together, our findings identify protein lactylation, especially that of MTA2, as a key regulatory event in chronic stress-induced tumor progression, providing new insights into the link between tumor epigenetics and chronic stress, and suggesting a potential biomarker and therapeutic target for prognostic assessment and clinical intervention in breast cancer patients under chronic stress.
中文摘要:慢性应激与乳腺癌转移风险升高及临床结局不良相关,但其机制尚未完全阐明。研究显示慢性应激提高肿瘤微环境中的乳酸水平,促进转移相关1家族成员2(MTA2)第460位赖氨酸发生乳酸化。机制上,慢性应激既增强肿瘤微环境内乳酸代谢,为乳酸化提供充足底物,又激活β2肾上腺素能受体(β2-AR)/PKA信号轴,引起P300磷酸化,协同促进MTA2乳酸化。该修饰削弱MTA2与RBBP7的相互作用,导致核小体重塑和组蛋白去乙酰化酶(NuRD)复合物不稳定及转录抑制受损,并伴随H3K9乙酰化升高以及MMP16、NRP1和VCAM1等肿瘤进展和转移相关基因上调。靶向MTA2乳酸化的细胞穿膜肽在慢性应激模型中可有效抑制乳腺肿瘤生长并减轻肺转移负荷。研究将蛋白乳酸化尤其是MTA2乳酸化确定为慢性应激诱导肿瘤进展的关键调控事件,为肿瘤表观遗传与慢性应激之间的联系提供新认识,并提示其可作为慢性应激乳腺癌患者预后评估和临床干预的潜在生物标志物及治疗靶点。
Dictyostelium discoideum is a model organism used to investigate a wide array of biological processes including chemotaxis, cell motility, phagocytosis, multicellular development, and autophagy. Many of its genes have human orthologs implicated in disease, making it a useful model organism for studying conditions ranging from cancer to neurodegeneration. dictyBase has served this community for two decades as a home for genomic data, protocols, a stock center, and community news. Here we describe a complete reimplementation of dictyBase as a self-contained service that uses static data files rather than a database server. Each gene record gathers curated function, human-disease context, developmental expression, and protein structure in a single webpage. The site also provides tools for sequence search, genome browsing, enrichment analysis, and experimental design. The complete Dicty Stock Center catalog of 7055 strains and 1265 plasmids is included, and both can be ordered from the site. New literature is curated by an author-in-the-loop pipeline. A language model drafts the annotations, the authors of the paper correct them, and a curator approves them. Analyses can be run on curator-approved annotations alone or extended to include those still awaiting review. dictyBase is freely available at https://dicty.org.
中文摘要:盘基网柄菌(Dictyostelium discoideum)是一种模式生物,用于研究趋化、细胞运动、吞噬、多细胞发育和自噬等多种生物学过程。它的许多基因具有与疾病相关的人类直系同源基因,因此成为研究从癌症到神经退行性疾病等病症的有用模式生物。dictyBase 二十年来服务于该领域,汇集基因组数据、实验方案、品系保藏中心和社区新闻。dictyBase 经过完整重构,作为自包含服务运行,使用静态数据文件而非数据库服务器。每条基因记录在单一网页中整合经审编的功能、人类疾病背景、发育表达和蛋白质结构。网站还提供序列搜索、基因组浏览、富集分析和实验设计工具。Dicty Stock Center 的全部目录包括 7055 个品系和 1265 个质粒,均可通过网站订购。新文献由作者参与审编的流程处理:语言模型起草注释,论文作者修正,审编员批准。分析既可仅基于审编员批准的注释运行,也可扩展至包含尚待审核的注释。dictyBase 可在 https://dicty.org 免费使用。
5临床/流行病学 (53篇)
临床研究 (32篇)
This single-center randomized controlled trial assessed the efficacy and safety of the ramucirumab plus nab-paclitaxel, lobaplatin, and S-1(RNPLS) regimen for conversion therapy in unresectable advanced gastric cancer. Seventy patients were equally assigned to receive either ramucirumab, nab-paclitaxel, lobaplatin, and S-1(RNPLS) therapy or nab-paclitaxel, lobaplatin, and S-1(NPLS) chemotherapy alone. Primary endpoints included pathological complete response (pCR) and secondary endpoints encompassed R0 resection rate, objective response rate (ORR), the disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and adverse events (AE). Although the difference in pCR rate was statistically insignificant between the two groups, the RNPLS group achieved significantly higher ORR, DCR, and R0 resection rate. Moreover, the RNPLS regimen yielded prolonged PFS, longer duration of response, and promising preliminary OS. While hypertension occurred more frequently in the RNPLS group, the incidence of grade ≥3 AEs was low and comparable in both cohorts. This exploratory single-center randomized trial showed preliminary favorable efficacy of RNPLS regimen for conversion therapy in unresectable advanced gastric cancer with manageable toxicity. ClinicalTrials.gov: NCT06169410.
中文摘要:这项单中心随机对照试验评估雷莫西尤单抗联合白蛋白结合型紫杉醇、洛铂和替吉奥(RNPLS)方案用于不可切除晚期胃癌转化治疗的有效性与安全性。70例患者等比分入RNPLS方案组或白蛋白结合型紫杉醇、洛铂和替吉奥(NPLS)单纯化疗组。主要终点为病理完全缓解(pCR),次要终点包括R0切除率、客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)、缓解持续时间(DOR)及不良事件(AE)。两组pCR率差异无统计学意义,RNPLS组ORR、DCR及R0切除率显著更高。RNPLS方案的PFS延长、缓解持续时间更长,OS初步结果令人期待。RNPLS组高血压发生更常见,两组3级及以上不良事件发生率均较低且相近。这项探索性单中心随机试验显示,RNPLS方案用于不可切除晚期胃癌转化治疗初步疗效良好,毒性可控。临床试验注册号:NCT06169410。
Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have evolved from glucose-lowering agents to foundational therapies for the management of type 2 diabetes mellitus, heart failure, and chronic kidney disease, with substantial benefits for cardiovascular, kidney, and survival outcomes. As their indications continue to expand, a comprehensive understanding of their safety and tolerability has become increasingly important for optimizing patient care. Building on our recent state-of-the-art review of glucagon-like peptide-1 receptor agonists, this review provides a contemporary synthesis of the evidence on the safety and tolerability of SGLT-2is. We critically appraise data from randomized controlled trials, cardiovascular and kidney outcome trials, pharmacovigilance databases, large observational studies, and systematic reviews and meta-analyses. The available evidence demonstrates that SGLT-2is have a favorable overall safety profile, with genital mycotic infections representing the most consistently observed adverse event. Volume depletion and euglycemic diabetic ketoacidosis remain clinically important but are uncommon and are largely preventable through appropriate patient selection, patient education, and temporary treatment interruption during high-risk clinical situations. Fournier's gangrene should be regarded as a very rare but serious complication requiring prompt recognition and treatment. In contrast, randomized trials and meta-analyses generally indicate a reduced risk of acute kidney injury, while evidence concerning fracture, lower-limb amputation, hepatotoxicity, pancreatitis, and cancer is less definitive. Although consistent class-wide increases in these latter outcomes have not been established, uncommon or agent-specific risks cannot be excluded, particularly where event numbers are small or follow-up is limited. Overall, treatment discontinuation because of adverse events is low across major cardiovascular, heart failure, and kidney outcome trials, supporting the excellent tolerability of this therapeutic class. Comparative evidence suggests only modest differences among individual SGLT-2is, although definitive conclusions remain limited by the absence of direct, large, randomized head-to-head trials. We also summarize practical strategies for adverse-event mitigation, monitoring, temporary treatment interruption, and individualized patient selection. As the clinical applications of SGLT-2is continue to broaden, ongoing pharmacovigilance, inclusive clinical trials, and comparative safety studies will be essential to further refine their benefit-risk profile and optimize their safe use across diverse patient populations.
中文摘要:SGLT-2抑制剂已从降糖药物发展为2型糖尿病、心力衰竭和慢性肾脏病管理的基础治疗,对心血管、肾脏和生存结局具有显著获益。随着适应证不断扩展,全面理解其安全性和耐受性对优化患者管理日益重要。在近期关于胰高血糖素样肽-1受体激动剂的最新综述基础上,该综述对SGLT-2抑制剂安全性和耐受性的证据进行了当代综合。作者批判性评价了随机对照试验、心血管和肾脏结局试验、药物警戒数据库、大型观察性研究以及系统综述和荟萃分析的数据。现有证据显示,SGLT-2抑制剂总体安全性良好,生殖器真菌感染是最持续观察到的不良事件。容量不足和正常血糖性糖尿病酮症酸中毒仍具有临床重要性,但并不常见,且通过合适的患者选择、患者教育以及在高危临床情境下暂时中断治疗,大多可以预防。Fournier坏疽应被视为非常罕见但严重的并发症,需要及时识别和处理。相比之下,随机试验和荟萃分析通常提示急性肾损伤风险降低,而关于骨折、下肢截肢、肝毒性、胰腺炎和癌症的证据尚不明确。尽管尚未确立这些后者结局在全类别中一致性增加,但不能排除不常见或药物特异性风险,尤其是在事件数较少或随访有限时。总体而言,在主要心血管、心力衰竭和肾脏结局试验中,因不良事件而停药的比例较低,支持该治疗类别具有良好的耐受性。比较证据提示单个SGLT-2抑制剂之间仅存在适度差异,但由于缺乏直接、大型、随机头对头试验,确定性结论仍受限。该综述还总结了不良事件缓解、监测、暂时中断治疗和个体化患者选择的实用策略。随着SGLT-2抑制剂的临床应用不断拓宽,持续的药物警戒、具有包容性的临床试验和比较安全性研究对于进一步完善其获益-风险特征并优化不同患者群体中的安全使用至关重要。
Results from the third interim analysis of the phase 3 KEYNOTE-585 study (NCT03221426) showed superior pathological complete response (pCR) with perioperative pembrolizumab and chemotherapy followed by adjuvant pembrolizumab versus placebo plus chemotherapy, then adjuvant placebo in locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma; differences in event-free survival (EFS) were not statistically significant. We present results from a complementary cohort that evaluated pembrolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) versus placebo plus FLOT. KEYNOTE-585 is a randomized, phase 3 study conducted at 143 medical centers. Participants were randomly assigned 1 : 1 to pembrolizumab plus FLOT or placebo plus FLOT. In this exploratory cohort, the primary endpoint was safety. Post hoc exploratory endpoints included pCR rate per the Mandard scale by blinded independent central review, EFS per RECIST v1.1 by investigator, and overall survival (OS). Overall, 203 participants were randomly assigned (pembrolizumab group, n = 100; placebo group, n = 103). Median time from randomization to data cut-off (16 February 2024) was 43.8 months (range, 36.5-69.8). Grade 3 or 4 treatment-related adverse event rates were 72.7% and 62.1%, respectively. Treatment-related deaths occurred in three participants (3.0%) in the pembrolizumab group and one participant (1.0%) in the placebo group. The pCR rate was 17.0% [95% confidence interval (CI), 10.2-25.8] in the pembrolizumab group and 6.8% (95% CI, 2.8-13.5) in the placebo group. Median EFS was not reached (NR; 95% CI, 28.2-NR) versus 31.6 months (95% CI, 22.8-NR), respectively [hazard ratio (HR) 0.75, 95% CI 0.50-1.13]. Median OS was NR in either group (HR 0.81, 95% CI 0.53-1.25); 36-month OS rates were 66.0% and 59.2%. Neoadjuvant/adjuvant pembrolizumab plus FLOT was feasible and showed an acceptable safety profile. Exploratory efficacy endpoints showed numerical trends consistent with those of the main cohort in locally advanced resectable gastric or gastroesophageal junction adenocarcinoma.
中文摘要:KEYNOTE-585研究(NCT03221426)第三次期中分析显示,在局部晚期可切除胃或胃食管结合部腺癌中,围手术期帕博利珠单抗联合化疗、序贯辅助帕博利珠单抗,相比安慰剂联合化疗后辅助安慰剂,病理完全缓解(pCR)更优;无事件生存(EFS)差异无统计学意义。本次报告一个补充队列的结果,该队列评估帕博利珠单抗联合氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛(FLOT)对比安慰剂联合FLOT。KEYNOTE-585是在143个医疗中心开展的随机3期研究,受试者按1:1随机分配至帕博利珠单抗联合FLOT组或安慰剂联合FLOT组。该探索性队列的主要终点为安全性。事后探索性终点包括由盲法独立中心评审按Mandard分级判定的pCR率、研究者按RECIST v1.1评估的EFS以及总生存(OS)。共203例受试者接受随机分配(帕博利珠单抗组100例,安慰剂组103例)。从随机分组至数据截止(2024年2月16日)的中位时间为43.8个月(范围36.5-69.8)。3级或4级治疗相关不良事件发生率分别为72.7%和62.1%。治疗相关死亡在帕博利珠单抗组有3例(3.0%),安慰剂组有1例(1.0%)。pCR率在帕博利珠单抗组为17.0%(95%置信区间10.2-25.8),安慰剂组为6.8%(95%置信区间2.8-13.5)。中位EFS分别为未达到(NR;95%置信区间28.2-NR)与31.6个月(95%置信区间22.8-NR),风险比0.75(95%置信区间0.50-1.13)。两组中位OS均未达到(风险比0.81,95%置信区间0.53-1.25);36个月OS率分别为66.0%和59.2%。新辅助/辅助帕博利珠单抗联合FLOT方案可行,安全性特征可接受。探索性疗效终点的数值趋势与主队列一致,适用于局部晚期可切除胃或胃食管结合部腺癌。
The biological mechanisms linking air pollution to lung carcinogenesis remain underexplored. This study aimed to identify key proteins and pathways involved in mediating the effects of air pollutants on lung cancer risk. We analyzed 95 matched lung cancer case-control pairs of ever-smokers with prediagnosis plasma protein profiles measured in the Cancer Prevention Study-II Nutrition Cohort. We assessed associations between protein levels and six individual air pollutants, air pollution mixture, and lung cancer risk, adjusting for confounders and multiple testing. We identified overlapping proteins and enriched pathways associated with both exposures and lung cancer risk, followed by an exploratory high-dimensional mediation analysis (HIMA) to investigate the potential mediating roles of proteins. Seventeen proteins were associated with both exposures and lung cancer, including CX3CL1, ADAM15, and CXCL17 (P < 0.05). HIMA identified six proteins, including CX3CL1 and CXCL17, as potential mediating proteins of individual pollutant-lung cancer associations (Bonferroni-corrected P < 0.05), while these findings did not remain significant when excluding cases diagnosed within one year of blood draw. The exploratory results suggest that proteins and pathways related to inflammatory chemokine signaling, immune modulation, and altered cell proliferation, migration, and survival may play significant roles in air pollution-lung cancer association among ever-smokers.
中文摘要:空气污染引发肺癌的生物学机制仍未被充分阐明。本研究旨在识别介导空气污染物影响肺癌风险的关键蛋白与通路。研究在癌症预防研究-II营养队列中分析95对匹配的有吸烟史者的肺癌病例与对照,其血浆蛋白谱均在诊断前测定。校正混杂因素与多重检验后,评估蛋白水平与六种单一空气污染物、空气污染混合物及肺癌风险之间的关联。研究找出既与暴露相关、又与肺癌风险相关的重叠蛋白及富集通路,随后用探索性高维中介分析(HIMA)考察蛋白的潜在中介作用。17种蛋白同时与暴露和肺癌相关,包括CX3CL1、ADAM15和CXCL17(P < 0.05)。HIMA识别出6种蛋白,包括CX3CL1和CXCL17,可能是单一污染物与肺癌关联的潜在中介蛋白(Bonferroni校正后P < 0.05);排除采血后一年内确诊的病例后,这些结果不再显著。探索性结果提示,与炎症趋化因子信号、免疫调节以及细胞增殖、迁移和存活改变相关的蛋白与通路,可能在有吸烟史者空气污染与肺癌的关联中起重要作用。
Gemcitabine resistance remains a major therapeutic barrier in pancreatic ductal adenocarcinoma (PDAC), for which median survival in advanced disease has remained near one year despite extensive clinical investigation. Using artificial intelligence (AI)-guided structure-based drug repurposing, we identified sitagliptin, a DPP-4 inhibitor for diabetes, as a candidate ribonucleotide reductase (RRM1/2) inhibitor that sensitizes PDAC to gemcitabine. Molecular dynamics simulations suggested that sitagliptin disrupts gemcitabine-RRM1/2 interactions, downregulating RRM1/2 expression and restoring chemosensitivity across PDAC cell lines, patient-derived organoids, and mouse models. Sitagliptin enhanced the anti-tumor efficacy of both gemcitabine-nab-paclitaxel (GnP) and FOLFIRINOX regimens in preclinical studies. We conducted SITGEM-CARE, a single-center phase 2 trial in 22 patients with locally advanced or metastatic PDAC (median age 65.0 years; ECOG performance status 1, 86.4%; Stage IV, 68.2%; liver metastases, 54.5%). Patients received sitagliptin 100 mg orally once daily continuously, plus gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m² on days 1 and 8 of 21-day cycles. Among 22 evaluable patients, eight achieved a partial response, and 11 had stable disease, yielding an objective response rate of 36.4% (95% CI: 17.2-59.3%) and a disease control rate of 86.4% (95% CI: 65.1-97.1%), with tumor shrinkage in 86.4% of patients. At a median follow-up of 9.9 months, the median progression-free survival was 6.6 months (95% CI: 4.8-12.4) with 6-month and 9-month PFS rates of 63.6% and 43.5%, respectively. Median overall survival was 12.5 months (95% CI: 7.8-not reached), with 62.9% of patients alive at 12 months. Furthermore, treatment was well tolerated, with no Grade 4/5 treatment-related adverse events. These findings are hypothesis-generating and warrant confirmation in adequately powered, randomized trials. ClinicalTrials.gov: NCT05947825.
中文摘要:吉西他滨耐药仍是胰腺导管腺癌(PDAC)的主要治疗障碍,晚期患者中位生存期尽管经过大量临床研究仍接近一年。通过人工智能引导的基于结构的药物重定位,发现糖尿病治疗药物DPP-4抑制剂西格列汀是候选核糖核苷酸还原酶(RRM1/2)抑制剂,可使PDAC对吉西他滨敏感。分子动力学模拟提示西格列汀破坏吉西他滨与RRM1/2的相互作用,下调RRM1/2表达,并在PDAC细胞系、患者来源类器官和小鼠模型中恢复化疗敏感性。临床前研究中,西格列汀增强吉西他滨联合白蛋白紫杉醇(GnP)和FOLFIRINOX方案的抗肿瘤疗效。开展SITGEM-CARE单中心2期试验,纳入22例局部晚期或转移性PDAC患者(中位年龄65.0岁;ECOG体能状态1分者86.4%;IV期68.2%;肝转移54.5%)。患者持续口服西格列汀100 mg每日一次,并在21天周期第1天和第8天接受吉西他滨1000 mg/m²与白蛋白紫杉醇125 mg/m²。22例可评估患者中,8例达到部分缓解,11例疾病稳定,客观缓解率为36.4%(95% CI 17.2-59.3%),疾病控制率为86.4%(95% CI 65.1-97.1%),86.4%的患者肿瘤缩小。中位随访9.9个月时,中位无进展生存期为6.6个月(95% CI 4.8-12.4),6个月和9个月无进展生存率分别为63.6%和43.5%。中位总生存期为12.5个月(95% CI 7.8-未达到),12个月时62.9%的患者存活。治疗耐受性良好,无4级或5级治疗相关不良事件。这些结果具有假设生成意义,需在足够把握度的随机试验中确认。ClinicalTrials.gov:NCT05947825。
Body Mass Index, Genetic Predisposition, and Obesity-Related Second Cancer Risk in Cancer Survivors.
Excess body weight is an established risk factor for second primary cancers (SPCs) among cancer survivors. Whether genetic susceptibility to higher body mass index (BMI) is associated with the risk of obesity-related SPCs remains unclear. To examine associations of genetic predisposition to higher BMI with the risk of obesity-related SPCs and its joint association with BMI. This prospective cohort study used data from the Cancer Prevention Study II Nutrition Cohort, a large prospective study of adults residing in 21 states in the US who were cancer-free at the time of the 1992 survey and responded to biennial follow-up questionnaires starting in 1997. Response rates to the biennial questionnaires ranged from 78.1% to 92.1%. Participants for this analysis included cancer survivors who received a diagnosis of a first primary, nonmetastatic invasive cancer between 1992 and 2015, provided a biospecimen sample, and were followed up through 2017. Analyses were conducted between September 2025 and August 2026. A polygenic score for BMI (PGS-BMI) and BMI. Cox proportional hazards models were used to evaluate associations between PGS-BMI and obesity-related SPC risk, as well as between BMI and obesity-related SPC risk stratified by PGS-BMI tertiles. This analysis included 14 309 cancer survivors. Their median (IQR) age at first cancer diagnosis was 72.9 (68.2-77.4) years. Approximately 58.6% (8378) of survivors were male, and 58.6% (8382) had a BMI in the overweight (25 to <30) or obese (≥30) range. During a median (IQR) follow-up of 9.1 (4.6-14.2) years, there were 722 (5.0%) obesity-related SPCs. Compared with survivors in the lowest PGS-BMI tertile, those in the highest tertile had greater risk of obesity-related SPCs (hazard ratio [HR], 1.26 [95% CI, 1.06-1.51]). Obesity was associated with increased risk across tertiles of the PGS-BMI without evidence of interaction (P = .89 for interaction). Compared with survivors with low genetic predisposition and BMI lower than 25, those with low genetic predisposition and obesity had higher obesity-related SPC risk (HR, 1.59 [95% CI, 1.21-2.09]) and those with high genetic predisposition and obesity had the highest risk (HR, 1.82 [95% CI, 1.38-2.40]). The 10-year cumulative incidence ranged from 3.4% (95% CI, 2.9%-4.0%) to 5.1% (95% CI, 4.3%-5.9%) across joint exposure groups. In this cohort study of cancer survivors, genetic susceptibility to higher BMI was associated with a modestly increased risk of obesity-related SPCs, whereas obesity was associated with greater risk regardless of genetic predisposition. These findings underscore the importance of weight management for all cancer survivors and suggest that a meaningful proportion of obesity-related SPCs may be preventable.
中文摘要:体重超标是癌症幸存者发生第二原发癌(SPCs)的已确立危险因素。对较高BMI的遗传易感性是否与肥胖相关SPCs风险相关仍不清楚。研究较高BMI遗传易感性与肥胖相关SPCs风险的关系及其与BMI的联合关联。这项前瞻性队列研究使用癌症预防研究II营养队列数据,该队列纳入居住于美国21个州、在1992年调查时无癌症、并从1997年起回答两年一次随访问卷的成年人。两年一次问卷应答率为78.1%至92.1%。本分析参与者为1992年至2015年间诊断为首个原发性、非转移性浸润性癌症、提供生物样本并随访至2017年的癌症幸存者。分析于2025年9月至2026年8月进行。暴露为BMI多基因评分(PGS-BMI)和BMI。采用Cox比例风险模型评估PGS-BMI与肥胖相关SPCs风险的关系,以及按PGS-BMI三分位分层后BMI与肥胖相关SPCs风险的关系。分析纳入14 309名癌症幸存者。首次癌症诊断时中位(IQR)年龄为72.9(68.2-77.4)岁。约58.6%(8378)为男性,58.6%(8382)BMI处于超重(25至<30)或肥胖(≥30)范围。中位(IQR)随访9.1(4.6-14.2)年期间,发生722例(5.0%)肥胖相关SPCs。与PGS-BMI最低三分位幸存者相比,最高三分位者肥胖相关SPCs风险更高(HR 1.26,95% CI 1.06-1.51)。肥胖与风险增加相关,且在各PGS-BMI三分位中均存在,无交互证据(交互P=.89)。与低遗传易感性且BMI低于25的幸存者相比,低遗传易感性且肥胖者肥胖相关SPCs风险更高(HR 1.59,95% CI 1.21-2.09),高遗传易感性且肥胖者风险最高(HR 1.82,95% CI 1.38-2.40)。联合暴露组10年累积发病率为3.4%(95% CI 2.9%-4.0%)至5.1%(95% CI 4.3%-5.9%)。在这项癌症幸存者队列研究中,较高BMI遗传易感性与肥胖相关SPCs风险轻度增加相关,而肥胖无论遗传易感性如何均与更高风险相关。这些发现强调所有癌症幸存者体重管理的重要性,并提示相当比例的肥胖相关SPCs可能可预防。
Although human epidermal growth factor receptor 2 (ERBB2/HER2) is a validated therapeutic target, the significance of ERBB3 (HER3) alterations across solid tumours remains poorly defined. We characterised such alterations to clarify the genomic landscape relevant to HER3-directed strategies, distinguishing somatic events from germline polymorphisms. We analysed real-world data from 5416 patients with metastatic solid tumours who underwent next-generation sequencing. As tumour-only sequencing cannot separate germline from somatic variants, recurrent germline-pattern variants were reclassified using gnomAD and Korean population databases, and remaining somatic variants were annotated for oncogenicity using OncoKB (v7.3, Memorial Sloan Kettering Cancer Center, New York, NY). Overall survival (OS) was analysed via Cox regression analysis stratified according to tumour type. ERBB3 alterations were initially identified in 12.9% of patients, dominated by mutations (12.3%) rather than amplifications (0.8%). However, the two most common variants, K498I and R1127H, proved to be common germline polymorphisms, and germline-pattern variants accounted for 63% of all mutation calls. After germline exclusion, the prevalence of somatic mutations was 4.5%, and oncogenic/likely-oncogenic mutations only 1.6%, matching a large pan-cancer series. Oncogenic mutations clustered in extracellular domains, were tumour-type-specific (V104M/L in colorectal and urothelial; G284R in gastric and biliary tract cancer), and persisted in nonhypermutated tumours. The ERBB3 mutation status was not prognostic (adjusted hazard ratio [HR] 0.97, P = 0.52), whereas ERBB3 amplification was independently associated with a worse OS (HR 1.43, P = 0.024). Most apparent ERBB3 mutations in this East Asian tumour-only cohort were likely germline polymorphisms; true somatic oncogenic mutations were uncommon and tumour-type-specific, whereas amplification was rare but prognostically adverse. As HER3-directed antibody-drug conjugates depend on HER3 protein expression, the integration of such data with HER3 immunohistochemistry and outcomes is essential to define the target population.
中文摘要:尽管人表皮生长因子受体2(ERBB2/HER2)是已获批的治疗靶点,ERBB3(HER3)改变在实体瘤中的意义仍不明确。我们刻画此类改变,以厘清与HER3导向策略相关的基因组格局,并区分体细胞事件与胚系多态性。我们分析了5416例接受下一代测序的转移性实体瘤患者的真实世界数据。由于仅肿瘤测序无法区分胚系与体细胞变异,复发性的胚系模式变异借助gnomAD和韩国人群数据库重新分类,其余体细胞变异用OncoKB(v7.3,Memorial Sloan Kettering Cancer Center,New York,NY)进行致癌性注释。总生存(OS)按肿瘤类型分层,采用Cox回归分析。ERBB3改变最初在12.9%的患者中检出,以突变(12.3%)为主,扩增(0.8%)较少。然而,最常见的两种变异K498I和R1127H被证实为常见胚系多态性,胚系模式变异占全部突变判读的63%。排除胚系后,体细胞突变患病率为4.5%,致癌/可能致癌突变仅1.6%,与大型泛癌系列相符。致癌突变聚集于细胞外结构域,具有肿瘤类型特异性(结直肠癌和尿路上皮癌中的V104M/L;胃癌和胆道癌中的G284R),并在非超突变肿瘤中持续存在。ERBB3突变状态无预后价值(校正风险比[HR] 0.97,P=0.52),而ERBB3扩增与更差OS独立相关(HR 1.43,P=0.024)。在这一东亚仅肿瘤组织测序队列中,多数表观ERBB3突变很可能是胚系多态性;真正的体细胞致癌突变不常见且具肿瘤类型特异性,扩增罕见但预后不良。由于HER3导向的抗体偶联药物依赖HER3蛋白表达,将此类数据与HER3免疫组化和结局整合,对于界定目标人群至关重要。
In resected liver-limited metastatic colorectal cancer (LL-mCRC), disease-free survival (DFS) and postsurgical overall survival (psOS) have been found to be weakly related in heterogeneous retrospective series, challenging the role of DFS as a surrogate biomarker of psOS. Additionally, it remains unclear whether early relapses (DFS <6 months) are associated with overall survival (OS) benefit. We analyzed individual data of patients with LL-mCRC enrolled in nine randomized trials of first-line chemotherapy plus biologics. Correlation and surrogacy between DFS and psOS were calculated with ρ and R2. psOS of resected patients with DFS <6 months was compared with time from minimum disease load (post-min OS) of unresected patients, with stratification according to baseline tumor burden score (TBS). Time on systemic therapy was also evaluated. Eight hundred fifty-five patients with LL-mCRC were included and 357 (42%) were radically resected. DFS and psOS were highly correlated (ρ = 0.73), with R2 at the patient and trial levels for surrogacy of 0.70 and 0.32, respectively. psOS and post-min OS in resected patients with early relapse (n= 115) and unresected patients (n = 498) were comparable [hazard ratio (HR) 0.88, 95% confidence interval (CI) 0.70-1.11, P = 0.29]. However, a benefit from surgery was detected in patients with high baseline TBS (HR 0.69, 95% CI 0.45-1.05, P = 0.09) but not in patients with low/medium baseline TBS (HR 1.12, 95% CI 0.74-1.69, P = 0.59) (p interaction = 0.10). Resection was associated with a lower percentage of time on systemic therapy (26%) regardless of DFS (47% if <6 months, 26% if ≥6 months) (P < 0.001). In LL-mCRC resected after first-line chemotherapy plus biologics, DFS is highly correlated with psOS, with high patient-level surrogacy. In high-burden patients, liver surgery seems associated with a trend toward long-term benefit, also after early relapse (<6 months), whereas time on systemic therapy is reduced.
中文摘要:在已切除的肝局限型转移性结直肠癌(LL-mCRC)中,异质性回顾性系列研究显示无病生存期(DFS)与术后总生存期(psOS)相关性较弱,这对DFS作为psOS替代生物标志物的作用提出挑战。早期复发(DFS<6个月)是否与总生存(OS)获益相关仍不明确。我们分析了九项一线化疗联合生物制剂随机试验中入组的LL-mCRC患者个体数据,用ρ和R²计算DFS与psOS之间的相关性和替代性。将DFS<6个月且已切除患者的psOS与未切除患者自最小疾病负荷起的时间(post-min OS)进行比较,并按基线肿瘤负荷评分(TBS)分层。也评估了全身治疗时间。共纳入855例LL-mCRC患者,357例(42%)接受根治性切除。DFS与psOS高度相关(ρ=0.73),患者水平和试验水平的替代性R²分别为0.70和0.32。早期复发且已切除患者(n=115)与未切除患者(n=498)的psOS和post-min OS相当[风险比(HR)0.88,95%置信区间(CI)0.70-1.11,P=0.29]。基线TBS高的患者中检测到手术获益(HR 0.69,95%CI 0.45-1.05,P=0.09),基线TBS低/中等的患者中未检测到(HR 1.12,95%CI 0.74-1.69,P=0.59)(交互作用P=0.10)。无论DFS如何,切除与全身治疗时间占比更低相关(26%)(DFS<6个月为47%,DFS≥6个月为26%)(P<0.001)。在一线化疗联合生物制剂后接受切除的LL-mCRC中,DFS与psOS高度相关,患者水平替代性高。在高负荷患者中,肝脏手术似乎与长期获益趋势相关,早期复发(<6个月)后亦然,同时全身治疗时间减少。
The integration of anthracyclines with HER2-targeted agents in neoadjuvant therapy for HER2-positive breast cancer has been limited by cardiotoxicity concerns. This randomized phase II METIS trial (NCT04172259) assessed whether concurrent pegylated liposomal doxorubicin (PLD)-containing chemotherapy plus dual HER2 blockade (trastuzumab/pertuzumab) could improve efficacy without increasing cardiac risk. A total of 156 patients with stage II-III HER2-positive breast cancer were randomized to a PLD-based concurrent regimen or an epirubicin and cyclophosphamide (EC)-based sequential regimen. The PLD-based concurrent group achieved a higher pathological complete response (pCR) rate (67.5% vs. 48.7%; difference, 18.8%; 95% confidence interval [CI], 3.6-34.0; P = 0.033) compared with the EC-based sequential group, with greater benefit in hormone receptor-positive disease (58.7% vs. 36.7%) and stage II tumors (82.1% vs. 48.0%). After a median follow-up of 37.5 months, fewer event-free survival (EFS) events occurred in the PLD-based concurrent group (3 vs. 8), yielding a hazard ratio (HR) of 0.35 (95% CI, 0.09-1.32; P = 0.105). The estimated 3-year EFS rates were 96.0% (95% CI, 88.1-98.7) versus 90.7% (95% CI, 81.5-95.6). Achieving pCR was significantly associated with improved EFS (HR = 0.15; 95% CI, 0.03-0.71; P = 0.006). Cardiac safety was comparable, with no symptomatic cardiac dysfunction and only one grade ≥3 cardiotoxicity in the EC-based sequential group. These findings support PLD-based concurrent therapy with trastuzumab and pertuzumab as an effective and safe neoadjuvant option for high-risk HER2-positive breast cancer, warranting further evaluation in phase III trials.
中文摘要:在HER2阳性乳腺癌新辅助治疗中,将蒽环类药物与HER2靶向药物联合应用受到心脏毒性顾虑的限制。随机II期METIS试验(NCT04172259)评估含聚乙二醇脂质体多柔比星(PLD)的化疗与双重HER2阻断(曲妥珠单抗/帕妥珠单抗)同期联合,能否在不增加心脏风险的情况下提高疗效。156例II-III期HER2阳性乳腺癌患者随机接受基于PLD的同期方案或基于表柔比星和环磷酰胺(EC)的序贯方案。与基于EC的序贯组相比,基于PLD的同期组病理完全缓解(pCR)率更高(67.5%对48.7%;差异18.8%;95%置信区间[CI] 3.6-34.0;P=0.033),在激素受体阳性疾病(58.7%对36.7%)和II期肿瘤(82.1%对48.0%)中获益更明显。中位随访37.5个月后,基于PLD的同期组无事件生存(EFS)事件更少(3对8),风险比(HR)为0.35(95% CI 0.09-1.32;P=0.105)。估计3年EFS率分别为96.0%(95% CI 88.1-98.7)和90.7%(95% CI 81.5-95.6)。达到pCR与EFS改善显著相关(HR=0.15;95% CI 0.03-0.71;P=0.006)。心脏安全性相当,无症状性心功能障碍,仅基于EC的序贯组出现1例≥3级心脏毒性。这些结果支持将基于PLD的同期治疗联合曲妥珠单抗和帕妥珠单抗作为高危HER2阳性乳腺癌有效且安全的新辅助选择,值得在III期试验中进一步评估。
Liquid biopsy has evolved over two decades from an extension of tissue genotyping into a minimally invasive approach for repeat and longitudinal molecular assessment across the cancer continuum. Advances in sequencing, digital PCR, error suppression, and computational analytics have expanded analytes beyond circulating tumor DNA and circulating tumor cells to extracellular vesicles, circulating RNAs, and tumor-educated platelets, while broadening readouts from mutations to methylation, fragmentomics, transcriptomics, proteomics, and multiomic integration. This review traces the field from its technological foundations to current applications in early detection and multicancer early detection, therapy selection and resistance monitoring, minimal residual disease, recurrence-risk stratification, and longitudinal response assessment across major cancers and selected nononcologic settings. We distinguish clinically established applications from emerging and exploratory strategies and emphasize that high analytical performance does not by itself establish clinical utility. We further discuss preanalytical handling, standardization, biological confounders, and evidence required for implementation. Future progress will depend on use-case-driven development, prospective utility studies, longitudinal and multimodal interpretation, and integration with established diagnostic pathways. Together, these priorities define a transition from molecular detectability toward reproducible, actionable, and clinically meaningful liquid biopsy.
中文摘要:液态活检在二十年间从组织基因分型的延伸,发展为可在癌症全程中重复、纵向进行分子评估的微创方法。测序、数字PCR、错误抑制和计算分析技术的进步,使分析物从循环肿瘤DNA和循环肿瘤细胞扩展到细胞外囊泡、循环RNA和肿瘤教育血小板,同时使读出内容从突变扩展到甲基化、片段组学、转录组学、蛋白质组学和多组学整合。本综述梳理该领域从技术基础到当前应用的发展,包括早期检测和多癌种早期检测、治疗选择与耐药监测、微小残留病、复发风险分层、纵向疗效评估,覆盖主要癌种及部分非肿瘤场景。文章区分已确立的临床应用与新兴和探索性策略,并强调高分析性能本身并不等于临床效用。文中还讨论分析前处理、标准化、生物学混杂因素以及实施所需证据。未来进展取决于以使用场景为导向的开发、前瞻性效用研究、纵向和多模态解读,以及与既有诊断路径的整合。这些优先事项共同定义了液态活检从分子可检测性走向可重复、可操作且具有临床意义的转变。
Advanced thymic carcinoma is a rare, aggressive malignancy with limited treatment options after chemotherapy failure. This randomized, double-blind, placebo-controlled trial (AL3810-202) aimed to evaluate lucitanib, a novel, orally potent tyrosine kinase inhibitor targeting VEGFR1‒3, FGFR1‒3, and PDGFRα/β in patients with advanced thymic carcinoma progressing after chemotherapy. Sixty-eight patients were randomized (2:1) to receive 10 mg lucitanib daily (n = 46) or placebo (n = 22). Although this study did not meet its primary endpoint of independent review committee (IRC)-assessed progression-free survival (PFS) (median 5.8 vs. 3.7 months; hazard ratio [HR]: 0.60; p = 0.1050), the prespecified log-rank test may have underestimated the treatment effect due to an observed non-proportional hazards pattern. Subsequent restricted mean survival time analysis demonstrated a statistically significant PFS benefit (p < 0.05), which was further supported by significantly prolonged investigator-assessed PFS (6.6 vs. 1.9 months; HR: 0.53; p = 0.0306). The most common grade 3 treatment-related adverse events (TRAEs) were hypertension (50%), proteinuria (15.2%), and thrombocytopenia (8.7%), with no grade 4/5 events. Considering the totality of the evidence and an acceptable safety profile, lucitanib may confer a meaningful clinical benefit for patients with advanced thymic carcinoma, warranting further investigation.
中文摘要:晚期胸腺癌是一种罕见且侵袭性强的恶性肿瘤,化疗失败后治疗选择有限。这项随机、双盲、安慰剂对照试验(AL3810-202)旨在评估lucitanib——一种新型口服强效酪氨酸激酶抑制剂,靶向VEGFR1‒3、FGFR1‒3和PDGFRα/β——用于化疗后进展的晚期胸腺癌患者。共68例患者按2:1随机接受每日10 mg lucitanib(n=46)或安慰剂(n=22)。研究未达到主要终点,即独立评审委员会(IRC)评估的无进展生存期(PFS)(中位5.8个月对3.7个月;风险比[HR]:0.60;p=0.1050),但预设的log-rank检验可能因观察到非比例风险模式而低估了治疗效应。随后的限制平均生存时间分析显示PFS获益具有统计学显著性(p<0.05),研究者评估的PFS显著延长(6.6个月对1.9个月;HR:0.53;p=0.0306)进一步支持这一结果。最常见的3级治疗相关不良事件(TRAE)为高血压(50%)、蛋白尿(15.2%)和血小板减少(8.7%),未发生4/5级事件。综合全部证据及可接受的安全性特征,lucitanib可能为晚期胸腺癌患者带来有意义的临床获益,值得进一步研究。
Elinzanetant is a dual neurokinin (NK)-1 and NK-3 receptor antagonist approved for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause, or those caused by adjuvant endocrine therapy for breast cancer treatment. In this pooled safety analysis, safety data were pooled from four randomized, placebo-controlled studies: the phase IIb SWITCH-1 trial (2018-2019) and phase III OASIS-1-3 trials (2021-2024). All four studies were multicentre, multinational, double-blind trials that included postmenopausal women aged 40-65 years experiencing moderate-to-severe VMS due to natural or surgical menopause. Data were analysed exploratively. Assessments included frequency of treatment-emergent adverse events (TEAEs) over 12 and 52 weeks, and exposure-adjusted incidence rates (EAIRs, with 95% confidence intervals [CIs]) over 52 weeks. EAIRs were calculated by weighting event counts against total exposure time (person-years) across studies. Additionally, liver safety and incidence of neoplasms were evaluated. The 12-week pooled safety analysis set included 1519 participants: 765 participants in the elinzanetant 120 mg group and 754 participants in the placebo group. The 52-week pooled safety analysis set included 1113 participants in the elinzanetant 120 mg group and 754 participants in the placebo group. TEAEs occurred in 50·8% and 43·2% of participants in the elinzanetant 120 mg and the placebo groups, respectively, over 12 weeks; EAIRs were 196·61 (95% CI 181·33-213·18) and 209·00 (95% CI: 188·96-231·15) in the elinzanetant and placebo groups, respectively, over 52 weeks. The most common TEAEs reported with elinzanetant were headache, fatigue, and somnolence. Treatment discontinuation was low with elinzanetant (7·8%) but higher than placebo (3·6%) over 12 weeks; EAIRs were 14·95 (95% CI 11·99-18·62) and 10·96 (95% CI 7·87-15·27), respectively, over 52 weeks. There were no Hy's Law cases or indication of cholestatic injury. EAIRs of malignant tumors had overlapping CIs between treatment groups. No endometrial hyperplasia/malignancy was reported in either group. The overall safety profile of elinzanetant appeared favorable in 1113 women based on this exploratory pooled safety analysis. Future time-to-event analyses of TEAEs and real-world post-marketing data are warranted to better characterize the long-term safety profile of elinzanetant. Bayer.
中文摘要:Elinzanetant 是一种双重神经激肽(NK)-1 和 NK-3 受体拮抗剂,已获批用于治疗与绝经相关的中重度血管舒缩症状(VMS),或乳腺癌辅助内分泌治疗引起的中重度 VMS。本汇总安全性分析汇总了四项随机、安慰剂对照研究的安全性数据:IIb 期 SWITCH-1 试验(2018—2019)和 III 期 OASIS-1—3 试验(2021—2024)。四项研究均为多中心、多国、双盲试验,纳入 40—65 岁、因自然绝经或手术绝经出现中重度 VMS 的绝经后女性。数据采用探索性分析。评估内容包括 12 周和 52 周内治疗中出现的不良事件(TEAE)发生频率,以及 52 周内暴露调整发生率(EAIR,含 95% 置信区间[CI])。EAIR 通过将事件数按各研究总暴露时间(人年)加权计算。另评估肝脏安全性和肿瘤发生率。12 周汇总安全性分析集包括 1519 名参与者:elinzanetant 120 mg 组 765 名,安慰剂组 754 名。52 周汇总安全性分析集包括 elinzanetant 120 mg 组 1113 名和安慰剂组 754 名。12 周内,elinzanetant 120 mg 组和安慰剂组 TEAE 发生率分别为 50.8% 和 43.2%;52 周内,两组 EAIR 分别为 196.61(95% CI 181.33—213.18)和 209.00(95% CI 188.96—231.15)。elinzanetant 组最常见 TEAE 为头痛、疲劳和嗜睡。12 周内 elinzanetant 组治疗停药率较低(7.8%),但高于安慰剂组(3.6%);52 周内 EAIR 分别为 14.95(95% CI 11.99—18.62)和 10.96(95% CI 7.87—15.27)。未见 Hy's Law 病例或胆汁淤积性损伤迹象。两组恶性肿瘤 EAIR 的 CI 有重叠。两组均未报告子宫内膜增生/恶性肿瘤。基于这项探索性汇总安全性分析,elinzanetant 在 1113 名女性中的总体安全性特征良好。未来需开展 TEAE 的时间到事件分析及真实世界上市后数据,以更好描述 elinzanetant 的长期安全性特征。Bayer。
Patients with advanced endometrial cancer (EC) have a poor prognosis and limited therapeutic options after failure of prior systemic therapy. In this multi-cohort Phase II study (ETER200), patients with metastatic or recurrent EC who had received at least one chemotherapy regimen were enrolled. Based on MSI/MMR status, patients received benmelstobart plus anlotinib (Cohort 1), benmelstobart (Cohort 2), or anlotinib (Cohort 3) every 3 weeks. Primary endpoint was objective response rate (ORR) assessed by independent review committee (IRC) per RECIST v1.1. Here, the results of Cohort 1 expansion stage were reported. As of May 9, 2024, 85 of the 107 non-MSI-H/pMMR EC patients enrolled in Cohort 1 constituted the expansion stage population for primary efficacy analysis. The IRC-assessed ORR was 34.1% (95% CI, 24.2-45.2), with a median duration of response of 15.2 months (95% CI, 6.9-not evaluable). Median progression-free and overall survival were 8.8 months (95% CI, 5.8-15.2) and 21.8 months (95% CI, 19.5-29.1), respectively. Grade ≥ 3 treatment-related adverse events occurred in 69.2% of patients, most commonly hypertension (21.2%) and palmar-plantar erythrodysesthesia syndrome (9.4%). Overall, benmelstobart plus anlotinib showed promising anti-tumor activity and an acceptable safety profile in advanced non-MSI-H/pMMR EC, supporting further evaluation of this combination in randomized Phase III studies. Trial Registration: ClinicalTrials.gov, NCT04574284.
中文摘要:晚期子宫内膜癌患者预后较差,既往系统治疗失败后可选方案有限。ETER200是一项多队列II期研究,纳入转移性或复发性子宫内膜癌且至少接受过一种化疗方案的患者。依据MSI/MMR状态,患者每3周接受贝莫苏拜单抗联合安罗替尼(队列1)、贝莫苏拜单抗(队列2)或安罗替尼(队列3)治疗。主要终点为独立评审委员会按RECIST v1.1评估的客观缓解率。本次报告队列1扩展阶段结果。截至2024年5月9日,队列1入组的107例非MSI-H/pMMR子宫内膜癌患者中,85例构成扩展阶段人群并用于主要疗效分析。独立评审委员会评估的客观缓解率为34.1%(95% CI,24.2-45.2),中位缓解持续时间为15.2个月(95% CI,6.9-未可评估)。中位无进展生存期和总生存期分别为8.8个月(95% CI,5.8-15.2)和21.8个月(95% CI,19.5-29.1)。≥3级治疗相关不良事件发生率为69.2%,最常见为高血压(21.2%)和手足红斑感觉异常综合征(9.4%)。总体而言,贝莫苏拜单抗联合安罗替尼在晚期非MSI-H/pMMR子宫内膜癌中显示出有前景的抗肿瘤活性和可接受的安全性,支持在随机III期研究中进一步评估该联合方案。试验注册:ClinicalTrials.gov,NCT04574284。
A single-cell atlas of human neutrophils reveals neutrophil heterogeneity across health and disease.
Neutrophils, the most abundant leukocytes in human blood, have multifaceted roles in health and disease. Here we assembled a single-cell atlas of human neutrophils (SCAHN) by integrating transcriptome data from 1 million human neutrophils from 781 samples and 43 independent datasets. Using SCAHN, we identified multiple neutrophil subsets with distinct functions across tissues and robust changes in gene expression and subset proportions in infection, cancer, immune suppression and sex differences at single-cell resolution. Cross-species reference mapping of mouse and nonhuman primate neutrophils onto SCAHN revealed both conserved and species-specific features. Using 17,023 bulk blood transcriptome profiles from 40 datasets, we found that neutrophil-specific signatures predicted mortality in acutely ill patients at presentation, were associated with cancer diagnosis and survival, and correlated with metabolic dysfunction and long-term all-cause mortality. Our study highlights how neutrophil biology can improve immune risk stratification and develop effective diagnostic and therapeutic strategies.
中文摘要:中性粒细胞是人类血液中最丰富的白细胞,在健康与疾病中具有多种作用。研究整合了来自43个独立数据集、781份样本的100万个人类中性粒细胞的转录组数据,构建了人类中性粒细胞单细胞图谱(SCAHN)。利用SCAHN,在单细胞分辨率下识别出多种具有不同功能的中性粒细胞亚群,这些亚群分布于不同组织,并在感染、癌症、免疫抑制和性别差异中表现出基因表达与亚群比例的明显变化。将小鼠和非人灵长类中性粒细胞跨物种参考映射到SCAHN,揭示了保守特征和物种特异性特征。利用来自40个数据集的17023份血液批量转录组谱,发现中性粒细胞特异性特征可在急性病患者就诊时预测死亡,与癌症诊断和生存相关,并与代谢功能障碍及长期全因死亡相关。这些发现提示中性粒细胞生物学可改进免疫风险分层,并有助于开发有效的诊断和治疗策略。
Current guidelines incorporate chemo-immunotherapy for stage III-IV mismatch repair-deficient (dMMR) endometrial cancer, but the evidence supporting omission of adjuvant radiotherapy remains insufficient. Given the pivotal role of pelvic radiotherapy in achieving durable locoregional control in high-risk endometrial cancer, and the lack of robust randomized evidence demonstrating equivalence of systemic therapy alone, the suggestion that EBRT may be safely omitted in the adjuvant treatment of dMMR high-risk disease warrants careful consideration. Importantly, PORTEC-3 (NCT00411138) included radiotherapy in both treatment groups and no immunotherapy, whereas in KEYNOTE-B21 (ENGOT-en11/GOG-3053, NCT04634877) radiotherapy was not randomized; neither trial therefore directly tested the safety of radiotherapy omission. In this Viewpoint, we review current evidence and unresolved questions in the adjuvant management of FIGO stage III dMMR endometrial cancer, with particular attention to the role of radiotherapy in the evolving chemo-immunotherapy era. While our discussion is intentionally focused on dMMR disease, many of the broader considerations regarding the interpretation of emerging evidence and the preservation of effective locoregional treatment are not exclusive to this molecular subgroup. Ongoing trials, including NRG-GY020 (NCT04214067) and the RAINBO MMRd-GREEN trial (ENGOT-en14/GREEN, NCT05255653), are expected to define the optimal integration of immunotherapy and adjuvant radiotherapy in molecularly stratified populations. Beyond survival, locoregional control, recurrence burden, and quality of life remain clinically meaningful endpoints. Future randomized trials should evaluate radiotherapy as an independent treatment variable within molecularly stratified populations, incorporating not only survival but also patterns of failure and patient-reported outcomes. Until such data become available, treatment de-escalation strategies should be adopted with caution.
中文摘要:现有指南已将化疗联合免疫治疗纳入III–IV期错配修复缺陷(dMMR)子宫内膜癌的治疗,但支持省略辅助放疗的证据仍不充分。盆腔放疗在高危子宫内膜癌中实现持久局部区域控制具有关键作用,而目前缺乏稳健的随机证据证明单纯系统治疗与之等效,因此提出在dMMR高危疾病的辅助治疗中可安全省略体外放疗(EBRT)需要审慎对待。PORTEC-3(NCT00411138)两个治疗组均包含放疗且未使用免疫治疗,KEYNOTE-B21(ENGOT-en11/GOG-3053,NCT04634877)中放疗并未随机化,两项试验都未直接检验省略放疗的安全性。本观点文章回顾FIGO III期dMMR子宫内膜癌辅助治疗的现有证据与未解问题,重点关注放疗在化疗联合免疫治疗时代演变中的角色。讨论有意聚焦于dMMR疾病,但关于新兴证据解读与保留有效局部区域治疗的许多更广泛考量并不限于该分子亚组。正在进行的NRG-GY020(NCT04214067)与RAINBO MMRd-GREEN试验(ENGOT-en14/GREEN,NCT05255653)有望在分子分层人群中确定免疫治疗与辅助放疗的最佳整合方式。除生存外,局部区域控制、复发负担与生活质量仍是具有临床意义的终点。未来随机试验应在分子分层人群中把放疗作为独立治疗变量加以评估,除生存外还需纳入失败模式与患者报告结局。在获得此类数据之前,降低治疗强度的策略应谨慎采用。
Gliomas are recognized as network-level diseases that remodel functional connectivity across the brain. Using resting-state functional MRI (rs-fMRI) data from 306 patients with pathologically confirmed glioma at two hospitals, we delineated individualized intra- and peritumoral functional networks to quantify tumor-related alterations. Two novel indices-the ratio of intratumoral functional regions (RIFR) and ratio of peritumoral tumor-related regions (RPTR)-were proposed to describe network remodeling. Both indices were related to pathological, structural, functional, cognitive, language, and survival measures. Lower RIFR indicated diminished intratumoral connectivity and worse prognosis, while higher values reflected preserved network integration and longer survival. Models incorporating network features yielded areas under the receiver operating characteristic curve of 0.90 in training and 0.86-0.88 in external validation. Supporting analyses suggested that intratumoral functional regions are associated with distinct molecular and cellular characteristics. These findings suggest that intra- and peritumoral networks reflect biologically and functionally distinct tumor subregions and are associated with network-level alterations, brain function, and patient outcome. Interpretation is limited by the hemodynamic basis of rs-fMRI, incomplete data, and limited intraoperative validation. These findings identify individualized intra- and peritumoral connectivity measures as candidate markers of glioma-associated network remodeling and prognosis that require prospective, multimodal validation.
中文摘要:胶质瘤被视为一种网络层面的疾病,会重塑全脑功能连接。研究使用两家医院306例经病理确诊胶质瘤患者的静息态功能MRI数据,勾勒个体化的瘤内与瘤周功能网络,以量化肿瘤相关改变。提出两个新指标——瘤内功能区域比例(RIFR)和瘤周肿瘤相关区域比例(RPTR)——用于描述网络重塑。两个指标均与病理、结构、功能、认知、语言及生存指标相关。RIFR较低提示瘤内连接减弱和预后较差,较高则反映网络整合保留和生存期更长。纳入网络特征的模型在训练集中曲线下面积为0.90,外部验证为0.86–0.88。支持性分析提示瘤内功能区域与不同的分子和细胞特征相关。这些发现提示瘤内与瘤周网络反映生物学和功能上不同的肿瘤亚区,并与网络层面改变、脑功能和患者结局相关。解释受限于rs-fMRI的血流动力学基础、数据不完整及术中验证有限。这些发现将个体化瘤内和瘤周连接指标视为胶质瘤相关网络重塑和预后的候选标志物,仍需前瞻性、多模态验证。
Ritlecitinib (Litfulo®) is an oral dual inhibitor of Janus kinase (JAK) 3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family of kinases. It is approved in several countries worldwide for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. In the pivotal, randomized, double-blind, placebo-controlled, phase 2b/3 ALLEGRO trial in adults and adolescents with alopecia areata with ≥ 50% scalp hair loss, ritlecitinib 50 mg once daily significantly increased the proportion of patients achieving ≤ 20% scalp hair loss at week 24 compared with placebo. Ritlecitinib also improved patient-reported outcomes, including Patient's Global Impression of Change responses. Response rates for key efficacy outcomes in the pivotal trial continued to increase through 48 weeks and were sustained for up to 3 years in the open-label phase 3 ALLEGRO-LT trial. Longer-term treatment was also associated with improvements in health-related quality of life. Ritlecitinib was generally well tolerated, with most adverse events being of mild or moderate severity. While further data are needed to fully characterize long-term safety, currently available data suggest that ritlecitinib is a valuable new option for the treatment of severe alopecia areata, including in adolescents for whom approved treatment options are limited.
中文摘要:利特昔替尼(Litfulo®)是一种口服双重抑制剂,作用于Janus激酶(JAK)3和肝细胞癌中表达的酪氨酸激酶(TEC)家族激酶。该药已在全球多个国家获批用于治疗成人和12岁及以上青少年的重度斑秃。在关键性、随机、双盲、安慰剂对照2b/3期ALLEGRO试验中,纳入头皮脱发≥50%的成人和青少年斑秃患者,利特昔替尼50 mg每日一次在第24周显著提高达到头皮脱发≤20%的患者比例,优于安慰剂。利特昔替尼还改善患者报告结局,包括患者总体印象变化应答。关键试验中关键疗效指标的应答率持续增加至48周,并在开放标签3期ALLEGRO-LT试验中维持至3年。更长期治疗还与健康相关生活质量改善相关。利特昔替尼总体耐受性良好,大多数不良事件为轻中度。虽然仍需更多数据充分描述长期安全性,现有数据提示利特昔替尼是治疗重度斑秃的有价值新选择,包括获批治疗选择有限的青少年。
The management of metastatic castration-resistant prostate cancer (mCRPC) after progression on androgen receptor pathway inhibitors (ARPI) and docetaxel presents a critical therapeutic choice between cabazitaxel and [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT). This review provides a comprehensive analysis of efficacy, toxicity, biomarkers, and treatment sequencing to guide clinical decision-making. A critical review of the scientific literature was conducted, integrating data from randomized clinical trials, real-world evidence (RWE) studies, and preliminary data presented at major scientific conferences. The head-to-head phase II TheraP trial demonstrated superior PSA response rates (66% vs 37%) and progression-free survival for [177Lu]Lu-PSMA-617 over cabazitaxel, without significant difference in overall survival (OS). In contrast, large RWE studies, including the ARON-3 study, consistently show a significant OS advantage for [177Lu]Lu-PSMA-617 (median OS 20.2 vs 14.8 months). [177Lu]Lu-PSMA-617 is associated with a more favorable safety profile, with a lower incidence of grade 3-4 adverse events (33% vs 53%) and superior patient-reported quality of life compared to cabazitaxel. PSMA-PET imaging serves as a key predictive biomarker, with a high SUVmean (≥10) identifying patients with the highest probability of response to PSMA-RLT. While both treatment sequences are clinically valid, a biological rationale may favor a PSMA-RLT -first approach. However, also cost-effectiveness analyses and local barriers play a role in the selection of the treatment pathway. Available data suggest [177Lu]Lu-PSMA-617 as the preferred therapeutic option for the majority of patients with PSMA-positive mCRPC who progressed to ARPI and docetaxel. PSMA-RLT is preferred for most PSMA positive patients, with eligibility assessed individually rather than by rigid thresholds. Cabazitaxel remains a crucial treatment for patients with low PSMA expression, those ineligible for PSMA-RLT, or as an effective sequential therapy. Modern management of mCRPC demands a personalized, multidisciplinary approach to optimally balance survival gain with quality of life.
中文摘要:转移性去势抵抗性前列腺癌(mCRPC)在雄激素受体通路抑制剂(ARPI)和多西他赛治疗后进展时,卡巴他赛与[177Lu]Lu-PSMA-617放射性配体治疗(PSMA-RLT)之间的选择构成关键治疗决策。本综述综合分析疗效、毒性、生物标志物和治疗顺序,为临床决策提供参考。对科学文献进行批判性综述,整合随机临床试验、真实世界证据(RWE)研究以及主要科学会议公布的初步数据。头对头II期TheraP试验显示,[177Lu]Lu-PSMA-617相比卡巴他赛有更高的PSA缓解率(66% vs 37%)和无进展生存优势,总生存(OS)无显著差异。与之相对,包括ARON-3在内的大型RWE研究一致显示[177Lu]Lu-PSMA-617具有显著OS优势(中位OS 20.2个月 vs 14.8个月)。[177Lu]Lu-PSMA-617安全性更好,3-4级不良事件发生率更低(33% vs 53%),患者报告的生活质量优于卡巴他赛。PSMA-PET显像是关键预测生物标志物,高SUVmean(≥10)可识别对PSMA-RLT缓解概率最高的患者。两种治疗顺序在临床上均可行,生物学依据可能支持PSMA-RLT优先方案。成本效果分析和当地可及性障碍也会影响治疗路径选择。现有数据提示,对于ARPI和多西他赛后进展的PSMA阳性mCRPC患者,[177Lu]Lu-PSMA-617可作为多数患者的首选治疗。PSMA-RLT适用于多数PSMA阳性患者,资格应个体化评估而非采用固定阈值。卡巴他赛仍是PSMA低表达、不适合PSMA-RLT患者的重要治疗,或作为有效的序贯治疗。现代mCRPC管理需要个体化、多学科方法,在生存获益与生活质量之间取得最佳平衡。
Histological variation is a prognostic feature of metastatic urothelial cancer1-3, but its evolutionary trajectory remains poorly defined. We developed a metastatic bladder cancer rapid autopsy programme enriched in histological subtypes4 to profile individuals with terminal disease. Here by reconstructing the evolutionary histories of patient tumours, we show that metastasis-to-metastasis seeding is the dominant pattern of cancer spread and that increased polyclonal migration predicts poor prognosis. The burden, heterogeneity and timing of genomic alterations differ markedly among histological subtypes. Plasmacytoid and neuroendocrine variants develop early driver alterations associated with shorter survival. Mutational signature analyses and experimental models demonstrated that plasmacytoid tumours uniquely use the Fanconi anaemia pathway to mitigate chemotherapy-induced genomic scarring. Single-nucleus profiling revealed mixed cell states in histological subtypes and an association between transcriptional heterogeneity and patient survival. Characterization of the tumour microenvironment uncovered distinct immune states across subtypes, with plasmacytoid tumours exhibiting immune-inflamed profiles, whereas squamous tumours are predominantly immunosuppressive. Last, we demonstrate that post-mortem cell-free DNA captures genomic and transcriptional heterogeneity of the subtypes, which provides a potential strategy for noninvasive assessment of tumour identity and aggressiveness. Our results provide new insights into how tumour heterogeneity shapes the evolutionary history of disease progression in bladder cancer histological subtypes.
中文摘要:组织学变异是转移性尿路上皮癌的预后特征,但其演化轨迹仍不清楚。我们建立了一个富含组织学亚型的转移性膀胱癌快速尸检项目,用以对终末期患者进行剖析。通过重建患者肿瘤的演化史,我们发现转移灶到转移灶的种植是癌症播散的主要模式,多克隆迁移增多预示预后不良。基因组改变的负荷、异质性与发生时点在组织学亚型之间差异显著。浆细胞样与神经内分泌变异在早期即出现与较短生存相关的驱动改变。突变特征分析与实验模型显示,浆细胞样肿瘤独特地利用范可尼贫血通路来减轻化疗诱导的基因组瘢痕。单核测序揭示组织学亚型中存在混合细胞状态,转录异质性与患者生存相关。对肿瘤微环境的刻画发现各亚型具有不同的免疫状态,浆细胞样肿瘤呈免疫炎症型特征,而鳞状肿瘤以免疫抑制为主。最后,我们证明死后游离DNA可捕获各亚型的基因组与转录异质性,为无创评估肿瘤属性与侵袭性提供了潜在策略。研究结果为肿瘤异质性如何塑造膀胱癌组织学亚型疾病进展的演化史提供了新认识。
Variation in hospice use for patients with cancer exists between palliative care programs, but factors underlying this heterogeneity are unknown. To identify hospital and palliative care program factors that may impact the ability of palliative care teams to affect hospice use in cancer. This multicenter qualitative study included 6 palliative care programs in the United States. Using a cohort of patients with metastatic cancer who received specialist palliative care, a positive-negative deviance approach was used to select 3 programs with high and 3 programs with low performance on hospice use. In-depth site visits were conducted and included semistructured interviews with palliative care and oncology clinicians and patients as well as in-person observation. Interviews were conducted from February 2025 to January 2026. Site visits were conducted from May 2025 to January 2026. Program-specific practices and their potential effect on hospice use for patients with cancer. A total of 93 interviews and 424 hours of in-person observation were conducted across 6 palliative care programs in the Midwest, Upper South, and Deep South regions of the United States. Interview participants had a median (IQR) age of 43 (37-47) years; 68 (73.1%) were female; clinicians had a median (IQR) of 11 (5-16) years of experience. There were notable differences in the relationships between palliative care and oncology teams between high- and low-performing programs. At high-performing programs, the relationship was characterized by mutual trust and respect, warmth and familiarity, and empathy for each other, whereas at low-performing programs, the relationship was characterized by a lack of trust and familiarity and negative regard for each other. Factors observed in programs with positive relationships included intentionality in relationship building, physical presence and proximity between teams, use of real-time communication, and the palliative care team having a service-oriented mentality and a reputation for reliable service. At high-performing programs, observable differences in care included collaborative care delivery, increased access and timeliness of palliative care, and earlier introduction of hospice by oncology clinicians. In this multicenter qualitative study, differences in the relationship between palliative care and oncology teams were identified that may mechanistically affect end-of-life patient outcomes. These findings are important to ensure the delivery of high-quality care for all patients with cancer.
中文摘要:不同姑息治疗项目之间,癌症患者使用临终关怀的情况存在差异,但这种异质性的潜在因素尚不清楚。本研究旨在识别医院及姑息治疗项目因素,这些因素可能影响姑息治疗团队对癌症患者临终关怀使用所发挥的作用。这项多中心定性研究纳入美国6个姑息治疗项目。研究利用一组接受专科姑息治疗的转移性癌症患者,采用正负偏离法选取临终关怀使用表现高的3个项目和表现低的3个项目。研究开展了深入现场访视,包括对姑息治疗与肿瘤科临床医生及患者进行半结构化访谈,并进行现场观察。访谈于2025年2月至2026年1月进行。现场访视于2025年5月至2026年1月进行。研究关注项目特有实践及其对癌症患者临终关怀使用的潜在影响。研究在美国中西部、上南部和深南部地区的6个姑息治疗项目中完成93次访谈和424小时现场观察。访谈参与者的年龄中位数(四分位距)为43(37-47)岁;68名(73.1%)为女性;临床医生的经验中位数(四分位距)为11(5-16)年。高表现与低表现项目之间,姑息治疗团队和肿瘤科团队的关系存在明显差异。在高表现项目中,这种关系以相互信任与尊重、温暖与熟悉、彼此共情为特征;在低表现项目中,这种关系以缺乏信任与熟悉、彼此负面看法为特征。在关系积极的项目中观察到的因素包括有意识地建立关系、团队之间的实际在场与邻近、使用实时沟通,以及姑息治疗团队具有服务导向心态和可靠服务的声誉。在高表现项目中,可观察到的照护差异包括协作式照护提供、姑息治疗可及性和及时性提高,以及肿瘤科临床医生更早引入临终关怀。在这项多中心定性研究中,识别出姑息治疗团队与肿瘤科团队关系的差异,这些差异可能从机制上影响终末期患者结局。这些发现对于确保所有癌症患者获得高质量照护十分重要。
Patients with prostate cancer have a high burden of cardiovascular risk factors, often suboptimally controlled, and adverse cardiovascular outcomes. To determine whether the routine referral of patients with prostate cancer to a cardiovascular specialist to implement a systematic risk factor strategy is more likely to reduce adverse cardiovascular outcomes and improve risk factor control than usual care. This randomized clinical trial included patients with prostate cancer from 55 sites in 8 countries between 2015 and 2025. Eligible patients were diagnosed with prostate cancer during the past 12 months; had received treatment with androgen deprivation therapy (ADT) for the first time within the past 6 months; or planned to start ADT in the next month. Patients taking a statin with a systolic blood pressure of 130 mm Hg or lower were ineligible. Data were analyzed from May 25 to August 7, 2026. Patients were allocated in a 1:1 ratio to receive usual care alone or usual care plus routine referral to an internist or cardiologist. The specialists provided a systematic intervention, including a target of systolic blood pressure of 130 mm Hg or lower and a statin medication, irrespective of the patient's cholesterol levels (even if not usual or guideline-driven practice); encourage smoking cessation; and provide guidance on diet and exercise. Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, suboptimal cholesterol (total cholesterol, >155 mg/dL [to convert to mmol/L, multiply by 0.0259]) and suboptimal blood pressure (systolic blood pressure, >130 mm Hg) as evaluated by the win ratio. The analysis included 2487 patients with prostate cancer (mean [SD] age, 68 [8] years). During median (IQR) follow-up of 5.8 (2.7-8.2) years, the win ratio in favor of the intervention was 1.60 (95% CI, 1.42-1.81), mostly attributable to lower cholesterol in the intervention group (mean difference, 12 mg/dL; 95% CI, 9-15 mg/dL) as a consequence of greater protocol-mandated statin use. Mean (SD) close-out systolic blood pressure values were 131.1 (16.9) mm Hg in the intervention group and 132.9 (18.3) mm Hg in the control group. There was no difference in time to cardiovascular death, myocardial infarction, stroke, or heart failure between groups (subdistribution hazard ratio, 1.08; 95% CI, 0.79-1.49). In this randomized clinical trial, routine referral of patients with prostate cancer to a cardiovascular specialist lead to improved outcomes, specifically through better cholesterol control. However, it is uncertain whether this reduced clinical cardiovascular events. ClinicalTrials.gov Identifier: NCT03127631.
中文摘要:前列腺癌患者的心血管危险因素负担较高,这些因素常控制不理想,并且患者存在不良心血管结局。本研究旨在确定:与常规医疗相比,将前列腺癌患者常规转诊至心血管专科医师,以实施系统性危险因素策略,是否更可能减少不良心血管结局并改善危险因素控制。这项随机临床试验于2015年至2025年纳入来自8个国家55个中心的前列腺癌患者。纳入条件为:过去12个月内诊断前列腺癌;过去6个月内首次接受雄激素剥夺治疗(ADT);或计划在下个月开始ADT。正在服用他汀且收缩压不超过130 mm Hg的患者不符合纳入条件。数据分析时间为2026年5月25日至8月7日。患者按1:1比例分配至单纯常规医疗组,或常规医疗加常规转诊至内科或心脏科医师组。专科医师提供系统性干预,包括将收缩压控制目标设为不超过130 mm Hg,并且不论患者胆固醇水平如何都使用他汀药物(即使这并非通常实践或指南驱动的实践);鼓励戒烟;并提供饮食和运动指导。主要结局为心血管死亡、心肌梗死、卒中、心力衰竭、胆固醇控制不佳(总胆固醇>155 mg/dL[换算为mmol/L需乘以0.0259])和血压控制不佳(收缩压>130 mm Hg)构成的分层复合终点,采用胜率比评估。分析纳入2487例前列腺癌患者(平均[SD]年龄68[8]岁)。在中位(IQR)随访5.8(2.7-8.2)年期间,支持干预的胜率比为1.60(95% CI,1.42-1.81),这主要归因于干预组胆固醇较低(平均差12 mg/dL;95% CI,9-15 mg/dL),而这是更多按方案使用他汀的结果。结束时平均(SD)收缩压干预组为131.1(16.9)mm Hg,对照组为132.9(18.3)mm Hg。两组至心血管死亡、心肌梗死、卒中或心力衰竭的时间无差异(亚分布风险比1.08;95% CI,0.79-1.49)。在这项随机临床试验中,将前列腺癌患者常规转诊至心血管专科医师改善了结局,具体通过更好的胆固醇控制实现。然而,这是否减少了临床心血管事件仍不确定。ClinicalTrials.gov注册号:NCT03127631。
Breast ultrasound is essential for lesion assessment and early cancer screening. However, deploying robust deep learning models in clinical practice faces two primary challenges. The first is intrinsic: lesions often exhibit complex textures, speckle-corrupted appearances, and indistinct boundaries. The second is extrinsic: the data is distributed across isolated medical centers with significant heterogeneity. To address these coupled challenges, this study introduces SFLFEM, a unified framework that combines advanced feature representation with personalized federated optimization for privacy-preserving multi-center breast ultrasound diagnosis. FEMamba, a dual-domain backbone, integrates the long-range modeling capacity of State-Space Models with a wavelet-based frequency pathway. This architecture captures global contextual dependencies as well as frequency-sensitive boundary and textural cues. Both are critical for distinguishing challenging lesions. At the optimization level, the pFedBM algorithm introduces a Bidirectional Gradient Masking mechanism to mitigate client heterogeneity and cross-site distribution shift in federated learning. This approach adaptively separates model parameters into globally shared and locally preserved components. Locally sensitive shared parameters are promoted into personalized subspaces, and weakly client-specific parameters are demoted back to the shared global subspace. This design reduces negative transfer and improves site-specific adaptation. Comprehensive evaluations on four datasets demonstrate that SFLFEM achieves strong overall performance, with an average accuracy of 85.14%, AUC of 92.35%, and MCC of 70.62%. It achieves competitive performance against representative centralized classification backbones and consistently improves over the evaluated federated learning baselines. The largest gains of pFedBM were observed under heterogeneous and data-limited settings.
中文摘要:乳腺超声对病灶评估和早期癌症筛查具有重要意义。在临床实践中部署稳健的深度学习模型面临两类主要挑战。其一是内在挑战:病灶常表现为复杂纹理、受斑点噪声影响的外观以及不清晰边界。其二是外在挑战:数据分布在相互隔离的医疗中心之间,并存在显著异质性。为应对这些相互关联的挑战,本研究提出 SFLFEM,一个将先进特征表示与个性化联邦优化相结合的统一框架,用于隐私保护的多中心乳腺超声诊断。FEMamba 是一种双域骨干网络,将状态空间模型的长程建模能力与小波频域通路相结合。该架构可捕获全局上下文依赖,以及频率敏感的边界与纹理线索,这两者对区分困难病灶均很关键。在优化层面,pFedBM 算法引入双向梯度掩码机制,以缓解联邦学习中的客户端异质性和跨站点分布偏移。该方法将模型参数自适应地分离为全局共享部分和本地保留部分。对本地敏感的共享参数被提升到个性化子空间,弱客户端特异性的参数被降回共享全局子空间。该设计减少负迁移并改善站点特定适配。在四个数据集上的综合评估显示,SFLFEM 取得较强的整体性能,平均准确率为 85.14%,AUC 为 92.35%,MCC 为 70.62%。其性能与代表性集中式分类骨干网络具有竞争力,并稳定优于所评估的联邦学习基线。pFedBM 的最大收益出现在异质性和数据受限场景下。
Tobacco use remains the leading preventable cause of cancer mortality worldwide, with marked disparities in cancer incidence and outcomes across racial and ethnic groups. This study investigates the genetic determinants of tobacco carcinogen metabolism among smokers, focusing on ancestry-informative markers (AIMs) near genes involved in metabolic activation (Phase I), detoxification (Phase II), and transport (Phase III) of tobacco-specific carcinogens. Using data from 274 smokers recruited in the United States and the Caribbean, we measured urinary NNAL (a metabolite of NNK) to classify metabolic phenotypes and performed genotyping with a customized array enriched for AIMs. Most participants (94%) were classified as poor metabolizers of NNAL, with a higher prevalence among Black/African American smokers. Multivariable analyses, after adjusting for age, sex, assay batch, and number of cigarettes smoked per day, identified 14 AIMs near Phase I, II, and III pathway genes significantly associated with NNAL metabolizer phenotype, with African ancestry alleles conferring increased odds of poor metabolism. Functional annotation revealed that most significant AIMs overlapped regulatory regions, and the CYP3A5 rs776746 variant demonstrated structural disruption likely to impair enzymatic activity. Majority of participants had high African ancestry and were poor NNAL metabolizers, consistent with the observed association between African ancestry and poor NNAL metabolism. These findings highlight the biological basis for tobacco-related cancer disparities and underscore the importance of integrating genetic ancestry and metabolic phenotyping in risk assessment and personalized prevention strategies for tobacco-associated cancers.
中文摘要:烟草使用仍是全球可预防癌症死亡的主要原因,不同种族和族裔群体之间的癌症发病率和结局存在明显差异。本研究考察吸烟者烟草致癌物代谢的遗传决定因素,聚焦于参与烟草特异性致癌物代谢活化(Ⅰ相)、解毒(Ⅱ相)和转运(Ⅲ相)相关基因附近的祖先信息标记(AIMs)。研究使用在美国和加勒比地区招募的274名吸烟者的数据,测定尿NNAL(NNK的代谢物)以划分代谢表型,并用富集AIMs的定制芯片进行基因分型。多数参与者(94%)被归类为NNAL弱代谢者,黑人/非洲裔美国吸烟者中比例更高。多变量分析调整年龄、性别、检测批次和每日吸烟支数后,识别出14个位于Ⅰ、Ⅱ、Ⅲ相通路基因附近的AIMs与NNAL代谢表型显著相关,非洲祖先等位基因提高弱代谢的几率。功能注释显示,多数显著AIMs与调控区域重叠,CYP3A5 rs776746变异存在可能损害酶活性的结构破坏。多数参与者具有高非洲祖先比例且为NNAL弱代谢者,这与非洲祖先与NNAL弱代谢之间的关联一致。这些发现凸显烟草相关癌症差异的生物学基础,并强调将遗传祖先和代谢表型纳入烟草相关癌症风险评估和个体化预防策略的重要性。
Very early recurrence (within 1 year after resection) of hepatocellular carcinoma (HCC) indicates aggressive tumor biology and poor prognosis; however, non-invasive prediction tools remain scarce. This study aimed to develop and validate MRI-based models for predicting very early recurrence and to explore their biological underpinnings. This international, multicenter cohort study retrospectively included 1,811 consecutive patients who underwent curative-intent resection for a single BCLC 0/A HCC and preoperative contrast-enhanced MRI or CT at 14 tertiary care hospitals in China, South Korea, Singapore, France, and the USA, as well as 40 eligible patients from the TCGA-LIHC dataset. To predict 1-year recurrence-free survival (RFS), MRI for Very Early Recurrence Prediction (MERP) models were developed using either preoperative variables alone (MERP-pre) or a combination of pre- and postoperative variables (MERP-post) in the derivation cohort (n = 628). The models were externally validated in Eastern (n = 775) and Western (n = 178) test cohorts and further evaluated in a CT test cohort (n = 230). Biological correlates were investigated using whole-exome and RNA sequencing. MERP-pre incorporated alpha-fetoprotein, tumor size, portal venous phase peritumoral hypoenhancement, and intratumoral blood products, whereas MERP-post replaced tumor size with microvascular invasion (MVI). Both models outperformed major staging systems and the IMbrave050 criteria across all test cohorts (C-index, 0.685-0.790 vs. 0.524-0.682; p values, <0.001 to 0.046) and improved risk reclassification (net reclassification improvement [NRI], 0.004-0.372). The MERP models consistently stratified patients into high- and low-risk groups with distinct 1-year RFS rates (all p <0.001). MERP-pre further improved MVI-based risk reclassification (NRI, 0.323) and survival risk stratification. Tumors classified as low risk by MERP-pre exhibited features of the non-proliferative class, increased lipid catabolism, and an immunoactive microenvironment. The MERP models may serve as robust, generalizable, and biologically informed tools for predicting very early HCC recurrence and may help refine risk-stratified management strategies. Very early recurrence (VER) of hepatocellular carcinoma (HCC) within 1 year after resection reflects aggressive tumor biology and is associated with poor prognosis, yet reliable tools for predicting VER remain scarce. In this large, international, multicenter cohort of patients with a single Barcelona Clinic Liver Cancer stage 0/A HCC undergoing curative-intent resection, we developed and externally validated two MRI-based models (MERP-pre and MERP-post) that integrate routinely available clinicopathological and imaging variables. The MERP models consistently outperformed existing prognostic systems and effectively stratified patients into high- and low-risk groups with distinct 1-year recurrence-free survival across diverse cohorts. These findings highlight the potential of the MERP models to complement existing prognostic systems and optimize risk-stratified management of HCC.
中文摘要:肝细胞癌(HCC)切除后1年内出现的非常早期复发提示肿瘤生物学侵袭性强、预后差,无创预测工具仍较少。本研究旨在开发并验证基于MRI的模型以预测非常早期复发,并探索其生物学基础。这项国际多中心队列研究回顾性纳入中国、韩国、新加坡、法国和美国14家三级医院中连续接受根治性意向切除、且术前有增强MRI或CT的单个BCLC 0/A期HCC患者1811例,另纳入TCGA-LIHC数据集中40例符合条件的患者。为预测1年无复发生存(RFS),在推导队列(n=628)中开发了基于MRI的非常早期复发预测(MERP)模型,分别仅使用术前变量(MERP-pre)或联合术前与术后变量(MERP-post)。模型在东方(n=775)和西方(n=178)测试队列中接受外部验证,并在CT测试队列(n=230)中进一步评估。采用全外显子组和RNA测序探讨生物学相关性。MERP-pre纳入甲胎蛋白、肿瘤大小、门静脉期瘤周低强化和瘤内血液产物,MERP-post则以微血管侵犯(MVI)替代肿瘤大小。两个模型在所有测试队列中均优于主要分期系统和IMbrave050标准(C-index 0.685~0.790对0.524~0.682;p值<0.001至0.046),并改善风险重分类(净重分类改善NRI 0.004~0.372)。MERP模型一致地将患者分为高危和低危组,两组1年RFS率不同(所有p<0.001)。MERP-pre进一步改善基于MVI的风险重分类(NRI 0.323)和生存风险分层。经MERP-pre判定为低风险的肿瘤表现出非增殖类特征、脂质分解代谢增强和免疫活跃微环境。MERP模型有望成为稳健、可推广且具有生物学依据的工具,用于预测HCC非常早期复发,并可能帮助优化风险分层管理策略。HCC切除后1年内的非常早期复发(VER)反映肿瘤生物学侵袭性强,与预后差相关,可靠预测VER的工具仍缺乏。在这项大型国际多中心队列中,纳入接受根治性意向切除的单个巴塞罗那临床肝癌分期0/A期HCC患者,开发并外部验证了两种基于MRI的模型(MERP-pre和MERP-post),整合了常规可获得的临床病理和影像变量。MERP模型在不同队列中一致优于现有预后系统,并有效将患者分为1年无复发生存不同的高危和低危组。这些发现提示MERP模型有潜力补充现有预后系统并优化HCC风险分层管理。
Bladder cancer (BC) remains difficult to detect non-invasively because current diagnostic methods are either invasive or insufficiently sensitive for early-stage disease. In this study, we developed a machine-learning-assisted artificial olfactory colorimetric sensor array (CSA) for urinary volatile organic compound (VOC)-based BC screening. The CSA was fabricated by integrating eight cross-reactive dyes into electrospun poly(vinylidene fluoride) (PVDF) nanofibrous membranes. The porous and hydrophobic PVDF matrix enabled uniform dye distribution, reduced humidity interference, and improved colorimetric reproducibility. Urine samples from 134 subjects, including 81 BC patients and 53 controls, were tested using a static headspace exposure method. Colorimetric changes before and after exposure were quantified by Euclidean distance (ED), and the resulting eight-dimensional response fingerprints were analyzed using a multilayer perceptron (MLP) classifier. Based on five-fold cross-validation, the MLP model achieved an accuracy of 0.806 ± 0.078, recall of 0.913 ± 0.050, F1-score of 0.851 ± 0.059, and AUC of 0.861 ± 0.042, outperforming conventional machine-learning models in overall classification performance. SHAP analysis and occlusion-based feature ablation further identified Dye 6 (bromocresol green) as the most influential sensing unit. These results suggest that electrospun CSA-based urinary VOC fingerprinting may provide a low-cost and non-invasive strategy for BC screening.
中文摘要:膀胱癌仍难以无创检出,现有诊断方法要么有创,要么对早期病变灵敏度不足。本研究开发了一种机器学习辅助的人工嗅觉比色传感器阵列,用于基于尿液挥发性有机物的膀胱癌筛查。该传感器阵列将八种交叉反应染料整合到静电纺聚偏二氟乙烯纳米纤维膜中制备而成。多孔疏水的聚偏二氟乙烯基质使染料分布均匀,降低湿度干扰,并提高比色重现性。采用静态顶空暴露法检测134名受试者的尿液样本,其中81例膀胱癌患者和53名对照。暴露前后的比色变化用欧氏距离量化,所得八维响应指纹采用多层感知机分类器分析。五折交叉验证显示,多层感知机模型准确率为0.806±0.078,召回率为0.913±0.050,F1分数为0.851±0.059,AUC为0.861±0.042,整体分类性能优于传统机器学习模型。SHAP分析和基于遮挡的特征消融进一步确定染料6(溴甲酚绿)为影响最大的传感单元。这些结果表明,基于静电纺比色传感器阵列的尿液挥发性有机物指纹分析可能为膀胱癌筛查提供一种低成本、无创的策略。
Information on long-term outcomes of colorectal endoscopic submucosal dissection (ESD) in real-world clinical practice remains limited. This study aimed to evaluate long-term local recurrence and its predictors after colorectal ESD. This prospective, multicenter study was conducted at 11 institutions in Hiroshima, Japan, and included all consecutive colorectal ESD cases (1838 lesions from 1732 patients) between 2014 and 2018. The primary outcome was the cumulative local recurrence rate. The secondary outcomes included factors associated with local recurrence, overall survival, and cancer-specific survival. Factors associated with local recurrence were evaluated using cause-specific Cox proportional hazards models using Firth's penalized partial likelihood. The cumulative local recurrence rates at 1, 3, and 5 years were 0.06%, 0.64%, and 0.75%, respectively. The longest interval to recurrence was 52 months. No local recurrence was observed in patients who achieved curative resection. Rectal lesions (hazard ratio [HR] 3.93; P = 0.04), high-risk pathologic features (HR 14.3; P < 0.001), R1 resection (HR 7.59; P = 0.003), and delayed bleeding (HR 7.72; P = 0.009) were associated with local recurrence. The 5-year overall survival and cancer-specific survival rates were 95.3% and 100%, respectively; however, 1/10 patients with local recurrence developed liver and lung metastases and subsequently died 64 months after ESD. Colorectal ESD had a very low long-term local recurrence rate in real-world clinical settings. No recurrence was observed in patients who underwent curative resection. Long-term surveillance is warranted after noncurative resection.
中文摘要:结直肠内镜黏膜下剥离术(ESD)在真实临床实践中的长期结局资料仍有限。本研究旨在评估结直肠ESD后的长期局部复发及其预测因素。这项前瞻性多中心研究在日本广岛11家机构开展,纳入2014年至2018年间所有连续结直肠ESD病例(1732例患者的1838个病灶)。主要结局为累积局部复发率。次要结局包括与局部复发相关的因素、总生存和肿瘤特异性生存。采用Firth惩罚偏似然的病因特异性Cox比例风险模型评估与局部复发相关的因素。1年、3年和5年累积局部复发率分别为0.06%、0.64%和0.75%。复发的最长间隔为52个月。达到治愈性切除的患者未观察到局部复发。直肠病灶(风险比[HR] 3.93;P=0.04)、高风险病理特征(HR 14.3;P<0.001)、R1切除(HR 7.59;P=0.003)和迟发性出血(HR 7.72;P=0.009)与局部复发相关。5年总生存率和肿瘤特异性生存率分别为95.3%和100%;然而,10例局部复发患者中有1例发生肝和肺转移,并在ESD后64个月死亡。在真实临床环境中,结直肠ESD的长期局部复发率很低。接受治愈性切除的患者未观察到复发。非治愈性切除后需要长期监测。
Prostate cancer remains a leading cause of cancer-related mortality in men worldwide. While hormone therapy is effective in the early stages of advanced disease, multimodal approaches are often required as disease progresses, including radiotherapy, hormonal agents and chemotherapy. In metastatic castration-resistant prostate cancer (mCRPC), tumour cells become resistant to hormone therapy, resulting in poor survival outcomes despite systemic treatments. Among emerging therapies, radioligand therapy targeting prostate-specific membrane antigen (PSMA) has shown promise. PSMA is a transmembrane glycoprotein highly expressed in prostate cancer cells, with minimal expression in normal tissues. This selective distribution enables precision targeting and minimises toxicity. The radiotheranostic agent [177Lu]Lu-PSMA-617 combines PSMA-617, a small molecule ligand, with the beta-emitting radioisotope 177Lutetium. This therapy has demonstrated efficacy in patients with mCRPC who have progressed after androgen receptor pathway inhibitors and taxane-based chemotherapy. Its regulatory approval in the USA, UK and Europe marks a pivotal advancement in prostate cancer management. Clinical trials such as TheraP, VISION and PSMAfore have established the role of [177Lu]Lu-PSMA-617 in mCRPC and its potential additive effects with other anti-tumour therapies are under investigation. Strategies to enhance PSMA expression may further improve therapeutic response. With no relevant drug-drug interaction risk, [177Lu]Lu-PSMA-617 may be safely considered for use in combination with other therapies, a key advantage for frail patients with mCRPC on polypharmacy. Post-treatment management remains a challenge and ongoing research aims to optimise long-term outcomes. This review provides a comprehensive update on [177Lu]Lu-PSMA-617 therapy, from molecular mechanisms to clinical application and outlines future directions in the treatment of advanced prostate cancer.
中文摘要:前列腺癌仍是全球男性癌症相关死亡的主要原因之一。激素治疗对晚期疾病的早期阶段有效,但疾病进展后常需多模式治疗,包括放疗、激素药物和化疗。在转移性去势抵抗性前列腺癌(mCRPC)中,肿瘤细胞对激素治疗产生抵抗,尽管接受全身治疗,生存结局仍较差。在新兴疗法中,靶向前列腺特异性膜抗原(PSMA)的放射配体治疗显示出前景。PSMA是一种跨膜糖蛋白,在前列腺癌细胞中高表达,在正常组织中表达很低。这种选择性分布使精准靶向成为可能并减少毒性。放射诊疗剂[177Lu]Lu-PSMA-617将小分子配体PSMA-617与发射β射线的放射性同位素177镥结合。该疗法在经雄激素受体通路抑制剂和紫杉类化疗后进展的mCRPC患者中已显示疗效。其在美国、英国和欧洲获得监管批准,标志着前列腺癌治疗的重要进展。TheraP、VISION和PSMAfore等临床试验确立了[177Lu]Lu-PSMA-617在mCRPC中的作用,其与其他抗肿瘤治疗的潜在叠加效应正在研究中。提高PSMA表达的策略可能进一步改善治疗反应。由于不存在相关药物相互作用风险,[177Lu]Lu-PSMA-617可安全考虑与其他治疗联合使用,这对接受多种药物治疗的虚弱mCRPC患者是一项关键优势。治疗后管理仍是挑战,正在开展的研究旨在优化长期结局。文章围绕[177Lu]Lu-PSMA-617治疗从分子机制到临床应用作全面更新,并概述晚期前列腺癌治疗的未来方向。
Surface-enhanced Raman scattering (SERS) is attractive for trace-level analysis in complex systems owing to its nondestructive readout and molecular fingerprint information. However, direct and reliable SERS analysis remains challenging because signals from trace analytes are readily obscured by matrix interference and competitive adsorption, complicating analysis in complex biofluids. Here, we introduce a SERS sensing approach that amplifies spectral differences through a novel response function, which enhances inter-sample separability and facilitates subsequent classification. As a practical demonstration, we apply this framework to urine-based cancer detection using three sensing molecules functionalized on silver nanorods (AgNRs). The sensing molecules report urine components through spectral variations of their own functional groups, while controlled experiments with representative urinary-related molecules revealed receptor-dependent response patterns across the three sensing interfaces, indicating partially shared but non-identical molecular-response information. Response functions derived from these responses are used to establish separate CNN-MLP models to generate receptor-specific cancer/healthy predictions, which are combined through a three-principal-substrate consistency gating strategy. In a dataset of 226 urine samples, the method achieved 92.0% screening coverage with 100% accuracy within the covered set. This work provides a practical response-function-based SERS framework for extracting molecular-response information from complex samples and integrating multi-receptor responses for reliable classification.
中文摘要:表面增强拉曼散射(SERS)具有无损读出和分子指纹信息,在复杂体系痕量分析中颇具吸引力。然而,痕量分析物信号易被基质干扰和竞争吸附掩盖,使复杂生物体液中的直接、可靠SERS分析仍具挑战。本研究提出一种SERS传感方法,通过新的响应函数放大光谱差异,增强样本间可分性并便于后续分类。作为实际演示,将该框架用于尿液癌症检测,在银纳米棒(AgNRs)上功能化三种传感分子。传感分子通过自身官能团的光谱变化报告尿液成分;对代表性尿液相关分子进行的对照实验显示,三种传感界面具有受体依赖的响应模式,表明分子响应信息部分共享但并不完全相同。由这些响应得到的响应函数用于建立独立的CNN-MLP模型,生成受体特异的癌症/健康预测,并通过三主基底一致性门控策略进行整合。在226份尿液样本的数据集中,该方法达到92.0%的筛查覆盖率,并在覆盖集合内实现100%准确率。该工作提供了一种基于响应函数的实用SERS框架,用于从复杂样本中提取分子响应信息并整合多受体响应以实现可靠分类。
Pancreatic ductal adenocarcinoma (PDAC) is a near-universally lethal malignancy, with KRAS mutations driving tumorigenesis in over 90% of cases. For decades considered undruggable, oncogenic KRAS has now been therapeutically engaged across multiple mutational subtypes, a revolution precipitated by allele-specific covalent inhibitors and accelerated by the emergence of RAS(ON) multi-selective inhibitors. The pivotal phase 3 RASolute 302 trial of daraxonrasib, a pan-RAS(ON) inhibitor, demonstrated nearly doubled median overall survival (13.2 versus 6.7 months; HR 0.40; P < 0.0001) over standard chemotherapy in previously treated metastatic PDAC. Concurrently, mutation-selective G12D inhibitors (zoldonrasib, VS-7375, INCB161734), G12D-targeted protein degraders (setidegrasib), G12C-selective RAS(ON) compounds (elironrasib), and next-generation MEK inhibitors (atebimetinib) are advancing through clinical evaluation. This review synthesizes the biological basis of KRAS-driven oncogenesis in the pancreas, the mutational landscape and its prognostic implications, the structural and mechanistic evolution of KRAS inhibitor classes, contemporary and emerging clinical data from recent trials, toxicity profiles and their management, and resistance mechanisms. The field stands at an inflection point: daraxonrasib now redefines second-line PDAC management, while first-line combination regimens with daraxonrasib plus chemotherapy have produced an ORR of 58% in early-phase single-arm data, a result now being tested in the randomized RASolute 303 trial. The challenge ahead lies in translating these results into durable remissions through rational combination therapy and in overcoming acquired resistance.
中文摘要:胰腺导管腺癌(PDAC)是一种几乎普遍致命的恶性肿瘤,90%以上病例由KRAS突变驱动肿瘤发生。数十年来被认为不可成药,如今致癌KRAS已在多个突变亚型中实现治疗性干预,这一转变由等位基因特异性共价抑制剂引发,并因RAS(ON)多选择性抑制剂的出现而加速。pan-RAS(ON)抑制剂daraxonrasib的关键3期RASolute 302试验显示,在既往接受过治疗的转移性PDAC中,其中位总生存期较标准化疗接近翻倍(13.2个月对6.7个月;HR 0.40;P<0.0001)。同时,突变选择性G12D抑制剂(zoldonrasib、VS-7375、INCB161734)、靶向G12D的蛋白降解剂(setidegrasib)、G12C选择性RAS(ON)化合物(elironrasib)以及下一代MEK抑制剂(atebimetinib)正在推进临床评估。本综述整合了胰腺中KRAS驱动致癌作用的生物学基础、突变谱及其预后意义、KRAS抑制剂类别的结构与机制演变、近期试验的当代与新出现临床数据、毒性特征及其管理,以及耐药机制。该领域正处在拐点:daraxonrasib重新定义了PDAC二线治疗,而daraxonrasib联合化疗的一线方案在早期单臂数据中ORR达58%,该结果正在随机RASolute 303试验中验证。未来挑战在于通过合理的联合治疗将这些结果转化为持久缓解,并克服获得性耐药。
Esophageal cancer (EC) remains a significant public health burden in China. Current diagnostics modalities such as endoscopy and imaging are invasive, poorly accessible, or insensitive for early-stage cases. DNA methylation alterations in circulating free DNA (cfDNA) are promising for non-invasive cancer detection. We aimed to develop and validate a methylation PCR-based assay for EC detection using EC-specific DNA methylation targets. Here, we report myESCAP, a PCR-based assay that amplifies and quantifies levels of EC-specific methylation in cfDNA METHODS: We conducted a multi-center, retrospective case-control study with 489 EC cases and 555 non-malignant controls (benign esophageal/gastric diseases or asymptomatic) to develop myESCAP, a methylation-specific PCR assay containing 11 EC-specific methylation markers from our previous genome-wide methylation screening, selected for strong discriminative performance and PCR compatibility. cfDNA was collected, bisulfite-converted, and tested by myESCAP, and results were analyzed by six modeling strategies (generalized linear model, k-nearest neighbors, C5.0 decision tree, gradient boosting machine, random forest, support vector machine) to train EC-prediction models using 347 EC cases and 349 non-malignant controls, and validated in 142 EC cases and 206 controls. All myESCAP markers demonstrated significant differential methylation between ECs and non-malignant controls, with adjusted p values between 5.8×10⁻3 and 3.1×10⁻88. The six models showed robust performance in the training cohort (average AUC = 0.835, average sensitivity = 76.13%, average specificity = 90.88%). They maintained performance in the validation cohort (average AUC = 0.823, average sensitivity = 75.59%, average specificity = 89%). Specifically, for stage I cases, myESCAP had an average sensitivity of 47.2%, highlighting the challenge of early detection with limited circulating tumor DNA and the need for further optimization. myESCAP accurately differentiated EC from non-malignant controls. The six models collectively confirm myESCAP's robustness and clinical potential as a cost-effective, non-invasive diagnostic tool for EC.
中文摘要:食管癌在中国仍构成显著公共卫生负担。内镜和影像等现有诊断方式具有侵入性、可及性差,或对早期病例不敏感。循环游离DNA(cfDNA)中的DNA甲基化改变为无创癌症检测提供了有前景的方向。研究旨在利用食管癌特异性DNA甲基化靶标开发并验证一种基于甲基化PCR的食管癌检测方法。myESCAP是一种扩增并定量cfDNA中食管癌特异性甲基化水平的PCR检测方法。方法部分:开展多中心回顾性病例对照研究,纳入489例食管癌病例和555例非恶性对照(良性食管/胃疾病或无症状者),以开发myESCAP;该甲基化特异性PCR检测包含11个食管癌特异性甲基化标志物,来源于既往全基因组甲基化筛选,依据强判别性能和PCR兼容性选出。收集cfDNA,经亚硫酸氢盐转化后用myESCAP检测,结果通过六种建模策略分析(广义线性模型、k近邻、C5.0决策树、梯度提升机、随机森林、支持向量机),以347例食管癌和349例非恶性对照训练食管癌预测模型,并在142例食管癌和206例对照中验证。所有myESCAP标志物在食管癌与非恶性对照之间均显示显著差异甲基化,校正p值介于5.8×10⁻3与3.1×10⁻88之间。六种模型在训练队列中表现稳健(平均AUC=0.835,平均敏感性=76.13%,平均特异性=90.88%),在验证队列中保持表现(平均AUC=0.823,平均敏感性=75.59%,平均特异性=89%)。对于I期病例,myESCAP平均敏感性为47.2%,提示循环肿瘤DNA有限时早期检测存在挑战,需进一步优化。myESCAP可准确区分食管癌与非恶性对照。六种模型共同证实myESCAP作为经济、无创的食管癌诊断工具具有稳健性和临床潜力。
Postoperative stereotactic radiotherapy (SRT) is the standard adjuvant treatment after resection of brain metastases. It nevertheless requires delineation of a dynamic postsurgical cavity, delays local treatment by 3 to 6 weeks (and thus resumption of systemic therapy) and carries substantial risks of radiation necrosis and leptomeningeal disease. Preoperative SRT targets an intact lesion and may address some of these limitations. In this open-label, single-arm, multicenter phase 2 trial, eligible adults had a Karnofsky performance status ≥70 and up to four brain metastases, including one resectable lesion ≤5 cm, from breast, non-small cell lung, kidney, or digestive cancer or melanoma. Patients received preoperative SRT (three fractions of 7.7 Gy prescribed to the encompassing 70% isodose line, equivalent to 11Gy per fraction at the isocenter) followed by surgical resection within 3 days of the last fraction. The primary outcome was 6-month local control on centrally reviewed MRI. Secondary outcomes included index-lesion radiation necrosis, leptomeningeal disease, distant intracranial control, overall survival, toxicity, cognition, and quality of life. Of 73 patients assessed, 67 were eligible and 63 received both SRT and surgery. Median age was 62 years. At a median follow-up of 12.7 months, the 6-month local control rate was 100% (95% CI, 95%-100%), meeting the primary endpoint; the 12-month rate was 96.4% (95% CI, 87%-99%). No leptomeningeal disease occurred. The 1-year cumulative incidence of index-lesion radiation necrosis was 7% (95% CI, 2%-16%), meeting the key secondary endpoint. Distant intracranial failure occurred in 22 patients (35%); 12-month overall survival was 81.2% (95% CI, 70%-89%). Postoperative complications occurred in 4 patients (6.3%); cognition and quality of life remained stable over the 12 months of protocol follow-up. Three-fraction preoperative SRT followed by resection was associated with high local control, low radiation necrosis, and no leptomeningeal disease, supporting evaluation in ongoing randomized trials.
中文摘要:脑转移瘤切除术后立体定向放疗(SRT)是标准辅助治疗,但需要勾画术后动态变化的瘤腔,使局部治疗延迟3至6周,也推迟全身治疗恢复,并带来较高的放射性坏死和软脑膜病变风险。术前SRT针对完整病灶,可能规避部分限制。这项开放标签、单臂、多中心2期试验纳入Karnofsky体能状态评分≥70的成人患者,脑转移灶不超过4个,其中1个可切除病灶≤5cm,原发肿瘤为乳腺癌、非小细胞肺癌、肾癌、消化道肿瘤或黑色素瘤。患者接受术前SRT(3次,每次7.7Gy,处方至覆盖靶区的70%等剂量线,相当于等中心每次11Gy),并在末次照射后3天内行手术切除。主要终点为中心复核MRI评估的6个月局部控制。次要终点包括责任病灶放射性坏死、软脑膜病变、颅内远处控制、总生存、毒性、认知和生活质量。评估73例,67例符合条件,63例同时接受SRT和手术。中位年龄62岁。中位随访12.7个月,6个月局部控制率100%(95%置信区间95%至100%),达到主要终点;12个月为96.4%(95%置信区间87%至99%)。未发生软脑膜病变。责任病灶放射性坏死1年累积发生率7%(95%置信区间2%至16%),达到关键次要终点。22例(35%)出现颅内远处失败;12个月总生存率81.2%(95%置信区间70%至89%)。4例(6.3%)发生术后并发症;方案随访12个月内认知和生活质量保持稳定。3次术前SRT后行切除术与高局部控制、低放射性坏死和无软脑膜病变相关,支持在正在进行的随机试验中进一步评估。
Obesity has traditionally been defined by body mass index (BMI), a pragmatic but biologically limited measure that fails to capture adiposity distribution, tissue dysfunction, and heterogeneity in disease risk. To address these limitations, a recent Lancet Diabetes & Endocrinology Commission proposed a disease-oriented redefinition of obesity, distinguishing clinical obesity-excess adiposity causing organ dysfunction or functional impairment-from preclinical obesity, characterized by excess adiposity without established dysfunction. This shift has important implications for diagnosis, epidemiology, and health policy. In this review, we critically appraise the conceptual framework, emerging evidence, and implementation challenges of the new Lancet Commission definition of clinical obesity. Population-based studies from diverse regions consistently demonstrate marked discordance between BMI-defined and clinical obesity, with clinical obesity showing stronger associations with cardiometabolic disease, mortality, functional limitation, and cancer risk. These findings highlight the limitations of universal BMI thresholds, particularly in Asian populations with a predisposition to visceral adiposity at lower BMI levels. We compare the Lancet Commission framework with existing staging systems, including the Edmonton Obesity Staging System and the European Association for the Study of Obesity framework, and identify key challenges related to causal attribution, binary classification, scalability, and ethnic adaptation. Finally, we propose a refined, population-sensitive and pragmatic approach that conceptualizes preclinical and clinical obesity as stages along a trajectory, incorporates ethnicity-adapted adiposity thresholds, and emphasizes readily available clinical criteria for determining dysfunction and disease. The resulting definition of clinical obesity should support more precise and equitable obesity care.
中文摘要:肥胖传统上由体重指数(BMI)定义,这是一种实用但在生物学上受限的指标,无法反映脂肪分布、组织功能障碍和疾病风险异质性。为应对这些局限,近期《柳叶刀糖尿病与内分泌学》委员会提出以疾病为导向的肥胖重新定义,区分临床肥胖,即导致器官功能障碍或功能受损的脂肪过多,与临床前肥胖,即脂肪过多但尚未确立功能障碍。这一转变对诊断、流行病学和卫生政策具有重要影响。本综述批判性评估新柳叶刀委员会临床肥胖定义的概念框架、新出现的证据和实施挑战。来自不同地区的人群研究一致显示,BMI定义的肥胖与临床肥胖之间存在明显不一致,临床肥胖与心脏代谢疾病、死亡率、功能受限和癌症风险的关联更强。这些发现凸显普适BMI阈值的局限,尤其在较低BMI水平即易发生内脏脂肪堆积的亚洲人群中。我们将柳叶刀委员会框架与现有分期系统比较,包括埃德蒙顿肥胖分期系统和欧洲肥胖研究协会框架,并指出因果归因、二分分类、可扩展性和种族适配方面的关键挑战。据此,我们提出一种细化、对人群敏感且务实的路径,将临床前肥胖和临床肥胖视为同一轨迹上的阶段,纳入经种族适配的脂肪阈值,并强调用于判定功能障碍和疾病的易获取临床标准。由此形成的临床肥胖定义应支持更精准和更公平的肥胖照护。
基础研究 (21篇)
Long non-coding RNAs (lncRNAs) play diverse regulatory roles in cancer, yet their functional interpretation remains largely based on molecular associations and computational predictions, while experimentally derived evidence is fragmented across heterogeneous resources. Here, we present lncRNAfunc 2.0, an updated knowledgebase for systematic functional interpretation of cancer lncRNAs through multi-source evidence integration. Compared with the previous version, lncRNAfunc 2.0 reprocesses pan-cancer data from The Cancer Genome Atlas, incorporates normal-tissue and cancer-cell-line contexts from GTEx and CCLE, substantially expands binding and interaction evidence, and introduces perturbation evidence for lncRNAs and their regulators. These resources are integrated with association-based analyses and computational predictions as complementary evidence for interpreting lncRNA-associated regulatory relationships. lncRNAfunc 2.0 organizes functional knowledge into six biological dimensions: dysregulation, upstream regulation, lncRNA-mediated mRNA regulation, transcript remodeling, protein regulation, and tumor phenotypes. This framework connects regulatory determinants of lncRNAs with their downstream molecular relationships and phenotypic associations, including mRNA regulation, alternative splicing, protein regulation, survival, molecular and immune phenotypes, and drug response. Overall, lncRNAfunc 2.0 provides an evidence-integrated framework for exploring context-dependent lncRNA functions and regulatory mechanisms across cancers. lncRNAfunc 2.0 is freely available at https://lncrnafunc.xu-bioinfo.com/.
中文摘要:长链非编码RNA(lncRNA)在癌症中发挥多种调控作用,但其功能解释仍主要依赖分子关联和计算预测,实验来源的证据分散于异质资源中。lncRNAfunc 2.0 是一个通过多来源证据整合对癌症lncRNA进行系统功能解释的更新版知识库。与前一版本相比,lncRNAfunc 2.0 重新处理了癌症基因组图谱的泛癌数据,纳入GTEx和CCLE提供的正常组织与癌细胞系背景,显著扩展了结合与相互作用证据,并引入针对lncRNA及其调控因子的扰动证据。这些资源与基于关联的分析及计算预测整合,作为解释lncRNA相关调控关系的补充证据。lncRNAfunc 2.0 将功能知识组织为六个生物学维度:失调、上游调控、lncRNA介导的mRNA调控、转录本重塑、蛋白调控和肿瘤表型。该框架将lncRNA的调控决定因素与其下游分子关系和表型关联连接起来,包括mRNA调控、可变剪接、蛋白调控、生存、分子与免疫表型以及药物反应。lncRNAfunc 2.0 为探索跨癌症的背景依赖性lncRNA功能及调控机制提供了证据整合框架。lncRNAfunc 2.0 可在 https://lncrnafunc.xu-bioinfo.com/ 免费获取。
Metastasis remains a leading cause of mortality in patients with esophageal squamous cell carcinoma (ESCC), underscoring the urgent need to elucidate the molecular mechanisms driving disease progression. In this study, we delineated that zinc finger BED-type containing 2 (ZBED2), a zinc finger protein, correlates with inferior survival outcomes and metastasis in patients with ESCC. ZBED2 formed phase-separated nuclear condensates that functionally promote tumor metastasis, and integrin-linked kinase (ILK) was pinpointed as a critical downstream effector in mediating the prometastatic function of ZBED2. Mechanistically, ZBED2 enhanced the transcription of HSP90AA1, promoted the physical interaction between HSP90AA1 and ILK, and consequently stabilized ILK by suppressing its ubiquitination. Subsequently, ILK promoted PD-L1 transcription and CD8+ T-cell exhaustion, thereby creating an immunosuppressive microenvironment that facilitates cancer metastasis. Collectively, these findings establish the pivotal role of ZBED2 in driving ESCC metastasis and immune evasion, thereby validating it as a promising therapeutic target for this aggressive malignancy. A ZBED2-HSP90AA1-ILK-PD-L1 regulatory axis drives esophageal squamous cell carcinoma metastasis and immune evasion, identifying targeting ZBED2 as a potential therapeutic strategy for improving the prognosis of patients.
中文摘要:转移仍是食管鳞状细胞癌(ESCC)患者死亡的主要原因,凸显阐明驱动疾病进展的分子机制的紧迫性。本研究揭示,含BED型锌指蛋白2(ZBED2)与ESCC患者较差的生存结局和转移相关。ZBED2形成相分离核凝聚体,并在功能上促进肿瘤转移;整合素连接激酶(ILK)被确定为介导ZBED2促转移作用的关键下游效应分子。机制上,ZBED2增强HSP90AA1转录,促进HSP90AA1与ILK的物理相互作用,并通过抑制ILK泛素化而稳定ILK。随后,ILK促进PD-L1转录和CD8+ T细胞耗竭,从而形成有利于癌症转移的免疫抑制微环境。这些发现确立了ZBED2在驱动ESCC转移和免疫逃逸中的关键作用,并验证其作为这一侵袭性恶性肿瘤有前景的治疗靶点。ZBED2-HSP90AA1-ILK-PD-L1调控轴驱动食管鳞状细胞癌转移和免疫逃逸,提示靶向ZBED2是改善患者预后的潜在治疗策略。
Ethanol directly stimulates and damages the gastric mucosa, leading to impairment of the mucus-bicarbonate barrier and mechanical barrier, which is the primary factor of gastric ulcer formation. Yeast protein (YP), an emerging microbial food ingredient, has shown potential in mucosal protection. However, its bioactive components and underlying mechanisms remain unclear. This study aims to evaluate the protective effect of YP hydrolyzed by papanin (YP-P) against ethanol-induced acute gastric mucosal injury, identify the key bioactive compound, and elucidate the molecular mechanism by which it alleviates gastric mucosal damage. In this study, enzyme-linked immunosorbent assay (ELISA), immunofluorescence (IF), western blotting (WB), transmission electron microscopy (TEM) and other experimental techniques were used to evaluate the protective effects of YP-P by establishing ethanol-induced gastric mucosal injury models in vitro and in vivo. RNA sequencing, untargeted metabolomics, peptidomics, virtual screening, molecular docking, network pharmacology, proteomics, and multi-omics analysis techniques were used to determine the potential targets and molecular mechanisms of YP-P in alleviating gastric mucosal damage. Finally, the inhibition of bioactive compounds identified in YP on the nucleotide-binding oligomerization domain (NOD)-like receptor signaling pathway was verified through cell experiments. The protective effects of papain-hydrolyzed YP (YP-P) were demonstrated by establishing ethanol-induced gastric mucosal injury models in vitro and in vivo. Fractionation via centrifugation and ultrafiltration identified the component with molecular weight less than 5 kDa (YP-P < 5 kDa) as the primary protective fraction. Integrating multi-omics with virtual screening and network pharmacology, methionine (Met) was identified as the key bioactive compound within YP-P < 5 kDa. Mechanism studies revealed that Met alleviates ethanol-induced acute gastric mucosal injury by targeting tumor necrosis factor-α (TNF-α)/inducible nitrogen oxide synthase (NOS2) and modulating the NOD-like receptor signaling pathway. These findings highlight the protective effect of YP and its bioactive compound in the prevention and management of gastric mucosal injury, providing reference for their application as gastric mucosal protectants in functional ingredient.
中文摘要:乙醇直接刺激并损伤胃黏膜,造成黏液-碳酸氢盐屏障和机械屏障受损,这是胃溃疡形成的主要因素。酵母蛋白(YP)作为一种新型微生物食品原料,在黏膜保护方面显示出潜力,但其生物活性成分及作用机制仍不清楚。本研究评估木瓜蛋白酶水解酵母蛋白(YP-P)对乙醇诱导急性胃黏膜损伤的保护作用,识别关键生物活性化合物,并阐明其缓解胃黏膜损伤的分子机制。研究采用酶联免疫吸附试验(ELISA)、免疫荧光(IF)、蛋白质印迹(WB)、透射电子显微镜(TEM)等技术,通过建立体外和体内乙醇诱导胃黏膜损伤模型评价YP-P的保护作用;运用RNA测序、非靶向代谢组学、肽组学、虚拟筛选、分子对接、网络药理学、蛋白质组学及多组学分析技术,确定YP-P缓解胃黏膜损伤的潜在靶点和分子机制。最后通过细胞实验验证YP中鉴定出的生物活性化合物对核苷酸结合寡聚化结构域(NOD)样受体信号通路的抑制作用。通过建立体外和体内乙醇诱导胃黏膜损伤模型,证实木瓜蛋白酶水解YP(YP-P)的保护作用。经离心和超滤分级,确定分子量低于5 kDa的组分(YP-P < 5 kDa)为主要保护组分。整合多组学、虚拟筛选和网络药理学,鉴定出甲硫氨酸(Met)为YP-P < 5 kDa中的关键生物活性化合物。机制研究显示,Met通过靶向肿瘤坏死因子-α(TNF-α)/诱导型一氧化氮合酶(NOS2)并调节NOD样受体信号通路,缓解乙醇诱导的急性胃黏膜损伤。这些发现突出YP及其生物活性化合物在胃黏膜损伤预防和管理中的保护作用,为其作为功能性配料中的胃黏膜保护剂应用提供参考。
Glioblastoma (GBM) is a highly aggressive malignancy, with chemoresistance acting as a major hurdle that severely limits clinical efficacy and long-term prognosis. Mitophagy, a core mechanism of mitochondrial quality control, enables tumor cells to adapt to chemotherapy-induced stress and maintain survival. However, its regulatory mechanism in GBM chemoresistance remains poorly understood. Here, we identify SLMO2 as a key factor mediating chemoresistance in GBM. Low-dose TMZ induces protective mitophagy, whereas SLMO2 knockdown abrogates this autophagic defense, thereby sensitizing GBM cells to TMZ-induced apoptosis. Mechanistically, TMZ treatment upregulates SLMO2, which potently activates HIF-1α signaling to transcriptionally drive BNIP3-mediated mitophagy, a process dependent on ROS-NF-κB signaling. Notably, this SLMO2-mediated cascade is also engaged under cisplatin-induced stress, indicating a broader role in chemoresistance. Collectively, our findings reveal that SLMO2 promotes chemoresistance in GBM by regulating BNIP3-mediated mitophagy. Targeting SLMO2 disrupts mitochondrial homeostasis by this process, offering a novel therapeutic strategy for enhancing chemosensitivity in GBM.
中文摘要:胶质母细胞瘤(GBM)是一种高度侵袭性的恶性肿瘤,化疗耐药是严重限制临床疗效和长期预后的主要障碍。线粒体自噬作为线粒体质量控制的核心机制,使肿瘤细胞能够适应化疗诱导的应激并维持生存,但其在GBM化疗耐药中的调控机制仍不清楚。SLMO2被确定为介导GBM化疗耐药的关键因子。低剂量替莫唑胺(TMZ)诱导保护性线粒体自噬,而敲低SLMO2可消除这种自噬防御,使GBM细胞对TMZ诱导的凋亡更敏感。机制上,TMZ处理上调SLMO2,后者有效激活HIF-1α信号,转录驱动BNIP3介导的线粒体自噬,该过程依赖ROS-NF-κB信号。SLMO2介导的这一级联反应在顺铂诱导的应激下同样被激活,提示其在化疗耐药中具有更广泛的作用。这些发现表明,SLMO2通过调控BNIP3介导的线粒体自噬促进GBM化疗耐药;靶向SLMO2可通过该过程破坏线粒体稳态,为增强GBM化疗敏感性提供新的治疗策略。
Cellular prion protein (PrPᶜ), encoded by PRNP, is increasingly recognized as a context-dependent regulator of cellular stress adaptation and intercellular communication beyond its canonical role as the physiological precursor of disease-associated prion conformers. Through its localization in membrane microdomains and interactions with receptors, adhesion molecules, chaperones, and extracellular vesicles (EVs), PrPᶜ has been linked to redox and mitochondrial homeostasis, survival signaling, senescence regulation, and tissue repair. However, these functions are neither uniformly pathogenic nor protective. In malignant systems, PrPᶜ-associated pathways may be co-opted to support cancer stem-like properties, mesenchymal plasticity, migration, therapeutic resistance, and EV-mediated tumor communication. In this review, we focused on regenerative systems, specifically in mesenchymal stem/stromal cells (MSCs). The most consistent perturbation-based evidence linked PrPᶜ to hypoxic and oxidative stress resistance, mitochondrial integrity, senescence control, paracrine competence, and reparative activity. Broader functions of PrPᶜ in other stem and progenitor populations were outside the primary scope. We further evaluated EV-associated PrPᶜ by distinguishing analytical association, regulated vesicular sorting and directly demonstrated recipient-cell signaling. Direct cross-system comparison indicates that causal support is strongest in selected colorectal-cancer and direct EV-signaling models, whereas regenerative MSC and MSC-EV evidence remains more model-specific and typically derives from multicomponent priming or rescue paradigms. We propose an evidence-informed, context-dependent framework in which PrPᶜ modulation is guided by cellular identity, disease context, and experimentally demonstrated functional dependence rather than by PRNP expression or PrPᶜ abundance alone.
中文摘要:细胞型朊蛋白(PrPᶜ)由PRNP编码,除了作为疾病相关朊蛋白构象的生理前体这一经典角色外,日益被视为细胞应激适应和细胞间通讯的情境依赖性调节因子。PrPᶜ定位于膜微区,并与受体、黏附分子、分子伴侣和细胞外囊泡(EV)相互作用,因而与氧化还原和线粒体稳态、生存信号、衰老调节及组织修复相关联。不过,这些功能既非一致致病,也非一致保护。在恶性系统中,PrPᶜ相关通路可能被劫持,以支持癌症干细胞样特性、间充质可塑性、迁移、治疗抵抗和EV介导的肿瘤通讯。本综述聚焦再生系统,尤其是间充质干/基质细胞(MSC)。最一致的扰动实验证据将PrPᶜ与缺氧和氧化应激抵抗、线粒体完整性、衰老控制、旁分泌能力及修复活性联系起来。PrPᶜ在其他干细胞和祖细胞群体中的更广泛功能不属于主要讨论范围。我们进一步评估EV相关PrPᶜ,区分分析性关联、受调控的囊泡分选和直接证实的受体细胞信号传导。跨系统直接比较表明,因果支持在选定的结直肠癌模型和直接EV信号模型中最强,而再生性MSC与MSC-EV证据仍更具模型特异性,通常来自多组分预处理或救援范式。我们提出一个循证、情境依赖的框架,其中PrPᶜ调控由细胞身份、疾病背景和实验证明的功能依赖性指导,而非仅由PRNP表达或PrPᶜ丰度决定。
Breast cancer brain metastasis (BCBM) represents one of the most aggressive and lethal complications of breast cancer, arising when malignant cells colonize the brain. Patients diagnosed with BCBM face a poor prognosis, with median survival times ranging from 2 to 25.3 months, and experience significantly reduced quality of life compared with those patients with extracranial metastases. Current therapeutic strategies, including surgical resection, whole-brain radiation therapy, and stereotactic radiosurgery, offer limited benefit and are rarely curative. Despite advances in breast cancer management, effective treatment for BCBM remains a major clinical challenge, primarily due to the restrictive nature of the blood-brain barrier (BBB), which hinders the delivery and accumulation of most chemotherapeutics within brain tissue. For example, paclitaxel, a widely used microtubule-targeting agent in breast cancer therapy, has limited efficacy against BCBM because it is a substrate of ATP-dependent efflux transporters, particularly P-glycoprotein, at the blood-brain barrier, with its physicochemical properties, such as high molecular weight, further restricting effective intracranial drug exposure. In contrast, emerging evidence suggests that colchicine-binding site inhibitors (CBSIs), a novel class of microtubule-targeting agents, possess the ability to penetrate the BBB, making them promising candidates for the treatment of BCBM. This review highlights recent advances in the development of CBSIs for BCBM and extends the discussion to their evaluation in other brain cancers, such as glioma. Furthermore, we examine strategies to enhance drug delivery across the BBB and to improve therapeutic selectivity toward cancer cells while sparing healthy brain tissue.
中文摘要:乳腺癌脑转移(BCBM)是乳腺癌最具侵袭性、致死性的并发症之一,发生于恶性细胞定植脑组织时。确诊BCBM的患者预后差,中位生存期为2至25.3个月,生活质量较仅有颅外转移的患者明显下降。现有治疗手段包括手术切除、全脑放疗和立体定向放射外科,获益有限,罕有治愈。乳腺癌诊疗虽有进步,BCBM的有效治疗仍是主要临床难题,主要原因是血脑屏障(BBB)的限制性,阻碍多数化疗药物进入脑组织并有效蓄积。例如,紫杉醇是乳腺癌治疗中广泛使用的微管靶向药物,但对BCBM疗效有限,因为它是ATP依赖性外排转运体尤其是血脑屏障处P-糖蛋白的底物,其高分子量等理化性质进一步限制颅内药物暴露。新证据提示,秋水仙碱结合位点抑制剂(CBSIs)这类新型微管靶向药物能够穿透BBB,是治疗BCBM有希望的候选药物。本综述总结CBSIs用于BCBM研发的最新进展,并将讨论延伸至胶质瘤等其他脑肿瘤中的评价。我们还探讨促进药物跨越BBB、提高对癌细胞治疗选择性并保护正常脑组织的策略。
Influenza vaccination may confer benefits that extend well beyond seasonal protection against respiratory infection: reduced cardiovascular morbidity and mortality, lower dementia incidence, fewer cardio-renal complications, improved survival in the very old, and emerging signals in oncology and diabetes. Although vulnerable to confounding and evidence in adults aged ≥ 75-80 years and in frail populations remains scarce, their magnitude, cross-organ consistency and apparent dose-response suggest that protection is not explained solely by prevention of infection, but points to a shared upstream mechanism: modulation of chronic inflammation. Recent single-cell multiomic studies provide a plausible substrate: inactivated influenza vaccine induces persistent epigenetic remodelling in monocytes and myeloid dendritic cells, lasting up to six months,and, consistent with a regulatory recalibration of innate reactivity, termed trained tolerance. This myeloid axis is also central to inflammaging, whose clinical expression in older people is frailty. We review multiomic, preclinical and epidemiological evidence supporting a framework in which influenza vaccination may exert effects beyond pathogen-specific protection. Murine models provide causal evidence that vaccination can modify vascular, neurodegenerative and tumour pathology through systemic immune mechanisms. We position these findings alongside heterologous effects of other vaccines and examine their relevance to chronic inflammation. Although innate immune reprogramming involves pathways shared with inflammaging, a direct effect on chronic low-grade inflammation remains unproven. Key uncertainties including healthy-vaccinee bias, the absence of frailty stratification and the age discordance between mechanistic and clinical evidence are discussed.
中文摘要:流感疫苗接种可能带来远超季节性呼吸道感染防护的益处:降低心血管发病率和死亡率、降低痴呆发生率、减少心肾并发症、改善高龄老人的生存,并在肿瘤学和糖尿病领域出现初步信号。尽管这些结果易受混杂因素影响,且75至80岁及以上成人及衰弱人群中的证据仍然稀少,但其效应幅度、跨器官一致性和明显的剂量反应提示,保护作用不能仅由预防感染解释,而指向一个共同的上游机制:对慢性炎症的调节。近期单细胞多组学研究提供了可能的机制基础:灭活流感疫苗可在单核细胞和髓系树突状细胞中诱导持续的表观遗传重塑,最长可达六个月,并与先天反应性的调节性重校准一致,被称为训练耐受。这一髓系轴也是炎症衰老的核心,而炎症衰老在老年人中的临床表现是衰弱。本综述整合多组学、临床前和流行病学证据,支持一个框架:流感疫苗接种可能产生超出病原体特异性保护的作用。小鼠模型提供了因果证据,表明疫苗接种可通过全身免疫机制改变血管、神经退行性和肿瘤病理。将这些发现与其他疫苗的异源效应并列考察,并审视其与慢性炎症的相关性。尽管先天免疫重编程涉及与炎症衰老共享的通路,其对慢性低度炎症的直接影响仍未得到证实。文中讨论了若干关键不确定性,包括健康接种者偏倚、缺乏衰弱分层,以及机制证据与临床证据之间的年龄不一致。
KRASG12D-selective and pan-RAS inhibitors have shown promise in pancreatic ductal adenocarcinoma (PDAC), yet adaptive resistance is anticipated to limit durability of response. Exportin 1 (XPO1), a nuclear export protein frequently overexpressed in PDAC, represents a potential vulnerability in KRAS-mutant cancers. We evaluated whether pharmacologic inhibition of XPO1 enhances therapeutic efficacy and durability of KRAS pathway inhibition. KRASG12D inhibitor- and pan-RAS inhibitor-resistant PDAC cellular models were generated and assessed for sensitivity to the second-generation XPO1 inhibitor Eltanexor. Antiproliferative synergistic effects of Eltanexor combined with MRTX1133, Zoldonrasib (RMC9805), or Daraxonrasib (RMC6236) were evaluated in PDAC 2D cultures, 3D spheroids, patient-derived organoids, and tumor-fibroblast co-culture models. Eltanexor sensitized KRAS inhibitor-resistant PDAC cells and synergistically enhanced growth suppression across multiple KRASG12D-mutant models. Combination treatment reduced clonogenic survival, disrupted 3D spheroid integrity, and significantly inhibited viability of patient-derived organoids. The in vivo efficacy of the combination was tested in PDAC cell-derived xenograft/allograft and patient-derived xenograft models. Combining sub-therapeutic doses of Eltanexor with allele-specific inhibitors or pan-RASi resulted in significant tumor regression, prevention of metastatic spread and prolonged survival in vivo. Notably, Eltanexor maintenance therapy suppressed tumor regrowth following RAS inhibitor withdrawal and preserved responsiveness upon re-challenge. Mechanistically, molecular and phosphokinome profiling showed that the combination broadened suppression of MAPK- and mTOR-associated signaling and reduced activity of multiple oncogenic kinases. In conclusion, XPO1 inhibitor Eltanexor enhances the efficacy and durability of KRAS and pan-RAS inhibition in PDAC models. These findings provide a preclinical rationale for clinically evaluating Eltanexor in combination with RAS-targeted therapies to delay or overcome adaptive resistance in KRAS-mutant PDAC.
中文摘要:KRASG12D选择性抑制剂和泛RAS抑制剂在胰腺导管腺癌(PDAC)中已显示出应用前景,但适应性耐药预计会限制缓解的持久性。核输出蛋白1(XPO1)是一种在PDAC中常过表达的核输出蛋白,是KRAS突变肿瘤的潜在易感靶点。本研究评估了药物抑制XPO1能否增强KRAS通路抑制的疗效与持久性。构建KRASG12D抑制剂和泛RAS抑制剂耐药的PDAC细胞模型,并检测其对第二代XPO1抑制剂Eltanexor的敏感性。在PDAC二维培养、三维球体、患者来源类器官及肿瘤-成纤维细胞共培养模型中,评价Eltanexor与MRTX1133、Zoldonrasib(RMC9805)或Daraxonrasib(RMC6236)联用的抗增殖协同效应。Eltanexor使KRAS抑制剂耐药的PDAC细胞恢复敏感,并在多种KRASG12D突变模型中协同增强生长抑制。联合处理降低克隆形成存活、破坏三维球体完整性,并显著抑制患者来源类器官的活力。在PDAC细胞来源异种移植/同种移植及患者来源异种移植模型中检验联合方案的体内疗效。将亚治疗剂量的Eltanexor与等位基因特异性抑制剂或泛RAS抑制剂联用,可在体内引起显著肿瘤消退、阻止转移扩散并延长生存。Eltanexor维持治疗可抑制RAS抑制剂撤除后的肿瘤再生长,并在再次给药时保留治疗反应性。机制上,分子与磷酸化蛋白质组谱分析显示,联合方案扩大了对MAPK和mTOR相关信号的抑制,并降低多种致癌激酶的活性。XPO1抑制剂Eltanexor可增强KRAS及泛RAS抑制在PDAC模型中的疗效与持久性。这些结果为难治性KRAS突变PDAC中联合RAS靶向治疗以延缓或克服适应性耐药的临床评价提供了临床前依据。
Whole Slide Image (WSI) analysis, with its ability to reveal detailed tissue structures in magnified views, plays a crucial role in cancer diagnosis and prognosis. Due to their giga-sized nature, WSIs require substantial storage and computational resources for processing and training predictive models. With the rapid increase in WSIs used in clinics and hospitals, there is a growing need for a continual learning system that can efficiently process and adapt existing models to new tasks without retraining or fine-tuning on previous tasks. Such a system must balance resource efficiency with high performance. In this study, we introduce COSFormer, a Transformer-based continual learning framework tailored for multi-task WSI analysis. COSFormer is designed to learn sequentially from new tasks wile avoiding the need to revisit full historical datasets. We evaluate COSFormer on a sequence of seven WSI datasets covering seven organs and six WSI-related tasks under both class-incremental and task-incremental settings. The results demonstrate COSFormer's superior generalizability and effectiveness compared to existing continual learning frameworks, establishing it as a robust solution for continual WSI analysis in clinical applications. The code is released at https://github.com/QuIIL/COSFormer.
中文摘要:全切片图像(WSI)分析能够在放大视野中揭示精细的组织结构,在肿瘤诊断与预后中具有重要作用。WSI 体积可达十亿像素级,处理和训练预测模型需要大量存储与计算资源。随着临床和医院中使用的 WSI 快速增加,需要一种持续学习系统,能够高效处理新任务并让现有模型适应新任务,同时无需在先前任务上重新训练或微调。此类系统必须在资源效率与高性能之间取得平衡。本研究提出 COSFormer,一种面向多任务 WSI 分析的 Transformer 持续学习框架。COSFormer 设计为从新任务中顺序学习,同时避免重新访问完整历史数据集。我们在覆盖七个器官、六类 WSI 相关任务的七个 WSI 数据集序列上,在类别增量和任务增量设置下评估 COSFormer。结果显示,与现有持续学习框架相比,COSFormer 具有更优的泛化性和有效性,可作为临床应用中进行持续 WSI 分析的稳健方案。代码发布于 https://github.com/QuIIL/COSFormer。
Neuroblastoma (NB) is the most prevalent pediatric solid tumor associated with a poor prognosis. While alternative polyadenylation (APA) is a key post-transcriptional regulatory mechanism in many cancers, its role in NB remains largely unexplored. We used public expression profiles from NB and normal samples, along with single-cell transcriptomic data from our MYCN-transgenic mouse models, to screen NB-upregulated APA-related genes. Knockdown method was used to examine the function of NUDT21 in NB cells and in nude mice. RNA-seq and polyadenylation signal (PAS)-seq were performed to identify differentially expressed genes with APA events. Cleavage under targets and tagmentation (CUT&Tag) was used to analyze the transcriptional activation of downstream genes. NUDT21 was found substantially upregulated in NB, driven by NB master transcription factors (TFs) like MYCN. NUDT21 knockdown inhibited NB cell proliferation, induced cycle arrest and apoptosis in vitro, and suppressed xenograft growth in nude mice. Mechanistically, NUDT21 silencing triggered global APA remodeling, with approximately 85% of APA genes shifting to proximal poly(A) sites. Integrative PAS-seq and RNA-seq analyses revealed that NUDT21 regulated E2F target genes (eg, MKI67) via APA, promoting longer 3' untranslated region (3' UTR) isoforms to enhance mRNA stability and translation. The CUT&Tag analysis further indicated direct transcriptional regulation on E2F target genes by NUDT21 through promoter binding. This convergence of APA-mediated post-transcriptional regulation and transcriptional activation on the E2F network established a sophisticated oncogenic paradigm. Our study identified NUDT21 as a critical driver of NB progression through both transcriptional and post-transcriptional mechanisms, laying the foundation for NUDT21-targeted NB therapies.
中文摘要:神经母细胞瘤(NB)是儿童最常见的实体肿瘤,预后较差。可变多聚腺苷酸化(APA)是多种癌症中的关键转录后调控机制,其在NB中的作用仍不明确。我们利用NB和正常样本的公共表达谱,以及来自MYCN转基因小鼠模型的单细胞转录组数据,筛选NB中上调的APA相关基因。采用敲低方法在NB细胞和裸鼠中检测NUDT21的功能。进行RNA-seq和polyadenylation signal(PAS)-seq以鉴定具有APA事件的差异表达基因。使用CUT&Tag分析下游基因的转录激活。发现NUDT21在NB中显著上调,由MYCN等NB主要转录因子驱动。NUDT21敲低在体外抑制NB细胞增殖,诱导周期阻滞和凋亡,并抑制裸鼠异种移植瘤生长。机制上,NUDT21沉默引发全局APA重塑,约85%的APA基因转向近端poly(A)位点。整合PAS-seq和RNA-seq分析显示,NUDT21通过APA调控E2F靶基因(如MKI67),促进较长3' UTR异构体以增强mRNA稳定性和翻译。CUT&Tag分析进一步表明NUDT21通过启动子结合直接转录调控E2F靶基因。APA介导的转录后调控与转录激活在E2F网络上的汇聚建立了复杂的致癌范式。该研究确定NUDT21通过转录和转录后机制成为NB进展的关键驱动因子,为靶向NUDT21的NB治疗奠定基础。
Beyond somatic initiation, cancer progression is governed by a multidimensional systemic metabolic architecture. This permissive macroenvironment, shaped by systemic nutrient fluxes, endocrine networks, and microbial co-metabolites, sustains tumor bioenergetics and immune evasion. Bridging the current translational gap requires decoding the spatiotemporal reciprocity between diet-induced metabolic shifts, tumor microenvironment plasticity, and genotoxic therapy responses. In this review, we deconstruct the host-tumor metabolic interface through a systems biology framework, tracing the biotransformation of macro-dietary inputs into subcellular oncogenic and immunological signals. We move beyond traditional nutritional epidemiology to define a precision nutritional oncology paradigm that leverages high-resolution multi-omic biomarkers to track real-time systemic flux, the spatial ecosystem of the microbiome as a localized metabolic bioreactor, and context-dependent metabolic regulation to exploit transient tumor vulnerabilities. We emphasize the need for precise spatiotemporal calibration, particularly during acute refeeding windows, to prevent paradoxical therapy resistance or accelerated cachexia. Finally, we envision a future in which precision nutrition is seamlessly integrated into oncologic care, powered by artificial intelligence and digital gut twins for in silico modeling. By incorporating the broader chemical exposome and addressing structural socioeconomic determinants through frameworks such as the Planetary Health Diet, we outline a roadmap toward global health equity and enhanced metabolic resilience in cancer survivorship.
中文摘要:除体细胞起始之外,癌症进展还受多维系统性代谢架构调控。这种允许性宏观环境由系统性营养通量、内分泌网络和微生物共代谢物塑造,维持肿瘤生物能量学与免疫逃逸。弥合当前转化差距,需要解析饮食诱导的代谢变化、肿瘤微环境可塑性与基因毒性治疗反应之间的时空互惠关系。本综述以系统生物学框架解构宿主-肿瘤代谢界面,追踪膳食宏量输入向亚细胞致癌信号与免疫信号的生物转化。研究超越传统营养流行病学,定义精准营养肿瘤学范式:利用高分辨率多组学生物标志物追踪实时系统性通量,将微生物组的空间生态系统视为局部代谢生物反应器,并依据情境依赖性代谢调控利用肿瘤的短暂脆弱性。需要精确的时空校准,尤其在急性再喂养窗口,以防止矛盾性治疗耐药或加速性恶病质。未来,精准营养可无缝整合到肿瘤诊疗中,由人工智能和数字肠道孪生驱动计算机模拟。通过纳入更广泛的化学暴露组,并借助行星健康饮食等框架应对结构性社会经济决定因素,可勾勒通往全球健康公平并增强癌症幸存者代谢韧性的路线图。
Single-mode biosensor is prone to external interference, and detection of a single biomarker is insufficient for accurate diagnosis of liver cancer. Herein, we report a 7-(Diethylamino)coumarin-3-carboxylic acid (7DCCA) functionalized aptamers induced photoelectrochemical(PEC)/fluorescence(FL) dual-mode aptasensor integrated into a three-channel microfluidic chip for multiplexed detection of three liver cancer biomarkers: alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and Golgi protein 73 (GP73). A robust PEC sensing platform was established using I/S co-doped oxygen-vacancy bismuth oxybromide (ISBO-OVs) modified with gold nanoparticles (Au NPs), with 7DCCA-labeled aptamers (7DCCA-Apt) serving as the unified recognition probes. In the presence of target analytes, 7DCCA-Apts bind to their corresponding targets, dissociating from the complementary strand and releasing into the electrolyte to activate the FL signal; simultaneously, this dissociation reduces the insulating layer thickness and restores the photocurrent response. Furthermore, superoxide anions (•O2-) are generated through the dissolution of oxygen by photogenerated electrons, which reacts with luminol to produce chemiluminescence that as an internal light source to further amplify the PEC signal. The integrated microfluidic aptasensor exhibits a wide linear range (1.0 × 102 fg/mL - 1.0 × 102 ng/mL), low detection limits (31 - 37 fg/mL across the three biomarkers), excellent specificity, stability, and reproducibility for both modes. This strategy enables integrated detection of liver cancer biomarkers, holding great promise for early clinical point-of-care screening.
中文摘要:单模式生物传感器易受外部干扰,检测单一生物标志物不足以准确诊断肝癌。报道一种7-(二乙氨基)香豆素-3-羧酸(7DCCA)功能化适配体诱导的光电化学(PEC)/荧光(FL)双模式适配体传感器,集成于三通道微流控芯片,用于多重检测三种肝癌生物标志物:甲胎蛋白(AFP)、癌胚抗原(CEA)和高尔基体蛋白73(GP73)。采用金纳米颗粒(Au NPs)修饰的碘/硫共掺杂氧空位溴氧化铋(ISBO-OVs)建立稳健的PEC传感平台,以7DCCA标记适配体(7DCCA-Apt)作为统一识别探针。目标分析物存在时,7DCCA-Apt与相应靶标结合,从互补链解离并释放到电解液中以激活FL信号;同时,该解离降低绝缘层厚度并恢复光电流响应。光生电子作用于溶解氧生成超氧阴离子(•O2-),其与鲁米诺反应产生化学发光,作为内部光源进一步放大PEC信号。该集成微流控适配体传感器在两种模式下均表现出宽线性范围(1.0×10^2 fg/mL至1.0×10^2 ng/mL)、低检测限(三种生物标志物为31–37 fg/mL)、良好特异性、稳定性和重现性。该策略实现肝癌生物标志物的集成检测,有望用于早期临床即时筛查。
Early detection and treatment of prostate cancer are essential for improving outcomes. Blood tests measuring prostate-specific antigen (PSA) are commonly used to assess cancer risk. However, PSA levels can be affected by non-cancer conditions, leading to possible misdiagnosis and stress for patients. To improve accuracy, a new detection system using gold electrodes modified with zinc protoporphyrin (Au/ZnPP) was developed. This system detects proteins in blood by using the interaction between zinc ions and protein groups, combined with differential pulse voltammetry. Three electrochemical sensors were made to detect PSA, free PSA (fPSA), and C-reactive protein (CRP). These sensors worked well in diluted human blood, detecting PSA from 0.01 to 50 ng/mL, fPSA from 5x10-3-50 ng/mL, and CRP from 5x10-3-500 μg/mL. The sensitivities of the PSA, fPSA and CRP sensors were 383.4 μA/log(ng/mL)-cm2, 406.2 μA/log(ng/mL)-cm2, and 252.7 μA/log(μg/mL)-cm2, respectively. All three markers can be measured within 3 min using this method. Furthermore, the clinical applicability of the proposed biosensor was validated using serum samples from 14 human subjects, including patients with benign prostatic hyperplasia (BPH) and stage I prostate cancer (PCa). The quantification results showed strong agreement with those obtained from conventional enzyme-linked immunosorbent assay (ELISA), confirming the accuracy and reliability of the proposed method in complex biological samples. This platform shows strong potential for early prostate cancer screening and post-surgery monitoring.
中文摘要:前列腺癌的早期发现和治疗对改善结局至关重要。检测前列腺特异性抗原(PSA)的血液检查常用于评估癌症风险。然而,PSA水平可受非癌性情况影响,可能导致误诊并给患者带来心理压力。为提高准确性,开发了一种使用锌原卟啉修饰金电极(Au/ZnPP)的新检测系统。该系统利用锌离子与蛋白基团之间的相互作用,结合差分脉冲伏安法检测血液中的蛋白。制备了三种电化学传感器,分别检测PSA、游离PSA(fPSA)和C反应蛋白(CRP)。这些传感器在稀释人血中表现良好,可检测0.01至50 ng/mL的PSA、5×10^-3至50 ng/mL的fPSA以及5×10^-3至500 μg/mL的CRP。PSA、fPSA和CRP传感器的灵敏度分别为383.4 μA/log(ng/mL)-cm²、406.2 μA/log(ng/mL)-cm²和252.7 μA/log(μg/mL)-cm²。该方法可在3分钟内测定所有三种标志物。使用14名受试者的血清样本验证了所提出生物传感器的临床适用性,受试者包括良性前列腺增生(BPH)和I期前列腺癌(PCa)患者。定量结果与常规酶联免疫吸附测定(ELISA)所得结果高度一致,证实了该方法在复杂生物样本中的准确性和可靠性。该平台在前列腺癌早期筛查和术后监测方面显示出较大潜力。
Long-term liver injury leads to acute hepatitis and chronic liver diseases, including fibrosis and hepatocellular carcinoma (HCC), which frequently necessitate liver transplantation and are associated with poor median survival. Transforming growth factor-β (TGF-β) signalling pathway is a key driver of fibrogenesis and tumor progression. Therapeutic approaches targeting this pathway-via TGF-β receptor blockade or inhibition of its chaperone protein Hsp90- are under pre-clinical and clinical trials, and despite some promising results none of them has been adopted as a definitive therapy. Engineered protein scaffolds have emerged as an attractive alternative owing to their high engineerability and ease of production. In particular, consensus tetratricopeptide repeat (CTPR) proteins are strong candidates because of their modularity, robustness, design flexibility, and amenability to functionalization. Here, we investigate the protein-nanocluster hybrid formulation comprising C390 and nanocluster-stabilizing domain (C390-AuNC) as a Hsp90 inhibitory platform to assess its potential dual anti-fibrotic and anti-tumor activity in two chemically-induced murine liver disease models: acute liver fibrosis and chronic HCC. In the fibrosis model, C390-AuNC markedly suppress the expression of profibrotic markers and promote degradation of collagen fibers in the liver, indicating effective attenuation of fibrogenesis. In the HCC model, C390-AuNC inhibit Hsp90, leading to reduced expression of oncogenic proteins that drive cancer cell proliferation and metastasis, and consequently diminish tumor burden. Collectively, these findings support C390-AuNC as a promising next-generation biotherapeutic platform with low anticipated immunogenicity and high therapeutic potential.
中文摘要:长期肝损伤会引发急性肝炎和慢性肝病,包括肝纤维化与肝细胞癌(HCC),这类疾病常需肝移植,中位生存期较差。转化生长因子-β(TGF-β)信号通路是纤维化生成和肿瘤进展的关键驱动因素。针对该通路的治疗策略,如阻断TGF-β受体或抑制其伴侣蛋白Hsp90,正处于临床前和临床研究阶段,尽管取得了一些有希望的结果,尚无一种成为确定性疗法。工程化蛋白支架因可设计性高、易于生产而成为有吸引力的替代方案。其中,共识四三肽重复(CTPR)蛋白因模块化、稳健性、设计灵活性和易于功能化而成为有力候选。本研究考察由C390与纳米簇稳定结构域组成的蛋白-纳米簇杂合制剂C390-AuNC作为Hsp90抑制平台,在两种化学诱导的小鼠肝病模型中评估其双重抗纤维化和抗肿瘤潜力:急性肝纤维化模型和慢性HCC模型。在纤维化模型中,C390-AuNC显著抑制促纤维化标志物表达,促进肝内胶原纤维降解,表明有效减轻纤维化生成。在HCC模型中,C390-AuNC抑制Hsp90,降低驱动癌细胞增殖和转移的致癌蛋白表达,进而减小肿瘤负荷。这些结果共同支持C390-AuNC作为一种有前景的下一代生物治疗平台,预期免疫原性低且治疗潜力高。
Genetic inactivation of PTEN is a frequent oncogenic event in prostate cancer (PCa) that disrupts cellular homeostasis and correlates with aggressive disease and poorer prognosis. Here, we show that PELO expression is elevated in patient-derived PTEN-low prostate tumors, with a positive correlation to high Gleason scores, indicating a coordinated role of PELO and PTEN loss in driving PCa progression. Using a Ptenpc-/- mouse model, we establish PELO as a critical cell-intrinsic driver of prostate tumorigenesis in the setting of PTEN deficiency: genetic deletion of Pelo abrogates fluid accumulation in the anterior prostate (AP), a hallmark of early tumor progression, and enhances the sensitivity of Pten-null prostate tumors to docetaxel treatment. Mechanistically, we uncover that PELO deficiency selectively dampens inflammatory responses in Ptenpc-/- mouse prostates by disrupting the JAK1/STAT1 signaling pathway, a key mediator of inflammation-driven tumorigenesis. Further molecular dissection reveals that PELO stabilizes the interaction between JAK1 and PIK3R3, thereby promoting JAK1 phosphorylation and subsequent activation of downstream inflammatory gene transcription, linking PELO to the core signaling networks perturbed by PTEN loss. Through small-molecule drug screening, we identify TN1 as a potential therapeutic agent that modulates PELO‑dependent functions to inhibit the progression of Pten-null PCa both in vitro and in vivo. Collectively, our findings elucidate a previously unrecognized PELO-dependent regulatory axis that connects PTEN loss to JAK1/STAT1-mediated inflammation and prostate tumor progression, providing new insights into the cellular and molecular mechanisms underlying PTEN-deficient PCa and highlighting PELO as a promising therapeutic target in this clinically relevant subgroup of tumors.
中文摘要:PTEN基因失活是前列腺癌中常见的致癌事件,会破坏细胞稳态,并与侵袭性疾病和较差预后相关。患者来源的PTEN低表达前列腺肿瘤中PELO表达升高,且与高格里森评分呈正相关,提示PELO与PTEN缺失在前列腺癌进展中具有协同作用。利用Ptenpc-/-小鼠模型,研究确认PELO是PTEN缺陷背景下前列腺肿瘤发生的关键细胞内在驱动因子:敲除Pelo可消除前叶前列腺积液这一早期肿瘤进展标志,并提高Pten缺失前列腺肿瘤对多西他赛治疗的敏感性。机制上,PELO缺失通过破坏JAK1/STAT1信号通路,选择性抑制Ptenpc-/-小鼠前列腺中的炎症反应,而该通路是炎症驱动肿瘤发生的关键介质。进一步分子解析显示,PELO稳定JAK1与PIK3R3之间的相互作用,促进JAK1磷酸化及下游炎症基因转录激活,从而将PELO与PTEN缺失所扰动的核心信号网络联系起来。通过小分子药物筛选,研究鉴定出TN1是一种潜在治疗药物,可调节PELO依赖的功能,并在体外和体内抑制Pten缺失前列腺癌的进展。这些发现阐明了一条此前未被认识的PELO依赖调控轴,将PTEN缺失与JAK1/STAT1介导的炎症及前列腺肿瘤进展连接起来,为理解PTEN缺陷型前列腺癌的细胞和分子机制提供了新认识,并提示PELO是该临床相关肿瘤亚群中有前景的治疗靶点。
Chronic psychological stress significantly exacerbates tumor initiation, progression, and metastasis through neuroendocrine dysregulation and tumor-associated immunosuppression. Beyond direct neural pathways, stress is increasingly recognized as a driver of gut microbiota dysbiosis, which triggers systemic or local metabolic reprogramming, and fosters a suppressive tumor immune microenvironment. Understanding the complex interplay between chronic stress and oncogenic process offers critical insights into the underlying mechanisms of cancer biology. The microbiota-gut-brain axis (MGBA), as the primary pathway connecting stress to tumorigenesis, represents a pivotal perspective for deciphering this link. Here, we introduce "gut-brain coherence", defined as a dynamic, synchronized homeostasis among the gut microbial ecosystem, neuroendocrine tone, and immune effector function. Based on this concept, we present a dual-direction framework including microbial interventions, behavioral modulation, and targeted pharmacological strategies to re-establish integrated functional equilibrium, offering a unified roadmap to improve survival and quality of life in stress-driven malignancies.
中文摘要:慢性心理应激通过神经内分泌失调和肿瘤相关免疫抑制,显著加剧肿瘤发生、进展和转移。除直接神经通路外,应激日益被视为肠道菌群失调的驱动因素,后者引发全身或局部代谢重编程,并促成抑制性肿瘤免疫微环境。理解慢性应激与致癌过程之间复杂的相互作用,可为癌症生物学潜在机制提供关键认识。微生物群-肠-脑轴(MGBA)作为连接应激与肿瘤发生的主要通路,为解析这一联系提供了关键视角。在此,我们提出「肠-脑一致性」,将其定义为肠道微生物生态系统、神经内分泌状态与免疫效应功能之间动态、同步的稳态。基于这一概念,我们提出一个双向框架,包含微生物干预、行为调节和靶向药理策略,以重建整合性功能平衡,为改善应激驱动恶性肿瘤患者的生存和生活质量提供统一路线图。
Chemotherapy-induced central neurotoxicity (CICN), commonly known as "chemo-brain", is a prevalent and debilitating condition in cancer survivors, characterized by persistent cognitive deficits that severely compromise quality of life. Despite extensive research, the pathophysiology of CICN remains fragmented, lacking a unifying model that explains how it progresses from peripheral insult to chronic cognitive consolidation. This review proposes a novel Three-Hit sequential model to reconceptualize CICN as a dynamic, staged pathological continuum. Unlike existing multi-hit hypotheses that largely describe cumulative or concurrent CNS risk factors, the Three-Hit model features a therapy-triggered, outside-in cascade with defined temporal checkpoints. The model aims to unify disparate mechanistic findings, explain the enduring nature of cognitive deficits after treatment cessation, and guide stage-specific, mechanism-based precision interventions. The model delineates three sequential pathological phases. The First Hit (peripheral priming) involves chemotherapy-induced gut dysbiosis and systemic inflammation. The Second Hit (central amplification) entails blood-brain barrier disruption, microglial activation, and oxidative stress-driven synaptic dysfunction. The Third Hit (network consolidation) is defined by epigenetic reprogramming, cellular senescence, and white matter degradation, which collectively solidify chronic cognitive impairment. This staged model may facilitate the design of phase-targeted interventions, including microbiota modulation (First Hit), anti-inflammatory and BBB-stabilizing agents (Second Hit), and senotherapeutics or HDAC6 inhibitors (Third Hit), and may guide neuroprotective strategies toward better-timed application. By linking mechanistic insights to a staged biomarker ecosystem, this review offers a conceptual roadmap for advancing stage-specific therapies for CICN.
中文摘要:化疗所致中枢神经毒性(CICN)常被称为「化疗脑」,在癌症幸存者中常见且造成明显负担,表现为持续性认知缺陷,严重影响生活质量。尽管已有大量研究,CICN的病理生理机制仍呈碎片化,缺少统一模型解释其如何从外周损伤进展为慢性认知固化。该综述提出一种新的三击序贯模型,将CICN重新概念化为动态、分阶段的病理连续过程。现有多次打击假说多描述累积或并行的中枢神经系统危险因素,三击模型则强调由治疗触发、由外向内的级联过程,并具有明确的时间检查点。该模型旨在统一分散的机制发现,解释治疗停止后认知缺陷持续存在的原因,并指导分期、基于机制的精准干预。模型划分三个序贯病理阶段。第一击(外周启动)涉及化疗诱导的肠道菌群失调和全身炎症。第二击(中枢放大)包括血脑屏障破坏、小胶质细胞激活以及氧化应激驱动的突触功能障碍。第三击(网络固化)由表观遗传重编程、细胞衰老和白质降解界定,这些过程共同巩固慢性认知损害。该分期模型可能有助于设计针对不同阶段的干预措施,包括菌群调节(第一击)、抗炎和稳定血脑屏障的药物(第二击)、衰老治疗药物或HDAC6抑制剂(第三击),并可能引导神经保护策略在更合适的时间窗应用。通过将机制认识与分期生物标志物体系相连,该综述为推进CICN的分期特异性治疗提供了概念路线图。
Complement activation-related pseudoallergy (CARPA) describes a proposed non-IgE-mediated hypersensitivity mechanism in which complement activation contributes causally, often through generation of the anaphylatoxins C3a and C5a. These mediators may activate responsive effector cells and contribute to systemic inflammatory responses that clinically resemble anaphylaxis. Complement activation and complement-associated immediate reactions have been reported with several therapeutic agents and drug-delivery systems, including micelle-solubilized formulations, liposomal drugs, nanoparticle-based therapeutics, PEGylated agents, and biologic therapies; however, the strength of causal evidence varies among products. Importantly, reactions may be driven not only by the active pharmaceutical ingredient but also by formulation components, such as surfactants, solubilizing agents, lipid carriers, and other drug vehicles. As compounded injectable therapies, including intralesional dutasteride, become increasingly used in dermatology, clinicians should recognize that formulation vehicles vary among manufacturers and compounding pharmacies. Certain formulations may contain complement-activating excipients, such as Cremophor EL (polyoxyethylated castor oil), which has been implicated in immediate pseudoallergic reactions. Although CARPA has been widely discussed in oncology, immunology, and nanomedicine, its relevance to a broader range of infusion and injectable therapies remains underrecognized. This narrative review summarizes the mechanisms, clinical features, drug classes, and formulation-related risk factors associated with complement activation and complement-associated reactions, with particular attention to injectables and compounded therapies. Greater awareness of complement-activating formulations may help recognize pseudoallergic reactions, evaluate excipients more carefully, and improve the safe administration of infusion and injectable therapies.
中文摘要:补体激活相关假性过敏(CARPA)指一种拟议的非IgE介导的超敏反应机制,其中补体激活以因果方式参与,常通过生成过敏毒素C3a和C5a实现。这些介质可激活有反应的效应细胞,并促成临床类似过敏性休克的全身炎症反应。已有报道显示,多种治疗药物和药物递送系统可出现补体激活及补体相关速发反应,包括胶束增溶制剂、脂质体药物、纳米颗粒治疗剂、PEG化药物和生物制剂;不过,各产品因果证据的强度并不一致。反应不仅可能由活性药物成分驱动,也可能由制剂成分驱动,如表面活性剂、增溶剂、脂质载体和其他药物载体。随着包括病灶内度他雄胺在内的配制型注射疗法在皮肤科的使用增多,临床医生应认识到不同生产商和配制药房所用的制剂载体存在差异。某些制剂可能含有可激活补体的辅料,如Cremophor EL(聚氧乙烯化蓖麻油),该辅料被认为与速发型假性过敏反应有关。CARPA虽在肿瘤学、免疫学和纳米医学中已有广泛讨论,但其与更广泛输注及注射疗法的相关性仍未被充分认识。这篇叙述性综述总结与补体激活及补体相关反应有关的机制、临床特征、药物类别和制剂相关危险因素,尤其关注注射剂和配制疗法。提高对补体激活制剂的认知,可能有助于识别假性过敏反应、更仔细地评估辅料,并改善输注和注射疗法的安全给药。
Urban topsoils are persistent reservoirs of hazardous metal(loid)s, yet reassessments rarely integrate censoring-aware statistics, geochemical enrichment and updated exposure modelling. We reassessed 137 topsoils collected in 2001 and 94 in 2017 across Urban, Industrial and Garden land uses in Alcalá de Henares, Spain. Eleven elements were compared temporally using left-censored methods with false-discovery-rate correction; Hg was retained as a 2017 descriptive endpoint because of poor historical comparability and high censoring. Urban Pb declined by 43.3%, whereas Be, Cr, Mn, Tl and V showed FDR-robust shifts towards higher 2017 acid-recoverable concentrations; because the digestion workflows differed between campaigns, the magnitude of these increases cannot be attributed exclusively to environmental accumulation. Sn showed a significant distributional shift, while the apparent 16.4% Cd decline was not robust to conservative analytical-threshold sensitivity. Industrial soils likewise showed higher 2017 acid-recoverable concentrations of As, Cr, Mn, Tl, V and Zn. Integrated enrichment was lowest in Urban soils and highest at the four sampled Garden locations; because the 2017 Garden subset comprised only n = 4, these metrics are interpreted as site-specific screening indicators rather than municipality-wide Garden estimates. Using updated U.S. EPA toxicity parameters and the historical-comparability assumption Cr(VI) = total Cr/6, 2017 hazard indices were 1.214 for Urban children, 0.156 for Urban adults, 0.0997 for Industrial workers, 2.173 for children at the sampled Garden locations and 0.278 for Garden adults. Cancer risks ranged from 4.13 × 10⁻⁵ to 2.16 × 10⁻⁴, with As dominating both non-cancer and cancer risk. From 2001-2017, Urban-child HI increased from 0.949 to 1.214, crossing the screening benchmark of 1. Excluding inferred Cr(VI) did not change this or any other qualitative receptor-level interpretation. Alcalá topsoils therefore show divergent contaminant trajectories, with declining legacy Urban Pb coexisting with higher 2017 acid-recoverable multi-element signatures and persistent child-exposure screening priorities.
中文摘要:城市表土是有害金属及类金属的持久储库,但再评估很少整合顾及未检出值截尾的统计方法、地球化学富集和更新后的暴露模型。我们重新评估了西班牙阿尔卡拉德埃纳雷斯城市、工业和园地三类土地利用下2001年采集的137个表土和2017年采集的94个表土。采用左截尾方法并作错误发现率校正,对11种元素进行时间比较;由于历史可比性差且截尾比例高,Hg仅作为2017年的描述性终点保留。城市土壤Pb下降43.3%,而Be、Cr、Mn、Tl和V表现出经FDR校正后稳健的向2017年更高酸可提取浓度偏移;由于两次调查的消解流程不同,这些升高的幅度不能完全归因于环境累积。Sn呈现显著的分布变化,而表观16.4%的Cd下降对保守的分析阈值敏感性并不稳健。工业土壤同样显示2017年As、Cr、Mn、Tl、V和Zn的酸可提取浓度更高。综合富集程度在城市土壤最低,在四个采样的园地位置最高;由于2017年园地子集仅含n=4,这些指标被解释为特定点位的筛查指标,而非全市园地估计。采用更新的美国EPA毒性参数以及历史可比性假设Cr(VI)=总Cr/6,2017年危害指数为:城市儿童1.214、城市成人0.156、工业工人0.0997、采样园地位置儿童2.173、园地成人0.278。致癌风险范围为4.13×10⁻⁵至2.16×10⁻⁴,As在非致癌风险和致癌风险中均占主导。2001—2017年,城市儿童HI由0.949升至1.214,越过筛查基准值1。排除推断的Cr(VI)未改变这一结果,也未改变其他任何受体层面的定性解释。因此,阿尔卡拉表土呈现分化的污染物轨迹:城市遗留Pb下降与2017年更高的酸可提取多元素特征并存,儿童暴露筛查仍是优先事项。
The assembly of cellular spheroids into spatially organized assembloids represents a transformative paradigm for modeling complex biological systems. However, the lack of standardized fabrication strategies fundamentally limits the precision and reproducibility of these models, hindering their widespread application. Here, we present a robotic micromanipulation platform-Fluid-Driven Tweezer with Visual Servo Control (FDT-VSC). By integrating multidimensional visual perception with microfluidic control, our system enables the gentle and programmable assembly of diverse cellular spheroids. Leveraging this platform, we achieve the bottom-up construction of structurally defined, heterogeneous multicellular tissues, and the programmed orchestration of multilineage models that recapitulate the complex microenvironments of early organogenesis. Crucially, the system improves consistency during the scalable fabrication of tumor-stroma assembloids, supporting reliable drug screening. These results demonstrate that FDT-VSC advances assembloid-based applications across modular tissue engineering, developmental biology, and drug discovery.
中文摘要:将细胞球体组装为空间有序的组装体,为模拟复杂生物系统提供了变革性范式。然而,缺乏标准化制备策略从根本上限制了这类模型的精度与可重复性,阻碍了其广泛应用。我们提出一种机器人微操作平台——流体驱动镊子与视觉伺服控制(FDT-VSC)。该系统将多维视觉感知与微流控相结合,可温和、可编程地组装多种细胞球体。借助该平台,我们自下而上构建了结构明确的异质多细胞组织,并程序化编排了多谱系模型,以重现早期器官发生的复杂微环境。该系统在肿瘤—基质组装体的规模化制备中提高了批次一致性,支持可靠的药物筛选。这些结果表明,FDT-VSC 可推动基于组装体的应用,覆盖模块化组织工程、发育生物学和药物发现。
Doxorubicin-induced cardiotoxicity remains a critical challenge in cancer chemotherapy, as current strategies rarely balance antitumor efficacy with prevention of systemic side effects. Herein, we develop a chiral amino acid-engineered ruthenium-based nanozyme platform for gut-heart axis-mediated cardioprotection. Systematic screening of 20 amino acids identifies L-Met as the optimal ligand, yielding L-AEN with superior superoxide dismutase- and catalase-like cascade activities and efficient scavenging of ROS and RNS. Chirality engineering further endows L-AEN with markedly enhanced antioxidant performance compared with its D- and DL-counterparts, while maintaining excellent biocompatibility. After enteric encapsulation to form L-AENC, oral administration enables intestinal-targeted release and improves in vivo bioavailability. In a doxorubicin-induced chronic cardiac injury model, L-AENC significantly improves cardiac function, reduces myocardial damage, and suppresses systemic oxidative stress without affecting the antitumor efficacy of doxorubicin. Mechanistically, L-AENC restores gut microbiota homeostasis by enriching beneficial taxa, particularly Muribaculaceae, and reshapes host metabolic profiles, notably involving tryptophan, glutathione, and butyrate metabolism, thereby strengthening gut microbiota-metabolite interactions. Collectively, this work demonstrates that a chirality-engineered nanozyme platform coordinates gut microbiota and host metabolism to protect against chemotherapy-induced cardiotoxicity via the gut-heart axis, highlighting stereochemical engineering as an effective strategy for nanozyme-based therapeutic design.
中文摘要:多柔比星诱导的心脏毒性仍是癌症化疗中的关键难题,现有策略很少能兼顾抗肿瘤疗效与全身副作用的预防。为此,我们构建了一种手性氨基酸工程化的钌基纳米酶平台,用于经肠-心轴实现心脏保护。系统筛选20种氨基酸后发现L-甲硫氨酸为最优配体,所得L-AEN具有更强的超氧化物歧化酶和过氧化氢酶级联活性,并能高效清除ROS和RNS。手性工程使L-AEN的抗氧化性能较D型和DL型对应物明显增强,同时保持良好生物相容性。经肠溶包覆形成L-AENC后,口服可实现肠道靶向释放并提高体内生物利用度。在多柔比星诱导的慢性心脏损伤模型中,L-AENC显著改善心功能、减轻心肌损伤并抑制全身氧化应激,且不影响多柔比星的抗肿瘤疗效。机制上,L-AENC通过富集有益菌群(尤其是Muribaculaceae)恢复肠道菌群稳态,并重塑宿主代谢谱,主要涉及色氨酸、谷胱甘肽和丁酸代谢,从而增强菌群-代谢物相互作用。该工作表明,手性工程化纳米酶平台可协调肠道菌群与宿主代谢,经肠-心轴对抗化疗诱导的心脏毒性,并提示立体化学工程是纳米酶治疗设计的有效策略。
6肺癌 (34篇)
临床研究 (12篇)
Bispecific antibodies targeting vascular endothelial growth factor (VEGF) and programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) pathways represent a promising therapeutic strategy for advanced non-small cell lung cancer (NSCLC). HB0025 is a novel bispecific antibody fusion targeting PD-L1 and VEGF. To evaluate the efficacy and safety of HB0025 plus chemotherapy in previously untreated advanced, driver variant-negative NSCLC. This open-label, multicenter, phase 2 nonrandomized clinical trial enrolled patients with stage IIIB/C or IV NSCLC without sensitizing EGFR, ALK, or ROS1 alterations across 13 hospitals in China. Participants included those with nonsquamous NSCLC and squamous NSCLC. Patients were enrolled from January 15, 2024, to May 21, 2025. Data cutoff was April 20, 2026. Patients received intravenous 10-mg/kg HB0025 every 3 weeks or 20-mg/kg HB0025 every 3 weeks plus chemotherapy: pemetrexed/carboplatin for nonsquamous and paclitaxel/carboplatin for squamous for up to 6 cycles, followed by HB0025 maintenance (with pemetrexed for nonsquamous) until disease progression or unacceptable toxic effects. The primary end points were safety and investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1. The secondary end points included disease control rate, duration of response, progression-free survival (PFS), and overall survival (OS). Treatment efficacy was evaluable in 169 enrolled patients. The nonsquamous cohort included 85 patients (median [IQR] age, 63.0 [58.0-68.0] years; 26 [30.6%] female and 59 [69.4%] male patients), and the squamous cohort included 84 patients (median [IQR] age, 65.0 [60.0-69.0] years; 6 [7.1%] female and 78 [92.9%] male patients). In the nonsquamous cohort, confirmed ORR was 36.4% (95% CI, 17.2%-59.3%) and 57.1% (95% CI, 44.1%-69.5%) in the 10-mg/kg and 20-mg/kg dose groups, respectively. In the squamous cohort, ORR reached 68.2% (95% CI, 45.1%-86.1%) and 74.2% (95%, 61.5%-84.5%) at the respective doses. Median PFS was 12.52 months (95% CI, 10.15-16.56) in the nonsquamous cohort and 14.78 months (95% CI, 11.30 to not estimable) in the squamous cohort. The 12-month PFS rates were 54.3% (95% CI, 41.6%-65.3%) and 62.1% (95% CI, 49.9%-72.1%) in the nonsquamous and squamous cohorts, and the 12-month OS rates were 75.8% (95% CI, 65.0%-83.7%) and 85.5% (95% CI, 75.8%-91.5%) , respectively. Grade 3 or higher treatment-related adverse events occurred in 56 of 85 patients (65.9%) in the nonsquamous cohort and 51 of 84 (60.7%) in the squamous cohort, mainly as hematologic toxic effects. Any-grade immune-related adverse events related to HB0025 occurred in 20 patients (23.5%) in the nonsquamous cohort and 21 patients (25%) in the squamous cohort. In this phase 2 nonrandomized clinical trial, HB0025 plus chemotherapy showed promising antitumor activity and manageable safety in patients with advanced, driver variant-negative NSCLC in both nonsquamous and squamous histologic types, supporting further evaluation in randomized phase 3 clinical trials. ClinicalTrials.gov Identifier: NCT06758557.
中文摘要:靶向血管内皮生长因子(VEGF)和程序性细胞死亡蛋白1(PD-1)/PD-1配体1(PD-L1)通路的双特异性抗体是晚期非小细胞肺癌(NSCLC)有前景的治疗策略。HB0025是一种新型靶向PD-L1和VEGF的双特异性抗体融合蛋白。评估HB0025联合化疗在既往未治疗、驱动基因变异阴性晚期NSCLC中的疗效与安全性。这项开放标签、多中心、2期非随机临床试验纳入中国13家医院的IIIB/C期或IV期、无致敏性EGFR、ALK或ROS1改变的NSCLC患者,包括非鳞状和鳞状NSCLC。患者入组时间为2024年1月15日至2025年5月21日,数据截止日期为2026年4月20日。患者接受每3周静脉10 mg/kg HB0025或每3周20 mg/kg HB0025联合化疗:非鳞状用培美曲塞/卡铂,鳞状用紫杉醇/卡铂,最多6个周期,随后HB0025维持治疗(非鳞状联合培美曲塞)直至疾病进展或不可接受毒性。主要终点为安全性和研究者按实体瘤疗效评价标准1.1版评估的客观缓解率(ORR)。次要终点包括疾病控制率、缓解持续时间、无进展生存期(PFS)和总生存期(OS)。169例入组患者可评估疗效。非鳞状队列85例(中位[IQR]年龄63.0[58.0-68.0]岁;女性26例[30.6%],男性59例[69.4%]),鳞状队列84例(中位[IQR]年龄65.0[60.0-69.0]岁;女性6例[7.1%],男性78例[92.9%])。非鳞状队列中,10 mg/kg和20 mg/kg剂量组确认ORR分别为36.4%(95% CI,17.2%-59.3%)和57.1%(95% CI,44.1%-69.5%)。鳞状队列中,相应剂量组ORR分别为68.2%(95% CI,45.1%-86.1%)和74.2%(95% CI,61.5%-84.5%)。非鳞状队列中位PFS为12.52个月(95% CI,10.15-16.56),鳞状队列为14.78个月(95% CI,11.30-不可估计)。非鳞状和鳞状队列12个月PFS率分别为54.3%(95% CI,41.6%-65.3%)和62.1%(95% CI,49.9%-72.1%),12个月OS率分别为75.8%(95% CI,65.0%-83.7%)和85.5%(95% CI,75.8%-91.5%)。非鳞状队列85例中56例(65.9%)、鳞状队列84例中51例(60.7%)发生3级及以上治疗相关不良事件,主要为血液学毒性。与HB0025相关的任何级别免疫相关不良事件在非鳞状队列20例(23.5%)、鳞状队列21例(25%)中发生。在这项2期非随机临床试验中,HB0025联合化疗在晚期、驱动基因变异阴性NSCLC的非鳞状和鳞状组织学类型中显示出有希望的抗肿瘤活性和可控的安全性,支持在随机3期临床试验中进一步评估。ClinicalTrials.gov注册号:NCT06758557。
Resectable non-small cell lung cancer (NSCLC) carries a high risk of postoperative recurrence, underscoring the need for effective perioperative therapies. This nonrandomized, noncomparative phase 2 trial evaluated neoadjuvant ivonescimab monotherapy (cohort 1) or in combination with chemotherapy (cohort 2), followed by surgery and adjuvant ivonescimab. In cohort 2, the major pathological response (MPR) rate was 70.1% (47/67; 95% confidence interval (CI) = 57.7-80.7); the lower bound of the 80% two-sided CI exceeded the historical control rate of 41% and the primary endpoint was met. The MPR rate in cohort 1 was 60.0% (6/10; 95% CI = 26.2-87.8). Among patients who achieved MPR, 83.3% (5/6) in cohort 1 and 97.9% (46/47) in cohort 2 had residual viable tumor (RVT) of ≤5%, respectively. Grade 3 or higher treatment-related adverse events (AEs) occurred in 36.4% (4/11) patients in cohort 1 and 30.4% (24/79) of those in cohort 2, with no grade 3 or higher hemorrhage or treatment-related death. Treatment-related surgery delay occurred in one (1.3%) patient. Surgery-related AEs related to ivonescimab occurred in 10.0% (1/10) and 10.4% (7/67) patients in the two cohorts, respectively, with no grade 3 or higher events reported. These data support perioperative ivonescimab with or without chemotherapy as a promising strategy for resectable NSCLC. ClinicalTrials.gov identifier: NCT05247684 .
中文摘要:可切除非小细胞肺癌(NSCLC)术后复发风险高,需要有效的围手术期治疗。这项非随机、非对照2期试验评估新辅助依沃西单抗单药(队列1)或联合化疗(队列2),随后手术及辅助依沃西单抗。队列2主要病理缓解(MPR)率为70.1%(47/67;95%置信区间(CI)=57.7-80.7);80%双侧CI下限超过历史对照率41%,达到主要终点。队列1 MPR率为60.0%(6/10;95% CI=26.2-87.8)。达到MPR的患者中,队列1有83.3%(5/6)、队列2有97.9%(46/47)残余存活肿瘤(RVT)≤5%。≥3级治疗相关不良事件(AE)在队列1为36.4%(4/11),队列2为30.4%(24/79);未见≥3级出血或治疗相关死亡。治疗相关手术延迟1例(1.3%)。与依沃西单抗相关的手术相关AE在两个队列分别为10.0%(1/10)和10.4%(7/67),无≥3级事件报告。这些数据支持围手术期依沃西单抗联合或不联合化疗作为可切除NSCLC有前景的策略。ClinicalTrials.gov注册号:NCT05247684。
Molecular evaluation is standard of care for patients with advanced non-small cell lung cancer (NSCLC) in the US. Patients in rural areas face disproportionate lung cancer mortality associated with reduced guideline-concordant evaluation and treatment receipt, but molecular testing patterns have not been described in this population. To characterize molecular testing patterns in the rural US following initial testing implementation. This cohort study used the Surveillance, Epidemiology, and End Results Program linked to Medicare claims data to identify individuals aged 66 years or older diagnosed with advanced NSCLC from January 2014 to December 2019. Data analysis was performed from December 2025 to August 2026. Sociodemographic variables, histology, and practitioner visits. The primary outcome was receipt of molecular testing. The cumulative incidence of testing overall and by patient subgroups defined at baseline were calculated using the total person-time at risk (30 days before diagnosis to death or 6 months after diagnosis) using a competing-risks framework, with death as the competing event. Among a total of 8259 Medicare beneficiaries residing in rural areas who were diagnosed with advanced NSCLC included in the study (mean [SD] age, 76.1 [6.7] years; 4672 males [56.6%]), 1775 (21.5%) were eligible for Medicaid, 3754 (45.5%) had adenocarcinoma histology, 2044 (24.7%) had squamous histology, and 2461 (29.8%) had other or unspecified histology. In the cohort, 2963 (35.9%) received molecular testing. The cumulative incidence of testing by 180 days after diagnosis was 0.36 (95% CI, 0.35-0.37). Increasing age (hazard ratio [HR], 0.96 [95% CI, 0.93-0.99]), later diagnosis year (HR, 1.05 [95% CI, 1.02-1.07]), dual Medicaid coverage (HR, 0.71 [95% CI, 0.64-0.79]), Part D enrollment (HR, 1.13 [95% CI, 1.04-1.22]), and squamous histology (HR, 0.35 [95% CI, 0.32-0.39]) were independently associated with testing. A greater percentage of patients who received testing had visits with both a proceduralist or a surgeon and an oncologist compared with those without testing (1257 [77.7%] vs 867 [58.9%]; P < .001). In this cohort study of Medicare beneficiaries with advanced NSCLC residing in the rural US, initial receipt of molecular testing was low. Dual Medicaid coverage, Part D enrollment, and subspecialist visits were independently associated with test receipt, highlighting key areas for future study to promote equitable delivery of guideline-concordant lung cancer care.
中文摘要:分子检测是美国晚期非小细胞肺癌(NSCLC)患者的标准诊疗。农村地区患者肺癌死亡率偏高,与符合指南的评估和治疗接受度较低有关,但该人群的分子检测模式尚未见描述。研究旨在描述美国农村地区在初始检测实施后的分子检测模式。这项队列研究利用监测、流行病学和最终结果计划(SEER)与Medicare理赔数据链接,识别2014年1月至2019年12月诊断的66岁及以上晚期NSCLC患者。数据分析时间为2025年12月至2026年8月。纳入社会人口学变量、组织学类型和医生就诊情况。主要结局为接受分子检测。采用竞争风险框架,以死亡为竞争事件,按总风险人时(诊断前30天至死亡或诊断后6个月)计算总体及基线定义亚组患者的检测累积发生率。研究纳入8259名居住在农村地区、诊断为晚期NSCLC的Medicare受益人,平均(SD)年龄76.1(6.7)岁,男性4672名(56.6%),1775名(21.5%)符合Medicaid资格,3754名(45.5%)为腺癌组织学,2044名(24.7%)为鳞状细胞癌组织学,2461名(29.8%)为其他或未明确组织学。队列中2963名(35.9%)接受了分子检测。诊断后180天检测累积发生率为0.36(95%CI,0.35-0.37)。年龄增加(风险比[HR],0.96[95%CI,0.93-0.99])、诊断年份较晚(HR,1.05[95%CI,1.02-1.07])、双重Medicaid覆盖(HR,0.71[95%CI,0.64-0.79])、Part D参保(HR,1.13[95%CI,1.04-1.22])和鳞状细胞癌组织学(HR,0.35[95%CI,0.32-0.39])与检测独立相关。接受检测者中同时就诊过操作医师或外科医师以及肿瘤科医师的比例高于未检测者(1257名[77.7%]对867名[58.9%];P<0.001)。在这项针对美国农村地区晚期NSCLC Medicare受益人的队列研究中,初始接受分子检测的比例较低。双重Medicaid覆盖、Part D参保和亚专科医师就诊与检测接受独立相关,提示未来研究应关注这些方面,以促进符合指南的肺癌诊疗公平实施。
Approximately one-quarter of lung cancers occur in people who never smoked (PWNS). For smoking-associated lung cancer, blood-based protein biomarkers can improve risk assessment. To identify protein biomarkers for lung cancer among PWNS. This nested case-control study from 4 cohorts in the Lung Cancer Cohort Consortium (LC3) was conducted for discovery to identify proteins, and a cohort study was conducted using data in the UK Biobank for replication. Participants were from the US, China, and the United Kingdom and donated blood samples between 1996 and 2010. Lung cancer case-control pairs of PWNS from 4 cohorts in the LC3 were matched by cohort, age, sex, and blood collection date. In addition, 49 291 participants in the UK Biobank were included. Data were analyzed from March 2024 to May 2025. A total of 2821 circulating proteins measured in prediagnostic blood samples collected up to 5 years before lung cancer diagnosis for cases. Primary measures were odds ratios (ORs) for discovery and hazard ratios (HRs) for replication. Among 180 case-control pairs of PWNS (360 participants) in the 4 LC3 cohorts, 256 participants (71.1%) were female, and the median (IQR) age at enrollment was 66 (55-70) years. In LC3, using a false discovery rate-adjusted P value threshold of .05, 2 proteins were identified as being associated with lung cancer among PWNS: carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) (OR, 1.65 [95% CI, 1.31-2.09]) and CEACAM6 (OR, 1.72 [95% CI, 1.33-2.22]). Associations for both proteins were successfully replicated among participants analyzed regardless of smoking history across 5 years of follow-up in the UK Biobank (CEACAM5: HR, 1.92 [95% CI, 1.66-2.22]; CEACAM6: HR, 1.86 [95% CI,1.59-2.16]). The correlation between CEACAM5 and CEACAM6 was weak (Pearson ρ = 0.25 in the LC3); therefore, both proteins maintained associations with high relative risks after mutual adjustment. For 36 proteins previously identified as robust markers of smoking-related lung cancer, most showed no evidence of an association among PWNS (median OR, 1.47 [IQR, 1.38-1.61] vs 1.01 [IQR, 0.94-1.13] in smoking-related vs nonsmoking lung cancer). In this nested case-control study, 2 proteins were identified, CEACAM5 and CEACAM6, that were associated with lung cancer in PWNS. Larger studies are needed to evaluate whether there are additional biomarkers associated with lung cancer in PWNS and whether they can identify PWNS with high lung cancer risk.
中文摘要:约四分之一的肺癌发生在从不吸烟者(PWNS)中。对于吸烟相关肺癌,血液蛋白标志物可改善风险评估。本研究旨在识别从不吸烟者中肺癌的蛋白标志物。研究采用肺癌队列联盟(LC3)4个队列的巢式病例对照设计进行蛋白发现,并利用英国生物银行数据进行队列研究的重复验证。参与者来自美国、中国和英国,于1996年至2010年间捐献血样。LC3的4个队列中从不吸烟者的肺癌病例对照对按队列、年龄、性别和采血日期匹配,另纳入49 291名英国生物银行参与者。数据分析时间为2024年3月至2025年5月。共检测2821种循环蛋白,样本为病例确诊肺癌前最多5年采集的诊断前血液。主要指标为发现阶段的比值比(OR)和验证阶段的风险比(HR)。4个LC3队列共180对从不吸烟者病例对照(360名参与者),其中256名(71.1%)为女性,入组时年龄中位数(IQR)为66(55-70)岁。在LC3中,以错误发现率校正P值阈值0.05为标准,识别出2种与从不吸烟者肺癌相关的蛋白:癌胚抗原相关细胞黏附分子5(CEACAM5)(OR,1.65[95% CI,1.31-2.09])和CEACAM6(OR,1.72[95% CI,1.33-2.22])。在英国生物银行5年随访中,无论吸烟史如何,所分析人群中这两种蛋白的关联均得到成功重复(CEACAM5:HR,1.92[95% CI,1.66-2.22];CEACAM6:HR,1.86[95% CI,1.59-2.16])。CEACAM5与CEACAM6的相关性较弱(LC3中Pearson ρ=0.25),因此相互校正后两种蛋白仍与较高的相对风险相关。对于既往被确定为吸烟相关肺癌稳健标志物的36种蛋白,多数在从不吸烟者中未见关联证据(吸烟相关肺癌与不吸烟肺癌的中位OR分别为1.47[IQR,1.38-1.61]和1.01[IQR,0.94-1.13])。这项巢式病例对照研究识别出CEACAM5和CEACAM6两种与从不吸烟者肺癌相关的蛋白。仍需更大规模的研究评估从不吸烟者中是否存在其他与肺癌相关的标志物,以及这些标志物能否识别肺癌高风险的从不吸烟者。
Presented at the 2026 World Conference on Lung Cancer, two phase III trials-PAPILLON and REZILIENT3-established amivantamab and zipalertinib combination therapies as effective first-line strategies for advanced NSCLC with EGFR exon 20 insertions, with significantly improved progression-free survival, although high crossover rates prevented them demonstrating an overall survival benefit. Separately, HARMONi-2 showed that the bispecific antibody ivonescimab improved overall survival versus pembrolizumab in PD-L1-positive NSCLC, supporting its use as standard of care in China while larger global trials continue.
中文摘要:在2026年世界肺癌大会上公布的两项III期试验PAPILLON和REZILIENT3,确立了amivantamab与zipalertinib联合方案作为EGFR外显子20插入晚期NSCLC有效一线策略,显著改善无进展生存期,但较高的交叉治疗率使其未能显示总生存获益。另一项HARMONi-2显示,双特异性抗体ivonescimab在PD-L1阳性NSCLC中较帕博利珠单抗改善总生存期,支持其在中国作为标准治疗,更大规模全球试验仍在继续。
A rare inherited EGFR mutation took root in Southern Appalachia after being carried to the United States by European settlers in the 1700s. Mapping the distribution of this germline EGFRT790M variant could help clinicians identify people at elevated risk of lung cancer and target them for genetic testing and closer surveillance.
中文摘要:一种罕见的遗传性EGFR突变在18世纪由欧洲定居者带到美国后,在南阿巴拉契亚地区扎根。绘制这种胚系EGFRT790M变异的分布图,可帮助临床医生识别肺癌风险升高的人群,并将其作为基因检测和更密切监测的目标人群。
Small cell lung cancer (SCLC) remains one of the most aggressive malignancies, with limited tools for predicting outcomes and guiding treatment. We developed an SCLC-Predictive Risk Score (PRS) model for patients treated with chemotherapy using least absolute shrinkage and selection operator regression. The model comprised five genes and was developed in a training cohort of 50 patients using an innovative 795-gene panel of tumor- and immune-related genes analyzed on the NanoString nCounter platform. Gene expression was measured in routine clinical formalin-fixed, paraffin-embedded SCLC specimens, predominantly puncture specimens (36/50). The SCLC-PRS model stratified patients into high-risk (PRS-H) and low-risk (PRS-L) groups; patients in the PRS-H group had significantly worse overall survival (hazard ratio [HR] = 0.35, 95% confidence interval [CI]: 0.18-0.69; p = 0.002) and progression-free survival (HR = 0.44, 95% CI: 0.23-0.84; p = 0.008). The prognostic performance of the model was externally validated in two independent cohorts (GSE60052, n = 38; George cohort, n = 47). Multivariate Cox analysis confirmed SCLC-PRS as an independent prognostic factor. PRS-L tumors exhibit a favorable tumor immune microenvironment, with increased CD45+ immune infiltration, reduced Tregs or exhausted CD8+ T cells, and upregulated antigen presentation (MHC-I/II). Overall, the SCLC-PRS model is an innovative, cross-platform-compatible, and clinically applicable prognostic tool with potential utility for risk stratification and personalized treatment.
中文摘要:小细胞肺癌(SCLC)仍是最具侵袭性的恶性肿瘤之一,预测结局和指导治疗的工具有限。我们使用最小绝对收缩和选择算子回归,为接受化疗的患者建立了SCLC预测风险评分(SCLC-PRS)模型。该模型包含5个基因,在50例患者的训练队列中构建,采用创新的795个肿瘤及免疫相关基因组合,并在NanoString nCounter平台上分析。基因表达在常规临床福尔马林固定石蜡包埋的SCLC标本中检测,以穿刺标本为主(36/50)。SCLC-PRS模型将患者分为高风险(PRS-H)和低风险(PRS-L)组;PRS-H组总生存显著更差(风险比[HR]=0.35,95%置信区间[CI]:0.18-0.69;p=0.002),无进展生存也显著更差(HR=0.44,95%CI:0.23-0.84;p=0.008)。该模型的预后性能在两个独立队列中完成外部验证(GSE60052,n=38;George队列,n=47)。多因素Cox分析确认SCLC-PRS为独立预后因素。PRS-L肿瘤表现出有利的肿瘤免疫微环境,CD45+免疫浸润增加,Tregs或耗竭CD8+ T细胞减少,抗原呈递(MHC-I/II)上调。总体而言,SCLC-PRS模型是一种创新、跨平台兼容且临床可用的预后工具,有望用于风险分层和个体化治疗。
We aimed to provide a comprehensive overview of the effectiveness of psychosocial interventions on informal caregivers' mental health, organized by the clinical condition(s) of the care recipient. We conducted an umbrella systematic review and random-effects meta-analyses to pool the results of the included studies for each combination of clinical condition, intervention type, comparison and outcome. We included 19 systematic reviews and 50 meta-analyses, with 26,481 participants. Several interventions improved mental health outcomes in caregivers, and across various clinical conditions of the care recipients. In dementia caregivers, multicomponent interventions significantly reduced depressive and anxiety symptoms, and caregiver burden (SMD from -0.65 to -0.19). For caregivers of people with lung cancer, psychoeducation and psychological support reduced depressive (SMD = -1.66, 95% CI -3.19 to -0.13) and anxiety symptoms (SMD = -1.37, 95% CI -2.54 to -0.21). Multicomponent interventions reduced depressive and anxiety symptoms in parents of children with cancer (SMD = -0.38, 95% CI -0.64 to -0.12; SMD = -0.89, 95% CI -1.33 to -0.45). Caregiver burden of caregivers of people with psychosis and schizophrenia decreased after psychoeducation and skills-training (SMD = -2.10, 95% CI -3.46 to -0.74; SMD = -0.94, 95% CI -1.72 to -0.17). Certainty of evidence was low to moderate, and the strength of association was overall weak. We rigorously assessed the quality, certainty of evidence, and the strength of associations. Despite the appraisals highlighting the need for further high-quality research, our results can inform policy and practice on the use of psychosocial interventions for caregivers of people with different clinical conditions.
中文摘要:旨在按被照护者的临床疾病分类,全面概述心理社会干预对非正式照护者心理健康的效果。我们开展伞形系统综述和随机效应荟萃分析,按临床疾病、干预类型、对照和结局的每种组合汇总纳入研究结果。共纳入19篇系统综述和50项荟萃分析,涉及26481名参与者。多种干预改善了照护者的心理健康结局,且见于被照护者的不同临床疾病。在痴呆照护者中,多成分干预显著减轻抑郁和焦虑症状及照护者负担(SMD为-0.65至-0.19)。对于肺癌患者照护者,心理教育和心理支持减轻抑郁症状(SMD=-1.66,95%CI -3.19至-0.13)和焦虑症状(SMD=-1.37,95%CI -2.54至-0.21)。多成分干预减轻癌症患儿父母的抑郁和焦虑症状(SMD=-0.38,95%CI -0.64至-0.12;SMD=-0.89,95%CI -1.33至-0.45)。精神病性障碍和精神分裂症患者照护者的照护者负担在心理教育和技能训练后下降(SMD=-2.10,95%CI -3.46至-0.74;SMD=-0.94,95%CI -1.72至-0.17)。证据确定性为低至中等,关联强度总体较弱。我们严格评估了质量、证据确定性和关联强度。尽管这些评价强调需要进一步高质量研究,结果可为不同临床疾病患者照护者使用心理社会干预的政策与实践提供信息。
RAS proteins (HRAS, KRAS, NRAS) contribute to many physiological signal transduction pathways involving cell growth, cell division, and survival. RAS proteins possess GTPase activity. These proteins toggle between inactive and active forms; the conversion of inactive RAS-GDP to active RAS-GTP is facilitated by guanine nucleotide exchange factors (GEFs) turning the switch on and the intrinsic RAS-GTPase activity accelerated by the GTPase activating proteins (GAPs) turning the switch off. RAS is the upstream component of the RAS-RAF-MEK-ERK and the PI3-kinase-AKT signaling cascades. One-fifth of all cancers bear RAS mutations and about 75% of them involve KRAS. Except for the GTP/GDP binding site, RAS proteins lack deep surface pockets able to bind high-affinity inhibitors, which impeded the development of specific antagonists. KRAS mutations occur frequently in pancreatic, lung, and colorectal cancers, which are among the deadliest cancers worldwide. RAS mutations include those of codon 12 G12D/V/C/R, codon 13 G13D, and codon 61 Q61R/K/L. Studies conducted over the last 15 years led to the discovery of the so-called RAS switch II pocket. Sotorasib and adagrasib, which interact with this pocket and directly block the action of KRAS following the covalent modification of KRAS C12, are FDA-approved for the second-line treatment of KRASG12C-mutant non-small cell lung cancer. Daraxonrasib, which is an indirect inhibitor of wildtype and mutant H/K/NRAS isoforms, is FDA approved for the second-line treatment of all RAS-mutant pancreatic cancers. Daraxonrasib first forms a complex with cyclophilin A (a chaperone protein), which then interacts with active RAS to block RAS signaling.
中文摘要:RAS蛋白(HRAS、KRAS、NRAS)参与细胞生长、分裂和存活的多种生理信号转导通路。RAS蛋白具有GTP酶活性。这些蛋白在无活性与活性形式之间切换;鸟嘌呤核苷酸交换因子(GEFs)促进无活性RAS-GDP向活性RAS-GTP转化,将开关打开,GTP酶激活蛋白(GAPs)加速RAS内在GTP酶活性,将开关关闭。RAS是RAS-RAF-MEK-ERK和PI3-激酶-AKT信号级联的上游组分。全部癌症中五分之一携带RAS突变,其中约75%涉及KRAS。除GTP/GDP结合位点外,RAS蛋白缺乏能够结合高亲和力抑制剂的深表面口袋,这阻碍了特异性拮抗剂的开发。KRAS突变常见于胰腺癌、肺癌和结直肠癌,这些癌症属于全球最致命的癌症。RAS突变包括密码子12的G12D/V/C/R、密码子13的G13D和密码子61的Q61R/K/L。过去15年的研究发现了所谓的RAS switch II口袋。Sotorasib和adagrasib与该口袋相互作用,并通过共价修饰KRAS C12直接阻断KRAS作用,已获FDA批准用于KRASG12C突变非小细胞肺癌的二线治疗。Daraxonrasib是野生型和突变型H/K/NRAS亚型的间接抑制剂,已获FDA批准用于所有RAS突变胰腺癌的二线治疗。Daraxonrasib先与亲环素A(一种伴侣蛋白)形成复合物,该复合物随后与活性RAS相互作用以阻断RAS信号传导。
Andamertinib (®) is a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) being developed by Beijing Avistone Biotechnology for the treatment of non-small cell lung cancer (NSCLC). On 30 April 2026, andamertinib received conditional approval in China for adult patients with locally advanced or metastatic NSCLC who have experienced disease progression during or following platinum-based chemotherapy, or who are intolerant to platinum-based chemotherapy, and who have been confirmed by testing to have an EGFR exon 20 insertion mutation. This article summarizes the milestones in the development of andamertinib leading to this first approval for NSCLC.
中文摘要:Andamertinib(®)是一种表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI),由北京鞍石生物科技开发,用于治疗非小细胞肺癌(NSCLC)。2026年4月30日,Andamertinib在中国获得附条件批准,用于成人局部晚期或转移性NSCLC患者,这些患者在含铂化疗期间或之后出现疾病进展,或对含铂化疗不耐受,且经检测确认存在EGFR 20号外显子插入突变。本文总结Andamertinib开发过程中促成其首次获批用于NSCLC的里程碑。
Only a subset of patients with non-small cell lung cancer (NSCLC) benefit from immunotherapy, and this is partly due to limited understanding of how oncogenic mutations shape the tumor microenvironment (TME). To define how EGFR and KRAS mutations influence the spatial organization and immune composition of the NSCLC TME. We conducted 38-marker high-plex immunofluorescence to 197 NSCLC tumors (>2 million cells) stratified by EGFR and KRAS genotypes. Quantitative phenotyping and spatial analyses, including cellular neighborhoods (CNs), nearest neighbors (NNs = 5-20), and spatial proximity profiling (25-100 μm), were performed to assess immune architecture and clinical correlations. EGFR- and KRAS-mutant tumors showed higher tumor cell density and reduced immune infiltration compared with wild-type tumors. Both mutation types were associated with depletion of cytotoxic T cells, dendritic cells, and granulocytes, while EGFR-mutant tumors showed enrichment of M2-like tumor-associated macrophages (TAMs). Cellular neighborhoods analysis identified 14 spatial clusters, with reduced cytotoxic and helper T cell-rich neighborhoods in mutant tumors. Nearest neighbors analysis revealed shorter distances between M2-like TAMs in EGFR-mutant tumors and greater immune exclusion in nonmutants. Spatial proximity revealed higher densities of regulatory T cells and TAMs near tumor cells in KRAS-mutant tumors. All spatial metrics correlated significantly with prognosis in Cox proportional hazards models, highlighting immune cell positioning as an important predictor of outcome. EGFR- and KRAS-mutant tumors remodel the NSCLC immune landscape, creating distinct immunosuppressive and immune-excluded niches. Spatial proteomics reveals prognostic immune architectures that may guide mutation-directed immunotherapy strategies.
中文摘要:只有一部分非小细胞肺癌(NSCLC)患者从免疫治疗中获益,部分原因在于对致癌突变如何塑造肿瘤微环境(TME)的认识有限。为明确EGFR和KRAS突变如何影响NSCLC TME的空间组织和免疫组成,对197例按EGFR和KRAS基因型分层的NSCLC肿瘤(超过200万个细胞)进行了38标志物高多重免疫荧光检测。通过定量表型分析和空间分析,包括细胞邻域(CNs)、最近邻(NNs=5-20)和空间邻近分析(25-100 μm),评估免疫架构及其与临床的相关性。与野生型肿瘤相比,EGFR突变和KRAS突变肿瘤显示更高的肿瘤细胞密度和减少的免疫浸润。两种突变类型均与细胞毒性T细胞、树突状细胞和粒细胞减少相关,而EGFR突变肿瘤显示M2样肿瘤相关巨噬细胞(TAMs)富集。细胞邻域分析识别出14个空间簇,突变肿瘤中富含细胞毒性T细胞和辅助性T细胞的邻域减少。最近邻分析显示EGFR突变肿瘤中M2样TAMs之间距离更短,非突变肿瘤中免疫排斥更明显。空间邻近分析显示KRAS突变肿瘤中肿瘤细胞附近调节性T细胞和TAMs密度更高。所有空间指标在Cox比例风险模型中均与预后显著相关,提示免疫细胞定位是结局的重要预测因素。EGFR突变和KRAS突变肿瘤重塑NSCLC免疫景观,形成不同的免疫抑制和免疫排斥生态位。空间蛋白质组学揭示了可能指导突变导向免疫治疗策略的预后免疫架构。
PD-(L)1×VEGF bispecific antibodies integrate immune checkpoint blockade and VEGF inhibition within a single molecule, offering a potential strategy to overcome angiogenesis-associated immune resistance. At the 2026 ASCO Annual Meeting, the randomized phase 3 HARMONi-6 trial demonstrated an overall survival benefit with ivonescimab plus chemotherapy over tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer (NSCLC), extending survival evidence to an active PD-1-based first-line comparator. Exploratory phase 2 studies of pumitamig, SSGJ-707, and HB0025 reported encouraging activity in first-line NSCLC, while phase 1 and 2 studies of IMM2510 and ivonescimab-based regimens suggested activity after prior immunotherapy. Smaller exploratory studies also reported activity in perioperative head and neck cancer, colorectal cancer, endometrial cancer, and mucosal melanoma. Collectively, these findings highlight the clinical potential of PD-(L)1×VEGF bispecific antibodies, with the strongest evidence in first-line squamous NSCLC and broader applications remaining hypothesis-generating. Future development should prioritize predictive biomarkers, resistance mechanisms, optimal treatment sequencing, and careful assessment of immune-related and VEGF-associated toxicities.
中文摘要:PD-(L)1×VEGF双特异性抗体在单一分子中整合免疫检查点阻断与VEGF抑制,为克服血管生成相关的免疫耐药提供了潜在策略。在2026年ASCO年会上,随机III期HARMONi-6试验显示,ivonescimab联合化疗在既往未经治疗的晚期鳞状非小细胞肺癌(NSCLC)中,相比替雷利珠单抗联合化疗带来总生存获益,将生存证据延伸至以PD-1为基础的一线活性对照。pumitamig、SSGJ-707与HB0025的探索性II期研究在一线NSCLC中报告了令人鼓舞的活性,IMM2510及以ivonescimab为基础方案的I期和II期研究提示在既往接受过免疫治疗后仍具活性。规模较小的探索性研究还在围手术期头颈癌、结直肠癌、子宫内膜癌及黏膜黑色素瘤中报告了活性。总体而言,这些结果凸显了PD-(L)1×VEGF双特异性抗体的临床潜力,其中一线鳞状NSCLC证据最为有力,更广泛的应用仍属假说生成性质。未来研发应优先关注预测性生物标志物、耐药机制、最佳治疗顺序,以及对免疫相关毒性和VEGF相关毒性的审慎评估。
基础研究 (22篇)
Resistance to targeted therapies is frequently associated with stem-like features and partial epithelial-to-mesenchymal transition (EMT). Understanding whether these programs directly drive resistance or instead reflect increased phenotypic plasticity is needed to guide strategies for overcoming resistance. Here, we found that resistance to ALK inhibitors (ALKi) in non-small cell lung cancer was associated with increased phenotypic plasticity, reflected in enhanced adaptability to orthogonal stressors and increased metastatic potential, without intrinsic cross-resistance in short-term assays. Computational modeling and experimental validation studies showed that plasticity was progressively enriched over multi-step resistance trajectories. Lineage tracing and clonal analyses revealed a substantial, heritable intra-cell line variability in adaptation potential. High adaptation potential was associated with increased chromatin accessibility at EMT/stemness regulators. Adaptation potential could be enhanced by inducing stemness/EMT programs and suppressed by SOX2 knockdown or epigenetic inhibition, with corresponding effects on resistance. Collectively, these findings indicate that targeted therapy indirectly selects for cells with increased phenotypic plasticity, providing a common basis for the resistance-EMT association and the substrate for multifactorial resistance and metastatic competence. Constraining plasticity could delay resistance and extend response durability.
中文摘要:靶向治疗耐药常与干细胞样特征和部分上皮-间质转化(EMT)相关。需要理解这些程序是直接驱动耐药,还是反映表型可塑性增加,以指导克服耐药的策略。本研究发现,非小细胞肺癌对ALK抑制剂(ALKi)的耐药与表型可塑性增加相关,表现为对正交应激源的适应能力增强和转移潜能提高,而在短期实验中不存在内在交叉耐药。计算建模和实验验证显示,可塑性在多步骤耐药轨迹中逐步富集。谱系追踪和克隆分析揭示,同一细胞系内适应潜能存在大量可遗传差异。高适应潜能与EMT/干性调控因子处染色质可及性增加相关。诱导干性/EMT程序可增强适应潜能,而SOX2敲低或表观遗传抑制可抑制适应潜能,并对耐药产生相应影响。这些结果提示靶向治疗间接选择出表型可塑性增强的细胞,为耐药与EMT关联提供了共同基础,也为多因素耐药和转移能力提供了底物。限制可塑性可能延缓耐药并延长缓解持续时间。
Cigarette smoking is strongly associated with aggressive non-small cell lung cancer (NSCLC), yet the mechanisms linking smoke exposure to metabolic reprogramming remain incompletely understood. Here, we integrated clinical, molecular, and functional analyses to define a smoking-associated metabolic axis in NSCLC. Lung cancer patients with a smoking history exhibited significantly higher tumor 18F-FDG uptake than never-smokers, suggesting an association between smoking exposure and increased tumor metabolic activity. Consistently, chronic exposure of NSCLC cells to cigarette smoke extract (CSE) or its ingredient benzo[α]pyrene (B[α]P) increased glucose uptake, glycolysis, ATP production, and malignant phenotypes, including proliferation, migration, and sphere formation. Mechanistically, GLUT3 protein, but not mRNA, was selectively upregulated in smoke-exposed tumors and cell models, suggesting post-transcriptional regulation. We identified miR-146a as a direct suppressor of GLUT3 through binding to its 3'UTR and found that cigarette smoke markedly reduced miR-146a expression. Smoker-derived NSCLC tumors exhibited lower miR-146a expression and higher GLUT3 levels, which were inversely correlated and associated with poor overall survival. Restoration of miR-146a reduced GLUT3 expression, glucose uptake, and tumor cell proliferation, supporting a central role for the miR-146a/GLUT3 axis in smoking-induced metabolic reprogramming. (-)Gallocatechin ((-)GC), a naturally occurring catechin, is further identified as a selective GLUT3 inhibitor and suppressed smoke-induced glucose uptake, tumor progression, and metastasis without detectable systemic toxicity. Collectively, these findings identify the miR-146a/GLUT3 axis as a key mechanism underlying smoking-driven metabolic reprogramming and establish GLUT3 as a potential metabolic target in NSCLC and other GLUT3-dependent malignancies.
中文摘要:吸烟与侵袭性非小细胞肺癌(NSCLC)密切相关,但烟雾暴露与代谢重编程之间的联系机制仍未完全阐明。通过整合临床、分子和功能分析,界定了NSCLC中与吸烟相关的代谢轴。有吸烟史的肺癌患者肿瘤18F-FDG摄取显著高于从不吸烟者,提示吸烟暴露与肿瘤代谢活性升高相关。与此一致,NSCLC细胞长期暴露于香烟烟雾提取物(CSE)或其成分苯并[α]芘(B[α]P)后,葡萄糖摄取、糖酵解、ATP生成以及包括增殖、迁移和成球在内的恶性表型均增加。机制上,烟雾暴露的肿瘤和细胞模型中GLUT3蛋白而非mRNA选择性上调,提示存在转录后调控。鉴定出miR-146a通过结合GLUT3的3'UTR直接抑制GLUT3,并发现香烟烟雾显著降低miR-146a表达。吸烟者来源的NSCLC肿瘤中miR-146a表达较低、GLUT3水平较高,二者呈负相关,并与较差的总生存相关。恢复miR-146a可降低GLUT3表达、葡萄糖摄取和肿瘤细胞增殖,支持miR-146a/GLUT3轴在吸烟诱导的代谢重编程中发挥核心作用。天然存在的儿茶素(-)没食子儿茶素((-)GC)被进一步鉴定为选择性GLUT3抑制剂,可抑制烟雾诱导的葡萄糖摄取、肿瘤进展和转移,且未检测到全身毒性。这些发现确定miR-146a/GLUT3轴是吸烟驱动代谢重编程的关键机制,并将GLUT3确立为NSCLC及其他依赖GLUT3的恶性肿瘤的潜在代谢靶点。
Respiratory diseases remain major causes of morbidity and mortality; however, inadequate pulmonary drug exposure and systemic toxicity continue to limit treatment efficacy. Inhaled nanomedicines offer opportunities for localized, sustained, and targeted therapy. This review examines how disease biology informs pulmonary delivery design across pulmonary fibrosis, lung cancer, chronic obstructive pulmonary disease, pulmonary infections, and acute lung injury/acute respiratory distress syndrome. It outlines anatomical and biological barriers and compares liposomes, lipid nanoparticles, polymeric and hybrid systems, biomimetic carriers, and stimuli-responsive formulations. Particular attention is given to matching therapeutic cargo and carrier properties to fibroblasts, macrophages, tumor cells, and alveolar type II cells. Emerging approaches include mRNA delivery, siRNA-mediated gene silencing, antisense oligonucleotides, and CRISPR-based editing, alongside alveolar regeneration and biomarker-guided treatment. These strategies are evaluated in relation to their delivery requirements and stage of development. The review also addresses aerosol-device compatibility, manufacturing, repeated-dose safety, regulatory considerations, and clinical outcomes. By connecting delivery mechanisms with disease-specific applications and clinical evidence, this review identifies both therapeutic opportunities and barriers to translation. This integrated perspective can guide the development of inhaled nanomedicines with more reproducible pulmonary delivery, improved treatment efficacy, and acceptable safety.
中文摘要:呼吸系统疾病仍是发病和死亡的主要原因;肺部药物暴露不足和全身毒性持续限制治疗效果。吸入纳米药物为局部、持续和靶向治疗提供了机会。本综述考察疾病生物学如何指导肺纤维化、肺癌、慢性阻塞性肺疾病、肺部感染以及急性肺损伤/急性呼吸窘迫综合征的肺部递送设计。文章概述解剖与生物学屏障,并比较脂质体、脂质纳米颗粒、聚合物及杂化系统、仿生载体和刺激响应制剂。特别关注将治疗货物与载体性质同成纤维细胞、巨噬细胞、肿瘤细胞和II型肺泡细胞相匹配。新兴方法包括mRNA递送、siRNA介导的基因沉默、反义寡核苷酸和基于CRISPR的编辑,同时涉及肺泡再生和生物标志物指导的治疗。这些策略依据其递送需求和开发阶段进行评估。综述还讨论气溶胶装置兼容性、生产、重复给药安全性、监管考虑和临床结局。通过将递送机制与疾病特异性应用及临床证据相联系,本综述识别了治疗机会和转化障碍。这一整合视角可指导开发肺部递送更可重复、治疗效果更好且安全性可接受的吸入纳米药物。
Maintenance and enhancement of the catalytic activity of natural enzymes remain challenging in the development of high-performance enzyme-based biosensors. In this work, we propose a rational ligand-engineering strategy for constructing enzyme@covalent organic framework (COF) composites by integrating nitrogen heterocyclic microenvironment regulation with a deep eutectic solvent (DES)-assisted mild synthesis approach for the enhancement of enzyme activity. Furthermore, a high-performance biosensor is fabricated for the detection of non-small cell lung cancer (NSCLC)-derived exosomes. Specifically, the incorporation of nitrogen-rich ligands into COF frameworks may create an electron-rich hydrogen-bonding microenvironment under biocompatible conditions provided by DES for rapid in situ growth of COFs. Enzyme kinetic analysis demonstrates that the introduction of nitrogen-heterocyclic ligands can effectively enhance enzymatic catalytic efficiency, and spectroscopic analyses further confirm the conformation changes in the enzyme caused by the introduction of the nitrogen-containing ligands. Consequently, a high-performance electrochemical biosensor is fabricated based on the enzyme@COF composites for the detection of NSCLC-derived exosomes. Experimental results reveal that the biosensor can exhibit a broad linear range and achieve a limit of detection (LOD) as low as 4 particles/μL. Moreover, clinical sample analysis confirms its capability to accurately discriminate NSCLC patients from healthy individuals.
中文摘要:维持并提升天然酶的催化活性,仍是构建高性能酶基生物传感器中的难点。本工作提出一种配体工程策略,通过将氮杂环微环境调控与低共熔溶剂(DES)辅助的温和合成方法结合,构建酶@共价有机框架(COF)复合物,以增强酶活性。进一步制备了用于检测非小细胞肺癌(NSCLC)来源外泌体的高性能生物传感器。具体而言,将富氮配体引入COF骨架,可在DES提供的生物相容条件下形成富电子氢键微环境,促进COF快速原位生长。酶动力学分析表明,氮杂环配体的引入能有效提高酶催化效率,光谱分析进一步证实含氮配体引入引起酶构象变化。据此,基于酶@COF复合物构建了高性能电化学生物传感器,用于检测NSCLC来源外泌体。实验结果显示,该传感器具有较宽的线性范围,检出限低至4个颗粒/μL。临床样本分析证实其能够准确区分NSCLC患者与健康个体。
To enable the precise localization and minimally invasive treatment of early-stage pulmonary lesions, we developed a magnetic catheter system integrating magnetic navigation, hypoxia fluorescence imaging, and multifunctional minimally invasive intervention. The distal end of the system incorporates multiple permanent magnets, a miniature camera equipped with an optical filter, multiple fiber-optic channels, and a flexibly switchable multifunctional working channel. Under a 40 mT magnetic field applied perpendicular to the initial catheter axis, the catheter incorporating 2.0 mm-diameter magnets achieved a bending angle of 39.63° ± 2.47° and successfully navigated to multiple designated branches in the bronchial phantom. A proof-of-concept model was established using A549 lung cancer spheroids labeled with hypoxia-responsive fluorescent probes, enabling fluorescence-guided localization of simulated hypoxic lesions. In the bronchial phantom, the system successfully identified simulated hypoxic lesions and subsequently performed biopsy sampling, simulated drug delivery, and localized laser irradiation. The system was further evaluated in porcine lungs to demonstrate its navigation and localized intervention capabilities. This magnetic catheter system provides a new technological strategy for the precise localization and in situ treatment of early-stage lung cancer.
中文摘要:为了实现早期肺部病变的精准定位与微创治疗,我们开发了一套磁性导管系统,整合磁导航、缺氧荧光成像与多功能微创介入。系统远端集成多个永磁体、带滤光片的微型摄像头、多路光纤通道以及可灵活切换的多功能工作通道。在与导管初始轴线垂直的40 mT磁场下,含直径2.0 mm磁体的导管达到39.63°±2.47°的弯曲角度,并在支气管体模中成功导航至多个指定分支。利用经缺氧响应荧光探针标记的A549肺癌球体建立概念验证模型,实现模拟缺氧病灶的荧光引导定位。在支气管体模中,系统成功识别模拟缺氧病灶,并随后完成活检取样、模拟给药和局部激光照射。系统进一步在猪肺中评估,展示其导航与局部介入能力。该磁性导管系统为早期肺癌的精准定位与原位治疗提供了新的技术策略。
Anoctamin 1 (ANO1/TMEM16A) is a calcium-activated chloride channel increasingly recognized as a compelling pharmacological target in oncology. Beyond its role in chloride flux, ANO1 has also been proposed to exert signaling-associated or scaffold-like functions in selected malignancies, including head and neck, breast, and lung cancers. Although pharmacological studies have progressed from broad inhibitors to selective probes and natural products, a critical need has emerged for a rigorous standard to evaluate these agents. A central challenge is distinguishing acute conductance blockade from protein-level downregulation, as these mechanisms may produce distinct biological outcomes. Channel inhibition suppresses ion flux while potentially leaving ANO1-associated protein complexes intact, whereas protein reduction may affect both conductance-dependent and signaling-associated functions; however, the extent to which these functions are mechanistically independent remains incompletely established. Consequently, regulation of ANO1 stability is emerging as a promising therapeutic strategy in tumors with high ANO1 expression and epidermal growth factor receptor (EGFR) activation. However, in clinically relevant EGFR-mutant non-small cell lung cancer models, the role of ANO1 should be interpreted cautiously. Current evidence supports ANO1 as a context-dependent preclinical vulnerability rather than an established mechanism for overcoming osimertinib resistance. To address methodological inconsistencies in the field, this review summarizes ANO1 cancer pharmacology and proposes a conservative operational evidence framework. By establishing strict validation criteria, we classify ANO1 modulators into functional inhibitors, dual modulators, protein-level downregulators, and protein-stability modulators while defining evidence requirements for bona fide targeted degrader designation.
中文摘要:Anoctamin 1(ANO1/TMEM16A)是一种钙激活氯通道,在肿瘤学中日益被视为有吸引力的药理学靶点。除氯离子转运外,ANO1还被提出在部分恶性肿瘤中发挥与信号转导相关或类似支架的功能,涉及头颈癌、乳腺癌和肺癌。药理学研究已从广谱抑制剂推进到选择性探针和天然产物,但对该类药物的严格评价标准仍有迫切需求。核心难题在于区分急性电导阻断与蛋白水平下调,因为二者可能产生不同的生物学结果。通道抑制可压制离子流,同时可能使ANO1相关蛋白复合物保持完整;蛋白减少则可能同时影响依赖电导和不依赖电导的信号相关功能;这些功能在机制上相互独立的程度仍未完全确立。因此,调控ANO1稳定性正成为ANO1高表达且表皮生长因子受体(EGFR)激活的肿瘤中有前景的治疗策略。但在临床相关的EGFR突变非小细胞肺癌模型中,对ANO1作用的解读应保持谨慎。现有证据支持ANO1是依赖背景的临床前易感靶点,而非克服奥希替尼耐药的确立机制。为处理方法学不一致,该综述总结ANO1肿瘤药理学,并提出保守的操作性证据框架。通过建立严格验证标准,我们将ANO1调节剂分为功能性抑制剂、双重调节剂、蛋白水平下调剂和蛋白稳定性调节剂,同时界定真正靶向降解剂认定所需的证据要求。
In this issue, two studies establish KRASG13C as a directly targetable oncoprotein in non-small cell lung cancer (NSCLC) while revealing distinct dependence of codon 13-mutant NSCLC on wild-type (WT) RAS and enhanced sensitivity to standard-of-care chemotherapy. A third study highlights rewired oncogenic signaling through WT RAS as a therapeutically tractable mechanism of resistance to KRASG12C inhibitors in the context of acquired oncogenic kinase fusions. See related article by Scaparone et al., p. 2242 See related article by Seamon et al., p. 2256 See related article by McDaid et al., p. 2274.
中文摘要:本期中,两项研究确立 KRASG13C 在非小细胞肺癌(NSCLC)中为可直接靶向的癌蛋白,同时揭示密码子13突变 NSCLC 对野生型(WT)RAS 的独特依赖,以及对标准治疗化疗的敏感性增强。第三项研究强调,在获得性致癌激酶融合背景下,通过 WT RAS 重编程的致癌信号是 KRASG12C 抑制剂耐药的可治疗机制。参见 Scaparone 等文章第2242页;参见 Seamon 等文章第2256页;参见 McDaid 等文章第2274页。
Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer.
Direct inhibitors of KRASG12C are now used as standard-of-care therapy in KRASG12C-mutant non-small cell lung cancer (NSCLC), but less is understood about the molecular mechanisms and consequent treatment vulnerabilities of KRAS codon 13 mutations in this setting. In this study, we characterized the tumorigenic properties of NSCLC harboring KRASG13X in a large multinational cohort of patients with NSCLC and in preclinical models of KRASG13X NSCLC. Induction of KRASG13C or KRASG13D expression confers reduced oncopotency compared with allele-specific controls affecting KRAS codon 12, particularly KRASG13C. We identified functionally relevant comutations in KRASG13X NSCLC, including KEAP1, STK11, BRAF, and NF1. The novel RAS(ON) G13C-selective inhibitor, RMC-8839, reduces viability in a panel of KRASG13C NSCLC cell models. To determine combination partners that enhance RAS(ON) mutant-selective inhibition, a drug repurposing screen revealed that KRASG13C models are selectively vulnerable to chemotherapy. Combination of docetaxel with RMC-8839 demonstrated robust antiproliferative activity in KRASG13C-driven NSCLC models in vitro and in vivo. We characterize the second most common KRAS mutational hotspot in NSCLC after codon 12, KRASG13X, from tumor initiation to advanced disease. KRASG13C is a novel, directly targetable subset of NSCLC, with vulnerability to the combination of chemotherapeutics and the mutant-selective RAS(ON) inhibitor RMC-8839, a finding immediately relevant to patient care. See related commentary by Araujo and Skoulidi, p. 2206 See related article by Seamon et al., p. 2256.
中文摘要:KRASG12C 的直接抑制剂现已成为 KRASG12C 突变非小细胞肺癌(NSCLC)的标准治疗,但 KRAS 第13位密码子突变在该背景下的分子机制及由此产生的治疗脆弱点仍知之较少。本研究在一个大型跨国 NSCLC 患者队列及 KRASG13X NSCLC 临床前模型中,刻画了携带 KRASG13X 的 NSCLC 的致瘤特性。诱导 KRASG13C 或 KRASG13D 表达所赋予的致瘤潜能低于针对 KRAS 第12位密码子的等位基因特异性对照,KRASG13C 尤为明显。我们识别出 KRASG13X NSCLC 中具有功能相关性的共突变,包括 KEAP1、STK11、BRAF 和 NF1。新型 RAS(ON) G13C 选择性抑制剂 RMC-8839 可降低一组 KRASG13C NSCLC 细胞模型的活力。为确定能增强 RAS(ON) 突变选择性抑制的组合伙伴,一项药物重定位筛选显示 KRASG13C 模型对化疗具有选择性易感性。多西他赛与 RMC-8839 联合在体外和体内 KRASG13C 驱动的 NSCLC 模型中表现出强效抗增殖活性。我们从肿瘤起始到晚期疾病层面刻画了 NSCLC 中仅次于第12位密码子的第二常见 KRAS 突变热点 KRASG13X。KRASG13C 是 NSCLC 中一个新的、可直接靶向的亚群,对化疗药物与突变选择性 RAS(ON) 抑制剂 RMC-8839 的联合治疗具有易感性,这一发现与患者诊疗直接相关。相关评论见 Araujo 与 Skoulidi,第2206页;相关文章见 Seamon 等,第2256页。
KRAS mutations are common oncogenic drivers in human cancers, with the KRASG12C variant being a key target in lung adenocarcinoma. Despite the FDA approval of KRASG12C-selective inhibitors, their clinical efficacy has been limited, as evidenced by trials showing modest response rates and resistance development through the selection of acquired genomic alterations. Our study explores the mechanisms underlying acquired EML4-ALK fusion in KRASG12C-driven tumors developing resistance to KRASG12C inhibitors and potential therapeutic strategies to overcome it. Our findings reveal that combined ALK/KRASG12C inhibition is an effective therapeutic approach in this context. Moreover, we observed that KRASG12C/EML4-ALK tumor cells kept under constant pressure with KRASG12C inhibitors exhibit sensitivity to single-agent ALK inhibitors, suggesting a potential for rationally designed sequential treatments. Mechanistically, EML4-ALK bypasses KRASG12C inhibition by activating wild-type RAS, highlighting an additional therapeutic opportunity for multiselective RAS inhibitors under clinical investigation. Acquired EML4-ALK fusions confer resistance to KRAS inhibition in KRASG12C-driven lung adenocarcinoma. By rewiring the oncogenic signaling under inhibitor pressure, EML4-ALK creates a new oncogenic dependency that can be exploited for more effective therapeutic strategies. See related commentary by Araujo and Skoulidi, p. 2206.
中文摘要:KRAS突变是人类癌症中常见的致癌驱动因素,KRASG12C变异是肺腺癌的重要治疗靶点。尽管KRASG12C选择性抑制剂已获FDA批准,其临床疗效仍然有限,试验显示缓解率不高,并可通过筛选获得性基因组改变产生耐药。研究探讨KRASG12C驱动肿瘤在出现KRASG12C抑制剂耐药时获得EML4-ALK融合的机制,以及克服耐药的潜在治疗策略。结果显示,ALK与KRASG12C联合抑制在这一情境下是有效的治疗方式。KRASG12C/EML4-ALK肿瘤细胞在KRASG12C抑制剂持续压力下对单药ALK抑制剂表现敏感,提示合理设计序贯治疗的可能。机制上,EML4-ALK通过激活野生型RAS绕过KRASG12C抑制,为正在临床研究的多选择性RAS抑制剂提供了额外治疗机会。获得性EML4-ALK融合使KRASG12C驱动的肺腺癌对KRAS抑制产生耐药。EML4-ALK在抑制剂压力下重编程致癌信号,形成新的致癌依赖,可被用于更有效的治疗策略。参见Araujo和Skoulidi的相关评论,第2206页。
Covalent KRASG12C inhibitors have changed the treatment landscape for patients with non-small cell lung cancer and colorectal cancer, but numerous RAS-mutant cancers lack approved targeted therapies. In this study, we describe RMC-8839, an oral RAS(ON) G13C-selective, covalent, tricomplex inhibitor that induced tumor regressions in selected KRASG13C-mutant xenograft models. However, one third of KRASG13C-mutant human cancer cell lines in vitro showed incomplete RAS pathway suppression despite near-complete KRASG13C engagement, suggesting a role for wild-type RAS(ON). We find that codon 13-mutant RAS differs from other KRAS mutations, exhibiting decreased stability, increased nucleotide exchange, and substantial intrinsic and guanosine triphosphatase-activating protein-stimulated GTP hydrolysis, which decreases oncogenicity. Furthermore, co-occurring RAS pathway mutations leading to increased wild-type RAS activation are enriched in codon 13-mutant tumors. Consistent with a role for wild-type RAS(ON) signaling, the combination of RMC-8839 with a RAS(ON) multiselective inhibitor resulted in deeper inhibition of KRASG13C-mutant xenograft tumor growth than either inhibitor alone. An enhanced understanding of the underlying biology of RAS mutations is critical to inform therapeutic strategies. Our preclinical data highlight that codon 13 mutant tumors are more reliant on wild-type RAS signaling than codon 12 tumors and demonstrate that this can be addressed by combining RAS(ON) G13C-selective and multiselective inhibitors. See related commentary by Araujo and Skoulidi, p. 2206 See related article by McDaid et al., p. 2274.
中文摘要:共价KRASG12C抑制剂改变了非小细胞肺癌和结直肠癌患者的治疗格局,但许多RAS突变癌症仍缺乏获批的靶向治疗。RMC-8839是一种口服RAS(ON) G13C选择性共价三复合物抑制剂,在部分KRASG13C突变异种移植模型中诱导肿瘤消退。体外培养的KRASG13C突变人癌细胞系中有三分之一在KRASG13C近乎完全结合的情况下仍表现为RAS通路抑制不充分,提示野生型RAS(ON)发挥作用。密码子13突变RAS与其他KRAS突变不同,表现为稳定性下降、核苷酸交换增加,以及明显的固有和GTP酶激活蛋白刺激的GTP水解,从而降低致癌性。导致野生型RAS活化增加的共存RAS通路突变在密码子13突变肿瘤中富集。与野生型RAS(ON)信号作用一致,RMC-8839与RAS(ON)多选择性抑制剂联合较任一单药更深地抑制KRASG13C突变异种移植肿瘤生长。更深入理解RAS突变的底层生物学对指导治疗策略至关重要。临床前数据表明,密码子13突变肿瘤比密码子12肿瘤更依赖野生型RAS信号,并证明可通过联合RAS(ON) G13C选择性抑制剂与多选择性抑制剂来应对。见Araujo与Skoulidi相关评论,第2206页;见McDaid等相关文章,第2274页。
In recent years, significant progress has been made in developing targeted therapy for non-small cell lung cancer (NSCLC). However, these therapies are only applicable to specific NSCLC groups with corresponding gene mutations. Therefore, developing novel targeted therapies to benefit more patients remains an important task. Our prior work demonstrated that LKB1-mutant NSCLC cells are highly susceptible to cell death induced by glucose starvation. In this study, we investigated a novel combinational therapeutic strategy utilizing a sodium-glucose co-transporter-2 (SGLT2) inhibitor canagliflozin and a covalent KRASG12C inhibitor adagrasib, two clinically approved therapeutics, to selectively target LKB1-KRASG12C co-mutated NSCLC. First, we verified the co-occurrence of LKB1 and KRAS mutations in clinical NSCLC cohorts. Second, compared to other SGLT2 inhibitors, canagliflozin induced higher cytotoxicity in LKB1-mutant cells, and SGLT2 knockdown partially attenuated this effect. Mechanistically, the high susceptibility to canagliflozin was associated with impaired activation of AMP-activated protein kinase (AMPK). Furthermore, canagliflozin suppressed mammalian target of rapamycin (mTOR) activity and robustly inhibited cell growth in LKB1-mutant models in vitro. Third, adagrasib exhibited selective cytotoxicity in KRASG12C-mutated NSCLC. Finally, the combination of canagliflozin and adagrasib synergistically reduced cell viability in LKB1-KRASG12C co-mutated H23 and H2122 cells in vitro. Importantly, canagliflozin attenuated the adaptive MAPK signaling rebound induced by adagrasib in vitro. The therapeutic potential of this combination was confirmed in an H2122 nude mouse xenograft model in vivo. Collectively, our findings demonstrate that a combination of canagliflozin and adagrasib suppresses LKB1-KRASG12C co-mutated NSCLC, laying a solid preclinical foundation for developing a new therapeutic strategy for this group of NSCLC.
中文摘要:近年来,非小细胞肺癌(NSCLC)靶向治疗开发取得显著进展。然而,这些疗法仅适用于具有相应基因突变的特定NSCLC人群。开发新的靶向疗法以使更多患者获益仍是一项重要任务。我们前期工作显示,LKB1突变NSCLC细胞对葡萄糖饥饿诱导的细胞死亡高度敏感。本研究探讨了一种新的联合治疗策略,利用临床已批准的两种药物——SGLT2抑制剂卡格列净和共价KRASG12C抑制剂阿达格拉西布——选择性靶向LKB1-KRASG12C共突变NSCLC。我们在临床NSCLC队列中验证了LKB1与KRAS突变的共现。与其他SGLT2抑制剂相比,卡格列净在LKB1突变细胞中诱导的细胞毒性更高,SGLT2敲低部分减弱了这一作用。机制上,对卡格列净的高敏感性涉及AMPK激活受损。卡格列净抑制mTOR活性,并在体外LKB1突变模型中强烈抑制细胞生长。阿达格拉西布在KRASG12C突变NSCLC中表现出选择性细胞毒性。卡格列净与阿达格拉西布联合在体外LKB1-KRASG12C共突变的H23和H2122细胞中协同降低细胞活力。卡格列净还在体外减弱了阿达格拉西布诱导的适应性MAPK信号反弹。该联合方案的治疗潜力在H2122裸鼠异种移植模型中体内得到确认。这些发现表明,卡格列净与阿达格拉西布联合可抑制LKB1-KRASG12C共突变NSCLC,为针对该组NSCLC开发新的治疗策略奠定了扎实的临床前基础。
OpenDVP: an experimental and computational framework for community-empowered deep visual proteomics.
Deep visual proteomics (DVP) is an emerging approach for cell-type-specific and spatially resolved proteomics. However, its broad adoption has been constrained by the lack of an open-source end-to-end workflow within a community-driven ecosystem. Here we introduce openDVP, an experimental and computational framework for accessible and scalable DVP. OpenDVP combines open-source image analysis tools (MCMICRO, QuPath and napari) with scverse formats (AnnData and SpatialData) for multiomics integration. It provides two workflows: a fast-track pipeline requiring no image analysis expertise, and an artificial intelligence-powered pipeline incorporating state-of-the-art methods for image preprocessing, segmentation and spatial analysis. We apply openDVP across three archival tissue studies (human placenta, early stage lung cancer and locally relapsed breast cancer), integrating spatial single-cell phenotypes with exploratory proteomic measurements. Finally, we introduce deep proteomic profiling of cellular neighborhoods as a scalable approach for spatial discovery proteomics.
中文摘要:深度视觉蛋白质组学(DVP)是一种新兴的、可实现细胞类型特异且空间分辨的蛋白质组学方法。其广泛应用受限于社区驱动生态中缺少开源端到端工作流。这里介绍openDVP,一个用于可及且可扩展DVP的实验与计算框架。OpenDVP将开源图像分析工具(MCMICRO、QuPath和napari)与scverse格式(AnnData和SpatialData)结合,用于多组学整合。它提供两种工作流:无需图像分析专业知识的快速通道流程,以及整合图像预处理、分割和空间分析最新方法的人工智能驱动流程。我们在三项存档组织研究中应用openDVP(人胎盘、早期肺癌和局部复发乳腺癌),将空间单细胞表型与探索性蛋白质组测量整合。最后,我们提出细胞邻域的深度蛋白质组分析,作为空间发现蛋白质组学的一种可扩展方法。
Tumor-immune cell crosstalk critically shapes the progression of non-small cell lung cancer (NSCLC), yet the mechanisms underlying exosome-mediated immune suppression remain incompletely understood. Here, we identify a previously unrecognized exosomal lncRNA-mediated immunoregulatory axis targeted by the natural compound Ophiopogonin D (OP-D). Transcriptomic profiling and mechanistic rescue experiments revealed that Lewis lung carcinoma (LLC)-derived exosomal MALAT1 suppresses dendritic cell (DC) maturation by increasing SIRT1 expression and attenuating p65 phosphorylation. Computational modeling combined with molecular dynamics simulation predicted a stable interaction between OP-D and MALAT1, which was further validated by biolayer interferometry (BLI) and microscale thermophoresis (MST) assays, supporting MALAT1 as a direct molecular target of OP-D. In vivo, OP-D markedly inhibited tumor growth and enhanced intratumoral DC activation. Mechanistically, OP-D reduced MALAT1 abundance in LLC-derived exosomes and decreased the accumulation of exosomal MALAT1 in recipient DCs, thereby suppressing SIRT1 signaling, restoring p65 phosphorylation, and promoting DC maturation and antitumor immune responses. Furthermore, MALAT1 overexpression attenuated the immunostimulatory effects of OP-D, confirming the functional importance of the exosomal MALAT1-SIRT1/p-p65 axis. Collectively, these findings identify exosomal MALAT1 as a critical mediator of tumor-induced DC dysfunction and establish OP-D as a promising immunomodulatory natural compound capable of reprogramming tumor-immune communication in NSCLC.
中文摘要:肿瘤与免疫细胞的相互作用深刻影响非小细胞肺癌(NSCLC)进展,但外泌体介导免疫抑制的机制仍未完全阐明。本研究识别出一条此前未被认识的外泌体lncRNA免疫调控轴,并发现天然化合物麦冬皂苷D(OP-D)可靶向该轴。转录组分析和机制性回补实验显示,Lewis肺癌(LLC)来源的外泌体MALAT1通过上调SIRT1表达、减弱p65磷酸化来抑制树突状细胞(DC)成熟。计算建模结合分子动力学模拟预测OP-D与MALAT1之间存在稳定相互作用,生物层干涉(BLI)和微量热泳动(MST)实验进一步验证了这一点,支持MALAT1是OP-D的直接分子靶点。体内实验中,OP-D明显抑制肿瘤生长并增强瘤内DC活化。机制上,OP-D降低LLC来源外泌体中的MALAT1丰度,减少外泌体MALAT1在受体DC中的蓄积,从而抑制SIRT1信号、恢复p65磷酸化,并促进DC成熟和抗肿瘤免疫应答。MALAT1过表达削弱了OP-D的免疫刺激作用,证实外泌体MALAT1-SIRT1/p-p65轴的功能重要性。这些结果将外泌体MALAT1确定为肿瘤诱导DC功能障碍的关键介质,并表明OP-D是一种有前景的免疫调节天然化合物,可重编程NSCLC中的肿瘤-免疫通讯。
Non-small cell lung cancer (NSCLC) harbouring mutations in the epidermal growth factor receptor (EGFR) represents a well-defined molecular subset that is amenable to targeted therapies. However, clinical heterogeneity in treatment response and resistance highlights the critical need for a deeper understanding of co-occurring genetic alterations. Among these, TP53 mutations are the most frequent co-mutations observed in EGFR-mutant NSCLC and are increasingly recognized for their prognostic and predictive relevance. With the emergence of next-generation sequencing in routine diagnostics and the growing arsenal of targeted therapies, the time is ripe to comprehensively assess how p53 co-mutations shape tumor biology, influence drug resistance, and impact patient outcomes. This review integrates recent mechanistic insights with therapeutic strategies and emerging clinical data, offering a timely and cohesive synthesis of a rapidly evolving field. The biological function of p53, its role in EGFR-mutant lung cancer, and the implications for current and future therapies are discussed.
中文摘要:携带表皮生长因子受体(EGFR)突变的非小细胞肺癌(NSCLC)是一个界定明确的分子亚群,适合接受靶向治疗。治疗反应和耐药性的临床异质性,凸显出深入理解共存基因改变的必要性。其中,TP53突变是EGFR突变NSCLC中最常见的共突变,其预后和预测意义日益受到重视。随着下一代测序进入常规诊断,以及靶向治疗选择不断增多,全面评估p53共突变如何塑造肿瘤生物学、影响耐药并改变患者结局的时机已经成熟。该综述整合近期机制认识、治疗策略与新出现的临床数据,对这一快速演变的领域作出及时而连贯的梳理。文中讨论p53的生物学功能、其在EGFR突变肺癌中的作用,以及对当前和未来治疗的意义。
Myeloperoxidase (MPO) is a heme peroxidase that is mainly expressed and secreted by neutrophils. MPO's role in inflammatory diseases has been highlighted in recent years, but its role in tumor development remains unclear. Therefore, we investigated the role of MPO in non-small cell lung cancer (NSCLC). In silico analysis revealed a survival benefit in patients with NSCLC and low MPO expression. Furthermore, a syngeneic tumor model using MPO knockout (KO) mice revealed that mice lacking MPO had lower tumor growth than controls. The reduction in tumor size was accompanied by an increase in lymphoid populations, including natural killer cells and CD8+ T cells, suggesting a shift to a more anti-tumorigenic immune environment in MPO-KO mouse tumors. The T cell induced interferon-gamma (IFN-γ) expression was increased in MPO-KO tumors, indicating increased tumoricidal activity. CD8 depletion abolished the previously observed reduction in tumor size in MPO-KO mice, indicating that CD8+ T cells play an important role. In vitro, T cells treated with MPO showed reduced proliferation and IFN-γ expression. Furthermore, MPO associated directly with T cells. Interestingly, MPO+ lymphocytes, including CD8+ T cells, were found in tumor samples from patients with NSCLC. Our findings suggest that MPO plays an immunosuppressive role in NSCLC.
中文摘要:髓过氧化物酶(MPO)是一种主要由中性粒细胞表达和分泌的血红素过氧化物酶。近年来MPO在炎症性疾病中的作用受到关注,但其在肿瘤发生发展中的作用仍不清楚。为此,研究探讨了MPO在非小细胞肺癌(NSCLC)中的作用。计算机模拟分析显示,MPO低表达的NSCLC患者具有生存获益。使用MPO敲除小鼠建立的同系肿瘤模型显示,缺乏MPO的小鼠肿瘤生长低于对照组。肿瘤体积减小伴随淋巴样细胞群增加,包括自然杀伤细胞和CD8+ T细胞,提示MPO敲除小鼠肿瘤中的免疫环境向更抗肿瘤的方向转变。MPO敲除肿瘤中T细胞诱导的干扰素-γ(IFN-γ)表达升高,表明杀伤肿瘤活性增强。清除CD8可消除此前在MPO敲除小鼠中观察到的肿瘤体积减小,说明CD8+ T细胞发挥重要作用。体外实验中,经MPO处理的T细胞增殖和IFN-γ表达降低。MPO与T细胞直接结合。在NSCLC患者的肿瘤样本中发现了MPO阳性淋巴细胞,包括CD8+ T细胞。研究结果提示,MPO在NSCLC中发挥免疫抑制作用。
Loss of methylthioadenosine phosphorylase (MTAP), which occurs in approximately 10-15% of non-small-cell lung cancers and other solid tumors, represents a key synthetic-lethal vulnerability linking tumor metabolism to epigenetic regulation. MTAP deletion disrupts the methionine salvage pathway, leading to accumulation of methylthioadenosine (MTA) and selective dependence on protein arginine methyltransferase 5 (PRMT5). This metabolic rewiring provides a unique therapeutic opportunity to target the MAT2A-PRMT5 axis. This review summarizes recent advances in understanding MTAP biology, including the PRMT5/MAT2A feedback network, tumor heterogeneity, and adaptive resistance mechanisms encompassing metabolic compensation, splicing plasticity, and immune-cold microenvironments associated with 9p21 co-deletion. Emerging clinical data on MTA-cooperative PRMT5 inhibitors and MAT2A inhibitors are discussed, alongside challenges in diagnostic accuracy, biomarker validation, and patient stratification. Despite encouraging early-phase activity, the translation of MTAP-directed therapy is constrained by diagnostic discordance, tumor adaptability, and the absence of prospective, biomarker-driven trials. Future progress will depend on harmonized detection methods, integration of metabolic biomarkers, and rational therapeutic combinations with targeted or immune-based approaches. Collectively, targeting the MTAP-MAT2A-PRMT5 axis exemplifies a metabolism-informed precision-oncology strategy with significant translational potential.
中文摘要:甲基硫代腺苷磷酸化酶(MTAP)缺失约见于10-15%的非小细胞肺癌及其他实体瘤,是连接肿瘤代谢与表观遗传调控的关键合成致死脆弱点。MTAP缺失破坏甲硫氨酸补救途径,导致甲基硫代腺苷(MTA)蓄积,肿瘤因而选择性依赖蛋白质精氨酸甲基转移酶5(PRMT5)。这一代谢重编程为靶向MAT2A-PRMT5轴提供了独特的治疗机会。近年MTAP生物学研究取得进展,涵盖PRMT5/MAT2A反馈网络、肿瘤异质性,以及伴随9p21共缺失的适应性耐药机制,包括代谢代偿、剪接可塑性和免疫冷微环境。MTA协同型PRMT5抑制剂与MAT2A抑制剂的早期临床数据已有报道,同时存在诊断准确性、生物标志物验证与患者分层方面的挑战。早期阶段活性令人鼓舞,MTAP导向治疗的转化仍受诊断结果不一致、肿瘤可适应性以及缺乏前瞻性生物标志物驱动试验的限制。未来进展取决于检测方法的统一、代谢标志物的整合,以及与靶向治疗或免疫治疗的合理联合。靶向MTAP-MAT2A-PRMT5轴体现了以代谢为导向的精准肿瘤学策略,具有可观的转化潜力。
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide, and the search for novel therapeutic strategies is ongoing. Chalcones, a class of naturally occurring and synthetically derived open-chain flavonoid precursors, have attracted attention because of their chemical versatility and broad biological activity. This review synthesizes current findings on the molecular mechanisms through which chalcones exert their effects in NSCLC, including modulation of oxidative stress, epithelial-mesenchymal transition, DNA damage responses, and diverse cell death pathways. Chalcones have been shown to interfere with key signaling cascades, such as TGF-β, PI3K/AKT/mTOR, JAK/STAT, and Wnt/β-catenin, with reported effects on tumor proliferation, migration, invasion, and therapy resistance. Their structural flexibility enables chemical optimization aimed at improve potency, selectivity, and pharmacokinetic profiles, supporting further preclinical investigation. Despite promising preclinical results, challenges remain regarding pharmacokinetics, bioavailability, and context-dependent off-target effects. Future research should prioritize integrated mechanistic studies, structure-activity relationship analyses, selective cytotoxicity assessment, and advanced delivery strategies to improve tumor specificity. Chalcones represent chemically versatile multitarget scaffolds for further optimization in NSCLC, particularly in strategies aimed at exploiting epithelial-mesenchymal plasticity, redox adaptation, and regulated cell death.
中文摘要:非小细胞肺癌仍是全球癌症相关死亡的主要原因,寻找新型治疗策略的工作持续进行。查尔酮类化合物是一类天然存在或人工合成的开链黄酮前体,因化学结构多样和生物活性广泛而受到关注。该综述整合了查尔酮在非小细胞肺癌中发挥作用的分子机制研究,包括对氧化应激、上皮-间质转化、DNA损伤应答以及多种细胞死亡通路的调节。研究显示查尔酮可干扰TGF-β、PI3K/AKT/mTOR、JAK/STAT和Wnt/β-catenin等关键信号级联,并报道其对肿瘤增殖、迁移、侵袭和治疗耐药的影响。其结构灵活性使化学优化成为可能,以提高活性、选择性和药代动力学特征,并支持进一步开展临床前研究。尽管临床前结果具有前景,药代动力学、生物利用度以及依赖背景的脱靶效应仍是待解决的问题。后续研究应优先开展整合性机制研究、构效关系分析、选择性细胞毒性评估和先进递送策略,以提高肿瘤特异性。查尔酮是化学结构多样的多靶点骨架,可在非小细胞肺癌中进一步优化,尤其适用于利用上皮-间质可塑性、氧化还原适应和调节性细胞死亡的策略。
Abnormal EGFR signaling is considered the cause of the occurrence and development of EGFR-addicted NSCLC. EGFR tyrosine kinase inhibitors (TKIs) have dramatically revolutionized the treatment landscape of NSCLC patients over the past two decades. Most patients with EGFR-activating mutations (such as deletions in exon 19 and the L858R substitution mutation) initially respond to the first-generation of EGFR TKIs, but acquired resistance will inevitably emerge during clinical treatment, most frequently owing to the secondary T790M mutation within the ATP binding site of the receptor. As second-generation TKIs have demonstrated limited clinical efficacy against EGFR T790M-mediated resistance, third-generation TKIs with improved selectivity have spurred intensive research efforts. However, tertiary EGFR C797S mutation-mediated resistance to third-generation of EGFR TKIs remains an unmet clinical need. Moreover, EGFR exon 20 insertion (exon20ins) mutations are insensitive to prior EGFR-TKIs and are associated with poor prognosis; consequently, novel inhibitors targeting these mutations are gaining traction. Moreover, tumor heterogeneity and complexity contribute to EGFR TKIs resistance through mechanisms such as bypass pathway activation, histological transformation, and emerging metabolic reprogramming. Therefore, the development of novel EGFR TKIs and the identification of potential combination therapies to overcome EGFR TKIs resistance have attracted significant attention. Here, we review the historical progress in the development of EGFR TKIs and "on-target"-mediated and EGFR-independent resistance mechanisms, aiming to summarize the current status of and provide future directions for EGFR TKI research.
中文摘要:异常EGFR信号被认为驱动EGFR依赖型非小细胞肺癌的发生与发展。过去二十年,EGFR酪氨酸激酶抑制剂(TKI)显著改变了非小细胞肺癌的治疗格局。多数携带EGFR激活突变的患者(如外显子19缺失和L858R替代突变)最初对第一代EGFR TKI有反应,但临床治疗过程中不可避免会出现获得性耐药,最常见原因是受体ATP结合位点内出现继发性T790M突变。第二代TKI对T790M介导的耐药临床疗效有限,选择性更好的第三代TKI由此推动了大量研究。第三代EGFR TKI治疗后出现的EGFR C797S突变介导的耐药仍是未被满足的临床需求。EGFR外显子20插入(exon20ins)突变对既往EGFR-TKI不敏感,并与不良预后相关,靶向这类突变的新型抑制剂正受到关注。肿瘤异质性和复杂性通过旁路通路激活、组织学转化以及新出现的代谢重编程等机制参与EGFR TKI耐药。开发新型EGFR TKI并寻找可能克服EGFR TKI耐药的联合治疗受到高度重视。本文回顾EGFR TKI的发展历程以及靶点内(on-target)介导和EGFR非依赖性耐药机制,旨在总结EGFR TKI研究现状并提供未来方向。
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer remains a pressing clinical challenge. Liquid-liquid phase separation has emerged as a new mechanism of drug resistance, yet its role in EGFR-TKI resistance in lung cancer is largely unexplored. Herein, we prioritized Sequestosome 1 (SQSTM1/p62) as a key condensate by integrating proteomics data from EGFR-TKI resistance cell lines and clinical biopsy specimens, in which the cytoplasmic p62 condensate formation positively correlated with EGFR-TKI resistance. Domain mapping demonstrated that the PB1 and UBA domains of p62 were critical for promoting phase separation and reducing sensitivity to EGFR-TKI treatment, whereas S403 phosphorylation promoted p62 condensation and EGFR-TKI resistance. Further xenograft studies validated that reduction of p62 condensation restores EGFR-TKI sensitivity. Kinase enrichment and interaction assays identified TBK1 as an upstream regulator of p62 S403 phosphorylation to promote p62 condensation after pharmacological inhibition of EGFR. Notably, among the five compounds identified from a drug library screen that both disrupted p62 condensate formation and inhibited the viability of resistant cells, the highly selective TBK1 inhibitor GSK8612 stood out. GSK8612 inhibited p62 S403 phosphorylation and consequently, at subcytotoxic doses, synergized with EGFR-TKIs to suppress the viability of resistant cells and tumor growth in the xenograft mouse model. These findings propose TBK1-p62 axis links p62 condensate homeostasis to EGFR-TKI resistance as an underlying mechanism of action and an emerging strategy to resensitize EGFR-TKI treatment in resistant lung cancer.
中文摘要:非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)的获得性耐药仍是紧迫的临床难题。液-液相分离被视为耐药的新机制,但其在肺癌EGFR-TKI耐药中的作用仍大多未被探索。本研究整合EGFR-TKI耐药细胞系与临床活检标本的蛋白质组学数据,确定SQSTM1/p62为关键凝聚体蛋白,其细胞质p62凝聚体形成与EGFR-TKI耐药呈正相关。结构域定位显示,p62的PB1和UBA结构域对促进相分离、降低EGFR-TKI治疗敏感性至关重要,而S403磷酸化促进p62凝聚和EGFR-TKI耐药。进一步的异种移植研究验证,减少p62凝聚可恢复EGFR-TKI敏感性。激酶富集与相互作用实验确定TBK1是p62 S403磷酸化的上游调控因子,在药物抑制EGFR后促进p62凝聚。药物库筛选中发现的五种化合物既能破坏p62凝聚体形成,又能抑制耐药细胞活力,其中高选择性TBK1抑制剂GSK8612尤为突出。GSK8612抑制p62 S403磷酸化,并在亚细胞毒性剂量下与EGFR-TKI协同抑制耐药细胞活力及异种移植小鼠模型中的肿瘤生长。这些发现提出TBK1-p62轴将p62凝聚体稳态与EGFR-TKI耐药联系起来,既是一种潜在作用机制,也是使耐药肺癌对EGFR-TKI治疗重新增敏的新策略。
Ferroptosis, a regulated cell death (RCD) process driven by iron-dependent lipid peroxidation, has emerged as a pivotal focus in recent therapeutic research for lung diseases. This comprehensive review synthesizes the latest breakthroughs in ferroptosis-based therapy development, highlighting the transformative potential of nanomedicine in the precise regulation of this cell death pathway-with particular emphasis on the critical role of immune remodeling in achieving optimal therapeutic outcomes. The ferroptosis execution cascade is first delineated, alongside its mechanistic differences from disulfidptosis: a novel RCD modality that shares key regulatory nodes with ferroptosis, yet possesses distinct execution mechanisms centered on sulfur metabolism and unique translational value in lung cancer. Central to this discussion is the lung-specific ferroptosis paradox: while targeted ferroptosis induction effectively eradicates therapy-resistant lung tumors, uncontrolled activation in alveolar epithelial cells (AECs) may initiate and exacerbate interstitial lung disease (ILD). Lung cancer-specific ferroptosis vulnerabilities are further characterized, including differential sensitivity between major non-small cell lung cancer (NSCLC) subtypes and unique therapeutic windows in high-frequency mutant subtypes (e.g., KEAP1-mutant lung adenocarcinoma). Promising therapeutic strategies focus on nanomedicine-driven approaches, including tumor-targeted nanocarriers, stimuli-responsive systems, and biomimetic vesicles, that enable spatiotemporally precise control of ferroptosis, thereby maximizing antitumor efficacy while mitigating the risks of immune dysregulation and off-target pulmonary toxicity. The mechanisms by which nanomedicines overcome the core clinical bottlenecks of ferroptosis therapy are elaborated, alongside a systematic comparison of intravenous, intratumoral, and inhalation administration routes tailored for lung disease interventions. The bidirectional crosstalk between ferroptosis and antitumor immunity within the lung tumor microenvironment (TME) is systematically dissected, with detailed characterization of how nanomedicine-mediated ferroptosis modulation optimizes this crosstalk to drive therapeutic pulmonary immune remodeling. Finally, key future directions for the advancement of precision ferroptosis medicine are outlined, including spatiotemporally controlled ferroptosis activation, biomarker-driven patient stratification panels, and rational strategies to balance therapeutic efficacy and pulmonary safety throughout clinical translation.
中文摘要:铁死亡是由铁依赖的脂质过氧化驱动的调节性细胞死亡过程,已成为肺部疾病治疗研究的重要焦点。本综述梳理了基于铁死亡的治疗开发方面的最新突破,重点说明纳米医学在精准调控这一细胞死亡通路上的转化潜力,尤其强调免疫重塑对实现最佳疗效的关键作用。文中首先勾勒铁死亡的执行级联,并阐明其与二硫死亡在机制上的差异:二硫死亡是一种新型调节性细胞死亡方式,与铁死亡共享关键调控节点,却以硫代谢为核心、执行机制不同,在肺癌中具有独特的转化价值。讨论的核心是肺部特异的铁死亡悖论:靶向诱导铁死亡能有效清除治疗耐药的肺部肿瘤,但肺泡上皮细胞中的失控激活可能引发并加重间质性肺病。文章进一步刻画肺癌特异的铁死亡易感性,包括主要非小细胞肺癌亚型之间的敏感性差异,以及高频突变亚型(如KEAP1突变肺腺癌)中独特的治疗窗口。有前景的治疗策略集中于纳米医学驱动的手段,包括肿瘤靶向纳米载体、刺激响应系统和仿生囊泡,它们实现对铁死亡的时空精准控制,从而在最大化抗肿瘤疗效的同时降低免疫失调与肺部脱靶毒性的风险。文中阐述了纳米药物克服铁死亡治疗核心临床瓶颈的机制,并系统比较了面向肺部疾病干预的静脉、瘤内与吸入给药途径。文章系统剖析了肺肿瘤微环境中铁死亡与抗肿瘤免疫之间的双向交互,细致刻画纳米药物介导的铁死亡调控如何优化这一交互、驱动治疗性肺部免疫重塑。最后,文章提出精准铁死亡医学发展的关键方向,包括时空可控的铁死亡激活、生物标志物驱动的患者分层方案,以及在临床转化全过程中平衡疗效与肺部安全性的合理策略。
High-performance room-temperature CO2 sensors are essential for noninvasive clinical diagnostics, yet achieving high sensitivity in metal-organic frameworks (MOFs) remains challenging due to restricted ionic conduction. Building upon our previous expertise in guest-ion-source assembly, a strategy is proposed to enhance ionic conductivity by constructing long-range order and stable hydrogen-bonding (H-bonding) networks via chiral molecular incorporation. D-Tryptophan (D-Trp) and L-tryptophan (L-Trp) were encapsulated within γ-CD-MOF cavities to serve as chiral ion sources, facilitating the creation of bioinspired anion channels. The results reveal that the superior sensing performance of γ-CD-MOF@D-Trp is attributed to host-guest chiral preference. D‑Trp achieves ordered molecular arrangement via steric hindrance regulation, constructing long‑range order H‑bonding networks to optimize ion hopping pathways and stable sensing channels. The resulting sensor achieves a high response (2.10 toward 1000 ppm CO2), a low practical limit of detection (pLOD) of 10 ppm, and good selectivity. In particular, this work presents superior stability among MOF‑based room-temperature chemiresistive CO2 sensors reported so far, still retaining approximately 90% of its initial value after 35 days. Crucially, the fabricated γ-CD-MOFs@D-Trp-based sensor is preliminarily capable of distinguishing the differences in exhaled CO2 concentration between healthy individuals and lung cancer patients.
中文摘要:高性能室温CO2传感器对无创临床诊断至关重要,但受限于离子传导,在金属有机框架(MOFs)中实现高灵敏度仍具挑战。基于此前在客体离子源组装方面的经验,提出通过引入手性分子构建长程有序且稳定的氢键网络以增强离子电导率的策略。将D-色氨酸(D-Trp)和L-色氨酸(L-Trp)封装于γ-CD-MOF空腔内作为手性离子源,促进仿生阴离子通道的形成。结果表明,γ-CD-MOF@D-Trp的优异传感性能源于主客体手性偏好。D-Trp通过位阻调控实现有序分子排列,构建长程有序氢键网络,从而优化离子跳跃路径并形成稳定传感通道。所得传感器实现对1000 ppm CO2的高响应(2.10)、10 ppm的低实际检测限(pLOD)及良好选择性。该工作在迄今报道的MOF基室温化学电阻型CO2传感器中表现出更优稳定性,35天后仍保持初始值约90%。关键的是,所制备的γ-CD-MOFs@D-Trp基传感器初步能够区分健康个体与肺癌患者呼出CO2浓度的差异。
Non-small cell lung cancer (NSCLC) represents the most prevalent form of malignant tumor and constitutes a principal cause of cancer-related mortality globally. Conventional therapeutic approaches predominantly induce apoptosis; however, their efficacy is often compromised by the development of drug resistance. Methuosis, a form of regulated cell death distinct from apoptosis, is characterized by aberrant macropinocytosis and the formation of cytoplasmic vacuoles. Aloperine (ALO), a naturally occurring antitumor alkaloid, has been observed to induce methuosis in cancer cells, although its precise molecular targets and mechanisms remain to be elucidated. This study investigated the anti-NSCLC effects of ALO using cell lines, patient-derived organoids, and mouse xenograft models. Through various assays, it was demonstrated that ALO directly interacts with VPS34 at the I760 residue and promotes TIP60-mediated lactylation of VPS34 at K356 and K781. This interaction inhibits VPS34 kinase activity and reduces intracellular PI(3)P production. The subsequent decrease in PI(3)P levels impedes Armus endosomal recruitment, disrupts Rab7 cycling, leads to the accumulation of macropinosomes, and impairs endolysosomal fusion, ultimately inducing methuosis. ALO exhibits significant antitumor efficacy and acts synergistically with cisplatin to co-activate methuosis and apoptosis, all while avoiding noticeable systemic toxicity. Collectively, ALO targets VPS34 lactylation and disrupts Armus/Rab7 signaling. When used in conjunction with cisplatin, it constitutes a safe and effective therapeutic strategy for NSCLC.
中文摘要:非小细胞肺癌是最常见的恶性肿瘤类型,也是全球癌症相关死亡的主要原因。常规治疗主要诱导凋亡,但疗效常因耐药而受限。Methuosis是一种不同于凋亡的调节性细胞死亡形式,以巨胞饮异常和胞质空泡形成为特征。苦豆碱(ALO)是一种天然抗肿瘤生物碱,已观察到其可在癌细胞中诱导methuosis,但精确分子靶点和机制尚待阐明。本研究采用细胞系、患者来源类器官和小鼠异种移植模型考察ALO的抗非小细胞肺癌作用。通过多种实验证明,ALO在I760残基处直接与VPS34相互作用,并促进TIP60介导的VPS34在K356和K781位点的乳酰化。该相互作用抑制VPS34激酶活性,减少细胞内PI(3)P生成。PI(3)P水平随之下降,阻碍Armus在内体上的募集,破坏Rab7循环,导致巨胞饮体积累并损害内溶酶体融合,最终诱导methuosis。ALO表现出显著抗肿瘤疗效,与顺铂协同共激活methuosis和凋亡,同时未出现明显全身毒性。ALO靶向VPS34乳酰化并破坏Armus/Rab7信号,与顺铂联用可构成安全有效的非小细胞肺癌治疗策略。
7乳腺癌 (29篇)
临床研究 (13篇)
The treatment landscape of ERBB2 (formerly HER2)-positive metastatic breast cancer has evolved substantially during the past decade, with emerging therapies challenging the long-standing induction-maintenance paradigm established by the CLEOPATRA trial (NCT00567190). However, optimal treatment selection, sequencing, and duration remain uncertain, particularly in the context of increasing therapeutic complexity and biologic heterogeneity. Taxane-based chemotherapy combined with trastuzumab and pertuzumab has long been the standard first-line induction regimen, followed by maintenance anti-ERBB2 therapy with or without endocrine therapy based on hormone receptor status. Recent data from the DESTINY-Breast09 trial (DB09; NCT04784715) demonstrate superior progression-free survival with trastuzumab deruxtecan plus pertuzumab, supporting its recent US Food and Drug Administration approval and prompting questions regarding the necessity of chemotherapy, optimal duration of antibody-drug conjugate therapy, and the role of a dual ERBB2 blockade. Maintenance strategies have also expanded, particularly in hormone receptor-positive disease, with incorporation of endocrine therapy and CDK4/6 inhibitors, as demonstrated in the PATINA trial (NCT02947685). The HER2CLIMB-05 trial (NCT05132582) provided an additional maintenance approach using a triplet anti-ERBB2 strategy. These nonchemotherapy maintenance options are designed to have fewer toxic effects and better quality of life than chemotherapy-based strategies. These developments raise questions regarding the necessity of chemotherapy, optimal duration of antibody-drug conjugate therapy, and the role of dual ERBB2 blockade. Emerging biomarker-driven approaches, including the HER2DX assay and circulating tumor DNA, remain investigational and are not yet part of routine clinical practice but aim to optimize treatment selection. Novel strategies, such as chemotherapy-free regimens and sequential multiagent approaches, as in the SAPPHO study (NCT06439693), are challenging traditional paradigms. The management of ERBB2-positive metastatic breast cancer is transitioning toward a more individualized approach that balances efficacy, toxic effects, and patient preferences. Integrating biomarker-driven strategies will be essential to optimize treatment selection, duration, and sequencing, with the goal of improving long-term outcomes while preserving quality of life.
中文摘要:过去十年,ERBB2(原HER2)阳性转移性乳腺癌的治疗格局发生了显著变化,新兴疗法对CLEOPATRA试验(NCT00567190)确立的长期诱导-维持范式提出挑战。然而,最佳治疗选择、序贯安排和持续时间仍不确定,尤其在治疗复杂性增加和生物学异质性背景下。紫杉类化疗联合曲妥珠单抗和帕妥珠单抗长期作为一线诱导方案,随后根据激素受体状态给予含或不含内分泌治疗的抗ERBB2维持治疗。近期DESTINY-Breast09试验(DB09;NCT04784715)数据显示,德曲妥珠单抗联合帕妥珠单抗可显著改善无进展生存期,支持其近期获美国食品药品监督管理局批准,并引发关于化疗必要性、抗体药物偶联物最佳治疗时长以及双重ERBB2阻断作用的疑问。维持策略也有所扩展,尤其在激素受体阳性疾病中,PATINA试验(NCT02947685)显示可纳入内分泌治疗和CDK4/6抑制剂。HER2CLIMB-05试验(NCT05132582)提供了另一种采用三药抗ERBB2策略的维持方案。这些非化疗维持方案旨在较化疗方案减少毒性反应并改善生活质量。上述进展提出化疗必要性、抗体药物偶联物最佳治疗时长以及双重ERBB2阻断作用的问题。新兴生物标志物驱动方法,包括HER2DX检测和循环肿瘤DNA,仍处于研究阶段,尚未纳入常规临床实践,但目标是优化治疗选择。新策略,如无化疗方案和序贯多药方法(SAPPHO研究,NCT06439693),正在挑战传统范式。ERBB2阳性转移性乳腺癌的管理正转向更个体化方法,在疗效、毒性和患者偏好之间取得平衡。整合生物标志物驱动策略对于优化治疗选择、时长和序贯安排至关重要,目标是在保持生活质量的同时改善长期结局。
[This corrects the article DOI: 10.1002/mco2.70468.].
中文摘要:本更正针对 DOI:10.1002/mco2.70468 一文。
Estrogen receptor (ER)-positive breast cancer treatment is based primarily on endocrine therapy. To dissect mechanisms of sensitivity to aromatase inhibitors in ER-positive breast cancer, we profiled tumor biopsies from 25 patients during neoadjuvant therapy using single-cell RNA sequencing, immune receptor sequencing and enhancer activity mapping. Malignant cells with high ER signaling and elevated activity of enhancers with ER binding sites were sensitive to treatment. Resistance was associated with androgen receptor signaling, dedifferentiation and epithelial-mesenchymal transition. Poor responders preferentially used the androgen receptor cis-regulome under treatment pressure. The baseline tumor microenvironment was associated with tumor downstaging. Poor responders exhibited a 'hot', yet ineffective immune landscape enriched for naive lymphoid and undifferentiated myeloid cells. Good responders showed an active immune microenvironment with sustained clonal expansion of T cells. Our longitudinal single-cell analyses elucidate the genetic, cellular and epigenetic mechanisms driving sensitivity and resistance to neoadjuvant aromatase inhibition in ER-positive breast cancer.
中文摘要:雌激素受体(ER)阳性乳腺癌的治疗以内分泌治疗为基础。为解析ER阳性乳腺癌对芳香化酶抑制剂的敏感性机制,研究团队对新辅助治疗期间25例患者的肿瘤活检样本进行了单细胞RNA测序、免疫受体测序与增强子活性图谱分析。ER信号高且带ER结合位点增强子活性升高的恶性细胞对治疗敏感。耐药与雄激素受体信号、去分化及上皮-间质转化相关。疗效差的患者在治疗压力下优先使用雄激素受体顺式调控组。基线肿瘤微环境与肿瘤降期相关。疗效差的患者呈现「热」但无效的免疫格局,其中富集初始淋巴样细胞与未分化髓系细胞。疗效好的患者免疫微环境活跃,T细胞克隆性扩增得以持续。纵向单细胞分析阐明了驱动ER阳性乳腺癌对新辅助芳香化酶抑制治疗敏感与耐药的遗传、细胞与表观遗传机制。
Chemoimmunotherapy has become a standard neoadjuvant treatment for stage II-III triple-negative breast cancer (TNBC). We previously reported a promising total pathological complete response (tpCR) rate with the de-escalated, platinum-free NeoTENNIS regimen; however, long-term outcomes have not been fully characterized. The single-arm, phase II NeoTENNIS trial evaluated neoadjuvant dose-dense epirubicin/cyclophosphamide followed by toripalimab plus nab-paclitaxel in patients with stage II-III TNBC. The protocol specified four neoadjuvant cycles of toripalimab, without mandatory continuation in the adjuvant setting. The primary endpoint was tpCR, and event-free survival (EFS) was a prespecified secondary endpoint. EFS was measured from the date of the first study dose. Among 70 enrolled patients, 62.9% had stage III disease. At a median follow-up of 44.7 months, 14 EFS events had occurred, and the estimated 3-year EFS rate was 80.6% (95% CI, 68.9-88.3%). The 3-year EFS rates were 92.2% and 66.0% in patients with and without tpCR, respectively. Non-tpCR was associated with inferior EFS in the multivariable model (adjusted hazard ratio [HR], 4.20; 95% CI, 1.11-15.92). In exploratory genomic analyses, pathogenic germline BRCA1 variants (HR, 4.36; 95% CI, 1.15-16.59; P = 0.031) and somatic JAK2 amplification (HR, 6.61; 95% CI, 1.38-31.58; P = 0.018) were associated with inferior EFS. The platinum-free neoadjuvant NeoTENNIS regimen was associated with encouraging EFS in a predominantly stage III, node-positive population. These findings warrant further evaluation of this neoadjuvant de-escalation strategy in randomized clinical trials. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT04418154, registered June 5, 2020.
中文摘要:化疗免疫治疗已成为II–III期三阴性乳腺癌的标准新辅助治疗。我们此前报道了降阶梯、不含铂的NeoTENNIS方案取得有希望的总病理完全缓解(tpCR)率,但长期结局尚未充分明确。单臂II期NeoTENNIS试验评估II–III期三阴性乳腺癌患者接受剂量密集表柔比星/环磷酰胺序贯特瑞普利单抗联合白蛋白紫杉醇的新辅助治疗。方案规定4个周期新辅助特瑞普利单抗,辅助阶段不强制继续使用。主要终点为tpCR,无事件生存(EFS)为预设次要终点。EFS自首次研究给药日期起计算。70例入组患者中,62.9%为III期。中位随访44.7个月时,发生14例EFS事件,估计3年EFS率为80.6%(95% CI,68.9–88.3%)。达到与未达到tpCR患者的3年EFS率分别为92.2%和66.0%。多变量模型中,未达到tpCR与较差EFS相关(校正风险比[HR],4.20;95% CI,1.11–15.92)。探索性基因组分析中,致病性胚系BRCA1变异(HR,4.36;95% CI,1.15–16.59;P=0.031)和体细胞JAK2扩增(HR,6.61;95% CI,1.38–31.58;P=0.018)与较差EFS相关。不含铂的新辅助NeoTENNIS方案在以III期、淋巴结阳性为主的人群中与令人鼓舞的EFS相关。这些发现值得在随机临床试验中进一步评估该新辅助降阶梯策略。临床试验注册:ClinicalTrials.gov,NCT04418154,注册于2020年6月5日。
Magrolimab blocks CD47, a molecule that mediates cancer immune evasion from phagocytes. The ELEVATE TNBC study evaluated magrolimab plus standard-of-care therapies in advanced/metastatic triple-negative breast cancer (mTNBC). Two cohorts were enrolled in the safety run-in (SRI) and phase II portions. Phase II cohort 1 randomly assigned 28 patients with untreated, programmed death-ligand 1-negative mTNBC to receive nab-paclitaxel or paclitaxel with/without magrolimab. Phase II cohort 2 enrolled 43 patients with mTNBC (one to two prior lines of treatment in the metastatic setting) to receive magrolimab with sacituzumab govitecan. Primary endpoints were adverse event (AE) incidence (SRIs), investigator-assessed progression-free survival (PFS; phase II cohort 1), and objective response rate (ORR; phase II cohort 2). No dose-limiting toxicities occurred. In phase II cohort 1, median PFS was 13.9 and 10.0 months (hazard ratio 0.456, 95% confidence interval 0.147-1.409) and ORRs were 35.7% and 21.4% for magrolimab-taxane and taxane therapy, respectively. In phase II cohort 2, ORR was 38.1%, and median PFS was 5.5 months. Early study closure limited interpretation of efficacy; PFS/ORR values should be considered descriptive. AE rates were consistent with known profiles for each agent, with no new safety signals or fatal AEs. Magrolimab plus standard of care was manageable. Further studies are needed to determine the role of anti-CD47 therapies in mTNBC.
中文摘要:Magrolimab通过阻断CD47发挥作用,CD47是介导肿瘤逃避免疫吞噬的分子。ELEVATE TNBC研究评估了magrolimab联合标准治疗在晚期/转移性三阴性乳腺癌(mTNBC)中的效果。安全性导入期和II期部分共纳入两个队列。II期队列1随机分配28例未经治疗、PD-L1阴性的mTNBC患者,接受白蛋白紫杉醇或紫杉醇联合或不联合magrolimab治疗。II期队列2纳入43例mTNBC患者(转移阶段既往接受过1–2线治疗),接受magrolimab联合戈沙妥珠单抗治疗。主要终点为不良事件发生率(安全性导入期)、研究者评估的无进展生存期(II期队列1)和客观缓解率(II期队列2)。未发生剂量限制性毒性。II期队列1中,magrolimab联合紫杉类与单用紫杉类的中位PFS分别为13.9个月和10.0个月(风险比0.456,95%置信区间0.147–1.409),ORR分别为35.7%和21.4%。II期队列2的ORR为38.1%,中位PFS为5.5个月。研究提前终止限制了对疗效的解读,PFS/ORR数值应视为描述性结果。不良事件发生率与各药物已知特征一致,未出现新的安全性信号或致死性不良事件。magrolimab联合标准治疗的安全性可控。需进一步研究确定抗CD47治疗在mTNBC中的作用。
Adjuvant endocrine therapy (AET) reduces recurrence and mortality for women with early-stage hormone receptor-positive breast cancer, yet long-term adherence is suboptimal, largely due to treatment-related symptoms. Remote patient monitoring (RPM) is a potential strategy to improve symptom management, but evidence of its cost-effectiveness is limited. To evaluate the cost-effectiveness of RPM for women prescribed AET for early-stage breast cancer. This economic evaluation used data from the THRIVE trial, which randomized adult women initiating AET to an application (app), the app with tailored feedback, or enhanced usual care (EUC) at a large cancer center with 14 clinics from November 15, 2018, to June 11, 2021. The intervention lasted 6 months, and participants were followed up for 12 months (completed September 19, 2022). Each of the 2 interventions was compared with EUC, with uncertainty assessed using probabilistic sensitivity analyses. Data analyses were performed from February 1, 2025, to September 2, 2026. Primary outcomes included costs, which were captured during the 12-month study period from a societal perspective, including medical costs, patient time and travel costs, clinician time costs responding to alerts, and app costs; quality-adjusted life years (QALYs), derived from patient-reported 12-item Short Form Health Survey scores; incremental cost-effectiveness ratios; and incremental net monetary benefit. Of 304 participants randomized, 214 had complete data. The mean (SD) age was 58.9 (10.8) years. Mean (SD) total costs were highest for the EUC arm ($11 596.10 [$30 231.95]) compared with the app arm ($6682.15 [$12 963.34]; difference, -$4913.95 [95% CI, -$12 864.27 to $3036.37]) and app plus feedback arm ($11 407.85 [$47 068.42]; difference, -$188.25 [95% CI, -$12 830.16 to $12 453.66]). The mean (SD) estimated QALYs were similar across arms (app, 0.79 [012]; app plus feedback, 0.78 [0.13]; EUC, 0.78 [0.12]). This results in an incremental net monetary benefit of $5813.95 (95% uncertainty interval [UI], -$1860.00 to $16 492.58) for app group and $88.25 (95% UI, -$14 781.73 to $13 849.34) for the app plus feedback group at $100 000 per QALY. Probabilistic sensitivity analyses suggest that the app intervention had a 68.2% to 78.1% probability of being cost-effective compared with EUC across a willingness-to-pay threshold of $0 to $200 000 per QALY, while the app plus feedback intervention had a 53.6% to 70.8% probability of being cost-effective. In this economic evaluation of RPM for women receiving AET, app-only RPM showed lower costs with similar QALY compared with EUC. Its simpler design may also be more readily scalable than the app plus feedback intervention, supporting its potential as a pragmatic, value-based supportive care strategy in oncology.
中文摘要:辅助内分泌治疗(AET)可降低早期激素受体阳性乳腺癌女性的复发和死亡,但长期依从性不理想,主要与治疗相关症状有关。远程患者监测(RPM)是改善症状管理的潜在策略,但成本效果证据有限。评估RPM用于接受AET的早期乳腺癌女性的成本效果。本经济学评价使用THRIVE试验数据,该试验于2018年11月15日至2021年6月11日在一家大型癌症中心的14家诊所,将开始AET的成年女性随机分配至应用程序(app)、app加个体化反馈或强化常规照护(EUC)。干预持续6个月,随访12个月(2022年9月19日完成)。两种干预分别与EUC比较,不确定性采用概率敏感性分析评估。数据分析于2025年2月1日至2026年9月2日进行。主要结局包括成本,从社会视角在12个月研究期间采集,含医疗成本、患者时间和交通成本、临床医生响应警报的时间成本及app成本;质量调整生命年(QALY),由患者报告的12项简表健康调查评分推导;增量成本效果比;增量净货币效益。304名随机参与者中214名有完整数据。平均(SD)年龄为58.9(10.8)岁。平均(SD)总成本以EUC组最高(11 596.10美元[30 231.95美元]),app组为6682.15美元[12 963.34美元](差值-4913.95美元[95% CI,-12 864.27至3036.37美元]),app加反馈组为11 407.85美元[47 068.42美元](差值-188.25美元[95% CI,-12 830.16至12 453.66美元])。平均(SD)估计QALY各组相近(app 0.79[0.12];app加反馈0.78[0.13];EUC 0.78[0.12])。在每QALY 100 000美元阈值下,app组增量净货币效益为5813.95美元(95%不确定性区间[UI],-1860.00至16 492.58美元),app加反馈组为88.25美元(95% UI,-14 781.73至13 849.34美元)。概率敏感性分析提示,在每QALY 0至200 000美元支付意愿阈值范围内,app干预相较EUC具有成本效果的概率为68.2%至78.1%,app加反馈干预为53.6%至70.8%。在这项针对接受AET女性的RPM经济学评价中,仅app的RPM相较EUC成本更低且QALY相近。其设计更简单,也可能比app加反馈干预更易推广,支持其作为肿瘤学中务实、基于价值的支持性照护策略的潜力。
Although surveillance mammography is commonly performed among older women, whether this practice improves clinical outcomes in this population is uncertain. To evaluate the association between surveillance mammography and second primary breast cancer stage at diagnosis among older women with a history of breast cancer. This retrospective longitudinal cohort study used Surveillance, Epidemiology, and End Results Program-Medicare data. Women with nonmetastatic breast cancer that was diagnosed from 2004 to 2008 at 67 years or older who had a surveillance mammogram at approximately 5 years after diagnosis were included. Analyses used cause-specific hazard models with inverse probability of treatment weighting to estimate the risk of stage-specific second primary breast cancer among women who continued surveillance mammography and those who did not. Analyses were stratified by hormone receptor (HR) status of the initial breast cancer. Follow-up continued until second breast cancer diagnosis, death, or end of the study (December 2021). Analyses were performed between November 2025 and August 2026. Continued surveillance mammography more than 5 years after initial diagnosis. Stage-specific cumulative incidence of a second primary breast cancer, categorized as in situ, localized, or advanced (regional or distant). Among 9888 women (mean [SD] age, 81.1 [5.5] years; 387 Hispanic [3.9%], 514 non-Hispanic Black [5.1%], and 8514 White individuals [86.1%]), 8055 (81.4%) had in situ or localized disease and 7621 (76.9%) had HR-positive tumors at initial diagnosis. Overall, 7940 women (80.3%) continued surveillance at cohort entry. Advanced second primary breast cancer was rare, and incidence did not differ among those who continued surveillance and those who did not (cumulative incidence, 1.65% vs 2.15%; hazard ratio, 0.76; 95% CI, 0.46-1.26). Results were similar in subgroups of women with initial HR-positive and HR-negative breast cancer. The results of this cohort study suggest that among older survivors of breast cancer, continued surveillance mammography was not associated with a reduced risk of advanced second primary breast cancer. The absolute risk of advanced cancer was low, and surveillance decisions should be individualized given the potential burdens of continued surveillance.
中文摘要:对高龄女性常规开展随访乳腺X线摄影,但这一做法能否改善该人群的临床结局尚不明确。评估随访乳腺X线摄影与有乳腺癌病史的高龄女性第二原发乳腺癌诊断分期之间的关联。本回顾性纵向队列研究使用监测、流行病学和最终结果项目-医疗保险(SEER-Medicare)数据。纳入2004年至2008年确诊非转移性乳腺癌、确诊时年龄67岁及以上、且在确诊约5年时接受过随访乳腺X线摄影的女性。分析采用病因特异性风险模型并结合逆概率治疗加权,估计继续随访乳腺X线摄影与未继续者发生分期特异性第二原发乳腺癌的风险。分析按初诊乳腺癌的激素受体(HR)状态分层。随访持续至第二原发乳腺癌确诊、死亡或研究结束(2021年12月)。分析实施于2025年11月至2026年8月。暴露为初诊确诊5年后继续随访乳腺X线摄影。结局为第二原发乳腺癌的分期特异性累积发生率,分为原位癌、局限期和晚期(区域或远处)。9888名女性(平均[SD]年龄81.1[5.5]岁;西班牙裔387人[3.9%]、非西班牙裔黑人514人[5.1%]、白人8514人[86.1%])中,8055人(81.4%)初诊时为原位癌或局限期病变,7621人(76.9%)为HR阳性肿瘤。总体有7940名女性(80.3%)在进入队列时继续随访。晚期第二原发乳腺癌少见,继续随访者与未继续者的发生率无差异(累积发生率1.65%对2.15%;风险比0.76;95% CI 0.46-1.26)。在初诊HR阳性和HR阴性亚组中结果相似。本队列研究结果表明,在乳腺癌高龄生存者中,继续随访乳腺X线摄影与晚期第二原发乳腺癌风险降低无关。晚期癌症的绝对风险较低,考虑到持续随访的潜在负担,随访决策应个体化。
Background Contrast-enhanced mammography (CEM) is increasingly used in breast cancer diagnostics; however, randomized trials assessing the added value of CEM in preoperative staging of breast cancer beyond digital mammography, digital breast tomosynthesis, and US are lacking. Purpose To assess the added value of CEM for preoperative breast cancer staging in a randomized controlled trial. Materials and Methods This prospective randomized controlled trial (Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions) enrolled women diagnosed with early-stage breast cancer eligible for primary surgery at two breast centers in Sweden. Participants were randomized 1:1 to preoperative CEM or control from November 2020 through April 2024. The primary outcome was a 10% change in treatment due to preoperative CEM findings. Secondary outcomes included differences in reoperation and mastectomy rates between groups and accuracy of malignant extent estimation with CEM, mammography/tomosynthesis, and US using histopathologic extent as the reference, assessed with Bland-Altman statistics and concordance analysis. Subgroup analyses were performed according to menopausal status, breast density, histopathologic type of cancer, lesion size, and presence of microcalcifications at baseline imaging. Results In total, 415 participants (median age, 66 years; IQR, 56-73 years) completed the trial: 202 in the CEM group and 213 in the control group. Treatment was changed in 17 of 202 participants (8.4%; 95% CI: 5.3, 13.1) based on CEM findings. No evidence of differences was observed between the CEM and control groups with regard to mastectomy (17% [35 of 202] vs 18% [39 of 213]; P = .78) or reoperation (7.9% [16 of 202] vs 10% [22 of 213]; P = .39) rates. CEM showed the closest agreement with histopathologic malignant extent (bias, 3.5 mm), outperforming mammography and/or tomosynthesis (4.8 mm) and US (10.7 mm) overall and in nine of 10 predefined subgroups, except for ductal carcinoma in situ. Conclusion This trial did not meet its primary end point of a 10% treatment change; however, preoperative CEM improved malignant extent estimation. ClinicalTrials.gov: NCT04437602 © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license. Supplemental material is available for this article. See also the editorial by Mesurolle and El Khoury in this issue.
中文摘要:背景:对比增强乳腺X线摄影(CEM)在乳腺癌诊断中的应用日益增多,但评估CEM在数字乳腺X线摄影、数字乳腺断层合成和超声之外对乳腺癌术前分期附加价值的随机试验仍缺乏。目的:在随机对照试验中评估CEM对乳腺癌术前分期的附加价值。材料与方法:这项前瞻性随机对照试验(术前对比增强乳腺X线摄影在恶性乳腺病灶分期中的附加价值,PROCEM)纳入在瑞典两家乳腺中心确诊为早期乳腺癌且适合原发手术的女性。2020年11月至2024年4月,参与者按1:1随机分入术前CEM组或对照组。主要结局为因术前CEM发现导致治疗改变达到10%。次要结局包括两组再手术率和乳房切除术率的差异,以及以组织病理学范围为参照,采用Bland-Altman统计和一致性分析评估CEM、乳腺X线摄影/断层合成和超声对恶性范围估计的准确性。按绝经状态、乳腺密度、组织病理学癌型、病灶大小和基线影像微钙化存在情况进行亚组分析。结果:共415名参与者完成试验(中位年龄66岁;四分位距56-73岁),CEM组202名,对照组213名。202名参与者中有17名(8.4%;95% CI:5.3,13.1)因CEM发现而改变治疗。CEM组与对照组在乳房切除术(17%[35/202]对18%[39/213];P=0.78)或再手术(7.9%[16/202]对10%[22/213];P=0.39)率方面未观察到差异证据。CEM与组织病理学恶性范围的一致性最接近(偏倚3.5 mm),总体及10个预设亚组中的9个均优于乳腺X线摄影和/或断层合成(4.8 mm)及超声(10.7 mm),导管原位癌除外。结论:本试验未达到治疗改变10%的主要终点,但术前CEM改善了恶性范围估计。ClinicalTrials.gov:NCT04437602。
The therapeutic landscape of HER2-positive metastatic breast cancer (HER2-positive mBC) has been transformed by increasingly effective HER2-directed therapies. Following the establishment of trastuzumab and pertuzumab as first-line standard treatment, highly active antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), together with HER2-selective tyrosine kinase inhibitors (TKIs) such as tucatinib, have substantially improved progression-free and overall survival (PFS, OS) while expanding treatment opportunities, including for patients with central nervous system (CNS) metastases. Consequently, the major clinical challenge has shifted from drug availability to treatment optimisation. Defining the optimal sequence of HER2-directed therapies, balancing efficacy with cumulative toxicity, identifying predictive biomarkers and integrating emerging therapeutic combinations remain unresolved. This review critically examines the evolution of treatment strategies for HER2-positive mBC, focusing on first-line treatment selection, maintenance, CNS management, post-T-DXd sequencing, long responders, mechanisms of resistance and biomarker development. Finally, we discuss emerging therapeutic strategies and future clinical-trial designs that are expected to shape the next generation of personalised HER2-directed therapy. METHODS: This narrative review synthesised current evidence, prioritising randomised phase III trials, pivotal phase II studies, international guidelines and clinically relevant translational research published or presented up to August 2026. Earlier landmark studies were included when necessary to contextualise current treatment strategies.
中文摘要:HER2靶向治疗疗效不断提升,已改变HER2阳性转移性乳腺癌的治疗格局。曲妥珠单抗联合帕妥珠单抗确立一线标准治疗后,高活性抗体偶联药物(ADC),尤其是德曲妥珠单抗(T-DXd),以及图卡替尼等HER2选择性酪氨酸激酶抑制剂(TKI),显著改善了无进展生存期和总生存期(PFS、OS),并扩大了治疗机会,包括中枢神经系统(CNS)转移患者。主要临床挑战已从药物可及性转向治疗优化。HER2靶向治疗的最佳序贯、疗效与累积毒性的平衡、预测性生物标志物的识别以及新兴治疗组合的整合仍未解决。本综述批判性审视HER2阳性mBC治疗策略的演变,重点讨论一线治疗选择、维持治疗、CNS管理、T-DXd后序贯治疗、长期缓解者、耐药机制和生物标志物研发,并讨论有望塑造下一代个体化HER2靶向治疗的新兴治疗策略和未来临床试验设计。方法:本叙述性综述综合当前证据,优先纳入截至2026年8月已发表或报告的关键性III期随机试验、II期研究、国际指南及具有临床相关性的转化研究,必要时纳入早期里程碑研究以说明当前治疗策略的背景。
Ductal carcinoma in situ (DCIS) and premalignant breast lesions represent a heterogeneous spectrum of non-invasive breast neoplasia with variable potential for progression to invasive breast cancer. The widespread use of screening mammography has led to a marked increase in DCIS detection, raising concerns about overtreatment and highlighting the need for risk-adapted management strategies. Current standard treatment for DCIS includes breast-conserving surgery or mastectomy, often followed by adjuvant radiotherapy to reduce local recurrence when breast conservative surgery (BCS) is performed. Endocrine therapy with tamoxifen or aromatase inhibitors is recommended for selected patients with hormone receptor-positive disease to lower the risk of ipsilateral and contralateral events. However, despite improved local control, these interventions have not consistently demonstrated a survival benefit, prompting reassessment of treatment intensity. Emerging strategies aim to individualize therapy by integrating clinicopathologic factors with molecular and genomic profiling to better stratify recurrence and progression risk. Ongoing clinical trials are evaluating active surveillance for carefully selected low-risk DCIS, as well as de-escalation approaches that may safely omit radiotherapy or surgery. Management of premalignant lesions such as atypical ductal hyperplasia increasingly emphasizes risk reduction, surveillance, and patient-centered decision-making. The aim of our review is to summarize current therapeutic approaches and emerging strategies in the management of DCIS and premalignant breast lesions, with a particular focus on risk stratification, treatment de-escalation, and future directions toward personalized care.
中文摘要:乳腺导管原位癌(DCIS)及癌前乳腺病变是一组异质性非浸润性乳腺肿瘤,进展为浸润性乳腺癌的潜能不一。筛查性乳腺X线摄影的普及使DCIS检出明显增加,带来过度治疗担忧,也凸显风险适配管理策略的必要。DCIS现行标准治疗包括保乳手术或乳房切除,保乳手术后常辅以放疗以降低局部复发。激素受体阳性且经选择的患者可接受他莫昔芬或芳香化酶抑制剂内分泌治疗,以降低同侧和对侧事件风险。局部控制虽改善,这些干预并未一致显示生存获益,促使重新评估治疗强度。新兴策略将临床病理因素与分子及基因组分析结合,以更好分层复发和进展风险,推动个体化治疗。正在开展的临床试验在严格选择的低风险DCIS中评估主动监测,也评估可安全省略放疗或手术的降阶梯方案。对导管上皮非典型增生等癌前病变,管理日益强调风险降低、监测和以患者为中心的决策。综述旨在总结DCIS及癌前乳腺病变治疗的现行方法与新兴策略,重点讨论风险分层、治疗降阶梯及走向个体化管理的未来方向。
Camizestrant (Etcamah®) is an orally available, potent selective estrogen receptor degrader (SERD) and complete estrogen receptor (ER) α antagonist being developed by AstraZeneca for the treatment of breast cancer. It received its first approval in the United Arab Emirates (UAE) in May 2025. At the time of writing, the drug had been subsequently approved in Saudi Arabia, Japan, the EU, Canada, the UK and the USA. In patients with ER-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a detectable ESR1 mutation, switching to camizestrant while continuing the same CDK4/6 inhibitor significantly prolonged progression-free survival in comparison with continuing treatment with an aromatase inhibitor in combination with a CDK4/6 inhibitor. This article summarizes the milestones in the development of camizestrant leading to this first approval for the treatment of adults with locally advanced or metastatic hormone receptor positive (HR+), HER2-negative breast cancer with an ESR1 gene mutation that emerges during first-line hormonal therapy, in combination with CDK4/6 inhibitors.
中文摘要:Camizestrant(Etcamah®)是一种口服、强效的选择性雌激素受体降解剂(SERD)和完全雌激素受体(ER)α拮抗剂,由阿斯利康开发用于乳腺癌治疗。该药于2025年5月在阿联酋获得首次批准。截至撰稿时,该药随后已在沙特阿拉伯、日本、欧盟、加拿大、英国和美国获批。在ER阳性且人表皮生长因子受体2(HER2)阴性、可检测到ESR1突变的乳腺癌患者中,在继续使用同一CDK4/6抑制剂的情况下换用camizestrant,与继续使用芳香化酶抑制剂联合CDK4/6抑制剂相比,显著延长了无进展生存期。文章总结了camizestrant开发过程中的里程碑,这些里程碑促成了其首次获批,用于治疗在一线激素治疗期间出现ESR1基因突变的局部晚期或转移性激素受体阳性(HR+)、HER2阴性乳腺癌成人患者,与CDK4/6抑制剂联合使用。
Selective estrogen receptor degraders (SERDs) have emerged as a key therapeutic class in hormone receptor-positive (HR+) breast cancer, combining estrogen receptor (ER) antagonism with direct receptor degradation. Despite this dual mechanism, pivotal trials of SERDs in premenopausal patients-across both metastatic and adjuvant settings-have mandated concurrent ovarian function suppression (OFS). Mechanistically, because ER undergoes continuous synthesis, both receptor antagonism and degradation require sustained occupancy of the ligand-binding domain. The central question is therefore one of competitive target engagement-whether oral SERDs can achieve and maintain adequate receptor occupancy in a high-estrogen premenopausal environment, independent of their intrinsic degradation efficiency. Reframing the debate around this competitive binding dynamic, rather than degradation capacity alone, offers a more mechanistically complete basis for evaluating OFS necessity in premenopausal patients. Window-of-opportunity (WOO) trials have offered an early opportunity to probe this question, consistently demonstrating rapid ER downregulation and antiproliferative activity with SERD monotherapy. Yet interpretation of these findings is complicated by substantial heterogeneity across trials in patient selection, comparator design, treatment duration, tissue sampling strategy, and endpoint definition. Moreover, the endpoints most used to gauge pharmacodynamic response-Ki67 suppression and complete cell cycle arrest (CCCA)-were validated in postmenopausal populations treated with aromatase inhibitors or tamoxifen, agents that act primarily through estrogen deprivation or competitive antagonism rather than receptor degradation. Their applicability to SERDs, and to the distinct estrogen milieu of premenopausal patients, remains under investigation. This narrative review critically summarizes the development of oral SERDs in metastatic HR+ breast cancer, review findings from window-of-opportunity trials, discuss emerging evidence in premenopausal women and addresses the methodological variability, underlying biological considerations, and limitations of conventional pharmacodynamic endpoints.
中文摘要:选择性雌激素受体降解剂(SERDs)已成为激素受体阳性(HR+)乳腺癌的重要治疗类别,兼具雌激素受体(ER)拮抗与直接降解受体的作用。尽管具有双重机制,SERDs在绝经前患者中的关键试验(涵盖转移和辅助治疗场景)均要求同时进行卵巢功能抑制(OFS)。机制上,ER持续合成,因此拮抗和降解都需要持续占据配体结合域。核心问题在于竞争性靶点结合:口服SERDs能否在高雌激素的绝经前环境中达到并维持足够的受体占据,而不取决于其内在降解效率。将讨论围绕竞争性结合动态而非仅降解能力展开,可为评估绝经前患者是否需要OFS提供机制上更完整的依据。机会窗(WOO)试验为探讨这一问题提供了早期机会,并一致显示SERD单药可快速下调ER并产生抗增殖活性。但患者选择、对照设计、治疗时长、组织采样策略和终点定义在各试验间差异明显,使这些结果的解读变得复杂。用于评估药效动力学的常用终点Ki67抑制和完全细胞周期阻滞(CCCA)是在接受芳香化酶抑制剂或他莫昔芬治疗的绝经后人群中验证的,这些药物主要通过雌激素剥夺或竞争性拮抗发挥作用,而非受体降解。这些终点对SERDs以及绝经前患者不同雌激素环境的适用性仍在研究中。这篇叙述性综述批判性总结口服SERDs在转移性HR+乳腺癌中的开发,回顾机会窗试验结果,讨论绝经前女性中的新证据,并处理方法学差异、潜在生物学考虑和传统药效动力学终点的局限。
Vepdegestrant (VEPPANU; formerly ARV 471) is a novel PROteolysis TArgeting Chimera (PROTAC) that is able to simultaneously bind the estrogen receptor (ER) and an E3 ubiquitin ligase complex, resulting in polyubiquitination of the ER and its subsequent degradation via a proteasome. It is being developed by Arvinas and Pfizer primarily as a treatment for ER+, HER2- breast cancer. In May 2026, vepdegestrant received its first global approval in the USA for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. This article summarizes the milestones in the development of vepdegestrant leading to its first approval in this indication.
中文摘要:Vepdegestrant(VEPPANU;原称 ARV 471)是一种新型蛋白降解靶向嵌合体(PROTAC),可同时结合雌激素受体(ER)与 E3 泛素连接酶复合物,使 ER 发生多聚泛素化,随后经蛋白酶体降解。该药由 Arvinas 与辉瑞共同开发,主要用于治疗 ER 阳性、HER2 阴性乳腺癌。2026 年 5 月,vepdegestrant 在美国获得全球首次批准,用于经 FDA 授权检测确认为 ER 阳性、HER2 阴性、ESR1 突变的晚期或转移性乳腺癌成人患者,且患者在接受至少一线内分泌治疗后出现疾病进展。本文概述 vepdegestrant 研发过程中的关键节点,直至其在该适应证下获得首次批准。
基础研究 (16篇)
Platinum-based chemotherapy is a cornerstone of triple-negative breast cancer (TNBC) treatment, yet resistance remains a significant clinical challenge. Sarcoma antigen 1 (SAGE1), a cancer-testis antigen, has been implicated in various malignancies, but its specific role in TNBC drug response and underlying mechanisms remain largely elusive. Using tumor specimens from two prospective TNBC trials, we found that high SAGE1 expression significantly correlates with inferior invasive disease-free survival in patients receiving carboplatin-containing chemotherapy. SAGE1 reduces carboplatin sensitivity in vitro and in vivo by accelerating DNA damage repair. Mechanistically, SAGE1 enhances global chromatin accessibility and H3K27ac enrichment at Fanconi Anemia (FA) pathway gene loci, interacting with p300 and BRD4 to promote H3K27ac deposition. The BET bromodomain inhibitor JQ1 reversed FA protein upregulation and restored carboplatin sensitivity in SAGE1-enriched cells. Furthermore, SAGE1 interacts with PARP1, and this interaction is associated with the regulation of PARP1 activity and with limited PARP inhibitor sensitivity. Notably, the triple combination of JQ1, carboplatin, and olaparib enhanced DNA damage and suppressed tumor growth in preclinical models. Thus, SAGE1 may contribute to an epigenetic-repair axis by facilitating chromatin opening and bolstering the FA pathway, and targeting this axis via combined carboplatin, PARP, and BET inhibition represents a promising therapeutic strategy for SAGE1-enriched TNBC.
中文摘要:铂类化疗是三阴性乳腺癌治疗的基石,但耐药仍是重要临床难题。肉瘤抗原1(SAGE1)是一种癌睾丸抗原,已在多种恶性肿瘤中被提及,但其在三阴性乳腺癌药物反应中的具体作用及潜在机制仍很不清楚。利用两项前瞻性三阴性乳腺癌试验的肿瘤标本,我们发现SAGE1高表达与接受含卡铂化疗患者的无侵袭性疾病生存期较差显著相关。SAGE1通过加速DNA损伤修复在体外和体内降低卡铂敏感性。机制上,SAGE1增强整体染色质可及性以及Fanconi贫血(FA)通路基因位点的H3K27ac富集,并与p300和BRD4相互作用以促进H3K27ac沉积。BET溴结构域抑制剂JQ1逆转FA蛋白上调,并在SAGE1富集细胞中恢复卡铂敏感性。此外,SAGE1与PARP1相互作用,这种相互作用与PARP1活性调节相关,并与有限的PARP抑制剂敏感性相关。JQ1、卡铂和奥拉帕利三药联合在临床前模型中增强DNA损伤并抑制肿瘤生长。因此,SAGE1可能通过促进染色质开放和增强FA通路参与表观遗传-修复轴,通过卡铂、PARP和BET抑制联合靶向该轴,是SAGE1富集型三阴性乳腺癌有前景的治疗策略。
Conventional platinum (Pt)-based chemotherapeutics elicit cancer cell death primarily through DNA binding, but this approach is inherently limited by poor site specificity and a lack of spatiotemporal control, which compromises therapeutic precision and safety. To overcome these limitations, we report DNATplatin, an in situ activatable and photooxidative Pt(IV) prodrug designed to combine precise recognition of DNA secondary structures with targeted genetic intervention through DNA photooxidation. By incorporating a bis-N-methylpyridinium moiety to selectively recognize DNA, DNATplatin shows a 10-fold increase in the levels in genomic DNA relative to oxaliplatin and a 2.5-fold emission turn-on selectivity for G-quadruplexes (G4s) over typical duplex DNA. Following precise nuclear localization, photoactivated DNATplatin acts as a potent photooxidant that oxidizes G4, dismantles G4 scaffolds, and abrogates circular dichroism signatures. These orchestrated lesions generate localized oxidative stress and selectively silence major G4-driven oncogenes, thereby effectively circumventing traditional Pt resistance by bypassing canonical adduct-dependent pathways. In a murine triple-negative breast tumor model, DNATplatin produces profound tumor suppression and elicits a robust systemic immune response, characterized by CD4+/CD8+ T-cell activation and depletion of Foxp3+ regulatory T cells. Collectively, this work establishes a controllable "target-and-destroy" strategy and underscores the potential of Pt(IV) photooxidants for topology-selective genetic intervention.
中文摘要:传统铂类化疗药主要通过结合DNA诱导癌细胞死亡,但位点特异性差且缺乏时空控制,限制了治疗精确性与安全性。为克服这些限制,我们报道DNATplatin,一种可原位激活的光氧化型Pt(IV)前药,将DNA二级结构的精确识别与通过DNA光氧化实现的靶向遗传干预结合。通过引入双-N-甲基吡啶鎓部分选择性识别DNA,DNATplatin在基因组DNA中的水平较奥沙利铂提高10倍,对G-四链体(G4)的发光开启选择性较典型双链DNA高2.5倍。精确入核后,光激活的DNATplatin作为强光氧化剂氧化G4、破坏G4支架并消除圆二色谱特征。这些协同损伤产生局部氧化应激,选择性沉默主要受G4驱动的癌基因,从而绕过经典加合物依赖通路,有效规避传统铂类耐药。在小鼠三阴性乳腺肿瘤模型中,DNATplatin产生显著肿瘤抑制并激发强健的系统性免疫应答,表现为CD4+/CD8+ T细胞活化及Foxp3+调节性T细胞减少。该工作建立了一种可控的「靶向并摧毁」策略,凸显Pt(IV)光氧化剂用于拓扑选择性遗传干预的潜力。
Super-enhancers (SEs) are operationally defined as clusters of cis-regulatory elements associated with high transcriptional activity and cell-identity genes. They display dense transcription factor and coactivator occupancy, strong H3K27 acetylation, and enhancer-promoter communication, but their annotation varies across platforms, algorithms, and thresholds. This review examines SE architecture, identification, and validation, distinguishing chromatin-based annotation from functional dependence demonstrated by locus-specific perturbations. Mechanisms of SE-associated transcription include pioneer factors, chromatin remodelers, three-dimensional genome organization, transcriptional condensates, non-coding RNAs, and extrachromosomal DNA. Physiological functions in development, immunity, and metabolic homeostasis are considered alongside context-dependent dysregulation in cancer, inflammatory and autoimmune diseases, neurological disorders, and metabolic diseases. Breast cancer provides a model for examining subtype-specific regulation and transcriptional plasticity. Particular attention is given to enhancer remodeling during endocrine therapy, cyclin-dependent kinase 4/6 (CDK4/6) inhibition, human epidermal growth factor receptor 2 (HER2)-targeted treatment, and chemotherapy, which may support bypass signaling, stemness, and persistent resistance. Causal regulatory changes must nevertheless be distinguished from correlates of treatment selection. Therapeutic approaches targeting bromodomain and extraterminal domain (BET) proteins, CDK7/9, chromatin regulators, enhancer RNAs, and regulatory loci are critically evaluated. Definitional uncertainty, model dependence, limited reproducibility, systemic toxicity, and insufficient clinical validation remain major barriers. Priorities include standardized annotation, temporally resolved perturbation, single-cell and spatial profiling, artificial intelligence-assisted integration, patient-derived models, and biomarker-guided therapeutic development. Together, these perspectives position SEs as a context-dependent framework linking regulatory architecture to disease progression and treatment resistance, while emphasizing the evidence required to establish therapeutic vulnerabilities.
中文摘要:超级增强子(SEs)在操作上被定义为与高转录活性和细胞身份基因相关的顺式调控元件簇。它们表现出密集的转录因子和共激活因子占据、强H3K27乙酰化以及增强子-启动子通讯,但其注释在不同平台、算法和阈值间存在差异。综述考察SE结构、鉴定与验证,区分基于染色质的注释与位点特异性扰动所证明的功能依赖。SE相关转录机制包括先锋因子、染色质重塑因子、三维基因组组织、转录凝聚体、非编码RNA和染色体外DNA。文中讨论其在发育、免疫和代谢稳态中的生理功能,以及在癌症、炎症和自身免疫病、神经系统疾病和代谢疾病中依赖背景的失调。乳腺癌提供了考察亚型特异性调控和转录可塑性的模型。特别关注内分泌治疗、CDK4/6抑制、HER2靶向治疗和化疗期间的增强子重塑,这些可能支持旁路信号、干性和持续耐药。因果性调控变化仍须与治疗选择的相关性区分。对靶向BET蛋白、CDK7/9、染色质调控因子、增强子RNA和调控位点的治疗策略进行批判性评估。定义不确定性、模型依赖性、可重复性有限、全身毒性和临床验证不足仍是主要障碍。优先方向包括标准化注释、时间分辨扰动、单细胞和空间谱分析、人工智能辅助整合、患者来源模型和生物标志物指导的治疗开发。这些视角将SE定位为连接调控结构与疾病进展及治疗耐药的情境依赖框架,同时强调建立治疗脆弱性所需的证据。
Golgiphagy contributes to Golgi quality control, yet its regulatory mechanisms and physiological functions remain poorly understood. We identify the deubiquitinase USP28 as an upstream regulator of TM9SF3-dependent Golgiphagy. Nutrient deprivation and Golgi stress induce CRM1-dependent nuclear export of USP28, enabling its translocation to the Golgi, where it removes K48-linked ubiquitin chains from TM9SF3 to prevent its proteasomal degradation and promote Golgiphagy. TM9SF3-dependent Golgiphagy regulates glycosyltransferase abundance through selective degradation of cargo such as MGAT5, thereby maintaining glycosylation homeostasis. Genetic or pharmacological inhibition of the USP28-TM9SF3-Golgiphagy pathway disrupts glycosylation homeostasis and suppresses breast tumor growth. Together, these findings establish the USP28-TM9SF3 axis as a regulatory mechanism linking Golgiphagy to glycosylation homeostasis and breast cancer progression.
中文摘要:高尔基体自噬参与高尔基体质量控制,但其调控机制与生理功能仍不清楚。研究识别出去泛素化酶USP28是TM9SF3依赖性高尔基体自噬的上游调控因子。营养剥夺和高尔基体应激诱导USP28以CRM1依赖方式出核,使其转位至高尔基体,在那里去除TM9SF3上的K48连接泛素链,阻止其蛋白酶体降解并促进高尔基体自噬。TM9SF3依赖性高尔基体自噬通过选择性降解MGAT5等货物调控糖基转移酶丰度,从而维持糖基化稳态。遗传或药理抑制USP28-TM9SF3-高尔基体自噬通路会破坏糖基化稳态并抑制乳腺肿瘤生长。这些发现确立USP28-TM9SF3轴作为连接高尔基体自噬与糖基化稳态及乳腺癌进展的调控机制。
Triple-negative breast cancer (TNBC) is characterized by low response rates and rapid acquired resistance to current immunotherapies, highlighting an urgent unmet clinical need for novel therapeutic strategies. Herein, we demonstrated that laminarin, a biocompatible β-1,3-glucan extracted from brown algae, exerts significant antitumor immune effects against TNBC with no evident toxicity under the tested conditions. In addition, laminarin suppressed pulmonary metastatic progression in a TNBC metastasis model. Via an innovative in silico target screening framework integrating AI-driven knowledge graph-based causal reasoning with transcriptional signature-based pattern matching, we identified the m6A reader YTHDF1 as the key functional target of laminarin in TNBC. Clinical data analysis revealed that YTHDF1 is significantly overexpressed in breast cancer, whose high expression correlates with poor prognosis and tumor immune evasion. We further validated that YTHDF1 directly upregulates programmed death-ligand 1 (PD-L1) expression in TNBC cells. Mechanistically, laminarin directly binds to the YTH domain of YTHDF1, disrupts its interaction with m6A-modified PD-L1 mRNA to suppress both basal and IFN-γ-induced PD-L1 upregulation at the translational level. In vitro and in vivo experiments confirmed that the antitumor immune efficacy of laminarin is largely YTHDF1-dependent. Our findings uncover a novel mechanism of action of laminarin, by which it modulates the YTHDF1-m6A-PD-L1 axis, providing preclinical evidence supporting further investigation of laminarin as a potential immunomodulatory strategy for TNBC.
中文摘要:三阴性乳腺癌(TNBC)对现有免疫治疗应答率低、易快速获得耐药,临床亟需新的治疗策略。海带多糖(laminarin)是从褐藻中提取的生物相容性β-1,3-葡聚糖;在测试条件下,它对TNBC表现出显著抗肿瘤免疫作用且无明显毒性。在TNBC转移模型中,海带多糖抑制肺转移进展。通过整合AI驱动知识图谱因果推理与转录特征模式匹配的计算机靶点筛选框架,研究确定m6A阅读蛋白YTHDF1为海带多糖在TNBC中的关键功能靶点。临床数据分析显示,YTHDF1在乳腺癌中显著高表达,其高表达与不良预后和肿瘤免疫逃逸相关。进一步验证表明,YTHDF1直接上调TNBC细胞中程序性死亡配体1(PD-L1)的表达。机制上,海带多糖直接结合YTHDF1的YTH结构域,破坏其与m6A修饰的PD-L1 mRNA的相互作用,在翻译水平抑制基础状态及IFN-γ诱导的PD-L1上调。体外和体内实验证实,海带多糖的抗肿瘤免疫疗效在很大程度上依赖YTHDF1。这些发现揭示了海带多糖调控YTHDF1-m6A-PD-L1轴的新作用机制,并提供临床前证据,支持进一步研究海带多糖作为TNBC潜在免疫调节策略。
The Warburg effect drives cancer cells to rely preferentially on glycolysis, resulting in diminished mitochondrial oxidative phosphorylation (OXPHOS). This metabolic phenotype limits the ability of excess copper (Cu) ions to trigger cuproptosis in dysfunctional mitochondria, leading to suboptimal therapeutic outcomes. Therefore, remodeling tumor energy metabolism to counteract the Warburg effect represents a pivotal strategy to enhance cuproptosis efficacy. Herein, we developed a Cu(I)-stabilized metal-organic framework nanoplatform (CuTz-1) encapsulated by Azurin (CuTz-1@Azurin) as a cuproptosis sensitizer. Mechanistically, Azurin increases p53 protein levels by intercepting MDM2-mediated ubiquitin-proteasome degradation. Elevated p53 subsequently inhibits pyruvate kinase M2 (PKM2) activity, suppressing glycolysis, while simultaneously promoting mitochondrial OXPHOS-collectively shifting cellular metabolism from glycolysis toward mitochondrial respiration and sensitizing tumor cells to Cu-induced proteotoxic stress. In addition, CuTz-1@Azurin triggers oxidative stress via reactive oxygen species (ROS) generation and glutathione (GSH) depletion, which act together with p53-mediated apoptosis to suppress tumor growth. Meanwhile, the oxidation of Cu(I) to paramagnetic Cu(II) enables real-time monitoring of the therapeutic process by magnetic resonance imaging (MRI). Both in vitro and in vivo results demonstrate good antitumor performance of CuTz-1@Azurin. This study highlights the potential of Azurin-mediated metabolic regulation as a promising strategy to potentiate cuproptosis for combined cancer therapy.
中文摘要:Warburg效应使癌细胞优先依赖糖酵解,线粒体氧化磷酸化(OXPHOS)随之减弱。这种代谢表型限制了过量铜离子在功能受损的线粒体中触发铜死亡的能力,治疗效果因而欠佳。重塑肿瘤能量代谢以对抗Warburg效应,是增强铜死亡疗效的关键策略。基于此,研究构建了由Azurin包裹的Cu(I)稳定金属有机框架纳米平台CuTz-1(CuTz-1@Azurin),作为铜死亡增敏剂。机制上,Azurin通过拦截MDM2介导的泛素-蛋白酶体降解提高p53蛋白水平。升高的p53随后抑制丙酮酸激酶M2(PKM2)活性、抑制糖酵解,同时促进线粒体OXPHOS,使细胞代谢由糖酵解转向线粒体呼吸,并增强肿瘤细胞对铜诱导的蛋白毒性应激的敏感性。CuTz-1@Azurin还通过产生活性氧(ROS)和消耗谷胱甘肽(GSH)触发氧化应激,与p53介导的凋亡共同抑制肿瘤生长。Cu(I)氧化为顺磁性Cu(II)使磁共振成像(MRI)能够实时监测治疗过程。体外和体内结果均显示CuTz-1@Azurin具有较好的抗肿瘤效果。该研究提示,Azurin介导的代谢调控可作为增强铜死亡并用于联合肿瘤治疗的有前景策略。
Breast cancer (BC) is the most fatal cancer in women worldwide, and in spite of progresses in cancer treatment methods, its therapy has remained as a primary health issue. Inadequate apoptosis level is one of the main reasons of radiotherapy and chemotherapy resistance in lots of cancers including BC. Besides, gene therapy is one of new methods which has been proposed and developed in recent decades for various diseases diagnosis and treatment containing cancer. Since changes in miRs level which are one of different types of RNA molecules have been proved in assorted diseases, they are utilized as a gene therapy agent in order to make influence in diverse signaling pathways which are effective in unappealing biological alteration. In lots of studies, miRs' role in apoptosis pathway in combination with radiotherapy, chemotherapy or solely have been investigated. Many miRNAs and anti-miRNAs have been demonstrated as radiosensitizers/radioresistance agents and chemosensitisers/chemoresistance agents through apoptosis cell death pathways, and numerous miRs have been introduced as apoptotic regulators and they have a good potential to be radiosensitizers and their role in these pathways must be investigated. In the current review, we have tried to investigate and summarize radiosensitizer and radioresistant miRs and anti-microRNAs (anti-miRs) which have been utilized in BC.
中文摘要:乳腺癌(BC)是全球女性中最致命的癌症,尽管癌症治疗方法已有进展,其治疗仍是主要健康问题。凋亡水平不足是包括BC在内的许多癌症对放疗和化疗抵抗的主要原因之一。基因治疗是近几十年来提出并发展用于多种疾病诊断和治疗(包括癌症)的新方法之一。由于已证明作为不同类型RNA分子之一的miR水平在多种疾病中发生变化,它们被用作基因治疗剂,以影响在不良生物学改变中起作用的多种信号通路。在许多研究中,miR在凋亡通路中的作用已与放疗、化疗联合或单独进行了研究。许多miRNA和抗miRNA已通过凋亡性细胞死亡通路被证明为放射增敏/放射抵抗剂和化疗增敏/化疗抵抗剂,大量miR被引入为凋亡调节因子,它们具有成为放射增敏剂的良好潜力,其在这些通路中的作用仍需研究。本综述试图研究和总结已在BC中使用过的放射增敏和放射抵抗miR及抗microRNA(anti-miR)。
While the immune landscape of primary tumors is increasingly understood, the dynamic immune remodeling within the evolving lung metastatic microenvironment remains poorly characterized. Here, by systematically comparing the microenvironments of primary and metastatic tumors using single-cell transcriptomics across diverse cancer models, we reveal that lung metastases consistently establish a profoundly T-cell-suppressed microenvironment. Concurrently, we identified a strictly metastasis-specific neutrophil gene program. Crucially, this program is highly concurrent with the metastatic microenvironment and is fundamentally distinct from neutrophil phenotypes observed in primary tumors or healthy lungs. Among the core genes defining this program, we identified the cell surface marker STEAP4 as a highly specific indicator of these metastasis-associated neutrophils. In both murine models and human patients, these STEAP4+ neutrophils were not only enriched within the local lung metastatic niche but also detectable in the circulation. Furthermore, the abundance of circulating STEAP4+ neutrophils discriminates breast cancer patients with lung metastasis from those with localized primary tumors or healthy donors. Our findings delineate the divergent immune remodeling trajectories of lung metastasis and highlight their association with STEAP4+ neutrophils, establishing a useful biological framework for future functional and mechanistic investigations.
中文摘要:原发肿瘤的免疫景观正日益被认识,但演化中的肺转移微环境内的动态免疫重塑仍缺乏表征。我们通过单细胞转录组学在多种癌症模型中系统比较原发肿瘤与转移肿瘤的微环境,发现肺转移一致地建立起深度抑制T细胞的微环境。同时,我们鉴定出一个严格转移特异的中性粒细胞基因程序。该程序与转移微环境高度共存,并与原发肿瘤或健康肺中观察到的中性粒细胞表型根本不同。在定义该程序的核心基因中,我们将细胞表面标志物STEAP4鉴定为这些转移相关中性粒细胞的高度特异指示物。在小鼠模型和人类患者中,这些STEAP4+中性粒细胞不仅在局部肺转移龛内富集,也可在循环中检测到。循环STEAP4+中性粒细胞的丰度可区分伴肺转移的乳腺癌患者与局限的原发肿瘤患者或健康供者。我们的发现描绘了肺转移不同的免疫重塑轨迹,并强调其与STEAP4+中性粒细胞的关联,为未来功能和机制研究建立有用的生物学框架。
Triple-negative breast cancer (TNBC) is a particularly aggressive and therapeutically challenging subtype of breast tumor, frequently marked by the relatively high expression of epidermal growth factor receptor (EGFR). As a tyrosine kinase, this enzyme plays a crucial role in driving tumor cell proliferation, progression, and metastases. This review describes the restricted clinical benefits of single EGFR targeting, its expression profile across TNBC subtypes, and the genomic and non-genomic determinants of EGFR transcription, followed by the possibilities of combinatorial and multi-targeted therapy approaches. By analyzing patterns of gene expression in EGFR-high and EGFR-low samples, additional co-targeting factors were identified, which could enhance the efficacy of anti-EGFR strategies in TNBC and serve as more precise and personalized treatment standards. The impact of simultaneous EGFR and selected factors on patient survival is presented. Finally, we mention the available nanocarriers capable of delivering two inhibitors, siRNAs, and antibodies, or their mixtures, for the reduction of EGFR and co-expressed partners.
中文摘要:三阴性乳腺癌(TNBC)是侵袭性强、治疗困难的乳腺肿瘤亚型,常以表皮生长因子受体(EGFR)表达相对较高为特征。EGFR作为酪氨酸激酶,在驱动肿瘤细胞增殖、进展和转移中起关键作用。综述内容涵盖单一EGFR靶向治疗有限的临床获益、EGFR在TNBC各亚型中的表达谱、EGFR转录的基因组与非基因组决定因素,以及联合治疗和多靶点治疗策略的可能性。通过分析EGFR高表达与低表达样本的基因表达模式,可识别额外的共靶向因子,这些因子有望提高TNBC抗EGFR策略的疗效,并成为更精确、更个性化的治疗标准。文中还呈现EGFR与选定因子同时作用对患者生存的影响。在递送层面,已有纳米载体可递送两种抑制剂、siRNA、抗体或其混合物,以降低EGFR及共表达分子的水平。
Triple-negative breast cancer (TNBC) is an aggressive and highly metastatic form of breast cancer and is associated with poor prognosis due to the lack of targeted therapies. Mitochondrial dysfunction is a crucial factor contributing to tumor growth and chemoresistance in TNBC. Dysregulation in mitochondrial dynamics leads to disruption of the normal process of oxidative phosphorylation, elevated reactive oxygen species generation, and resistance to apoptosis, contributing to TNBC aggressiveness. Moreover, alterations in mitochondrial energetics, including elevated glycolysis and glutamine addiction, provide metabolic advantages for TNBC growth and survival. Emerging therapeutic strategies targeting mitochondrial vulnerabilities have shown potential for TNBC management. Inhibitors targeting mitochondrial dynamics, including Mdivi-1, dynasore, and cepharanthine, act by restoring mitochondrial homeostasis and impairing excessive fission to stimulate apoptosis. Mitochondrial energetics inhibitors, such as 2DG, 3BP, clotrimazole, and etomoxir, disrupt mitochondrial metabolic processes and reduce tumor growth in TNBC. This review highlights the latest advancements in mitochondrial dynamics and energetics in TNBC and explores the molecular mechanisms underlying their dysregulation. It also explores the therapeutic potential of targeting mitochondrial function for personalized strategies leading to improved clinical management of TNBC.
中文摘要:三阴性乳腺癌(TNBC)是一种侵袭性强、转移率高的乳腺癌,因缺乏靶向治疗而预后较差。线粒体功能障碍是促进TNBC肿瘤生长和化疗耐药的关键因素。线粒体动力学失调会破坏正常氧化磷酸化过程,增加活性氧生成,并提高凋亡抵抗,进而增强TNBC的侵袭性。线粒体能量代谢改变,包括糖酵解增强和谷氨酰胺成瘾,为TNBC的生长和存活提供代谢优势。针对线粒体脆弱性的新兴治疗策略已显示出用于TNBC管理的潜力。靶向线粒体动力学的抑制剂,如Mdivi-1、dynasore和cepharanthine,通过恢复线粒体稳态并削弱过度分裂来促进凋亡。线粒体能量代谢抑制剂,如2DG、3BP、clotrimazole和etomoxir,可干扰线粒体代谢过程并降低TNBC肿瘤生长。本综述重点介绍TNBC中线粒体动力学与能量代谢的最新进展,并探讨其失调的分子机制,同时讨论靶向线粒体功能用于个体化策略、改善TNBC临床管理的治疗潜力。
A dual-band GHz metamaterial absorber (MPA) biosensor is presented as a proof-of-concept platform for dielectric-sensitive electromagnetic sensing integrated with AI-assisted broadband spectral analysis. The proposed three-layer copper-FR-4-copper structure exhibits near-unity absorption at 6.0 GHz and 9.1 GHz and demonstrates engineered negative-index behavior, which enhances electromagnetic field confinement and sensitivity to dielectric perturbations. The biosensor was fabricated using standard PCB technology and experimentally validated through free-space microwave measurements, showing excellent agreement with simulations and absorption exceeding 92.5% and 99.8% at the two resonant frequencies. For dielectric-sensitive analysis, the sensor response was evaluated under simulation-based loading conditions using low-loss COC/COP coverslip layers and literature-reported electromagnetic properties representative of healthy-like and malignant-like breast environments. Distinct broadband spectral perturbations were observed across the 5-10 GHz frequency range, demonstrating sensitivity to dielectric-property variations. Sensor performance was assessed using quality factor, sensitivity, and figure-of-merit metrics. An AI-assisted spectral interpretation framework was developed using distance- and correlation-based analysis of the broadband electromagnetic response. The results demonstrate that the proposed platform combines dual-band high-Q absorption, engineered triple-negative electromagnetic characteristics, and AI-assisted spectral analysis within a unified microwave biosensing framework. No biological samples were evaluated in this study; therefore, the reported results should be interpreted as simulation-based dielectric-loading analyses rather than validated cancer-detection outcomes.
中文摘要:提出一种双频段GHz超材料吸波器(MPA)生物传感器,作为将介电敏感电磁传感与AI辅助宽带光谱分析相结合的概念验证平台。所提出的铜-FR-4-铜三层结构在6.0 GHz与9.1 GHz处呈现接近单位的吸收,并表现出人工设计的负折射率行为,从而增强电磁场约束能力与对介电扰动的敏感性。传感器采用标准PCB工艺制作,通过自由空间微波测量完成实验验证,结果与仿真吻合良好,两个谐振频率处的吸收率分别超过92.5%与99.8%。在介电敏感分析方面,以低损耗COC/COP盖玻片层并按文献报道的电磁参数模拟类健康与类恶性的乳腺环境,在仿真加载条件下评估传感器响应;在5-10 GHz范围内观察到明显的宽带光谱扰动,说明对介电常数变化具有敏感性。传感器性能以品质因数、灵敏度与优值指标进行评价。构建了基于距离与相关性分析宽带电磁响应的AI辅助光谱解读框架。结果表明,该平台在同一微波生物传感框架内整合了双频高Q吸收、人工设计的三负电磁特性与AI辅助光谱分析。本研究未对生物样本进行检测,因此所报道的结果应理解为基于仿真的介电加载分析,而非经过验证的癌症检测结论。
Currently, DNA walker-based biosensors used for bioanalysis often suffer from limited amplification efficiency due to irreversible walker consumption and a restricted walking distance. Herein, we report an autonomous positive-feedback DNA walker biosensor for the ultrasensitive electrochemical detection of uracil-DNA glycosylase (UDG) and human alkyladenine DNA glycosylase (hAAG). The platform employs a single bifunctional hairpin probe that integrates target recognition and signal transduction. Through the synergistic action of terminal deoxynucleotidyl transferase (TdT) and exonuclease III (Exo III), a positive-feedback "cleavage-extension-recutting" loop is established, enabling continuous walker regeneration and signal amplification. Benefiting from this autonomous positive-feedback mechanism, the proposed biosensor achieves detection limits of 6.8 × 10-7 U/mL for UDG and 1.5 × 10-6 U/mL for hAAG, representing a reduction of over two orders of magnitude compared with conventional feed-forward DNA walker systems. The sensor exhibits excellent selectivity toward the target glycosylases over structurally similar enzymes and potential interferents, and shows recoveries ranging from 97.8% to 105.4% in serum spike-recovery tests. Furthermore, the platform successfully discriminates cancer cells from normal cells and differentiates serum samples from breast cancer patients and healthy individuals. These results demonstrate that the proposed autonomous positive-feedback DNA walker strategy holds great promise as a versatile and highly sensitive platform for DNA repair enzyme analysis and disease-related biomarker detection.
中文摘要:现有基于DNA步行器的生物传感器在生物分析中常因步行器不可逆消耗和行走距离受限而放大效率不高。我们报道一种自主正反馈DNA步行器生物传感器,用于尿嘧啶DNA糖基化酶(UDG)和人烷基腺嘌呤DNA糖基化酶(hAAG)的超灵敏电化学检测。该平台采用单一双功能发夹探针,将靶标识别与信号转导整合在一起。在末端脱氧核苷酸转移酶(TdT)和外切核酸酶III(Exo III)的协同作用下,构建正反馈的「切割—延伸—再切割」循环,实现步行器持续再生和信号放大。借助这一自主正反馈机制,该生物传感器对UDG的检出限为6.8×10⁻⁷ U/mL,对hAAG的检出限为1.5×10⁻⁶ U/mL,相较传统前馈DNA步行器体系降低两个数量级以上。传感器对靶标糖基化酶具有良好选择性,可区分结构相近的酶和潜在干扰物,在血清加标回收试验中回收率为97.8%至105.4%。该平台还能区分癌细胞与正常细胞,并区分乳腺癌患者血清与健康人血清。这些结果表明,所提出的自主正反馈DNA步行器策略有望成为DNA修复酶分析和疾病相关生物标志物检测的多功能、高灵敏平台。
The detection of cancer cells not only facilitates the early diagnosis of cancers but also provides valuable support for formulating personalized treatment plans for patients. In this work, we develop a new aptamer-based electrochemical biosensing method for cancer cell detection, employing an electrochemically activated DNA circuit as a signal generation module. Specifically, target cells are captured onto the indium tin oxide electrodes through aptamer-mediated recognition of surface proteins. Then, a DNA circuit begins with the potential-driven selective bioconjugation of inherent tyrosine residues on the cell surface. This is subsequently followed by the incorporation of a facile click chemistry reaction and a netlike cascade assembly involving multiple hairpin probes. As a result, a large number of electroactive methylene blue molecules are recruited to the cell surface, thereby ensuring highly efficient electrochemical signal generation. Taking breast cancer cells MDA-MB-231 as a model, this method enables the detection of target cells in the linear range from 5 to 1 × 104 cells with a limit of detection down to 4.2 cells, and also demonstrates high specificity and applicability to complex samples with good recoveries from 95.0% to 106.2%. Furthermore, the DNA circuit-based signal generation module exhibits excellent universality and signal stability, allowing the method to be adapted for detecting other cancer cells, such as HER-2-positive BT-474 and MDA-MB-453 cells through simple aptamer replacement. Therefore, this work presents a reliable new tool for cancer cell detection, which holds great promise for playing an important role in future cancer diagnostic practices.
中文摘要:癌细胞的检测既有助于癌症早期诊断,也能为制定患者个体化治疗方案提供支持。本工作开发了一种新的基于适配体的电化学生物传感方法用于癌细胞检测,并以电化学激活的DNA电路作为信号产生模块。目标细胞通过适配体介导的表面蛋白识别被捕获到氧化铟锡电极上。随后,DNA电路由电位驱动的细胞表面固有酪氨酸残基选择性生物偶联启动,再引入简便的点击化学反应以及涉及多个发夹探针的网状级联组装。大量电活性亚甲蓝分子由此被招募到细胞表面,保证高效的电化学信号产生。以乳腺癌细胞MDA-MB-231为模型,该方法可在5至1×10^4个细胞的线性范围内检测目标细胞,检测限低至4.2个细胞,并表现出高特异性以及对复杂样品的适用性,回收率为95.0%至106.2%。该基于DNA电路的信号产生模块还表现出良好的通用性和信号稳定性,通过简单替换适配体即可用于检测其他癌细胞,如HER-2阳性的BT-474和MDA-MB-453细胞。这项工作为癌细胞检测提供了一种可靠的新工具,有望在未来癌症诊断实践中发挥重要作用。
Surgical resection combined with chemotherapy remains the standard clinical intervention for triple-negative breast cancer (TNBC). However, the elevated expression of COX-2/PGE2, often exacerbated by chemotherapeutic agents, is significantly associated with high postoperative recurrence and metastasis. Tailored for the TNBC postoperative setting, we developed a photopolymerizable, dual-asymmetric hemostatic Janus hydrogel patch (DJ-Patch) based on the synergistic pharmacodynamic rationale of gambogic acid (GA) and celecoxib (CXB) pairing. The DJ-Patch exhibits a stratified bilayer configuration comprising a rapid-release layer (5% GelMA) encapsulating GA, juxtaposed with an extended-release layer (10% GelMA/2.5% PEGNB) containing the selective COX-2 inhibitor CXB. In vitro study corroborated this differential release modality, revealing asymmetric kinetics wherein GA achieved ∼20% release at 8 h escalating to greater than 60% by day 3, whereas CXB demonstrated ∼10% release at 8 h and ∼30% by day 3. In vivo release profiles further substantiated these findings, demonstrating that CXB exhibited a 2-fold prolonged release duration relative to GA. The asymmetric adhesive design, featuring a high-adhesion interface manifesting adhesion strength 12.5-fold superior to GelMA alone, facilitated rapid intraoperative hemostasis with clotting time reduced to 160 s versus 440 s in untreated controls, and effected efficacious wound sealing as validated in a mouse liver laceration model. In an orthotopic 4T1-Luc TNBC resection model, the DJ-Patch achieved 86% survival, complete tumor clearance by day 7, and suppressed lung metastasis through sustained COX-2/PGE2 axis inhibition, Treg cell reduction, and remodeled the immunosuppressive tumor microenvironment (TME). Collectively, this integrated platform offers a promising strategy for comprehensive TNBC postsurgical management.
中文摘要:手术切除联合化疗仍是三阴性乳腺癌(TNBC)的标准临床干预方式。COX-2/PGE2表达升高常被化疗药物进一步加剧,并与术后高复发和转移显著相关。针对TNBC术后场景,基于藤黄酸(GA)与塞来昔布(CXB)配伍的协同药效学思路,构建了一种可光聚合的双不对称止血Janus水凝胶贴片(DJ-Patch)。DJ-Patch具有分层双层结构,由包载GA的快速释放层(5% GelMA)与含选择性COX-2抑制剂CXB的缓释层(10% GelMA/2.5% PEGNB)并置组成。体外研究证实了这种差异释放模式,呈现非对称动力学:GA在8小时释放约20%,第3天升至60%以上;CXB在8小时释放约10%,第3天约30%。体内释放曲线进一步支持上述结果,CXB的释放持续时间较GA延长2倍。非对称黏附设计具有高黏附界面,黏附强度为单独GelMA的12.5倍,可在术中快速止血,凝血时间缩短至160秒,而未处理对照组为440秒,并在小鼠肝脏撕裂模型中验证了有效的创面封闭。在原位4T1-Luc TNBC切除模型中,DJ-Patch实现86%生存率、第7天肿瘤完全清除,并通过持续抑制COX-2/PGE2轴、减少Treg细胞及重塑免疫抑制性肿瘤微环境(TME)抑制肺转移。该一体化平台为TNBC术后综合管理提供了有前景的策略。
Breast cancer (BC) remains the most frequently diagnosed cancer and the second leading cause of cancer-related mortality among women worldwide. Medical imaging is essential in the diagnosis and management of BC, delivering crucial information about tumor location, heterogeneity, and metastatic progression. Nuclear medicine imaging offers non-invasive functional assessment through probes, which capture biological characteristics of tumors more effectively than conventional structural imaging modalities such as CT or MRI. The identification of specific molecular targets has become pivotal for accurate tumor subtyping, prognosis assessment, and tailoring effective therapies. In this review, these molecular targets are classified according to a three-dimensional spatial framework of BC, encompassing (1) intracellular metabolic processes, (2) cell-surface receptor expression, and (3) the extracellular TME. Through multi-dimensional targeting approaches from intracellular processes to microenvironmental networks, nuclear medicine imaging decodes BC biology: metabolism imaging reveals core cellular functions, receptor imaging identifies actionable therapeutic targets and evaluates molecular expression levels, and TME imaging elucidates complex microenvironmental interactions. Collectively, this spatially-informed targeting strategy allows for the non-invasive evaluation of therapeutic targets, assessment of tumor heterogeneity, and dynamic monitoring of treatment response. Furthermore, these advances are increasingly extending beyond diagnostics toward theranostic applications, where diagnostic probes are paired with therapeutic radionuclides to enable image-guided radioligand therapy. By consolidating current knowledge and outlining future directions, this review aims to inform both clinical practice and the development of next-generation imaging and theranostic platforms in precision oncology.
中文摘要:乳腺癌仍是全球女性中最常被诊断的癌症,也是癌症相关死亡的第二大原因。医学影像在乳腺癌诊断和管理中至关重要,可提供肿瘤位置、异质性和转移进展的关键信息。核医学成像通过探针提供无创功能评估,比CT或MRI等传统结构成像方式更有效地捕捉肿瘤生物学特征。识别特异性分子靶点已成为准确进行肿瘤分型、预后评估和制定有效个体化治疗的关键。本综述按照乳腺癌三维空间框架对这些分子靶点进行分类,涵盖细胞内代谢过程、细胞表面受体表达和细胞外肿瘤微环境。通过从细胞内过程到微环境网络的多维靶向策略,核医学成像解读乳腺癌生物学:代谢成像揭示核心细胞功能,受体成像识别可干预治疗靶点并评估分子表达水平,肿瘤微环境成像阐明复杂的微环境相互作用。这种基于空间信息的靶向策略可在无创条件下评估治疗靶点、肿瘤异质性和治疗反应动态。这些进展正日益从诊断拓展到诊疗一体化应用,将诊断探针与治疗性放射性核素配对,实现影像引导的放射性配体治疗。通过整合现有知识并展望未来方向,本综述旨在为临床实践以及精准肿瘤学中下一代成像与诊疗一体化平台的开发提供参考。
Metabolism dysregulation induces distinct thiol profiles between cancer and healthy cells, offering an attractive therapeutic target. However, systemically targeting cancer-specific thiols remains challenging due to the widespread presence of these groups in the physiological environment. Here, we design a molecular navigator (MONA) with spatiotemporally programmable thiol-reactivity to target the thiols on cancer cells upon intravenous injection. MONA operates through a bioresponsive "Hide-and-Seek" mechanism based on tunable disulfide exchange across biological compartments. In the "Hide" phase, MONA circulates stealthily through rapid conjugation with endogenous albumin via disulfide bonding. In the "Seek" phase, albumin facilitates MONA transcytosis into tumors, where elevated glutathione levels trigger disulfide exchange, releasing MONA to multivalently engage with thiols on cancer cells. When conjugated with a photosensitizer, MONA induces cancer cell membrane disruption upon light irradiation, enabling potent phototherapy. This approach leads to complete tumor regression and systemic abscopal effects in an immunosuppressive murine breast cancer model. These findings highlight MONA as a powerful strategy for precise thiol-targeted cancer therapy.
中文摘要:代谢失调使癌细胞与健康细胞呈现不同的巯基谱,从而提供有吸引力的治疗靶点。然而,由于这些基团在生理环境中广泛存在,全身性靶向癌症特异性巯基仍具挑战。我们设计了一种具有时空可编程巯基反应性的分子导航器(MONA),可在静脉注射后靶向癌细胞上的巯基。MONA通过基于跨生物区室可调二硫键交换的生物响应性「隐藏—寻找」机制发挥作用。在「隐藏」阶段,MONA通过与内源性白蛋白经二硫键快速结合而在循环中隐蔽存在。在「寻找」阶段,白蛋白促进MONA转胞吞进入肿瘤,肿瘤内升高的谷胱甘肽水平触发二硫键交换,释放MONA以多价方式与癌细胞上的巯基结合。与光敏剂偶联后,MONA在光照下诱导癌细胞膜破坏,实现强效光疗。该方法在免疫抑制小鼠乳腺癌模型中实现肿瘤完全消退和全身性远隔效应。这些发现表明MONA是精准靶向巯基的癌症治疗的有力策略。
8泌尿生殖肿瘤 (26篇)
临床研究 (11篇)
Although highly preventable, cervical cancer remains one of the most common malignancies among women worldwide. As part of the Global Burden of Disease study, we estimated cervical cancer incidence, mortality and disability-adjusted life-years (DALYs) across 204 countries and territories from 1990 to 2023, with forecasts to 2050. In 2023, 887,000 new cases (95% uncertainty interval 682,000-1,170,000), 369,000 deaths (292,000-475,000) and 13.3 million DALYs (10.1-17.4) were estimated globally. Age-standardized incidence rate (ASIR) and age-standardized mortality rates (ASMR) were more than four and seven times higher in low- versus high-income countries. Between 1990 and 2023, global ASIR was largely stable (-0.4% (-26.6 to 34.7)), whereas ASMR changed by -17.5% (-36.2 to 13.4). All cervical cancer DALYs were attributable to human papillomavirus infection, with tobacco use contributing 5.9% (3.2-9.3) globally. By 2050, global ASIR and ASMR are forecast to change by -12.5% (-25.7 to 3.5) and -9.0% (-21.5 to 6.6) from 2024, yet absolute cases and deaths are forecast to rise by 20.2% (4.6-38.5) and 39.3% (23.6-57.3). ASIR and ASMR are forecast to remain highest in low-income countries. Intensified action is needed to accelerate progress.
中文摘要:宫颈癌虽高度可预防,仍是全球女性常见恶性肿瘤之一。作为全球疾病负担研究的一部分,我们估算1990至2023年204个国家和地区的宫颈癌发病、死亡和伤残调整生命年(DALYs),并预测至2050年。2023年全球估计新发887,000例(95%不确定性区间682,000–1,170,000)、死亡369,000例(292,000–475,000)和1330万DALYs(1010万–1740万)。低收入国家年龄标化发病率(ASIR)和年龄标化死亡率(ASMR)分别较高收入国家高四倍以上和七倍以上。1990至2023年,全球ASIR基本稳定(-0.4%(-26.6至34.7)),ASMR变化为-17.5%(-36.2至13.4)。所有宫颈癌DALYs归因于人乳头瘤病毒感染,烟草使用全球贡献5.9%(3.2–9.3)。至2050年,全球ASIR和ASMR预计较2024年分别变化-12.5%(-25.7至3.5)和-9.0%(-21.5至6.6),但绝对病例数和死亡数预计上升20.2%(4.6–38.5)和39.3%(23.6–57.3)。ASIR和ASMR预计仍在低收入国家最高。需要加强行动以加速进展。
[This corrects the article DOI: 10.1002/mco2.70470.].
中文摘要:本更正针对文章 DOI: 10.1002/mco2.70470。
Routine prostate-specific antigen (PSA) screening in men with limited life expectancy is low-value care, yet US Department of Veterans Affairs (VA) PSA testing and biopsy rates have not been benchmarked against non-VA care. To determine whether PSA testing and prostate biopsy rates are associated with likelihood of benefit from screening in VA or fee-for-service (FFS) Medicare primary care. This retrospective cohort study used national linked VA-Medicare data for fiscal years 2004 to 2023, with up to 20 years of follow up. A 30% random sample of male veterans 65 years or older who were dually enrolled in VA and FFS Medicare Parts A and B were included; men with prior prostate cancer or only Medicare Advantage enrollment were excluded. Time-varying predominant primary care setting (VA, FFS Medicare, or dual use), assigned from primary care visit distribution across systems over a rolling 36-month window. PSA testing and prostate biopsy rates per 1000 person-years. Contemporary incidence rate ratios (IRRs) were estimated with covariate-adjusted Poisson regression and stratified by age and predicted life expectancy. Among 1.41 million dually enrolled male veterans (mean [SD] age, 71.3 [7.1] years), 8.67 million person-years were observed. PSA testing declined across settings from 2008 to 2017, with steeper declines in the VA system. From 2018 to 2023, among men 80 years or older, adjusted PSA testing rates were 187.9 vs 267.9 per 1000 person-years in VA primary care vs FFS Medicare (IRR, 0.70; 95% CI, 0.69-0.71), and biopsy rates were 3.38 vs 5.05 (IRR, 0.67; 95% CI, 0.60-0.75). Among men with fewer than 5 years predicted life expectancy, PSA testing in the VA setting was lower (IRR, 0.84; 95% CI, 0.82-0.86). Age- and life expectancy-based differences persisted across sensitivity analyses. In contrast, in the primary analysis, PSA testing in the VA setting was higher among men aged 65 to 69 years (IRR, 1.10; 95% CI, 1.09-1.11). In this cohort study, compared with FFS Medicare, VA primary care was associated with lower PSA testing and biopsy rates among veterans least likely to benefit, suggesting closer alignment of testing intensity with likelihood of benefit.
中文摘要:对预期寿命有限的男性进行常规前列腺特异性抗原(PSA)筛查属于低价值医疗,但美国退伍军人事务部(VA)的PSA检测与活检率尚未与非VA医疗进行基准比较。旨在确定VA或按服务收费(FFS)Medicare初级保健中PSA检测和前列腺活检率是否与筛查获益可能性相关。这项回顾性队列研究使用2004至2023财年全国关联的VA-Medicare数据,随访最长20年。纳入65岁及以上、同时在VA和FFS Medicare A、B部分注册的男性退伍军人30%随机样本;既往前列腺癌或仅参加Medicare Advantage者被排除。按滚动36个月窗口内跨系统初级保健就诊分布,设定随时间变化的主要初级保健场所(VA、FFS Medicare或双系统使用)。结局为每1000人年的PSA检测率和前列腺活检率。采用协变量校正的Poisson回归估计当代发病率比(IRR),并按年龄和预测预期寿命分层。在141万名双重注册男性退伍军人(平均[SD]年龄71.3[7.1]岁)中,观察867万人年。2008至2017年各场所PSA检测均下降,VA系统降幅更大。2018至2023年,80岁及以上男性中,VA初级保健与FFS Medicare的校正PSA检测率分别为每1000人年187.9与267.9(IRR 0.70;95% CI 0.69-0.71),活检率分别为3.38与5.05(IRR 0.67;95% CI 0.60-0.75)。在预测预期寿命不足5年的男性中,VA场所PSA检测较低(IRR 0.84;95% CI 0.82-0.86)。基于年龄和预期寿命的差异在敏感性分析中持续存在。相反,在主分析中,65至69岁男性在VA场所的PSA检测较高(IRR 1.10;95% CI 1.09-1.11)。在这项队列研究中,与FFS Medicare相比,VA初级保健与最不可能获益的退伍军人中较低的PSA检测和活检率相关,提示检测强度与获益可能性更一致。
Accurate non-invasive tools for bladder cancer detection and preoperative assessment of muscle invasion remain limited. We developed a plasma cell-free DNA (cfDNA) fragmentomics assay to support two clinically related tasks: detection of bladder cancer and preoperative estimation of muscle-invasive risk. Using low-pass whole-genome sequencing, we extracted fragment size coverage, copy-number variation, and nucleosome positioning features. The multicenter cohort included 656 participants and an external extension of 31 cancer cases (total, 687). An integrated classifier was first trained for cancer detection. Subsequently, a separate non-muscle-invasive bladder cancer (NMIBC) versus muscle-invasive bladder cancer (MIBC) classifier was developed using definitively staged cases from the training cohort with internal threshold selection and independent external validation. For cancer detection, the model achieved AUCs of 0.9484 (training), 0.9446 (internal validation), and 0.9390 (external validation). At the locked threshold of 0.592, selected in the internal validation cohort, sensitivities were 81.0%, 80.0%, and 84.3%, with specificities of 95.0%, 94.7%, and 91.8% against healthy controls and 93.3% and 91.1% against benign disease controls in internal and external validation, respectively. For invasion stratification, the NMIBC/MIBC classifier achieved AUCs of 0.9254, 0.9004, and 0.8845 in the training, internal validation, and expanded external validation cohorts, respectively, with 90.3% sensitivity and 77.4% specificity for MIBC detection externally. The assay demonstrated high reproducibility across storage conditions and sequencing batches. This blood-based framework supports multicenter bladder cancer detection and preoperative stratification of muscle invasion as an adjunctive translational approach, while prospective validation in defined clinical use settings remains necessary.
中文摘要:用于膀胱癌检出及术前肌层浸润评估的准确无创手段仍然有限。我们建立了一种血浆游离DNA(cfDNA)片段组学检测方法,用于支持两项临床相关任务:膀胱癌检出与肌层浸润风险的术前评估。采用低深度全基因组测序,提取片段长度覆盖、拷贝数变异与核小体定位特征。多中心队列共纳入656名受试者,外部扩展队列另纳入31例癌症病例(合计687例)。先训练一个整合分类器用于癌症检出;随后利用训练队列中分期明确的病例构建单独的NMIBC与MIBC分类器,并进行内部阈值选择与独立外部验证。癌症检出方面,模型在训练、内部验证与外部验证中的AUC分别为0.9484、0.9446与0.9390。在内部验证队列中选定的锁定阈值0.592下,三个队列的灵敏度分别为81.0%、80.0%与84.3%,对健康对照的特异度分别为95.0%、94.7%与91.8%,内部与外部验证中对良性疾病对照的特异度分别为93.3%与91.1%。浸润分层方面,NMIBC/MIBC分类器在训练、内部验证与扩展外部验证队列中的AUC分别为0.9254、0.9004与0.8845,外部验证中检出MIBC的灵敏度为90.3%、特异度为77.4%。该方法在不同储存条件与测序批次间表现出较高重复性。这一基于血液的框架可作为辅助转化手段,支持多中心膀胱癌检出与肌层浸润的术前分层,但仍需在明确的临床使用场景中开展前瞻性验证。
We report the results of a prospective trial aimed at describing the feasibility and accuracy of prostate-specific membrane antigen (PSMA) radio-guided surgery (RGS) during robot-assisted radical prostatectomy (RARP) with extended pelvic lymph node dissection (ePLND) in patients with prostate cancer (PCa). This was a phase 2 study (NCT04832958) that enrolled 82 patients with localized PCa and a lymph node invasion (LNI) risk >5%. All patients underwent preoperative PSMA positron emission tomography (PET). [99mTc]Tc-PSMA-I&S was administered intravenously the day before surgery, followed by single-photon emission computed tomography/computed tomography. Side effects, perioperative outcomes, and the performance characteristics of PSMA-RGS for LNI detection were measured. A total of 62 patients completed all study procedures and were included in the final analyses. Median blood loss and length of stay were 50 ml and 4 d, respectively. No adverse events after tracer administration or intraoperative complications were recorded. Four patients experienced a Clavien-Dindo grade 3 complication within 30 d. Overall, PSMA-RGS identified two additional patients with high-risk PCa and pathologically node-positive (pN1) disease compared with preoperative PSMA PET, exhibiting a lower positive predictive value (PPV) and a similar negative predictive value (NPV) in the per-patient analysis (PPV: 50% vs 70%; NPV: 83% vs 83%). The PPV and NPV at per-region analysis in patients with molecular imaging node-positive (miN1) disease were higher for PSMA-RGS than for PSMA PET (PPV: 55% vs 42%; NPV: 85% vs 81%). In conclusion, PSMA-RGS identifies additional patients with pN1 disease missed by preoperative PSMA-PET among men with high-risk PCa, and extends the ePLND template in patients with miN1 disease, in whom PSMA PET underestimates the nodal burden. However, its NPV is suboptimal for avoiding ePLND in patients with PCa who have a LNI risk >5% and negative PSMA-RGS findings during RARP.
中文摘要:该2期前瞻性研究(NCT04832958)纳入82例局限性前列腺癌且淋巴结侵犯风险>5%的患者,旨在描述机器人辅助根治性前列腺切除联合扩大盆腔淋巴结清扫术中,前列腺特异性膜抗原(PSMA)放射引导手术的可行性与准确性。所有患者术前接受PSMA正电子发射断层成像(PET)。手术前一日静脉给予[99mTc]Tc-PSMA-I&S,随后行单光子发射计算机断层成像/计算机断层成像。研究评估不良反应、围手术期结局及PSMA放射引导手术检测淋巴结侵犯的性能。62例完成全部研究流程并纳入最终分析。中位失血量和住院时间分别为50 ml和4 d。示踪剂给药后未记录到不良事件,术中无并发症。4例在30 d内发生Clavien-Dindo 3级并发症。总体上,与术前PSMA PET相比,PSMA放射引导手术额外识别出2例高危前列腺癌且病理淋巴结阳性(pN1)患者;患者层面分析中其阳性预测值较低、阴性预测值相近(阳性预测值50% vs 70%;阴性预测值83% vs 83%)。在分子影像淋巴结阳性(miN1)患者中,区域层面分析显示PSMA放射引导手术的阳性预测值和阴性预测值均高于PSMA PET(阳性预测值55% vs 42%;阴性预测值85% vs 81%)。结论为,在高危前列腺癌患者中,PSMA放射引导手术可识别出术前PSMA PET漏诊的额外pN1患者,并在miN1患者中扩大扩大盆腔淋巴结清扫范围,而PSMA PET在该类患者中低估淋巴结负荷。对于淋巴结侵犯风险>5%且机器人辅助根治性前列腺切除术中PSMA放射引导手术阴性的前列腺癌患者,其阴性预测值不足以支持避免扩大盆腔淋巴结清扫。
Clinical complete response to systemic therapy for patients with muscle-invasive bladder cancer should be approached as rigorously as one would approach any biomarker. This requires uniform assessments and consistent definitions. Emerging data indicate that clinical response assessment may allow individualized treatment for patients with muscle-invasive bladder cancer but further studies are needed.
中文摘要:对肌层浸润性膀胱癌患者全身治疗后的临床完全缓解,应像对待任何生物标志物一样严谨。这需要统一的评估和一致的定义。新出现的数据表明,临床缓解评估或许能让肌层浸润性膀胱癌患者获得个体化治疗,但仍需进一步研究。
We performed a systematic review and meta-analysis to evaluate the diagnostic accuracy, safety, and clinical impact of renal tumor biopsy (RTB) in managing renal cell carcinoma. MEDLINE, Embase, and Cochrane CENTRAL were systematically searched for studies evaluating diagnostic accuracy, complications, and clinical impact of RTB. Diagnostic performance was synthesized using hierarchical bivariate random-effects models; concordance between biopsy and surgical specimens was assessed using pooled proportions that were estimated using random-effects meta-analysis. Risk of bias was evaluated with QUADAS-2. Overall, 103 studies were included. The pooled diagnostic yield of RTB was 90%. Summary sensitivity and specificity for malignancy were 99% and 85%, respectively. Concordance between RTB and surgical pathology was high for benign versus malignant (96%) and histological subtype (89%), but moderate for grade (four-tier: 64%; two-tier: 78%). The overall complication rate was low (3%), with negligible (<1%) Clavien-Dindo ≥3 complications and 1% bleeding events (with only two patients requiring embolization). Tumor seeding was reported only in one study with a pooled seeding proportion of 0%. RTB findings was associated with a change in clinical management in 39% of patients and avoidance of active treatment in 28%. Most studies were at high risk of bias, mainly due to patient selection and flow/timing, and were predominantly retrospective. RTB is safe and high-yield, with excellent sensitivity, high concordance for benign vs malignant and histotype, but only moderate reliability for tumor grade. RTB is therefore an important aid in refining diagnosis in patients with a renal mass and supporting individualized decision-making.
中文摘要:对肾肿瘤活检(RTB)在肾细胞癌诊疗中的诊断准确性、安全性与临床影响进行系统评价与meta分析。检索 MEDLINE、Embase 与 Cochrane CENTRAL,纳入评估 RTB 诊断准确性、并发症及临床影响的研究。诊断效能采用分层双变量随机效应模型合并,活检与手术标本的一致性以随机效应meta分析估计的合并比例评估,偏倚风险用 QUADAS-2 评价。共纳入103项研究。RTB 合并诊断取材成功率为90%,诊断恶性肿瘤的合并敏感度与特异度分别为99%与85%。RTB 与手术病理的一致性在良性 vs 恶性(96%)和组织学亚型(89%)上较高,在分级上仅为中等(四级分类64%,二级分类78%)。总体并发症发生率低(3%),Clavien-Dindo ≥3级并发症可忽略(<1%),出血事件1%(仅2例需栓塞)。肿瘤种植仅1项研究报告,合并种植比例为0%。39%的患者因 RTB 结果改变了临床处理,28%因此避免了积极治疗。多数研究存在高偏倚风险,主要源于患者选择与流程/时机,且以回顾性研究为主。RTB 安全性好、取材成功率高,敏感度优异,良性 vs 恶性及组织学亚型一致性高,但对肿瘤分级的可靠性仅为中等。RTB 因而有助于完善肾脏肿物患者的诊断并支持个体化决策。
Human papillomavirus (HPV) infection is a leading cause of cervical cancer and other malignancies, underscoring the urgent need for accurate and rapid early diagnostic strategies. Herein, we report a dual-mode colorimetric and electron spin resonance (ESR) method for the qualitative detection of HPV-16, based on the integration of the CRISPR/Cas12a system with a metal-organic framework (MOF). A peroxidase-mimicking iron-based MOF, designated MIL-101(Fe), was conjugated to magnetic beads via a single-stranded DNA linker to serve as a signal probe. Upon recognition of the target nucleic acid, MIL-101(Fe) catalyzes the decomposition of hydrogen peroxide to generate hydroxyl radicals, which oxidize a chromogenic substrate to produce a visible color change. Meanwhile, the generated radicals are captured by a spin trap and detected by ESR spectroscopy. The assay enables sensitive and rapid detection of HPV-16, with clear discrimination even in mixtures containing both HPV-16 and HPV-18. Importantly, when evaluated with clinical specimens, the method achieved 100% sensitivity and specificity. Overall, this work provides a feasible and promising strategy for ultrasensitive nucleic acid detection and offers a new avenue for advancing CRISPR-based multimodal diagnostic platforms toward practical applications.
中文摘要:HPV感染是宫颈癌及其他恶性肿瘤的主要病因之一,准确、快速的早期诊断策略需求迫切。本工作报道一种基于CRISPR/Cas12a系统与金属有机框架(MOF)整合的双模式比色与电子自旋共振(ESR)方法,用于HPV-16的定性检测。将具有过氧化物酶模拟活性的铁基MOF MIL-101(Fe)通过单链DNA连接臂偶联到磁珠上,作为信号探针。识别目标核酸后,MIL-101(Fe)催化过氧化氢分解产生羟基自由基,自由基氧化显色底物并产生可见颜色变化;生成的自由基被自旋捕获剂捕获,并由ESR谱检测。该检测方法可灵敏、快速地检测HPV-16,在同时含HPV-16与HPV-18的混合物中也能清晰区分。使用临床标本评估时,该方法达到100%灵敏度和特异性。该工作为超灵敏核酸检测提供了一种可行且有前景的策略,也为推动基于CRISPR的多模态诊断平台走向实际应用提供了新途径。
Radical cystectomy remains the standard of care after neoadjuvant therapy for muscle-invasive bladder cancer. While newer regimens (NIAGRA, KEYNOTE-B15/905) achieve impressive pathological complete response rates, the survival benefits from these trials were built on consolidative surgery, with a 88% cystectomy rate bladder preservation. Clinical complete response agrees with true pathological complete response only about half the time, meaning current restaging tools cannot reliably identify who is truly disease-free. Bladder preservation trials using systemic therapy alone (RETAIN-1/2, HCRN GU 16-257) have shown concerning rates of recurrence and metastasis even with biomarker selection. Trimodal approaches incorporating radiation (IMMUNOPRESERVE, INDIBLADE) are promising but remain early-phase. Until validated biomarkers and prospective trials prove otherwise, cystectomy should remain part of the curative-intent treatment paradigm.
中文摘要:肌层浸润性膀胱癌接受新辅助治疗后,根治性膀胱切除术仍是标准治疗。NIAGRA、KEYNOTE-B15/905等较新方案虽取得令人瞩目的病理完全缓解率,但这些试验的生存获益建立在巩固性手术基础上,膀胱切除率为88%。临床完全缓解与真正病理完全缓解的一致率仅约一半,现有再分期工具无法可靠识别真正无病者。仅用全身治疗的膀胱保留试验RETAIN-1/2、HCRN GU 16-257显示,即使采用生物标志物筛选,复发和转移发生率仍令人担忧。联合放疗的三模式方案IMMUNOPRESERVE、INDIBLADE具有前景,但仍处于早期阶段。在经验证的生物标志物和前瞻性试验提供相反证据之前,膀胱切除术应继续作为治愈性治疗策略的一部分。
Recurrence after nephrectomy in high-risk localized renal cell carcinoma is common, but the genomic and transcriptomic differences between primary and recurrent tumors are not well understood. In the IMmotion010 trial, patients were randomized to receive adjuvant atezolizumab versus placebo. Tumor tissue was collected at pre-treatment baseline (n = 754) and subsequently at the time of recurrence (n = 80). We performed matched transcriptomic (n = 80) and genomic (n = 52) analyses on primary versus recurrent samples. Using previously described transcriptomic classifications, resected primary tumors had a higher proportion of angiogenic and small nucleolar RNA transcriptomic signatures and lower proportion of T-effector/proliferative and stromal/proliferative signatures compared with published metastatic cohorts. Sites of recurrence exhibited upregulation of signatures related to cell proliferation, fatty acid synthesis, and stromal biology, including matrix and fibroblasts. Comparing treatment arms, tumors that recurred in placebo-treated patients demonstrated increased B cell and macrophage signatures, while tumors that recurred despite adjuvant atezolizumab showed downregulation of major histocompatibility complex (MHC)-I. Although requiring further clinical validation, the latter finding may substantiate scientifically a potential rationale for transitioning to vascular endothelial growth factor (VEGF)-inhibition after adjuvant checkpoint inhibition.
中文摘要:高危局限性肾细胞癌患者在肾切除术后复发较为常见,但原发肿瘤与复发肿瘤之间的基因组和转录组差异尚不清楚。在 IMmotion010 试验中,患者被随机分配接受辅助阿替利珠单抗或安慰剂治疗。肿瘤组织分别于治疗前基线(n=754)和复发时(n=80)采集。我们对原发与复发样本进行了配对的转录组(n=80)和基因组(n=52)分析。采用既往描述的转录组分类,与原发灶相比,已发表转移队列中原发切除肿瘤具有更高比例的血管生成和核仁小 RNA 转录组特征,以及更低比例的 T 效应/增殖和基质/增殖特征。复发部位显示与细胞增殖、脂肪酸合成及基质生物学(包括基质与成纤维细胞)相关的特征上调。比较治疗组,安慰剂治疗患者的复发肿瘤表现出 B 细胞和巨噬细胞特征增加,而在接受辅助阿替利珠单抗后仍复发的肿瘤中,主要组织相容性复合体(MHC)-I 呈下调。后一发现仍需进一步临床验证,但可能从科学上为在辅助免疫检查点抑制后转换为血管内皮生长因子(VEGF)抑制提供潜在依据。
Biochemical recurrence (BCR) after radical prostatectomy (RP) is a heterogeneous disease state in prostate cancer with multiple treatment options. Improved risk stratification could enable more personalized decision-making. We developed and validated a digital pathology-based multimodal artificial intelligence (MMAI) model to predict outcomes in post-RP BCR patients undergoing salvage therapy. An MMAI model was trained to predict distant metastasis (DM) using prostate histopathology image features and clinical variables (pathologic grade group, pathologic T stage, prostate-specific antigen level before salvage radiotherapy [SRT], age, and surgical margin). The locked model was validated in 533 patients from NRG/RTOG 9601 and 0534 treated with SRT ± hormone therapy (HT), using Cox regression and time-dependent area under the receiver operating characteristic curve. With a median follow-up of 9.3 yrs, MMAI score was significantly associated with DM (subdistribution hazard ratio = 2.17 per standard deviation [95% confidence interval 1.65-2.85]; p < 0.001) and remained independently prognostic after adjusting for clinical variables and treatment. The 10-yr time-dependent area under the receiver operating characteristic curve for MMAI was 0.74 compared with 0.68 for a clinical nomogram. Binary risk categorization demonstrated higher 10-yr DM incidence in the MMAI high-risk (25%) than in the low-risk (8.8%) group. The absolute reduction in 10-yr DM incidence with HT plus SRT versus SRT alone was 21% in the high-risk group versus 2.5% in the low-risk group. Limitations include the use of archived trial cohorts. The post-RP MMAI model provides individualized risk estimates after SRT ± HT and may support shared decision-making about salvage treatment. External and prospective validation are ongoing.
中文摘要:根治性前列腺切除术后生化复发是前列腺癌中异质性较强的疾病状态,可选治疗方式多样。改进风险分层有助于实现更个体化的决策。研究开发并验证了一种基于数字病理的多模态人工智能模型,用于预测接受挽救治疗的术后生化复发患者的结局。该模型利用前列腺组织病理图像特征与临床变量(病理分级分组、病理T分期、挽救性放疗前前列腺特异性抗原水平、年龄和手术切缘)训练以预测远处转移。锁定模型在NRG/RTOG 9601和0534试验中533例接受挽救性放疗±激素治疗的患者中验证,采用Cox回归和时依受试者工作特征曲线下面积评估。中位随访9.3年,MMAI评分与远处转移显著相关(每标准差亚分布风险比=2.17,95%置信区间1.65-2.85;p<0.001),在校正临床变量和治疗后仍具有独立预后价值。MMAI的10年时依受试者工作特征曲线下面积为0.74,临床列线图为0.68。二分类风险分组显示,MMAI高风险组10年远处转移发生率(25%)高于低风险组(8.8%)。高风险组中激素治疗联合挽救性放疗相较单纯挽救性放疗的10年远处转移发生率绝对降低21%,低风险组为2.5%。局限性包括使用归档试验队列。术后MMAI模型可提供挽救性放疗±激素治疗后的个体化风险估计,或有助于挽救治疗的共同决策。外部验证与前瞻性验证正在进行。
基础研究 (15篇)
High-grade serous ovarian carcinoma (HGSOC), the most lethal subtype of ovarian cancer, is often diagnosed at advanced stages and remains associated with poor clinical outcome. In this study, we identify a critical oncogenic role of the RNA methyltransferase METTL3 and the N6-methyladenosine (m6A) RNA modification pathway in HGSOC. Suppression of METTL3, either genetically or pharmacologically, and depletion of its binding partner METTL14 impair ovarian cancer proliferation and tumor progression. Mechanistically, we show that METTL3-mediated m6A deposition enhances the translation of DNA methyltransferase 1 (DNMT1), the primary maintenance DNA methyltransferase responsible for preserving genome-wide methylation patterns and silencing tumor suppressor genes. Pharmacological inhibition of DNMT1 induces widespread DNA hypomethylation and up-regulation of the tumor suppressors TNFAIP3 and FBXO32. Consistently, METTL3 suppression reduces DNMT1 abundance and derepresses TNFAIP3 and FBXO32 expression. Knockdown and rescue studies further reveal that DNMT1 primarily mediates METTL3-dependent regulation of cell migration, whereas the antiproliferative effects of METTL3 suppression are likely driven by additional downstream targets. Collectively, these findings identify the m6A-METTL3-DNMT1 axis as a mechanistic link between RNA and DNA methylation pathways and a potential therapeutic vulnerability in HGSOC.
中文摘要:高级别浆液性卵巢癌(HGSOC)是卵巢癌中致死率最高的亚型,确诊时常已属晚期,临床结局较差。本研究确认了RNA甲基转移酶METTL3及N6-甲基腺苷(m6A)RNA修饰通路在HGSOC中具有关键的促癌作用。通过遗传学或药理学手段抑制METTL3,以及敲除其结合伙伴METTL14,均可削弱卵巢癌的增殖与肿瘤进展。机制上,METTL3介导的m6A沉积增强了DNA甲基转移酶1(DNMT1)的翻译;DNMT1是主要的维持性DNA甲基转移酶,负责维持全基因组甲基化模式并沉默抑癌基因。药理学抑制DNMT1引起广泛的DNA低甲基化,并上调抑癌基因TNFAIP3与FBXO32。与此一致,抑制METTL3会降低DNMT1丰度,并解除对TNFAIP3和FBXO32表达的抑制。敲低与回补实验进一步显示,DNMT1主要介导METTL3依赖的细胞迁移调控,而抑制METTL3所产生的抗增殖效应可能由其他下游靶点驱动。总体而言,这些发现将m6A-METTL3-DNMT1轴确定为RNA甲基化与DNA甲基化通路之间的机制联系,并提示其为HGSOC潜在的治療脆弱点。
Enzalutamide (Enz)-resistant prostate cancer (PCa) is a lethal disease that affects a broad population of elderly men. Experimental and clinical evidence has demonstrated that androgen receptor variant 7 (ARv7) plays a critical role in Enz-resistant (EnzR) PCa by functioning as a constitutively active transcription factor driving disease progression. However, the predictive value of the ARv7 transcript has not been fully recognized due to its low frequency in castration-resistant PCa. In this study, we identified ARv7 mRNA as an N6-methyladenosine (m6A)-modified transcript. Enz treatment increases METTL3-dependent m6A methylation of ARv7 mRNA at the A1177 site, which is subsequently recognized by the reader protein YTHDC2, leading to enhanced translation efficiency of ARv7. Furthermore, EnzR PCa exhibited elevated lactate metabolism, which regulated AR transcription through promoter-mediated epigenetic modifications at H3K9 and H3K14. Reactivated AR exhibited enhanced phase separation to transcriptionally up-regulate YTHDC2 expression. In vivo experiments demonstrated that targeting the METTL3-YTHDC2-ARv7 axis represents a promising therapeutic strategy to suppress EnzR PCa progression. Moreover, the METTL3 inhibitor STM2457 synergized with Enz to inhibit tumor growth without observable toxicity. Collectively, our findings suggest that the clinical utility of ARv7 may need to be reconsidered in light of its m6A-dependent translational regulation.
中文摘要:恩扎卢胺耐药的前列腺癌是致死性疾病,累及广泛的老年男性人群。实验与临床证据显示,雄激素受体变体7(ARv7)作为持续活化的转录因子驱动疾病进展,在恩扎卢胺耐药前列腺癌中起关键作用。但ARv7转录本在去势抵抗性前列腺癌中出现频率低,其预测价值尚未被充分认识。本研究发现ARv7 mRNA是受N6-甲基腺苷(m6A)修饰的转录本。恩扎卢胺处理使ARv7 mRNA在A1177位点的METTL3依赖性m6A甲基化增加,该修饰随后被阅读蛋白YTHDC2识别,从而提高ARv7的翻译效率。恩扎卢胺耐药前列腺癌还表现出乳酸代谢升高,乳酸代谢通过启动子介导的H3K9与H3K14表观遗传修饰调控AR转录。重新活化的AR相分离增强,在转录水平上调YTHDC2表达。体内实验表明,靶向METTL3-YTHDC2-ARv7轴是抑制恩扎卢胺耐药前列腺癌进展的有前景的治疗策略;METTL3抑制剂STM2457与恩扎卢胺协同抑制肿瘤生长,未观察到明显毒性。这些结果提示,鉴于ARv7受m6A依赖性翻译调控,其临床应用价值可能需要重新评估。
The mechanisms underlying renal cell carcinoma (RCC) progression remain incompletely understood. Here, we identify phytanoyl-CoA dioxygenase domain containing 1 (PHYHD1) as a tumor suppressor that regulates translational homeostasis and RCC progression. Progressive PHYHD1 loss promotes tumor advancement and predicts poor prognosis, as revealed by integrative deep learning analysis of pan-cancer datasets. Restoring PHYHD1 suppresses tumor growth in RCC cell and patient-derived xenograft (PDX) models independently of its dioxygenase activity. Mechanistically, PHYHD1 interacts with translation elongation factor eEF1A1, alters its association with ribosomes, and restrains protein translation. Ribosome profiling and RNA-seq identify ceramide transporter 1 (CERT1) as a key effector of the PHYHD1-eEF1A1 axis. PHYHD1 depletion enhances CERT1 translation, whereas targeting CERT1 impairs proliferation of PHYHD1-deficient cells. These findings define a PHYHD1-eEF1A1-CERT1 axis that controls translation during RCC progression and highlight CERT1 as a potential therapeutic target in PHYHD1-deficient tumors.
中文摘要:肾细胞癌(RCC)进展的机制仍未完全阐明。PHYHD1(含植物酰辅酶A双加氧酶结构域蛋白1)被鉴定为调控翻译稳态与RCC进展的抑癌因子。对泛癌数据集的整合深度学习分析显示,PHYHD1进行性缺失促进肿瘤进展并提示预后不良。在RCC细胞及患者来源异种移植(PDX)模型中,恢复PHYHD1可抑制肿瘤生长,且不依赖其双加氧酶活性。机制上,PHYHD1与翻译延伸因子eEF1A1相互作用,改变其与核糖体的结合,并限制蛋白翻译。核糖体图谱与RNA测序将神经酰胺转运蛋白1(CERT1)确定为PHYHD1-eEF1A1轴的关键效应分子。PHYHD1缺失增强CERT1翻译,而靶向CERT1可损害PHYHD1缺陷细胞的增殖。这些发现界定了一条在RCC进展中控制翻译的PHYHD1-eEF1A1-CERT1轴,并提示CERT1是PHYHD1缺陷肿瘤的潜在治疗靶点。
Approaches that promote ferroptosis have emerged as promising therapeutic strategies for chemotherapy-resistant cancers; however, the mechanisms regulating ferroptosis during acquired therapeutic resistance remain incompletely understood. Using RNA sequencing, we identified that Nuclear Factor Erythroid-2 Related Factor 1 (NFE2L1) is upregulated in cisplatin-resistant ovarian cancer (OC) cells and patient tissues, as well as in ferroptosis-resistant models. Genetic knockdown of NFE2L1 resensitized cells to cisplatin both in vitro and in vivo. Notably, this effect was largely reversed by ferroptosis inhibitors, which significantly rescued cell survival following NFE2L1 depletion under cisplatin treatment. Further experiments demonstrated that modulating NFE2L1 expression affects the response to ferroptosis inducers by regulating iron accumulation and lipid peroxidation. Mechanistically, NFE2L1 silencing increased the transcription of long-chain fatty acid transport protein 2 (SLC27A2/FATP2). Chromatin immunoprecipitation and dual-luciferase reporter assays showed that NFE2L1 bound directly to the SLC27A2 promoter, where it competitively inhibited the recruitment of the transcription factor SP1. As a key member of the long-chain acyl-CoA synthetase family, FATP2 promotes the uptake and activation of long-chain fatty acids, processes that have been implicated in the regulation of ferroptosis. Subsequent LC-MS-based lipidomic analysis revealed that NFE2L1 reprogrammed intracellular fatty acid metabolism, characterized by increased polyunsaturated fatty acid (PUFA) levels and decreased monounsaturated fatty acid (MUFA) levels within phosphatidylethanolamines (PEs), thereby increasing cellular susceptibility to ferroptosis. Consistent with these findings, supplementation with exogenous unsaturated fatty acids modulated NFE2L1-mediated ferroptosis sensitivity. Collectively, our findings reveal a novel NFE2L1/SLC27A2 axis that drives cisplatin resistance in OC by suppressing ferroptosis, and suggest a potential therapeutic strategy for treating cisplatin-resistant ovarian cancer.
中文摘要:促铁死亡策略已成为化疗耐药肿瘤有前景的治疗方向,但获得性治疗耐药过程中铁死亡的调控机制仍不完全清楚。通过RNA测序,我们发现核因子E2相关因子1(NFE2L1)在顺铂耐药卵巢癌细胞、患者组织以及铁死亡耐药模型中上调。基因敲低NFE2L1在体外和体内均使细胞对顺铂重新敏感。铁死亡抑制剂在很大程度上逆转了这一效应,并显著挽救顺铂处理下NFE2L1缺失后的细胞存活。进一步实验表明,调节NFE2L1表达可通过调控铁蓄积和脂质过氧化影响细胞对铁死亡诱导剂的反应。机制上,沉默NFE2L1增加了长链脂肪酸转运蛋白2(SLC27A2/FATP2)的转录。染色质免疫沉淀和双荧光素酶报告实验显示,NFE2L1直接结合SLC27A2启动子,并竞争性抑制转录因子SP1的募集。作为长链酰基辅酶A合成酶家族的关键成员,FATP2促进长链脂肪酸的摄取和活化,这些过程与铁死亡调控有关。随后基于LC-MS的脂质组学分析显示,NFE2L1重编程细胞内脂肪酸代谢,表现为磷脂酰乙醇胺中多不饱和脂肪酸水平升高、单不饱和脂肪酸水平降低,从而增加细胞对铁死亡的易感性。与这些发现一致,补充外源性不饱和脂肪酸可调节NFE2L1介导的铁死亡敏感性。这些结果揭示了一条新的NFE2L1/SLC27A2轴,其通过抑制铁死亡驱动卵巢癌顺铂耐药,并提示治疗顺铂耐药卵巢癌的潜在策略。
Several tRNAs that differ only in their body sequence decode the same codon, yet their levels and behavior vary across cell types and disease contexts. In a landmark 2014 study, a mutation in the arginine isodecoder Arg-TCT-4 was linked to neurodegeneration in mice. In 2021, increased expression of the Arg-TCT family, especially Arg-TCT-4, was unexpectedly linked to oncogenic transformation in multiple cancer models. A recent publication by Kim and colleagues reports that loss of a single tRNA isodecoder, Arg-TCT-1, drives lineage plasticity and resistance to androgen receptor pathway inhibitors in prostate cancer by reducing the translation of AGA-rich mRNAs. Together, these findings raise a broader question: what do differences in isodecoder sequence actually do? They may influence tRNA processing, charging, interactions with elongation factors and the ribosome, or the modifications tRNAs receive. This commentary places the new findings in the context of prior work and considers potential mechanisms behind the functional diversity of Arg-TCT isodecoders and their role in cancer.
中文摘要:仅主体序列不同而解码同一密码子的若干tRNA,其水平与行为会随细胞类型和疾病背景而变化。2014年一项里程碑研究将精氨酸同工解码器Arg-TCT-4的突变与小鼠神经退行性变联系起来。2021年,Arg-TCT家族尤其是Arg-TCT-4表达升高,在多种癌症模型中被意外发现与致癌转化相关。Kim等近期报道,单一tRNA同工解码器Arg-TCT-1缺失通过降低富含AGA的mRNA翻译,驱动前列腺癌谱系可塑性和对雄激素受体通路抑制剂的耐药。这些发现共同提出更广泛的问题:同工解码器序列差异究竟起什么作用。它们可能影响tRNA加工、装载、与延伸因子及核糖体的互作,或tRNA所接受的修饰。本评论将新发现置于既往研究背景中,并探讨Arg-TCT同工解码器功能多样性背后的潜在机制及其在癌症中的作用。
The rare HOXB13 G84E variant is one of few established high-risk prostate cancer (PrCa) variants, yet the underlying molecular mechanisms by which it drives tumor development remain unknown. Prostate tumors from six heterozygous G84E variant carriers and 18 non-carriers (wild-type) were examined using the Human AmpliSeq Transcriptome Gene Expression Panel, and proteomes were generated by mass spectrometry (SWATH). We identified a 799-gene expression profile and a 75-protein expression profile in G84E-positive tumors when compared with wild-type tumors. Cluster analysis revealed a top-ranked 23 protein profile, which mapped to lipogenesis pathways. Integration of transcriptome and proteome data revealed overlapping differential expression of three genes (NCLN, NFIB, and VASN), two of which have an established link to lipid metabolic pathways. Examination of publicly available transcriptome data from 493 primary PrCa tumors from the The Cancer Genome Atlas (TCGA) tumors revealed 52 tumors with a similar differential expression profile for these three genes. Herein, an innovative proteogenomic approach was used to map molecular changes unique to HOXB13 perturbation in prostate tumors, revealing upregulation of genes in the steroid metabolic, lipid biosynthesis, and fatty acid metabolic pathways.
中文摘要:罕见的HOXB13 G84E变异是少数已确立的高危前列腺癌变异之一,但其驱动肿瘤发生的分子机制仍不清楚。研究采用Human AmpliSeq Transcriptome Gene Expression Panel检测了6例杂合G84E变异携带者和18例非携带者(野生型)的前列腺肿瘤,并通过质谱(SWATH)生成蛋白质组数据。与野生型肿瘤相比,G84E阳性肿瘤中鉴定出799个基因表达谱和75个蛋白表达谱。聚类分析显示排名最高的23个蛋白谱,映射到脂肪生成通路。整合转录组和蛋白质组数据发现三个基因(NCLN、NFIB和VASN)存在重叠的差异表达,其中两个基因与脂质代谢通路有明确关联。对来自TCGA的493例原发前列腺癌肿瘤公开转录组数据进行分析,发现52例肿瘤具有这三个基因相似的差异表达谱。研究采用创新的蛋白质基因组学方法描绘了前列腺肿瘤中HOXB13扰动特有的分子变化,显示类固醇代谢、脂质生物合成和脂肪酸代谢通路中的基因上调。
Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has recently been recognized as a crucial determinant of therapeutic response in prostate cancer (PCa). However, how androgen receptor (AR) signaling regulates ferroptotic susceptibility remains poorly understood. Here, we identify ZNF419, a previously uncharacterized zinc finger protein, as an AR-regulated factor associated with reduced ferroptosis susceptibility in PCa cells. Transcriptomic profiling and functional validation revealed that ZNF419 expression is markedly elevated in PCa and correlates with poor clinical outcome. Promoter-proximal AR occupancy was detected at predicted ARE-containing regions of the ZNF419 locus and contributed to ZNF419 promoter activation in reporter assays, whereas enzalutamide treatment or AR knockdown reduced ZNF419 expression and increased ferroptosis-associated vulnerability. Mechanistically, ZNF419 promotes ZDHHC20 expression and is associated with activation of a candidate downstream enhancer region. ZDHHC20, a palmitoyltransferase, contributes to GPX4 palmitoylation-associated stabilization and limits ubiquitin-mediated proteasomal degradation of GPX4. Pharmacological interference with palmitoylation attenuates ZNF419-associated GPX4 stabilization, whereas ZDHHC20 restoration partially reverses the increased ferroptosis-associated vulnerability of ZNF419-deficient cells. Collectively, our findings support a previously unrecognized AR-associated ZNF419-ZDHHC20-GPX4 regulatory axis that links AR activity to ferroptosis-associated vulnerability. These findings provide a rationale for further investigating whether modulation of this pathway may influence responses to AR-targeted therapy in advanced PCa.
中文摘要:铁死亡是一种由脂质过氧化驱动的铁依赖性调节性细胞死亡形式,近年被视为前列腺癌治疗反应的关键决定因素。雄激素受体(AR)信号如何调控铁死亡易感性仍不清楚。我们鉴定出ZNF419,一种此前未表征的锌指蛋白,作为AR调控因子,与前列腺癌细胞铁死亡易感性降低相关。转录组分析和功能验证显示,ZNF419在前列腺癌中显著升高,并与不良临床结局相关。在ZNF419基因座预测含ARE区域检测到启动子近端AR占据,并在报告基因实验中促进ZNF419启动子激活,而恩扎卢胺处理或AR敲低降低ZNF419表达并增加铁死亡相关脆弱性。机制上,ZNF419促进ZDHHC20表达,并与候选下游增强子区域激活相关。ZDHHC20是一种棕榈酰转移酶,参与GPX4棕榈酰化相关稳定化,并限制泛素介导的GPX4蛋白酶体降解。药理学干扰棕榈酰化减弱ZNF419相关的GPX4稳定化,而恢复ZDHHC20部分逆转ZNF419缺陷细胞增加的铁死亡相关脆弱性。这些结果共同支持一个此前未认识的AR相关ZNF419-ZDHHC20-GPX4调控轴,将AR活性与铁死亡相关脆弱性联系起来。这些发现为进一步研究调节该通路是否影响晚期前列腺癌对AR靶向治疗的反应提供了依据。
Bladder cancer lung metastasis poses a major therapeutic challenge because of pronounced tumor heterogeneity. However, the mechanisms regulating bladder cancer metastasis remain elusive. Here, we established a lung-tropic bladder cancer subline through iterative in vivo selection, enabling stepwise enrichment of metastatic competence while minimizing intratumoral variability. Using integrated multiomics analyses combined with functional validation, we identified an IGF2BP2-m⁶A-complement axis that is progressively engaged during metastatic evolution and contributes to lung colonization by bladder cancer cells. IGF2BP2 expression increased stepwise during the metastatic cascade and selectively enhanced the translation of m⁶A-modified complement C3 mRNA through direct binding to its 3' region, without altering transcript abundance. Tumor-derived C3 is subsequently processed, thereby promoting neutrophil recruitment and phenotypic remodeling toward a prometastatic, T3-like state. Single-cell transcriptomic profiling revealed that loss of IGF2BP2 disrupted neutrophil recruitment and was accompanied by enhanced T-cell proliferative activity within lung metastatic lesions. Genetic ablation or pharmacological inhibition of IGF2BP2 attenuated neutrophil accumulation and significantly restricted metastatic outgrowth in vivo. Consistent with these experimental findings, elevated IGF2BP2 expression in clinical bladder cancer specimens correlated with advanced disease stage, increased metastatic risk, and poor patient survival. Collectively, our findings reveal a translationally regulated complement-immune circuit that shapes the lung metastatic microenvironment and identify IGF2BP2 as a potential therapeutic target in metastatic bladder cancer.
中文摘要:膀胱癌肺转移因肿瘤异质性显著而成为重大治疗挑战。调控膀胱癌转移的机制仍不明确。我们通过反复体内筛选建立了肺趋向性膀胱癌亚系,在尽量减少瘤内变异的同时逐步富集转移能力。结合整合多组学分析与功能验证,我们识别出一条在转移演化过程中逐步启用并促进膀胱癌细胞肺定植的IGF2BP2-m⁶A-补体轴。IGF2BP2表达在转移级联中逐步升高,并通过直接结合m⁶A修饰的补体C3 mRNA的3'区域选择性增强其翻译,而不改变转录本丰度。肿瘤来源的C3随后被加工,促进中性粒细胞募集并向促转移、T3样状态发生表型重塑。单细胞转录组分析显示,IGF2BP2缺失破坏中性粒细胞募集,并伴随肺转移灶内T细胞增殖活性增强。IGF2BP2的基因敲除或药理学抑制减少中性粒细胞积聚,并显著限制体内转移灶生长。与实验发现一致,临床膀胱癌标本中IGF2BP2表达升高与疾病分期进展、转移风险增加和患者生存不良相关。这些结果揭示了一个翻译调控的补体-免疫回路,其塑造肺转移微环境,并将IGF2BP2确定为转移性膀胱癌的潜在治疗靶点。
Neuroblastoma is a pediatric solid malignancy that primarily arises from poorly differentiated sympathoadrenal cells in the developing autonomic nervous system. The neuroblastoma genetic landscape is characterized by a paucity of somatic mutations and a far more common occurrence of chromosome copy number variations (CNVs). Two of the most common genetic abnormalities in neuroblastoma are the amplification of MYCN and the unbalanced gain of the long arm of chromosome 17 (17q+), both of which correlate with poor prognosis. Although mouse models exist for MYCN-driven neuroblastoma, no mouse models exist for 17q+. Thus, the mechanism by which 17q + contributes to poor prognosis remains largely unknown. Here, we used a human pluripotent stem cell (PSC) model of neuroblastoma to show that 17q + cooperates with MYCN amplification to accelerate tumorigenesis compared to MYCN amplification alone. We identified six genes on 17q that are upregulated in both our 17q + PSC-derived tumors and 17q + neuroblastoma patient tumors compared to WT 17q, correlate with poor prognosis in neuroblastoma patients, and are overexpressed at the protein level in our MYCN/17q + tumors compared to MYCN alone. Of these six genes, knockdown of BIRC5, CDC6, IGF2BP1, or TK1 in MYCN/17q + cells increases tumor latency in vivo and contributes to tumor progression through diverse mechanisms. Furthermore, knockdown of CDC6, IGF2BP1, and TK1 in neuroblastoma patient-derived xenografts with 17q + slowed growth in vivo. Our findings provide new insights into potential candidate 17q drivers of neuroblastoma tumorigenesis and possible therapeutic vulnerabilities.
中文摘要:神经母细胞瘤是一种儿童实体恶性肿瘤,主要起源于发育中的自主神经系统中分化不良的交感肾上腺细胞。其遗传学特征为体细胞突变较少,而染色体拷贝数变异(CNV)更为常见。神经母细胞瘤最常见的两类遗传异常是MYCN扩增和17号染色体长臂的不平衡获得(17q+),二者均与不良预后相关。虽然已有MYCN驱动神经母细胞瘤的小鼠模型,但尚无17q+的小鼠模型,因此17q+导致不良预后的机制仍大多不清楚。这里,我们使用神经母细胞瘤的人多能干细胞(PSC)模型显示,与单独MYCN扩增相比,17q+与MYCN扩增协同加速肿瘤发生。我们在17q+ PSC来源肿瘤和17q+神经母细胞瘤患者肿瘤中,鉴定出六个17q上的基因,相较于野生型17q均上调,与神经母细胞瘤患者不良预后相关,并在我们的MYCN/17q+肿瘤中较单独MYCN在蛋白水平过表达。在这六个基因中,在MYCN/17q+细胞中敲低BIRC5、CDC6、IGF2BP1或TK1可增加体内肿瘤潜伏期,并通过不同机制促进肿瘤进展。此外,在携带17q+的神经母细胞瘤患者来源异种移植瘤中敲低CDC6、IGF2BP1和TK1可减缓体内生长。我们的发现为神经母细胞瘤肿瘤发生的潜在17q驱动基因和可能的治疗脆弱性提供了新见解。
Active Surveillance (AS) is a treatment option for managing low and intermediate-risk prostate cancer (PCa), aiming to avoid overtreatment while monitoring disease progression through serial MRI and clinical follow-up. Accurate prostate segmentation is an important preliminary step for automating this process, enabling automated detection and diagnosis of PCa. However, existing deep-learning segmentation models are often trained on single-time-point, expertly annotated datasets, making them unsuitable for longitudinal AS analysis, where multiple time points and a scarcity of expert labels hinder effective fine-tuning. To address these challenges, we propose MambaX-Net, a novel semi-supervised, dual-scan 3D segmentation architecture that computes the segmentation for time point t by leveraging the MRI and the corresponding segmentation mask from the previous time point. We introduce two new components: (i) a Mamba-enhanced Cross-Attention Module, which integrates the Mamba block into cross-attention to efficiently capture temporal evolution and long-range spatial dependencies, and (ii) a Shape Extractor Module that encodes the previous segmentation mask into a latent anatomical representation for refined zone delineation. Moreover, we use a semi-supervised self-training strategy that leverages pseudo-labels generated from a pre-trained nnU-Net, enabling effective learning without expert annotations. MambaX-Net was evaluated on a longitudinal AS dataset, and results showed that it significantly outperforms state-of-the-art U-Net and Transformer-based models, achieving superior prostate zone segmentation even when trained on limited and noisy data.
中文摘要:主动监测(AS)是管理低危和中危前列腺癌(PCa)的一种治疗选择,目标是在通过连续MRI和临床随访监测疾病进展的同时避免过度治疗。准确的前列腺分割是实现该流程自动化的重要前置步骤,可支持PCa的自动检测和诊断。现有深度学习分割模型多在单时间点、由专家标注的数据集上训练,难以适用于纵向AS分析,因为多时间点与专家标签稀缺会限制有效微调。为应对这些挑战,我们提出MambaX-Net,一种新的半监督双扫描3D分割架构,通过利用前一时间点的MRI及对应分割掩膜计算时间点t的分割。引入两个新组件:(i)Mamba增强交叉注意力模块,将Mamba块整合到交叉注意力中,以高效捕捉时间演变和长程空间依赖;(ii)形状提取模块,将前一分割掩膜编码为潜在解剖表示,用于更精细的区域勾画。我们还采用半监督自训练策略,利用预训练nnU-Net生成的伪标签,在没有专家标注的情况下实现有效学习。MambaX-Net在纵向AS数据集上评估,结果显示其显著优于最先进的U-Net和基于Transformer的模型,即使在有限且含噪声数据上训练,也能获得更优的前列腺区域分割。
Clear cell renal cell carcinoma (ccRCC), the most common pathological subtype of renal cancer, is characterized by distinctive metabolic reprogramming that serves as a core molecular pathological basis driving tumorigenesis, progression, and therapeutic resistance. The metabolic remodeling in ccRCC primarily manifests as dysregulated glucose metabolism, lipid accumulation, imbalanced amino acid utilization, and mitochondrial dysfunction. These alterations collectively sustain tumor cell bioenergetic demands, biosynthetic precursor supply, and redox homeostasis maintenance. Recent advances in multi-omics technologies and spatially resolved analytical methods have propelled ccRCC metabolism research beyond macroscopic description toward mechanistic investigation and targeted intervention. This article systematically reviews research progress focusing on metabolic reprogramming of ccRCC and the development of related therapeutic agents for this cancer.
中文摘要:透明细胞肾细胞癌(ccRCC)是肾癌最常见的病理亚型,具有独特的代谢重编程特征,这种重编程是驱动肿瘤发生、进展和治疗耐药的核心分子病理基础。ccRCC的代谢重塑主要表现为糖代谢失调、脂质积聚、氨基酸利用失衡和线粒体功能障碍。这些改变共同维持肿瘤细胞的生物能量需求、生物合成前体供应和氧化还原稳态。多组学技术和空间分辨分析方法的进展推动ccRCC代谢研究从宏观描述走向机制探究和靶向干预。文章系统梳理ccRCC代谢重编程及相关治疗药物研发的研究进展。
Prostate cancer, a disease with high incidence among elderly men, is one of the most prevalent malignant tumors in the male urogenital system. In contrast to other cancers, prostate cancer typically has a lower mortality rate relative to its incidence. Consequently, differentiating between progressive and non-progressive prostate cancer proves instrumental for early detection and accurate staging of the disease. PC3 and LNCaP cell lines are representative of distinct prostate cancer subtypes and present as circulating tumor cells (CTCs) at various stages of prostate cancer. LNCaP cells exhibit epithelial characteristics, whereas PC3 cells display mesenchymal traits and are more prone to metastasis. As CTCs serve as important liquid biopsy markers, this study aims to define the characteristics of their heterogeneous surface proteins, providing a potential tool for precise staging and prognostic evaluation in prostate cancer diagnosis and treatment. We developed a programmable multi-stage microfluidic chip integrated with a 7 μm thick photoresist filter and microchannels equipped with multiple functional units. In the prefiltration structure of this chip, a micro-dam with micropillar arrays was utilized to separate blood cells from CTCs based on size differences. Subsequently, prefiltered CTCs, which were conjugated with surface enhanced Raman scattering (SERS) nanoprobes, were captured on the micro-nano hierarchical filter through a synergetic capture strategy involving size exclusion, surface protein recognition, and topographical interaction, and then detected by SERS. Our results showed that the microfluidic chip exhibited a remarkable capture efficiency of about 91.2% for CTCs. Notably, by employing dual Raman reporter molecules, we could easily distinguish two subtypes of prostate cancer CTCs using the chip, enabling both efficient capture and phenotype analysis of CTCs.
中文摘要:前列腺癌在老年男性中发病率较高,是男性泌尿生殖系统最常见的恶性肿瘤之一。与其他癌症不同,前列腺癌的死亡率相对其发病率偏低。因此,区分进展性与非进展性前列腺癌有助于疾病的早期发现和准确分期。PC3 与 LNCaP 细胞系代表不同的前列腺癌亚型,并可在前列腺癌不同阶段作为循环肿瘤细胞(CTC)出现。LNCaP 细胞呈上皮特征,PC3 细胞呈间质特征且更易转移。CTC 是重要的液体活检标志物,本研究旨在表征其异质性表面蛋白特征,为前列腺癌诊疗中的精准分期和预后评估提供潜在工具。我们研制了一种可编程多级微流控芯片,集成 7 μm 厚光刻胶滤膜和配备多个功能单元的微通道。芯片预过滤结构利用带微柱阵列的微坝,依据尺寸差异将血细胞与 CTC 分离。随后,与表面增强拉曼散射(SERS)纳米探针结合的前列腺癌 CTC 通过尺寸排阻、表面蛋白识别和拓扑相互作用协同捕获策略,被微纳分级滤器捕获并经 SERS 检测。结果显示,该微流控芯片对 CTC 的捕获效率约为 91.2%。采用双拉曼报告分子后,该芯片可区分两种前列腺癌 CTC 亚型,实现 CTC 的高效捕获与表型分析。
In this work, an intra-nanocomposite resonance energy transfer-based electrochemiluminescence (RET-ECL) biosensor was developed for detecting microRNA (miRNA-21), a cervical cancer relative biomarker. By means of the in-situ reduction method, silver nanoparticles (Ag NPs) were uniformly coated on the surface of Zirconium-based metal organic frameworks (UiO-66-NH2) encapsulated with Ru(bpy)32+ (Ru@UiO-66-NH2), thus forming the Ru@UiO-66-NH2@Ag nanocomposite. Because of the incorporation of both ECL donor (Ru(bpy)32+) and acceptor (Ag NPs) within a single nanostructure, Ru@UiO-66-NH2@Ag showed high RET efficiency, causing a significantly quenched ECL response. Afterward, the presence of miRNA-21 activated the upstream toehold-mediated strand displacement reactions (TSDR) to generate abundant S strands, which could further trigger the downstream catalytic hairpin assembly (CHA). Immobilizing glucose oxidase (GOD) on the surface of Ru@UiO-66-NH2@Ag enabled the catalysis of glucose oxidation and then the produced H2O2 proceeded to etch Ag NPs to Ag+. As a result, a notably recovered ECL response was obtained for miRNA-21 assay with a low detection limit of 30 aM. Moreover, the biosensor successfully analyzed miRNA-21 expression levels in serum samples collected from cervical cancer patient and healthy volunteers, whose results were consistent with those of the standard methods. Therefore, this biosensor held huge potential in analysis of cervical cancer-related miRNA.
中文摘要:本工作构建了一种基于纳米复合物内部共振能量转移的电化学发光(RET-ECL)生物传感器,用于检测宫颈癌相关标志物微小RNA(miRNA-21)。采用原位还原法将银纳米颗粒(Ag NPs)均匀包覆于封装了Ru(bpy)32+的锆基金属有机框架(UiO-66-NH2)表面,形成Ru@UiO-66-NH2@Ag纳米复合物。由于ECL供体(Ru(bpy)32+)与受体(Ag NPs)共存于同一纳米结构内,该复合物表现出较高的RET效率,ECL响应被显著猝灭。miRNA-21存在时激活上游toehold介导的链置换反应(TSDR),产生大量S链,进而触发下游催化发夹组装(CHA)。将葡萄糖氧化酶(GOD)固定于Ru@UiO-66-NH2@Ag表面,可催化葡萄糖氧化,生成的H2O2进一步将Ag NPs刻蚀为Ag+。由此,miRNA-21检测获得明显恢复的ECL响应,检出限低至30 aM。该传感器对宫颈癌患者与健康志愿者血清样本中miRNA-21表达水平进行分析,结果与标准方法一致。该生物传感器在宫颈癌相关miRNA分析中具有较大潜力。
The standard treatment of ovarian cancer involves surgical resection followed by chemotherapy to target residual microscopic tumors. Current chemotherapy is most commonly delivered intravenously (i.v.) because of the toxicity and difficulty in administering intraperitoneal (i.p.) chemotherapy. However, clinical trials have demonstrated that i.p. chemotherapy is superior to i.v. chemotherapy because it can achieve a higher therapeutic concentration and prolonged retention in the peritoneal cavity. To improve the efficacy and safety of i.p. chemotherapy, we developed an injectable hyaluronic acid (HA)-based hydrogel platform for combinatorial and localized delivery of bevacizumab (BVZ), albumin-bound paclitaxel (nab-paclitaxel, nab-PTX) and carboplatin (CPT) in a manner that responds to the high level of matrix metalloproteinases (MMPs) in the i.p. space. HA and dextran sulfate (DS) are chemically modified to allow hydrogels to form with MMP-degradable crosslinkers in less than 1 min upon injection. The in vitro release of BVZ, nab-PTX and CPT is sensitive to MMP concentration and is sustained for up to 28 days. The combined release of BVZ, nab-PTX and CPT from the hydrogels effectively inhibits angiogenesis and tumor cell proliferation in vitro. Moreover, the i.p. administration of the hydrogel system results in tumor burden reduction comparable to the multiple injections of the free drug combination, with reduced systemic side effects. Our work suggests that the injectable MMP responsive hydrogel is a promising i.p. delivery system of BVZ, nab-PTX and CPT to improve i.p. retention and clinical therapeutic effects for ovarian cancer treatment with minimum side effects. STATEMENT OF SIGNIFICANCE: This study presents the first use of hydrogels for intraperitoneal delivery of bevacizumab (BVZ), carboplatin (CPT), and albumin-bound paclitaxel (nab-PTX) to locally treat ovarian cancer. An injectable hyaluronic acid (HA)-based hydrogels platform can be engineered for combinatorial and localized delivery of BVZ, nab-PTX, and CPT in a manner that responds to the high level of matrix metalloproteinases (MMPs) in the intraperitoneal (i.p.) space. HA and dextran sulfate (DS) are chemically modified to allow hydrogels to form with MMP-degradable crosslinkers in less than 1 min upon injection. The combined release of BVZ, nab-PTX and CPT from the hydrogels results in tumor burden reduction comparable to the multiple injections of the free drug combination, with reduced systemic side effects. This work significantly impacts the field of stimuli-responsive biomaterials and cancer therapeutics by offering a robust, modular, and translationally promising drug delivery platform.
中文摘要:卵巢癌的标准治疗包括手术切除,随后以化疗清除残留的微小肿瘤。现有化疗多经静脉给药,原因是腹腔内化疗存在毒性和给药困难。临床试验显示,腹腔内化疗优于静脉化疗,可在腹腔内达到更高治疗浓度并延长滞留时间。为提高腹腔内化疗的疗效与安全性,我们开发了一种可注射的透明质酸(HA)基水凝胶平台,用于贝伐珠单抗(BVZ)、白蛋白结合型紫杉醇(nab-PTX)和卡铂(CPT)的联合局部递送,并以腹腔内高水平基质金属蛋白酶(MMPs)为响应条件。HA和硫酸葡聚糖(DS)经化学修饰,使水凝胶可在注射后1分钟内与可被MMP降解的交联剂成胶。BVZ、nab-PTX和CPT的体外释放对MMP浓度敏感,并可持续长达28天。水凝胶释放的BVZ、nab-PTX和CPT联合作用可在体外有效抑制血管生成和肿瘤细胞增殖。腹腔内给予该水凝胶系统可使肿瘤负荷下降,效果与多次注射游离药物组合相当,且全身副作用减少。该工作提示,可注射MMP响应性水凝胶是有前景的腹腔内递送系统,可提高BVZ、nab-PTX和CPT的腹腔内滞留和临床疗效,并以较小副作用治疗卵巢癌。意义声明:本研究首次将水凝胶用于腹腔内递送贝伐珠单抗、卡铂和白蛋白结合型紫杉醇,以局部治疗卵巢癌。可注射透明质酸基水凝胶平台可被设计用于BVZ、nab-PTX和CPT的联合局部递送,并以腹腔内高水平MMPs为响应条件。HA和DS经化学修饰,使水凝胶可在注射后1分钟内与可被MMP降解的交联剂成胶。水凝胶释放的BVZ、nab-PTX和CPT联合作用可使肿瘤负荷下降,效果与多次注射游离药物组合相当,且全身副作用减少。该工作通过提供稳健、模块化且具转化前景的药物递送平台,对刺激响应生物材料和肿瘤治疗领域具有重要意义。
Hypoxia-inducible factors (HIFs) are constitutively active in clear cell renal cell carcinoma (ccRCC) cells. Here, we investigated whether these cells could still respond to hypoxia independently of canonical HIF activation. We found that hypoxia provokes a NADH reductive stress that attenuates lactate release when the supply of extracellular pyruvate becomes limited, a response that was restored by the ectopic expression of the cytosolic and mitochondria-targeted NADH oxidase (LbNOX). Suppression of the mitochondrial electron transport chain (mtETC) alone is sufficient to attenuate glycolytic flux when extracellular pyruvate is limited, a situation consistent with metabolomic data from human ccRCCs. Furthermore, this response can be mimicked by pharmacological or genetic inhibition of mitochondrial complex IV (CIV) activity and restored by the mitochondrial-targeted alternative oxidase (AOX). Therefore, our data suggest that cells can respond to low oxygen tension through a mitochondrial-dependent elevation of NADH/NAD+, resulting in the suppression of glycolysis when pyruvate availability is compromised.
中文摘要:在透明细胞肾细胞癌(ccRCC)细胞中,缺氧诱导因子(HIFs)呈持续激活状态。我们考察这些细胞是否仍能在不依赖经典HIF激活的情况下对缺氧作出反应。发现当细胞外丙酮酸供应受限时,缺氧会引发NADH还原应激,减弱乳酸释放;异位表达胞质及线粒体靶向的NADH氧化酶(LbNOX)可恢复该反应。仅抑制线粒体电子传递链(mtETC)就足以在细胞外丙酮酸受限时减弱糖酵解通量,这一情况与人类ccRCC的代谢组学数据一致。药理学或遗传学抑制线粒体复合物IV(CIV)活性可模拟该反应,线粒体靶向的替代氧化酶(AOX)可将其恢复。因此,数据提示细胞可通过线粒体依赖性的NADH/NAD+升高对低氧张力作出反应,在丙酮酸可用性受损时导致糖酵解受抑制。
9神经系统肿瘤 (20篇)
临床研究 (6篇)
Contemporary risk stratification of isocitrate dehydrogenase (IDH)-mutant lower-grade gliomas relies primarily on molecular characteristics and surgical tumor burden but does not capture dynamic tumor behavior. Our primary objective was to determine whether pretherapeutic tumor growth velocity (TGV) provides independent prognostic information for overall survival (OS) beyond established factors. This multicenter retrospective study included 569 adults with grade 2-3 IDH-mutant gliomas from three French centers, comprising a development cohort (n = 440) and two external validation cohorts (n = 129). TGV was derived from automated, outcome-blinded volumetric analysis of serial preoperative MRI using mean diameter expansion and log-volume growth. Prognostic value was assessed using multivariable Cox regression, external validation, decision curve analysis, and exploratory random survival forests. During a median follow-up of 6.8 years, 73 deaths occurred in the development cohort. Higher TGV was independently associated with shorter overall survival after adjustment for age, sex, grade, 1p/19q status, and postoperative residual tumor volume (HR per 1-mm/year increase, 1.046; 95%CI, 1.011-1.083; P=.011), and was independently replicated externally (HR, 1.077; 95% CI, 1.005-1.153; P=.035). Findings were consistent using log-volume growth and after accounting for CDKN2A/B status. Adding TGV improved prognostic model fit (likelihood-ratio χ²=5.70; P=.017), with greatest incremental value in astrocytomas. Decision curve analysis demonstrated additional clinical utility, while survival forests identified TGV among the strongest survival predictors alongside 1p/19q status and postoperative residual tumor volume. Pretherapeutic TGV independently predicts survival beyond contemporary molecular and surgical factors in IDH-mutant lower-grade gliomas. This accessible MRI-derived biomarker may refine individualized risk stratification, particularly in astrocytoma.
中文摘要:当前对异柠檬酸脱氢酶(IDH)突变型低级别胶质瘤的风险分层主要依赖分子特征与手术肿瘤负荷,未反映肿瘤的动态行为。本研究主要目的是确定治疗前肿瘤生长速度(TGV)能否在既有因素之外提供总生存(OS)的独立预后信息。这项多中心回顾性研究纳入法国三家中心的569例成人2-3级IDH突变型胶质瘤患者,包括开发队列440例和两个外部验证队列129例。TGV由系列术前MRI的自动化、结局盲法体积分析得出,采用平均直径扩张和log体积增长计算。预后价值通过多变量Cox回归、外部验证、决策曲线分析和探索性随机生存森林评估。开发队列中位随访6.8年,发生73例死亡。校正年龄、性别、分级、1p/19q状态和术后残留肿瘤体积后,较高TGV与较短总生存独立相关(每增加1 mm/年,HR 1.046;95%CI 1.011-1.083;P=.011),并在外部独立重复验证(HR 1.077;95%CI 1.005-1.153;P=.035)。采用log体积增长及校正CDKN2A/B状态后结果一致。加入TGV改善预后模型拟合(似然比χ²=5.70;P=.017),在星形细胞瘤中增量价值最大。决策曲线分析显示额外临床效用,生存森林将TGV列为最强生存预测因素之一,与1p/19q状态和术后残留肿瘤体积并列。治疗前TGV可独立预测IDH突变型低级别胶质瘤患者超越当代分子与手术因素的生存。这一易获取的MRI衍生生物标志物可能改善个体化风险分层,尤其在星形细胞瘤中。
Accurate prediction of patient outcomes remains a critical challenge in oncology, in particular for childhood brain tumors, in which treatment decisions need to carefully balance risk of tumor recurrence and death against severe therapy-induced sequelae. Here, we developed MANTIS (methylation profiling and artificial neural networks for time-dependent individualized survival predictions), a precision artificial intelligence (AI) tool for medulloblastoma and ependymoma outcome prediction built on genome-wide DNA methylation array data from 2,786 patients. MANTIS generates individualized survival probabilities over a 10-year period and achieves concordance indices as high as 0.80 ± 0.07, significantly exceeding the predictive accuracy of current clinical indicators. Extending MANTIS to estimate individualized treatment effects identifies ~60% of patients with average-risk medulloblastoma without a significant survival disadvantage (P = 0.683) when treated with less intensive craniospinal irradiation doses, which is associated with improved neurocognitive outcomes. In conclusion, our study establishes a foundation for AI-based precision prognostics and therapy personalization in childhood brain tumors and offers a blueprint for similar initiatives in other cancer types.
中文摘要:准确预测患者结局仍是肿瘤学中的关键难题,儿童脑肿瘤尤为突出,治疗决策需在肿瘤复发和死亡风险与严重治疗相关后遗症之间谨慎权衡。研究团队开发了MANTIS(基于甲基化谱和人工神经网络的时依个体化生存预测),这是一种用于髓母细胞瘤和室管膜瘤结局预测的精准人工智能工具,构建于2786例患者的全基因组DNA甲基化芯片数据之上。MANTIS可生成10年内的个体化生存概率,一致性指数最高达0.80±0.07,显著超过现有临床指标的预测准确性。将MANTIS扩展用于估计个体化治疗效果后发现,约60%的平均风险髓母细胞瘤患者在接受较低强度颅脊髓照射剂量时未出现显著生存劣势(P=0.683),而该治疗策略与神经认知结局改善相关。研究为儿童脑肿瘤的基于人工智能的精准预后和个体化治疗奠定了基础,并为其他癌种的类似工作提供了蓝图。
The Central Brain Tumor Registry of the United States (CBTRUS) is the largest population-based site-specific registry in the world and is focused exclusively on primary brain and other central nervous system (CNS) tumors diagnosed in the United States (US). CBTRUS obtained de-identified incidence data from 48 central cancer registries (CCRs) from the Centers for Disease Control and Prevention's National Program of Cancer Registries and 4 CCRs from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. CBTRUS represents the entire US population and is inclusive of cases of all primary malignant and non-malignant brain and other CNS tumors for 50 state registries, plus the District of Columbia and Puerto Rico. Additional survival data from 21 CCRs were obtained from SEER. From 2019-2023, 515,112 tumors were reported, corresponding to an average annual age-adjusted incidence rate (AAAIR) of 27.02 per 100,000 population. Across the 50 states, AAAIR for all primary brain and other CNS tumors varied. Meningioma was the most frequently diagnosed tumor type (43.4%). Females had a higher overall incidence of primary brain and other CNS tumors than males, whereas males had higher incidence of many glioma subtypes, including glioblastoma, IDH-wildtype. Incidence varied by race/Hispanic ethnicity, sex, age, and tumor type. For children 0-14 years of age at diagnosis, primary brain and other CNS tumors were the leading cause of cancer-related mortality which is disproportionate to the AAAIR of these tumors in this age group. For most tumor sites, five-year relative survival generally decreased with older age at diagnosis, with children, adolescents, and young adults generally having better survival outcomes. This report provides a current, comprehensive source for the descriptive epidemiology of all primary brain and other CNS tumors in the United States.
中文摘要:美国中枢脑肿瘤登记处(CBTRUS)是全球最大的基于人群的特定部位登记处,专门聚焦于美国诊断的原发性脑及其他中枢神经系统(CNS)肿瘤。CBTRUS从疾病控制与预防中心国家癌症登记计划下属的48个中央癌症登记处(CCR)以及国家癌症研究所监测、流行病学和最终结果(SEER)计划的4个CCR获取去标识化发病数据。CBTRUS覆盖美国全部人口,纳入50个州登记处以及哥伦比亚特区和波多黎各的所有原发性恶性与非恶性脑及其他CNS肿瘤病例。另从SEER获取21个CCR的生存数据。2019—2023年共报告515,112例肿瘤,平均年年龄调整发病率(AAAIR)为每10万人27.02例。50个州的全部原发性脑及其他CNS肿瘤AAAIR存在差异。脑膜瘤是最常诊断的肿瘤类型(43.4%)。女性原发性脑及其他CNS肿瘤总体发病率高于男性,男性多种胶质瘤亚型发病率更高,包括IDH野生型胶质母细胞瘤。发病率随种族/西班牙裔族裔、性别、年龄和肿瘤类型而变化。对于诊断时0—14岁儿童,原发性脑及其他CNS肿瘤是癌症相关死亡的首位原因,这与该年龄组这些肿瘤的AAAIR不相称。对于大多数肿瘤部位,五年相对生存率通常随诊断年龄增加而下降,儿童、青少年和年轻成人一般有更好的生存结局。本报告为美国全部原发性脑及其他CNS肿瘤的描述性流行病学提供了当前、全面的来源。
Focused ultrasound-mediated blood-brain barrier opening (FUS-BBBO) is hypothesized to enhance liquid biopsy by facilitating the release of tumor material into the circulation. This study aimed to evaluate the impact of MR-guided FUS-BBBO on plasma extracellular vesicle (EV) concentrations and size distributions, alongside cell-free DNA (cfDNA) profiles, to determine the clinical efficacy of this approach in glioblastoma (GB) patients. We performed 14 MR-guided FUS-BBBO procedures in patients with GB with blood sampling 1 h before and 1 h after sonication. Plasma EVs were isolated by size-exclusion chromatography and quantified by tunable resistive pulse sensing technology. cfDNA concentration and fragment profiles were assessed using fluorometric and electrophoretic methods. EV concentration showed no consistent change after FUS-BBBO, with marked inter-patient and inter-procedure heterogeneity. In contrast, EV size displayed a reproducible diameter reduction of ∼8-10 nm, driven predominantly by contraction of the upper tail of the size distribution, indicating selective modulation of larger vesicle subpopulations. cfDNA concentrations and fragmentation showed a heterogeneous pattern, with occasional patient-specific increases. Exploratory analyses revealed no significant associations between biomarker changes and procedural parameters except for treated volume. Our findings challenge the assumption that clinical BBBO uniformly increases biomarker abundance. The consistent shift toward smaller EVs suggests a selective modulation rather than an increased release. While BBBO may enhance the detectability of analytes that poorly cross the BBB, this may not apply to EVs, which are able to traverse the BBB under physiological conditions, further supporting their value as liquid-biopsy substrates in neuro-oncology. Future studies integrating clinical data with mechanistic models are necessary to refine FUS-enhanced diagnostic strategies.
中文摘要:聚焦超声介导的血脑屏障开放(FUS-BBBO)被认为可通过促使肿瘤物质释放入循环来增强液体活检。该研究评估MR引导FUS-BBBO对胶质母细胞瘤(GB)患者血浆细胞外囊泡(EV)浓度与粒径分布的影响,并结合游离DNA(cfDNA)图谱,判断这一方法在GB患者中的临床效能。研究在GB患者中实施14次MR引导FUS-BBBO,于声处理前1小时和声处理后1小时采血。血浆EV经尺寸排阻色谱分离,并用可调电阻脉冲传感技术定量。cfDNA浓度与片段图谱采用荧光法和电泳法评估。FUS-BBBO后EV浓度未见一致变化,患者间和操作间异质性明显。相反,EV粒径出现可重复的约8-10 nm直径缩小,主要由粒径分布上尾收缩驱动,提示对大囊泡亚群的选择性调节。cfDNA浓度与片段化呈异质模式,偶见患者特异性升高。探索性分析未发现生物标志物变化与操作参数之间的显著关联,治疗体积除外。结果对临床血脑屏障开放会均匀增加生物标志物丰度的假设提出挑战。EV持续向较小粒径偏移提示选择性调节,而非释放增加。血脑屏障开放可能提高难以跨越血脑屏障的分析物检出率,但这一作用未必适用于生理条件下能够跨血脑屏障的EV,进一步支持其作为神经肿瘤液体活检底物的价值。后续研究需将临床数据与机制模型整合,以优化FUS增强的诊断策略。
Molecular profiling has become an integral part of glioma classification. The extent to which the incidence of molecularly defined adult-type gliomas varies by demographics is unknown. We describe national-level incidence and overall survival patterns of selected glioma subtypes by race/ethnicity. We generated standardized average annual age-adjusted incidence rates of molecularly defined glioma subtypes by race/ethnicity from the Central Brain Tumor Registry of the United States (CBTRUS) using newly diagnosed cases from January 1, 2018, to December 31, 2022. Survival data from the National Cancer Database (NCDB) were used from newly diagnosed cases from January 1, 2018, to December 31, 2021 (with follow-up through December 31, 2022) to evaluate 4-year overall survival, median survival, and multivariable Cox proportional hazards ratios. CBTRUS identified 68 172 glioma cases; IDH-wild-type glioblastoma was most common (n = 51 548). Non-Hispanic White individuals had a significantly higher incidence of all gliomas compared to other groups (P > .001). Non-Hispanic Black individuals had the lowest incidence for IDH-mutant astrocytoma and oligodendroglioma, and shared lowest incidence of IDH-mutant glioblastoma and IDH-wild-type astrocytoma with non-Hispanic other individuals, who had the lowest incidence of IDH-wild-type glioblastoma (P < .001). The odds of having an IDH-mutant (versus IDH-wildtype) astrocytoma or glioblastoma were significantly lower for males, those of older age, and non-Hispanic Black individuals (P < .001). Non-Hispanic other individuals also had increased adjusted overall survival for most glioma subtypes compared to other racial/ethnic groups (P < .001). Four-year overall survival was lowest in all racial/ethnic groups for IDH-wild-type glioblastoma (P < .001). Our findings reveal significant disparities in incidence and survival by race/ethnicity with notable variations present based on glioma biomarkers.
中文摘要:分子谱分析已成为胶质瘤分类不可或缺的组成部分。分子定义的成人型胶质瘤发病率在不同人口学特征间的差异程度尚不清楚。我们按种族/族裔描述选定胶质瘤亚型的全国层面发病率和总生存模式。利用美国中枢脑肿瘤登记处(CBTRUS)2018年1月1日至2022年12月31日的新诊断病例,生成按种族/族裔划分的分子定义胶质瘤亚型标准化年均年龄调整发病率。使用国家癌症数据库(NCDB)2018年1月1日至2021年12月31日的新诊断病例(随访至2022年12月31日)的生存数据,评估4年总生存、中位生存和多变量Cox比例风险比。CBTRUS识别出68172例胶质瘤病例;IDH野生型胶质母细胞瘤最常见(n=51548)。非西班牙裔白人的全部胶质瘤发病率显著高于其他人群(P > .001)。非西班牙裔黑人在IDH突变型星形细胞瘤和少突胶质细胞瘤中发病率最低,并与非西班牙裔其他个体共同在IDH突变型胶质母细胞瘤和IDH野生型星形细胞瘤中发病率最低;非西班牙裔其他个体的IDH野生型胶质母细胞瘤发病率最低(P < .001)。男性、年龄较大者和非西班牙裔黑人患IDH突变型(相对于IDH野生型)星形细胞瘤或胶质母细胞瘤的几率显著更低(P < .001)。与其他种族/族裔群体相比,非西班牙裔其他个体在大多数胶质瘤亚型中的校正总生存也更高(P < .001)。在所有种族/族裔群体中,IDH野生型胶质母细胞瘤的4年总生存最低(P < .001)。我们的发现揭示,按种族/族裔划分的发病率和生存存在显著差异,且这些差异随胶质瘤生物标志物呈现明显变化。
Radiation necrosis (RN) complicates neuro-oncological care, mimicking tumor recurrence and lacking high-level evidence for standardized management. A European Association of Neuro-Oncology (EANO) expert panel utilized a 3-round Delphi process to create a comprehensive expert opinion document based on the available current scientific evidence. A series of statements, derived from the published literature were created by the experts in each field. Consensus was defined as ≥80% agreement using a 5-point Likert scale. After 3 rounds among 20 experts that included adaptation of statements, the Delphi process reached a consensus (≥80% agreement) on 53 statements out of 57. RN occurs in 4%-30% of patients, typically appearing 6-24 months after radiotherapy for primary (glial) or metastatic brain tumors. Experts identified perfusion MRI and amino acid PET as the most suitable imaging modalities for differentiation from tumor recurrence. While histopathology remains the gold standard, identifying viable tumor cells in irradiated gliomas is challenging due to overlapping cytological features with reactive glia. For symptomatic management, corticosteroids may be tried, and bevacizumab is recommended for corticosteroid-refractory cases, with evidence suggesting profound efficacy even at low doses. Surgery is considered effective for rapid symptom relief and definitive diagnosis in accessible lesions. Laser Interstitial Thermal Therapy (LITT) can be considered an additional treatment option for symptomatic RN. Despite the absence of Level 1 evidence, these Delphi-survey-formulated recommendations provide actionable guidance for clinical practice. There is a need for prospective randomized trials focusing on symptomatic RN.
中文摘要:放射性坏死(RN)使神经肿瘤诊疗复杂化,可模拟肿瘤复发,且标准化管理缺乏高级别证据。欧洲神经肿瘤协会(EANO)专家组采用3轮Delphi流程,基于现有科学证据形成一份全面的专家意见文件。各领域专家根据已发表文献提出一系列陈述。共识定义为5点Likert量表上≥80%同意。20名专家经3轮(包括陈述修订)后,57条陈述中53条达成共识(≥80%同意)。RN发生于4%-30%的患者,通常在原发性(胶质)或转移性脑肿瘤放疗后6-24个月出现。专家认为灌注MRI和氨基酸PET最适合用于与肿瘤复发鉴别。组织病理学仍是金标准,但受照射胶质瘤中识别存活肿瘤细胞具有挑战性,因其细胞学特征与反应性胶质细胞重叠。对症处理可尝试糖皮质激素,激素难治性病例推荐贝伐珠单抗,证据提示即使低剂量也有显著疗效。对可及病灶,手术可快速缓解症状并明确诊断。激光间质热疗(LITT)可作为症状性RN的额外治疗选择。尽管缺乏1级证据,这些经Delphi调查形成的推荐为临床实践提供可操作指导。仍需针对症状性RN开展前瞻性随机试验。
基础研究 (14篇)
High-grade gliomas are the most aggressive brain tumors because of their invasive nature and resilience. Recent advances have shown that glioma cells form synapse-like contacts with neurons, responding to neuronal activity and promoting tumor growth. Glioma-neuron communication is initiated by the release of neurotrophic factors from tumors that exploit host neuronal plasticity mechanisms, subsequently inducing the formation and electrical activity of neuron-glioma synapses. Here, we review the evidence supporting functional neuron-glioma interactions and the molecular regulators underlying neuronal plasticity. Furthermore, we discuss the effects of cancer on neural circuits and the possible prognostic value of connectome studies. Finally, we outline therapeutic strategies and challenges in targeting the neuron-glioma interface to reduce brain cancer progression.
中文摘要:高级别胶质瘤因侵袭性和耐受性成为最具侵袭性的脑肿瘤。近期研究显示,胶质瘤细胞与神经元形成突触样接触,响应神经元活动并促进肿瘤生长。胶质瘤与神经元的通讯始于肿瘤释放神经营养因子,这些因子利用宿主神经元可塑性机制,继而诱导神经元-胶质瘤突触形成与电活动。综述梳理支持功能性神经元-胶质瘤相互作用的证据及神经元可塑性相关分子调控因素,并讨论癌症对神经回路的影响以及连接组研究的潜在预后价值。针对神经元-胶质瘤界面的治疗策略与挑战亦被概述,以延缓脑肿瘤进展。
Cancer cells show highly heterogeneous and plastic states in glioblastoma, an incurable brain tumour1-5. However, how these malignant states arise and whether they follow defined cellular trajectories across tumours is poorly understood. Here we generated a deep single-cell and spatial multi-omic atlas of human glioblastoma that pairs transcriptomic, epigenomic and genomic profiling of 12 tumours across many regions. We identify that glioblastoma heterogeneity is driven by spatially patterned transitions of cancer cells from developmental-like states towards those defined by a glial injury response and hypoxia. This cellular trajectory regionalizes tumours into distinct tissue microenvironments and manifests in a molecularly conserved manner across tumours as well as genetically distinct tumour subclones. Consistently, using a new deep-learning framework to map cancer cell states jointly with clones in situ, we show that tumour subclones are finely spatially intermixed through glioblastoma tissue microenvironments. We validate this cellular trajectory by using somatic mutation-based hierarchies in vivo and an experimental patient-derived organoid model ex vivo. Finally, we show that this cancer cell trajectory is intimately linked to myeloid heterogeneity and unfolds across regionalized myeloid signalling environments. Our findings define a stereotyped trajectory of cancer cells in glioblastoma and unify glioblastoma tumour heterogeneity into a tractable cellular and tissue framework.
中文摘要:胶质母细胞瘤是一种无法治愈的脑肿瘤,其癌细胞呈现高度异质和可塑的状态。但这些恶性状态如何产生、是否在肿瘤间遵循确定的细胞轨迹仍不清楚。我们构建了人胶质母细胞瘤的深度单细胞与空间多组学图谱,对12个肿瘤的多个区域同时进行转录组、表观基因组和基因组分析。研究发现,胶质母细胞瘤的异质性由癌细胞从发育样状态向胶质损伤反应和缺氧相关状态的空间模式化转变所驱动。该细胞轨迹使肿瘤区域化为不同的组织微环境,并在不同肿瘤以及遗传上不同的肿瘤亚克隆中以分子上保守的方式呈现。与此一致,利用新的深度学习框架将癌细胞状态与原位克隆联合映射,我们发现肿瘤亚克隆在胶质母细胞瘤组织微环境中空间上精细混合。我们通过体内体细胞突变层级和体外实验性患者来源类器官模型验证了这一细胞轨迹。最后,该癌细胞轨迹与髓系异质性密切相关,并在区域化的髓系信号环境中展开。我们的发现定义了胶质母细胞瘤中癌细胞的刻板轨迹,并将胶质母细胞瘤的肿瘤异质性统一为可处理的细胞与组织框架。
Glioblastoma (GBM) is one of the most lethal human malignancies, with a five-year survival rate of approximately 5% and limited effective therapeutic options beyond standard-of-care regimens, underscoring an urgent need for novel therapeutic agents and druggable targets. Here, we report that PM534, a marine sponge-derived synthetic compound, potently suppresses GBM malignancy in orthotopic patient-derived xenograft (PDX) models and in vitro, with IC50 value of 1.86nM in patient-derived GBM#P3 cells. Target identification via activity-based protein profiling (ABPP) revealed P23, a co-chaperone of HSP90, as the direct molecular target of PM534. Subsequent LC-MS/MS analysis, molecular dynamics simulation, and site-directed mutagenesis collectively demonstrated that PM534 covalently bond P23 at Cys58 and Cys75. P23 demonstrated significant upregulation in human GBM tissues and orthotopic PDX models, correlating with tumor progression. Mechanistic studies exhibited that P23 interacted with splicing factor proline- and glutamine-rich protein (SFPQ) to regulate liquid-liquid phase separation (LLPS). Covalent engagement of P23 by PM534 disrupted the interaction of SFPQ with the HSP90/P23 complex, thereby triggering proteasomal degradation of SFPQ and consequently abrogating SFPQ-driven LLPS and oncogenic condensate formation. These findings establish PM534 as a promising drug candidate for clinical GBM therapy and highlight P23 as a therapeutic target in GBM.
中文摘要:胶质母细胞瘤(GBM)是致死性最高的人类恶性肿瘤之一,五年生存率约5%,除标准治疗方案外有效治疗选择有限,迫切需要新型治疗药物和可成药靶点。PM534是一种来源于海绵的合成化合物,在原位患者来源异种移植(PDX)模型和体外实验中强效抑制GBM恶性进展,在患者来源GBM#P3细胞中的IC50为1.86 nM。通过活性蛋白质谱(ABPP)进行靶点鉴定,发现HSP90共伴侣蛋白P23是PM534的直接分子靶点。随后LC-MS/MS分析、分子动力学模拟和定点突变共同表明,PM534在Cys58和Cys75位点与P23共价结合。P23在人GBM组织和原位PDX模型中显著上调,并与肿瘤进展相关。机制研究显示,P23与富含脯氨酸和谷氨酰胺的剪接因子(SFPQ)相互作用,调控液-液相分离(LLPS)。PM534与P23共价结合后,破坏SFPQ与HSP90/P23复合物的相互作用,引发SFPQ经蛋白酶体降解,进而消除SFPQ驱动的LLPS和致癌凝聚体形成。这些发现确立PM534作为临床GBM治疗的有前景候选药物,并突出P23作为GBM治疗靶点。
Diffuse gliomas arise within and become functionally integrated into neural circuits, establishing bidirectional interactions between malignant cells and the surrounding brain. Neuronal activity promotes glioma growth and progression, while glioma cells remodel the excitability, connectivity, and functional organization of the neural circuits they infiltrate. Pathological excitation-inhibition imbalance can impair cortical information processing, while tumor infiltration simultaneously disrupts, preserves, and induces adaptive reorganization of distributed functional networks. Language processing provides a well defined framework for examining these competing effects because language processing depends on distributed cortical and subcortical networks whose organization can be interrogated using neuroimaging, electrophysiology, and direct cortical stimulation. The pattern and severity of glioma-associated language dysfunction reflect the interaction among tumor location, growth kinetics, molecular and histopathological features, white matter involvement, and the capacity for adaptive redistribution of function within ipsilateral and contralateral networks. Slowly growing gliomas can permit substantial functional reorganization, whereas rapidly infiltrating tumors may constrain the time and biological substrate available for effective network adaptation. In this review, we examine reciprocal glioma-neural circuit interactions, with particular emphasis on the mechanisms of glioma-associated neuronal hyperexcitability and the disruption, preservation, and adaptive remodeling of language networks.
中文摘要:弥漫性胶质瘤起源于神经回路内部,并在功能上整合进神经回路,使恶性细胞与周围脑组织形成双向相互作用。神经元活动促进胶质瘤生长和进展,胶质瘤细胞则重塑其所浸润神经回路的兴奋性、连接性和功能组织。病理性兴奋-抑制失衡可损害皮层信息处理,肿瘤浸润同时会破坏、保留并诱导分布式功能网络的适应性重组。语言处理为考察这些相互竞争的影响提供了界定清晰的框架,因为语言处理依赖分布式皮层和皮层下网络,而这些网络的组织可通过神经影像、电生理和直接皮层刺激加以探查。胶质瘤相关语言功能障碍的模式和严重程度反映肿瘤位置、生长动力学、分子与组织病理学特征、白质受累以及同侧和对侧网络内功能适应性重分布能力之间的相互作用。生长缓慢的胶质瘤可允许显著的功能重组,而快速浸润的肿瘤可能限制有效网络适应所需的时间和生物学基础。本综述考察胶质瘤与神经回路的双向相互作用,重点讨论胶质瘤相关神经元超兴奋性的机制以及语言网络的破坏、保留和适应性重塑。
Glioblastoma invasion into healthy brain tissue remains a major barrier to effective treatment, but the dynamic single-cell behaviors underlying this process remain difficult to measure across patient models. Here, we introduce GlioTrace, an ex vivo imaging and computational framework for real-time tracking of glioblastoma invasion in patient-derived xenograft brain slices. Combining whole-specimen confocal microscopy with machine learning-based morphology classification and probabilistic modeling of state transitions, GlioTrace reconstructs how tumor cells switch between invasion phenotypes and how these dynamics are shaped by local tissue context and therapy. Across six patient-derived models, GlioTrace reveals that invasion plasticity is patient-specific, spatially organized, and modulated by vascular proximity and microglial interaction. Targeted therapies selectively alter phenotype composition and transition probabilities, whereas standard-of-care treatment enriches a highly motile, transition-connected branching state consistent with a treatment-tolerant invasive phenotype. Thus, GlioTrace makes glioblastoma invasion a measurable dynamic process for comparing patient-specific treatment responses in living brain tissue.
中文摘要:胶质母细胞瘤向健康脑组织侵袭仍是有效治疗的主要障碍,但这一过程背后的单细胞动态行为难以在多种患者模型中进行测量。我们提出 GlioTrace,一个离体成像与计算框架,用于在患者来源异种移植脑切片中实时追踪胶质母细胞瘤侵袭。GlioTrace 将全标本共聚焦显微镜与基于机器学习的形态分类及状态转换概率建模结合,重建肿瘤细胞如何在侵袭表型之间切换,以及局部组织环境和治疗如何塑造这些动态。在六个患者来源模型中,GlioTrace 显示侵袭可塑性具有患者特异性、空间组织性,并受血管邻近和微胶质细胞相互作用调节。靶向治疗选择性改变表型组成和转换概率,而标准治疗富集一种高度运动、转换连接的分支状态,符合治疗耐受性侵袭表型。因此,GlioTrace 使胶质母细胞瘤侵袭成为可测量的动态过程,用于在活体脑组织中比较患者特异性治疗反应。
Aneuploidy is a hallmark of human tumors. Although patient-level copy-number alteration (CNA) differences have been investigated extensively in large cohorts, their intratumoral heterogeneity remains understudied. In this study, we conducted a pan-cancer analysis of 94 human tumors at single-cell resolution, representing seven cancer types: bladder, breast, colon, glioblastoma, kidney, lung, and ovarian. Single-cell copy-number profiling was used to analyze 62,646 aneuploid cells, in addition to bulk exome sequencing of most patients and single-nucleus RNA sequencing of six samples. In many cancer types, increased subclonal diversity was associated with higher CNA burden, whole-genome doubling (WGD), TP53 mutations, and increased geographic diversity. Cancer cells from each patient shared a set of truncal CNAs, suggesting evolution from a single ancestral cell. Many tumors accumulated CNAs in bursts of evolution, suggesting that punctuated evolution is common in diverse cancer types. This study greatly improves our knowledge of intratumoral chromosome diversity across human cancers. This study presents one of the largest pan-cancer single-cell DNA sequencing analyses, profiling intratumoral copy-number heterogeneity across seven major cancer types. The data identified punctuated evolution, clonal origins, subclonal WGD, spatial heterogeneity, and associations between copy-number and transcriptional diversity, with implications for both cancer diagnosis and treatment.
中文摘要:非整倍体是人类肿瘤的标志。患者层面的拷贝数改变差异已在大规模队列中得到广泛研究,但肿瘤内异质性仍缺乏深入认识。本研究在单细胞分辨率下分析了94例人类肿瘤,覆盖膀胱癌、乳腺癌、结肠癌、胶质母细胞瘤、肾癌、肺癌和卵巢癌七种癌症类型。单细胞拷贝数谱分析共纳入62,646个非整倍体细胞,并对多数患者进行了批量外显子组测序,对6份样本进行了单核RNA测序。在多种癌症类型中,亚克隆多样性增加与更高的拷贝数改变负荷、全基因组加倍、TP53突变及地理多样性增加相关。每例患者的癌细胞共享一组主干拷贝数改变,提示其由单一祖先细胞演化而来。许多肿瘤以演化爆发的方式积累拷贝数改变,提示间断性演化在多种癌症类型中较为常见。本研究显著提升了对人类癌症肿瘤内染色体多样性的认识。该研究是规模最大的泛癌单细胞DNA测序分析之一,刻画了七种主要癌症类型的肿瘤内拷贝数异质性。数据揭示了间断性演化、克隆起源、亚克隆全基因组加倍、空间异质性以及拷贝数与转录多样性之间的关联,对癌症诊断和治疗具有意义。
Brain tumors are increasingly understood as having components of a development organization in which malignant cells leverage neural progenitor programs, lineage hierarchies, and circuit interactions that normally shape the developing brain. This review examines how these principles inform the biology of ependymoma and gliomas across the age spectrum, including H3 K27-altered diffuse midline glioma, H3 G34-mutant diffuse hemispheric glioma, IDH-mutant glioma, and glioblastoma. We highlight how tumor identity reflects developmental timing, regional context, and cell-of-origin competence, while also emphasizing that malignant cells can acquire plasticity beyond their normal counterparts. Across entities, single-cell, spatial, lineage-tracing, and organoid studies reveal progenitor-like compartments that sustain tumor growth, generate heterogeneous malignant states, and interact dynamically with the neural and immune microenvironment. Cancer neuroscience further extends this developmental framework by showing that neuronal activity, synaptic input, and neuromodulatory signaling can regulate tumor proliferation, migration, epigenetic state, and therapeutic response. Together, these findings argue that brain tumors should be viewed not as disorganized cellular masses but as aberrant developmental systems. Defining the developmental dependencies and circuit vulnerabilities of malignant progenitor states may enable more precise therapies that target tumor biology while preserving essential brain function.
中文摘要:人们日益认识到,脑肿瘤包含发育组织的成分,恶性细胞会借用通常塑造发育中大脑的神经祖细胞程序、谱系层级和回路互作。这篇综述考察这些原则如何解释室管膜瘤和不同年龄谱系胶质瘤的生物学,包括H3 K27改变型弥漫性中线胶质瘤、H3 G34突变型弥漫性半球胶质瘤、IDH突变型胶质瘤和胶质母细胞瘤。文章强调肿瘤身份反映发育时序、区域背景和起源细胞潜能,同时指出恶性细胞可获得超出正常对应细胞的可塑性。在不同肿瘤实体中,单细胞、空间、谱系追踪和类器官研究揭示维持肿瘤生长、产生异质性恶性状态并与神经和免疫微环境动态互作的祖细胞样区室。癌症神经科学进一步拓展这一发育框架,显示神经元活动、突触输入和神经调质信号可调控肿瘤增殖、迁移、表观遗传状态和治疗反应。这些发现共同表明,脑肿瘤不应被视为无序的细胞团块,而应被视为异常的发育系统。明确恶性祖细胞状态的发育依赖性和回路脆弱性,可能促成更精确的疗法,在靶向肿瘤生物学的同时保留关键脑功能。
This study explores the pivotal role of NRF2 signaling in conferring resistance to chemotherapy and ferroptosis in medulloblastoma (MB), a highly malignant pediatric brain tumor. Using newly developed in vitro models of MB cells, resistant to standard chemotherapeutics (vincistine, etoposide, cisplatin, and cyclophosphamide), we observed that chemotolerant cells exhibit an enhanced antioxidant response. Specifically, we found higher levels of glutathione, compared to sensitive cells, and increased thioredoxin reductase activity, both key components in maintaining redox homeostasis. Furthermore, we identified a metabolic shift in resistant cells, marked by increased flux through the pentose phosphate pathway (PPP), which boosts NADPH production and supports the antioxidant defense mechanisms. This adaptive antioxidant response is largely mediated by hyperactivation of the NRF2 transcription factor and the consequent upregulation of a set of antioxidant genes, thus effectively reducing intracellular reactive oxygen species (ROS) levels and enhancing cells' ability to tolerate oxidative stress. Intriguingly, our results suggest that NRF2 activation not only supports the acquisition of chemotherapy resistance but also confers protection against ferroptosis induction. Indeed, resistant cells upregulate iron sequestration proteins and ferroptosis-suppressing genes, directly controlled by NRF2, thereby reducing vulnerability to lipid peroxidation-induced cell death. Inhibition of NRF2 in resistant cells increased their sensitivity to both chemotherapy and ferroptosis inducers and, more interestingly, its knockdown prevented sensitive cells from acquiring resistance. Overall, our study underscores the crucial role of NRF2-controlled redox homeostasis in mediating resistance mechanisms in MB, highlighting the therapeutic potential of targeting this pathway. Targeting NRF2 signaling may provide a novel approach to overcome therapy resistance and improve treatment outcomes for patients with this challenging cancer.
中文摘要:研究聚焦NRF2信号在髓母细胞瘤(MB)化疗耐药与铁死亡抵抗中的关键作用;MB是高度恶性的儿童脑肿瘤。研究者建立对标准化疗药长春新碱、依托泊苷、顺铂和环磷酰胺耐药的MB细胞体外模型,观察到化疗耐受细胞表现出增强的抗氧化反应。与敏感细胞相比,耐受细胞的谷胱甘肽水平更高,硫氧还蛋白还原酶活性增加,二者都是维持氧化还原稳态的关键成分。耐药细胞还出现代谢转变,戊糖磷酸途径(PPP)通量增加,促进NADPH生成并支持抗氧化防御机制。这种适应性抗氧化反应主要由NRF2转录因子过度激活及其下游一组抗氧化基因上调介导,从而有效降低细胞内活性氧(ROS)水平并增强细胞耐受氧化应激的能力。结果提示,NRF2激活不仅支持化疗耐药性的获得,也提供对铁死亡诱导的保护。耐药细胞上调由NRF2直接控制的铁隔离蛋白和抑制铁死亡基因,降低对脂质过氧化诱导细胞死亡的易感性。在耐药细胞中抑制NRF2可提高其对化疗和铁死亡诱导剂的敏感性,敲低NRF2还能阻止敏感细胞获得耐药性。研究强调NRF2控制的氧化还原稳态在MB耐药机制中的关键作用,并指出靶向该通路具有治疗潜力。靶向NRF2信号可能成为克服治疗耐药、改善这类难治癌症患者治疗结局的新途径。
Glioblastoma harbors a subpopulation of glioma stem cells (GSCs) that drive tumor relapse and invasion. Although GSC properties are known to be regulated by key transcription factors and chromatin remodeling, the mechanisms governing stemness-associated gene expression and the role of histone proteins in this process remain poorly understood. Here, we revealed that GSCs possessed an increased level of histone variant H2AX and phosphorylated H2AX at Ser 139 (γH2AX). CRISPR-Cas9-mediated deletion of H2AX demonstrated its critical role in maintaining GSC self-renewal, tumorigenicity, and the expression of multiple stemness-associated genes. Reintroduction of wild-type H2AX, but not the phosphorylation-deficient S139A mutant, restored GSC properties in H2AX-knockout cells, underscoring the importance of H2AX phosphorylation. We further identified that the elevated γH2AX levels in GSCs result from suppressed PP2A phosphatase activity, driven by increased expression of the SET oncoprotein. Pharmacological reactivation of PP2A effectively reduced γH2AX levels in GSCs. Collectively, our findings uncover a novel mechanism for GSC maintenance and highlight the SET-PP2A axis as a key regulator of γH2AX levels, offering a potential therapeutic target to disrupt GSC-driven tumor growth.
中文摘要:胶质母细胞瘤中存在一小群胶质瘤干细胞(GSCs),可驱动肿瘤复发和侵袭。GSC特性受关键转录因子和染色质重塑调控,但维持干性相关基因表达的机制及组蛋白在此过程中的作用仍不清楚。我们发现GSCs中组蛋白变体H2AX及Ser139磷酸化H2AX(γH2AX)水平升高。CRISPR-Cas9介导的H2AX缺失表明其对维持GSC自我更新、致瘤性及多个干性相关基因表达具有关键作用。回补野生型H2AX可恢复H2AX敲除细胞的GSC特性,而磷酸化缺陷的S139A突变体不能恢复,说明H2AX磷酸化很重要。进一步发现GSCs中γH2AX升高源于SET癌蛋白表达增加导致的PP2A磷酸酶活性受抑。药理再激活PP2A可有效降低GSCs中的γH2AX水平。这些结果揭示GSC维持的新机制,并将SET-PP2A轴确定为γH2AX水平的关键调控者,为破坏GSC驱动的肿瘤生长提供潜在治疗靶点。
Multi-modal magnetic resonance imaging (MRI) plays a crucial role in brain tumor diagnosis. However, the substantial physiological sensitivity discrepancies across imaging modalities create a severe domain gap that challenges current cross-modality segmentation methods. Many unsupervised domain adaptation (UDA) approaches reduce this gap through image style translation or distribution alignment, which have shown promising results but may struggle to preserve modality-specific anatomical and pathological information. In contrast, few-shot segmentation (FSS) provides a promising alternative paradigm with strong cross-domain generalization capability, avoiding explicit domain alignment. Therefore, in this work, we propose a novel Structure-aware Attention Prototype Network (SAPNet) for cross-modality few-shot brain tumor segmentation, which fully exploits task-agnostic, multi-scale features from the large vision model. Specifically, our SAPNet consists of three main components. First, we introduce a masked support feature reconstruction (MSFR) module to encourage the network to understand anatomically meaningful structures. Second, a patch-level attention-to-prototype alignment (APA) module is proposed to adaptively balance the aggressive and conservative segmentation tendencies by cross-attention (CA) and prototype-based learning. Third, a lightweight multi-scale decoder with the contrastive embedding space is employed to enhance fine-grained pixel-level prediction. Extensive experiments on three public benchmarks, BraTS 2020, VS-SEG, and BraTS 2023 PED datasets, demonstrate that SAPNet consistently outperforms state-of-the-art UDA and FSS methods, exhibiting strong generalization and robustness.
中文摘要:多模态磁共振成像(MRI)在脑肿瘤诊断中起关键作用。不同成像模态之间的生理敏感性差异显著,形成严重的域间隙,给现有跨模态分割方法带来挑战。许多无监督域适应(UDA)方法通过图像风格转换或分布对齐缩小该间隙,已取得有希望的结果,但可能难以保留模态特异的解剖与病理信息。相比之下,小样本分割(FSS)提供了一种有前景的替代范式,具有较强跨域泛化能力,避免显式域对齐。因此,本工作提出一种新的结构感知注意力原型网络(SAPNet),用于跨模态小样本脑肿瘤分割,充分利用大型视觉模型中的任务无关多尺度特征。具体而言,SAPNet由三个主要部分组成。其一,引入掩蔽支持特征重建(MSFR)模块,促使网络理解具有解剖意义的结构。其二,提出块级注意力到原型对齐(APA)模块,通过交叉注意力(CA)和基于原型的学习,自适应平衡激进与保守的分割倾向。其三,采用带对比嵌入空间的轻量多尺度解码器,增强细粒度像素级预测。在BraTS 2020、VS-SEG和BraTS 2023 PED三个公开基准上的大量实验表明,SAPNet持续优于最先进的UDA和FSS方法,表现出强泛化和鲁棒性。
Vision impairment is a significant concern for children with neurofibromatosis type 1 (NF1)-associated optic pathway glioma (OPG). While carboplatin-containing chemotherapy is often first-line therapy for NF1-OPG, it does not consistently improve visual function. Furthermore, chemotherapy is associated with altered white matter microstructure in individuals with NF1-OPG, suggesting a detrimental effect on oligodendroglia. We analyzed the tumor-independent effects of carboplatin on oligodendrocytes in Nf1-mutant mice and evaluated pharmacological strategies for reducing this chemotherapy-associated toxicity. Carboplatin- or vehicle-treated Nf1+/- mice or Nf1-mutant optic glioma cells were employed to assess the effects of restorative interventions on optic nerve oligodendrocytes in vivo and tumor cell growth in vitro, respectively. Clinically relevant carboplatin dosing induced oligodendrocyte loss and impaired myelin sheath structure in the optic nerves of Nf1+/- mice, an effect not observed following vinca alkaloids or MEK inhibitor (selumetinib) treatment. Carboplatin downregulates genes essential for cholesterol biosynthesis and decreases cholesterol levels in Nf1+/- optic nerves, such that dietary cholesterol supplementation after carboplatin exposure restored oligodendrocyte numbers. Carboplatin also increases the density of monocytes (microglia/macrophages) in the Nf1+/- optic nerves. Using PLX5622 (a CSF1R inhibitor) to reduce monocyte numbers or using clemastine to promote the generation and survival of oligodendrocytes, alleviated the oligodendrocyte loss caused by carboplatin treatment. Notably, PLX5622 and clemastine reduced the viability of Nf1-mutant optic glioma tumor cells. Our findings demonstrate that carboplatin induces oligodendroglial toxicity in Nf1-mutant optic nerves, which can be mitigated by clemastine, PLX5622, or dietary cholesterol following carboplatin exposure.
中文摘要:视力损害是1型神经纤维瘤病(NF1)相关视路胶质瘤(OPG)患儿的重要问题。含卡铂化疗常为NF1-OPG的一线治疗,但并不能稳定改善视功能。化疗还与NF1-OPG患者白质微结构改变相关,提示其对少突胶质细胞可能存在不利影响。我们分析了卡铂对Nf1突变小鼠少突胶质细胞的非肿瘤依赖性效应,并评估减轻这种化疗相关毒性的药物策略。分别采用卡铂或溶媒处理的Nf1+/-小鼠以及Nf1突变视路胶质瘤细胞,在体内评估恢复性干预对小鼠视神经少突胶质细胞的影响,在体外评估对肿瘤细胞生长的影响。临床相关剂量的卡铂导致Nf1+/-小鼠视神经少突胶质细胞丢失和髓鞘结构受损,而长春碱类或MEK抑制剂司美替尼治疗未观察到该效应。卡铂下调胆固醇生物合成必需基因并降低Nf1+/-视神经胆固醇水平,因此卡铂暴露后补充膳食胆固醇可恢复少突胶质细胞数量。卡铂还增加Nf1+/-视神经中单核细胞(小胶质细胞/巨噬细胞)密度。使用PLX5622(CSF1R抑制剂)减少单核细胞数量,或使用氯马斯汀促进少突胶质细胞生成和存活,可减轻卡铂治疗引起的少突胶质细胞丢失。PLX5622和氯马斯汀还降低Nf1突变视路胶质瘤肿瘤细胞的活力。我们的发现表明,卡铂在Nf1突变视神经中诱导少突胶质细胞毒性,卡铂暴露后使用氯马斯汀、PLX5622或膳食胆固醇可减轻该毒性。
Pediatric high-grade gliomas (pHGG) are the leading cause of childhood cancer-related deaths. Those arising in the midline harboring a lysine to methionine substitution at position 27 in histone 3 (H3K27M), termed diffuse midline glioma (or DIPG when occurring in the pons), are particularly deadly and in need of additional therapeutic options. Our group and others have found upregulation of the RAS/MAPK pathway across HGGs, including DIPG; however, RAS is notoriously difficult to target therapeutically, with no approved drugs that can target nonmutant RAS proteins. We leveraged a pan-RAS-cleaving biologic (RRSP-DTB) to define RAS dependency in DIPG and employed proteomic profiling of patient-derived tumors to identify enriched cell-surface receptors for tumor-selective targeting. RRSP was re-engineered to engage the lead candidate receptor, tumor endothelial marker 8 (TEM8/ANTXR1), generating a targeted RAS-degrading biologic evaluated in vitro and in orthotopic DIPG xenograft models. Pan-RAS cleavage revealed DIPG to be critically dependent on RAS/MAPK signaling compared to other RAS/MAPK HGGs. Targeting RRSP to TEM8 enabled efficient intracellular delivery, resulting in complete RAS ablation and apoptotic cell death in patient-derived DIPG cells at low picomolar concentrations. In vivo, intracerebroventricular delivery reduced leptomeningeal disease burden (P = .04), while convection-enhanced delivery extended survival in orthotopic DIPG models (median survival 68 vs. 57 days; P = .016). We demonstrate RAS-dependency in DIPG targetable by RRSP-DTT-TEM8, a novel, first-in-class pan-RAS biotherapeutic, supporting its potential as a therapeutic strategy for this otherwise untreatable disease.
中文摘要:儿童高级别胶质瘤是儿童肿瘤相关死亡的首要原因。发生于中线、组蛋白3第27位赖氨酸被甲硫氨酸取代(H3K27M)的肿瘤,即弥漫性中线胶质瘤(发生在脑桥时称DIPG),致死性尤其高,亟需更多治疗选择。研究团队及他人已发现RAS/MAPK通路在包括DIPG在内的多种高级别胶质瘤中上调,但RAS向来难以成药,目前尚无靶向非突变RAS蛋白的获批药物。研究者利用一种可切割泛RAS的生物制剂RRSP-DTB界定DIPG对RAS的依赖性,并对患者来源肿瘤进行蛋白质组学分析,以寻找可用于肿瘤选择性靶向的富集细胞表面受体。随后将RRSP重新改造使其结合候选受体肿瘤内皮标志物8(TEM8/ANTXR1),得到靶向型RAS降解生物制剂,并在体外及原位DIPG异种移植模型中评价。泛RAS切割显示,与其他RAS/MAPK型高级别胶质瘤相比,DIPG对RAS/MAPK信号高度依赖。将RRSP靶向TEM8后实现了高效的胞内递送,在低皮摩尔浓度下即可使患者来源DIPG细胞的RAS完全清除并发生凋亡。体内实验中,经脑室内递送降低了软脑膜病变负荷(P = .04),而对流增强递送延长了原位DIPG模型的生存期(中位生存68天对57天;P = .016)。研究显示DIPG存在可被RRSP-DTT-TEM8靶向的RAS依赖性,该药为新型首创泛RAS生物治疗药物,有望成为这一目前无法治疗的疾病的治疗策略。
Glioblastoma (GBM) remains clinically challenging due to its pronounced resistance to conventional chemotherapy. Ferroptosis, an iron-dependent form of programmed cell death, has emerged as a promising alternative, yet its efficacy is limited by the hypoxic tumor microenvironment and adaptive mitochondrial defenses. To overcome these limitations, we developed a piezoelectric nanoplatform (V-BT@PDA@PMS) comprising double-vacancy-engineered barium titanate (BaTiO3) nanoparticles, coated with polydopamine (PDA), and loaded with peroxymonosulfate (PMS). This platform constructs a "Dual-Channel Electron Expressway" to significantly amplify ultrasound (US)-triggered generation of sulfate radicals (⋅SO4-). Internally, barium and oxygen vacancies within the BaTiO3 lattice facilitate charge carrier separation; externally, the tumor-acid-responsive PDA coating optimizes PMS adsorption and activation via imino protonation. The resulting massive ⋅SO4- yield exerts a dual-pronged effect: it directly initiates lipid peroxidation to drive ferroptosis and precipitates intracellular Ca2+ as CaSO4. This localized Ca2+ depletion triggers profound mitochondrial Ca2+ efflux and the irreversible opening of the mitochondrial permeability transition pore (mPTP). The subsequent structural collapse facilitates a secondary iron influx, establishing a self-amplifying cycle of reactive oxygen species (ROS) generation via Fenton-like reactions. By systematically dismantling mitochondrial defenses against ferroptosis, this cascade achieves a 2.9-fold enhancement in temozolomide (TMZ) chemosensitivity in vitro and demonstrates significant tumor inhibition in chemoresistant in vivo models. Overall, this study elucidates a physical-biochemical mechanism for electron-transport-mediated mitochondrial destabilization, offering a rational design strategy for piezocatalytic nanotherapeutics against drug-resistant malignancies.
中文摘要:胶质母细胞瘤(GBM)对常规化疗耐药明显,临床治疗仍具挑战。铁死亡是一种铁依赖性程序性细胞死亡方式,已显示出替代治疗潜力,但缺氧肿瘤微环境和线粒体的适应性防御限制了其效果。为克服这些限制,研究构建了压电纳米平台V-BT@PDA@PMS,由双空位调控的钛酸钡(BaTiO3)纳米颗粒、聚多巴胺(PDA)包覆层和负载的过一硫酸盐(PMS)组成。该平台建立「双通道电子高速路」,显著增强超声(US)触发的硫酸根自由基(⋅SO4−)生成。在颗粒内部,BaTiO3晶格中的钡空位和氧空位促进电荷载流子分离;在颗粒外部,肿瘤酸性响应型PDA包覆层通过亚氨基质子化优化PMS吸附与活化。大量生成的⋅SO4−产生双重作用:直接启动脂质过氧化推动铁死亡,并将细胞内Ca2+沉淀为CaSO4。这种局部Ca2+耗竭引发显著的线粒体Ca2+外流和线粒体通透性转换孔(mPTP)不可逆开放。随后的结构崩解促进二次铁流入,通过类Fenton反应形成ROS生成的自放大循环。该级联通过系统性破坏线粒体对铁死亡的防御,在体外使替莫唑胺(TMZ)化疗敏感性提高2.9倍,并在耐药体内模型中表现出显著抑瘤作用。这项研究阐明了电子传递介导线粒体失稳的物理-生化机制,为针对耐药恶性肿瘤的压电催化纳米治疗提供了合理设计策略。
PDS5A, a cohesin regulatory subunit, and topoisomerase IIB (TOP2B), an enzyme resolving DNA topological problems, interact with CTCF and regulate transcription and genome organization. We ascertained that PDS5A and TOP2B are recruited to CTCF-bound chromatin cooperatively and that catalytically active TOP2B increases PDS5A occupancy genome wide. Notably, the amino-terminal 95 to 116 amino acids of CTCF interacts with PDS5A, giving rise to CTCF-PDS5A-TOP2B interaction in vitro and to PDS5A chromatin enrichment via active TOP2B in vivo. PDS5A-TOP2B function together in moderating the resultant gene expression and genome organization. Loss of CTCF (95 to 116 amino acids) led to dysregulated gene expression and mildly reduced chromatin loops. In gliomas, PDS5A and TOP2B expression levels vary, but correlate, contributing to distinctive gene expression patterns. Inducible PDS5A knockdown led to reduced TOP2B occupancy and altered gene expression. Furthermore, PDS5A mediated sensitivity to TOP2 cancer drugs in glioma cells. This functional interaction between PDS5A and TOP2B at CTCF boundaries expands upon the mechanisms affecting gene regulation through genome organization, with implications for glioma therapeutics.
中文摘要:PDS5A是黏连蛋白调节亚基,TOP2B是解决DNA拓扑问题的拓扑异构酶IIB,二者与CTCF相互作用并调控转录和基因组组织。研究发现PDS5A与TOP2B协同招募至CTCF结合的染色质,具有催化活性的TOP2B可提高PDS5A在全基因组的占据。CTCF氨基端第95至116位氨基酸与PDS5A相互作用,在体外形成CTCF-PDS5A-TOP2B相互作用,并在体内通过活性TOP2B促进PDS5A在染色质上的富集。PDS5A与TOP2B共同调节由此产生的基因表达和基因组组织。缺失CTCF第95至116位氨基酸会导致基因表达失调并轻度减少染色质环。在胶质瘤中,PDS5A与TOP2B表达水平存在差异但相互关联,促成不同的基因表达模式。诱导性PDS5A敲低会降低TOP2B占据并改变基因表达。PDS5A还介导胶质瘤细胞对TOP2类抗癌药物的敏感性。PDS5A与TOP2B在CTCF边界的这种功能性相互作用拓展了对基因组组织影响基因调控机制的认识,并对胶质瘤治疗具有意义。
10儿童丙肝 (1篇)
临床研究 (1篇)
Paediatric chronic hepatitis C (PCHC) is often asymptomatic and underdiagnosed, and its contemporary global burden remains incompletely characterised. We estimated global, national, and socioeconomic trends in PCHC using Global Burden of Disease (GBD) 2023 estimates, and hepatitis C virus (HCV)-related liver cancer as a limited Supplementary analysis. We analysed GBD 2023 estimates of prevalence, mortality, and disability-adjusted life years (DALYs) for PCHC in people younger than 20 years from 1990 to 2023. Results were summarised globally, across seven official GBD super-regions, and for 204 countries and territories using annual point estimates and supplied 95% uncertainty intervals. Because HCV-related liver cancer estimates were unavailable for children younger than 10 years, analyses of this endpoint were restricted to ages 10-19 years. Global PCHC prevalence was 0.380% (95% uncertainty interval [UI] 0.314-0.452) in 2023, representing a decline from 0.443% (0.376-0.514) in 1990, with an absolute change of -0.062 percentage points and a relative change of -14.1%. Mortality declined from 0.0890 (0.0504-0.1538) to 0.0595 (0.0303-0.1023) deaths per 100,000 population younger than 20 years, and the DALY rate declined from 7.49 (4.36-12.92) to 5.06 (2.62-8.40) per 100,000. The highest prevalences clustered in Central Asia, South-East Asia, and sub-Saharan Africa. The PCHC burden has declined globally, particularly mortality and DALYs, but prevalence has fallen only modestly. The continued high burden in Central Asia, South-East Asia, and sub-Saharan Africa, and marked country heterogeneity highlight the need to integrate antenatal screening, follow-up of perinatally exposed infants, and access to curative treatment for children aged 3 years or older into hepatitis elimination programmes in order to reach the 2030 elimination targets. National Institutes of Health.
中文摘要:儿童慢性丙型肝炎(PCHC)常无症状且诊断不足,其当代全球负担仍未得到完整描述。我们利用全球疾病负担研究(GBD)2023估计,评估PCHC的全球、国家和社会经济趋势,并将丙型肝炎病毒(HCV)相关肝癌作为有限的补充分析。我们分析了GBD 2023中1990至2023年20岁以下人群PCHC的患病率、死亡率和伤残调整生命年(DALY)估计。结果按全球、七个GBD官方超级区域以及204个国家和地区汇总,使用年度点估计和提供的95%不确定区间。由于10岁以下儿童缺少HCV相关肝癌估计,该终点的分析仅限于10-19岁。2023年全球PCHC患病率为0.380%(95%不确定区间[UI] 0.314-0.452),低于1990年的0.443%(0.376-0.514),绝对变化为-0.062个百分点,相对变化为-14.1%。死亡率从每10万20岁以下人群0.0890(0.0504-0.1538)例死亡降至0.0595(0.0303-0.1023),DALY率从每10万7.49(4.36-12.92)降至5.06(2.62-8.40)。患病率最高值集中于中亚、东南亚和撒哈拉以南非洲。全球PCHC负担已下降,尤其是死亡率和DALY,但患病率仅小幅下降。中亚、东南亚和撒哈拉以南非洲的持续高负担以及显著的国家间异质性,突出表明需要将产前筛查、围产期暴露婴儿随访以及3岁及以上儿童获得治愈性治疗纳入肝炎消除规划,以实现2030年消除目标。美国国立卫生研究院。
11类风湿关节炎 (1篇)
基础研究 (1篇)
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent synovial inflammation and progressive joint destruction. Numerous clinical studies have revealed that exercise is extremely beneficial for the outcome of RA. However, the underlying mechanism remains poorly understood. In the present study, we investigated the therapeutic efficacy of irisin, an exercise hormone, on K/BxN serum and collagen-induced arthritis (CIA), two well established mouse models for RA research. Mechanistically, irisin interacted with ITGAV (integrin subunit alpha V) and ITGB5 (integrin subunit beta 5) to activate mitophagy and remove leaked mitochondrial DNA (mtDNA) and reactive oxygen species (ROS), which suppressed the activation of NLRP3 (NLR family pyrin domain containing 3) inflammasome and then hindered the pathological process of experimental arthritis. Notably, the beneficial effects of irisin on the treatment of experimental arthritis were significantly abolished in mice with atg5 (autophagy related 5) conditional knockout in myeloid cells (atg5fl/flLyz2). Our study elucidated the underlying mechanism through which exercise alleviated experimental arthritis and offered a feasible therapeutic strategy for RA.Abbreviations: 3-MA: 3-methyladenine Ac-TUBA: acetylated TUBA; ACP5: acid phosphatase 5, tartrate resistant; AIM2: absent in melanoma 2; ANOVA: analysis of variance; ATP: adenosine triphosphate; BAF: bafilomycin A1; BV:TV: bone volume per total volume; BMD: bone mineral density; BMDMs: bone marrow-derived macrophages; CASP1: caspase 1; CTSB: cathepsin B; CIA: collagen-indcued arthritis; DNM1L: dynamin 1 like; CYCS: cytochrome c, somatic; EtBr: ethidium bromide; FNDC5: fibronectin type III domain containing 5; FL-GSDMD: GSDMD full length; GSDMD: gasdermin D; HE: hematoxylin and eosin; iBMDMs: immortalized bone marrow-derived macrophages; IL1B: interleukin 1 beta; IL6: interleukin 6; IL18: interleukin 18; LDH: lactate dehydrogenase; LPS: lipopolysaccharide; MAP1LC3: microtubule associated protein 1 light chain 3; MSU: monosodium urate; mtROS: mitochondrial reactive oxygen species; mtDNA: mitochondrial DNA; NLRC4: NLR family CARD domain containing 4; NLRP1: NLR family pyrin domain containing 1; NLRP3: NLR family pyrin domain containing 3; NT-GSDMD: GSDMD N-terminal fragment; NAC: N-acetylcysteine; ox-mtDNA: oxidized mitochondrial DNA; PYCARD: PYD and CARD domain containing; PRKAA: protein kinase AMP-activated catalytic subunit alpha 1; PINK1: PTEN induced kinase 1; PRKN: parkin RBR E3 ubiquitin protein ligase; RA: rheumatoid arthritis; ROS: reactive oxygen species; SD: standard deviation; SiO2: silicon dioxide; SQSTM1: sequestosome 1; Tb.Th: trabecular thickness; Tb.N: trabecular number; Tp.Sp: trabecular separation; TNF/TNF-α: tumor necrosis factor; TOMM20: translocase of outer mitochondrial membrane 20; TUBA: tubulin alpha; ULK1: unc-51 like autophagy activating kinase 1; WT: wild type.
中文摘要:类风湿关节炎(RA)是一种慢性系统性自身免疫病,以持续性滑膜炎和进行性关节破坏为特征。大量临床研究显示,运动对RA结局极为有益,但其内在机制仍不清楚。本研究探讨运动激素鸢尾素(irisin)对K/BxN血清诱导和胶原诱导性关节炎(CIA)两种成熟RA小鼠模型的治疗作用。机制上,irisin与ITGAV和ITGB5相互作用,激活线粒体自噬,清除泄漏的线粒体DNA和活性氧,抑制NLRP3炎症小体活化,进而阻碍实验性关节炎的病理进程。在髓系细胞条件性敲除atg5的小鼠中,irisin对实验性关节炎的治疗益处显著消失。该研究阐明了运动缓解实验性关节炎的机制,并为RA提供了可行的治疗策略。
12其他 (42篇)
临床研究 (5篇)
T cell receptors (TCRs) can enable detection and elimination of cancer cells via recognition of cancer-specific peptides presented on human leukocyte antigen (HLA). We speculated that shared cancer antigens could be recognized by recurrent ("public") TCRs, which might be identifiable using statistical methods. Here, we identified public TCRs against therapeutically relevant targets via computational analysis of large-scale bulk RNA sequencing data obtained from routine clinical genomics testing. Using data from ∼150,000 patient tumor samples, we identified TCR chains that were associated with well-known cancer antigens, including human papillomavirus, mutated KRAS, and CT83. We devised methods for pairing enriched TCR-α and TCR-β chain sequences and validated 44 TCRs across nine peptide-HLA targets for antigen recognition, including potent cytotoxic TCRs. Our results suggest that public anticancer TCRs are common and may represent a new source for the development of cancer therapeutics.
中文摘要:T细胞受体(TCR)通过识别人类白细胞抗原(HLA)呈递的肿瘤特异性肽段,可实现对癌细胞的检测与清除。我们推测,共享的肿瘤抗原可被反复出现的(「公共」)TCR识别,并可能通过统计方法加以鉴定。在这里,我们通过对常规临床基因组检测获得的大规模批量RNA测序数据进行计算分析,鉴定了针对治疗相关靶点的公共TCR。利用约150,000例患者肿瘤样本的数据,我们发现了与已知肿瘤抗原相关的TCR链,包括人乳头瘤病毒、突变KRAS和CT83。我们设计了配对富集TCR-α与TCR-β链序列的方法,并在九个肽-HLA靶点上验证了44个TCR的抗原识别能力,其中包括强效细胞毒性TCR。结果提示,公共抗肿瘤TCR较为常见,可能成为肿瘤治疗开发的新来源。
Population ageing is reshaping cancer burden in later life. For stomach cancer, declining age-standardised mortality may coexist with sustained or increasing absolute deaths as older populations expand. We assessed stomach cancer burden among adults aged 65 years or older in aged and super-aged societies from 1990 to 2023. Using Global Burden of Disease Study 2023 estimates, we analysed deaths, disability-adjusted life-years (DALYs), age-standardised rates, age-specific mortality, sex-specific patterns, estimated annual percentage change, decomposition of changes in deaths, and trajectories around transition into super-aged status. Countries and territories were included if adults aged 65 years or older accounted for at least 14% of the population in 2023; super-aged societies were defined by a proportion of 21% or higher. Sixty countries and territories were included: 33 aged and 27 super-aged societies. In aged societies, deaths increased from 307,928 (95% UI 252,700-378,610) in 1990 to 336,454 (250,465-441,049) in 2023, despite a decline in the age-standardised death rate (ASDR) from 203.69 per 100,000 (166.46-251.77) to 90.12 (66.98-118.05). In super-aged societies, deaths decreased modestly from 105,330 (95,791-113,945) to 101,143 (81,472-116,462), while the ASDR declined from 162.13 (146.60-176.00) to 69.05 (57.17-78.77). ASDRs declined significantly in 59 of 60 countries and territories; Georgia showed a non-significant increase. Reductions were smaller at older ages, falling by 65% at ages 65-69 years but only 9% at ages 95 years or older. Decomposition showed that epidemiological improvements reduced deaths in nearly all countries, but population growth and ageing offset these gains in several settings, particularly China, Japan, and the Republic of Korea. Stomach cancer mortality rates declined substantially among adults aged 65 years or older, but absolute deaths declined less because demographic growth and ageing offset epidemiological gains, with burden increasingly concentrated at the oldest ages. Progress should therefore be assessed using both age-standardised rates and absolute burden.
中文摘要:人口老龄化正在重塑晚年癌症负担。对胃癌而言,年龄标化死亡率下降可能与老年人口扩张带来的绝对死亡数持平或上升并存。研究评估了1990至2023年老龄化社会和超老龄化社会中65岁及以上成年人的胃癌负担。利用全球疾病负担研究2023年估计值,分析了死亡数、伤残调整生命年、年龄标化率、年龄别死亡率、性别差异模式、估计年度百分比变化、死亡数变化的分解分析,以及进入超老龄化状态前后的变化轨迹。纳入标准为2023年65岁及以上成年人占总人口至少14%的国家和地区;超老龄化社会定义为该比例达到21%或更高。共纳入60个国家和地区,其中33个为老龄化社会,27个为超老龄化社会。在老龄化社会中,死亡数从1990年的307928例(95% UI 252700-378610)增至2023年的336454例(250465-441049),但年龄标化死亡率从每10万人203.69例(166.46-251.77)降至90.12例(66.98-118.05)。在超老龄化社会中,死亡数从105330例(95791-113945)小幅降至101143例(81472-116462),年龄标化死亡率从162.13例(146.60-176.00)降至69.05例(57.17-78.77)。60个国家和地区中有59个年龄标化死亡率显著下降;格鲁吉亚呈非显著上升。年龄越大,死亡率降幅越小,65-69岁组下降65%,95岁及以上组仅下降9%。分解分析显示,流行病学改善在几乎所有国家都减少了死亡,但人口增长和老龄化在部分国家抵消了这些收益,尤其是中国、日本和韩国。65岁及以上成年人的胃癌死亡率大幅下降,但绝对死亡数降幅较小,因为人口增长和老龄化抵消了流行病学改善,负担日益集中于高龄人群。因此,进展评估应同时采用年龄标化率和绝对负担。
Suboptimal human-artificial intelligence (AI) interaction is a potential roadblock for implementation of AI in clinical practice. We aimed to evaluate the interaction between AI and endoscopists in the optical diagnosis of colorectal carcinoma (CRC). International endoscopists were invited to diagnose colorectal lesions online. After a pretest of 15 videos, the diagnosis could be adjusted in the subsequent 35 videos after receiving a simulated AI diagnosis. Histology was the gold standard. Endoscopists' diagnoses before and after AI were compared using the signal detection theory. Inappropriate response to AI was defined as decreased diagnostic performance by the endoscopist after AI. In 2730 diagnoses, the 78 participating endoscopists reached diagnostic accuracies of 71.4 % before and 73.7 % after AI (P < 0.001). Before AI, endoscopists missed only a few true CRCs (mean hit rate 0.86), at the cost of a mean false alarm rate of 0.35. Inappropriate response to AI was observed in 28.2 % of endoscopists. After AI, most endoscopists (41.0 %) shifted toward a more conservative attitude, tending to diagnose a lesion as non-CRC. Inappropriate response to AI is an issue in human-AI interaction for the optical diagnosis of CRC. Before using AI, endoscopists should become familiar with their own optical diagnostic performance, and that of the AI system, to possibly improve interaction.
中文摘要:人机交互不理想可能阻碍AI在临床实践中的实施。本研究旨在评估AI与内镜医师在结直肠癌光学诊断中的交互。研究邀请国际内镜医师在线诊断结直肠病变。在15个视频的前测后,医师可在随后35个视频中于获得模拟AI诊断后调整诊断。组织学为金标准。采用信号检测论比较内镜医师在AI介入前后的诊断。对AI的不当反应定义为内镜医师在AI介入后诊断表现下降。在2730次诊断中,78名参与的内镜医师在AI介入前诊断准确率为71.4%,介入后为73.7%(P < 0.001)。AI介入前,内镜医师仅漏诊少量真性结直肠癌(平均命中率0.86),代价是平均误报率0.35。28.2%的内镜医师表现出对AI的不当反应。AI介入后,多数内镜医师(41.0%)转向更保守的态度,倾向于将病变诊断为非结直肠癌。对AI的不当反应是结直肠癌光学诊断中人机交互的一个问题。使用AI前,内镜医师应熟悉自身的光学诊断表现以及AI系统的表现,以可能改善交互。
The relationship between long-term glycaemic control and liver-related events (LREs) in patients with type 2 diabetes mellitus (T2DM) remains unclear. We assessed associations of time-weighted average haemoglobin A1c (HbA1c), time-to-target HbA1c, HbA1c variability, and individual HbA1c trajectories with LREs in T2DM. A territory-wide cohort of adults newly diagnosed with T2DM (Jan 2000-Dec 2016) was identified in Hong Kong. HbA1c trajectories were identified via time-series clustering and externally validated in the UK Biobank. Their associations with LREs were estimated in the Hong Kong territory-wide cohort using cause-specific hazards models, with non-liver-related death as a competing risk. Among 294,096 patients identified (mean age, 60.6 years; 50.6% males), 3,438 (1.2%) developed LREs over a median follow-up of 7.4 years (IQR 4.5-10.0). Higher time-weighted average HbA1c (adjusted cause-specific hazard ratio [aCSHR] 1.12 per 1%, 95% CI 1.08-1.16, p <0.001) and greater HbA1c variability were associated with a higher risk of LREs, whereas more years with HbA1c <7% were associated with a lower risk (aCSHR 0.95 per year, 95% CI 0.93-0.96, p <0.001). Three trajectories were identified: rapid decreasing (n = 43,712; 14.9%), mild decreasing (n = 114,413; 38.9%), and increasing (n = 135,971; 46.2%). Compared with rapid decreasing, mild decreasing (aCSHR 1.30, 95% CI 1.13-1.50, p <0.001) and increasing (aCSHR 1.37, 95% CI 1.16-1.61, p <0.001) trajectories conferred higher risks. Compared to patients with baseline HbA1c <7% and a mild decreasing trajectory, those with baseline HbA1c ≥9% and mild decreasing (aCSHR 1.27, 95% CI 1.08-1.50, p <0.001) or increasing (aCSHR 1.84, 95% CI 1.45-2.34, p <0.001) trajectories had higher LRE risks. In contrast, a rapid decreasing trajectory was not associated with a higher risk (aCSHR 1.05, 95% CI 0.90-1.22, p = 0.57). Time-weighted average HbA1c, cumulative duration of good glycaemic control, HbA1c variability, and HbA1c trajectories were associated with LREs in T2DM. A rapid decreasing trajectory may mitigate LRE risk in patients with high baseline HbA1c. The relationship between long-term glycaemic control and liver-related events (LREs) in patients with type 2 diabetes mellitus (T2DM) remains unclear. In this real-world territory-wide cohort study of 294,096 patients with newly diagnosed T2DM, patients with higher average HbA1c, cumulative exposure to high HbA1c and high HbA1c variability had a higher risk of LREs. Among patients with baseline HbA1c ≥9%, a rapid decreasing HbA1c trajectory was associated with a lower risk of LREs, with no statistically significant difference compared to patients whose baseline HbA1c was <7% and had a mild decreasing HbA1c trajectory, while those with baseline HbA1c ≥9% and mild decreasing or increasing HbA1c trajectories were at increased risk of LREs. These findings suggest that achieving rapid glycaemic improvement after T2DM diagnosis may reduce the risk of LREs, while patients who follow mild decreasing or increasing HbA1c trajectories may benefit from closer monitoring and more intensive intervention.
中文摘要:2型糖尿病患者长期血糖控制与肝脏相关事件(LREs)的关系仍不明确。该研究评估了时间加权平均糖化血红蛋白(HbA1c)、达到目标HbA1c所需时间、HbA1c变异性及个体HbA1c轨迹与T2DM患者LREs的关联。研究在香港识别了一个新诊断T2DM成人全境队列(2000年1月至2016年12月)。通过时间序列聚类识别HbA1c轨迹,并在英国生物银行进行外部验证。在香港全境队列中,采用病因特异性风险模型估计其与LREs的关联,并将非肝脏相关死亡作为竞争风险。在294,096例患者(平均年龄60.6岁;男性50.6%)中,中位随访7.4年(IQR 4.5-10.0)期间,3,438例(1.2%)发生LREs。较高的时间加权平均HbA1c(每升高1%,校正病因特异性风险比[aCSHR] 1.12,95% CI 1.08-1.16,p <0.001)和较大的HbA1c变异性与LREs风险升高相关,而HbA1c <7%的年份更多与风险降低相关(aCSHR 0.95/年,95% CI 0.93-0.96,p <0.001)。识别出三种轨迹:快速下降(n = 43,712;14.9%)、轻度下降(n = 114,413;38.9%)和上升(n = 135,971;46.2%)。与快速下降相比,轻度下降(aCSHR 1.30,95% CI 1.13-1.50,p <0.001)和上升(aCSHR 1.37,95% CI 1.16-1.61,p <0.001)轨迹带来更高风险。与基线HbA1c <7%且呈轻度下降轨迹的患者相比,基线HbA1c ≥9%且呈轻度下降(aCSHR 1.27,95% CI 1.08-1.50,p <0.001)或上升(aCSHR 1.84,95% CI 1.45-2.34,p <0.001)轨迹者的LRE风险更高。相反,快速下降轨迹与风险升高无关(aCSHR 1.05,95% CI 0.90-1.22,p = 0.57)。时间加权平均HbA1c、良好血糖控制的累积持续时间、HbA1c变异性及HbA1c轨迹均与T2DM患者的LREs相关。对于基线HbA1c较高的患者,快速下降轨迹可能降低LRE风险。2型糖尿病患者长期血糖控制与肝脏相关事件(LREs)的关系仍不明确。在这项纳入294,096例新诊断T2DM患者的真实世界全境队列研究中,平均HbA1c更高、高HbA1c累积暴露更多及HbA1c变异性更高的患者LREs风险更高。在基线HbA1c ≥9%的患者中,快速下降的HbA1c轨迹与较低的LREs风险相关,与基线HbA1c <7%且呈轻度下降轨迹的患者相比无统计学显著差异;而基线HbA1c ≥9%且呈轻度下降或上升轨迹者LREs风险增加。这些发现提示,T2DM诊断后实现血糖快速改善可能降低LREs风险,而呈轻度下降或上升HbA1c轨迹的患者可能从更密切监测和更强化干预中获益。
Neoplastic recurrence risk at scheduled surveillance intervals after colorectal endoscopic submucosal dissection (ESD), as well as its association with histologic risk features, is unclear, resulting in uncertainty for post-ESD surveillance recommendations. We conducted a systematic review and meta-analysis of 1-, 3-, and 5-year post-ESD neoplastic recurrence with subgroup analyses. A systematic search was performed up until October 2025. Eligible studies were assessed for neoplastic recurrence at or near the resection site at 1-, 3-, and 5-year scheduled surveillance colonoscopies. Rates of metachronous neoplastic lesions at the same time-intervals were also collected. Data were pooled using a random-effects model, and subgroup analyses were conducted for histology of the index lesion (low or high grade dysplasia, and T1 cancer) and resection quality (R0 vs. non-R0). 10 studies encompassing 5306 lesions met the inclusion criteria. The pooled R0 resection rate was 82% (95%CI 79%-85%). Overall neoplastic recurrence rates were low and stable over time: 1.2% (95%CI 0.4%-2.6%), 1.4% (95%CI 1.0%-1.9%), and 1.9% (95%CI 0.9%-3.1%) at 1, 3, and 5 years, respectively. Malignant recurrence was rare (0.2%) and confined to noncurative resections or deep submucosal invasion. The pooled rate of metachronous lesions was 1.4% (95%CI 0.4%-3.0%). Limited time-stratified data suggest progressive accrual of metachronous neoplasia during follow-up rather than early post-ESD failure. Neoplastic recurrence is rare up to the 5-year endoscopic surveillance, especially in those with R0 resection and favorable histology. In low risk patients, an extended surveillance interval of up to 5 years can be considered, mostly because of an increased risk of metachronous lesions.
中文摘要:结直肠内镜黏膜下剥离术(ESD)后按计划监测间隔发生肿瘤复发的风险及其与组织学危险特征的关系尚不清楚,导致术后监测建议存在不确定性。本研究对ESD后1年、3年和5年肿瘤复发进行系统综述和荟萃分析,并开展亚组分析。检索截至2025年10月。纳入研究评估计划监测结肠镜检查在1年、3年和5年时切除部位或附近肿瘤复发,同时收集相同时间间隔异时性肿瘤病变发生率。采用随机效应模型汇总数据,并按原发病灶组织学(低级别或高级别异型增生及T1癌)和切除质量(R0与非R0)进行亚组分析。10项研究共5306个病变符合纳入标准。汇总R0切除率为82%(95%CI 79%-85%)。总体肿瘤复发率较低且随时间稳定:1年、3年和5年分别为1.2%(95%CI 0.4%-2.6%)、1.4%(95%CI 1.0%-1.9%)和1.9%(95%CI 0.9%-3.1%)。恶性复发少见(0.2%),仅见于非治愈性切除或深部黏膜下浸润。异时性病变汇总发生率为1.4%(95%CI 0.4%-3.0%)。有限的时间分层数据提示异时性肿瘤在随访期间逐步累积,而非ESD后早期失败。截至5年内镜监测,肿瘤复发少见,尤其在R0切除且组织学有利者中。低风险患者可考虑将监测间隔延长至5年,主要因异时性病变风险增加。
基础研究 (37篇)
In this issue of Molecular Cell, Li et al.1 define TEtrans, a class of RNA transcripts that initiate and splice between transposable elements independent of host genes. Mining population-scale transcriptome databases, they uncover a widespread, tumor-enriched repertoire of protein-coding and non-coding TEtrans associated with cancer outcomes.
中文摘要:在本期 Molecular Cell 中,Li 等定义了 TEtrans,一类在转座元件之间起始和剪接、不依赖宿主基因的 RNA 转录本。通过挖掘群体规模转录组数据库,他们揭示了广泛存在、在肿瘤中富集、与癌症结局相关的编码与非编码 TEtrans 图谱。
Covering: up to 2025Toll-like receptor 2 (TLR2) is a versatile pattern recognition receptor whose activity can be tuned in either direction-agonism or antagonism-to produce distinct therapeutic outcomes, ranging from vaccine adjuvants and cancer immunotherapeutics to anti-inflammatory agents for sepsis, neuroinflammation, and autoimmune disease. Natural products from bacteria, fungi, plants, and marine organisms have emerged as a structurally rich source of TLR2 modulators, encompassing acylated lipopeptides, glycolipids, polysaccharides, flavonoids, non-flavonoid polyphenols, an aromatic aldehyde, an aporphine alkaloid, and even large bacterial antagonist proteins. This review surveys these natural TLR2 agonists and inhibitors, highlighting how the effective allocation of hydrophobic chains between the TLR2 pocket and its partner receptor, rather than total acyl-chain number alone, combines with chain branching, stereochemical presentation and polar head-group interactions to govern TLR1/TLR6 heterodimer selectivity among bacterial and gut-commensal lipids, and how mechanistically distinct inhibitory strategies-direct receptor competition, transcriptional downregulation, and TIR-domain interference-converge on a shared druggable interface exploited independently by plant polyphenols and staphylococcal virulence factors alike. Persistent experimental challenges are also discussed, including microbial contamination of natural extracts and structural heterogeneity of isolated lipids, along with how total synthesis and chemically defined oligomers have resolved these ambiguities, underscoring natural products as a promising yet still underexploited chemical space for developing selective TLR2-targeted therapeutics.
中文摘要:覆盖至2025年。Toll样受体2(TLR2)是一种功能多样的模式识别受体,其活性可向激动或拮抗两个方向调节,从而产生不同的治疗结果,范围从疫苗佐剂、肿瘤免疫治疗药物,到用于脓毒症、神经炎症和自身免疫病的抗炎药物。来自细菌、真菌、植物和海洋生物的天然产物已成为结构丰富的TLR2调节剂来源,涵盖酰化脂肽、糖脂、多糖、黄酮类、非黄酮多酚、一种芳香醛、一种阿朴啡生物碱,甚至大型细菌拮抗蛋白。本综述梳理这些天然TLR2激动剂和抑制剂,重点说明疏水链在TLR2口袋与其伙伴受体之间的有效分配,而非仅总酰基链数目,如何与链分支、立体化学呈现和极性头基相互作用共同决定细菌脂质和肠道共生菌脂质对TLR1/TLR6异二聚体的选择性;也说明机制不同的抑制策略——直接受体竞争、转录下调和TIR结构域干扰——如何汇聚于一个共同的可成药界面,植物多酚和葡萄球菌毒力因子分别独立利用该界面。文中还讨论持续存在的实验挑战,包括天然提取物的微生物污染和分离脂质的结构异质性,以及全合成和化学定义寡聚体如何解决这些不确定性,强调天然产物是开发选择性TLR2靶向治疗药物仍有待深入开发的有前景化学空间。
Alternative transcript initiation, splicing, and 3'-end processing jointly shape transcript isoform diversity, but these regulatory layers remain fragmented across separate single-cell and spatial resources. Here, we present scSpAS, an integrated database of alternative transcription start site (ATS), alternative splicing, full-length transcript isoforms, and alternative polyadenylation (APA) in human and mouse. It contains 123 datasets, including over 418 000 cells and 82 000 spatial spots across healthy and disease contexts, covering 13 cancer types, 5 infectious conditions, 8 inflammatory diseases, and 90 healthy samples. Based on uniformly standardized pipelines, we utilized 5' capture and 3' capture single-cell RNA-sequencing data to identify ATS and APA sites, and the Smart-seq2 and long-read sequencing data to identify the alternative splicing events and isoforms. In total, scSpAS contains >648 000 alternative splicing events, 432 000 ATS, and 621 000 APA sites, as well as over 551 000 transcript isoforms. The database further integrates regulatory annotations derived from CLIP-seq, ATAC-seq, and CAGE-seq, together with predicted splicing regulatory motifs. scSpAS enables users to retrieve events, isoforms and genes, examine differential usage at cell-type and spatial levels, and in different biological and physiological conditions; furthermore, users can inspect the potential regulatory mechanisms of all events. It is freely available at https://scspas.chenlulab.com/.
中文摘要:可变转录起始、剪接和3'端加工共同塑造转录本异构体多样性,但这些调控层面分散于彼此独立的单细胞和空间资源中。我们构建了scSpAS,一个整合人类和小鼠可变转录起始位点(ATS)、可变剪接、全长转录本异构体和可变多聚腺苷酸化(APA)的数据库。该数据库包含123个数据集,涵盖健康和疾病背景下的超过418000个细胞和82000个空间位点,覆盖13种癌症、5种感染性疾病、8种炎症性疾病和90个健康样本。基于统一标准化的流程,我们利用5'捕获和3'捕获单细胞RNA测序数据鉴定ATS和APA位点,并利用Smart-seq2和长读长测序数据鉴定可变剪接事件和异构体。scSpAS共包含超过648000个可变剪接事件、432000个ATS和621000个APA位点,以及超过551000个转录本异构体。该数据库还整合了来自CLIP-seq、ATAC-seq和CAGE-seq的调控注释,以及预测的剪接调控基序。scSpAS支持用户检索事件、异构体和基因,检查细胞类型和空间水平以及不同生物学和生理条件下的差异使用情况;用户还可查看所有事件的潜在调控机制。数据库可通过https://scspas.chenlulab.com/免费访问。
Metabolic differences between cancer and normal cells are accentuated by the selection pressure of therapy. Persisting cells enter a therapy-induced state of heightened, time-limited metabolic dependency. We argue that this interval can be exploited with metabolic modifiers to achieve persister cell death and improve cancer outcomes.
中文摘要:癌症与正常细胞之间的代谢差异会因治疗选择压力而更加突出。持续存在的细胞进入一种由治疗诱导的、代谢依赖增强且持续时间有限的状态。我们认为,这一时间窗口可利用代谢调节剂来杀死残留细胞并改善癌症结局。
Lactate has been recast from a waste product to a fuel and signaling molecule, yet why aggressive tumors invest so heavily in exporting it has remained unexplained. In a recent study in Molecular Cell, Wang et al. show that upon excess lactate production, AARS1 charges lactate onto tRNAs, generating dead-end lactyl-tRNAs that obstruct translation elongation to re-balance metabolism, a molecular "brake" that cancer cells avoid through upregulation of lactate exporters.
中文摘要:乳酸已从废物被重新认识为燃料和信号分子,但侵袭性肿瘤为何大量投入将乳酸导出仍无解释。在《Molecular Cell》最近一项研究中,Wang等发现乳酸生成过多时,AARS1将乳酸加载到tRNA上,产生无法继续延伸的乳酰化tRNA,阻碍翻译延伸以重新平衡代谢,形成一种分子「刹车」,而癌细胞通过上调乳酸外排蛋白来避开这一刹车。
Gut bacteria are established drivers of steatotic liver disease and liver cancer-gut fungi, much less so. Zhou et al. show that Rhizopus arrhizus promotes MASLD-associated liver cancer through kynurenic acid, a metabolite that bypasses its own surface receptors to engage the cytoplasmic scaffold IQGAP1.
中文摘要:肠道细菌已被确认为脂肪性肝病和肝癌的驱动因素,肠道真菌的作用则远未明确。Zhou等发现,少根根霉通过犬尿喹啉酸促进MASLD相关肝癌;该代谢物绕过其自身表面受体,直接结合胞质支架蛋白IQGAP1。
Secretory proteins encode cellular states not only through their abundance but also through their intracellular transport before being released. However, visualizing protein secretion behavior with molecular specificity and a low background remains challenging. Here, we report VEGF-responsive electrochemiluminescence (ECL) nanoemitters that enable spatiotemporal mapping of intracellular protein distribution at different stages of the secretion process by integrating a metal-organic framework (MOF) confining Ru(bpy)32+ with DNA tetrahedral gates (DTGs) programmed with aptamers. The MOF core provides bright, stable, and electrically addressable ECL emission, whereas the discrete DTGs regulate coreactant accessibility and prevent premature emission until VEGF recognition triggers gate displacement and restores ECL activity, converting intracellular molecular recognition events to quantitative optical signals. This architecture enables rapid, concentration-dependent, and selective activation, allowing high contrast discrimination of VEGF-rich tumor cells from epithelial cells. Under DFO stimulation, single-cell ECL imaging revealed heterogeneous VEGF upregulation and mapped its progressive redistribution from the perinuclear region to the cell periphery during secretion. This gated ECL platform enables quantitative spatiotemporal visualization of protein secretion behavior beyond the static molecular localization.
中文摘要:分泌蛋白不仅通过丰度编码细胞状态,也通过释放前的胞内运输编码细胞状态。然而,以分子特异性和低背景可视化蛋白分泌行为仍具挑战。研究报道了VEGF响应型电化学发光(ECL)纳米发射体,将限制Ru(bpy)3^2+的金属有机框架(MOF)与程序化适配体DNA四面体门(DTG)整合,可对不同分泌阶段的胞内蛋白分布进行时空成像。MOF核心提供明亮、稳定且可电寻址的ECL发射,离散DTG调控共反应物可及性,并在VEGF识别触发门位移、恢复ECL活性前阻止过早发光,从而把胞内分子识别事件转化为定量光学信号。该结构实现快速、浓度依赖和选择性的激活,可高对比区分富含VEGF的肿瘤细胞与上皮细胞。在DFO刺激下,单细胞ECL成像显示VEGF上调具有异质性,并描绘其在分泌过程中从核周区域向细胞周边的渐进重分布。该门控ECL平台实现了对蛋白分泌行为的定量时空可视化,超越了静态分子定位。
Following the successes of the messenger RNA (mRNA) lipid nanoparticle (LNP) vaccines against COVID-19, mRNA-LNPs are being explored for varied multidose applications including cancer immunotherapies and protein replacement therapies. LNPs rely on poly(ethylene glycol)-lipid (PEG-lipid) coatings for stability, but increasing anti-PEG antibody prevalence threatens repeat-dose efficacy and increases pseudoallergic risk, creating an urgent need for alternatives. Here, we introduce poly(acrylamido) lipids (PAM-lipids), a family of polymer lipids that effectively replace PEG-lipids in mRNA-LNP formulations. Systematic variation of monomer chemistry, molar mass, and end group reveals critical structure-activity relationships determining LNP size, polydispersity, and transfection efficiency. Varying PAM monomer chemistry allows minimization of antipolymer antibody cross-reactivity, with multiple PAM-lipids demonstrating no anti-PEG antibody binding. Several PAM-LNPs exhibit superior mRNA transfection efficacy to PEGylated clinical benchmarks in vitro and in vivo across multiple cell types, organs, routes of administration, and mRNA cargos. In particular, lead PAM-LNPs enhance mRNA delivery to dendritic cells (up to 120-fold in vitro and 3-fold in vivo) and macrophages (4-fold in vivo), with 2.5-fold superior lymph node expression, driven in part by increased cellular association and lymphoid targeting. Crucially, PAM-LNPs evade circulating anti-PEG antibodies to rescue lost mRNA efficacy after repeated dosing, resulting in 300% mRNA expression relative to that of PEG-LNPs. These findings demonstrate PAM-lipids as a chemically varied, immunologically compatible family of PEG alternatives for mRNA-LNP therapeutics.
中文摘要:在针对COVID-19的mRNA脂质纳米颗粒(LNP)疫苗取得成功后,mRNA-LNP正被探索用于多种多剂量应用,包括肿瘤免疫治疗和蛋白替代治疗。LNP依赖聚乙二醇脂质(PEG-脂质)包覆来维持稳定,但抗PEG抗体流行率上升威胁重复给药疗效并增加假性过敏风险,迫切需要替代方案。这里介绍聚(丙烯酰胺基)脂质(PAM-脂质),一类可在mRNA-LNP制剂中有效替代PEG-脂质的聚合物脂质。系统改变单体化学结构、摩尔质量和端基,揭示了决定LNP粒径、多分散性和转染效率的关键构效关系。改变PAM单体化学结构可最小化抗聚合物抗体的交叉反应,多种PAM-脂质显示不与抗PEG抗体结合。若干PAM-LNP在体外和体内、跨多种细胞类型、器官、给药途径和mRNA载荷时,表现出优于PEG化临床基准的mRNA转染效力。尤其是先导PAM-LNP增强mRNA向树突状细胞的递送(体外最高120倍,体内3倍)和巨噬细胞(体内4倍),淋巴结表达提高2.5倍,部分由细胞结合增加和淋巴靶向增强驱动。关键的是,PAM-LNP可规避循环抗PEG抗体,在重复给药后挽回丧失的mRNA疗效,使mRNA表达达到PEG-LNP的300%。这些发现表明PAM-脂质是一类化学结构多样、免疫学相容的PEG替代物,可用于mRNA-LNP治疗。
A single-nucleus analysis of 189 colorectal tumors found that early-onset cancers differ from those in older patients in cellular composition, gene signaling, and expression of regulatory RNAs. The findings offer clues to the biology of early-onset disease, but further studies are needed to determine whether these molecular features drive tumor development or progression.
中文摘要:对189例结直肠肿瘤的单核分析发现,早发性肿瘤在细胞组成、基因信号传导及调控RNA表达上与老年患者肿瘤不同。这些结果为早发性疾病的生物学提供了线索,但仍需进一步研究以确定这些分子特征是否驱动肿瘤发生或进展。
Loss of skeletal muscle mass is a major driver of frailty and disability, yet how systemic metabolic cues protect muscle integrity remains unclear. We identify Serpina3n, an adipose-derived adipokine, as a key mediator of the protective effects of nicotinamide adenine dinucleotide (NAD+) supplementation against muscle atrophy. Elevation of NAD+ in adipose tissue activates signal transducer and activator of transcription (STAT)1-dependent transcription of Serpina3n, leading to its systemic release and muscle protection across models of aging, disuse, and cancer cachexia. In muscle, Serpina3n preserves pyruvate carboxylase protein level, promoting anaplerosis, oxidative metabolism, and protein synthesis. These findings define an NAD+-responsive adipose-to-muscle signaling axis that links metabolic status to tissue preservation, defining a systemic mechanism by which inter-organ communication maintains muscle integrity and suggesting potential strategies to counteract muscle degeneration.
中文摘要:骨骼肌质量丢失是衰弱和失能的重要驱动因素,但全身代谢信号如何保护肌肉完整性仍不清楚。研究识别出脂肪来源脂肪因子Serpina3n是烟酰胺腺嘌呤二核苷酸(NAD+)补充对抗肌肉萎缩的关键介质。脂肪组织中NAD+升高激活信号转导及转录激活因子(STAT)1依赖的Serpina3n转录,促使其全身释放,并在衰老、废用和癌症恶病质模型中保护肌肉。在肌肉中,Serpina3n维持丙酮酸羧化酶蛋白水平,促进回补反应、氧化代谢和蛋白质合成。这些发现定义了一条NAD+响应的脂肪至肌肉信号轴,将代谢状态与组织保存联系起来,阐明器官间通讯维持肌肉完整性的全身机制,并提示对抗肌肉退变的潜在策略。
Hyperactive WNT signaling is a potent cancer driver but clinical translation of WNT inhibitors has been hampered by on-target toxicities. WNT signaling can be constrained through inhibition of the PARP-family enzymes tankyrase 1 (TNKS1) and TNKS2; however, existing TNKS inhibitors suppress WNT signaling in both tumor and healthy tissues. In this Article, we show that genomic loss of TNKS1 on chromosome 8p creates a collateral vulnerability that drives a tumor-restricted dependency on TNKS2 for cellular TNKS activity. Through structure-guided design, we identify a flexible loop in TNKS2 that can be exploited to enable TNKS2-selective drug targeting and we generate a first-in-class TNKS2 inhibitor to drive selective WNT inhibition in TNKS1-deficient cell and organoid models. This work demonstrates a targetable cancer-specific vulnerability in multiple cancer types, providing a new approach for WNT-targeted therapies.
中文摘要:过度活跃的WNT信号是强效的癌症驱动因素,但WNT抑制剂的临床转化一直受制于靶向毒性。WNT信号可通过抑制PARP家族酶端锚聚合酶1(TNKS1)和TNKS2受到限制;现有TNKS抑制剂在肿瘤和健康组织中都会抑制WNT信号。本文显示,8p染色体上TNKS1的基因组缺失产生一种旁路脆弱性,使细胞TNKS活性对TNKS2形成肿瘤限制性依赖。通过结构导向设计,我们识别出TNKS2中一个可被利用的柔性环,以实现TNKS2选择性药物靶向,并开发出首个TNKS2抑制剂,在TNKS1缺陷的细胞和类器官模型中驱动选择性WNT抑制。这项工作展示了多种癌症类型中可靶向的癌症特异性脆弱性,为WNT靶向治疗提供了新途径。
T-cell recognition is elicited by the binding between T-cell receptors (TCRs) and epitopes. Many machine learning approaches have been proposed to model TCR-epitope recognition specificity, but most of them act as black boxes. To visualize TCR-epitope recognition specificity, we developed the TCR Motif Atlas (https://tcrmotifatlas.unil.ch). This database builds upon the probabilistic framework of TCR specificity profiles (TSPs) to visualize V and J genes as well as complementarity-determining Region 3 (CDR3) lengths and amino acids enriched in epitope-specific TCRs with respect to baseline TCR repertoires for hundreds of epitopes. An interactive interface enables users to build TSPs based on their own set of TCR sequences to investigate epitope recognition specificity or to explore potential biases in TCR repertoires of known or undetermined specificity. The TCR Motif Atlas further provides links to curated compilations of epitope-specific TCRs and crystal structures of TCR-epitope complexes.
中文摘要:T细胞识别由T细胞受体(TCR)与表位结合引发。已有许多机器学习方法用于建模TCR-表位识别特异性,但多数方法仍是黑箱。为可视化TCR-表位识别特异性,我们开发了TCR Motif Atlas(https://tcrmotifatlas.unil.ch)。该数据库基于TCR特异性谱(TSPs)的概率框架,针对数百个表位,展示相对于基线TCR库,在表位特异性TCR中富集的V和J基因、互补决定区3(CDR3)长度及氨基酸。交互界面使用户能基于自己的TCR序列集构建TSP,以研究表位识别特异性,或探索已知或未确定特异性TCR库中的潜在偏倚。TCR Motif Atlas还提供指向表位特异性TCR精选汇编及TCR-表位复合物晶体结构的链接。
Foundation models are transforming cancer AI, but no single model consistently excels across every task. Researchers are increasingly combining models to improve performance and robustness, from interpreting pathology slides to selecting drugs for individual tumors.
中文摘要:基础模型正在改变癌症人工智能,但没有任何单一模型能在所有任务上持续胜出。研究人员越来越多地把模型组合起来,以提高性能和稳健性,应用范围从解读病理切片到为个体肿瘤选择药物。
The nuclear pore complex (NPC) and its building-block proteins, nucleoporins (NUP), play fundamental roles in maintaining cellular fitness by regulating nucleocytoplasmic transport, chromatin and transcriptional activity, and genome stability. These core biological processes are critical for cancer cells, and thus, tumor-driven co-option of NUP-regulated functions has emerged as an important mechanism contributing to the pathogenesis of multiple malignancies. This review discusses how NUP dysregulation mechanistically contributes to tumor initiation and progression and how these insights open opportunities for innovative anticancer therapies, including using clinical-grade molecular glues that induce selective NUP degradation and pharmacologically inhibiting NPC-regulated epigenomic/transcriptomic signaling and nucleocytoplasmic transport. Recent studies demonstrate that NUPs play fundamental roles in cancer pathogenesis by dysregulating key NPC functions and driving tumorigenesis and disease progression. NUPs and NPC-regulated mechanisms can be pharmacologically targeted, providing a strong rationale for developing much-needed innovative therapeutic strategies to combat cancer.
中文摘要:核孔复合体(NPC)及其构建蛋白核孔蛋白(NUP)通过调控核质运输、染色质与转录活性以及基因组稳定性,在维持细胞适应性中发挥基础性作用。这些核心生物学过程对癌细胞至关重要,肿瘤对NUP调控功能的劫持已成为促进多种恶性肿瘤发病的重要机制。本综述讨论NUP失调如何在机制上促进肿瘤发生与进展,以及这些认识如何为创新抗癌治疗提供机会,包括使用临床级分子胶诱导选择性NUP降解,以及药理学抑制NPC调控的表观基因组/转录组信号和核质运输。近期研究表明,NUP通过失调关键NPC功能、驱动肿瘤发生和疾病进展,在癌症发病机制中发挥基础性作用。NUP及NPC调控机制可被药物靶向,为开发亟需的创新抗癌治疗策略提供了有力依据。
Keith T. Flaherty, MD, who began a 1-year term as president of the American Association for Cancer Research in April 2026, spoke with Cancer Discovery's Suzanne Rose about his work, what he sees as the most exciting advances in cancer research, and his vision for the future.
中文摘要:Keith T. Flaherty,医学博士,于2026年4月开始担任美国癌症研究协会主席,任期一年。他接受《Cancer Discovery》的 Suzanne Rose 采访,谈了自己的工作、他认为癌症研究中最令人振奋的进展,以及对未来的愿景。
Hydrogen peroxide (H2O2)-mediated catalysis is key to oxidative chemical transformations and catalytic cancer therapies. However, its efficiency is limited by the lack of controllable catalytic systems capable of selectively driving two-electron oxygen reduction under physiologically relevant conditions. Herein, photocatalytic H2O2 generation in carbon systems was discovered to be governed by programmable electronic structures rather than material composition. By exploiting a framework-derived transformation, a series of carbon nanostructures were constructed with continuously adjustable electronic states, which enabled correlation between electronic configuration and photocatalytic behavior. Thus, a non-monotonic dependence of activity on graphitization degree was identified, where an intermediate semi-graphitized phase maximizes near-infrared (NIR) absorption, charge separation, and selective two-electron oxygen reduction. In contrast, insufficient conjugation limits excitation efficiency, while excessive delocalization accelerates carrier recombination, defining an electronic-structure window for optimal catalysis. This electronically optimized structure enables NIR-driven H2O2 generation without sacrificial agents, which further couples with Fe2+-mediated Fenton reactions and hole-driven glutathione depletion to achieve a self-amplifying redox cascade for cancer therapy. The as-obtained system achieves efficient oxidative transformation in vitro and significant tumor suppression in vivo. These findings suggest an electronic-structure-associated paradigm for carbon-based photocatalysis and provide a generalizable strategy for modulating reaction selectivity and efficiency in metal-free systems.
中文摘要:过氧化氢(H2O2)介导的催化是氧化化学转化和催化癌症治疗的关键。然而,其效率受限于缺乏可在生理相关条件下选择性驱动两电子氧还原的可控催化体系。本研究发现,碳体系中的光催化H2O2生成由可编程电子结构而非材料组成决定。利用框架衍生转化,构建了一系列具有连续可调电子态的碳纳米结构,使电子构型与光催化行为之间得以关联。由此识别出活性对石墨化程度的非单调依赖关系,其中中间半石墨化相最大化近红外(NIR)吸收、电荷分离和选择性两电子氧还原。相比之下,共轭不足限制激发效率,过度离域则加速载流子复合,从而界定出最佳催化的电子结构窗口。这一电子结构优化后的结构可在无牺牲剂条件下实现NIR驱动的H2O2生成,并进一步与Fe2+介导的Fenton反应和空穴驱动的谷胱甘肽耗竭耦合,形成用于癌症治疗的自增强氧化还原级联。所得体系在体外实现高效氧化转化,并在体内显著抑制肿瘤。这些发现提出了与电子结构相关的碳基光催化范式,并为无金属体系中调节反应选择性和效率提供了可推广策略。
Cell-free RNA (cfRNA) is emerging as a promising analyte for liquid biopsy because it captures dynamic changes in gene expression across tissues and disease states. However, interpretation of cfRNA profiles remains limited by the lack of a unifying framework describing how extracellular RNAs are released, processed, and stabilized. Here, we propose that concepts from cell-free DNA fragmentomics provide a useful lens to interpret cfRNA biology and introduce the concept of cfRNA fragmentomics. We argue that many cfRNAs originate as intracellular ribonucleoprotein complexes that undergo extracellular ribonuclease processing, generating stable fragmented RNAs associated with proteins and other carriers. Under this framework, informative cfRNA signatures may arise not only from diseased tissues but also from indirect systemic responses to disease.
中文摘要:游离RNA(cfRNA)正成为液体活检中颇具前景的分析物,因为它能捕捉不同组织和疾病状态下基因表达的动态变化。然而,由于缺乏描述细胞外RNA如何释放、加工和稳定的统一框架,对cfRNA图谱的解读仍受限。我们提出,游离DNA片段组学的概念可为解读cfRNA生物学提供有用视角,并引入cfRNA片段组学这一概念。我们认为,许多cfRNA起源于细胞内核糖核蛋白复合物,这些复合物在细胞外经历核糖核酸酶加工,生成与蛋白质及其他载体结合的稳定片段化RNA。在该框架下,有信息价值的cfRNA特征不仅可能来自病变组织,也可能来自机体对疾病的间接全身性反应。
Transcription factor NRF2 (encoded by the NFE2L2 gene) is a central signalling hub that coordinates antioxidant, detoxification, anti-inflammatory and metabolic programmes to maintain cellular homeostasis, with broad relevance to degenerative diseases, chronic inflammation and cancer. NFE2L2 is transcribed from two promoters: the canonical promoter (P1) and an alternative promoter (P2), generating transcripts that differ solely in their first exon. Exon 1 of P1-derived transcripts contains the AUG start codon, whereas the considerably longer exon 1' of P2-derived transcripts forms an extended 5' untranslated region (5'UTR). Consequently, the P1-derived NRF2 isoform 1 contains 16 additional N-terminal amino acids relative to the P2-derived isoform 2. Although transcripts from both promoters are expressed in human tissues, the existence of isoform 2 protein and the functional significance of alternative promoter usage have remained unresolved. Here, we identify an endogenous NRF2 protein species consistent with isoform 2 using an isoform-specific siRNA strategy. Isoform 2 is negatively regulated by KEAP1 and retains the ability to activate canonical NRF2 target genes. Despite similar stability of the two isoforms, isoform 2 accumulates at substantially lower basal levels, which is associated with reduced translational engagement of P2-derived transcripts. Polysome profiling revealed that P1-derived transcripts are predominantly associated with polysomes, whereas P2-derived transcripts are distributed between polysomal and subpolysomal fractions. The extended P2-specific 5'UTR contains evolutionarily conserved structural features that may contribute to translational regulation. Finally, the electrophilic NRF2 activator omaveloxolone (RTA-408) induced translation of transcripts from both promoters, demonstrating that NRF2 stress response is coordinated through the combined regulation of mRNA translation and protein stability.
中文摘要:转录因子NRF2(由NFE2L2基因编码)是协调抗氧化、解毒、抗炎和代谢程序的中心信号枢纽,维持细胞稳态,与退行性疾病、慢性炎症和癌症广泛相关。NFE2L2由两个启动子转录:经典启动子P1和替代启动子P2,产生的转录本仅第一外显子不同。P1来源转录本的外显子1含AUG起始密码子,而P2来源转录本明显更长的外显子1'形成延长的5'非翻译区(5'UTR)。因此,P1来源的NRF2异构体1比P2来源的异构体2多16个N端氨基酸。两种启动子的转录本均在人体组织中表达,但异构体2蛋白是否存在以及替代启动子使用的功能意义仍未明确。采用异构体特异性siRNA策略,鉴定出与异构体2一致的内源性NRF2蛋白。异构体2受KEAP1负调控,并保留激活经典NRF2靶基因的能力。两种异构体稳定性相似,但异构体2的基础水平显著更低,这与P2来源转录本的翻译参与减少有关。多聚核糖体谱分析显示,P1来源转录本主要与多聚核糖体结合,而P2来源转录本分布于多聚核糖体组分和亚多聚核糖体组分之间。P2特异性延长的5'UTR含进化保守的结构特征,可能参与翻译调控。亲电性NRF2激活剂omaveloxolone(RTA-408)诱导两个启动子来源转录本的翻译,表明NRF2应激反应通过mRNA翻译和蛋白稳定性的联合调控实现协调。
Connexins are classically defined as structural subunits of gap junction channels that mediate direct intercellular communication, and their dysregulation is a recognized feature of many cancers. Growing evidence suggests that connexins can influence cancer by regulating nuclear activity via both gap junction-mediated transfer of signaling molecules and channel-independent functions. However, much of the available evidence remains observational, and the mechanisms underlying these transcriptional effects are incompletely understood. More recent studies have begun to address this gap, including work showing that connexins can localize to the nucleus and directly influence gene expression. In this review, we examine current evidence that connexins regulate nuclear activity in cancer, addressing both tumor-promoting and tumor-suppressive functions. We discuss how gap junctional intercellular communication influences nuclear activity through the exchange of ions and signaling molecules and distinguish these effects from those mediated by connexin protein interactions, scaffold functions, and the nuclear or perinuclear localization of connexins or their truncated isoforms. We propose that connexins integrate intercellular communication with intracellular signaling to shape nuclear regulatory programs in a context-dependent manner, and we highlight the key challenges that must be addressed before these mechanisms can be fully understood and therapeutically targeted.
中文摘要:连接蛋白经典上被定义为介导细胞间直接通讯的间隙连接通道的结构亚基,其失调是许多癌症的已知特征。越来越多证据提示,连接蛋白可通过间隙连接介导的信号分子转移以及不依赖通道的功能调控核活动,从而影响癌症。现有证据大多仍为观察性研究,这些转录效应背后的机制尚未完全阐明。近期研究开始填补这一空白,包括显示连接蛋白可定位至细胞核并直接影响基因表达的工作。本综述梳理连接蛋白调控癌症核活动的现有证据,涵盖促瘤与抑瘤功能。我们讨论间隙连接细胞间通讯如何通过离子和信号分子交换影响核活动,并将这些效应与连接蛋白蛋白相互作用、支架功能以及连接蛋白或其截短异构体的核内或核周定位所介导的效应区分开来。我们提出,连接蛋白以情境依赖方式整合细胞间通讯与细胞内信号,塑造核调控程序,并指出在充分理解这些机制并实现治疗靶向之前必须解决的关键挑战。
GAIP-interacting protein C-terminal 1 (GIPC1/GIPC) is a well-established protein in the field of cancer biology. Recent studies have revealed that GIPC1 may exert opposing, context-dependent functions in various diseases or physiological processes, although the underlying regulatory mechanisms remain to be explored. Since GIPC1 contains a PDZ domain that interacts with various proteins, this domain is a promising therapeutic target. Molecular probes designed against the GIPC1-PDZ domain could therefore be valuable in developing targeted interventions. This review systematically summarizes the advances in GIPC1 research over the past decade. We discuss recent progress in understanding the roles of GIPC1 and its interacting proteins in human pathophysiology and disease, with a focus on GIPC1-interacting molecules and associated signaling pathways. Additionally, we identify key obstacles that must be overcome to realize the therapeutic potential of GIPC1. This review proposes an emerging conceptual model in which GIPC1 functions primarily as a context-dependent "signal tuner" and "trafficking gatekeeper," rather than as a simple scaffolding protein. This paradigm shift fundamentally transforms our understanding of how GIPC1 integrates diverse receptor inputs to regulate cellular behavior and highlights new directions for targeted therapeutic applications.
中文摘要:GAIP相互作用蛋白C端1(GIPC1/GIPC)是癌症生物学领域一个已被充分确认的蛋白。近期研究显示,GIPC1在不同疾病或生理过程中可能发挥相反且依赖情境的功能,尽管其潜在调控机制仍有待探索。GIPC1含有一个可与多种蛋白相互作用的PDZ结构域,该结构域是有前景的治疗靶点。因此,针对GIPC1-PDZ结构域设计的分子探针可能有助于开发靶向干预。本综述系统总结了过去十年GIPC1研究的进展。我们讨论了对GIPC1及其相互作用蛋白在人类病理生理和疾病中作用认识的最新进展,重点聚焦GIPC1相互作用分子及相关信号通路。此外,我们指出了实现GIPC1治疗潜力必须克服的关键障碍。本综述提出一个新兴概念模型:GIPC1主要作为依赖情境的「信号调谐器」和「运输守门员」发挥作用,而非简单的支架蛋白。这一范式转变从根本上改变了我们对GIPC1如何整合多种受体输入以调控细胞行为的理解,并突出了靶向治疗应用的新方向。
The field of horizontal mitochondrial transfer (HMT), also referred to as intercellular mitochondrial transfer, has recently gained momentum due to an increasing number of publications that go well beyond diseases such as cancer. From co-culture experiments to in vivo evidence in mouse cancer models, noncancerous diseases, and normal tissue and organ homeostasis and development, it is becoming increasingly clear that HMT is a fundamental physiological phenomenon broadly relevant to complex organisms. Recent methodological advances, epitomized by ultra-high-resolution microscopy and spatial and single-cell multiomics technologies, allow for research that strongly supports HMT as an emerging area of cell biology.
中文摘要:水平线粒体转移(HMT),也称细胞间线粒体转移,近年来因越来越多出版物超越癌症等疾病范围而受到关注。从共培养实验到小鼠癌症模型、非癌症疾病以及正常组织和器官稳态与发育中的体内证据,HMT正日益被视为一种与复杂生物体广泛相关的基本生理现象。以超高分辨率显微镜及空间和单细胞多组学技术为代表的最新方法学进展,使研究能够有力支持HMT成为细胞生物学的新兴领域。
Growing evidence indicates that cancer cell mitochondria remain functional and represent attractive therapeutic targets. Mitochondria-targeted drug delivery commonly uses triphenylphosphonium (TPP+)-conjugated compounds, which preferentially accumulate in cancer cell mitochondria because of their highly negative membrane potential. Many TPP+-conjugated agents inhibit mitochondrial electron transport chain complexes I and II, suppressing mitochondrial respiration and cancer cell proliferation. Recent studies suggest that electron-withdrawing substituents, such as trifluoromethyl groups, on the TPP+ phenyl rings alter electron density around the phosphorus center, enhancing mitochondrial uncoupling activity and antiproliferative effects. To determine how TPP+ electronic substituents influence redox properties, mitochondrial complex III interactions, and biological activity, we used mitochondria-targeted atovaquone (Mito-ATO) as a model system. Atovaquone (ATO), a hydroxy-1,4-naphthoquinone and the only FDA-approved mitochondrial complex III inhibitor, is currently undergoing clinical evaluation for cancer therapy. We synthesized a series of mitochondria-targeted ATO derivatives (MitoR-ATOs) containing electron-donating or electron-withdrawing substituents on the TPP+ moiety. Their effects on enzymatic superoxide generation were assessed by EPR spin trapping, mitochondrial oxygen consumption by Seahorse XF96 analysis, complex III Qi-site binding by computational modeling, and cancer cell proliferation using IncuCyte live-cell imaging. Unexpectedly, several MitoR-ATO derivatives emerged as potent complex III inhibitors through enhanced binding at the Qi site. Structure-activity relationship analysis revealed that the intrinsic redox properties of TPP+-conjugated MitoR-ATO analogs alone do not predict biological activity. Instead, accurate prediction of the therapeutic efficacy of mitochondria-targeted complex III inhibitors requires integrating redox properties with computational analyses of ligand-protein interactions at the mitochondrial complex III Qi site.
中文摘要:越来越多证据表明,癌细胞线粒体仍保持功能,是有吸引力的治疗靶点。线粒体靶向药物递送常用三苯基膦(TPP+)偶联化合物,这类化合物因癌细胞线粒体膜电位高度为负而优先积聚。许多TPP+偶联剂抑制线粒体电子传递链复合物I和II,抑制线粒体呼吸和癌细胞增殖。近期研究提示,TPP+苯环上的吸电子取代基如三氟甲基可改变磷中心周围电子密度,增强线粒体解偶联活性和抗增殖作用。为确定TPP+电子取代基如何影响氧化还原性质、与线粒体复合物III的相互作用及生物活性,采用线粒体靶向阿托伐醌(Mito-ATO)作为模型体系。阿托伐醌(ATO)是一种羟基-1,4-萘醌,也是唯一获FDA批准的线粒体复合物III抑制剂,目前正在接受癌症治疗临床评估。我们合成了一系列线粒体靶向ATO衍生物(MitoR-ATOs),其TPP+部分带有给电子或吸电子取代基。通过EPR自旋捕获评估其对酶促超氧化物生成的影响,通过Seahorse XF96分析评估线粒体耗氧,通过计算建模评估复合物III Qi位点结合,通过IncuCyte活细胞成像评估癌细胞增殖。出乎预期的是,若干MitoR-ATO衍生物通过增强Qi位点结合而成为强效复合物III抑制剂。构效关系分析显示,仅凭TPP+偶联MitoR-ATO类似物的内在氧化还原性质不能预测生物活性。准确预测线粒体靶向复合物III抑制剂的治疗疗效,需要将氧化还原性质与线粒体复合物III Qi位点配体-蛋白相互作用的计算分析相结合。
Multiple Instance Learning (MIL) has become the dominant paradigm for analyzing histopathology whole slide images (WSIs). However, the inherent spatial heterogeneity of WSIs poses a significant challenge to existing MIL methods. This heterogeneity, where morphologically similar tissue patches often exhibit multifocal distributions across the WSI, hinders the ability of current models to effectively capture long-range spatial dependencies and complex inter-tissue semantic associations. To mitigate these limitations, we propose DisCo, a novel Dispersion-to-Consolidation MIL framework that consolidates dispersed semantics through context-aware clustering for WSI analysis. DisCo operates by iteratively routing and aggregating instances into a compact set of semantic anchors that represent distinct morphological patterns. Specifically, a Cluster Router module dynamically aggregates spatially dispersed yet semantically similar instances into tissue-specific semantic groups, strengthening intra-group feature interactions through dynamic routing and local aggregation. Subsequently, a Cluster Merger module consolidates redundant semantic anchors and captures inter-group associations by learning a dynamic assignment that projects fine-grained anchors into coarser anchors. Extensive experiments on 15 large-scale public cancer datasets across three challenging tasks demonstrate that DisCo consistently outperforms state-of-the-art methods. The source code is available at https://github.com/junjianli106/DisCo.
中文摘要:多实例学习已成为组织病理全切片图像分析的主流范式。全切片图像固有的空间异质性对现有多实例学习方法构成明显挑战。形态相似的组织斑块常在全切片图像中呈多灶分布,这种异质性妨碍现有模型有效捕获长程空间依赖和复杂的组织间语义关联。为缓解这些限制,作者提出DisCo,一种新的从分散到整合的多实例学习框架,通过上下文感知聚类整合分散语义以用于全切片图像分析。DisCo通过迭代地将实例路由并聚合为紧凑的语义锚点来运作,这些锚点代表不同的形态模式。具体而言,聚类路由器模块将空间分散但语义相似的实例动态聚合为组织特异的语义组,并通过动态路由和局部聚合增强组内特征交互。随后,聚类合并模块通过学习动态分配将细粒度锚点投影为更粗粒度锚点,从而整合冗余语义锚点并捕获组间关联。在15个大型公共癌症数据集上针对三项挑战性任务的大量实验表明,DisCo持续优于最先进方法。源代码见https://github.com/junjianli106/DisCo。
Cardiomyocyte differentiation is an important process during heart development that involves the specification of a series of cardiac lineage cells differentiated from mesendoderm to cardiac mesoderm, precisely regulated by multiple genes and signaling pathways. Our study aims to explore the role of the deleted in liver cancer 1 (DLC1) gene in cardiomyocyte differentiation and the molecular mechanisms underlying it. We constructed a Dlc1 knockout mouse embryonic stem cell (mESC) line using CRISPR/Cas9 and an mESC-cardiomyocyte differentiation model to investigate the role of the Dlc1 gene in the cardiac progenitor differentiation process. Flow cytometry, real-time PCR, teratoma formation assay, RNA sequencing, and other cellular and molecular biology assays were used to detect the cellular processes and differentiation ability of the knockout cell line at different stages. We found that the cardiac contractility of embryonic bodies was weakened by Dlc1 deletion at the late stage of differentiation. Moreover, Dlc1 deficiency promoted mesoderm specification and the subsequent differentiation and accumulation of cardiac progenitors, which may later impair cardiomyocyte generation. RNA sequencing analysis revealed that Dlc1 deficiency promoted mesoderm specification by activating canonical Wnt signaling, which subsequently enhanced cardiac progenitor differentiation. These results were confirmed by rescue experiments with the Wnt pathway inhibitor XAV-939. Furthermore, we found that the Dlc1 knockout activated canonical Wnt signaling by affecting the degradation and nuclear transportation of β-catenin. In conclusion, Dlc1 is involved in regulating embryonic stem cell cardiac differentiation by affecting canonical Wnt signaling at an early stage.
中文摘要:心肌细胞分化是心脏发育中的重要过程,涉及从内胚层到心脏中胚层的一系列心脏谱系细胞特化,并受多个基因和信号通路精确调控。本研究旨在探讨肝癌缺失基因1(DLC1)在心肌细胞分化中的作用及其分子机制。利用CRISPR/Cas9构建Dlc1敲除小鼠胚胎干细胞(mESC)系,并结合mESC-心肌细胞分化模型,研究Dlc1基因在心脏祖细胞分化过程中的作用。采用流式细胞术、实时PCR、畸胎瘤形成实验、RNA测序及其他细胞与分子生物学实验,检测敲除细胞系在不同阶段的细胞过程与分化能力。结果显示,Dlc1缺失在分化晚期削弱了拟胚体的心脏收缩能力。Dlc1缺陷促进了中胚层特化以及随后心脏祖细胞的分化与积累,这可能 later 损害心肌细胞生成。RNA测序分析显示,Dlc1缺陷通过激活经典Wnt信号促进中胚层特化,随后增强心脏祖细胞分化。Wnt通路抑制剂XAV-939的挽救实验证实了这些结果。进一步发现,Dlc1敲除通过影响β-catenin的降解与核转运激活经典Wnt信号。结论:Dlc1在早期通过影响经典Wnt信号参与调控胚胎干细胞的心脏分化。
Glycolysis fuels vital cellular functions, and its dysregulation has been implicated in cancer, neurodegeneration, antibiotic resistance and diabetes. The glycolytic dependency of cancer, known as the Warburg effect, represents a key vulnerability for development of targeted anticancer agents; however, the development of such agents remains challenging owing to metabolic heterogeneity and resistance. Here we developed a covalent phosphofructokinase-1 liver type (PFKL) activator that couples glycolytic activation with delivery of a cytotoxic carnitine palmitoyltransferase 2 (CPT2)-targeting payload to cancer cells in vitro and in vivo. The electrophile-drug conjugate site-specifically and proteome-wide selectively modifies K677 in the allosteric effector site to stabilize the R-state tetramer of PFKL, while concomitantly releasing a CPT2-selective inhibitor to destabilize cell metabolism. The delivery mechanism of electrophile-drug conjugates is analogous to that of antibody-drug conjugates, but differentiated by their selective covalent targeting of intracellular proteins.
中文摘要:糖酵解为关键细胞功能供能,其失调与癌症、神经退行性疾病、抗生素耐药和糖尿病相关。肿瘤对糖酵解的依赖(Warburg效应)是开发靶向抗癌药物的关键脆弱点;但受代谢异质性和耐药性影响,此类药物研发仍具挑战。我们开发了一种共价磷酸果糖激酶-1肝型(PFKL)激活剂,在体外和体内将糖酵解激活与向癌细胞递送靶向肉碱棕榈酰转移酶2(CPT2)的细胞毒性载荷相偶联。该亲电药物偶联物在位点特异且蛋白质组范围选择性地修饰变构效应位点的K677,稳定PFKL的R态四聚体,同时释放CPT2选择性抑制剂以破坏细胞代谢。亲电药物偶联物的递送机制类似抗体-药物偶联物,区别在于其对细胞内蛋白的选择性共价靶向。
The successful development of KRASG12C mutation-specific covalent inhibitors made direct targeting of KRAS a reality, yet the limitations in mutational coverage and susceptibility to resistance have spurred the pursuit of broader and more durable strategies. This review highlights the most recent developments on innovative strategies beyond traditional inhibitors, including molecular glues (MGs) and protein-protein interaction (PPI) modulators. Molecular glues, such as the RMC macrocyclic series (e.g., RMC-6291 as a G12C-selective MG, RMC-6236 as a pan-MG), function by recruiting endogenous chaperone proteins to form ternary complexes that sterically block KRAS-effector interactions or allosterically restore GTPase activity. This macrocyclic platform enables rational design of mutation-selective and broad-spectrum MGs. Another parallel advancement involves the design of small molecular MGs to strengthen KRAS engagement with E3 ligases (e.g., NEDD4-1 or LZTR1), thereby resulting in enhanced PPI or degradation of KRAS. Complementarily, PPI inhibitors (e.g., BBO-10203, VVD-699) disrupt critical oncogenic interfaces between KRAS and PI3Kα, offering a strategy to inhibit oncogenic signaling with fewer side effects. Collectively, balancing broad-spectrum versus selective targeting of KRAS, attaining optimal drug-like properties and establishing rational combination therapies with other modalities remain key challenges. The ongoing evolution of MGs and PPI modulators heralds a major expansion of the therapeutic frontier for KRAS-driven cancers and is redrawing the boundaries of precision oncology.
中文摘要:KRAS G12C突变特异性共价抑制剂的成功开发使直接靶向KRAS成为现实,但突变覆盖范围有限且易产生耐药,促使人们寻求更广谱、更持久的策略。本综述聚焦传统抑制剂之外的新近进展,包括分子胶(MG)与蛋白-蛋白相互作用(PPI)调节剂。分子胶如RMC大环系列(RMC-6291为G12C选择性分子胶,RMC-6236为泛突变型分子胶)通过招募内源性伴侣蛋白形成三元复合物,以空间位阻阻断KRAS与效应蛋白的相互作用,或通过变构方式恢复GTP酶活性。该大环平台支持合理设计突变选择性及广谱分子胶。另一条并行进展是设计小分子分子胶以增强KRAS与E3连接酶(如NEDD4-1或LZTR1)的结合,从而增强PPI或促进KRAS降解。PPI抑制剂(如BBO-10203、VVD-699)则破坏KRAS与PI3Kα之间的关键致癌界面,提供了在抑制致癌信号的同时减少副作用的策略。总体而言,如何在广谱靶向与选择性靶向KRAS之间取得平衡、获得理想成药性,并与其他治疗模式建立合理的联合方案,仍是关键挑战。分子胶与PPI调节剂的持续演进预示着KRAS驱动癌症治疗边界的显著拓展,并正在重新界定精准肿瘤学的范围。
Formaldehyde is highly reactive, causing irritation and acute and chronic toxicity in target tissues (the eyes, respiratory tract, and skin) following inhalation and/or skin contact. Moreover, formaldehyde is a local carcinogen after inhalation exposure. It induces nasal squamous cell carcinoma in laboratory animals and nasopharyngeal carcinoma in humans, albeit less convincingly. While formaldehyde has been evaluated and classified by different organizations and committees in recent years, the question has arisen of how to deal with substances that release formaldehyde. These releasers decompose in aqueous media and are frequently used as biocides in water-miscible metalworking fluids, adhesives, paints, disinfectants, and cosmetics. In this context, the MAK Commission has developed a concept for differential evaluation regarding carcinogen classification and MAK value derivation. This approach is based on hydrolysis rates as a function of pH, temperature, and concentration under physiological conditions. Furthermore, vapor pressure is considered to determine whether the formaldehyde releaser will be present as a vapor or aerosol upon inhalation. This concept is demonstrated using four examples that lead to different carcinogen classifications and MAK value derivations. Additionally, the releasers were evaluated for percutaneous absorption and sensitization.
中文摘要:甲醛具有高度反应性,经吸入和/或皮肤接触后可引起眼、呼吸道和皮肤等靶组织刺激以及急性和慢性毒性。吸入暴露后,甲醛还是局部致癌物。它可诱导实验动物发生鼻鳞状细胞癌,并在人类中引起鼻咽癌,尽管后一证据的说服力较弱。近年来不同组织和委员会已对甲醛进行评价和分类,但如何处理释放甲醛的物质成为问题。此类释放剂在水介质中分解,常作为杀生物剂用于水溶性金属加工液、胶黏剂、涂料、消毒剂和化妆品。在此背景下,MAK委员会提出了一个概念,用于在致癌物分类和MAK值推导方面进行差异化评价。该方法基于生理条件下水解速率随pH、温度和浓度变化的关系。此外,还考虑蒸气压,以判断甲醛释放剂在吸入时以蒸气还是气溶胶形式存在。通过四个示例展示该概念,这些示例导致不同的致癌物分类和MAK值推导。另外,还评价了这些释放剂的经皮吸收和致敏性。
To overcome drawbacks such as the need for biomarker labels, low automation, low-throughput, low integration, and high cost, an online cancer cell recognition application based on extracted multi-spectral lens-free cell diffraction fingerprint features is proposed. A high-throughput lens-free wide-field diffraction imaging platform captures diffraction images of four cancer and two normal cell types under multi-spectral illumination. Cell diffraction fingerprints are normalized by binary masking, features are extracted via Gray Level Co-occurrence Matrix (GLCM), and a Bayesian-Optimized Support Vector Machine (SVM) performs model training and recognition. Multi-spectral recognition accuracy is compared with five single-spectral modes. Co-culture experiments of cancer and normal cells are designed to validate the recognition accuracy of the models. This engineering application enables accurate real-time recognition of four types of cancer cells and two types of normal cells with accuracies of 96.0%, 98.0%, 95.2%, and 96.0% for HeLa, Huh-7, A549, and MCF-7 cells, respectively. The core advantages of this application lie in its complete elimination of chemical labeling or staining and the achievement of rapid imaging and recognition using a portable device, showing potential in reducing operational costs, simplifying workflows, and facilitating clinical application.
中文摘要:为克服需要生物标志物标记、自动化程度低、通量低、集成度低和成本高等缺点,提出一种基于提取的多光谱无透镜细胞衍射指纹特征的在线癌细胞识别应用。高通量无透镜宽场衍射成像平台在多光谱照明下捕获四种癌细胞和两种正常细胞类型的衍射图像。细胞衍射指纹通过二值掩膜进行归一化,利用灰度共生矩阵(GLCM)提取特征,并由贝叶斯优化的支持向量机(SVM)进行模型训练和识别。将多光谱识别准确率与五种单光谱模式进行比较。设计癌细胞与正常细胞的共培养实验,以验证模型的识别准确率。该工程应用可实时准确识别四类癌细胞和两类正常细胞,对HeLa、Huh-7、A549和MCF-7细胞的准确率分别为96.0%、98.0%、95.2%和96.0%。该应用的核心优势在于完全无需化学标记或染色,并利用便携设备实现快速成像与识别,在降低运行成本、简化流程和促进临床转化方面显示出潜力。
β-Carboline alkaloids are natural products built around an indole-pyridine tricyclic core. Their relatively simple structure and ease of modification have drawn lasting interest from medicinal chemists. This review organizes their pharmacological activities according to structural types: simple β-carbolines, those with substitutions at the C-1, N-2/N-9 or C-3 positions, cyclized derivatives, and bis-β-carboline dimers. For each type, we discuss reported mechanisms, such as inhibition of CDK4, HDAC, and topoisomerases. The available data point to promising applications in cancer, inflammatory disorders, and infectious diseases. Overall, the structural diversity of β-carbolines makes them a valuable source of lead compounds for drug discovery.
中文摘要:β-咔啉生物碱是以吲哚-吡啶三环核心为骨架的天然产物。其结构相对简单、易于修饰,长期吸引药物化学家的兴趣。本综述按结构类型梳理其药理活性:简单β-咔啉、C-1位、N-2/N-9位或C-3位取代的β-咔啉、环化衍生物以及双β-咔啉二聚体。针对每一类型,讨论已报道的作用机制,如抑制CDK4、HDAC和拓扑异构酶。现有数据表明其在癌症、炎症性疾病和感染性疾病中具有应用前景。总体而言,β-咔啉的结构多样性使其成为药物发现中先导化合物的宝贵来源。
Gold nanoparticles (AuNPs) are widely used in fiber-optic (FO) local surface plasmon resonance (LSPR) biosensors due to their ease of modification, high dielectric constant, and biocompatibility. However, salt ions and cross-linking agents often cause AuNPs aggregation during modification, which significantly degrades the sensing sensitivity of FO-based LSPR. Herein, tetrahedron DNA-encapsulated AuNPs (TDN-AuNPs) were served as a new nanolayer on FO surface for a sensitive biosensor. TDN improved the salt-resistance and cross-linking agent-resistance, also served as a gap to hinder the nanolayer close to each other, which could avoid the AuNPs aggregation on the FO surface. Further, a significant merit of molar ratio-dependent refractive index sensitivity was found in the FO-based LSPR through the three kinds of modification methods, namely self-assembled monolayer (SAM)-based, ployA-based, and complementary strand (CS)-based methods. Further, CS-based method maintained strong chemical stability under weak acid or neutral environment and exhibited stronger binding stability and long-term stability compared to the other two methods. Finally, the CS-based method also showed a new merit of molar ratio-dependent sensing sensitivity. The mole ratio of TDN: AuNPs played a vital role in sensing sensitivity. Under the optimal conditions, the lowest limit of detection of 12 cells/mL was obtained within 50 min. Since high stability, sensitivity, and selectivity for cancer cell sensing, FO-based LSPR biosensor via CS-based method had great potential for cancer diagnosis in the early stage.
中文摘要:金纳米颗粒(AuNPs)易修饰、介电常数高且生物相容性好,广泛用于光纤(FO)局域表面等离子体共振(LSPR)生物传感器。修饰过程中盐离子和交联剂常引起AuNPs聚集,明显降低FO-LSPR的传感灵敏度。为此,研究将四面体DNA封装AuNPs(TDN-AuNPs)作为FO表面的新型纳米层,用于构建灵敏生物传感器。TDN提高了耐盐性和耐交联剂能力,并作为间隔物阻碍纳米层相互靠近,从而避免AuNPs在FO表面聚集。通过自组装单层(SAM)法、polyA法和互补链(CS)法三种修饰方式,发现FO-LSPR具有明显的摩尔比依赖性折射率灵敏度。CS法在弱酸或中性环境下保持较强化学稳定性,相比另外两种方法表现出更强的结合稳定性和长期稳定性。CS法还展现出摩尔比依赖性传感灵敏度这一新优势,TDN与AuNPs的摩尔比对传感灵敏度起关键作用。在优化条件下,50分钟内获得最低检测限12 cells/mL。该FO-LSPR生物传感器对癌细胞传感具有高稳定性、灵敏度和选择性,在早期癌症诊断中具有较大潜力。
Signal transducer and activator of transcription 6 (STAT6) is a key transcription factor in cytokine signaling, serving as the central effector of the IL-4 and IL-13 pathways. STAT6 orchestrates a range of physiological and pathological processes, including immune homeostasis and tumor development, making it an attractive therapeutic target for Th2-driven diseases and certain cancers. While the development of STAT6-directed agents remains at an early stage, the rapid clinical progression of the highly selective degrader KT-621 has revitalized interest in this target. In this review, we systematically summarize recent advances in STAT6 inhibitors and degraders, with a focus on structural features, design strategies, and biological evaluation. We also highlight current challenges and future opportunities, aiming to provide useful guidance for the discovery and optimization of next-generation STAT6-directed therapeutics.
中文摘要:信号转导与转录激活因子6(STAT6)是细胞因子信号中的关键转录因子,也是IL-4与IL-13通路的中心效应分子。STAT6参与调控免疫稳态、肿瘤发生发展等多种生理与病理过程,因此成为Th2驱动性疾病及部分癌症中具有吸引力的治疗靶点。靶向STAT6的药物研发仍处于早期阶段,高选择性降解剂KT-621在临床上的快速推进重新激发了对该靶点的关注。本综述系统梳理STAT6抑制剂与降解剂的最新进展,侧重结构特征、设计策略与生物学评价,并讨论当前挑战与未来机会,为下一代STAT6靶向疗法的发现与优化提供参考。
The P2Y14 receptor (P2Y14R) is a G protein-coupled receptor (GPCR) that can be activated by the extracellular nucleotide uridine diphosphate glucose (UDPG). It performs crucial regulatory roles in diverse pathophysiological contexts, such as immune modulation, inflammatory responses, tumor progression, and metabolic disorders. Therefore, it represents a highly attractive therapeutic target. This review elucidates the signal transduction mechanism of P2Y14R and its pathological functions in conditions such as gouty arthritis (GA) and neuropathic pain (NP). Meanwhile, P2Y14R inhibitors based on multiple drug discovery strategies are also comprehensively summarized. Furthermore, this review analyzes the key challenges currently faced in inhibitors research and development. By integrating the latest reported crystal structure of P2Y14R, it looks forward to the prospects of precise drug design based on structure and clinical translation. This provides a theoretical basis and innovative direction for the future development of P2Y14R-targeted therapeutic drugs.
中文摘要:P2Y14受体(P2Y14R)是一种可被胞外核苷酸尿苷二磷酸葡萄糖(UDPG)激活的G蛋白偶联受体(GPCR)。它在免疫调节、炎症反应、肿瘤进展和代谢紊乱等多种病理生理过程中发挥关键调控作用,因而成为颇具吸引力的治疗靶点。本综述阐述P2Y14R的信号转导机制及其在痛风性关节炎(GA)和神经病理性疼痛(NP)等疾病中的病理功能,并系统总结基于多种药物发现策略的P2Y14R抑制剂。同时分析当前抑制剂研发面临的关键挑战。结合新近报道的P2Y14R晶体结构,展望基于结构的精准药物设计与临床转化前景,为未来P2Y14R靶向治疗药物的开发提供理论依据和创新方向。
Organic photoelectrochemical transistor (OPECT) has been demonstrated as advanced organic electronic sensing platforms for investigating a wide range of biomolecular species. However, their further development is constrained by the types of electrodes employed and the limitations of fixed signal modulation strategies. Inspired by self-powered photoelectrochemical biosensors with dual-photoelectrodes, a novel operational mode for OPECT was proposed in this work, which disrupted the potential equilibrium between CdS/Eu-MOF and CdIn2S4 dual photoanodes. Specifically, by integrating coenzyme-amplified bioassay technology with Ag+-induced modulation of the photoelectric conversion efficiency at the CdIn2S4 photoanode, the potential balance between the two photoanodes was perturbed to enable signal output. This configuration was embedded within a typical ion-gated circuit featuring an Ag/AgCl-gated poly(3,4-ethylenedioxythiophene): poly-(styrenesulfonate) channel. Through this design, highly sensitive detection of cancer biomarker microRNA-141 was achieved, with a linear detection range from 1 fM to 100 pM and a low limit of detection of 0.76 fM (S/N ≥ 3). This work establishes a biosensing platform with superior detection sensitivity, demonstrating significant potential for advanced biomolecular analysis.
中文摘要:有机光电化学晶体管(OPECT)已被证明是研究多种生物分子的先进有机电子传感平台。然而,其进一步发展受限于所用电极类型和固定信号调制策略的局限。受双光电极自供能光电化学生物传感器启发,该工作提出了一种新的OPECT工作模式,打破CdS/Eu-MOF与CdIn2S4双光阳极之间的电位平衡。具体而言,将辅酶放大生物检测技术与Ag+诱导的CdIn2S4光阳极光电转换效率调制相结合,扰动两个光阳极之间的电位平衡以实现信号输出。该构型嵌入典型的离子门控电路,电路包含Ag/AgCl门控的聚(3,4-乙撑二氧噻吩):聚(苯乙烯磺酸盐)通道。通过该设计,实现了对癌症生物标志物microRNA-141的高灵敏检测,线性检测范围为1 fM至100 pM,检出限低至0.76 fM(信噪比≥3)。该工作建立了一个具有优异检测灵敏度的生物传感平台,展示了用于先进生物分子分析的重要潜力。
Human telomerase processively adds telomeric repeats (dGGTTAG) to chromosome 3'-ends to maintain telomere length. While mostly absent in somatic cells, telomerase is aberrantly upregulated in most tumor cells to sustain cellular immortality, making it a promising oncology target. However, to date there are no reported structures of human telomerase with inhibitor, impeding structure-based drug design and optimization. We report nine cryo-electron microscopy structures of human telomerase with and without BIBR1532, a highly selective small-molecule telomerase inhibitor. Unexpectedly, BIBR1532 binds a previously unknown pocket between TERT finger and palm. BIBR1532 inhibits each step but disproportionately affects the rate-limiting first step of telomere repeat nucleotide addition. The structures reveal a rigid finger that explains telomerase's slow rate and low fidelity. Our study provides insights into telomerase catalytic mechanism and its inhibition by BIBR1532, explains why prior BIBR derivatives did not improve potency and suggests a rational approach for design of small-molecule telomerase inhibitors.
中文摘要:人端粒酶以持续合成方式将端粒重复序列(dGGTTAG)加到染色体3'末端,维持端粒长度。端粒酶在体细胞中大多缺失,但在多数肿瘤细胞中异常上调以维持细胞永生化,因此是颇具前景的肿瘤学靶点。迄今尚无端粒酶与抑制剂复合物的结构报道,阻碍了基于结构的药物设计与优化。我们报道了9个冷冻电镜结构,包括人端粒酶单独及与BIBR1532结合的结构;BIBR1532是一种高选择性小分子端粒酶抑制剂。出乎意料的是,BIBR1532结合于TERT手指区与手掌区之间一个此前未知的口袋。BIBR1532抑制每一步反应,但对端粒重复核苷酸添加的限速第一步影响尤为显著。这些结构揭示了一个刚性手指区,可解释端粒酶较慢的速率和较低的保真性。该研究为端粒酶催化机制及其被BIBR1532抑制提供了见解,解释了既往BIBR衍生物为何未能提高效力,并为小分子端粒酶抑制剂的合理设计提供了思路。
Pediatric tumors represent a major cause of disease-related mortality in children and exhibit biological features that differ markedly from those of adult cancers. Pediatric malignancies display unique molecular architectures, with lower mutation frequency, higher frequency of chromosomal alterations such as gene rearrangement and amplification, a distinct alteration spectrum marked by dysregulated developmental genes, as well as a characteristic pattern of differentiation blockage. These alterations often arise during developmental windows and sustain tumor dependency, providing unique drug targets for targeted therapy. This review first describes the molecular characteristics and oncogenic drivers of pediatric tumors, as well as the potential mechanisms underlying the formation of oncogenic driver events in these tumors. It subsequently systematically synthesizes recent advances in targeted therapeutic strategies for pediatric tumors, categorizing strategies by disease type and oncogenic driver events, including oncofusion-directed inhibitors, agents targeting amplified or mutated genes, differentiation-inducing approaches, antibody-based therapies, and cellular therapies. We highlight both pediatric-specific drug development and the extrapolation of adult therapies to pediatric patients, while underscoring persistent challenges in clinical translation. This work advocates for a biology-driven framework to accelerate the development of effective targeted therapies for pediatric tumors.
中文摘要:儿童肿瘤是儿童疾病相关死亡的主要原因,其生物学特征与成人癌症明显不同。儿童恶性肿瘤具有独特的分子构架:突变频率较低,基因重排和扩增等染色体改变频率较高,以发育相关基因失调为标志的特殊改变谱,以及特征性的分化阻滞模式。这些改变常发生在发育窗口期并维持肿瘤依赖性,为靶向治疗提供了独特药物靶点。本综述首先阐述儿童肿瘤的分子特征和致癌驱动因素,以及这些肿瘤中致癌驱动事件形成的潜在机制。随后系统总结儿童肿瘤靶向治疗策略的最新进展,按疾病类型和致癌驱动事件分类,包括针对致癌融合的抑制剂、靶向扩增或突变基因的药物、诱导分化策略、抗体疗法和细胞疗法。我们既关注儿童特异性药物开发,也关注将成人疗法外推至儿童患者,同时强调临床转化中持续存在的挑战。本工作倡导以生物学驱动的框架加速儿童肿瘤有效靶向治疗的开发。
Extracellular vesicles (EVs) are nanoscale membrane structures secreted by cells and play a key mediating role in intercellular communication. Their biosynthesis and function are profoundly modulated by mechanical signals from the cellular microenvironment. Mechanical forces, including shear stress, tensile strain, and matrix stiffness, exert fundamental effects on cellular behavior and disease progression by regulating the biogenesis, composition, and function of EVs. This review summarizes current knowledge on how biomechanical cues regulate EV-mediated intercellular communication in diseases such as atherosclerosis, osteoarthritis, and cancer. Specifically, we explore the mechanisms by which abnormal mechanical forces alter the cargo of EVs, such as miRNAs, proteins, and lipids, thereby driving disease progression through pathways like plaque instability, metastatic niche formation, and bone metabolism imbalance. Additionally, this review evaluates the therapeutic potential of mechanically regulated EVs, with a focus on their roles as diagnostic biomarkers and targeted drug delivery vehicles. By integrating cutting-edge perspectives from mechanobiology and EV research, this review lays a theoretical foundation for developing novel precision medicine strategies targeting biomechanically driven diseases.
中文摘要:细胞外囊泡(EVs)是由细胞分泌的纳米级膜结构,在细胞间通讯中发挥关键介导作用。细胞微环境的机械信号深刻调控其生物合成与功能。剪切应力、拉伸应变和基质刚度等机械力通过调节EVs的发生、组成和功能,对细胞行为和疾病进展产生基础性影响。本综述总结生物力学线索如何调控EVs介导的细胞间通讯在动脉粥样硬化、骨关节炎和癌症等疾病中的作用。我们探讨异常机械力改变EVs货物(如miRNA、蛋白质和脂质)的机制,进而通过斑块不稳定、转移龛形成和骨代谢失衡等途径推动疾病进展。本综述评估机械调控EVs的治疗潜力,重点关注其作为诊断生物标志物和靶向药物递送载体的作用。通过整合力学生物学与EV研究的前沿视角,本综述为开发针对生物力学驱动疾病的新型精准医学策略奠定理论基础。
Diffusion MRI tractography enables non-invasive mapping of brain connectivity but is commonly summarized as region-to-region graphs, obscuring the fine-grained organization of white-matter pathways. Voxelwise connection distribution maps (CDMs) preserve this information by representing the relative distribution of tractography-derived connections to anatomical targets at each voxel. However, normalized streamline-count profiles are noisy estimates of latent streamline-target compositions, and existing approaches neither quantify their uncertainty nor use population information to stabilize individual estimates. We propose individualized connection distribution mapping (iCDM), which extends CDM through an isometric log-ratio (ILR) representation, hierarchical empirical-Bayes inference of latent individual compositions, and quantification of inferential uncertainty and individual-population support. Individual streamline counts define the likelihood, while a spatially varying population prior is estimated from group data; its precision reflects between-subject dispersion, and its mean can be conditioned on independently learned subject characteristics. Simulations showed lower estimation error than naive and Dirichlet-multinomial estimates, with additional benefit from characteristic-conditioned priors when the characteristic explained substantial variation. Compositions remained similar under within-tractogram split-half sampling and tested changes in seeding and streamline budget. In independent scan-rescan data, data-information maps were reproducible, and greater data information was associated with lower compositional divergence. In a pediatric cohort, iCDM detected age-related compositional variation at voxel and tract levels. In tumor patients, posterior support shifted from predominantly population-based in lesion cores toward greater individual-data support with distance from the lesion. iCDM provides uncertainty-aware voxelwise connectivity inference for population-level and individualized analyses in basic and clinical research.
中文摘要:扩散MRI纤维束成像可无创绘制脑连接,但通常被概括为脑区到脑区的图,掩盖了白质通路的精细组织。逐体素连接分布图(CDM)通过在每个体素表示纤维束成像所得连接至解剖靶区的相对分布,保留了这些信息。然而,归一化流线计数剖面是对潜在流线-靶区组成的含噪估计,现有方法既不量化其不确定性,也不利用群体信息稳定个体估计。我们提出个体化连接分布映射(iCDM),通过等距对数比(ILR)表示、潜在个体组成的层级经验贝叶斯推断,以及推断不确定性与个体-群体支持度的量化来扩展CDM。个体流线计数定义似然,空间变化的群体先验由组数据估计;其精度反映受试者间离散度,其均值可以以独立学习的受试者特征为条件。模拟显示,其估计误差低于朴素估计和Dirichlet-多项估计,当特征解释较大变异时,以特征为条件的先验带来额外收益。在纤维束图内分半采样以及测试改变种子和流线预算时,组成保持相似。在独立扫描-重扫描数据中,数据信息图可重复,且数据信息越大与组成差异越小相关。在一个儿童队列中,iCDM在体素和纤维束水平检测到与年龄相关的组成变化。在肿瘤患者中,后验支持从病灶核心以群体为主转向随距病灶距离增加而更多依赖个体数据。iCDM为基础和临床研究中的群体水平与个体化分析提供不确定性感知的逐体素连接推断。